Inclusion NCT03923946 0 9 O
Criteria NCT03923946 10 18 O
: NCT03923946 19 20 O

- NCT03923946 24 25 O
Eligible NCT03923946 27 35 O
for NCT03923946 36 39 O
the NCT03923946 40 43 O
early NCT03923946 44 49 O
supported NCT03923946 50 59 O
discharge NCT03923946 60 69 B-Encounter-Type___Encounter-Type-Value:discharge
pathway NCT03923946 70 77 O
this NCT03923946 78 82 O
includes NCT03923946 83 91 O
: NCT03923946 92 93 O

- NCT03923946 102 103 O
Confirmed NCT03923946 105 114 O
diagnosis NCT03923946 115 124 O
of NCT03923946 125 127 O
a NCT03923946 128 129 O
new NCT03923946 130 133 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
stroke NCT03923946 134 140 B-Condition-Name
. NCT03923946 141 142 O

- NCT03923946 151 152 O
Over NCT03923946 154 158 B-Eq-Operator___Eq-Operator-Value:GT
18 NCT03923946 160 162 B-Eq-Value
Years NCT03923946 163 168 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03923946 169 172 O
. NCT03923946 173 174 O

- NCT03923946 183 184 O
Able NCT03923946 186 190 O
to NCT03923946 191 193 O
consent NCT03923946 194 201 O
to NCT03923946 202 204 O
being NCT03923946 205 210 O
in NCT03923946 211 213 O
the NCT03923946 214 217 O
study NCT03923946 218 223 O
. NCT03923946 224 225 O

- NCT03923946 234 235 O
The NCT03923946 237 240 O
patient NCT03923946 241 248 O
and NCT03923946 249 252 O
their NCT03923946 253 258 O
family NCT03923946 259 265 O
/ NCT03923946 266 267 O
carer NCT03923946 268 273 O
agree NCT03923946 274 279 O
to NCT03923946 280 282 O
rehabilitation NCT03923946 283 297 B-Procedure-Name
process NCT03923946 298 305 O
continuing NCT03923946 306 316 O
at NCT03923946 317 319 O
home NCT03923946 320 324 B-Location___Location-Value:residence
. NCT03923946 325 326 O

- NCT03923946 335 336 O
The NCT03923946 338 341 O
home NCT03923946 342 346 O
environment NCT03923946 347 358 O
is NCT03923946 359 361 O
conducive NCT03923946 362 371 O
to NCT03923946 372 374 O
the NCT03923946 375 378 O
community NCT03923946 379 388 O
- NCT03923946 389 390 O
based NCT03923946 391 396 O
rehabilitation NCT03923946 397 411 O
. NCT03923946 412 413 O

- NCT03923946 422 423 O
Achievable NCT03923946 425 435 O
rehabilitation NCT03923946 436 450 B-Procedure-Name
goals NCT03923946 451 456 O
can NCT03923946 457 460 O
be NCT03923946 461 463 O
identified NCT03923946 464 474 O
. NCT03923946 475 476 O

- NCT03923946 485 486 O
Document NCT03923946 488 496 O
acknowledgement NCT03923946 497 512 O
that NCT03923946 513 517 O
the NCT03923946 518 521 O
patient NCT03923946 522 529 O
is NCT03923946 530 532 O
sufficiently NCT03923946 533 545 O
well NCT03923946 546 550 O
enough NCT03923946 551 557 O
from NCT03923946 558 562 O
a NCT03923946 563 564 O
medical NCT03923946 565 572 O
perspective NCT03923946 573 584 O
to NCT03923946 585 587 O
be NCT03923946 588 590 O
managed NCT03923946 591 598 O
in NCT03923946 599 601 O
the NCT03923946 602 605 O
community NCT03923946 606 615 O
. NCT03923946 616 617 O

- NCT03923946 626 627 O
The NCT03923946 629 632 O
patient NCT03923946 633 640 O
's NCT03923946 640 642 O
language NCT03923946 643 651 O
and NCT03923946 652 655 O
/ NCT03923946 656 657 O
or NCT03923946 658 660 O
cognitive NCT03923946 661 670 O
skills NCT03923946 671 677 O
are NCT03923946 678 681 O
at NCT03923946 682 684 O
a NCT03923946 685 686 O
level NCT03923946 687 692 O
for NCT03923946 693 696 O
them NCT03923946 697 701 O
to NCT03923946 702 704 O
manage NCT03923946 705 711 O
on NCT03923946 712 714 O
their NCT03923946 715 720 O
own NCT03923946 721 724 O
for NCT03923946 725 728 O
periods NCT03923946 729 736 O
as NCT03923946 737 739 O
is NCT03923946 740 742 O
necessary NCT03923946 743 752 O
. NCT03923946 753 754 O

In NCT03923946 756 758 O
addition NCT03923946 759 767 O
to NCT03923946 768 770 O
ESSD NCT03923946 771 775 B-Condition-Name
criteria NCT03923946 776 784 O
participants NCT03923946 785 797 O
must NCT03923946 798 802 O
; NCT03923946 802 803 O

- NCT03923946 806 807 O
Have NCT03923946 809 813 O
a NCT03923946 814 815 O
good NCT03923946 816 820 O
grasp NCT03923946 821 826 O
of NCT03923946 827 829 O
the NCT03923946 830 833 O
English NCT03923946 834 841 B-Language
language NCT03923946 842 850 I-Language

- NCT03923946 853 854 O
Have NCT03923946 856 860 O
been NCT03923946 861 865 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
discharged NCT03923946 866 876 B-Encounter-Type___Encounter-Type-Value:discharge
from NCT03923946 877 881 O
the NCT03923946 882 885 O
ESSD NCT03923946 886 890 B-Condition-Name
pathway NCT03923946 891 898 O

Exclusion NCT03923946 899 908 O
Criteria NCT03923946 909 917 O
: NCT03923946 918 919 O

- NCT03923946 923 924 O
Participants NCT03923946 926 938 O
will NCT03923946 939 943 O
be NCT03923946 944 946 O
excluded NCT03923946 947 955 O
if NCT03923946 956 958 O
they NCT03923946 959 963 O
: NCT03923946 964 965 O

- NCT03923946 974 975 O
Have NCT03923946 977 981 O
any NCT03923946 982 985 O
communication NCT03923946 986 999 B-Condition-Name
difficulties NCT03923946 1000 1012 I-Condition-Name
that NCT03923946 1013 1017 O
would NCT03923946 1018 1023 O
prevent NCT03923946 1024 1031 O
them NCT03923946 1032 1036 O
from NCT03923946 1037 1041 O
engaging NCT03923946 1042 1050 O
in NCT03923946 1051 1053 O
the NCT03923946 1054 1057 O
intervention NCT03923946 1058 1070 B-Procedure-Name
( NCT03923946 1071 1072 O
including NCT03923946 1073 1082 O
hearing NCT03923946 1083 1090 B-Condition-Name
impairments NCT03923946 1091 1102 I-Condition-Name
, NCT03923946 1103 1104 O
visual NCT03923946 1105 1111 B-Condition-Name
impairments NCT03923946 1112 1123 I-Condition-Name
, NCT03923946 1124 1125 O
inability NCT03923946 1126 1135 O
to NCT03923946 1136 1138 O
understand NCT03923946 1139 1149 O
English NCT03923946 1150 1157 B-Language
) NCT03923946 1158 1159 O
. NCT03923946 1161 1162 O
These NCT03923946 1164 1169 O
will NCT03923946 1170 1174 O
be NCT03923946 1175 1177 O
assessed NCT03923946 1178 1186 O
at NCT03923946 1187 1189 O
researcher NCT03923946 1190 1200 O
's NCT03923946 1200 1202 O
discretion NCT03923946 1203 1213 O
during NCT03923946 1214 1220 O
baseline NCT03923946 1221 1229 O
assessments NCT03923946 1230 1241 O
. NCT03923946 1242 1243 O

- NCT03923946 1252 1253 O
Had NCT03923946 1255 1258 O
a NCT03923946 1259 1260 O
diagnosis NCT03923946 1261 1270 O
of NCT03923946 1271 1273 O
dementia NCT03923946 1274 1282 B-Condition-Name
prior NCT03923946 1283 1288 O
to NCT03923946 1289 1291 O
the NCT03923946 1292 1295 O
stroke NCT03923946 1296 1302 B-Condition-Name
. NCT03923946 1303 1304 O

- NCT03923946 1313 1314 O
Are NCT03923946 1316 1319 O
deemed NCT03923946 1320 1326 O
to NCT03923946 1327 1329 O
lack NCT03923946 1330 1334 O
capacity NCT03923946 1335 1343 O
to NCT03923946 1344 1346 O
give NCT03923946 1347 1351 O
informed NCT03923946 1352 1360 O
consent NCT03923946 1361 1368 O
. NCT03923946 1369 1370 O
This NCT03923946 1372 1376 O
will NCT03923946 1377 1381 O
be NCT03923946 1382 1384 O
judged NCT03923946 1385 1391 O
via NCT03923946 1392 1395 O
a NCT03923946 1396 1397 O
qualified NCT03923946 1398 1407 O
clinician NCT03923946 1408 1417 O
. NCT03923946 1418 1419 O

- NCT03923946 1428 1429 O
Have NCT03923946 1431 1435 O
had NCT03923946 1436 1439 O
previous NCT03923946 1440 1448 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
experience NCT03923946 1449 1459 O
of NCT03923946 1460 1462 O
CFT NCT03923946 1463 1466 B-Procedure-Name

- NCT03923946 1474 1475 O
Were NCT03923946 1477 1481 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
receiving NCT03923946 1482 1491 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
medical NCT03923946 1492 1499 O
or NCT03923946 1500 1502 O
psychological NCT03923946 1503 1516 O
treatment NCT03923946 1517 1526 B-Procedure-Name
for NCT03923946 1527 1530 O
a NCT03923946 1531 1532 O
mental NCT03923946 1533 1539 B-Condition-Name
illness NCT03923946 1540 1547 I-Condition-Name
at NCT03923946 1548 1550 O
the NCT03923946 1551 1554 O
time NCT03923946 1555 1559 O
of NCT03923946 1560 1562 O
their NCT03923946 1563 1568 O
stroke NCT03923946 1569 1575 B-Condition-Name
. NCT03923946 1576 1577 O

Inclusion NCT03923985 0 9 O
Criteria NCT03923985 10 18 O
: NCT03923985 19 20 O

- NCT03923985 24 25 O
Healthy NCT03923985 27 34 B-Condition-Name
women NCT03923985 35 40 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
between NCT03923985 41 48 O
18 NCT03923985 50 52 B-Eq-Value
and NCT03923985 53 56 O
45 NCT03923985 58 60 B-Eq-Value
years NCT03923985 61 66 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03923985 67 70 O

- NCT03923985 73 74 O
Women NCT03923985 76 81 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
without NCT03923985 82 89 O
current NCT03923985 90 97 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
symptoms NCT03923985 98 106 O
of NCT03923985 107 109 O
vaginal NCT03923985 110 117 B-Condition-Name
infection NCT03923985 118 127 I-Condition-Name

- NCT03923985 130 131 O
Negative NCT03923985 133 141 B-Polarity___Polarity-Value:negative
bacteriological NCT03923985 142 157 O
and NCT03923985 158 161 O
clinical NCT03923985 162 170 O
examination NCT03923985 171 182 B-Procedure-Name

Exclusion NCT03923985 183 192 O
Criteria NCT03923985 193 201 O
: NCT03923985 202 203 O

- NCT03923985 207 208 O
Women NCT03923985 210 215 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
with NCT03923985 216 220 O
vaginal NCT03923985 221 228 B-Condition-Name
infection NCT03923985 229 238 I-Condition-Name

- NCT03923985 241 242 O
Women NCT03923985 244 249 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
with NCT03923985 250 254 O
undiagnosed NCT03923985 255 266 O
vaginal NCT03923985 267 274 B-Condition-Name
bleeding NCT03923985 275 283 I-Condition-Name

- NCT03923985 286 287 O
Patients NCT03923985 289 297 O
with NCT03923985 298 302 O
endometrial NCT03923985 303 314 B-Condition-Name
hyperplasia NCT03923985 315 326 I-Condition-Name

- NCT03923985 329 330 O
Suspicion NCT03923985 332 341 O
of NCT03923985 342 344 O
neoplasia NCT03923985 345 354 B-Condition-Name
or NCT03923985 355 357 O
active NCT03923985 358 364 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
neoplasia NCT03923985 365 374 B-Condition-Name

- NCT03923985 377 378 O
Women NCT03923985 380 385 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
with NCT03923985 386 390 O
intolerance NCT03923985 391 402 B-Condition-Name
, NCT03923985 403 404 O
allergy NCT03923985 405 412 O
or NCT03923985 413 415 O
hypersensitivity NCT03923985 416 432 B-Condition-Name
to NCT03923985 433 435 O
the NCT03923985 436 439 O
components NCT03923985 440 450 O
of NCT03923985 451 453 O
the NCT03923985 454 457 O
probiotic NCT03923985 458 467 B-Drug-Name

- NCT03923985 470 471 O
Women NCT03923985 473 478 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
with NCT03923985 479 483 O
immunosuppressive NCT03923985 484 501 B-Condition-Name
disorders NCT03923985 502 511 I-Condition-Name
or NCT03923985 512 514 O
with NCT03923985 515 519 O
HIV NCT03923985 520 523 B-Condition-Name

- NCT03923985 526 527 O
Women NCT03923985 529 534 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
who NCT03923985 535 538 O
are NCT03923985 539 542 O
currently NCT03923985 543 552 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
using NCT03923985 553 558 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
probiotics NCT03923985 559 569 B-Drug-Name
by NCT03923985 570 572 O
any NCT03923985 573 576 O
route NCT03923985 577 582 O
of NCT03923985 583 585 O
administration NCT03923985 586 600 O

- NCT03923985 603 604 O
Women NCT03923985 606 611 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
who NCT03923985 612 615 O
are NCT03923985 616 619 O
using NCT03923985 620 625 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
some NCT03923985 626 630 O
treatment NCT03923985 631 640 O
for NCT03923985 641 644 O
vaginal NCT03923985 645 652 O
sepsis NCT03923985 653 659 B-Condition-Name

- NCT03923985 662 663 O
Chronic NCT03923985 665 672 O
decompensated NCT03923985 673 686 O
noncommunicable NCT03923985 687 702 B-Condition-Name
diseases NCT03923985 703 711 I-Condition-Name
( NCT03923985 712 713 O
diabetes NCT03923985 714 722 B-Condition-Name
mellitus NCT03923985 723 731 I-Condition-Name
, NCT03923985 732 733 O
heart NCT03923985 734 739 B-Condition-Name
disease NCT03923985 740 747 I-Condition-Name
. NCT03923985 749 750 O
. NCT03923985 751 752 O
. NCT03923985 753 754 O
) NCT03923985 755 756 O

- NCT03923985 760 761 O
Pregnant NCT03923985 763 771 B-Condition-Name
women NCT03923985 772 777 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
or NCT03923985 778 780 O
those NCT03923985 781 786 O
with NCT03923985 787 791 O
precocious NCT03923985 792 802 B-Condition-Name
menopause NCT03923985 803 812 I-Condition-Name

Inclusion NCT03926143 0 9 O
Criteria NCT03926143 10 18 O
: NCT03926143 19 20 O

- NCT03926143 24 25 O
Participants NCT03926143 27 39 O
ongoing NCT03926143 40 47 O
in NCT03926143 48 50 O
an NCT03926143 51 53 O
applicable NCT03926143 54 64 O
Bayer NCT03926143 65 70 O
- NCT03926143 71 72 O
sponsored NCT03926143 73 82 O
anetumab NCT03926143 83 91 B-Drug-Name
ravtansine NCT03926143 92 102 I-Drug-Name
parent NCT03926143 103 109 O
study NCT03926143 110 115 O
at NCT03926143 116 118 O
the NCT03926143 119 122 O
time NCT03926143 123 127 O
of NCT03926143 128 130 O
its NCT03926143 131 134 O
planned NCT03926143 135 142 O
study NCT03926143 143 148 O
closure NCT03926143 149 156 O
. NCT03926143 157 158 O

- NCT03926143 162 163 O
For NCT03926143 165 168 O
on NCT03926143 169 171 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
- NCT03926143 172 173 O
treatment NCT03926143 174 183 O
participants NCT03926143 184 196 O
: NCT03926143 197 198 O
participant NCT03926143 199 210 O
is NCT03926143 211 213 O
eligible NCT03926143 214 222 O
to NCT03926143 223 225 O
receive NCT03926143 226 233 O
the NCT03926143 234 237 O
next NCT03926143 238 242 O
dose NCT03926143 243 247 O
of NCT03926143 248 250 O
study NCT03926143 251 256 O
intervention NCT03926143 257 269 O
per NCT03926143 270 273 O
the NCT03926143 274 277 O
parent NCT03926143 278 284 O
study NCT03926143 285 290 O
protocol NCT03926143 291 299 O
. NCT03926143 300 301 O

Exclusion NCT03926143 303 312 O
Criteria NCT03926143 313 321 O
: NCT03926143 322 323 O

- NCT03926143 327 328 O
For NCT03926143 330 333 O
on NCT03926143 334 336 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
- NCT03926143 337 338 O
treatment NCT03926143 339 348 O
participants NCT03926143 349 361 O
: NCT03926143 362 363 O
a NCT03926143 364 365 O
positive NCT03926143 366 374 B-Polarity___Polarity-Value:positive
serum NCT03926143 375 380 B-Observation-Name___Observation-Type-Value:lab
pregnancy NCT03926143 381 390 I-Observation-Name___Observation-Type-Value:lab
test NCT03926143 391 395 I-Observation-Name___Observation-Type-Value:lab
. NCT03926143 396 397 O

- NCT03926143 401 402 O
For NCT03926143 404 407 O
on NCT03926143 408 410 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
- NCT03926143 411 412 O
treatment NCT03926143 413 422 O
participants NCT03926143 423 435 O
: NCT03926143 436 437 O
use NCT03926143 438 441 O
of NCT03926143 442 444 O
one NCT03926143 445 448 B-Eq-Value
or NCT03926143 449 451 B-Eq-Operator___Eq-Operator-Value:GTEQ
more NCT03926143 452 456 I-Eq-Operator___Eq-Operator-Value:GTEQ
of NCT03926143 457 459 O
the NCT03926143 460 463 O
prohibited NCT03926143 464 474 O
medications NCT03926143 475 486 O
listed NCT03926143 487 493 O
in NCT03926143 494 496 O
the NCT03926143 497 500 O
respective NCT03926143 501 511 O
parent NCT03926143 512 518 O
study NCT03926143 519 524 O
protocol NCT03926143 525 533 O
. NCT03926143 534 535 O

- NCT03926143 539 540 O
Participants NCT03926143 542 554 O
who NCT03926143 555 558 O
are NCT03926143 559 562 O
receiving NCT03926143 563 572 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
standard NCT03926143 573 581 O
- NCT03926143 582 583 O
of NCT03926143 584 586 O
- NCT03926143 587 588 O
care NCT03926143 589 593 O
agent NCT03926143 594 599 O
( NCT03926143 600 601 O
s NCT03926143 602 603 O
) NCT03926143 604 605 O
but NCT03926143 606 609 O
not NCT03926143 610 613 O
anetumab NCT03926143 614 622 B-Drug-Name
ravtansine NCT03926143 623 633 I-Drug-Name
in NCT03926143 634 636 O
the NCT03926143 637 640 O
parent NCT03926143 641 647 O
study NCT03926143 648 653 O
, NCT03926143 654 655 O
and NCT03926143 656 659 O
are NCT03926143 660 663 O
able NCT03926143 664 668 O
to NCT03926143 669 671 O
receive NCT03926143 672 679 O
standard NCT03926143 680 688 O
- NCT03926143 689 690 O
of NCT03926143 691 693 O
- NCT03926143 694 695 O
care NCT03926143 696 700 O
agent NCT03926143 701 706 O
outside NCT03926143 707 714 O
of NCT03926143 715 717 O
the NCT03926143 718 721 O
clinical NCT03926143 722 730 O
study NCT03926143 731 736 O
. NCT03926143 737 738 O

Inclusion NCT03926962 0 9 O
Criteria NCT03926962 10 18 O
: NCT03926962 19 20 O

- NCT03926962 24 25 O
BMI NCT03926962 27 30 B-Observation-Name___Observation-Type-Value:vital
: NCT03926962 31 32 O
18 NCT03926962 34 36 B-Eq-Value
- NCT03926962 37 38 B-Eq-Operator___Eq-Operator-Value:BETWEEN
30 NCT03926962 40 42 B-Eq-Value
kg NCT03926962 43 45 B-Eq-Unit
/ NCT03926962 46 47 O
m NCT03926962 48 49 B-Eq-Unit
2 NCT03926962 50 51 I-Eq-Unit
( NCT03926962 52 53 O
Body NCT03926962 54 58 B-Observation-Name___Observation-Type-Value:vital
Mass NCT03926962 59 63 I-Observation-Name___Observation-Type-Value:vital
Index NCT03926962 64 69 I-Observation-Name___Observation-Type-Value:vital
[ NCT03926962 70 71 O
BMI NCT03926962 72 75 B-Observation-Name___Observation-Type-Value:vital
] NCT03926962 76 77 O
[ NCT03926962 78 79 O
kg NCT03926962 80 82 O
/ NCT03926962 83 84 O
m NCT03926962 85 86 O
2 NCT03926962 87 88 O
] NCT03926962 89 90 O
= NCT03926962 91 92 O
Body NCT03926962 93 97 O
weight NCT03926962 98 104 O
[ NCT03926962 105 106 O
kg NCT03926962 107 109 O
] NCT03926962 110 111 O
Height NCT03926962 112 118 O
2 NCT03926962 119 120 O
[ NCT03926962 121 122 O
m NCT03926962 123 124 O
2 NCT03926962 125 126 O
] NCT03926962 127 128 O
) NCT03926962 130 131 O

- NCT03926962 135 136 O
Ability NCT03926962 138 145 O
and NCT03926962 146 149 O
willingness NCT03926962 150 161 O
to NCT03926962 162 164 O
abstain NCT03926962 165 172 O
from NCT03926962 173 177 O
alcohol NCT03926962 178 185 B-Drug-Name
, NCT03926962 186 187 O
methylxanthine NCT03926962 188 202 B-Drug-Name
- NCT03926962 203 204 O
containing NCT03926962 205 215 O
beverages NCT03926962 216 225 O
or NCT03926962 226 228 O
food NCT03926962 229 233 O
( NCT03926962 234 235 O
coffee NCT03926962 236 242 O
, NCT03926962 243 244 O
tea NCT03926962 245 248 O
, NCT03926962 249 250 O
cola NCT03926962 251 255 O
, NCT03926962 256 257 O
chocolate NCT03926962 258 267 O
, NCT03926962 268 269 O
" NCT03926962 270 271 O
powerdrinks NCT03926962 271 282 O
" NCT03926962 282 283 O
) NCT03926962 284 285 O
, NCT03926962 287 288 O
grapefruit NCT03926962 289 299 O
( NCT03926962 300 301 O
juice NCT03926962 302 307 O
) NCT03926962 308 309 O
from NCT03926962 310 314 O
48 NCT03926962 316 318 B-Eq-Value
h NCT03926962 319 320 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:hour
prior NCT03926962 321 326 O
to NCT03926962 327 329 O
entry NCT03926962 330 335 O
in NCT03926962 336 338 O
the NCT03926962 339 342 O
clinical NCT03926962 343 351 O
research NCT03926962 352 360 O
center NCT03926962 361 367 O
until NCT03926962 368 373 O
discharge NCT03926962 374 383 B-Encounter-Type___Encounter-Type-Value:discharge

- NCT03926962 386 387 O
Medical NCT03926962 389 396 O
history NCT03926962 397 404 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
without NCT03926962 405 412 O
major NCT03926962 413 418 O
pathology NCT03926962 419 428 B-Condition-Name

Exclusion NCT03926962 429 438 O
Criteria NCT03926962 439 447 O
: NCT03926962 448 449 O

- NCT03926962 453 454 O
Evidence NCT03926962 456 464 O
of NCT03926962 465 467 O
clinically NCT03926962 468 478 O
relevant NCT03926962 479 487 O
pathology NCT03926962 488 497 B-Condition-Name

- NCT03926962 500 501 O
Mental NCT03926962 503 509 B-Condition-Name
handicap NCT03926962 510 518 I-Condition-Name

- NCT03926962 521 522 O
History NCT03926962 524 531 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03926962 532 534 O
relevant NCT03926962 535 543 O
drug NCT03926962 544 548 B-Allergy-Name
and NCT03926962 549 552 O
/ NCT03926962 553 554 O
or NCT03926962 555 557 O
food NCT03926962 558 562 B-Allergy-Name
allergies NCT03926962 563 572 O

- NCT03926962 575 576 O
Regular NCT03926962 578 585 O
/ NCT03926962 586 587 O
routine NCT03926962 588 595 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
treatment NCT03926962 596 605 O
with NCT03926962 606 610 O
non NCT03926962 611 614 O
- NCT03926962 615 616 O
topical NCT03926962 617 624 B-Drug-Name
medications NCT03926962 625 636 I-Drug-Name
within NCT03926962 637 643 B-Eq-Operator___Eq-Operator-Value:LTEQ
30 NCT03926962 645 647 B-Eq-Value
days NCT03926962 648 652 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
prior NCT03926962 653 658 O
to NCT03926962 659 661 O
entry NCT03926962 662 667 O
into NCT03926962 668 672 O
the NCT03926962 673 676 O
clinical NCT03926962 677 685 O
research NCT03926962 686 694 O
center NCT03926962 695 701 O

- NCT03926962 704 705 O
Smoking NCT03926962 707 714 B-Condition-Name
within NCT03926962 715 721 B-Eq-Operator___Eq-Operator-Value:LTEQ
60 NCT03926962 723 725 B-Eq-Value
days NCT03926962 726 730 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
prior NCT03926962 731 736 O
to NCT03926962 737 739 O
drug NCT03926962 740 744 O
administration NCT03926962 745 759 O
and NCT03926962 760 763 O
through NCT03926962 764 771 O
the NCT03926962 772 775 O
follow NCT03926962 776 782 B-Encounter-Type___Encounter-Type-Value:outpatient
- NCT03926962 783 784 I-Encounter-Type___Encounter-Type-Value:outpatient
up NCT03926962 785 787 I-Encounter-Type___Encounter-Type-Value:outpatient
visit NCT03926962 788 793 I-Encounter-Type___Encounter-Type-Value:outpatient

- NCT03926962 796 797 O
History NCT03926962 799 806 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03926962 807 809 O
alcohol NCT03926962 810 817 B-Condition-Name
abuse NCT03926962 818 823 I-Condition-Name
or NCT03926962 824 826 O
drug NCT03926962 827 831 B-Condition-Name
addiction NCT03926962 832 841 I-Condition-Name
( NCT03926962 842 843 O
including NCT03926962 844 853 O
soft NCT03926962 854 858 B-Condition-Name
drugs NCT03926962 859 864 I-Condition-Name
like NCT03926962 865 869 O
cannabis NCT03926962 870 878 B-Condition-Name
products NCT03926962 879 887 O
) NCT03926962 888 889 O

Inclusion NCT03922906 0 9 O
Criteria NCT03922906 10 18 O
: NCT03922906 19 20 O

1 NCT03922906 25 26 O
. NCT03922906 26 27 O
Subjects NCT03922906 29 37 O
with NCT03922906 38 42 O
history NCT03922906 43 50 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03922906 51 53 O
inadequate NCT03922906 54 64 B-Condition-Name
bowel NCT03922906 65 70 I-Condition-Name
preparation NCT03922906 71 82 I-Condition-Name
. NCT03922906 83 84 O

2 NCT03922906 89 90 O
. NCT03922906 90 91 O
Subjects NCT03922906 93 101 O
in NCT03922906 102 104 O
the NCT03922906 105 108 O
age NCT03922906 109 112 O
range NCT03922906 113 118 O
of NCT03922906 119 121 O
22 NCT03922906 123 125 B-Eq-Value
- NCT03922906 126 127 B-Eq-Operator___Eq-Operator-Value:BETWEEN
75 NCT03922906 129 131 B-Eq-Value
years NCT03922906 132 137 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
inclusive NCT03922906 138 147 O

3 NCT03922906 151 152 O
. NCT03922906 152 153 O
Subjects NCT03922906 155 163 O
with NCT03922906 164 168 O
BodyMass NCT03922906 169 177 B-Observation-Name___Observation-Type-Value:vital
Index NCT03922906 178 183 I-Observation-Name___Observation-Type-Value:vital
( NCT03922906 184 185 O
BMI NCT03922906 186 189 B-Observation-Name___Observation-Type-Value:vital
) NCT03922906 190 191 O
within NCT03922906 192 198 O
the NCT03922906 199 202 O
range NCT03922906 203 208 O
of NCT03922906 209 211 O
18.5 NCT03922906 213 217 B-Eq-Value
- NCT03922906 218 219 B-Eq-Operator___Eq-Operator-Value:BETWEEN
35 NCT03922906 221 223 B-Eq-Value
inclusive NCT03922906 224 233 O

4 NCT03922906 237 238 O
. NCT03922906 238 239 O
Subject NCT03922906 241 248 O
has NCT03922906 249 252 O
signed NCT03922906 253 259 O
the NCT03922906 260 263 O
informed NCT03922906 264 272 O
consent NCT03922906 273 280 O

Exclusion NCT03922906 281 290 O
Criteria NCT03922906 291 299 O
: NCT03922906 300 301 O

1 NCT03922906 306 307 O
. NCT03922906 307 308 O
Patients NCT03922906 310 318 O
with NCT03922906 319 323 O
active NCT03922906 324 330 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
Inflammatory NCT03922906 331 343 B-Condition-Name
Bowel NCT03922906 344 349 I-Condition-Name
Disease NCT03922906 350 357 I-Condition-Name

2 NCT03922906 361 362 O
. NCT03922906 362 363 O
Patients NCT03922906 365 373 O
with NCT03922906 374 378 O
previous NCT03922906 379 387 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
history NCT03922906 388 395 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03922906 396 398 O
acute NCT03922906 399 404 B-Severity___Severity-Value:severe
diverticulitis NCT03922906 405 419 B-Condition-Name
disease NCT03922906 420 427 I-Condition-Name
or NCT03922906 428 430 O
with NCT03922906 431 435 O
prior NCT03922906 436 441 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
incomplete NCT03922906 442 452 O
colonoscopy NCT03922906 453 464 B-Procedure-Name
due NCT03922906 465 468 O
to NCT03922906 469 471 O
diverticular NCT03922906 472 484 B-Condition-Name
disease NCT03922906 485 492 I-Condition-Name

3 NCT03922906 496 497 O
. NCT03922906 497 498 O
Patients NCT03922906 500 508 O
with NCT03922906 509 513 O
known NCT03922906 514 519 O
bowel NCT03922906 520 525 B-Condition-Name
obstruction NCT03922906 526 537 I-Condition-Name
/ NCT03922906 538 539 O
strictures NCT03922906 540 550 B-Condition-Name

4 NCT03922906 554 555 O
. NCT03922906 555 556 O
History NCT03922906 558 565 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03922906 566 568 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
prior NCT03922906 569 574 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
surgery NCT03922906 575 582 B-Procedure-Name
to NCT03922906 583 585 O
colon NCT03922906 586 591 O
and NCT03922906 592 595 O
/ NCT03922906 596 597 O
or NCT03922906 598 600 O
rectum NCT03922906 601 607 O

5 NCT03922906 611 612 O
. NCT03922906 612 613 O
ASA NCT03922906 615 618 B-Condition-Name
≥ NCT03922906 619 620 B-Eq-Operator___Eq-Operator-Value:GTEQ
III NCT03922906 621 624 B-Eq-Value

6 NCT03922906 628 629 O
. NCT03922906 629 630 O
Renal NCT03922906 632 637 B-Condition-Name
insufficiency NCT03922906 638 651 I-Condition-Name
( NCT03922906 652 653 O
Creatinine NCT03922906 654 664 B-Observation-Name___Observation-Type-Value:lab
≥ NCT03922906 665 666 B-Eq-Operator___Eq-Operator-Value:GTEQ
1.5 NCT03922906 668 671 B-Eq-Value
mg NCT03922906 672 674 B-Eq-Unit
/ NCT03922906 675 676 O
dL NCT03922906 677 679 B-Eq-Unit
) NCT03922906 680 681 O
( NCT03922906 682 683 O
based NCT03922906 684 689 O
on NCT03922906 690 692 O
medical NCT03922906 693 700 O
history NCT03922906 701 708 O
) NCT03922906 709 710 O

7 NCT03922906 715 716 O
. NCT03922906 716 717 O
Abnormal NCT03922906 719 727 B-Polarity___Polarity-Value:abnormal
Liver NCT03922906 728 733 B-Condition-Name
enzymes NCT03922906 734 741 I-Condition-Name
( NCT03922906 742 743 O
ALT NCT03922906 744 747 B-Observation-Name___Observation-Type-Value:lab
/ NCT03922906 748 749 O
AST NCT03922906 750 753 B-Observation-Name___Observation-Type-Value:lab
≥ NCT03922906 754 755 B-Eq-Operator___Eq-Operator-Value:GTEQ
2 NCT03922906 757 758 B-Eq-Value
times NCT03922906 759 764 O
upper NCT03922906 765 770 B-Eq-Unit___Eq-Unit-Value:ref-range-normal
limits NCT03922906 771 777 I-Eq-Unit___Eq-Unit-Value:ref-range-normal
of NCT03922906 778 780 I-Eq-Unit___Eq-Unit-Value:ref-range-normal
normal NCT03922906 781 787 I-Eq-Unit___Eq-Unit-Value:ref-range-normal
) NCT03922906 788 789 O
( NCT03922906 790 791 O
based NCT03922906 792 797 O
on NCT03922906 798 800 O
medical NCT03922906 801 808 O
history NCT03922906 809 816 O
) NCT03922906 817 818 O

8 NCT03922906 823 824 O
. NCT03922906 824 825 O
Patients NCT03922906 827 835 O
taking NCT03922906 836 842 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
anticoagulants NCT03922906 843 857 B-Drug-Name
drugs NCT03922906 858 863 I-Drug-Name
( NCT03922906 864 865 O
excluding NCT03922906 866 875 O
aspirin NCT03922906 876 883 B-Drug-Name
) NCT03922906 884 885 O
or NCT03922906 886 888 O
dual NCT03922906 889 893 O
antiplatelet NCT03922906 894 906 B-Procedure-Name
therapy NCT03922906 907 914 I-Procedure-Name

9 NCT03922906 918 919 O
. NCT03922906 919 920 O
Patients NCT03922906 922 930 O
with NCT03922906 931 935 O
known NCT03922906 936 941 O
coagulation NCT03922906 942 953 B-Condition-Name
disorder NCT03922906 954 962 I-Condition-Name
( NCT03922906 963 964 O
INR NCT03922906 965 968 B-Observation-Name___Observation-Type-Value:lab
> NCT03922906 969 970 B-Eq-Operator___Eq-Operator-Value:GT
1.5 NCT03922906 972 975 B-Eq-Value
) NCT03922906 976 977 O
. NCT03922906 979 980 O

10 NCT03922906 984 986 O
. NCT03922906 986 987 O
Patients NCT03922906 989 997 O
at NCT03922906 998 1000 O
risk NCT03922906 1001 1005 O
of NCT03922906 1006 1008 O
hypokalemia NCT03922906 1009 1020 B-Condition-Name
or NCT03922906 1021 1023 O
hyponatremia NCT03922906 1024 1036 B-Condition-Name

11 NCT03922906 1039 1041 O
. NCT03922906 1041 1042 O
Patients NCT03922906 1044 1052 O
with NCT03922906 1053 1057 O
congestive NCT03922906 1058 1068 B-Condition-Name
cardiac NCT03922906 1069 1076 I-Condition-Name
failure NCT03922906 1077 1084 I-Condition-Name

12 NCT03922906 1087 1089 O
. NCT03922906 1089 1090 O
Pregnancy NCT03922906 1092 1101 B-Condition-Name
( NCT03922906 1102 1103 O
as NCT03922906 1104 1106 O
stated NCT03922906 1107 1113 O
by NCT03922906 1114 1116 O
patient NCT03922906 1117 1124 O
) NCT03922906 1125 1126 O
or NCT03922906 1127 1129 O
breast NCT03922906 1130 1136 B-Condition-Name
feeding NCT03922906 1137 1144 I-Condition-Name

13 NCT03922906 1147 1149 O
. NCT03922906 1149 1150 O
Patients NCT03922906 1152 1160 O
with NCT03922906 1161 1165 O
altered NCT03922906 1166 1173 B-Condition-Name
mental NCT03922906 1174 1180 I-Condition-Name
status NCT03922906 1181 1187 I-Condition-Name
/ NCT03922906 1188 1189 O
inability NCT03922906 1190 1199 O
to NCT03922906 1200 1202 O
provide NCT03922906 1203 1210 O
informed NCT03922906 1211 1219 O
consent NCT03922906 1220 1227 O

14 NCT03922906 1230 1232 O
. NCT03922906 1232 1233 O
Patients NCT03922906 1235 1243 O
who NCT03922906 1244 1247 O
have NCT03922906 1248 1252 O
participated NCT03922906 1253 1265 O
in NCT03922906 1266 1268 O
another NCT03922906 1269 1276 O
interventional NCT03922906 1277 1291 O
clinical NCT03922906 1292 1300 O
study NCT03922906 1301 1306 O
in NCT03922906 1307 1309 O
the NCT03922906 1310 1313 O
last NCT03922906 1314 1318 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
2 NCT03922906 1320 1321 B-Eq-Value
months NCT03922906 1322 1328 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

Inclusion NCT03925714 0 9 O
Criteria NCT03925714 10 18 O
: NCT03925714 19 20 O

- NCT03925714 24 25 O
Prediabetic NCT03925714 27 38 B-Condition-Name
subjects NCT03925714 39 47 O
. NCT03925714 48 49 O

Exclusion NCT03925714 51 60 O
Criteria NCT03925714 61 69 O
: NCT03925714 70 71 O

- NCT03925714 75 76 O
Confirmed NCT03925714 78 87 O
diabetes NCT03925714 88 96 B-Condition-Name
. NCT03925714 97 98 O

- NCT03925714 102 103 O
Hepatic NCT03925714 105 112 O
or NCT03925714 113 115 O
renal NCT03925714 116 121 O
impairment NCT03925714 122 132 B-Condition-Name
. NCT03925714 133 134 O

Inclusion NCT03926221 0 9 O
Criteria NCT03926221 10 18 O
: NCT03926221 19 20 O

1 NCT03926221 25 26 O
. NCT03926221 26 27 O
Age NCT03926221 29 32 O
between NCT03926221 33 40 B-Eq-Operator___Eq-Operator-Value:BETWEEN
10 NCT03926221 42 44 B-Eq-Value
and NCT03926221 45 48 O
18 NCT03926221 50 52 B-Eq-Value
and NCT03926221 53 56 O
living NCT03926221 57 63 O
with NCT03926221 64 68 O
a NCT03926221 69 70 O
parent NCT03926221 71 77 O
or NCT03926221 78 80 O
guardian NCT03926221 81 89 O

2 NCT03926221 93 94 O
. NCT03926221 94 95 O
Lowest NCT03926221 97 103 B-Polarity___Polarity-Value:low
quartile NCT03926221 104 112 O
of NCT03926221 113 115 O
the NCT03926221 116 119 O
widely NCT03926221 120 126 O
used NCT03926221 127 131 O
and NCT03926221 132 135 O
well NCT03926221 136 140 O
- NCT03926221 141 142 O
validated NCT03926221 143 152 O
Children NCT03926221 153 161 B-Observation-Name___Observation-Type-Value:survey-or-questionnaire
's NCT03926221 161 163 I-Observation-Name___Observation-Type-Value:survey-or-questionnaire
Morningness NCT03926221 164 175 I-Observation-Name___Observation-Type-Value:survey-or-questionnaire
- NCT03926221 176 177 I-Observation-Name___Observation-Type-Value:survey-or-questionnaire
Eveningness NCT03926221 178 189 I-Observation-Name___Observation-Type-Value:survey-or-questionnaire
Preferences NCT03926221 190 201 I-Observation-Name___Observation-Type-Value:survey-or-questionnaire
Scale NCT03926221 202 207 I-Observation-Name___Observation-Type-Value:survey-or-questionnaire
( NCT03926221 208 209 O
CMEP NCT03926221 210 214 B-Observation-Name
; NCT03926221 214 215 O
27 NCT03926221 217 219 B-Eq-Value
or NCT03926221 220 222 B-Eq-Operator___Eq-Operator-Value:LTEQ
lower NCT03926221 223 228 I-Eq-Operator___Eq-Operator-Value:LTEQ
) NCT03926221 229 230 O
and NCT03926221 231 234 O

3 NCT03926221 238 239 O
. NCT03926221 239 240 O
Youth NCT03926221 242 247 O
self NCT03926221 248 252 O
- NCT03926221 253 254 O
reported NCT03926221 255 263 O
weekday NCT03926221 264 271 O
sleep NCT03926221 272 277 B-Observation-Name___Observation-Type-Value:measurement
onset NCT03926221 278 283 I-Observation-Name___Observation-Type-Value:measurement
time NCT03926221 284 288 I-Observation-Name___Observation-Type-Value:measurement
for NCT03926221 289 292 O
the NCT03926221 293 296 O
past NCT03926221 297 301 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
month NCT03926221 302 307 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
later NCT03926221 308 313 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03926221 314 318 I-Eq-Operator___Eq-Operator-Value:GT
10 NCT03926221 320 322 B-Eq-Value
: NCT03926221 323 324 I-Eq-Value
40 NCT03926221 326 328 I-Eq-Value
pm NCT03926221 329 331 I-Eq-Value
for NCT03926221 332 335 O
10 NCT03926221 337 339 B-Eq-Value
- NCT03926221 340 341 O
to NCT03926221 342 344 O
13 NCT03926221 346 348 B-Eq-Value
- NCT03926221 349 350 O
year NCT03926221 351 355 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
- NCT03926221 356 357 O
olds NCT03926221 358 362 O
; NCT03926221 362 363 O
11 NCT03926221 365 367 B-Eq-Value
: NCT03926221 368 369 I-Eq-Value
00 NCT03926221 371 373 I-Eq-Value
pm NCT03926221 374 376 I-Eq-Value
for NCT03926221 377 380 O
14 NCT03926221 382 384 B-Eq-Value
- NCT03926221 385 386 B-Eq-Operator___Eq-Operator-Value:BETWEEN
16 NCT03926221 388 390 B-Eq-Value
year NCT03926221 391 395 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
olds NCT03926221 396 400 O
, NCT03926221 401 402 O
and NCT03926221 403 406 O
later NCT03926221 407 412 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03926221 413 417 I-Eq-Operator___Eq-Operator-Value:GT
11 NCT03926221 419 421 B-Eq-Value
: NCT03926221 422 423 I-Eq-Value
20 NCT03926221 425 427 I-Eq-Value
for NCT03926221 428 431 O
17 NCT03926221 433 435 B-Eq-Value
- NCT03926221 436 437 B-Eq-Operator___Eq-Operator-Value:BETWEEN
18 NCT03926221 439 441 B-Eq-Value
year NCT03926221 442 446 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
olds NCT03926221 447 451 O
at NCT03926221 452 454 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03926221 455 460 I-Eq-Operator___Eq-Operator-Value:GTEQ
3 NCT03926221 462 463 B-Eq-Value
nights NCT03926221 464 470 O
per NCT03926221 471 474 O
week NCT03926221 475 479 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
; NCT03926221 479 480 O

4 NCT03926221 484 485 O
. NCT03926221 485 486 O
English NCT03926221 488 495 B-Language
language NCT03926221 496 504 O
fluency NCT03926221 505 512 O
; NCT03926221 512 513 O

5 NCT03926221 517 518 O
. NCT03926221 518 519 O
able NCT03926221 521 525 O
and NCT03926221 526 529 O
willing NCT03926221 530 537 O
to NCT03926221 538 540 O
give NCT03926221 541 545 O
informed NCT03926221 546 554 O
assent NCT03926221 555 561 O
; NCT03926221 561 562 O

6 NCT03926221 566 567 O
. NCT03926221 567 568 O
at NCT03926221 570 572 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03926221 573 578 I-Eq-Operator___Eq-Operator-Value:GTEQ
one NCT03926221 579 582 B-Eq-Value
parent NCT03926221 583 589 O
/ NCT03926221 590 591 O
primary NCT03926221 592 599 O
caregiver NCT03926221 600 609 O
who NCT03926221 610 613 O
lives NCT03926221 614 619 O
in NCT03926221 620 622 O
the NCT03926221 623 626 O
same NCT03926221 627 631 O
household NCT03926221 632 641 O
as NCT03926221 642 644 O
the NCT03926221 645 648 O
teen NCT03926221 649 653 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
for NCT03926221 654 657 O
at NCT03926221 658 660 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03926221 661 666 I-Eq-Operator___Eq-Operator-Value:GTEQ
50 NCT03926221 668 670 B-Eq-Value
% NCT03926221 671 672 B-Eq-Unit
of NCT03926221 673 675 O
the NCT03926221 676 679 O
week NCT03926221 680 684 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
must NCT03926221 685 689 O
participate NCT03926221 690 701 O
in NCT03926221 702 704 O
all NCT03926221 705 708 O
study NCT03926221 709 714 O
sessions NCT03926221 715 723 O
. NCT03926221 724 725 O

Exclusion NCT03926221 727 736 O
Criteria NCT03926221 737 745 O
: NCT03926221 746 747 O

1 NCT03926221 752 753 O
. NCT03926221 753 754 O
An NCT03926221 756 758 O
active NCT03926221 759 765 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
, NCT03926221 766 767 O
progressive NCT03926221 768 779 O
physical NCT03926221 780 788 B-Condition-Name
illness NCT03926221 789 796 I-Condition-Name
directly NCT03926221 797 805 O
related NCT03926221 806 813 O
to NCT03926221 814 816 O
the NCT03926221 817 820 O
onset NCT03926221 821 826 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
and NCT03926221 827 830 O
course NCT03926221 831 837 O
of NCT03926221 838 840 O
the NCT03926221 841 844 O
sleep NCT03926221 845 850 B-Condition-Name
disturbance NCT03926221 851 862 I-Condition-Name
; NCT03926221 862 863 O

2 NCT03926221 867 868 O
. NCT03926221 868 869 O
evidence NCT03926221 871 879 O
of NCT03926221 880 882 O
sleep NCT03926221 883 888 B-Condition-Name
apnea NCT03926221 889 894 I-Condition-Name
, NCT03926221 895 896 O
restless NCT03926221 897 905 B-Condition-Name
legs NCT03926221 906 910 I-Condition-Name
or NCT03926221 911 913 O
periodic NCT03926221 914 922 O
limb NCT03926221 923 927 B-Condition-Name
movements NCT03926221 928 937 I-Condition-Name
; NCT03926221 937 938 O

3 NCT03926221 942 943 O
. NCT03926221 943 944 O
significantly NCT03926221 946 959 B-Severity___Severity-Value:severe
impairing NCT03926221 960 969 O
pervasive NCT03926221 970 979 O
developmental NCT03926221 980 993 B-Condition-Name
disorder NCT03926221 994 1002 I-Condition-Name
; NCT03926221 1002 1003 O

4 NCT03926221 1007 1008 O
. NCT03926221 1008 1009 O
history NCT03926221 1011 1018 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03926221 1019 1021 O
substance NCT03926221 1022 1031 B-Condition-Name
dependence NCT03926221 1032 1042 I-Condition-Name
in NCT03926221 1043 1045 O
the NCT03926221 1046 1049 O
past NCT03926221 1050 1054 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
six NCT03926221 1055 1058 B-Eq-Value
months NCT03926221 1059 1065 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
; NCT03926221 1065 1066 O

5 NCT03926221 1070 1071 O
. NCT03926221 1071 1072 O
suicide NCT03926221 1074 1081 B-Condition-Name
risk NCT03926221 1082 1086 O
; NCT03926221 1086 1087 O
bipolar NCT03926221 1088 1095 B-Condition-Name
disorder NCT03926221 1096 1104 I-Condition-Name
or NCT03926221 1105 1107 O
schizophrenia NCT03926221 1108 1121 B-Condition-Name
or NCT03926221 1122 1124 O
another NCT03926221 1125 1132 O
current NCT03926221 1133 1140 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
Axis NCT03926221 1141 1145 B-Eq-Unit
I NCT03926221 1146 1147 B-Eq-Value
disorder NCT03926221 1148 1156 B-Condition-Name
if NCT03926221 1157 1159 O
there NCT03926221 1160 1165 O
is NCT03926221 1166 1168 O
a NCT03926221 1169 1170 O
significant NCT03926221 1171 1182 B-Severity___Severity-Value:severe
risk NCT03926221 1183 1187 O
of NCT03926221 1188 1190 O
harm NCT03926221 1191 1195 B-Condition-Name
and NCT03926221 1196 1199 O
/ NCT03926221 1200 1201 O
or NCT03926221 1202 1204 O
decompensation NCT03926221 1205 1219 B-Condition-Name
if NCT03926221 1220 1222 O
treatment NCT03926221 1223 1232 O
of NCT03926221 1233 1235 O
that NCT03926221 1236 1240 O
comorbid NCT03926221 1241 1249 O
condition NCT03926221 1250 1259 O
is NCT03926221 1260 1262 O
delayed NCT03926221 1263 1270 B-Stability___Stability-Value:change
as NCT03926221 1271 1273 O
a NCT03926221 1274 1275 O
function NCT03926221 1276 1284 O
of NCT03926221 1285 1287 O
participating NCT03926221 1288 1301 O
in NCT03926221 1302 1304 O
any NCT03926221 1305 1308 O
stage NCT03926221 1309 1314 O
of NCT03926221 1315 1317 O
this NCT03926221 1318 1322 O
study NCT03926221 1323 1328 O
; NCT03926221 1328 1329 O

6 NCT03926221 1333 1334 O
. NCT03926221 1334 1335 O
Participants NCT03926221 1337 1349 O
will NCT03926221 1350 1354 O
not NCT03926221 1355 1358 O
be NCT03926221 1359 1361 O
excluded NCT03926221 1362 1370 O
if NCT03926221 1371 1373 O
medications NCT03926221 1374 1385 O
are NCT03926221 1386 1389 O
stable NCT03926221 1390 1396 B-Stability___Stability-Value:stable
( NCT03926221 1397 1398 O
> NCT03926221 1400 1401 B-Eq-Operator___Eq-Operator-Value:GT
4 NCT03926221 1403 1404 B-Eq-Value
weeks NCT03926221 1405 1410 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
) NCT03926221 1411 1412 O
. NCT03926221 1414 1415 O

Inclusion NCT03924999 0 9 O
Criteria NCT03924999 10 18 O
: NCT03924999 19 20 O

- NCT03924999 24 25 O
Subject NCT03924999 27 34 O
diagnosed NCT03924999 35 44 O
with NCT03924999 45 49 O
lipedema NCT03924999 50 58 B-Condition-Name
according NCT03924999 59 68 O
to NCT03924999 69 71 O
the NCT03924999 72 75 O
criteria NCT03924999 76 84 O
of NCT03924999 85 87 O
revised NCT03924999 88 95 O
Wold NCT03924999 96 100 O
. NCT03924999 101 102 O

- NCT03924999 106 107 O
Subject NCT03924999 109 116 O
did NCT03924999 117 120 O
not NCT03924999 121 124 O
participate NCT03924999 125 136 O
in NCT03924999 137 139 O
any NCT03924999 140 143 O
exercise NCT03924999 144 152 B-Procedure-Name
program NCT03924999 153 160 I-Procedure-Name
within NCT03924999 161 167 B-Eq-Operator___Eq-Operator-Value:LTEQ
the NCT03924999 168 171 O
last NCT03924999 172 176 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
three NCT03924999 177 182 B-Eq-Value
months NCT03924999 183 189 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
. NCT03924999 190 191 O

- NCT03924999 195 196 O
No NCT03924999 198 200 O
pregnancy NCT03924999 201 210 B-Condition-Name
/ NCT03924999 211 212 O
breastfeeding NCT03924999 213 226 B-Condition-Name

Exclusion NCT03924999 227 236 O
Criteria NCT03924999 237 245 O
: NCT03924999 246 247 O

- NCT03924999 251 252 O
History NCT03924999 254 261 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03924999 262 264 O
acute NCT03924999 265 270 B-Severity___Severity-Value:severe
infection NCT03924999 271 280 B-Condition-Name
, NCT03924999 281 282 O
cancer NCT03924999 283 289 B-Condition-Name
, NCT03924999 290 291 O
inflammatory NCT03924999 292 304 O
rheumatic NCT03924999 305 314 O
/ NCT03924999 315 316 O
connective NCT03924999 317 327 O
tissue NCT03924999 328 334 O
diseases NCT03924999 335 343 B-Condition-Name

- NCT03924999 346 347 O
History NCT03924999 349 356 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03924999 357 359 O
cardiovascular NCT03924999 360 374 O
or NCT03924999 375 377 O
musculoskeletal NCT03924999 378 393 O
problems NCT03924999 394 402 B-Condition-Name
that NCT03924999 403 407 O
may NCT03924999 408 411 O
prevent NCT03924999 412 419 O
them NCT03924999 420 424 O
from NCT03924999 425 429 O
participating NCT03924999 430 443 O
in NCT03924999 444 446 O
the NCT03924999 447 450 O
exercise NCT03924999 451 459 B-Procedure-Name
program NCT03924999 460 467 I-Procedure-Name

Inclusion NCT03926156 0 9 O
Criteria NCT03926156 10 18 O
: NCT03926156 19 20 O

1 NCT03926156 25 26 O
. NCT03926156 26 27 O
Provision NCT03926156 29 38 O
of NCT03926156 39 41 O
signed NCT03926156 42 48 O
and NCT03926156 49 52 O
dated NCT03926156 53 58 O
informed NCT03926156 59 67 O
consent NCT03926156 68 75 O
form NCT03926156 76 80 O

2 NCT03926156 84 85 O
. NCT03926156 85 86 O
Stated NCT03926156 88 94 O
willingness NCT03926156 95 106 O
to NCT03926156 107 109 O
comply NCT03926156 110 116 O
with NCT03926156 117 121 O
all NCT03926156 122 125 O
study NCT03926156 126 131 O
procedures NCT03926156 132 142 B-Procedure-Name
and NCT03926156 143 146 O
availability NCT03926156 147 159 O
for NCT03926156 160 163 O
the NCT03926156 164 167 O
duration NCT03926156 168 176 O
of NCT03926156 177 179 O
the NCT03926156 180 183 O
study NCT03926156 184 189 O

3 NCT03926156 193 194 O
. NCT03926156 194 195 O
Men NCT03926156 197 200 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
and NCT03926156 201 204 O
women NCT03926156 205 210 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
≥ NCT03926156 211 212 B-Eq-Operator___Eq-Operator-Value:GTEQ
18 NCT03926156 214 216 B-Eq-Value
year NCT03926156 217 221 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
- NCT03926156 222 223 O
old NCT03926156 224 227 O

4 NCT03926156 231 232 O
. NCT03926156 232 233 O
Diagnosed NCT03926156 235 244 O
with NCT03926156 245 249 O
moderate NCT03926156 250 258 B-Severity___Severity-Value:moderate
to NCT03926156 259 261 B-Eq-Operator___Eq-Operator-Value:BETWEEN
severe NCT03926156 262 268 B-Severity___Severity-Value:severe
mitral NCT03926156 269 275 B-Condition-Name
stenosis NCT03926156 276 284 I-Condition-Name
who NCT03926156 285 288 O
have NCT03926156 289 293 O
a NCT03926156 294 295 O
history NCT03926156 296 303 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03926156 304 306 O
AF NCT03926156 307 309 B-Condition-Name
of NCT03926156 310 312 O
any NCT03926156 313 316 O
duration NCT03926156 317 325 O
documented NCT03926156 326 336 O
by NCT03926156 337 339 O
any NCT03926156 340 343 O
electrical NCT03926156 344 354 B-Procedure-Name
tracing NCT03926156 355 362 I-Procedure-Name
within NCT03926156 363 369 O
the NCT03926156 370 373 O
prior NCT03926156 374 379 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
12 NCT03926156 381 383 B-Eq-Value
months NCT03926156 384 390 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
and NCT03926156 391 394 O
for NCT03926156 395 398 O
which NCT03926156 399 404 O
anticoagulation NCT03926156 405 420 B-Procedure-Name
is NCT03926156 421 423 O
indicated NCT03926156 424 433 O
and NCT03926156 434 437 O
planned NCT03926156 438 445 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
for NCT03926156 446 449 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
the NCT03926156 450 453 O
duration NCT03926156 454 462 O
of NCT03926156 463 465 O
the NCT03926156 466 469 O
study NCT03926156 470 475 O
. NCT03926156 476 477 O

5 NCT03926156 482 483 O
. NCT03926156 483 484 O
Ability NCT03926156 486 493 O
to NCT03926156 494 496 O
take NCT03926156 497 501 O
oral NCT03926156 502 506 B-Procedure-Name
medication NCT03926156 507 517 I-Procedure-Name
and NCT03926156 518 521 O
be NCT03926156 522 524 O
willing NCT03926156 525 532 O
to NCT03926156 533 535 O
adhere NCT03926156 536 542 O
to NCT03926156 543 545 O
the NCT03926156 546 549 O
rivaroxaban NCT03926156 550 561 B-Drug-Name
regimen NCT03926156 562 569 O

Exclusion NCT03926156 570 579 O
Criteria NCT03926156 580 588 O
: NCT03926156 589 590 O

1 NCT03926156 595 596 O
. NCT03926156 596 597 O
Left NCT03926156 599 603 O
atrial NCT03926156 604 610 O
clot NCT03926156 611 615 B-Condition-Name

2 NCT03926156 619 620 O
. NCT03926156 620 621 O
Severe NCT03926156 623 629 B-Severity___Severity-Value:severe
renal NCT03926156 630 635 B-Condition-Name
dysfunction NCT03926156 636 647 I-Condition-Name
( NCT03926156 648 649 O
creatinine NCT03926156 650 660 B-Observation-Name___Observation-Type-Value:lab
clearance NCT03926156 661 670 I-Observation-Name___Observation-Type-Value:lab
[ NCT03926156 671 672 O
CrCl NCT03926156 673 677 B-Observation-Name
] NCT03926156 678 679 O
< NCT03926156 680 681 B-Eq-Operator___Eq-Operator-Value:LT
15 NCT03926156 683 685 B-Eq-Value
mL NCT03926156 686 688 B-Eq-Unit
/ NCT03926156 689 690 O
min NCT03926156 691 694 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:minute
) NCT03926156 695 696 O
, NCT03926156 698 699 O
subjects NCT03926156 700 708 O
with NCT03926156 709 713 O

3 NCT03926156 717 718 O
. NCT03926156 718 719 O
A NCT03926156 721 722 O
condition NCT03926156 723 732 O
associated NCT03926156 733 743 O
with NCT03926156 744 748 O
a NCT03926156 749 750 O
high NCT03926156 751 755 B-Polarity___Polarity-Value:high
risk NCT03926156 756 760 O
of NCT03926156 761 763 O
bleeding NCT03926156 764 772 B-Condition-Name

4 NCT03926156 776 777 O
. NCT03926156 777 778 O
Allergic NCT03926156 780 788 O
to NCT03926156 789 791 O
rivaroxabn NCT03926156 792 802 B-Drug-Name
/ NCT03926156 803 804 O
warfarin NCT03926156 805 813 B-Drug-Name

Inclusion NCT03920527 0 9 O
Criteria NCT03920527 10 18 O
: NCT03920527 19 20 O
includes NCT03920527 21 29 O
presence NCT03920527 30 38 O
of NCT03920527 39 41 O
all NCT03920527 42 45 O
the NCT03920527 46 49 O
following NCT03920527 50 59 O
: NCT03920527 60 61 O

- NCT03920527 65 66 O
one NCT03920527 68 71 B-Eq-Value
or NCT03920527 72 74 B-Eq-Operator___Eq-Operator-Value:GTEQ
more NCT03920527 75 79 I-Eq-Operator___Eq-Operator-Value:GTEQ
clinical NCT03920527 80 88 O
symptoms NCT03920527 89 97 O
( NCT03920527 98 99 O
persistent NCT03920527 100 110 O
cough NCT03920527 111 116 B-Condition-Name
, NCT03920527 117 118 O
recurrent NCT03920527 119 128 O
hemoptysis NCT03920527 129 139 B-Condition-Name
, NCT03920527 140 141 O
weight NCT03920527 142 148 B-Condition-Name
loss NCT03920527 149 153 I-Condition-Name
, NCT03920527 154 155 O
malaise NCT03920527 156 163 B-Condition-Name
, NCT03920527 164 165 O
fever NCT03920527 166 171 B-Condition-Name
and NCT03920527 172 175 O
dyspnea NCT03920527 176 183 B-Condition-Name
) NCT03920527 184 185 O
for NCT03920527 186 189 O
≥ NCT03920527 190 191 B-Eq-Operator___Eq-Operator-Value:GTEQ
3 NCT03920527 193 194 B-Eq-Value
months NCT03920527 195 201 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

- NCT03920527 204 205 O
slowly NCT03920527 207 213 O
progressive NCT03920527 214 225 O
or NCT03920527 226 228 O
persistent NCT03920527 229 239 O
radiological NCT03920527 240 252 B-Procedure-Name
findings NCT03920527 253 261 O
( NCT03920527 262 263 O
one NCT03920527 264 267 B-Eq-Value
or NCT03920527 268 270 B-Eq-Operator___Eq-Operator-Value:GTEQ
more NCT03920527 271 275 I-Eq-Operator___Eq-Operator-Value:GTEQ
cavities NCT03920527 276 284 B-Condition-Name
and NCT03920527 285 288 O
surrounding NCT03920527 289 300 O
fibrosis NCT03920527 301 309 B-Condition-Name
, NCT03920527 310 311 O
infiltrates NCT03920527 312 323 B-Condition-Name
, NCT03920527 324 325 O
consolidation NCT03920527 326 339 B-Condition-Name
, NCT03920527 340 341 O
with NCT03920527 342 346 O
or NCT03920527 347 349 O
without NCT03920527 350 357 O
fungal NCT03920527 358 364 B-Condition-Name
ball NCT03920527 365 369 I-Condition-Name
or NCT03920527 370 372 O
progressive NCT03920527 373 384 O
pleural NCT03920527 385 392 B-Condition-Name
thickening NCT03920527 393 403 I-Condition-Name
) NCT03920527 404 405 O
on NCT03920527 406 408 O
computed NCT03920527 409 417 B-Procedure-Name
tomography NCT03920527 418 428 I-Procedure-Name
( NCT03920527 429 430 O
CT NCT03920527 431 433 B-Procedure-Name
) NCT03920527 434 435 O
of NCT03920527 436 438 O
the NCT03920527 439 442 O
thorax NCT03920527 443 449 O

- NCT03920527 452 453 O
immunological NCT03920527 455 468 O
( NCT03920527 469 470 O
A NCT03920527 471 472 B-Organism-Name
. NCT03920527 473 474 I-Organism-Name
fumigatus NCT03920527 475 484 I-Organism-Name
- NCT03920527 485 486 O
specific NCT03920527 487 495 O
IgG NCT03920527 496 499 B-Observation-Name___Observation-Type-Value:lab
> NCT03920527 500 501 B-Eq-Operator___Eq-Operator-Value:GT
27 NCT03920527 503 505 B-Eq-Value
mgA NCT03920527 506 509 B-Eq-Unit
/ NCT03920527 510 511 O
L NCT03920527 512 513 B-Eq-Unit
or NCT03920527 514 516 O
positive NCT03920527 517 525 B-Polarity___Polarity-Value:positive
Aspergillus NCT03920527 526 537 B-Organism-Name
precipitins NCT03920527 538 549 I-Organism-Name
) NCT03920527 550 551 O
or NCT03920527 552 554 O
microbiological NCT03920527 555 570 B-Observation-Name___Observation-Type-Value:lab
evidence NCT03920527 571 579 O
of NCT03920527 580 582 O
Aspergillus NCT03920527 583 594 O
infection NCT03920527 595 604 B-Condition-Name
( NCT03920527 605 606 O
growth NCT03920527 607 613 O
of NCT03920527 614 616 O
Aspergillus NCT03920527 617 628 B-Organism-Name
in NCT03920527 629 631 O
respiratory NCT03920527 632 643 B-Observation-Specimen
secretions NCT03920527 644 654 I-Observation-Specimen
or NCT03920527 655 657 O
serum NCT03920527 658 663 B-Observation-Name___Observation-Type-Value:lab
galactomannan NCT03920527 664 677 I-Observation-Name___Observation-Type-Value:lab
index NCT03920527 678 683 I-Observation-Name___Observation-Type-Value:lab
> NCT03920527 684 685 B-Eq-Operator___Eq-Operator-Value:GT
0.5 NCT03920527 687 690 B-Eq-Value
or NCT03920527 691 693 O
BALF NCT03920527 694 698 B-Observation-Name___Observation-Type-Value:lab
galactomannan NCT03920527 699 712 I-Observation-Name___Observation-Type-Value:lab
index NCT03920527 713 718 I-Observation-Name___Observation-Type-Value:lab
> NCT03920527 719 720 B-Eq-Operator___Eq-Operator-Value:GT
1 NCT03920527 722 723 B-Eq-Value
) NCT03920527 724 725 O
and NCT03920527 726 729 O
, NCT03920527 730 731 O

- NCT03920527 735 736 O
exclusion NCT03920527 738 747 O
of NCT03920527 748 750 O
other NCT03920527 751 756 O
pulmonary NCT03920527 757 766 O
disorders NCT03920527 767 776 B-Condition-Name
with NCT03920527 777 781 O
similar NCT03920527 782 789 O
presentation NCT03920527 790 802 O
. NCT03920527 803 804 O

Exclusion NCT03920527 806 815 O
Criteria NCT03920527 816 824 O
: NCT03920527 825 826 O

- NCT03920527 830 831 O
failure NCT03920527 833 840 O
to NCT03920527 841 843 O
provide NCT03920527 844 851 O
informed NCT03920527 852 860 O
consent NCT03920527 861 868 O

- NCT03920527 871 872 O
patients NCT03920527 874 882 O
on NCT03920527 883 885 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
immunosuppressive NCT03920527 886 903 B-Drug-Name
drugs NCT03920527 904 909 I-Drug-Name
, NCT03920527 910 911 O
intake NCT03920527 912 918 O
of NCT03920527 919 921 O
prednisolone NCT03920527 922 934 B-Drug-Name
( NCT03920527 935 936 O
or NCT03920527 937 939 O
equivalent NCT03920527 940 950 O
) NCT03920527 951 952 O
> NCT03920527 953 954 B-Eq-Operator___Eq-Operator-Value:GT
10 NCT03920527 956 958 B-Eq-Value
mg NCT03920527 959 961 B-Eq-Unit
for NCT03920527 962 965 O
at NCT03920527 966 968 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03920527 969 974 I-Eq-Operator___Eq-Operator-Value:GTEQ
3 NCT03920527 976 977 B-Eq-Value
weeks NCT03920527 978 983 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
or NCT03920527 984 986 O
a NCT03920527 987 988 O
diagnosis NCT03920527 989 998 O
of NCT03920527 999 1001 O
human NCT03920527 1002 1007 B-Condition-Name
immunodeficiency NCT03920527 1008 1024 I-Condition-Name
virus NCT03920527 1025 1030 I-Condition-Name
syndrome NCT03920527 1031 1039 I-Condition-Name

- NCT03920527 1042 1043 O
intake NCT03920527 1045 1051 O
antifungal NCT03920527 1052 1062 B-Drug-Name
azoles NCT03920527 1063 1069 I-Drug-Name
for NCT03920527 1070 1073 O
> NCT03920527 1074 1075 B-Eq-Operator___Eq-Operator-Value:GT
3 NCT03920527 1077 1078 B-Eq-Value
weeks NCT03920527 1079 1084 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
in NCT03920527 1085 1087 O
the NCT03920527 1088 1091 O
preceding NCT03920527 1092 1101 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
six NCT03920527 1102 1105 B-Eq-Value
months NCT03920527 1106 1112 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

- NCT03920527 1115 1116 O
subjects NCT03920527 1118 1126 O
with NCT03920527 1127 1131 O
active NCT03920527 1132 1138 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
pulmonary NCT03920527 1139 1148 O
infection NCT03920527 1149 1158 B-Condition-Name
due NCT03920527 1159 1162 O
to NCT03920527 1163 1165 O
mycobacterium NCT03920527 1166 1179 B-Organism-Name
tuberculosis NCT03920527 1180 1192 I-Organism-Name
or NCT03920527 1193 1195 O
mycobacteria NCT03920527 1196 1208 B-Organism-Name
other NCT03920527 1209 1214 O
than NCT03920527 1215 1219 O
tuberculosis NCT03920527 1220 1232 B-Condition-Name
( NCT03920527 1233 1234 O
MOTT NCT03920527 1235 1239 B-Condition-Name
) NCT03920527 1240 1241 O

- NCT03920527 1245 1246 O
subjects NCT03920527 1248 1256 O
with NCT03920527 1257 1261 O
others NCT03920527 1262 1268 O
forms NCT03920527 1269 1274 O
of NCT03920527 1275 1277 O
pulmonary NCT03920527 1278 1287 O
aspergillosis NCT03920527 1288 1301 B-Condition-Name
( NCT03920527 1302 1303 O
allergic NCT03920527 1304 1312 O
bronchopulmonary NCT03920527 1313 1329 O
aspergillosis NCT03920527 1330 1343 B-Condition-Name
, NCT03920527 1344 1345 O
chronic NCT03920527 1346 1353 O
necrotizing NCT03920527 1354 1365 O
aspergillosis NCT03920527 1366 1379 B-Condition-Name
and NCT03920527 1380 1383 O
angio NCT03920527 1384 1389 O
- NCT03920527 1390 1391 O
invasive NCT03920527 1392 1400 O
aspergillosis NCT03920527 1401 1414 B-Condition-Name
) NCT03920527 1415 1416 O

- NCT03920527 1420 1421 O
pregnancy NCT03920527 1423 1432 B-Condition-Name

Inclusion NCT03920241 0 9 O
Criteria NCT03920241 10 18 O
: NCT03920241 19 20 O

- NCT03920241 24 25 O
18 NCT03920241 28 30 B-Eq-Value
years NCT03920241 31 36 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03920241 37 39 O
age NCT03920241 40 43 O
or NCT03920241 44 46 B-Eq-Operator___Eq-Operator-Value:GTEQ
more NCT03920241 47 51 I-Eq-Operator___Eq-Operator-Value:GTEQ

- NCT03920241 54 55 O
Fluency NCT03920241 57 64 O
in NCT03920241 65 67 O
oral NCT03920241 68 72 O
and NCT03920241 73 76 O
written NCT03920241 77 84 O
Spanish NCT03920241 85 92 B-Language

Exclusion NCT03920241 93 102 O
Criteria NCT03920241 103 111 O
: NCT03920241 112 113 O

- NCT03920241 117 118 O
Having NCT03920241 120 126 O
any NCT03920241 127 130 O
current NCT03920241 131 138 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
of NCT03920241 139 141 O
serious NCT03920241 142 149 B-Severity___Severity-Value:severe
psychological NCT03920241 150 163 B-Condition-Name
disorder NCT03920241 164 172 I-Condition-Name
or NCT03920241 173 175 O
substance NCT03920241 176 185 B-Condition-Name
abuse NCT03920241 186 191 O
/ NCT03920241 192 193 O
dependence NCT03920241 194 204 O
. NCT03920241 205 206 O

- NCT03920241 210 211 O
Being NCT03920241 213 218 O
currently NCT03920241 219 228 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
enrolled NCT03920241 229 237 O
in NCT03920241 238 240 O
another NCT03920241 241 248 O
standardized NCT03920241 249 261 O
meditation NCT03920241 262 272 B-Procedure-Name
program NCT03920241 273 280 I-Procedure-Name

Inclusion NCT03927274 0 9 O
Criteria NCT03927274 10 18 O
: NCT03927274 19 20 O

- NCT03927274 24 25 O
Histologically NCT03927274 27 41 B-Procedure-Name
confirmed NCT03927274 42 51 O
diagnosis NCT03927274 52 61 O
of NCT03927274 62 64 O
supratentorial NCT03927274 65 79 O
WHO NCT03927274 80 83 O
Grade NCT03927274 84 89 B-Eq-Unit
III NCT03927274 90 93 B-Eq-Value
or NCT03927274 94 96 O
IV NCT03927274 97 99 B-Eq-Value
Glioma NCT03927274 100 106 B-Condition-Name
( NCT03927274 107 108 O
High NCT03927274 109 113 O
Grade NCT03927274 114 119 O
Glioma NCT03927274 120 126 B-Condition-Name
) NCT03927274 127 128 O
that NCT03927274 129 133 O
has NCT03927274 134 137 O
undergone NCT03927274 138 147 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
surgical NCT03927274 148 156 B-Procedure-Name
biopsy NCT03927274 157 163 I-Procedure-Name
or NCT03927274 164 166 O
resection NCT03927274 167 176 B-Procedure-Name
followed NCT03927274 177 185 O
by NCT03927274 186 188 O
adjuvant NCT03927274 189 197 B-Procedure-Name
chemoradiotherapy NCT03927274 198 215 I-Procedure-Name
, NCT03927274 216 217 O
that NCT03927274 218 222 O
has NCT03927274 223 226 O
evidence NCT03927274 227 235 O
of NCT03927274 236 238 O
recurrence NCT03927274 239 249 O
or NCT03927274 250 252 O
progression NCT03927274 253 264 O
based NCT03927274 265 270 O
on NCT03927274 271 273 O
imaging NCT03927274 274 281 B-Procedure-Name
studies NCT03927274 282 289 O
and NCT03927274 290 293 O
a NCT03927274 294 295 O
stereotactic NCT03927274 296 308 O
biopsy NCT03927274 309 315 B-Procedure-Name
is NCT03927274 316 318 O
indicated NCT03927274 319 328 O
for NCT03927274 329 332 O
confirmation NCT03927274 333 345 O
of NCT03927274 346 348 O
recurrence NCT03927274 349 359 O
/ NCT03927274 360 361 O
progression NCT03927274 362 373 O
. NCT03927274 374 375 O

- NCT03927274 379 380 O
18 NCT03927274 383 385 B-Eq-Value
years NCT03927274 386 391 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03927274 392 394 O
age NCT03927274 395 398 O
or NCT03927274 399 401 B-Eq-Operator___Eq-Operator-Value:GTEQ
older NCT03927274 402 407 I-Eq-Operator___Eq-Operator-Value:GTEQ

- NCT03927274 410 411 O
Karnofsky NCT03927274 413 422 B-Observation-Name___Observation-Type-Value:clinical-score
Performance NCT03927274 423 434 I-Observation-Name___Observation-Type-Value:clinical-score
Status NCT03927274 435 441 I-Observation-Name___Observation-Type-Value:clinical-score
70 NCT03927274 443 445 B-Eq-Value
- NCT03927274 446 447 B-Eq-Operator___Eq-Operator-Value:BETWEEN
100 NCT03927274 449 452 B-Eq-Value
; NCT03927274 453 454 O

- NCT03927274 457 458 O
MRI NCT03927274 460 463 B-Procedure-Name
demonstration NCT03927274 464 477 O
of NCT03927274 478 480 O
a NCT03927274 481 482 O
stereotactically NCT03927274 483 499 O
accessible NCT03927274 500 510 O
enhancing NCT03927274 511 520 O
or NCT03927274 521 523 O
predominantly NCT03927274 524 537 O
non NCT03927274 538 541 O
- NCT03927274 542 543 O
enhancing NCT03927274 544 553 O
mass NCT03927274 554 558 B-Condition-Name
that NCT03927274 559 563 O
does NCT03927274 564 568 O
not NCT03927274 569 572 O
require NCT03927274 573 580 O
resection NCT03927274 581 590 B-Procedure-Name
to NCT03927274 591 593 O
relieve NCT03927274 594 601 O
clinically NCT03927274 602 612 O
significant NCT03927274 613 624 B-Severity___Severity-Value:severe
mass NCT03927274 625 629 B-Condition-Name
effect NCT03927274 630 636 I-Condition-Name
; NCT03927274 636 637 O

- NCT03927274 640 641 O
Participant NCT03927274 643 654 O
understands NCT03927274 655 666 O
the NCT03927274 667 670 O
procedures NCT03927274 671 681 O
and NCT03927274 682 685 O
agrees NCT03927274 686 692 O
to NCT03927274 693 695 O
comply NCT03927274 696 702 O
with NCT03927274 703 707 O
the NCT03927274 708 711 O
study NCT03927274 712 717 O
requirements NCT03927274 718 730 O
by NCT03927274 731 733 O
providing NCT03927274 734 743 O
written NCT03927274 744 751 O
informed NCT03927274 752 760 O
consent NCT03927274 761 768 O

- NCT03927274 771 772 O
Adequate NCT03927274 774 782 B-Polarity___Polarity-Value:normal
organ NCT03927274 783 788 B-Condition-Name
function NCT03927274 789 797 I-Condition-Name
as NCT03927274 798 800 O
indicated NCT03927274 801 810 O
in NCT03927274 811 813 O
protocol NCT03927274 814 822 O

Exclusion NCT03927274 823 832 O
Criteria NCT03927274 833 841 O
: NCT03927274 842 843 O

- NCT03927274 847 848 O
Participant NCT03927274 850 861 O
is NCT03927274 862 864 O
mentally NCT03927274 865 873 O
or NCT03927274 874 876 O
legally NCT03927274 877 884 O
incapacitated NCT03927274 885 898 B-Condition-Name
at NCT03927274 899 901 O
the NCT03927274 902 905 O
time NCT03927274 906 910 O
of NCT03927274 911 913 O
the NCT03927274 914 917 O
study NCT03927274 918 923 O
; NCT03927274 923 924 O

- NCT03927274 927 928 O
Known NCT03927274 930 935 O
HIV NCT03927274 936 939 B-Condition-Name
( NCT03927274 940 941 B-Polarity___Polarity-Value:positive
+ NCT03927274 943 944 I-Polarity___Polarity-Value:positive
) NCT03927274 946 947 I-Polarity___Polarity-Value:positive
or NCT03927274 948 950 O
has NCT03927274 951 954 O
been NCT03927274 955 959 O
diagnosed NCT03927274 960 969 O
with NCT03927274 970 974 O
AIDS NCT03927274 975 979 B-Condition-Name

- NCT03927274 982 983 O
Participation NCT03927274 985 998 O
in NCT03927274 999 1001 O
another NCT03927274 1002 1009 O
investigational NCT03927274 1010 1025 O
drug NCT03927274 1026 1030 O
study NCT03927274 1031 1036 O
in NCT03927274 1037 1039 O
the NCT03927274 1040 1043 O
prior NCT03927274 1044 1049 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
4 NCT03927274 1051 1052 B-Eq-Value
weeks NCT03927274 1053 1058 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week

- NCT03927274 1061 1062 O
Positive NCT03927274 1064 1072 B-Polarity___Polarity-Value:positive
pregnancy NCT03927274 1073 1082 B-Observation-Name
test NCT03927274 1083 1087 I-Observation-Name
in NCT03927274 1088 1090 O
a NCT03927274 1091 1092 O
female NCT03927274 1093 1099 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female

- NCT03927274 1102 1103 O
Patient NCT03927274 1105 1112 O
, NCT03927274 1113 1114 O
in NCT03927274 1115 1117 O
the NCT03927274 1118 1121 O
opinion NCT03927274 1122 1129 O
of NCT03927274 1130 1132 O
the NCT03927274 1133 1136 O
investigator NCT03927274 1137 1149 O
, NCT03927274 1150 1151 O
is NCT03927274 1152 1154 O
likely NCT03927274 1155 1161 O
to NCT03927274 1162 1164 O
be NCT03927274 1165 1167 O
poorly NCT03927274 1168 1174 O
compliant NCT03927274 1175 1184 O
. NCT03927274 1185 1186 O

- NCT03927274 1190 1191 O
Diffuse NCT03927274 1193 1200 B-Condition-Name
subependymal NCT03927274 1201 1213 I-Condition-Name
or NCT03927274 1214 1216 O
Cerebral NCT03927274 1217 1225 O
Spinal NCT03927274 1226 1232 O
Fluid NCT03927274 1233 1238 O
( NCT03927274 1239 1240 O
CSF NCT03927274 1241 1244 B-Condition-Name
) NCT03927274 1245 1246 O
disease NCT03927274 1247 1254 B-Condition-Name

- NCT03927274 1257 1258 O
Tumors NCT03927274 1260 1266 B-Condition-Name
involving NCT03927274 1267 1276 O
the NCT03927274 1277 1280 O
cerebellum NCT03927274 1281 1291 O

- NCT03927274 1294 1295 O
Tumor NCT03927274 1297 1302 B-Condition-Name
enhancement NCT03927274 1303 1314 O
involving NCT03927274 1315 1324 O
both NCT03927274 1325 1329 O
hemispheres NCT03927274 1330 1341 O

- NCT03927274 1344 1345 O
Active NCT03927274 1347 1353 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
infection NCT03927274 1354 1363 B-Condition-Name
requiring NCT03927274 1364 1373 O
treatment NCT03927274 1374 1383 O

- NCT03927274 1386 1387 O
Unexplained NCT03927274 1389 1400 O
febrile NCT03927274 1401 1408 B-Condition-Name
illness NCT03927274 1409 1416 I-Condition-Name

- NCT03927274 1419 1420 O
Radiation NCT03927274 1422 1431 B-Procedure-Name
or NCT03927274 1432 1434 O
chemotherapy NCT03927274 1435 1447 B-Procedure-Name
within NCT03927274 1448 1454 B-Eq-Operator___Eq-Operator-Value:LTEQ
4 NCT03927274 1456 1457 B-Eq-Value
weeks NCT03927274 1458 1463 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
of NCT03927274 1464 1466 O
enrollment NCT03927274 1467 1477 O

- NCT03927274 1480 1481 O
Systemic NCT03927274 1483 1491 O
diseases NCT03927274 1492 1500 B-Condition-Name
associated NCT03927274 1501 1511 O
with NCT03927274 1512 1516 O
unacceptable NCT03927274 1517 1529 O
anesthesia NCT03927274 1530 1540 B-Procedure-Name
or NCT03927274 1541 1543 O
operative NCT03927274 1544 1553 B-Procedure-Name
risk NCT03927274 1554 1558 O

- NCT03927274 1561 1562 O
Inability NCT03927274 1564 1573 O
to NCT03927274 1574 1576 O
undergo NCT03927274 1577 1584 O
magnetic NCT03927274 1585 1593 B-Procedure-Name
resonance NCT03927274 1594 1603 I-Procedure-Name
imaging NCT03927274 1604 1611 I-Procedure-Name
( NCT03927274 1612 1613 O
MRI NCT03927274 1614 1617 B-Procedure-Name
) NCT03927274 1618 1619 O

Inclusion NCT03921177 0 9 O
Criteria NCT03921177 10 18 O
: NCT03921177 19 20 O

- NCT03921177 24 25 O
Resident NCT03921177 27 35 O
of NCT03921177 36 38 O
566 NCT03921177 40 43 O
rural NCT03921177 44 49 O
sectors NCT03921177 50 57 O
( NCT03921177 58 59 O
clusters NCT03921177 60 68 O
) NCT03921177 69 70 O
in NCT03921177 71 73 O
Gaibandha NCT03921177 74 83 B-Location___Location-Value:residence
district NCT03921177 84 92 I-Location___Location-Value:residence

- NCT03921177 95 96 O
Recently NCT03921177 98 106 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:recent
- NCT03921177 107 108 O
married NCT03921177 109 116 B-Condition-Name
woman NCT03921177 117 122 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female

- NCT03921177 125 126 O
Nulligravid NCT03921177 128 139 B-Condition-Name

Exclusion NCT03921177 140 149 O
Criteria NCT03921177 150 158 O
: NCT03921177 159 160 O

- NCT03921177 164 165 O
Women NCT03921177 167 172 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
with NCT03921177 173 177 O
a NCT03921177 178 179 O
history NCT03921177 180 187 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03921177 188 190 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
previous NCT03921177 191 199 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
pregnancy NCT03921177 200 209 B-Condition-Name

- NCT03921177 212 213 O
Women NCT03921177 215 220 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
who NCT03921177 221 224 O
refuse NCT03921177 225 231 O
consent NCT03921177 232 239 O
for NCT03921177 240 243 O
participation NCT03921177 244 257 O

Inclusion NCT03925311 0 9 O
Criteria NCT03925311 10 18 O
: NCT03925311 19 20 O

Age NCT03925311 22 25 O
20 NCT03925311 27 29 B-Eq-Value
- NCT03925311 30 31 B-Eq-Operator___Eq-Operator-Value:BETWEEN
40 NCT03925311 33 35 B-Eq-Value
years NCT03925311 36 41 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
. NCT03925311 42 43 O

Exclusion NCT03925311 45 54 O
Criteria NCT03925311 55 63 O
: NCT03925311 64 65 O

- NCT03925311 69 70 O
Uncorrected NCT03925311 72 83 O
uterine NCT03925311 84 91 O
anomalies NCT03925311 92 101 B-Condition-Name
, NCT03925311 102 103 O
such NCT03925311 104 108 O
as NCT03925311 109 111 O
septate NCT03925311 112 119 O
or NCT03925311 120 122 O
bicornuate NCT03925311 123 133 O
uterus NCT03925311 134 140 B-Condition-Name
, NCT03925311 141 142 O
fibroids NCT03925311 143 151 B-Condition-Name
( NCT03925311 152 153 O
submucous NCT03925311 154 163 O
/ NCT03925311 164 165 O
intramural NCT03925311 166 176 O
) NCT03925311 177 178 O
. NCT03925311 180 181 O

- NCT03925311 185 186 O
Intrauterine NCT03925311 188 200 B-Condition-Name
adhesions NCT03925311 201 210 I-Condition-Name
. NCT03925311 211 212 O

- NCT03925311 216 217 O
Adenomyosis NCT03925311 219 230 B-Condition-Name
. NCT03925311 231 232 O

Key NCT03926195 0 3 O
Inclusion NCT03926195 4 13 O
Criteria NCT03926195 14 22 O
: NCT03926195 23 24 O

- NCT03926195 28 29 O
Male NCT03926195 31 35 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
participants NCT03926195 36 48 O
who NCT03926195 49 52 O
are NCT03926195 53 56 O
between NCT03926195 57 64 B-Eq-Operator___Eq-Operator-Value:BETWEEN
the NCT03926195 65 68 O
ages NCT03926195 69 73 O
of NCT03926195 74 76 O
21 NCT03926195 78 80 B-Eq-Value
and NCT03926195 81 84 O
65 NCT03926195 86 88 B-Eq-Value
years NCT03926195 89 94 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
( NCT03926195 95 96 O
inclusive NCT03926195 97 106 O
) NCT03926195 107 108 O
on NCT03926195 109 111 O
the NCT03926195 112 115 O
day NCT03926195 116 119 O
of NCT03926195 120 122 O
signing NCT03926195 123 130 O
informed NCT03926195 131 139 O
consent NCT03926195 140 147 O

- NCT03926195 150 151 O
Diagnosis NCT03926195 153 162 O
of NCT03926195 163 165 O
active NCT03926195 166 172 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
rheumatoid NCT03926195 173 183 B-Condition-Name
arthritis NCT03926195 184 193 I-Condition-Name
, NCT03926195 194 195 O
psoriatic NCT03926195 196 205 B-Condition-Name
arthritis NCT03926195 206 215 I-Condition-Name
, NCT03926195 216 217 O
ankylosing NCT03926195 218 228 B-Condition-Name
spondylitis NCT03926195 229 240 I-Condition-Name
or NCT03926195 241 243 O
, NCT03926195 244 245 O
non NCT03926195 246 249 O
- NCT03926195 250 251 O
radiographic NCT03926195 252 264 O
axial NCT03926195 265 270 B-Condition-Name
spondyloarthritis NCT03926195 271 288 I-Condition-Name
for NCT03926195 289 292 O
at NCT03926195 293 295 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03926195 296 301 I-Eq-Operator___Eq-Operator-Value:GTEQ
12 NCT03926195 303 305 B-Eq-Value
weeks NCT03926195 306 311 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
prior NCT03926195 312 317 O
to NCT03926195 318 320 O
screening NCT03926195 321 330 O
, NCT03926195 331 332 O
meeting NCT03926195 333 340 O
the NCT03926195 341 344 O
corresponding NCT03926195 345 358 O
specific NCT03926195 359 367 O
disease NCT03926195 368 375 O
classification NCT03926195 376 390 O
criteria NCT03926195 391 399 O
as NCT03926195 400 402 O
specified NCT03926195 403 412 O
in NCT03926195 413 415 O
the NCT03926195 416 419 O
protocol NCT03926195 420 428 O

Key NCT03926195 429 432 O
Exclusion NCT03926195 433 442 O
Criteria NCT03926195 443 451 O
: NCT03926195 452 453 O

- NCT03926195 457 458 O
Previously NCT03926195 460 470 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
documented NCT03926195 471 481 O
problems NCT03926195 482 490 B-Condition-Name
with NCT03926195 491 495 I-Condition-Name
male NCT03926195 496 500 I-Condition-Name
reproductive NCT03926195 501 513 I-Condition-Name
health NCT03926195 514 520 I-Condition-Name

- NCT03926195 523 524 O
Prior NCT03926195 526 531 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
diagnosis NCT03926195 532 541 O
of NCT03926195 542 544 O
male NCT03926195 545 549 B-Condition-Name
infertility NCT03926195 550 561 I-Condition-Name

- NCT03926195 564 565 O
Use NCT03926195 567 570 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
of NCT03926195 571 573 O
any NCT03926195 574 577 O
prohibited NCT03926195 578 588 O
concomitant NCT03926195 589 600 O
medication NCT03926195 601 611 O
as NCT03926195 612 614 O
outlined NCT03926195 615 623 O
by NCT03926195 624 626 O
protocol NCT03926195 627 635 O

Note NCT03926195 636 640 O
: NCT03926195 641 642 O
Other NCT03926195 643 648 O
protocol NCT03926195 649 657 O
- NCT03926195 658 659 O
defined NCT03926195 660 667 O
Inclusion NCT03926195 668 677 O
/ NCT03926195 678 679 O
Exclusion NCT03926195 680 689 O
criteria NCT03926195 690 698 O
may NCT03926195 699 702 O
apply NCT03926195 703 708 O
. NCT03926195 709 710 O

Inclusion NCT03928379 0 9 O
Criteria NCT03928379 10 18 O
: NCT03928379 19 20 O

- NCT03928379 24 25 O
Have NCT03928379 27 31 O
Type NCT03928379 32 36 B-Condition-Name
II NCT03928379 37 39 I-Condition-Name
diabetes NCT03928379 40 48 I-Condition-Name

- NCT03928379 51 52 O
Body NCT03928379 54 58 B-Observation-Name___Observation-Type-Value:vital
mass NCT03928379 59 63 I-Observation-Name___Observation-Type-Value:vital
index NCT03928379 64 69 I-Observation-Name___Observation-Type-Value:vital
( NCT03928379 70 71 O
BMI NCT03928379 72 75 B-Observation-Name___Observation-Type-Value:vital
) NCT03928379 76 77 O
of NCT03928379 78 80 O
25 NCT03928379 82 84 B-Eq-Value
- NCT03928379 85 86 B-Eq-Operator___Eq-Operator-Value:BETWEEN
40 NCT03928379 88 90 B-Eq-Value
kilograms NCT03928379 91 100 B-Eq-Unit
per NCT03928379 101 104 O
square NCT03928379 105 111 B-Eq-Unit
meter NCT03928379 112 117 I-Eq-Unit
( NCT03928379 118 119 O
kg NCT03928379 120 122 B-Eq-Unit
/ NCT03928379 123 124 O
m² NCT03928379 125 127 B-Eq-Unit
) NCT03928379 128 129 O
, NCT03928379 131 132 O
inclusive NCT03928379 133 142 O

- NCT03928379 145 146 O
Have NCT03928379 148 152 O
a NCT03928379 153 154 O
body NCT03928379 155 159 B-Observation-Name___Observation-Type-Value:vital
weight NCT03928379 160 166 I-Observation-Name___Observation-Type-Value:vital
of NCT03928379 167 169 O
< NCT03928379 170 171 B-Eq-Operator___Eq-Operator-Value:LT
150 NCT03928379 173 176 B-Eq-Value
kilograms NCT03928379 177 186 B-Eq-Unit
( NCT03928379 187 188 O
kg NCT03928379 189 191 B-Eq-Unit
) NCT03928379 192 193 O

- NCT03928379 197 198 O
Have NCT03928379 200 204 O
clinical NCT03928379 205 213 O
lab NCT03928379 214 217 B-Observation-Name___Observation-Type-Value:lab
test NCT03928379 218 222 I-Observation-Name___Observation-Type-Value:lab
results NCT03928379 223 230 O
within NCT03928379 231 237 B-Eq-Operator___Eq-Operator-Value:LTEQ
normal NCT03928379 238 244 B-Eq-Unit___Eq-Unit-Value:ref-range-normal
reference NCT03928379 245 254 I-Eq-Unit___Eq-Unit-Value:ref-range-normal
range NCT03928379 255 260 I-Eq-Unit___Eq-Unit-Value:ref-range-normal
for NCT03928379 261 264 O
the NCT03928379 265 268 O
population NCT03928379 269 279 O
or NCT03928379 280 282 O
investigator NCT03928379 283 295 O
site NCT03928379 296 300 O
, NCT03928379 301 302 O
or NCT03928379 303 305 O
results NCT03928379 306 313 O
with NCT03928379 314 318 O
acceptable NCT03928379 319 329 O
deviations NCT03928379 330 340 O
that NCT03928379 341 345 O
are NCT03928379 346 349 O
judged NCT03928379 350 356 O
to NCT03928379 357 359 O
be NCT03928379 360 362 O
not NCT03928379 363 366 O
clinically NCT03928379 367 377 O
significant NCT03928379 378 389 O
by NCT03928379 390 392 O
the NCT03928379 393 396 O
investigator NCT03928379 397 409 O
; NCT03928379 409 410 O
however NCT03928379 411 418 O
, NCT03928379 419 420 O
should NCT03928379 421 427 O
have NCT03928379 428 432 O
serum NCT03928379 433 438 B-Observation-Name___Observation-Type-Value:lab
magnesium NCT03928379 439 448 I-Observation-Name___Observation-Type-Value:lab
and NCT03928379 449 452 O
potassium NCT03928379 453 462 B-Observation-Name___Observation-Type-Value:lab
levels NCT03928379 463 469 I-Observation-Name___Observation-Type-Value:lab
, NCT03928379 470 471 O
along NCT03928379 472 477 O
with NCT03928379 478 482 O
lactate NCT03928379 483 490 B-Observation-Name___Observation-Type-Value:lab
dehydrogenase NCT03928379 491 504 I-Observation-Name___Observation-Type-Value:lab
, NCT03928379 505 506 O
CK NCT03928379 507 509 B-Observation-Name___Observation-Type-Value:lab
values NCT03928379 510 516 O
within NCT03928379 517 523 B-Eq-Operator___Eq-Operator-Value:LTEQ
the NCT03928379 524 527 O
normal NCT03928379 528 534 B-Eq-Unit___Eq-Unit-Value:ref-range-normal
range NCT03928379 535 540 I-Eq-Unit___Eq-Unit-Value:ref-range-normal
at NCT03928379 541 543 O
screening NCT03928379 544 553 O
and NCT03928379 554 557 O
Day NCT03928379 558 561 O
- NCT03928379 562 563 O
2 NCT03928379 565 566 O
. NCT03928379 566 567 O

Exclusion NCT03928379 569 578 O
Criteria NCT03928379 579 587 O
: NCT03928379 588 589 O

- NCT03928379 593 594 O
Have NCT03928379 596 600 O
Type NCT03928379 601 605 B-Condition-Name
1 NCT03928379 607 608 I-Condition-Name
diabetes NCT03928379 609 617 I-Condition-Name
or NCT03928379 618 620 O
latent NCT03928379 621 627 O
autoimmune NCT03928379 628 638 O
diabetes NCT03928379 639 647 B-Condition-Name
in NCT03928379 648 650 O
adults NCT03928379 651 657 O

- NCT03928379 660 661 O
Have NCT03928379 663 667 O
uncontrolled NCT03928379 668 680 O
diabetes NCT03928379 681 689 B-Condition-Name
defined NCT03928379 690 697 O
as NCT03928379 698 700 O
an NCT03928379 701 703 O
episode NCT03928379 704 711 O
of NCT03928379 712 714 O
ketoacidosis NCT03928379 715 727 B-Condition-Name
or NCT03928379 728 730 O
hyperosmolar NCT03928379 731 743 B-Condition-Name
state NCT03928379 744 749 I-Condition-Name
requiring NCT03928379 750 759 O
hospitalization NCT03928379 760 775 B-Encounter-Type___Encounter-Type-Value:inpatient
for NCT03928379 776 779 O
6 NCT03928379 781 782 B-Eq-Value
months NCT03928379 783 789 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
prior NCT03928379 790 795 O
to NCT03928379 796 798 O
screening NCT03928379 799 808 O

- NCT03928379 811 812 O
Have NCT03928379 814 818 O
had NCT03928379 819 822 O
an NCT03928379 823 825 O
episode NCT03928379 826 833 O
of NCT03928379 834 836 O
severe NCT03928379 837 843 B-Severity___Severity-Value:severe
hypoglycemia NCT03928379 844 856 B-Condition-Name
, NCT03928379 857 858 O
defined NCT03928379 859 866 O
by NCT03928379 867 869 O
the NCT03928379 870 873 O
occurrence NCT03928379 874 884 O
of NCT03928379 885 887 O
neuroglycopenic NCT03928379 888 903 B-Condition-Name
symptoms NCT03928379 904 912 O
requiring NCT03928379 913 922 O
the NCT03928379 923 926 O
assistance NCT03928379 927 937 B-Observation-Name
of NCT03928379 938 940 I-Observation-Name
another NCT03928379 941 948 I-Observation-Name
person NCT03928379 949 955 I-Observation-Name
for NCT03928379 956 959 O
recovery NCT03928379 960 968 O
, NCT03928379 969 970 O
within NCT03928379 971 977 B-Eq-Operator___Eq-Operator-Value:LTEQ
6 NCT03928379 979 980 B-Eq-Value
months NCT03928379 981 987 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
prior NCT03928379 988 993 O
to NCT03928379 994 996 O
Visit NCT03928379 997 1002 O
1 NCT03928379 1004 1005 O

- NCT03928379 1009 1010 O
Have NCT03928379 1012 1016 O
an NCT03928379 1017 1019 O
abnormal NCT03928379 1020 1028 B-Polarity___Polarity-Value:abnormal
12 NCT03928379 1030 1032 B-Procedure-Name
- NCT03928379 1033 1034 I-Procedure-Name
lead NCT03928379 1035 1039 I-Procedure-Name
electrocardiogram NCT03928379 1040 1057 I-Procedure-Name
( NCT03928379 1058 1059 O
ECG NCT03928379 1060 1063 B-Procedure-Name
) NCT03928379 1064 1065 O
at NCT03928379 1066 1068 O
screening NCT03928379 1069 1078 O
and NCT03928379 1079 1082 O
/ NCT03928379 1083 1084 O
or NCT03928379 1085 1087 O
Day NCT03928379 1088 1091 O
- NCT03928379 1092 1093 O
2 NCT03928379 1095 1096 O
that NCT03928379 1097 1101 O
, NCT03928379 1102 1103 O
in NCT03928379 1104 1106 O
the NCT03928379 1107 1110 O
opinion NCT03928379 1111 1118 O
of NCT03928379 1119 1121 O
the NCT03928379 1122 1125 O
investigator NCT03928379 1126 1138 O
, NCT03928379 1139 1140 O
increases NCT03928379 1141 1150 B-Stability___Stability-Value:change
the NCT03928379 1151 1154 O
risks NCT03928379 1155 1160 O
associated NCT03928379 1161 1171 O
with NCT03928379 1172 1176 O
participating NCT03928379 1177 1190 O
in NCT03928379 1191 1193 O
the NCT03928379 1194 1197 O
study NCT03928379 1198 1203 O
or NCT03928379 1204 1206 O
may NCT03928379 1207 1210 O
confound NCT03928379 1211 1219 O
ECG NCT03928379 1220 1223 O
data NCT03928379 1224 1228 O
analysis NCT03928379 1229 1237 O

- NCT03928379 1240 1241 O
Have NCT03928379 1243 1247 O
poorly NCT03928379 1248 1254 O
controlled NCT03928379 1255 1265 O
hypertension NCT03928379 1266 1278 B-Condition-Name
at NCT03928379 1279 1281 O
screening NCT03928379 1282 1291 O
; NCT03928379 1291 1292 O
or NCT03928379 1293 1295 O
a NCT03928379 1296 1297 O
change NCT03928379 1298 1304 B-Stability___Stability-Value:change
in NCT03928379 1305 1307 O
antihypertensive NCT03928379 1308 1324 B-Drug-Name
medication NCT03928379 1325 1335 I-Drug-Name
within NCT03928379 1336 1342 B-Eq-Operator___Eq-Operator-Value:LTEQ
30 NCT03928379 1344 1346 B-Eq-Value
days NCT03928379 1347 1351 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
of NCT03928379 1352 1354 O
screening NCT03928379 1355 1364 O

- NCT03928379 1367 1368 O
Have NCT03928379 1370 1374 O
an NCT03928379 1375 1377 O
estimated NCT03928379 1378 1387 B-Observation-Name___Observation-Type-Value:lab
glomerular NCT03928379 1388 1398 I-Observation-Name___Observation-Type-Value:lab
filtration NCT03928379 1399 1409 I-Observation-Name___Observation-Type-Value:lab
rate NCT03928379 1410 1414 I-Observation-Name___Observation-Type-Value:lab
< NCT03928379 1415 1416 B-Eq-Operator___Eq-Operator-Value:LT
45 NCT03928379 1418 1420 B-Eq-Value
milliliters NCT03928379 1421 1432 B-Eq-Unit
per NCT03928379 1433 1436 O
minute NCT03928379 1437 1443 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:minute
per NCT03928379 1444 1447 O
1.73 NCT03928379 1449 1453 B-Eq-Unit
meters NCT03928379 1454 1460 I-Eq-Unit
squared NCT03928379 1461 1468 I-Eq-Unit
of NCT03928379 1469 1471 O
body NCT03928379 1472 1476 O
surface NCT03928379 1477 1484 O
area NCT03928379 1485 1489 O
( NCT03928379 1490 1491 O
mL NCT03928379 1492 1494 B-Eq-Unit
/ NCT03928379 1495 1496 O
min NCT03928379 1497 1500 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:minute
/ NCT03928379 1501 1502 O
1.73 NCT03928379 1504 1508 B-Eq-Unit
m² NCT03928379 1509 1511 I-Eq-Unit
) NCT03928379 1512 1513 O

Inclusion NCT03925649 0 9 O
Criteria NCT03925649 10 18 O
: NCT03925649 19 20 O

- NCT03925649 24 25 O
Cognitively NCT03925649 27 38 O
intact NCT03925649 39 45 O
, NCT03925649 46 47 O
capable NCT03925649 48 55 O
of NCT03925649 56 58 O
giving NCT03925649 59 65 O
informed NCT03925649 66 74 O
consent NCT03925649 75 82 O

- NCT03925649 85 86 O
Clinical NCT03925649 88 96 O
diagnosis NCT03925649 97 106 O
of NCT03925649 107 109 O
a NCT03925649 110 111 O
non NCT03925649 112 115 O
- NCT03925649 116 117 O
penetrating NCT03925649 118 129 O
traumatic NCT03925649 130 139 O
SCI NCT03925649 140 143 B-Condition-Name

- NCT03925649 146 147 O
Asia NCT03925649 149 153 B-Condition-Name
Impairment NCT03925649 154 164 I-Condition-Name
Scale NCT03925649 165 170 I-Condition-Name
grade NCT03925649 171 176 B-Eq-Unit
of NCT03925649 177 179 O
A NCT03925649 180 181 B-Eq-Value
, NCT03925649 182 183 O
B NCT03925649 184 185 B-Eq-Value
, NCT03925649 186 187 O
or NCT03925649 188 190 O
C NCT03925649 191 192 B-Eq-Value

Exclusion NCT03925649 193 202 O
Criteria NCT03925649 203 211 O
: NCT03925649 212 213 O

1 NCT03925649 218 219 O
. NCT03925649 219 220 O
Prior NCT03925649 222 227 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
history NCT03925649 228 235 O
of NCT03925649 236 238 O
: NCT03925649 239 240 O

- NCT03925649 249 250 O
Brain NCT03925649 252 257 O
injury NCT03925649 258 264 B-Condition-Name

- NCT03925649 272 273 O
Recent NCT03925649 275 281 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:recent
or NCT03925649 282 284 O
ongoing NCT03925649 285 292 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
infection NCT03925649 293 302 B-Condition-Name

- NCT03925649 310 311 O
Clinically NCT03925649 313 323 O
significant NCT03925649 324 335 B-Severity___Severity-Value:severe
cardiovascular NCT03925649 336 350 O
, NCT03925649 351 352 O
lung NCT03925649 353 357 O
, NCT03925649 358 359 O
renal NCT03925649 360 365 O
, NCT03925649 366 367 O
hepatic NCT03925649 368 375 O
or NCT03925649 376 378 O
endocrine NCT03925649 379 388 O
disease NCT03925649 389 396 B-Condition-Name
, NCT03925649 397 398 O

- NCT03925649 407 408 O
Neurodegenerative NCT03925649 410 427 B-Condition-Name
disorders NCT03925649 428 437 I-Condition-Name

- NCT03925649 445 446 O
Cancer NCT03925649 448 454 B-Condition-Name

- NCT03925649 462 463 O
Immunosuppression NCT03925649 465 482 B-Condition-Name
as NCT03925649 483 485 O
defined NCT03925649 486 493 O
by NCT03925649 494 496 O
WBC NCT03925649 497 500 B-Observation-Name___Observation-Type-Value:lab
< NCT03925649 501 502 B-Eq-Operator___Eq-Operator-Value:LT
3 NCT03925649 504 505 B-Eq-Value
, NCT03925649 506 507 I-Eq-Value
000 NCT03925649 508 511 I-Eq-Value
cells NCT03925649 512 517 B-Eq-Unit
/ NCT03925649 518 519 O
ml NCT03925649 520 522 B-Eq-Unit
at NCT03925649 523 525 O
baseline NCT03925649 526 534 O
screening NCT03925649 535 544 O
, NCT03925649 545 546 O

- NCT03925649 555 556 O
HIV NCT03925649 558 561 B-Condition-Name
+ NCT03925649 562 563 B-Polarity___Polarity-Value:positive

- NCT03925649 572 573 O
Chemical NCT03925649 575 583 O
or NCT03925649 584 586 O
ETOH NCT03925649 587 591 O
dependency NCT03925649 592 602 B-Condition-Name

2 NCT03925649 606 607 O
. NCT03925649 607 608 O
Having NCT03925649 610 616 O
a NCT03925649 617 618 O
contraindication NCT03925649 619 635 O
to NCT03925649 636 638 O
MRI NCT03925649 639 642 B-Procedure-Name
scans NCT03925649 643 648 O

3 NCT03925649 652 653 O
. NCT03925649 653 654 O
Other NCT03925649 656 661 O
acute NCT03925649 662 667 B-Severity___Severity-Value:severe
or NCT03925649 668 670 O
chronic NCT03925649 671 678 O
medical NCT03925649 679 686 O
conditions NCT03925649 687 697 O
that NCT03925649 698 702 O
, NCT03925649 703 704 O
in NCT03925649 705 707 O
the NCT03925649 708 711 O
opinion NCT03925649 712 719 O
of NCT03925649 720 722 O
the NCT03925649 723 726 O
investigator NCT03925649 727 739 O
, NCT03925649 740 741 O
may NCT03925649 742 745 O
increase NCT03925649 746 754 B-Stability___Stability-Value:change
the NCT03925649 755 758 O
risks NCT03925649 759 764 O
associated NCT03925649 765 775 O
with NCT03925649 776 780 O
study NCT03925649 781 786 O
participation NCT03925649 787 800 O
or NCT03925649 801 803 O
HB NCT03925649 804 806 B-Drug-Name
- NCT03925649 807 808 I-Drug-Name
adMSC NCT03925649 809 814 I-Drug-Name
administration NCT03925649 815 829 O

4 NCT03925649 833 834 O
. NCT03925649 834 835 O
Participation NCT03925649 837 850 O
in NCT03925649 851 853 O
other NCT03925649 854 859 O
interventional NCT03925649 860 874 O
research NCT03925649 875 883 O
studies NCT03925649 884 891 O

5 NCT03925649 895 896 O
. NCT03925649 896 897 O
Unwillingness NCT03925649 899 912 O
to NCT03925649 913 915 O
return NCT03925649 916 922 O
for NCT03925649 923 926 O
follow NCT03925649 927 933 O
- NCT03925649 934 935 O
up NCT03925649 936 938 O
visits NCT03925649 939 945 O

Inclusion NCT03922126 0 9 O
Criteria NCT03922126 10 18 O
: NCT03922126 19 20 O

- NCT03922126 24 25 O
male NCT03922126 27 31 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
sex NCT03922126 32 35 O
( NCT03922126 36 37 O
at NCT03922126 38 40 O
birth NCT03922126 41 46 O
) NCT03922126 47 48 O

- NCT03922126 52 53 O
adult NCT03922126 55 60 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
aged NCT03922126 61 65 O
18 NCT03922126 67 69 B-Eq-Value
and NCT03922126 70 73 B-Eq-Operator___Eq-Operator-Value:GTEQ
older NCT03922126 74 79 I-Eq-Operator___Eq-Operator-Value:GTEQ

- NCT03922126 82 83 O
immigrant NCT03922126 85 94 B-Observation-Name
( NCT03922126 95 96 O
not NCT03922126 97 100 O
born NCT03922126 101 105 O
in NCT03922126 106 108 O
continental NCT03922126 109 120 B-Location___Location-Value:residence
U NCT03922126 121 122 I-Location___Location-Value:residence
. NCT03922126 123 124 I-Location___Location-Value:residence
S NCT03922126 125 126 I-Location___Location-Value:residence
. NCT03922126 127 128 I-Location___Location-Value:residence
) NCT03922126 129 130 O

- NCT03922126 134 135 O
Latino NCT03922126 137 143 B-Ethnicity
( NCT03922126 144 145 O
identifies NCT03922126 146 156 O
as NCT03922126 157 159 O
either NCT03922126 160 166 O
Latinx NCT03922126 167 173 B-Ethnicity
or NCT03922126 174 176 O
Hispanic NCT03922126 177 185 B-Ethnicity

- NCT03922126 188 189 O
reports NCT03922126 191 198 O
sex NCT03922126 199 202 B-Observation-Name
with NCT03922126 203 207 O
men NCT03922126 208 211 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
in NCT03922126 212 214 O
past NCT03922126 215 219 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
12 NCT03922126 221 223 B-Eq-Value
months NCT03922126 224 230 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

- NCT03922126 233 234 O
reports NCT03922126 236 243 O
not NCT03922126 244 247 O
knowing NCT03922126 248 255 O
their NCT03922126 256 261 O
HIV NCT03922126 262 265 B-Condition-Name
status NCT03922126 266 272 O
or NCT03922126 273 275 O
being NCT03922126 276 281 O
HIV NCT03922126 282 285 B-Condition-Name
negative NCT03922126 286 294 B-Polarity___Polarity-Value:negative

Exclusion NCT03922126 295 304 O
Criteria NCT03922126 305 313 O
: NCT03922126 314 315 O

- NCT03922126 319 320 O
Does NCT03922126 322 326 O
not NCT03922126 327 330 O
identify NCT03922126 331 339 O
as NCT03922126 340 342 O
Latino NCT03922126 343 349 B-Ethnicity
/ NCT03922126 350 351 O
Hispanic NCT03922126 352 360 B-Ethnicity

- NCT03922126 363 364 O
Born NCT03922126 366 370 O
in NCT03922126 371 373 O
the NCT03922126 374 377 O
continental NCT03922126 378 389 B-Location___Location-Value:residence
U NCT03922126 390 391 I-Location___Location-Value:residence
. NCT03922126 392 393 I-Location___Location-Value:residence
S NCT03922126 394 395 I-Location___Location-Value:residence
. NCT03922126 396 397 I-Location___Location-Value:residence

- NCT03922126 401 402 O
Female NCT03922126 404 410 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
sex NCT03922126 411 414 I-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
( NCT03922126 415 416 O
at NCT03922126 417 419 O
birth NCT03922126 420 425 O
) NCT03922126 426 427 O

- NCT03922126 431 432 O
Does NCT03922126 434 438 O
not NCT03922126 439 442 O
report NCT03922126 443 449 O
sex NCT03922126 450 453 B-Condition-Name
with NCT03922126 454 458 I-Condition-Name
men NCT03922126 459 462 I-Condition-Name
in NCT03922126 463 465 O
the NCT03922126 466 469 O
last NCT03922126 470 474 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
12 NCT03922126 476 478 B-Eq-Value
months NCT03922126 479 485 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

- NCT03922126 488 489 O
Reports NCT03922126 491 498 O
being NCT03922126 499 504 O
HIV NCT03922126 505 508 B-Condition-Name
positive NCT03922126 509 517 B-Polarity___Polarity-Value:positive

- NCT03922126 520 521 O
Younger NCT03922126 523 530 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03922126 531 535 I-Eq-Operator___Eq-Operator-Value:LT
18 NCT03922126 537 539 B-Eq-Value
years NCT03922126 540 545 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03922126 546 549 O

Inclusion NCT03924557 0 9 O
Criteria NCT03924557 10 18 O
: NCT03924557 19 20 O

- NCT03924557 24 25 O
Must NCT03924557 27 31 O
have NCT03924557 32 36 O
a NCT03924557 37 38 O
clinical NCT03924557 39 47 O
diagnosis NCT03924557 48 57 O
of NCT03924557 58 60 O
solid NCT03924557 61 66 O
tumor NCT03924557 67 72 O
cancer NCT03924557 73 79 B-Condition-Name
and NCT03924557 80 83 O
be NCT03924557 84 86 O
seeking NCT03924557 87 94 O
treatment NCT03924557 95 104 O
and NCT03924557 105 108 O
supportive NCT03924557 109 119 B-Procedure-Name
care NCT03924557 120 124 I-Procedure-Name
at NCT03924557 125 127 O
the NCT03924557 128 131 O
UF NCT03924557 132 134 B-Location___Location-Value:hospital
Health NCT03924557 135 141 I-Location___Location-Value:hospital
Cancer NCT03924557 142 148 I-Location___Location-Value:hospital
Center NCT03924557 149 155 I-Location___Location-Value:hospital
( NCT03924557 156 157 O
Medical NCT03924557 158 165 O
Plaza NCT03924557 166 171 O
) NCT03924557 172 173 O

- NCT03924557 177 178 O
Patients NCT03924557 180 188 O
must NCT03924557 189 193 O
plan NCT03924557 194 198 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
to NCT03924557 199 201 O
receive NCT03924557 202 209 O
chemotherapy NCT03924557 210 222 B-Procedure-Name
known NCT03924557 223 228 O
to NCT03924557 229 231 O
be NCT03924557 232 234 O
associated NCT03924557 235 245 O
with NCT03924557 246 250 O
the NCT03924557 251 254 O
need NCT03924557 255 259 O
for NCT03924557 260 263 O
supportive NCT03924557 264 274 O
care NCT03924557 275 279 O
within NCT03924557 280 286 B-Eq-Operator___Eq-Operator-Value:LTEQ
30 NCT03924557 288 290 B-Eq-Value
days NCT03924557 291 295 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
of NCT03924557 296 298 O
enrollment NCT03924557 299 309 O

- NCT03924557 312 313 O
Life NCT03924557 315 319 B-Observation-Name
expectancy NCT03924557 320 330 I-Observation-Name
must NCT03924557 331 335 O
be NCT03924557 336 338 O
greater NCT03924557 339 346 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03924557 347 351 I-Eq-Operator___Eq-Operator-Value:GT
6 NCT03924557 353 354 B-Eq-Value
months NCT03924557 355 361 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

- NCT03924557 364 365 O
Must NCT03924557 367 371 O
have NCT03924557 372 376 O
Eastern NCT03924557 377 384 B-Observation-Name___Observation-Type-Value:clinical-score
Cooperative NCT03924557 385 396 I-Observation-Name___Observation-Type-Value:clinical-score
Oncology NCT03924557 397 405 I-Observation-Name___Observation-Type-Value:clinical-score
Group NCT03924557 406 411 I-Observation-Name___Observation-Type-Value:clinical-score
( NCT03924557 412 413 O
ECOG NCT03924557 414 418 B-Observation-Name
) NCT03924557 419 420 O
performance NCT03924557 421 432 O
status NCT03924557 433 439 O
of NCT03924557 440 442 O
0 NCT03924557 444 445 B-Eq-Value
- NCT03924557 446 447 B-Eq-Operator___Eq-Operator-Value:BETWEEN
2 NCT03924557 449 450 B-Eq-Value

- NCT03924557 454 455 O
Written NCT03924557 457 464 O
informed NCT03924557 465 473 O
consent NCT03924557 474 481 O
obtained NCT03924557 482 490 O
from NCT03924557 491 495 O
the NCT03924557 496 499 O
patient NCT03924557 500 507 O

- NCT03924557 510 511 O
The NCT03924557 513 516 O
ability NCT03924557 517 524 O
for NCT03924557 525 528 O
the NCT03924557 529 532 O
patient NCT03924557 533 540 O
to NCT03924557 541 543 O
comply NCT03924557 544 550 O
with NCT03924557 551 555 O
all NCT03924557 556 559 O
the NCT03924557 560 563 O
study NCT03924557 564 569 O
- NCT03924557 570 571 O
related NCT03924557 572 579 O
procedures NCT03924557 580 590 B-Procedure-Name
. NCT03924557 591 592 O

Exclusion NCT03924557 594 603 O
Criteria NCT03924557 604 612 O
: NCT03924557 613 614 O

- NCT03924557 618 619 O
Patients NCT03924557 621 629 O
unwilling NCT03924557 630 639 O
or NCT03924557 640 642 O
unable NCT03924557 643 649 O
to NCT03924557 650 652 O
provide NCT03924557 653 660 O
voluntary NCT03924557 661 670 O
informed NCT03924557 671 679 O
consent NCT03924557 680 687 O

- NCT03924557 690 691 O
Patients NCT03924557 693 701 O
who NCT03924557 702 705 O
are NCT03924557 706 709 O
unwilling NCT03924557 710 719 O
or NCT03924557 720 722 O
unable NCT03924557 723 729 O
to NCT03924557 730 732 O
comply NCT03924557 733 739 O
with NCT03924557 740 744 O
protocol NCT03924557 745 753 O
requirement NCT03924557 754 765 O
and NCT03924557 766 769 O
/ NCT03924557 770 771 O
or NCT03924557 772 774 O
follow NCT03924557 775 781 O
- NCT03924557 782 783 O
up NCT03924557 784 786 O
procedures NCT03924557 787 797 O

- NCT03924557 800 801 O
Patients NCT03924557 803 811 O
planned NCT03924557 812 819 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
to NCT03924557 820 822 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
undergo NCT03924557 823 830 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
cancer NCT03924557 831 837 B-Condition-Name
therapy NCT03924557 838 845 B-Procedure-Name
other NCT03924557 846 851 O
than NCT03924557 852 856 O
chemotherapy NCT03924557 857 869 B-Procedure-Name
( NCT03924557 870 871 O
i NCT03924557 872 873 O
. NCT03924557 874 875 O
e NCT03924557 876 877 O
. NCT03924557 878 879 O
, NCT03924557 880 881 O
radiation NCT03924557 882 891 B-Procedure-Name
, NCT03924557 892 893 O
surgery NCT03924557 894 901 B-Procedure-Name
or NCT03924557 902 904 O
hormonal NCT03924557 905 913 B-Procedure-Name
treatment NCT03924557 914 923 I-Procedure-Name
alone NCT03924557 924 929 O
) NCT03924557 930 931 O

- NCT03924557 935 936 O
Prisoners NCT03924557 938 947 B-Observation-Name
or NCT03924557 948 950 O
patients NCT03924557 951 959 O
who NCT03924557 960 963 O
are NCT03924557 964 967 O
involuntarily NCT03924557 968 981 B-Observation-Name
incarcerated NCT03924557 982 994 I-Observation-Name
. NCT03924557 995 996 O
Patients NCT03924557 998 1006 O
who NCT03924557 1007 1010 O
are NCT03924557 1011 1014 O
compulsorily NCT03924557 1015 1027 O
detained NCT03924557 1028 1036 O
for NCT03924557 1037 1040 O
treatment NCT03924557 1041 1050 O
of NCT03924557 1051 1053 O
either NCT03924557 1054 1060 O
a NCT03924557 1061 1062 O
psychiatric NCT03924557 1063 1074 O
or NCT03924557 1075 1077 O
physical NCT03924557 1078 1086 O
illness NCT03924557 1087 1094 B-Condition-Name
. NCT03924557 1095 1096 O

Inclusion NCT03927937 0 9 O
Criteria NCT03927937 10 18 O
: NCT03927937 19 20 O

- NCT03927937 24 25 O
Tooth NCT03927937 27 32 O
with NCT03927937 33 37 O
imposible NCT03927937 38 47 O
prognosis NCT03927937 48 57 O

- NCT03927937 60 61 O
Plaque NCT03927937 63 69 B-Observation-Name___Observation-Type-Value:clinical-score
index NCT03927937 70 75 I-Observation-Name___Observation-Type-Value:clinical-score
score NCT03927937 76 81 I-Observation-Name___Observation-Type-Value:clinical-score
less NCT03927937 82 86 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03927937 87 91 I-Eq-Operator___Eq-Operator-Value:LT
30 NCT03927937 93 95 B-Eq-Value
% NCT03927937 96 97 B-Eq-Unit

- NCT03927937 101 102 O
No NCT03927937 104 106 O
relevant NCT03927937 107 115 O
systemic NCT03927937 116 124 O
disease NCT03927937 125 132 B-Condition-Name

- NCT03927937 135 136 O
Smokers NCT03927937 138 145 B-Observation-Name___Observation-Type-Value:social-habit
( NCT03927937 146 147 O
Less NCT03927937 148 152 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03927937 153 157 I-Eq-Operator___Eq-Operator-Value:LT
20 NCT03927937 159 161 B-Eq-Value
cigars NCT03927937 162 168 B-Eq-Unit
/ NCT03927937 169 170 O
day NCT03927937 171 174 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
) NCT03927937 175 176 O

Exclusion NCT03927937 178 187 O
Criteria NCT03927937 188 196 O
: NCT03927937 197 198 O

- NCT03927937 202 203 O
Pregnancy NCT03927937 205 214 B-Condition-Name
- NCT03927937 215 216 O
Lactation NCT03927937 217 226 B-Condition-Name

- NCT03927937 229 230 O
Relevant NCT03927937 232 240 O
systemic NCT03927937 241 249 O
disease NCT03927937 250 257 B-Condition-Name

Inclusion NCT03929926 0 9 O
Criteria NCT03929926 10 18 O
: NCT03929926 19 20 O

- NCT03929926 24 25 O
Had NCT03929926 27 30 O
a NCT03929926 31 32 O
recent NCT03929926 33 39 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:recent
office NCT03929926 40 46 B-Encounter-Type___Encounter-Type-Value:outpatient
visit NCT03929926 47 52 I-Encounter-Type___Encounter-Type-Value:outpatient
with NCT03929926 53 57 O
a NCT03929926 58 59 O
primary NCT03929926 60 67 B-Provider-Type
care NCT03929926 68 72 I-Provider-Type
physician NCT03929926 73 82 B-Provider-Role
in NCT03929926 83 85 O
one NCT03929926 86 89 O
of NCT03929926 90 92 O
the NCT03929926 93 96 O
study NCT03929926 97 102 B-Location
practices NCT03929926 103 112 I-Location
. NCT03929926 113 114 O

- NCT03929926 118 119 O
History NCT03929926 121 128 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03929926 129 131 O
smoking NCT03929926 132 139 B-Condition-Name
( NCT03929926 140 141 O
current NCT03929926 142 149 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
or NCT03929926 150 152 O
former NCT03929926 153 159 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
) NCT03929926 160 161 O
in NCT03929926 162 164 O
the NCT03929926 165 168 O
electronic NCT03929926 169 179 O
health NCT03929926 180 186 O
record NCT03929926 187 193 O
( NCT03929926 194 195 O
EHR NCT03929926 196 199 O
) NCT03929926 200 201 O
. NCT03929926 203 204 O

Exclusion NCT03929926 206 215 O
Criteria NCT03929926 216 224 O
: NCT03929926 225 226 O

- NCT03929926 230 231 O
LDCT NCT03929926 233 237 B-Procedure-Name
performed NCT03929926 238 247 O
in NCT03929926 248 250 O
the NCT03929926 251 254 O
12 NCT03929926 256 258 B-Eq-Value
months NCT03929926 259 265 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
prior NCT03929926 266 271 O
to NCT03929926 272 274 O
study NCT03929926 275 280 O
initiation NCT03929926 281 291 O
according NCT03929926 292 301 O
to NCT03929926 302 304 O
EHR NCT03929926 305 308 O
. NCT03929926 309 310 O

- NCT03929926 314 315 O
Diagnosis NCT03929926 317 326 O
of NCT03929926 327 329 O
lung NCT03929926 330 334 O
cancer NCT03929926 335 341 B-Condition-Name
indicated NCT03929926 342 351 O
in NCT03929926 352 354 O
problem NCT03929926 355 362 B-Condition-Type___Condition-Type-Value:problem-list
list NCT03929926 363 367 I-Condition-Type___Condition-Type-Value:problem-list
in NCT03929926 368 370 O
the NCT03929926 371 374 O
EHR NCT03929926 375 378 O
. NCT03929926 379 380 O

Inclusion NCT03928392 0 9 O
Criteria NCT03928392 10 18 O
: NCT03928392 19 20 O

- NCT03928392 24 25 O
18 NCT03928392 28 30 B-Eq-Value
to NCT03928392 31 33 B-Eq-Operator___Eq-Operator-Value:BETWEEN
95 NCT03928392 35 37 B-Eq-Value
years NCT03928392 38 43 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03928392 44 46 O
age NCT03928392 47 50 O

- NCT03928392 53 54 O
Participation NCT03928392 56 69 O
in NCT03928392 70 72 O
WAVES NCT03928392 73 78 O
Project NCT03928392 79 86 O
for NCT03928392 87 90 O
at NCT03928392 91 93 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03928392 94 99 I-Eq-Operator___Eq-Operator-Value:GTEQ
3 NCT03928392 101 102 B-Eq-Value
months NCT03928392 103 109 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

- NCT03928392 112 113 O
Completion NCT03928392 115 125 O
of NCT03928392 126 128 O
3 NCT03928392 130 131 B-Eq-Value
open NCT03928392 132 136 B-Observation-Name___Observation-Type-Value:social-habit
water NCT03928392 137 142 I-Observation-Name___Observation-Type-Value:social-habit
dives NCT03928392 143 148 I-Observation-Name___Observation-Type-Value:social-habit

- NCT03928392 151 152 O
Proficient NCT03928392 154 164 O
in NCT03928392 165 167 O
written NCT03928392 168 175 O
and NCT03928392 176 179 O
verbal NCT03928392 180 186 O
English NCT03928392 187 194 B-Language

Exclusion NCT03928392 195 204 O
Criteria NCT03928392 205 213 O
: NCT03928392 214 215 O

- NCT03928392 219 220 O
Younger NCT03928392 222 229 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03928392 230 234 I-Eq-Operator___Eq-Operator-Value:LT
18 NCT03928392 236 238 B-Eq-Value
years NCT03928392 239 244 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03928392 245 247 O
age NCT03928392 248 251 O
or NCT03928392 252 254 O
older NCT03928392 255 260 B-Eq-Operator___Eq-Operator-Value:GTEQ
than NCT03928392 261 265 I-Eq-Operator___Eq-Operator-Value:GTEQ
95 NCT03928392 267 269 B-Eq-Value
years NCT03928392 270 275 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03928392 276 278 O
age NCT03928392 279 282 O

- NCT03928392 285 286 O
Not NCT03928392 288 291 O
a NCT03928392 292 293 O
member NCT03928392 294 300 O
of NCT03928392 301 303 O
WAVES NCT03928392 304 309 O
Project NCT03928392 310 317 O
within NCT03928392 318 324 B-Eq-Operator___Eq-Operator-Value:LTEQ
3 NCT03928392 326 327 B-Eq-Value
months NCT03928392 328 334 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
of NCT03928392 335 337 O
study NCT03928392 338 343 O
recruitment NCT03928392 344 355 O

- NCT03928392 358 359 O
Has NCT03928392 361 364 O
not NCT03928392 365 368 O
completed NCT03928392 369 378 O
3 NCT03928392 380 381 B-Eq-Value
open NCT03928392 382 386 B-Observation-Name___Observation-Type-Value:social-habit
water NCT03928392 387 392 I-Observation-Name___Observation-Type-Value:social-habit
dives NCT03928392 393 398 I-Observation-Name___Observation-Type-Value:social-habit

- NCT03928392 401 402 O
Not NCT03928392 404 407 O
proficient NCT03928392 408 418 O
in NCT03928392 419 421 O
written NCT03928392 422 429 O
and NCT03928392 430 433 O
verbal NCT03928392 434 440 O
English NCT03928392 441 448 B-Language

Inclusion NCT03922867 0 9 O
Criteria NCT03922867 10 18 O
: NCT03922867 19 20 O

- NCT03922867 24 25 O
Meets NCT03922867 27 32 O
diagnostic NCT03922867 33 43 O
criteria NCT03922867 44 52 O
for NCT03922867 53 56 O
fibromyalgia NCT03922867 57 69 B-Condition-Name

- NCT03922867 72 73 O
Has NCT03922867 75 78 O
insomnia NCT03922867 79 87 B-Condition-Name

- NCT03922867 90 91 O
Have NCT03922867 93 97 O
internet NCT03922867 98 106 O
access NCT03922867 107 113 O
and NCT03922867 114 117 O
a NCT03922867 118 119 O
device NCT03922867 120 126 O
that NCT03922867 127 131 O
can NCT03922867 132 135 O
access NCT03922867 136 142 O
the NCT03922867 143 146 O
web NCT03922867 147 150 O
- NCT03922867 151 152 O
based NCT03922867 153 158 O
program NCT03922867 159 166 O
. NCT03922867 167 168 O

Exclusion NCT03922867 170 179 O
Criteria NCT03922867 180 188 O
: NCT03922867 189 190 O

- NCT03922867 194 195 O
Active NCT03922867 197 203 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
sleep NCT03922867 204 209 B-Condition-Name
disorder NCT03922867 210 218 I-Condition-Name
which NCT03922867 219 224 O
is NCT03922867 225 227 O
not NCT03922867 228 231 O
treated NCT03922867 232 239 O
( NCT03922867 240 241 O
obstructive NCT03922867 242 253 B-Condition-Name
sleep NCT03922867 254 259 I-Condition-Name
apnea NCT03922867 260 265 I-Condition-Name
, NCT03922867 266 267 O
obesity NCT03922867 268 275 B-Condition-Name
hypoventilation NCT03922867 276 291 I-Condition-Name
syndrome NCT03922867 292 300 I-Condition-Name
) NCT03922867 301 302 O

- NCT03922867 306 307 O
Active NCT03922867 309 315 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
psychiatric NCT03922867 316 327 B-Condition-Name
disorder NCT03922867 328 336 I-Condition-Name
( NCT03922867 337 338 O
Bipolar NCT03922867 339 346 B-Condition-Name
affective NCT03922867 347 356 I-Condition-Name
disorder NCT03922867 357 365 I-Condition-Name
, NCT03922867 366 367 O
anxiety NCT03922867 368 375 B-Condition-Name
, NCT03922867 376 377 O
depression NCT03922867 378 388 B-Condition-Name
, NCT03922867 389 390 O
schizophrenia NCT03922867 391 404 B-Condition-Name
) NCT03922867 405 406 O
which NCT03922867 407 412 O
is NCT03922867 413 415 O
not NCT03922867 416 419 O
optimally NCT03922867 420 429 O
managed NCT03922867 430 437 O
. NCT03922867 438 439 O

- NCT03922867 443 444 O
Chronic NCT03922867 446 453 O
fatigue NCT03922867 454 461 B-Condition-Name
syndrome NCT03922867 462 470 I-Condition-Name

- NCT03922867 473 474 O
Morbid NCT03922867 476 482 B-Condition-Name
obesity NCT03922867 483 490 I-Condition-Name

Inclusion NCT03920891 0 9 O
Criteria NCT03920891 10 18 O
: NCT03920891 19 20 O

- NCT03920891 24 25 O
1 NCT03920891 28 29 O
. NCT03920891 29 30 O
Patient NCT03920891 32 39 O
with NCT03920891 40 44 O
hemodynamic NCT03920891 45 56 O
corrected NCT03920891 57 66 O
valvular NCT03920891 67 75 O
atrial NCT03920891 76 82 B-Condition-Name
fibrillation NCT03920891 83 95 I-Condition-Name
who NCT03920891 96 99 O
is NCT03920891 100 102 O
scheduled NCT03920891 103 112 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
for NCT03920891 113 116 O
ablation NCT03920891 117 125 B-Procedure-Name
procedure NCT03920891 126 135 I-Procedure-Name
and NCT03920891 136 139 O
≥ NCT03920891 140 141 B-Eq-Operator___Eq-Operator-Value:GTEQ
20 NCT03920891 143 145 B-Eq-Value
and NCT03920891 146 149 O
≤ NCT03920891 150 151 B-Eq-Operator___Eq-Operator-Value:LTEQ
80 NCT03920891 153 155 B-Eq-Value
years NCT03920891 156 161 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03920891 162 164 O
age NCT03920891 165 168 O

- NCT03920891 171 172 O
2 NCT03920891 175 176 O
. NCT03920891 176 177 O
Left NCT03920891 179 183 B-Observation-Name___Observation-Type-Value:measurement
atrium NCT03920891 184 190 I-Observation-Name___Observation-Type-Value:measurement
size NCT03920891 191 195 I-Observation-Name___Observation-Type-Value:measurement
< NCT03920891 196 197 B-Eq-Operator___Eq-Operator-Value:LT
50 NCT03920891 199 201 B-Eq-Value
mm NCT03920891 202 204 B-Eq-Unit

- NCT03920891 207 208 O
3 NCT03920891 211 212 O
. NCT03920891 212 213 O
paroxysmal NCT03920891 215 225 O
atrial NCT03920891 226 232 B-Condition-Name
fibrillation NCT03920891 233 245 I-Condition-Name
that NCT03920891 246 250 O
is NCT03920891 251 253 O
recurrence NCT03920891 254 264 O
during NCT03920891 265 271 O
antiarrhythmic NCT03920891 272 286 B-Drug-Name
drug NCT03920891 287 291 I-Drug-Name
treatment NCT03920891 292 301 O
or NCT03920891 302 304 O
is NCT03920891 305 307 O
not NCT03920891 308 311 O
able NCT03920891 312 316 O
to NCT03920891 317 319 O
use NCT03920891 320 323 O
an NCT03920891 324 326 O
antiarrhythmic NCT03920891 327 341 B-Drug-Name
drug NCT03920891 342 346 I-Drug-Name
. NCT03920891 347 348 O

- NCT03920891 352 353 O
4 NCT03920891 356 357 O
. NCT03920891 357 358 O
Patient NCT03920891 360 367 O
who NCT03920891 368 371 O
is NCT03920891 372 374 O
indicated NCT03920891 375 384 O
for NCT03920891 385 388 O
anticoagulation NCT03920891 389 404 B-Procedure-Name
therapy NCT03920891 405 412 I-Procedure-Name
( NCT03920891 413 414 O
for NCT03920891 415 418 O
prevention NCT03920891 419 429 O
of NCT03920891 430 432 O
cerebral NCT03920891 433 441 B-Condition-Name
infarction NCT03920891 442 452 I-Condition-Name
) NCT03920891 453 454 O

Exclusion NCT03920891 456 465 O
Criteria NCT03920891 466 474 O
: NCT03920891 475 476 O

- NCT03920891 480 481 O
1 NCT03920891 484 485 O
. NCT03920891 485 486 O
Patients NCT03920891 488 496 O
with NCT03920891 497 501 O
permanent NCT03920891 502 511 O
atrial NCT03920891 512 518 B-Condition-Name
fibrillation NCT03920891 519 531 I-Condition-Name

- NCT03920891 534 535 O
2 NCT03920891 538 539 O
. NCT03920891 539 540 O
Atrial NCT03920891 542 548 B-Condition-Name
fibrillation NCT03920891 549 561 I-Condition-Name
associated NCT03920891 562 572 O
with NCT03920891 573 577 O
severe NCT03920891 578 584 B-Severity___Severity-Value:severe
cardiac NCT03920891 585 592 B-Condition-Name
malformation NCT03920891 593 605 I-Condition-Name
or NCT03920891 606 608 O
a NCT03920891 609 610 O
structural NCT03920891 611 621 O
heart NCT03920891 622 627 B-Condition-Name
disease NCT03920891 628 635 I-Condition-Name
that NCT03920891 636 640 O
is NCT03920891 641 643 O
hemodynamically NCT03920891 644 659 O
affected NCT03920891 660 668 B-Stability___Stability-Value:change

- NCT03920891 671 672 O
3 NCT03920891 675 676 O
. NCT03920891 676 677 O
Patients NCT03920891 679 687 O
with NCT03920891 688 692 O
severe NCT03920891 693 699 B-Severity___Severity-Value:severe
renal NCT03920891 700 705 O
impairment NCT03920891 706 716 B-Condition-Name
or NCT03920891 717 719 O
CT NCT03920891 720 722 B-Procedure-Name
imaging NCT03920891 723 730 I-Procedure-Name
difficulty NCT03920891 731 741 O
using NCT03920891 742 747 O
contrast NCT03920891 748 756 B-Procedure-Name
media NCT03920891 757 762 I-Procedure-Name

- NCT03920891 765 766 O
4 NCT03920891 769 770 O
. NCT03920891 770 771 O
Patients NCT03920891 773 781 O
with NCT03920891 782 786 O
a NCT03920891 787 788 O
past NCT03920891 789 793 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
history NCT03920891 794 801 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03920891 802 804 O
radiofrequency NCT03920891 805 819 B-Procedure-Name
ablation NCT03920891 820 828 I-Procedure-Name
for NCT03920891 829 832 O
atrial NCT03920891 833 839 B-Condition-Name
fibrillation NCT03920891 840 852 I-Condition-Name
or NCT03920891 853 855 O
other NCT03920891 856 861 O
cardiac NCT03920891 862 869 O
surgery NCT03920891 870 877 B-Procedure-Name

- NCT03920891 880 881 O
5 NCT03920891 884 885 O
. NCT03920891 885 886 O
Patients NCT03920891 888 896 O
with NCT03920891 897 901 O
active NCT03920891 902 908 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
internal NCT03920891 909 917 O
bleeding NCT03920891 918 926 B-Condition-Name

- NCT03920891 929 930 O
6 NCT03920891 933 934 O
. NCT03920891 934 935 O
Patients NCT03920891 937 945 O
with NCT03920891 946 950 O
contraindications NCT03920891 951 968 O
for NCT03920891 969 972 O
anticoagulation NCT03920891 973 988 B-Procedure-Name
therapy NCT03920891 989 996 I-Procedure-Name
( NCT03920891 997 998 O
for NCT03920891 999 1002 O
prevention NCT03920891 1003 1013 O
of NCT03920891 1014 1016 O
cerebral NCT03920891 1017 1025 B-Condition-Name
infarction NCT03920891 1026 1036 I-Condition-Name
) NCT03920891 1037 1038 O
and NCT03920891 1039 1042 O
antiarrhythmic NCT03920891 1043 1057 B-Drug-Name
drugs NCT03920891 1058 1063 I-Drug-Name

- NCT03920891 1066 1067 O
7 NCT03920891 1070 1071 O
. NCT03920891 1071 1072 O
Patients NCT03920891 1074 1082 O
with NCT03920891 1083 1087 O
non NCT03920891 1088 1091 O
- NCT03920891 1092 1093 O
valvular NCT03920891 1094 1102 O
atrial NCT03920891 1103 1109 B-Condition-Name
fibrillation NCT03920891 1110 1122 I-Condition-Name

- NCT03920891 1125 1126 O
8 NCT03920891 1129 1130 O
. NCT03920891 1130 1131 O
Patients NCT03920891 1133 1141 O
with NCT03920891 1142 1146 O
a NCT03920891 1147 1148 O
severe NCT03920891 1149 1155 B-Severity___Severity-Value:severe
comorbid NCT03920891 1156 1164 B-Condition-Name
disease NCT03920891 1165 1172 I-Condition-Name

- NCT03920891 1175 1176 O
9 NCT03920891 1179 1180 O
. NCT03920891 1180 1181 O
Expected NCT03920891 1183 1191 B-Observation-Name
survival NCT03920891 1192 1200 I-Observation-Name
< NCT03920891 1201 1202 B-Eq-Operator___Eq-Operator-Value:LT
1 NCT03920891 1204 1205 B-Eq-Value
year NCT03920891 1206 1210 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03920891 1213 1214 O
10 NCT03920891 1217 1219 O
. NCT03920891 1219 1220 O
Drug NCT03920891 1222 1226 B-Condition-Name
addicts NCT03920891 1227 1234 I-Condition-Name
or NCT03920891 1235 1237 O
alcoholics NCT03920891 1238 1248 B-Condition-Name

- NCT03920891 1251 1252 O
11 NCT03920891 1255 1257 O
. NCT03920891 1257 1258 O
Patients NCT03920891 1260 1268 O
who NCT03920891 1269 1272 O
can NCT03920891 1273 1276 O
not NCT03920891 1276 1279 O
read NCT03920891 1280 1284 O
the NCT03920891 1285 1288 O
consent NCT03920891 1289 1296 O
form NCT03920891 1297 1301 O
( NCT03920891 1302 1303 O
illiterates NCT03920891 1304 1315 B-Condition-Name
, NCT03920891 1316 1317 O
foreigners NCT03920891 1318 1328 O
, NCT03920891 1329 1330 O
etc NCT03920891 1331 1334 O
. NCT03920891 1335 1336 O
) NCT03920891 1337 1338 O

- NCT03920891 1342 1343 O
12 NCT03920891 1346 1348 O
. NCT03920891 1348 1349 O
Other NCT03920891 1351 1356 O
patients NCT03920891 1357 1365 O
who NCT03920891 1366 1369 O
are NCT03920891 1370 1373 O
judged NCT03920891 1374 1380 O
by NCT03920891 1381 1383 O
the NCT03920891 1384 1387 O
principal NCT03920891 1388 1397 O
or NCT03920891 1398 1400 O
sub NCT03920891 1401 1404 O
- NCT03920891 1405 1406 O
investigator NCT03920891 1407 1419 O
to NCT03920891 1420 1422 O
be NCT03920891 1423 1425 O
ineligible NCT03920891 1426 1436 O
for NCT03920891 1437 1440 O
participation NCT03920891 1441 1454 O
in NCT03920891 1455 1457 O
this NCT03920891 1458 1462 O
clinical NCT03920891 1463 1471 O
study NCT03920891 1472 1477 O

Inclusion NCT03924349 0 9 O
Criteria NCT03924349 10 18 O
: NCT03924349 19 20 O

- NCT03924349 24 25 O
Cases NCT03924349 27 32 O
which NCT03924349 33 38 O
are NCT03924349 39 42 O
deemed NCT03924349 43 49 O
necessary NCT03924349 50 59 O
to NCT03924349 60 62 O
mark NCT03924349 63 67 O
the NCT03924349 68 71 O
location NCT03924349 72 80 O
of NCT03924349 81 83 O
the NCT03924349 84 87 O
colon NCT03924349 88 93 O
lesion NCT03924349 94 100 B-Condition-Name
before NCT03924349 101 107 O
surgery NCT03924349 108 115 B-Procedure-Name

Exclusion NCT03924349 116 125 O
Criteria NCT03924349 126 134 O
: NCT03924349 135 136 O

- NCT03924349 140 141 O
Pre NCT03924349 143 146 O
operative NCT03924349 147 156 B-Procedure-Name
colonoscopy NCT03924349 157 168 B-Procedure-Name
is NCT03924349 169 171 O
not NCT03924349 172 175 O
possible NCT03924349 176 184 O
due NCT03924349 185 188 O
to NCT03924349 189 191 O
intestinal NCT03924349 192 202 B-Condition-Name
obstruction NCT03924349 203 214 I-Condition-Name

- NCT03924349 217 218 O
If NCT03924349 220 222 O
the NCT03924349 223 226 O
lesion NCT03924349 227 233 B-Condition-Name
is NCT03924349 234 236 O
located NCT03924349 237 244 O
in NCT03924349 245 247 O
the NCT03924349 248 251 O
rectal NCT03924349 252 258 O
area NCT03924349 259 263 O
and NCT03924349 264 267 O
the NCT03924349 268 271 O
lesion NCT03924349 272 278 B-Condition-Name
can NCT03924349 279 282 O
be NCT03924349 283 285 O
confirmed NCT03924349 286 295 O
by NCT03924349 296 298 O
digital NCT03924349 299 306 O
rectal NCT03924349 307 313 B-Procedure-Name
exam NCT03924349 314 318 I-Procedure-Name

- NCT03924349 321 322 O
disagreement NCT03924349 324 336 O
with NCT03924349 337 341 O
the NCT03924349 342 345 O
study NCT03924349 346 351 O

Inclusion NCT03923426 0 9 O
Criteria NCT03923426 10 18 O
: NCT03923426 19 20 O

1 NCT03923426 25 26 O
. NCT03923426 26 27 O
Hospitalized NCT03923426 29 41 B-Encounter-Type___Encounter-Type-Value:inpatient
patient NCT03923426 42 49 O
≥ NCT03923426 50 51 B-Eq-Operator___Eq-Operator-Value:GTEQ
18 NCT03923426 53 55 B-Eq-Value
years NCT03923426 56 61 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03923426 62 65 O
or NCT03923426 66 68 O
considered NCT03923426 69 79 O
an NCT03923426 80 82 O
adult NCT03923426 83 88 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
in NCT03923426 89 91 O
accordance NCT03923426 92 102 O
with NCT03923426 103 107 O
the NCT03923426 108 111 O
age NCT03923426 112 115 O
of NCT03923426 116 118 O
majority NCT03923426 119 127 O
in NCT03923426 128 130 O
the NCT03923426 131 134 O
participant NCT03923426 135 146 O
's NCT03923426 146 148 O
country NCT03923426 149 156 O
of NCT03923426 157 159 O
residence NCT03923426 160 169 O
at NCT03923426 170 172 O
the NCT03923426 173 176 O
time NCT03923426 177 181 O
of NCT03923426 182 184 O
treatment NCT03923426 185 194 O
with NCT03923426 195 199 O
ceftazidime NCT03923426 200 211 B-Drug-Name
- NCT03923426 212 213 I-Drug-Name
avibactam NCT03923426 214 223 I-Drug-Name
. NCT03923426 224 225 O

2 NCT03923426 230 231 O
. NCT03923426 231 232 O
Patient NCT03923426 234 241 O
received NCT03923426 242 250 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
≥ NCT03923426 251 252 B-Eq-Operator___Eq-Operator-Value:GTEQ
1 NCT03923426 254 255 B-Eq-Value
dose NCT03923426 256 260 O
of NCT03923426 261 263 O
ceftazidime NCT03923426 264 275 B-Drug-Name
- NCT03923426 276 277 I-Drug-Name
avibactam NCT03923426 278 287 I-Drug-Name
in NCT03923426 288 290 O
routine NCT03923426 291 298 O
practice NCT03923426 299 307 O
at NCT03923426 308 310 O
participating NCT03923426 311 324 O
site NCT03923426 325 329 O
since NCT03923426 330 335 B-Eq-Operator___Eq-Operator-Value:GTEQ
01 NCT03923426 337 339 B-Eq-Value
January NCT03923426 340 347 I-Eq-Value
, NCT03923426 348 349 I-Eq-Value
2018 NCT03923426 351 355 I-Eq-Value
onwards NCT03923426 356 363 O
or NCT03923426 364 366 O
since NCT03923426 367 372 O
the NCT03923426 373 376 O
date NCT03923426 377 381 O
of NCT03923426 382 384 O
launch NCT03923426 385 391 O
in NCT03923426 392 394 O
the NCT03923426 395 398 O
country NCT03923426 399 406 O
if NCT03923426 407 409 O
it NCT03923426 410 412 O
is NCT03923426 413 415 O
after NCT03923426 416 421 O
01 NCT03923426 423 425 O
January NCT03923426 426 433 O
, NCT03923426 434 435 O
2018 NCT03923426 437 441 O
. NCT03923426 441 442 O

3 NCT03923426 447 448 O
. NCT03923426 448 449 O
Patient NCT03923426 451 458 O
underwent NCT03923426 459 468 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
microbiologic NCT03923426 469 482 B-Observation-Name___Observation-Type-Value:lab
sampling NCT03923426 483 491 I-Observation-Name___Observation-Type-Value:lab
≤ NCT03923426 492 493 B-Eq-Operator___Eq-Operator-Value:LTEQ
5 NCT03923426 495 496 B-Eq-Value
days NCT03923426 497 501 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
before NCT03923426 502 508 O
the NCT03923426 509 512 O
initiation NCT03923426 513 523 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
of NCT03923426 524 526 O
ceftazidime NCT03923426 527 538 B-Drug-Name
- NCT03923426 539 540 I-Drug-Name
avibactam NCT03923426 541 550 I-Drug-Name
( NCT03923426 551 552 O
irrespective NCT03923426 553 565 O
of NCT03923426 566 568 O
results NCT03923426 569 576 O
and NCT03923426 577 580 O
actual NCT03923426 581 587 O
bacteriological NCT03923426 588 603 O
identification NCT03923426 604 618 O
) NCT03923426 619 620 O
. NCT03923426 622 623 O

4 NCT03923426 628 629 O
. NCT03923426 629 630 O
Patient NCT03923426 632 639 O
has NCT03923426 640 643 O
all NCT03923426 644 647 O
required NCT03923426 648 656 O
essential NCT03923426 657 666 O
data NCT03923426 667 671 O
elements NCT03923426 672 680 O
which NCT03923426 681 686 O
include NCT03923426 687 694 O
: NCT03923426 695 696 O

1 NCT03923426 706 707 O
. NCT03923426 707 708 O
Start NCT03923426 710 715 O
and NCT03923426 716 719 O
stop NCT03923426 720 724 O
dates NCT03923426 725 730 O
of NCT03923426 731 733 O
ceftazidime NCT03923426 734 745 B-Drug-Name
- NCT03923426 746 747 I-Drug-Name
avibactam NCT03923426 748 757 I-Drug-Name
, NCT03923426 758 759 O

2 NCT03923426 769 770 O
. NCT03923426 770 771 O
Start NCT03923426 773 778 O
and NCT03923426 779 782 O
stop NCT03923426 783 787 O
dates NCT03923426 788 793 O
of NCT03923426 794 796 O
prior NCT03923426 797 802 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
antibiotic NCT03923426 803 813 B-Procedure-Name
therapy NCT03923426 814 821 I-Procedure-Name
used NCT03923426 822 826 O
for NCT03923426 827 830 O
the NCT03923426 831 834 O
index NCT03923426 835 840 O
infection NCT03923426 841 850 B-Condition-Name
, NCT03923426 851 852 O

3 NCT03923426 862 863 O
. NCT03923426 863 864 O
Type NCT03923426 866 870 O
of NCT03923426 871 873 O
combined NCT03923426 874 882 O
antibiotic NCT03923426 883 893 B-Procedure-Name
therapy NCT03923426 894 901 I-Procedure-Name
( NCT03923426 902 903 O
if NCT03923426 904 906 O
applicable NCT03923426 907 917 O
) NCT03923426 918 919 O
and NCT03923426 920 923 O
start NCT03923426 924 929 O
and NCT03923426 930 933 O
stop NCT03923426 934 938 O
dates NCT03923426 939 944 O
of NCT03923426 945 947 O
any NCT03923426 948 951 O
antibiotic NCT03923426 952 962 B-Drug-Name
combined NCT03923426 963 971 O
with NCT03923426 972 976 O
ceftazidime NCT03923426 977 988 B-Drug-Name
- NCT03923426 989 990 I-Drug-Name
avibactam NCT03923426 991 1000 I-Drug-Name
. NCT03923426 1001 1002 O

5 NCT03923426 1007 1008 O
. NCT03923426 1008 1009 O
Evidence NCT03923426 1011 1019 O
of NCT03923426 1020 1022 O
a NCT03923426 1023 1024 O
personally NCT03923426 1025 1035 O
signed NCT03923426 1036 1042 O
and NCT03923426 1043 1046 O
dated NCT03923426 1047 1052 O
informed NCT03923426 1053 1061 O
consent NCT03923426 1062 1069 O
document NCT03923426 1070 1078 O
indicating NCT03923426 1079 1089 O
that NCT03923426 1090 1094 O
the NCT03923426 1095 1098 O
patient NCT03923426 1099 1106 O
( NCT03923426 1107 1108 O
or NCT03923426 1109 1111 O
a NCT03923426 1112 1113 O
legally NCT03923426 1114 1121 O
acceptable NCT03923426 1122 1132 O
representative NCT03923426 1133 1147 O
) NCT03923426 1148 1149 O
has NCT03923426 1150 1153 O
been NCT03923426 1154 1158 O
informed NCT03923426 1159 1167 O
of NCT03923426 1168 1170 O
all NCT03923426 1171 1174 O
pertinent NCT03923426 1175 1184 O
aspects NCT03923426 1185 1192 O
of NCT03923426 1193 1195 O
the NCT03923426 1196 1199 O
study NCT03923426 1200 1205 O
where NCT03923426 1206 1211 O
required NCT03923426 1212 1220 O
by NCT03923426 1221 1223 O
local NCT03923426 1224 1229 O
regulations NCT03923426 1230 1241 O
. NCT03923426 1242 1243 O

Exclusion NCT03923426 1245 1254 O
Criteria NCT03923426 1255 1263 O
: NCT03923426 1264 1265 O

Patients NCT03923426 1267 1275 O
must NCT03923426 1276 1280 O
not NCT03923426 1281 1284 O
meet NCT03923426 1285 1289 O
any NCT03923426 1290 1293 O
of NCT03923426 1294 1296 O
the NCT03923426 1297 1300 O
following NCT03923426 1301 1310 O
exclusion NCT03923426 1311 1320 O
criteria NCT03923426 1321 1329 O
to NCT03923426 1330 1332 O
be NCT03923426 1333 1335 O
eligible NCT03923426 1336 1344 O
: NCT03923426 1345 1346 O

1 NCT03923426 1351 1352 O
. NCT03923426 1352 1353 O
The NCT03923426 1355 1358 O
patient NCT03923426 1359 1366 O
is NCT03923426 1367 1369 O
enrolled NCT03923426 1370 1378 O
in NCT03923426 1379 1381 O
any NCT03923426 1382 1385 O
clinical NCT03923426 1386 1394 O
trial NCT03923426 1395 1400 O
of NCT03923426 1401 1403 O
an NCT03923426 1404 1406 O
investigational NCT03923426 1407 1422 O
product NCT03923426 1423 1430 O
. NCT03923426 1431 1432 O
Patients NCT03923426 1434 1442 O
who NCT03923426 1443 1446 O
are NCT03923426 1447 1450 O
enrolled NCT03923426 1451 1459 O
in NCT03923426 1460 1462 O
non NCT03923426 1463 1466 O
- NCT03923426 1467 1468 O
interventional NCT03923426 1469 1483 O
studies NCT03923426 1484 1491 O
( NCT03923426 1492 1493 O
NISs NCT03923426 1494 1498 O
) NCT03923426 1499 1500 O
( NCT03923426 1501 1502 O
e NCT03923426 1503 1504 O
. NCT03923426 1505 1506 O
g NCT03923426 1507 1508 O
. NCT03923426 1509 1510 O
registries NCT03923426 1512 1522 O
) NCT03923426 1523 1524 O
are NCT03923426 1525 1528 O
eligible NCT03923426 1529 1537 O
for NCT03923426 1538 1541 O
inclusion NCT03923426 1542 1551 O
. NCT03923426 1552 1553 O

2 NCT03923426 1558 1559 O
. NCT03923426 1559 1560 O
The NCT03923426 1562 1565 O
patient NCT03923426 1566 1573 O
has NCT03923426 1574 1577 O
received NCT03923426 1578 1586 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
ceftazidime NCT03923426 1587 1598 B-Drug-Name
- NCT03923426 1599 1600 I-Drug-Name
avibactam NCT03923426 1601 1610 I-Drug-Name
in NCT03923426 1611 1613 O
a NCT03923426 1614 1615 O
compassionate NCT03923426 1616 1629 B-Procedure-Name
care NCT03923426 1630 1634 I-Procedure-Name
program NCT03923426 1635 1642 I-Procedure-Name
setting NCT03923426 1643 1650 O
. NCT03923426 1651 1652 O

3 NCT03923426 1657 1658 O
. NCT03923426 1658 1659 O
The NCT03923426 1661 1664 O
patient NCT03923426 1665 1672 O
was NCT03923426 1673 1676 O
exposed NCT03923426 1677 1684 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
to NCT03923426 1685 1687 O
ceftazidime NCT03923426 1688 1699 B-Drug-Name
- NCT03923426 1700 1701 I-Drug-Name
avibactam NCT03923426 1702 1711 I-Drug-Name
before NCT03923426 1712 1718 O
use NCT03923426 1719 1722 O
for NCT03923426 1723 1726 O
the NCT03923426 1727 1730 O
index NCT03923426 1731 1736 O
infection NCT03923426 1737 1746 B-Condition-Name
. NCT03923426 1747 1748 O

Inclusion NCT03929679 0 9 O
Criteria NCT03929679 10 18 O
: NCT03929679 19 20 O

- NCT03929679 24 25 O
Signed NCT03929679 27 33 O
informed NCT03929679 34 42 O
consent NCT03929679 43 50 O
obtained NCT03929679 51 59 O
before NCT03929679 60 66 O
any NCT03929679 67 70 O
study NCT03929679 71 76 O
- NCT03929679 77 78 O
related NCT03929679 79 86 O
activities NCT03929679 87 97 O
( NCT03929679 98 99 O
study NCT03929679 100 105 O
- NCT03929679 106 107 O
related NCT03929679 108 115 O
activities NCT03929679 116 126 O
are NCT03929679 127 130 O
any NCT03929679 131 134 O
procedures NCT03929679 135 145 O
related NCT03929679 146 153 O
to NCT03929679 154 156 O
recording NCT03929679 157 166 O
of NCT03929679 167 169 O
data NCT03929679 170 174 O
according NCT03929679 175 184 O
to NCT03929679 185 187 O
protocol NCT03929679 188 196 O
) NCT03929679 197 198 O

- NCT03929679 202 203 O
The NCT03929679 205 208 O
decision NCT03929679 209 217 O
to NCT03929679 218 220 O
initiate NCT03929679 221 229 O
treatment NCT03929679 230 239 O
with NCT03929679 240 244 O
commercially NCT03929679 245 257 O
available NCT03929679 258 267 O
semaglutide NCT03929679 268 279 O
has NCT03929679 280 283 O
been NCT03929679 284 288 O
made NCT03929679 289 293 O
by NCT03929679 294 296 O
the NCT03929679 297 300 O
patient NCT03929679 301 308 O
/ NCT03929679 309 310 O
Legally NCT03929679 311 318 O
Acceptable NCT03929679 319 329 O
Representative NCT03929679 330 344 O
and NCT03929679 345 348 O
the NCT03929679 349 352 O
treating NCT03929679 353 361 O
physician NCT03929679 362 371 O
before NCT03929679 372 378 O
and NCT03929679 379 382 O
independently NCT03929679 383 396 O
from NCT03929679 397 401 O
the NCT03929679 402 405 O
decision NCT03929679 406 414 O
to NCT03929679 415 417 O
include NCT03929679 418 425 O
the NCT03929679 426 429 O
patient NCT03929679 430 437 O
in NCT03929679 438 440 O
this NCT03929679 441 445 O
study NCT03929679 446 451 O

- NCT03929679 454 455 O
Male NCT03929679 457 461 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
or NCT03929679 462 464 O
female NCT03929679 465 471 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
, NCT03929679 472 473 O
age NCT03929679 474 477 O
greater NCT03929679 478 485 B-Eq-Operator___Eq-Operator-Value:GTEQ
than NCT03929679 486 490 I-Eq-Operator___Eq-Operator-Value:GTEQ
or NCT03929679 491 493 I-Eq-Operator___Eq-Operator-Value:GTEQ
equal NCT03929679 494 499 I-Eq-Operator___Eq-Operator-Value:GTEQ
to NCT03929679 500 502 O
18 NCT03929679 504 506 B-Eq-Value
years NCT03929679 507 512 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
at NCT03929679 513 515 O
the NCT03929679 516 519 O
time NCT03929679 520 524 O
of NCT03929679 525 527 O
signing NCT03929679 528 535 O
informed NCT03929679 536 544 O
consent NCT03929679 545 552 O

- NCT03929679 555 556 O
Diagnosed NCT03929679 558 567 O
with NCT03929679 568 572 O
type NCT03929679 573 577 B-Condition-Name
2 NCT03929679 579 580 I-Condition-Name
diabetes NCT03929679 581 589 I-Condition-Name
at NCT03929679 590 592 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03929679 593 598 I-Eq-Operator___Eq-Operator-Value:GTEQ
12 NCT03929679 600 602 B-Eq-Value
weeks NCT03929679 603 608 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
prior NCT03929679 609 614 O
to NCT03929679 615 617 O
inclusion NCT03929679 618 627 O

- NCT03929679 630 631 O
Available NCT03929679 633 642 O
and NCT03929679 643 646 O
documented NCT03929679 647 657 O
haemoglobin NCT03929679 658 669 B-Observation-Name___Observation-Type-Value:lab
A NCT03929679 670 671 I-Observation-Name___Observation-Type-Value:lab
1c NCT03929679 672 674 I-Observation-Name___Observation-Type-Value:lab
( NCT03929679 675 676 O
HbA NCT03929679 677 680 B-Observation-Name___Observation-Type-Value:lab
1c NCT03929679 681 683 I-Observation-Name___Observation-Type-Value:lab
) NCT03929679 684 685 O
value NCT03929679 686 691 O
less NCT03929679 692 696 B-Eq-Operator___Eq-Operator-Value:LTEQ
than NCT03929679 697 701 I-Eq-Operator___Eq-Operator-Value:LTEQ
or NCT03929679 702 704 I-Eq-Operator___Eq-Operator-Value:LTEQ
equal NCT03929679 705 710 I-Eq-Operator___Eq-Operator-Value:LTEQ
to NCT03929679 711 713 O
12 NCT03929679 715 717 B-Eq-Value
weeks NCT03929679 718 723 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
prior NCT03929679 724 729 O
to NCT03929679 730 732 O
initiation NCT03929679 733 743 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
of NCT03929679 744 746 O
semaglutide NCT03929679 747 758 B-Drug-Name
treatment NCT03929679 759 768 O

Exclusion NCT03929679 769 778 O
Criteria NCT03929679 779 787 O
: NCT03929679 788 789 O

- NCT03929679 793 794 O
Previous NCT03929679 796 804 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
participation NCT03929679 805 818 O
in NCT03929679 819 821 O
this NCT03929679 822 826 O
study NCT03929679 827 832 O
. NCT03929679 833 834 O
Participation NCT03929679 836 849 O
is NCT03929679 850 852 O
defined NCT03929679 853 860 O
as NCT03929679 861 863 O
having NCT03929679 864 870 O
given NCT03929679 871 876 O
informed NCT03929679 877 885 O
consent NCT03929679 886 893 O
in NCT03929679 894 896 O
this NCT03929679 897 901 O
study NCT03929679 902 907 O

- NCT03929679 910 911 O
Mental NCT03929679 913 919 B-Condition-Name
incapacity NCT03929679 920 930 I-Condition-Name
, NCT03929679 931 932 O
unwillingness NCT03929679 933 946 O
or NCT03929679 947 949 O
language NCT03929679 950 958 B-Condition-Name
barriers NCT03929679 959 967 I-Condition-Name
precluding NCT03929679 968 978 O
adequate NCT03929679 979 987 O
understanding NCT03929679 988 1001 O
or NCT03929679 1002 1004 O
cooperation NCT03929679 1005 1016 O

- NCT03929679 1019 1020 O
Treatment NCT03929679 1022 1031 O
with NCT03929679 1032 1036 O
any NCT03929679 1037 1040 O
investigational NCT03929679 1041 1056 O
drug NCT03929679 1057 1061 O
within NCT03929679 1062 1068 B-Eq-Operator___Eq-Operator-Value:LTEQ
90 NCT03929679 1070 1072 B-Eq-Value
days NCT03929679 1073 1077 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
prior NCT03929679 1078 1083 O
to NCT03929679 1084 1086 O
enrolment NCT03929679 1087 1096 O
into NCT03929679 1097 1101 O
the NCT03929679 1102 1105 O
study NCT03929679 1106 1111 O

- NCT03929679 1114 1115 O
Hypersensitivity NCT03929679 1117 1133 B-Condition-Name
to NCT03929679 1134 1136 O
semaglutide NCT03929679 1137 1148 B-Drug-Name
or NCT03929679 1149 1151 O
to NCT03929679 1152 1154 O
any NCT03929679 1155 1158 O
of NCT03929679 1159 1161 O
the NCT03929679 1162 1165 O
excipients NCT03929679 1166 1176 O

Inclusion NCT03924375 0 9 O
Criteria NCT03924375 10 18 O
: NCT03924375 19 20 O

- NCT03924375 24 25 O
Gastroscopy NCT03924375 27 38 B-Procedure-Name
can NCT03924375 39 42 O
be NCT03924375 43 45 O
performed NCT03924375 46 55 O

- NCT03924375 58 59 O
Serologic NCT03924375 61 70 B-Observation-Name___Observation-Type-Value:lab
markers NCT03924375 71 78 I-Observation-Name___Observation-Type-Value:lab
including NCT03924375 79 88 O
serum NCT03924375 89 94 B-Observation-Name___Observation-Type-Value:lab
pepsinogen NCT03924375 95 105 I-Observation-Name___Observation-Type-Value:lab
can NCT03924375 106 109 O
be NCT03924375 110 112 O
measured NCT03924375 113 121 O

Exclusion NCT03924375 122 131 O
Criteria NCT03924375 132 140 O
: NCT03924375 141 142 O

- NCT03924375 146 147 O
Age NCT03924375 149 152 O
< NCT03924375 153 154 B-Eq-Operator___Eq-Operator-Value:LT
20 NCT03924375 156 158 B-Eq-Value
or NCT03924375 159 161 O
> NCT03924375 162 163 B-Eq-Operator___Eq-Operator-Value:GT
70 NCT03924375 165 167 B-Eq-Value
years NCT03924375 168 173 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03924375 176 177 O
Anemia NCT03924375 179 185 B-Condition-Name
( NCT03924375 186 187 O
serum NCT03924375 188 193 B-Observation-Name___Observation-Type-Value:lab
hemoglobin NCT03924375 194 204 I-Observation-Name___Observation-Type-Value:lab
level NCT03924375 205 210 I-Observation-Name___Observation-Type-Value:lab
< NCT03924375 211 212 B-Eq-Operator___Eq-Operator-Value:LT
10 NCT03924375 214 216 B-Eq-Value
g NCT03924375 217 218 B-Eq-Unit
/ NCT03924375 219 220 O
dL NCT03924375 221 223 B-Eq-Unit
) NCT03924375 224 225 O

- NCT03924375 229 230 O
Severe NCT03924375 232 238 B-Severity___Severity-Value:severe
systemic NCT03924375 239 247 O
disease NCT03924375 248 255 B-Condition-Name

- NCT03924375 258 259 O
Advanced NCT03924375 261 269 B-Severity___Severity-Value:severe
chronic NCT03924375 270 277 O
liver NCT03924375 278 283 B-Condition-Name
disease NCT03924375 284 291 I-Condition-Name

- NCT03924375 294 295 O
Use NCT03924375 297 300 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
of NCT03924375 301 303 O
certain NCT03924375 304 311 O
medications NCT03924375 312 323 O
, NCT03924375 324 325 O
including NCT03924375 326 335 O
proton NCT03924375 336 342 B-Drug-Name
pump NCT03924375 343 347 I-Drug-Name
inhibitors NCT03924375 348 358 I-Drug-Name
, NCT03924375 359 360 O
H NCT03924375 361 362 B-Drug-Name
2 NCT03924375 363 364 I-Drug-Name
- NCT03924375 365 366 I-Drug-Name
receptor NCT03924375 367 375 I-Drug-Name
antagonists NCT03924375 376 387 I-Drug-Name
, NCT03924375 388 389 O
or NCT03924375 390 392 O
antibiotics NCT03924375 393 404 B-Drug-Name

- NCT03924375 407 408 O
History NCT03924375 410 417 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03924375 418 420 O
H NCT03924375 421 422 B-Organism-Name
. NCT03924375 423 424 I-Organism-Name
pylori NCT03924375 426 432 I-Organism-Name
eradication NCT03924375 433 444 B-Condition-Name

- NCT03924375 447 448 O
History NCT03924375 450 457 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03924375 458 460 O
gastric NCT03924375 461 468 B-Procedure-Name
surgery NCT03924375 469 476 I-Procedure-Name

- NCT03924375 479 480 O
Recent NCT03924375 482 488 O
history NCT03924375 489 496 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03924375 497 499 O
upper NCT03924375 500 505 O
gastrointestinal NCT03924375 506 522 O
bleeding NCT03924375 523 531 B-Condition-Name

Inclusion NCT03921580 0 9 O
Criteria NCT03921580 10 18 O
: NCT03921580 19 20 O

- NCT03921580 24 25 O
Men NCT03921580 27 30 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
and NCT03921580 31 34 O
women NCT03921580 35 40 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
from NCT03921580 41 45 O
18 NCT03921580 47 49 B-Eq-Value
to NCT03921580 50 52 B-Eq-Operator___Eq-Operator-Value:BETWEEN
65 NCT03921580 54 56 B-Eq-Value
years NCT03921580 57 62 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03921580 63 66 O
. NCT03921580 67 68 O

- NCT03921580 72 73 O
Body NCT03921580 75 79 B-Observation-Name___Observation-Type-Value:vital
Mass NCT03921580 80 84 I-Observation-Name___Observation-Type-Value:vital
Index NCT03921580 85 90 I-Observation-Name___Observation-Type-Value:vital
( NCT03921580 91 92 O
BMI NCT03921580 93 96 B-Observation-Name___Observation-Type-Value:vital
) NCT03921580 97 98 O
≥ NCT03921580 99 100 B-Eq-Operator___Eq-Operator-Value:GTEQ
25 NCT03921580 102 104 B-Eq-Value
and NCT03921580 105 108 O
< NCT03921580 109 110 B-Eq-Operator___Eq-Operator-Value:LT
30 NCT03921580 112 114 B-Eq-Value
kg NCT03921580 115 117 B-Eq-Unit
/ NCT03921580 118 119 O
m NCT03921580 120 121 B-Eq-Unit
2 NCT03921580 122 123 I-Eq-Unit
. NCT03921580 123 124 O

- NCT03921580 128 129 O
Adequate NCT03921580 131 139 O
cultural NCT03921580 140 148 O
level NCT03921580 149 154 O
and NCT03921580 155 158 O
understanding NCT03921580 159 172 O
for NCT03921580 173 176 O
the NCT03921580 177 180 O
clinical NCT03921580 181 189 O
trial NCT03921580 190 195 O
. NCT03921580 196 197 O

- NCT03921580 201 202 O
Signed NCT03921580 204 210 O
informed NCT03921580 211 219 O
consent NCT03921580 220 227 O

Exclusion NCT03921580 228 237 O
Criteria NCT03921580 238 246 O
: NCT03921580 247 248 O

- NCT03921580 252 253 O
Subjects NCT03921580 255 263 O
with NCT03921580 264 268 O
BMI NCT03921580 269 272 B-Observation-Name___Observation-Type-Value:vital
≥ NCT03921580 273 274 B-Eq-Operator___Eq-Operator-Value:GTEQ
30 NCT03921580 276 278 B-Eq-Value
or NCT03921580 279 281 O
< NCT03921580 282 283 B-Eq-Operator___Eq-Operator-Value:LT
25 NCT03921580 285 287 B-Eq-Value
kg NCT03921580 288 290 B-Eq-Unit
/ NCT03921580 291 292 O
m NCT03921580 293 294 B-Eq-Unit
2 NCT03921580 295 296 I-Eq-Unit

- NCT03921580 299 300 O
Subjects NCT03921580 302 310 O
diagnosed NCT03921580 311 320 O
with NCT03921580 321 325 O
Diabetes NCT03921580 326 334 B-Condition-Name
Mellitus NCT03921580 335 343 I-Condition-Name
. NCT03921580 344 345 O

- NCT03921580 349 350 O
Subjects NCT03921580 352 360 O
with NCT03921580 361 365 O
dyslipidemia NCT03921580 366 378 B-Condition-Name
on NCT03921580 379 381 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
pharmacological NCT03921580 382 397 B-Procedure-Name
treatment NCT03921580 398 407 I-Procedure-Name

- NCT03921580 410 411 O
Subjects NCT03921580 413 421 O
with NCT03921580 422 426 O
hypertension NCT03921580 427 439 B-Condition-Name
on NCT03921580 440 442 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
pharmacological NCT03921580 443 458 B-Procedure-Name
treatment NCT03921580 459 468 I-Procedure-Name

- NCT03921580 471 472 O
Subjects NCT03921580 474 482 O
with NCT03921580 483 487 O
established NCT03921580 488 499 O
diagnosis NCT03921580 500 509 O
of NCT03921580 510 512 O
eating NCT03921580 513 519 B-Condition-Name
disorder NCT03921580 520 528 I-Condition-Name

- NCT03921580 531 532 O
Smokers NCT03921580 534 541 O
or NCT03921580 542 544 O
those NCT03921580 545 550 O
subjects NCT03921580 551 559 O
with NCT03921580 560 564 O
high NCT03921580 565 569 B-Polarity___Polarity-Value:high
alcohol NCT03921580 570 577 B-Observation-Name___Observation-Type-Value:social-habit
consumption NCT03921580 578 589 I-Observation-Name___Observation-Type-Value:social-habit
( NCT03921580 590 591 O
> NCT03921580 593 594 B-Eq-Operator___Eq-Operator-Value:GT
2 NCT03921580 596 597 B-Eq-Value
- NCT03921580 598 599 B-Eq-Operator___Eq-Operator-Value:BETWEEN
3 NCT03921580 601 602 B-Eq-Value
servings NCT03921580 603 611 B-Eq-Unit
/ NCT03921580 612 613 O
day NCT03921580 614 617 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
in NCT03921580 618 620 O
men NCT03921580 621 624 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
and NCT03921580 625 628 O
> NCT03921580 629 630 B-Eq-Operator___Eq-Operator-Value:GT
1 NCT03921580 632 633 B-Eq-Value
serving NCT03921580 634 641 B-Eq-Unit
/ NCT03921580 642 643 O
day NCT03921580 644 647 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
in NCT03921580 648 650 O
women NCT03921580 651 656 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
( NCT03921580 657 658 O
1 NCT03921580 660 661 O
serving NCT03921580 662 669 O
= NCT03921580 670 671 O
1 NCT03921580 673 674 O
glass NCT03921580 675 680 O
of NCT03921580 681 683 O
wine NCT03921580 684 688 O
or NCT03921580 689 691 O
1 NCT03921580 693 694 O
bottle NCT03921580 695 701 O
of NCT03921580 702 704 O
beer NCT03921580 705 709 O
) NCT03921580 710 711 O

- NCT03921580 715 716 O
Subjects NCT03921580 718 726 O
under NCT03921580 727 732 O
pharmacological NCT03921580 733 748 B-Procedure-Name
treatment NCT03921580 749 758 I-Procedure-Name
( NCT03921580 759 760 O
except NCT03921580 761 767 O
oral NCT03921580 768 772 B-Drug-Name
contraceptives NCT03921580 773 787 I-Drug-Name
) NCT03921580 788 789 O

- NCT03921580 793 794 O
Subjects NCT03921580 796 804 O
with NCT03921580 805 809 O
large NCT03921580 810 815 B-Polarity___Polarity-Value:high
weight NCT03921580 816 822 B-Observation-Name___Observation-Type-Value:vital
fluctuations NCT03921580 823 835 B-Stability___Stability-Value:change
of NCT03921580 836 838 O
more NCT03921580 839 843 B-Eq-Operator___Eq-Operator-Value:GTEQ
than NCT03921580 844 848 I-Eq-Operator___Eq-Operator-Value:GTEQ
4 NCT03921580 850 851 B-Eq-Value
kg NCT03921580 852 854 B-Eq-Unit
or NCT03921580 855 857 O
who NCT03921580 858 861 O
have NCT03921580 862 866 O
undergone NCT03921580 867 876 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
in NCT03921580 877 879 O
six NCT03921580 880 883 B-Eq-Value
months NCT03921580 884 890 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
a NCT03921580 891 892 O
weight NCT03921580 893 899 B-Procedure-Name
loss NCT03921580 900 904 I-Procedure-Name
diet NCT03921580 905 909 I-Procedure-Name

- NCT03921580 912 913 O
Subjects NCT03921580 915 923 O
with NCT03921580 924 928 O
sensory NCT03921580 929 936 O
problems NCT03921580 937 945 O

- NCT03921580 948 949 O
Subjects NCT03921580 951 959 O
with NCT03921580 960 964 O
gastrointestinal NCT03921580 965 981 B-Condition-Name
diseases NCT03921580 982 990 I-Condition-Name
that NCT03921580 991 995 O
affect NCT03921580 996 1002 B-Stability___Stability-Value:change
the NCT03921580 1003 1006 O
digestion NCT03921580 1007 1016 B-Condition-Name
or NCT03921580 1017 1019 O
absorption NCT03921580 1020 1030 B-Condition-Name
of NCT03921580 1031 1033 I-Condition-Name
nutrients NCT03921580 1034 1043 I-Condition-Name

- NCT03921580 1046 1047 O
Pregnant NCT03921580 1049 1057 B-Condition-Name
or NCT03921580 1058 1060 O
breastfeeding NCT03921580 1061 1074 B-Condition-Name
women NCT03921580 1075 1080 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female

- NCT03921580 1083 1084 O
Women NCT03921580 1086 1091 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
with NCT03921580 1092 1096 O
menstrual NCT03921580 1097 1106 B-Condition-Name
irregularities NCT03921580 1107 1121 I-Condition-Name
( NCT03921580 1122 1123 O
absence NCT03921580 1124 1131 B-Condition-Name
of NCT03921580 1132 1134 I-Condition-Name
menstrual NCT03921580 1135 1144 I-Condition-Name
cycle NCT03921580 1145 1150 I-Condition-Name
at NCT03921580 1151 1153 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03921580 1154 1159 I-Eq-Operator___Eq-Operator-Value:GTEQ
2 NCT03921580 1161 1162 B-Eq-Value
months NCT03921580 1163 1169 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
) NCT03921580 1170 1171 O

- NCT03921580 1175 1176 O
Subjects NCT03921580 1178 1186 O
with NCT03921580 1187 1191 O
intense NCT03921580 1192 1199 B-Severity___Severity-Value:severe
physical NCT03921580 1200 1208 B-Observation-Name___Observation-Type-Value:social-habit
activity NCT03921580 1209 1217 I-Observation-Name___Observation-Type-Value:social-habit
. NCT03921580 1218 1219 O

- NCT03921580 1223 1224 O
Subjects NCT03921580 1226 1234 O
with NCT03921580 1235 1239 O
food NCT03921580 1240 1244 B-Allergy-Name
allergies NCT03921580 1245 1254 O
to NCT03921580 1255 1257 O
meals NCT03921580 1258 1263 O
included NCT03921580 1264 1272 O
in NCT03921580 1273 1275 O
breakfast NCT03921580 1276 1285 O
, NCT03921580 1286 1287 O
study NCT03921580 1288 1293 O
product NCT03921580 1294 1301 O
or NCT03921580 1302 1304 O
lunch NCT03921580 1305 1310 O
or NCT03921580 1311 1313 O
that NCT03921580 1314 1318 O
reject NCT03921580 1319 1325 O
their NCT03921580 1326 1331 O
consumption NCT03921580 1332 1343 O

- NCT03921580 1346 1347 O
Subjects NCT03921580 1349 1357 O
with NCT03921580 1358 1362 O
a NCT03921580 1363 1364 O
diagnosis NCT03921580 1365 1374 O
of NCT03921580 1375 1377 O
celiac NCT03921580 1378 1384 B-Condition-Name
disease NCT03921580 1385 1392 I-Condition-Name
or NCT03921580 1393 1395 O
a NCT03921580 1396 1397 O
gluten NCT03921580 1398 1404 B-Condition-Name
intolerance NCT03921580 1405 1416 I-Condition-Name

Inclusion NCT03929692 0 9 O
Criteria NCT03929692 10 18 O
: NCT03929692 19 20 O

- NCT03929692 24 25 O
Intervention NCT03929692 27 39 O
group NCT03929692 40 45 O
: NCT03929692 46 47 O
Participants NCT03929692 48 60 O
must NCT03929692 61 65 O
be NCT03929692 66 68 O
in NCT03929692 69 71 O
10 NCT03929692 73 75 O
th NCT03929692 76 78 O
school NCT03929692 79 85 O
grade NCT03929692 86 91 O
or NCT03929692 92 94 O
aged NCT03929692 95 99 O
15 NCT03929692 101 103 B-Eq-Value
to NCT03929692 104 106 B-Eq-Operator___Eq-Operator-Value:BETWEEN
16 NCT03929692 108 110 B-Eq-Value
years NCT03929692 111 116 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
when NCT03929692 117 121 O
recruited NCT03929692 122 131 O
in NCT03929692 132 134 O
training NCT03929692 135 143 O
companies NCT03929692 144 153 O
. NCT03929692 154 155 O

- NCT03929692 159 160 O
Control NCT03929692 162 169 O
Group NCT03929692 170 175 O
: NCT03929692 176 177 O
Participants NCT03929692 178 190 O
must NCT03929692 191 195 O
be NCT03929692 196 198 O
in NCT03929692 199 201 O
12 NCT03929692 203 205 O
th NCT03929692 206 208 O
school NCT03929692 209 215 O
grade NCT03929692 216 221 O
or NCT03929692 222 224 O
aged NCT03929692 225 229 O
17 NCT03929692 231 233 B-Eq-Value
to NCT03929692 234 236 B-Eq-Operator___Eq-Operator-Value:BETWEEN
18 NCT03929692 238 240 B-Eq-Value
years NCT03929692 241 246 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
when NCT03929692 247 251 O
recruited NCT03929692 252 261 O
in NCT03929692 262 264 O
training NCT03929692 265 273 O
companies NCT03929692 274 283 O
. NCT03929692 284 285 O

Exclusion NCT03929692 287 296 O
Criteria NCT03929692 297 305 O
: NCT03929692 306 307 O

- NCT03929692 310 311 O
none NCT03929692 312 316 O

Inclusion NCT03927456 0 9 O
Criteria NCT03927456 10 18 O
: NCT03927456 19 20 O

1 NCT03927456 25 26 O
. NCT03927456 26 27 O
Has NCT03927456 29 32 O
the NCT03927456 33 36 O
pathologically NCT03927456 37 51 O
- NCT03927456 52 53 O
confirmed NCT03927456 54 63 O
diagnosis NCT03927456 64 73 O
of NCT03927456 74 76 O
locally NCT03927456 77 84 O
recurrent NCT03927456 85 94 O
or NCT03927456 95 97 O
metastatic NCT03927456 98 108 O
, NCT03927456 109 110 O
hormone NCT03927456 111 118 O
- NCT03927456 119 120 O
receptor NCT03927456 121 129 O
positive NCT03927456 130 138 O
, NCT03927456 139 140 O
HER NCT03927456 141 144 O
2 NCT03927456 145 146 O
negative NCT03927456 147 155 O
Breast NCT03927456 156 162 O
Cancer NCT03927456 163 169 B-Condition-Name
. NCT03927456 170 171 O

2 NCT03927456 176 177 O
. NCT03927456 177 178 O
Age NCT03927456 180 183 O
: NCT03927456 184 185 O
18 NCT03927456 187 189 B-Eq-Value
- NCT03927456 190 191 B-Eq-Operator___Eq-Operator-Value:BETWEEN
75 NCT03927456 193 195 B-Eq-Value
years NCT03927456 196 201 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03927456 202 205 O
, NCT03927456 206 207 O
postmenopausal NCT03927456 208 222 B-Condition-Name
women NCT03927456 223 228 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
or NCT03927456 229 231 O
prepostmenopausal NCT03927456 232 249 B-Condition-Name
women NCT03927456 250 255 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female

3 NCT03927456 259 260 O
. NCT03927456 260 261 O
Received NCT03927456 263 271 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
prior NCT03927456 272 277 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
endocrine NCT03927456 278 287 B-Procedure-Name
therapy NCT03927456 288 295 I-Procedure-Name

4 NCT03927456 299 300 O
. NCT03927456 300 301 O
One NCT03927456 303 306 B-Eq-Value
previous NCT03927456 307 315 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
line NCT03927456 316 320 O
of NCT03927456 321 323 O
chemotherapy NCT03927456 324 336 B-Procedure-Name
for NCT03927456 337 340 O
advanced NCT03927456 341 349 O
/ NCT03927456 350 351 O
metastatic NCT03927456 352 362 O
disease NCT03927456 363 370 B-Condition-Name
is NCT03927456 371 373 O
allowed NCT03927456 374 381 O
in NCT03927456 382 384 O
addition NCT03927456 385 393 O
to NCT03927456 394 396 O
endocrine NCT03927456 397 406 B-Procedure-Name
therapy NCT03927456 407 414 I-Procedure-Name
. NCT03927456 415 416 O

5 NCT03927456 421 422 O
. NCT03927456 422 423 O
Eastern NCT03927456 425 432 B-Condition-Name
Cooperative NCT03927456 433 444 I-Condition-Name
Oncology NCT03927456 445 453 I-Condition-Name
Group NCT03927456 454 459 I-Condition-Name
[ NCT03927456 460 461 O
ECOG NCT03927456 462 466 B-Condition-Name
] NCT03927456 467 468 O
0 NCT03927456 470 471 B-Eq-Value
- NCT03927456 472 473 B-Eq-Operator___Eq-Operator-Value:BETWEEN
1 NCT03927456 475 476 B-Eq-Value

Exclusion NCT03927456 478 487 O
Criteria NCT03927456 488 496 O
: NCT03927456 497 498 O

1 NCT03927456 503 504 O
. NCT03927456 504 505 O
Patients NCT03927456 507 515 O
who NCT03927456 516 519 O
received NCT03927456 520 528 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
prior NCT03927456 529 534 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
treatment NCT03927456 535 544 O
with NCT03927456 545 549 O
any NCT03927456 550 553 O
CDK NCT03927456 554 557 B-Drug-Name
4 NCT03927456 558 559 I-Drug-Name
/ NCT03927456 560 561 I-Drug-Name
6 NCT03927456 563 564 I-Drug-Name
inhibitor NCT03927456 565 574 I-Drug-Name
, NCT03927456 575 576 O
everolimus NCT03927456 577 587 B-Drug-Name
or NCT03927456 588 590 O
fulvestant NCT03927456 591 601 B-Drug-Name
. NCT03927456 602 603 O

2 NCT03927456 608 609 O
. NCT03927456 609 610 O
Clinically NCT03927456 612 622 O
significant NCT03927456 623 634 B-Severity___Severity-Value:severe
cardiovascular NCT03927456 635 649 O
and NCT03927456 650 653 O
cerebrovascular NCT03927456 654 669 O
diseases NCT03927456 670 678 B-Condition-Name
, NCT03927456 679 680 O
including NCT03927456 681 690 O
but NCT03927456 691 694 O
not NCT03927456 695 698 O
limited NCT03927456 699 706 O
to NCT03927456 707 709 O
severe NCT03927456 710 716 B-Severity___Severity-Value:severe
acute NCT03927456 717 722 B-Condition-Name
myocardial NCT03927456 723 733 I-Condition-Name
infarction NCT03927456 734 744 I-Condition-Name
within NCT03927456 745 751 B-Eq-Operator___Eq-Operator-Value:LTEQ
6 NCT03927456 753 754 B-Eq-Value
months NCT03927456 755 761 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
before NCT03927456 762 768 O
enrollment NCT03927456 769 779 O
, NCT03927456 780 781 O
unstable NCT03927456 782 790 O
or NCT03927456 791 793 O
severe NCT03927456 794 800 B-Severity___Severity-Value:severe
angina NCT03927456 801 807 B-Condition-Name
, NCT03927456 808 809 O
Congestive NCT03927456 810 820 B-Condition-Name
heart NCT03927456 821 826 I-Condition-Name
failure NCT03927456 827 834 I-Condition-Name
( NCT03927456 835 836 O
New NCT03927456 837 840 B-Condition-Name
York NCT03927456 841 845 I-Condition-Name
heart NCT03927456 846 851 I-Condition-Name
association NCT03927456 852 863 I-Condition-Name
( NCT03927456 864 865 O
NYHA NCT03927456 866 870 B-Condition-Name
) NCT03927456 871 872 O
class NCT03927456 873 878 B-Eq-Unit
> NCT03927456 879 880 B-Eq-Operator___Eq-Operator-Value:GT
2 NCT03927456 882 883 B-Eq-Value
) NCT03927456 884 885 O
, NCT03927456 887 888 O
or NCT03927456 889 891 O
ventricular NCT03927456 892 903 B-Condition-Name
arrhythmia NCT03927456 904 914 I-Condition-Name
which NCT03927456 915 920 O
need NCT03927456 921 925 O
medical NCT03927456 926 933 O
intervention NCT03927456 934 946 B-Procedure-Name
. NCT03927456 947 948 O

Inclusion NCT03920488 0 9 O
Criteria NCT03920488 10 18 O
: NCT03920488 19 20 O

1 NCT03920488 25 26 O
. NCT03920488 26 27 O
age NCT03920488 29 32 O
between NCT03920488 33 40 B-Eq-Operator___Eq-Operator-Value:BETWEEN
18 NCT03920488 42 44 B-Eq-Value
and NCT03920488 45 48 O
60 NCT03920488 50 52 B-Eq-Value
years NCT03920488 53 58 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

2 NCT03920488 62 63 O
. NCT03920488 63 64 O
has NCT03920488 66 69 O
signed NCT03920488 70 76 O
informed NCT03920488 77 85 O
consent NCT03920488 86 93 O

3 NCT03920488 97 98 O
. NCT03920488 98 99 O
histologically NCT03920488 101 115 B-Procedure-Name
confirmed NCT03920488 116 125 O
triple NCT03920488 126 132 O
negative NCT03920488 133 141 B-Polarity___Polarity-Value:negative
breast NCT03920488 142 148 O
cancer NCT03920488 149 155 B-Condition-Name
( NCT03920488 156 157 O
ER NCT03920488 158 160 B-Observation-Name
( NCT03920488 161 162 O
Estrogen NCT03920488 163 171 B-Observation-Name___Observation-Type-Value:lab
Receptors NCT03920488 172 181 I-Observation-Name___Observation-Type-Value:lab
) NCT03920488 182 183 O
< NCT03920488 184 185 B-Eq-Operator___Eq-Operator-Value:LT
1 NCT03920488 187 188 B-Eq-Value
% NCT03920488 189 190 B-Eq-Unit
, NCT03920488 192 193 O
PgR NCT03920488 194 197 B-Observation-Name
( NCT03920488 198 199 O
Progesterone NCT03920488 200 212 B-Observation-Name___Observation-Type-Value:lab
Receptors NCT03920488 213 222 I-Observation-Name___Observation-Type-Value:lab
) NCT03920488 223 224 O
< NCT03920488 225 226 B-Eq-Operator___Eq-Operator-Value:LT
1 NCT03920488 228 229 B-Eq-Value
% NCT03920488 230 231 B-Eq-Unit
, NCT03920488 233 234 O
HER NCT03920488 235 238 B-Condition-Name
2 NCT03920488 239 240 I-Condition-Name
/ NCT03920488 241 242 O
neu NCT03920488 243 246 B-Condition-Name
negative NCT03920488 247 255 B-Polarity___Polarity-Value:negative
( NCT03920488 256 257 O
IHC NCT03920488 258 261 B-Observation-Name
0 NCT03920488 263 264 B-Eq-Value
, NCT03920488 265 266 O
1 NCT03920488 268 269 B-Eq-Value
+ NCT03920488 270 271 O
or NCT03920488 272 274 O
2 NCT03920488 276 277 B-Eq-Value
+ NCT03920488 278 279 O
FISH NCT03920488 280 284 B-Condition-Name
negative NCT03920488 285 293 B-Polarity___Polarity-Value:negative
) NCT03920488 294 295 O
. NCT03920488 297 298 O

4 NCT03920488 303 304 O
. NCT03920488 304 305 O
Stage NCT03920488 307 312 B-Eq-Unit
I NCT03920488 313 314 B-Eq-Value
- NCT03920488 315 316 B-Eq-Operator___Eq-Operator-Value:BETWEEN
III NCT03920488 317 320 B-Eq-Value

5 NCT03920488 324 325 O
. NCT03920488 325 326 O
Able NCT03920488 328 332 O
to NCT03920488 333 335 O
undergo NCT03920488 336 343 O
surgery NCT03920488 344 351 B-Procedure-Name
( NCT03920488 352 353 O
primary NCT03920488 354 361 O
or NCT03920488 362 364 O
post NCT03920488 365 369 O
- NCT03920488 370 371 O
neoadjuvant NCT03920488 372 383 B-Procedure-Name
) NCT03920488 384 385 O

6 NCT03920488 390 391 O
. NCT03920488 391 392 O
Availability NCT03920488 394 406 O
of NCT03920488 407 409 O
surgical NCT03920488 410 418 O
/ NCT03920488 419 420 O
bioptic NCT03920488 421 428 O
material NCT03920488 429 437 B-Observation-Name
within NCT03920488 438 444 B-Eq-Operator___Eq-Operator-Value:LTEQ
6 NCT03920488 446 447 B-Eq-Value
months NCT03920488 448 454 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
from NCT03920488 455 459 O
enrolment NCT03920488 460 469 O

Exclusion NCT03920488 470 479 O
Criteria NCT03920488 480 488 O
: NCT03920488 489 490 O

- NCT03920488 494 495 O
unable NCT03920488 497 503 O
or NCT03920488 504 506 O
unwilling NCT03920488 507 516 O
to NCT03920488 517 519 O
receive NCT03920488 520 527 O
genetic NCT03920488 528 535 B-Procedure-Name
counselling NCT03920488 536 547 I-Procedure-Name

Inclusion NCT03923803 0 9 O
Criteria NCT03923803 10 18 O
: NCT03923803 19 20 O

- NCT03923803 23 24 O
Patients NCT03923803 25 33 O
admitted NCT03923803 34 42 B-Encounter-Type___Encounter-Type-Value:inpatient
to NCT03923803 43 45 O
the NCT03923803 46 49 O
hospital NCT03923803 50 58 B-Location___Location-Value:hospital

Exclusion NCT03923803 59 68 O
Criteria NCT03923803 69 77 O
: NCT03923803 78 79 O

- NCT03923803 83 84 O
patients NCT03923803 86 94 O
with NCT03923803 95 99 O
malignancies NCT03923803 100 112 B-Condition-Name

- NCT03923803 115 116 O
patients NCT03923803 118 126 O
with NCT03923803 127 131 O
other NCT03923803 132 137 O
systemic NCT03923803 138 146 O
infection NCT03923803 147 156 B-Condition-Name

- NCT03928639 1 2 O
INCLUSION NCT03928639 4 13 O
CRITERIA NCT03928639 14 22 O
: NCT03928639 23 24 O

- NCT03928639 28 29 O
Adults NCT03928639 31 37 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
age NCT03928639 38 41 O
greater NCT03928639 42 49 B-Eq-Operator___Eq-Operator-Value:GTEQ
than NCT03928639 50 54 I-Eq-Operator___Eq-Operator-Value:GTEQ
or NCT03928639 55 57 I-Eq-Operator___Eq-Operator-Value:GTEQ
equal NCT03928639 58 63 I-Eq-Operator___Eq-Operator-Value:GTEQ
to NCT03928639 64 66 O
18 NCT03928639 68 70 B-Eq-Value
years NCT03928639 71 76 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
. NCT03928639 77 78 O

- NCT03928639 82 83 O
Receiving NCT03928639 85 94 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
care NCT03928639 95 99 O
from NCT03928639 100 104 O
the NCT03928639 105 108 O
structural NCT03928639 109 119 B-Location___Location-Value:clinic
heart NCT03928639 120 125 I-Location___Location-Value:clinic
and NCT03928639 126 129 I-Location___Location-Value:clinic
valve NCT03928639 130 135 I-Location___Location-Value:clinic
program NCT03928639 136 143 I-Location___Location-Value:clinic
at NCT03928639 144 146 O
the NCT03928639 147 150 O
participating NCT03928639 151 164 O
NHLBI NCT03928639 165 170 B-Location
structural NCT03928639 171 181 I-Location
heart NCT03928639 182 187 I-Location
disease NCT03928639 188 195 I-Location
network NCT03928639 196 203 I-Location
site NCT03928639 204 208 I-Location
. NCT03928639 209 210 O

- NCT03928639 214 215 O
Consent NCT03928639 217 224 O
to NCT03928639 225 227 O
participate NCT03928639 228 239 O
in NCT03928639 240 242 O
the NCT03928639 243 246 O
protocol NCT03928639 247 255 O
, NCT03928639 256 257 O
directly NCT03928639 258 266 O
, NCT03928639 267 268 O
or NCT03928639 269 271 O
through NCT03928639 272 279 O
legally NCT03928639 280 287 O
authorized NCT03928639 288 298 O
representatives NCT03928639 299 314 O
( NCT03928639 315 316 O
LAR NCT03928639 317 320 O
) NCT03928639 321 322 O
. NCT03928639 324 325 O

EXCLUSION NCT03928639 327 336 O
CRITERIA NCT03928639 337 345 O
: NCT03928639 346 347 O

- NCT03928639 350 351 O
Does NCT03928639 352 356 O
not NCT03928639 357 360 O
consent NCT03928639 361 368 O
to NCT03928639 369 371 O
participate NCT03928639 372 383 O
in NCT03928639 384 386 O
this NCT03928639 387 391 O
protocol NCT03928639 392 400 O
. NCT03928639 401 402 O

Inclusion NCT03927287 0 9 O
Criteria NCT03927287 10 18 O
: NCT03927287 19 20 O

For NCT03927287 22 25 O
the NCT03927287 26 29 O
two NCT03927287 30 33 O
retrospective NCT03927287 34 47 O
cohorts NCT03927287 48 55 O
: NCT03927287 56 57 O

1 NCT03927287 62 63 O
. NCT03927287 63 64 O
All NCT03927287 66 69 O
patients NCT03927287 70 78 O
that NCT03927287 79 83 O
older NCT03927287 84 89 B-Eq-Operator___Eq-Operator-Value:GTEQ
than NCT03927287 90 94 I-Eq-Operator___Eq-Operator-Value:GTEQ
18 NCT03927287 96 98 B-Eq-Value
treated NCT03927287 99 106 O
for NCT03927287 107 110 O
localized NCT03927287 111 120 O
adenocarcinoma NCT03927287 121 135 B-Condition-Name
of NCT03927287 136 138 O
the NCT03927287 139 142 O
prostate NCT03927287 143 151 O
between NCT03927287 152 159 B-Eq-Operator___Eq-Operator-Value:BETWEEN
2000 NCT03927287 161 165 B-Eq-Value
and NCT03927287 166 169 O
2017 NCT03927287 171 175 B-Eq-Value
with NCT03927287 176 180 O
either NCT03927287 181 187 O
radical NCT03927287 188 195 B-Procedure-Name
prostatectomy NCT03927287 196 209 I-Procedure-Name
or NCT03927287 210 212 O
radiotherapy NCT03927287 213 225 B-Procedure-Name

2 NCT03927287 229 230 O
. NCT03927287 230 231 O
All NCT03927287 233 236 O
treated NCT03927287 237 244 O
patients NCT03927287 245 253 O
had NCT03927287 254 257 O
a NCT03927287 258 259 O
rising NCT03927287 260 266 B-Polarity___Polarity-Value:high
post NCT03927287 267 271 O
- NCT03927287 272 273 O
treatment NCT03927287 274 283 O
PSA NCT03927287 284 287 B-Observation-Name___Observation-Type-Value:lab
, NCT03927287 288 289 O
with NCT03927287 290 294 O
at NCT03927287 295 297 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03927287 298 303 I-Eq-Operator___Eq-Operator-Value:GTEQ
one NCT03927287 304 307 B-Eq-Value
post NCT03927287 308 312 O
- NCT03927287 313 314 O
treatment NCT03927287 315 324 O
free NCT03927287 325 329 O
PSA NCT03927287 330 333 B-Observation-Name___Observation-Type-Value:lab
blood NCT03927287 334 339 I-Observation-Name___Observation-Type-Value:lab
test NCT03927287 340 344 I-Observation-Name___Observation-Type-Value:lab
. NCT03927287 345 346 O

For NCT03927287 348 351 O
the NCT03927287 352 355 O
biobank NCT03927287 356 363 O
validation NCT03927287 364 374 O
cohort NCT03927287 375 381 O
: NCT03927287 382 383 O

1 NCT03927287 386 387 O
. NCT03927287 387 388 O
All NCT03927287 390 393 O
patients NCT03927287 394 402 O
treated NCT03927287 403 410 O
with NCT03927287 411 415 O
radical NCT03927287 416 423 B-Procedure-Name
prostatectomy NCT03927287 424 437 I-Procedure-Name
for NCT03927287 438 441 O
localized NCT03927287 442 451 O
prostate NCT03927287 452 460 O
cancer NCT03927287 461 467 B-Condition-Name
between NCT03927287 468 475 B-Eq-Operator___Eq-Operator-Value:BETWEEN
2000 NCT03927287 477 481 B-Eq-Value
and NCT03927287 482 485 O
2017 NCT03927287 487 491 B-Eq-Value
who NCT03927287 492 495 O
had NCT03927287 496 499 O
biobank NCT03927287 500 507 B-Observation-Name___Observation-Type-Value:lab
samples NCT03927287 508 515 I-Observation-Name___Observation-Type-Value:lab
taken NCT03927287 516 521 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
when NCT03927287 522 526 O
developing NCT03927287 527 537 O
biochemical NCT03927287 538 549 B-Condition-Name
recurrence NCT03927287 550 560 I-Condition-Name
. NCT03927287 561 562 O

Exclusion NCT03927287 564 573 O
Criteria NCT03927287 574 582 O
: NCT03927287 583 584 O

1 NCT03927287 589 590 O
. NCT03927287 590 591 O
Patients NCT03927287 593 601 O
that NCT03927287 602 606 O
were NCT03927287 607 611 O
younger NCT03927287 612 619 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03927287 620 624 I-Eq-Operator___Eq-Operator-Value:LT
18 NCT03927287 626 628 B-Eq-Value
, NCT03927287 629 630 O

2 NCT03927287 636 637 O
. NCT03927287 637 638 O
Patients NCT03927287 640 648 O
with NCT03927287 649 653 O
prostate NCT03927287 654 662 O
cancer NCT03927287 663 669 B-Condition-Name
other NCT03927287 670 675 O
than NCT03927287 676 680 O
adenocarcinoma NCT03927287 681 695 B-Condition-Name
, NCT03927287 696 697 O
such NCT03927287 698 702 O
as NCT03927287 703 705 O
small NCT03927287 706 711 O
cell NCT03927287 712 716 O
and NCT03927287 717 720 O
neuroendocrine NCT03927287 721 735 O
cancer NCT03927287 736 742 B-Condition-Name

3 NCT03927287 746 747 O
. NCT03927287 747 748 O
Patients NCT03927287 750 758 O
with NCT03927287 759 763 O
prostate NCT03927287 764 772 O
adenocarcinoma NCT03927287 773 787 B-Condition-Name
that NCT03927287 788 792 O
did NCT03927287 793 796 O
not NCT03927287 797 800 O
develop NCT03927287 801 808 O
biochemical NCT03927287 809 820 B-Condition-Name
recurrence NCT03927287 821 831 I-Condition-Name
. NCT03927287 832 833 O

4 NCT03927287 838 839 O
. NCT03927287 839 840 O
In NCT03927287 842 844 O
the NCT03927287 845 848 O
retrospective NCT03927287 849 862 O
cohorts NCT03927287 863 870 O
- NCT03927287 871 872 O
patients NCT03927287 873 881 O
that NCT03927287 882 886 O
did NCT03927287 887 890 O
not NCT03927287 891 894 O
have NCT03927287 895 899 O
at NCT03927287 900 902 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03927287 903 908 I-Eq-Operator___Eq-Operator-Value:GTEQ
one NCT03927287 909 912 B-Eq-Value
post NCT03927287 913 917 O
- NCT03927287 918 919 O
treatment NCT03927287 920 929 O
free NCT03927287 930 934 O
PSA NCT03927287 935 938 B-Observation-Name___Observation-Type-Value:lab
blood NCT03927287 939 944 I-Observation-Name___Observation-Type-Value:lab
test NCT03927287 945 949 I-Observation-Name___Observation-Type-Value:lab
. NCT03927287 950 951 O

Inclusion NCT03921190 0 9 O
Criteria NCT03921190 10 18 O
: NCT03921190 19 20 O

- NCT03921190 24 25 O
Adult NCT03921190 27 32 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
patients NCT03921190 33 41 O
( NCT03921190 42 43 O
16 NCT03921190 45 47 B-Eq-Value
years NCT03921190 48 53 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03921190 54 57 O
and NCT03921190 58 61 B-Eq-Operator___Eq-Operator-Value:GTEQ
older NCT03921190 62 67 I-Eq-Operator___Eq-Operator-Value:GTEQ
) NCT03921190 68 69 O

- NCT03921190 73 74 O
Healthy NCT03921190 76 83 B-Condition-Name
( NCT03921190 84 85 O
American NCT03921190 86 94 B-Condition-Name
Society NCT03921190 95 102 I-Condition-Name
of NCT03921190 103 105 I-Condition-Name
Anaesthesiologists NCT03921190 106 124 I-Condition-Name
( NCT03921190 125 126 O
ASA NCT03921190 127 130 B-Condition-Name
) NCT03921190 131 132 O
category NCT03921190 133 141 B-Eq-Unit
I NCT03921190 142 143 B-Eq-Value
or NCT03921190 144 146 O
II NCT03921190 147 149 B-Eq-Value
) NCT03921190 150 151 O

- NCT03921190 155 156 O
A NCT03921190 158 159 O
maxillary NCT03921190 160 169 O
posterior NCT03921190 170 179 O
tooth NCT03921190 180 185 O
( NCT03921190 186 187 O
excluding NCT03921190 188 197 O
third NCT03921190 198 203 O
molars NCT03921190 204 210 O
) NCT03921190 211 212 O
referred NCT03921190 213 221 O
for NCT03921190 222 225 O
root NCT03921190 226 230 B-Procedure-Name
canal NCT03921190 231 236 I-Procedure-Name
treatment NCT03921190 237 246 I-Procedure-Name
and NCT03921190 247 250 O
diagnosed NCT03921190 251 260 O
with NCT03921190 261 265 O
irreversible NCT03921190 266 278 B-Condition-Name
pulpitis NCT03921190 279 287 I-Condition-Name
and NCT03921190 288 291 O
normal NCT03921190 292 298 B-Polarity___Polarity-Value:normal
apical NCT03921190 299 305 B-Condition-Name
tissues NCT03921190 306 313 I-Condition-Name

Exclusion NCT03921190 314 323 O
Criteria NCT03921190 324 332 O
: NCT03921190 333 334 O

- NCT03921190 338 339 O
Psychological NCT03921190 341 354 B-Condition-Name
disorders NCT03921190 355 364 I-Condition-Name

- NCT03921190 367 368 O
Intraoral NCT03921190 370 379 O
soft NCT03921190 380 384 B-Condition-Name
tissue NCT03921190 385 391 I-Condition-Name
abnormalities NCT03921190 392 405 I-Condition-Name

- NCT03921190 408 409 O
necrotic NCT03921190 411 419 B-Condition-Name
pulp NCT03921190 420 424 I-Condition-Name
with NCT03921190 425 429 O
/ NCT03921190 430 431 O
without NCT03921190 432 439 O
apical NCT03921190 440 446 B-Condition-Name
pathology NCT03921190 447 456 I-Condition-Name

- NCT03921190 459 460 O
tenderness NCT03921190 462 472 B-Condition-Name
to NCT03921190 473 475 O
palpation NCT03921190 476 485 B-Procedure-Name
and NCT03921190 486 489 O
/ NCT03921190 490 491 O
or NCT03921190 492 494 O
percussion NCT03921190 495 505 B-Procedure-Name

- NCT03921190 508 509 O
The NCT03921190 511 514 O
use NCT03921190 515 518 O
of NCT03921190 519 521 O
analgesics NCT03921190 522 532 B-Drug-Name
in NCT03921190 533 535 O
the NCT03921190 536 539 O
preceding NCT03921190 540 549 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
12 NCT03921190 551 553 B-Eq-Value
hours NCT03921190 554 559 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:hour
before NCT03921190 560 566 O
the NCT03921190 567 570 O
appointment NCT03921190 571 582 B-Encounter-Type___Encounter-Type-Value:outpatient
. NCT03921190 583 584 O

Inclusion NCT03921437 0 9 O
conditions NCT03921437 10 20 O
: NCT03921437 21 22 O

1 NCT03921437 27 28 O
. NCT03921437 28 29 O
The NCT03921437 31 34 O
fifth NCT03921437 35 40 B-Eq-Value
stage NCT03921437 41 46 B-Eq-Unit
of NCT03921437 47 49 O
chronic NCT03921437 50 57 O
renal NCT03921437 58 63 B-Condition-Name
failure NCT03921437 64 71 I-Condition-Name
diagnosed NCT03921437 72 81 O
by NCT03921437 82 84 O
a NCT03921437 85 86 O
physician NCT03921437 87 96 O
. NCT03921437 97 98 O

2 NCT03921437 103 104 O
. NCT03921437 104 105 O
The NCT03921437 107 110 O
physician NCT03921437 111 120 O
advises NCT03921437 121 128 O
and NCT03921437 129 132 O
informs NCT03921437 133 140 O
the NCT03921437 141 144 O
patient NCT03921437 145 152 O
who NCT03921437 153 156 O
has NCT03921437 157 160 O
to NCT03921437 161 163 O
undergo NCT03921437 164 171 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
renal NCT03921437 172 177 B-Procedure-Name
replacement NCT03921437 178 189 I-Procedure-Name
therapy NCT03921437 190 197 I-Procedure-Name
but NCT03921437 198 201 O
has NCT03921437 202 205 O
not NCT03921437 206 209 O
yet NCT03921437 210 213 O
decided NCT03921437 214 221 O
what NCT03921437 222 226 O
treatment NCT03921437 227 236 O
to NCT03921437 237 239 O
take NCT03921437 240 244 O
. NCT03921437 245 246 O

3 NCT03921437 251 252 O
. NCT03921437 252 253 O
Being NCT03921437 255 260 O
able NCT03921437 261 265 O
to NCT03921437 266 268 O
communicate NCT03921437 269 280 O
in NCT03921437 281 283 O
Mandarin NCT03921437 284 292 B-Language
and NCT03921437 293 296 O
Taiwan NCT03921437 297 303 B-Language
. NCT03921437 304 305 O

4 NCT03921437 310 311 O
. NCT03921437 311 312 O
Ages NCT03921437 314 318 O
over NCT03921437 319 323 O
20 NCT03921437 325 327 B-Eq-Value
years NCT03921437 328 333 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03921437 334 337 O
. NCT03921437 338 339 O

Exclusion NCT03921437 341 350 O
conditions NCT03921437 351 361 O
: NCT03921437 362 363 O

1 NCT03921437 368 369 O
. NCT03921437 369 370 O
Cognitive NCT03921437 372 381 B-Condition-Name
impairment NCT03921437 382 392 I-Condition-Name
: NCT03921437 393 394 O
The NCT03921437 395 398 O
MMSE NCT03921437 399 403 B-Observation-Name
of NCT03921437 404 406 O
the NCT03921437 407 410 O
above NCT03921437 411 416 O
- NCT03921437 417 418 O
mentioned NCT03921437 419 428 O
educators NCT03921437 429 438 O
was NCT03921437 439 442 O
26 NCT03921437 444 446 B-Eq-Value
points NCT03921437 447 453 B-Eq-Unit
, NCT03921437 454 455 O
and NCT03921437 456 459 O
the NCT03921437 460 463 O
national NCT03921437 464 472 B-Observation-Name
minimum NCT03921437 473 480 I-Observation-Name
was NCT03921437 481 484 O
< NCT03921437 485 486 B-Eq-Operator___Eq-Operator-Value:LT
21 NCT03921437 488 490 B-Eq-Value
points NCT03921437 491 497 B-Eq-Unit
, NCT03921437 498 499 O
those NCT03921437 500 505 O
who NCT03921437 506 509 O
are NCT03921437 510 513 O
not NCT03921437 514 517 O
educated NCT03921437 518 526 B-Condition-Name
are NCT03921437 527 530 O
< NCT03921437 531 532 B-Eq-Operator___Eq-Operator-Value:LT
16 NCT03921437 534 536 B-Eq-Value
points NCT03921437 537 543 B-Eq-Unit
, NCT03921437 544 545 O
and NCT03921437 546 549 O
the NCT03921437 550 553 O
case NCT03921437 554 558 O
is NCT03921437 559 561 O
excluded NCT03921437 562 570 O
. NCT03921437 571 572 O

2 NCT03921437 577 578 O
. NCT03921437 578 579 O
Patients NCT03921437 581 589 O
who NCT03921437 590 593 O
have NCT03921437 594 598 O
received NCT03921437 599 607 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
non NCT03921437 608 611 O
- NCT03921437 612 613 O
emergency NCT03921437 614 623 O
dialysis NCT03921437 624 632 B-Procedure-Name
treatment NCT03921437 633 642 I-Procedure-Name
. NCT03921437 643 644 O

3 NCT03921437 649 650 O
. NCT03921437 650 651 O
Patients NCT03921437 653 661 O
with NCT03921437 662 666 O
severe NCT03921437 667 673 B-Severity___Severity-Value:severe
cardiopulmonary NCT03921437 674 689 O
dysfunction NCT03921437 690 701 B-Condition-Name
, NCT03921437 702 703 O
severe NCT03921437 704 710 B-Severity___Severity-Value:severe
shock NCT03921437 711 716 B-Condition-Name
, NCT03921437 717 718 O
low NCT03921437 719 722 B-Condition-Name
blood NCT03921437 723 728 I-Condition-Name
pressure NCT03921437 729 737 I-Condition-Name
, NCT03921437 738 739 O
and NCT03921437 740 743 O
large NCT03921437 744 749 B-Polarity___Polarity-Value:high
bleeding NCT03921437 750 758 B-Condition-Name
are NCT03921437 759 762 O
not NCT03921437 763 766 O
controlled NCT03921437 767 777 O
. NCT03921437 778 779 O

4 NCT03921437 784 785 O
. NCT03921437 785 786 O
Patients NCT03921437 788 796 O
with NCT03921437 797 801 O
chronic NCT03921437 802 809 O
active NCT03921437 810 816 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
hepatitis NCT03921437 817 826 B-Condition-Name
, NCT03921437 827 828 O
cirrhosis NCT03921437 829 838 B-Condition-Name
or NCT03921437 839 841 O
liver NCT03921437 842 847 B-Condition-Name
failure NCT03921437 848 855 I-Condition-Name
. NCT03921437 856 857 O

5 NCT03921437 862 863 O
. NCT03921437 863 864 O
A NCT03921437 866 867 O
history NCT03921437 868 875 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03921437 876 878 O
cancer NCT03921437 879 885 B-Condition-Name
that NCT03921437 886 890 O
may NCT03921437 891 894 O
be NCT03921437 895 897 O
transferred NCT03921437 898 909 O
. NCT03921437 910 911 O

6 NCT03921437 916 917 O
. NCT03921437 917 918 O
Severe NCT03921437 920 926 B-Severity___Severity-Value:severe
bleeding NCT03921437 927 935 B-Condition-Name
tendency NCT03921437 936 944 O
. NCT03921437 945 946 O

7 NCT03921437 951 952 O
. NCT03921437 952 953 O
Loss NCT03921437 955 959 B-Stability___Stability-Value:change
of NCT03921437 960 962 O
peritoneal NCT03921437 963 973 B-Condition-Name
function NCT03921437 974 982 I-Condition-Name
or NCT03921437 983 985 O
extensive NCT03921437 986 995 B-Polarity___Polarity-Value:high
peritoneal NCT03921437 996 1006 B-Condition-Name
adhesion NCT03921437 1007 1015 I-Condition-Name
, NCT03921437 1016 1017 O
unable NCT03921437 1018 1024 O
to NCT03921437 1025 1027 O
use NCT03921437 1028 1031 O
peritoneal NCT03921437 1032 1042 B-Procedure-Name
dialysis NCT03921437 1043 1051 I-Procedure-Name
. NCT03921437 1052 1053 O

8 NCT03921437 1058 1059 O
. NCT03921437 1059 1060 O
Unable NCT03921437 1062 1068 O
to NCT03921437 1069 1071 O
correct NCT03921437 1072 1079 O
physiological NCT03921437 1080 1093 B-Condition-Name
defects NCT03921437 1094 1101 I-Condition-Name
, NCT03921437 1102 1103 O
may NCT03921437 1104 1107 O
interfere NCT03921437 1108 1117 B-Stability___Stability-Value:change
with NCT03921437 1118 1122 O
peritoneal NCT03921437 1123 1133 B-Procedure-Name
dialysis NCT03921437 1134 1142 I-Procedure-Name
, NCT03921437 1143 1144 O
or NCT03921437 1145 1147 O
increase NCT03921437 1148 1156 B-Polarity___Polarity-Value:high
the NCT03921437 1157 1160 O
chance NCT03921437 1161 1167 O
of NCT03921437 1168 1170 O
infection NCT03921437 1171 1180 B-Condition-Name
, NCT03921437 1181 1182 O
such NCT03921437 1183 1187 O
as NCT03921437 1188 1190 O
umbilical NCT03921437 1191 1200 B-Condition-Name
hernia NCT03921437 1201 1207 I-Condition-Name
. NCT03921437 1208 1209 O

9 NCT03921437 1214 1215 O
. NCT03921437 1215 1216 O
The NCT03921437 1218 1221 O
patient NCT03921437 1222 1229 O
is NCT03921437 1230 1232 O
unable NCT03921437 1233 1239 O
to NCT03921437 1240 1242 O
operate NCT03921437 1243 1250 O
the NCT03921437 1251 1254 O
fluid NCT03921437 1255 1260 B-Procedure-Name
change NCT03921437 1261 1267 I-Procedure-Name
, NCT03921437 1268 1269 O
hand NCT03921437 1270 1274 O
shake NCT03921437 1275 1280 O
, NCT03921437 1281 1282 O
and NCT03921437 1283 1286 O
no NCT03921437 1287 1289 O
family NCT03921437 1290 1296 O
members NCT03921437 1297 1304 O
can NCT03921437 1305 1308 O
assist NCT03921437 1309 1315 O
. NCT03921437 1316 1317 O

10 NCT03921437 1321 1323 O
. NCT03921437 1323 1324 O
Patients NCT03921437 1326 1334 O
who NCT03921437 1335 1338 O
are NCT03921437 1339 1342 O
blind NCT03921437 1343 1348 B-Condition-Name
, NCT03921437 1349 1350 O
have NCT03921437 1351 1355 O
poor NCT03921437 1356 1360 B-Condition-Name
eyesight NCT03921437 1361 1369 I-Condition-Name
, NCT03921437 1370 1371 O
and NCT03921437 1372 1375 O
have NCT03921437 1376 1380 O
difficulty NCT03921437 1381 1391 B-Condition-Name
operating NCT03921437 1392 1401 I-Condition-Name
. NCT03921437 1402 1403 O

Inclusion NCT03929731 0 9 O
Criteria NCT03929731 10 18 O
: NCT03929731 19 20 O

- NCT03929731 24 25 O
Participants NCT03929731 27 39 O
will NCT03929731 40 44 O
have NCT03929731 45 49 O
completed NCT03929731 50 59 O
the NCT03929731 60 63 O
previous NCT03929731 64 72 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
PCV NCT03929731 73 76 B-Procedure-Name
RCTs NCT03929731 77 81 O
: NCT03929731 82 83 O
EVEREST NCT03929731 84 91 O
II NCT03929731 92 94 O
, NCT03929731 95 96 O
PLANET NCT03929731 97 103 O
and NCT03929731 104 107 O
PCV NCT03929731 108 111 B-Procedure-Name
T&amp;E NCT03929731 112 119 O
studies NCT03929731 120 127 O

- NCT03929731 130 131 O
Are NCT03929731 133 136 O
able NCT03929731 137 141 O
to NCT03929731 142 144 O
give NCT03929731 145 149 O
consent NCT03929731 150 157 O
for NCT03929731 158 161 O
this NCT03929731 162 166 O
follow NCT03929731 167 173 O
up NCT03929731 174 176 O
study NCT03929731 177 182 O

Exclusion NCT03929731 183 192 O
Criteria NCT03929731 193 201 O
: NCT03929731 202 203 O

- NCT03929731 207 208 O
No NCT03929731 210 212 O
exclusion NCT03929731 213 222 O
criteria NCT03929731 223 231 O
unless NCT03929731 232 238 O
they NCT03929731 239 243 O
do NCT03929731 244 246 O
not NCT03929731 247 250 O
meet NCT03929731 251 255 O
the NCT03929731 256 259 O
inclusion NCT03929731 260 269 O
criteria NCT03929731 270 278 O

Inclusion NCT03920098 0 9 O
Criteria NCT03920098 10 18 O
: NCT03920098 19 20 O

- NCT03920098 24 25 O
Primipara NCT03920098 27 36 B-Condition-Name
( NCT03920098 37 38 O
no NCT03920098 39 41 O
previous NCT03920098 42 50 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
pregnancies NCT03920098 51 62 B-Condition-Name
) NCT03920098 63 64 O

- NCT03920098 68 69 O
18 NCT03920098 72 74 B-Eq-Value
to NCT03920098 75 77 B-Eq-Operator___Eq-Operator-Value:BETWEEN
25 NCT03920098 79 81 B-Eq-Value
years NCT03920098 82 87 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03920098 88 90 O
age NCT03920098 91 94 O

- NCT03920098 97 98 O
Gestation NCT03920098 100 109 B-Observation-Name___Observation-Type-Value:measurement
< NCT03920098 110 111 B-Eq-Operator___Eq-Operator-Value:LT
15 NCT03920098 113 115 B-Eq-Value
weeks NCT03920098 116 121 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
at NCT03920098 122 124 O
first NCT03920098 125 130 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
prenatal NCT03920098 131 139 B-Condition-Name
visit NCT03920098 140 145 O

- NCT03920098 148 149 O
No NCT03920098 151 153 O
intention NCT03920098 154 163 O
to NCT03920098 164 166 O
move NCT03920098 167 171 B-Observation-Name
outside NCT03920098 172 179 O
the NCT03920098 180 183 O
city NCT03920098 184 188 O
of NCT03920098 189 191 O
Santiago NCT03920098 192 200 B-Location___Location-Value:residence
in NCT03920098 201 203 O
the NCT03920098 204 207 O
next NCT03920098 208 212 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
to NCT03920098 213 215 B-Eq-Value
years NCT03920098 216 221 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

Exclusion NCT03920098 222 231 O
Criteria NCT03920098 232 240 O
: NCT03920098 241 242 O

- NCT03920098 246 247 O
Multipara NCT03920098 249 258 B-Condition-Name

- NCT03920098 261 262 O
Pre NCT03920098 264 267 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
- NCT03920098 268 269 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
existing NCT03920098 270 278 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
cancer NCT03920098 279 285 B-Condition-Name
( NCT03920098 286 287 O
except NCT03920098 288 294 O
non NCT03920098 295 298 O
- NCT03920098 299 300 O
melanoma NCT03920098 301 309 O
skin NCT03920098 310 314 O
cancer NCT03920098 315 321 B-Condition-Name
) NCT03920098 322 323 O

- NCT03920098 327 328 O
Family NCT03920098 330 336 O
history NCT03920098 337 344 O
of NCT03920098 345 347 O
breast NCT03920098 348 354 O
cancer NCT03920098 355 361 B-Condition-Name
( NCT03920098 362 363 O
one NCT03920098 364 367 B-Eq-Value
first NCT03920098 368 373 O
- NCT03920098 374 375 O
degree NCT03920098 376 382 O
female NCT03920098 383 389 O
relative NCT03920098 390 398 O
diagnosed NCT03920098 399 408 O
with NCT03920098 409 413 O
breast NCT03920098 414 420 O
cancer NCT03920098 421 427 B-Condition-Name
) NCT03920098 428 429 O

- NCT03920098 433 434 O
High NCT03920098 436 440 O
- NCT03920098 441 442 O
risk NCT03920098 443 447 O
pregnancy NCT03920098 448 457 B-Condition-Name
according NCT03920098 458 467 O
to NCT03920098 468 470 O
national NCT03920098 471 479 O
guidelines NCT03920098 480 490 O

- NCT03920098 493 494 O
During NCT03920098 496 502 O
the NCT03920098 503 506 O
follow NCT03920098 507 513 O
- NCT03920098 514 515 O
up NCT03920098 516 518 O
, NCT03920098 519 520 O
pregnant NCT03920098 521 529 B-Condition-Name
women NCT03920098 530 535 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
under NCT03920098 536 541 O
any NCT03920098 542 545 O
treatment NCT03920098 546 555 O
that NCT03920098 556 560 O
may NCT03920098 561 564 O
affect NCT03920098 565 571 B-Stability___Stability-Value:change
the NCT03920098 572 575 O
levels NCT03920098 576 582 O
of NCT03920098 583 585 O
metabolic NCT03920098 586 595 B-Observation-Name
markers NCT03920098 596 603 I-Observation-Name
will NCT03920098 604 608 O
be NCT03920098 609 611 O
excluded NCT03920098 612 620 O
from NCT03920098 621 625 O
the NCT03920098 626 629 O
analysis NCT03920098 630 638 O

- NCT03920098 641 642 O
Pregnant NCT03920098 644 652 B-Condition-Name
women NCT03920098 653 658 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
with NCT03920098 659 663 O
pre NCT03920098 664 667 B-Condition-Name
- NCT03920098 668 669 I-Condition-Name
eclampsia NCT03920098 670 679 I-Condition-Name
or NCT03920098 680 682 O
with NCT03920098 683 687 O
preterm NCT03920098 688 695 B-Condition-Name
birth NCT03920098 696 701 I-Condition-Name
( NCT03920098 702 703 O
less NCT03920098 704 708 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03920098 709 713 I-Eq-Operator___Eq-Operator-Value:LT
37 NCT03920098 715 717 B-Eq-Value
weeks NCT03920098 718 723 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
of NCT03920098 724 726 O
gestational NCT03920098 727 738 B-Observation-Name___Observation-Type-Value:measurement
age NCT03920098 739 742 I-Observation-Name___Observation-Type-Value:measurement
) NCT03920098 743 744 O
will NCT03920098 745 749 O
be NCT03920098 750 752 O
also NCT03920098 753 757 O
excluded NCT03920098 758 766 O

Inclusion NCT03926403 0 9 O
Criteria NCT03926403 10 18 O
: NCT03926403 19 20 O

- NCT03926403 24 25 O
Patient NCT03926403 27 34 O
treated NCT03926403 35 42 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
under NCT03926403 43 48 O
local NCT03926403 49 54 B-Procedure-Name
anaesthesia NCT03926403 55 66 I-Procedure-Name
in NCT03926403 67 69 O
the NCT03926403 70 73 O
Maxillo NCT03926403 74 81 B-Location___Location-Value:clinic
Facial NCT03926403 82 88 I-Location___Location-Value:clinic
Surgery NCT03926403 89 96 I-Location___Location-Value:clinic
department NCT03926403 97 107 I-Location___Location-Value:clinic
with NCT03926403 108 112 O
ultra NCT03926403 113 118 B-Procedure-Name
- NCT03926403 119 120 I-Procedure-Name
short NCT03926403 121 126 I-Procedure-Name
circuit NCT03926403 127 134 I-Procedure-Name

- NCT03926403 137 138 O
Patient NCT03926403 140 147 O
undergoing NCT03926403 148 158 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
face NCT03926403 159 163 O
surgery NCT03926403 164 171 B-Procedure-Name

- NCT03926403 174 175 O
Patient NCT03926403 177 184 O
who NCT03926403 185 188 O
has NCT03926403 189 192 O
received NCT03926403 193 201 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
appropriate NCT03926403 202 213 O
information NCT03926403 214 225 O
and NCT03926403 226 229 O
has NCT03926403 230 233 O
provided NCT03926403 234 242 O
informed NCT03926403 243 251 O
consent NCT03926403 252 259 O

- NCT03926403 262 263 O
Adult NCT03926403 265 270 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
patient NCT03926403 271 278 O
≥ NCT03926403 279 280 B-Eq-Operator___Eq-Operator-Value:GTEQ
18 NCT03926403 282 284 B-Eq-Value
years NCT03926403 285 290 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03926403 291 294 O

- NCT03926403 297 298 O
Patient NCT03926403 300 307 O
with NCT03926403 308 312 O
a NCT03926403 313 314 O
score NCT03926403 315 320 O
of NCT03926403 321 323 O
≥ NCT03926403 324 325 B-Eq-Operator___Eq-Operator-Value:GTEQ
46 NCT03926403 327 329 B-Eq-Value
on NCT03926403 330 332 O
the NCT03926403 333 336 O
initial NCT03926403 337 344 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
anxiety NCT03926403 345 352 B-Observation-Name___Observation-Type-Value:survey-or-questionnaire
self NCT03926403 353 357 I-Observation-Name___Observation-Type-Value:survey-or-questionnaire
- NCT03926403 358 359 I-Observation-Name___Observation-Type-Value:survey-or-questionnaire
assessment NCT03926403 360 370 I-Observation-Name___Observation-Type-Value:survey-or-questionnaire
questionnaire NCT03926403 371 384 I-Observation-Name___Observation-Type-Value:survey-or-questionnaire

Exclusion NCT03926403 385 394 O
Criteria NCT03926403 395 403 O
: NCT03926403 404 405 O

- NCT03926403 409 410 O
Patient NCT03926403 412 419 O
under NCT03926403 420 425 O
general NCT03926403 426 433 B-Procedure-Name
anaesthesia NCT03926403 434 445 I-Procedure-Name

- NCT03926403 448 449 O
Patients NCT03926403 451 459 O
treated NCT03926403 460 467 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
in NCT03926403 468 470 O
conventional NCT03926403 471 483 O
inpatient NCT03926403 484 493 B-Encounter-Type___Encounter-Type-Value:inpatient
care NCT03926403 494 498 I-Encounter-Type___Encounter-Type-Value:inpatient
or NCT03926403 499 501 O
in NCT03926403 502 504 O
the NCT03926403 505 508 O
traditional NCT03926403 509 520 O
ambulatory NCT03926403 521 531 B-Encounter-Type___Encounter-Type-Value:outpatient
circuit NCT03926403 532 539 I-Encounter-Type___Encounter-Type-Value:outpatient

- NCT03926403 542 543 O
Patient NCT03926403 545 552 O
under NCT03926403 553 558 B-Observation-Name
guardianship NCT03926403 559 571 I-Observation-Name
or NCT03926403 572 574 O
trusteeship NCT03926403 575 586 B-Observation-Name

- NCT03926403 589 590 O
Minor NCT03926403 592 597 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
patient NCT03926403 598 605 O
< NCT03926403 606 607 B-Eq-Operator___Eq-Operator-Value:LT
18 NCT03926403 609 611 B-Eq-Value
years NCT03926403 612 617 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03926403 618 620 O
age NCT03926403 621 624 O

- NCT03926403 627 628 O
Patient NCT03926403 630 637 O
who NCT03926403 638 641 O
has NCT03926403 642 645 O
not NCT03926403 646 649 O
provided NCT03926403 650 658 O
informed NCT03926403 659 667 O
consent NCT03926403 668 675 O
or NCT03926403 676 678 O
who NCT03926403 679 682 O
can NCT03926403 683 686 O
not NCT03926403 686 689 O
submit NCT03926403 690 696 O
to NCT03926403 697 699 O
the NCT03926403 700 703 O
study NCT03926403 704 709 O
protocol NCT03926403 710 718 O

- NCT03926403 721 722 O
Patient NCT03926403 724 731 O
suffering NCT03926403 732 741 O
from NCT03926403 742 746 O
cognitive NCT03926403 747 756 B-Condition-Name
disorders NCT03926403 757 766 I-Condition-Name
( NCT03926403 767 768 O
ex NCT03926403 769 771 O
: NCT03926403 772 773 O
Alzheimer NCT03926403 774 783 B-Condition-Name
's NCT03926403 783 785 I-Condition-Name
disease NCT03926403 786 793 I-Condition-Name
) NCT03926403 794 795 O

- NCT03926403 799 800 O
Patients NCT03926403 802 810 O
who NCT03926403 811 814 O
are NCT03926403 815 818 O
deaf NCT03926403 819 823 B-Condition-Name
or NCT03926403 824 826 O
hearing NCT03926403 827 834 B-Condition-Name
- NCT03926403 835 836 I-Condition-Name
impaired NCT03926403 837 845 I-Condition-Name

Inclusion NCT03922659 0 9 O
Criteria NCT03922659 10 18 O
: NCT03922659 19 20 O

- NCT03922659 24 25 O
Diagnosis NCT03922659 27 36 O
as NCT03922659 37 39 O
heroin NCT03922659 40 46 B-Condition-Name
dependence NCT03922659 47 57 I-Condition-Name
according NCT03922659 58 67 O
to NCT03922659 68 70 O
DSM NCT03922659 71 74 O
- NCT03922659 75 76 O
IV NCT03922659 77 79 O
criteria NCT03922659 80 88 O

- NCT03922659 91 92 O
No NCT03922659 94 96 O
definite NCT03922659 97 105 O
history NCT03922659 106 113 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03922659 114 116 O
neurological NCT03922659 117 129 B-Condition-Name
diseases NCT03922659 130 138 I-Condition-Name
and NCT03922659 139 142 O
psychological NCT03922659 143 156 B-Condition-Name
problems NCT03922659 157 165 I-Condition-Name

- NCT03922659 168 169 O
Volunteer NCT03922659 171 180 O
to NCT03922659 181 183 O
participate NCT03922659 184 195 O
the NCT03922659 196 199 O
study NCT03922659 200 205 O
, NCT03922659 206 207 O
cooperate NCT03922659 208 217 O
to NCT03922659 218 220 O
be NCT03922659 221 223 O
followed NCT03922659 224 232 O
up NCT03922659 233 235 O

Exclusion NCT03922659 236 245 O
Criteria NCT03922659 246 254 O
: NCT03922659 255 256 O

- NCT03922659 260 261 O
Acute NCT03922659 263 268 B-Severity___Severity-Value:severe
withdrawal NCT03922659 269 279 B-Condition-Name
state NCT03922659 280 285 I-Condition-Name
and NCT03922659 286 289 O
CIWA NCT03922659 290 294 B-Observation-Name
score NCT03922659 295 300 O
> NCT03922659 301 302 B-Eq-Operator___Eq-Operator-Value:GT
9 NCT03922659 304 305 B-Eq-Value

- NCT03922659 309 310 O
With NCT03922659 312 316 O
other NCT03922659 317 322 O
neurological NCT03922659 323 335 B-Condition-Name
diseases NCT03922659 336 344 I-Condition-Name
and NCT03922659 345 348 O
psychological NCT03922659 349 362 B-Condition-Name
problems NCT03922659 363 371 I-Condition-Name

- NCT03922659 374 375 O
With NCT03922659 377 381 O
ever NCT03922659 382 386 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:anytime
brain NCT03922659 387 392 O
trauma NCT03922659 393 399 B-Condition-Name
and NCT03922659 400 403 O
damage NCT03922659 404 410 B-Condition-Name

- NCT03922659 413 414 O
With NCT03922659 416 420 O
other NCT03922659 421 426 O
psychological NCT03922659 427 440 B-Drug-Name
medications NCT03922659 441 452 I-Drug-Name
or NCT03922659 453 455 O
other NCT03922659 456 461 O
substance NCT03922659 462 471 B-Condition-Name
dependence NCT03922659 472 482 I-Condition-Name

- NCT03922659 485 486 O
With NCT03922659 488 492 O
other NCT03922659 493 498 O
contraindications NCT03922659 499 516 O
to NCT03922659 517 519 O
have NCT03922659 520 524 O
transcranial NCT03922659 525 537 B-Procedure-Name
magnetic NCT03922659 538 546 I-Procedure-Name
stimulation NCT03922659 547 558 I-Procedure-Name

Inclusion NCT03929718 0 9 O
Criteria NCT03929718 10 18 O
: NCT03929718 19 20 O

- NCT03929718 24 25 O
diagnosis NCT03929718 27 36 O
of NCT03929718 37 39 O
typical NCT03929718 40 47 O
AFL NCT03929718 48 51 B-Condition-Name
confirmed NCT03929718 52 61 O
by NCT03929718 62 64 O
12 NCT03929718 66 68 B-Procedure-Name
- NCT03929718 69 70 I-Procedure-Name
lead NCT03929718 71 75 I-Procedure-Name
ECG NCT03929718 76 79 I-Procedure-Name

- NCT03929718 82 83 O
no NCT03929718 85 87 O
documented NCT03929718 88 98 O
AF NCT03929718 99 101 B-Condition-Name
on NCT03929718 102 104 O
ECG NCT03929718 105 108 B-Procedure-Name
, NCT03929718 109 110 O
ambulatory NCT03929718 111 121 B-Procedure-Name
monitor NCT03929718 122 129 I-Procedure-Name
, NCT03929718 130 131 O
pacemaker NCT03929718 132 141 B-Procedure-Name
or NCT03929718 142 144 O
ICD NCT03929718 145 148 B-Procedure-Name
at NCT03929718 149 151 O
any NCT03929718 152 155 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:anytime
time NCT03929718 156 160 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:anytime

- NCT03929718 163 164 O
scheduled NCT03929718 166 175 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
to NCT03929718 176 178 O
undergo NCT03929718 179 186 O
catheter NCT03929718 187 195 B-Procedure-Name
ablation NCT03929718 196 204 I-Procedure-Name
of NCT03929718 205 207 O
the NCT03929718 208 211 O
CTI NCT03929718 212 215 O
for NCT03929718 216 219 O
treatment NCT03929718 220 229 O
of NCT03929718 230 232 O
AFL NCT03929718 233 236 B-Condition-Name

- NCT03929718 239 240 O
history NCT03929718 242 249 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03929718 250 252 O
hypertension NCT03929718 253 265 B-Condition-Name
( NCT03929718 266 267 O
HTN NCT03929718 268 271 B-Condition-Name
) NCT03929718 272 273 O
or NCT03929718 274 276 O
heart NCT03929718 277 282 B-Condition-Name
failure NCT03929718 283 290 I-Condition-Name
( NCT03929718 291 292 O
HF NCT03929718 293 295 B-Condition-Name
) NCT03929718 296 297 O
( NCT03929718 298 299 O
reduced NCT03929718 300 307 O
or NCT03929718 308 310 O
preserved NCT03929718 311 320 O
systolic NCT03929718 321 329 B-Condition-Name
function NCT03929718 330 338 I-Condition-Name
) NCT03929718 339 340 O

Exclusion NCT03929718 342 351 O
Criteria NCT03929718 352 360 O
: NCT03929718 361 362 O

- NCT03929718 366 367 O
history NCT03929718 369 376 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03929718 377 379 O
known NCT03929718 380 385 O
AF NCT03929718 386 388 B-Condition-Name
episodes NCT03929718 389 397 O

- NCT03929718 400 401 O
previous NCT03929718 403 411 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
CTI NCT03929718 412 415 O
or NCT03929718 416 418 O
PVI NCT03929718 419 422 O
ablation NCT03929718 423 431 B-Procedure-Name
procedure NCT03929718 432 441 I-Procedure-Name

- NCT03929718 444 445 O
other NCT03929718 447 452 O
SVT NCT03929718 453 456 B-Condition-Name
mechanisms NCT03929718 457 467 I-Condition-Name
demonstrated NCT03929718 468 480 O
( NCT03929718 481 482 O
AVNRT NCT03929718 483 488 B-Condition-Name
, NCT03929718 489 490 O
AVRT NCT03929718 491 495 B-Condition-Name
or NCT03929718 496 498 O
accessory NCT03929718 499 508 B-Condition-Name
pathways NCT03929718 509 517 I-Condition-Name
) NCT03929718 518 519 O

- NCT03929718 523 524 O
amiodarone NCT03929718 526 536 B-Drug-Name
usage NCT03929718 537 542 O
within NCT03929718 543 549 B-Eq-Operator___Eq-Operator-Value:LTEQ
the NCT03929718 550 553 O
past NCT03929718 554 558 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
3 NCT03929718 560 561 B-Eq-Value
months NCT03929718 562 568 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
, NCT03929718 569 570 O

- NCT03929718 574 575 O
unwillingness NCT03929718 577 590 O
to NCT03929718 591 593 O
participate NCT03929718 594 605 O
or NCT03929718 606 608 O
undergo NCT03929718 609 616 O
insertable NCT03929718 617 627 B-Procedure-Name
monitor NCT03929718 628 635 I-Procedure-Name
implantation NCT03929718 636 648 I-Procedure-Name

- NCT03929718 651 652 O
hyperkalemia NCT03929718 654 666 B-Condition-Name
( NCT03929718 667 668 O
potassium NCT03929718 669 678 B-Observation-Name___Observation-Type-Value:lab
> NCT03929718 679 680 B-Eq-Operator___Eq-Operator-Value:GT
5.0 NCT03929718 682 685 B-Eq-Value
mEq NCT03929718 686 689 B-Eq-Unit
/ NCT03929718 690 691 O
L NCT03929718 692 693 B-Eq-Unit
) NCT03929718 694 695 O

- NCT03929718 699 700 O
severe NCT03929718 702 708 B-Severity___Severity-Value:severe
renal NCT03929718 709 714 B-Condition-Name
disease NCT03929718 715 722 I-Condition-Name
( NCT03929718 723 724 O
Cr NCT03929718 725 727 B-Observation-Name___Observation-Type-Value:lab
> NCT03929718 728 729 B-Eq-Operator___Eq-Operator-Value:GT
2.5 NCT03929718 731 734 B-Eq-Value
mg NCT03929718 735 737 B-Eq-Unit
/ NCT03929718 738 739 O
dL NCT03929718 740 742 B-Eq-Unit
[ NCT03929718 743 744 O
men NCT03929718 745 748 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
] NCT03929718 749 750 O
, NCT03929718 752 753 O
> NCT03929718 754 755 B-Eq-Operator___Eq-Operator-Value:GT
2.0 NCT03929718 757 760 B-Eq-Value
mg NCT03929718 761 763 B-Eq-Unit
/ NCT03929718 764 765 O
dL NCT03929718 766 768 B-Eq-Unit
[ NCT03929718 769 770 O
women NCT03929718 771 776 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
, NCT03929718 777 778 O
GFR NCT03929718 779 782 B-Observation-Name___Observation-Type-Value:lab
< NCT03929718 783 784 B-Eq-Operator___Eq-Operator-Value:LT
30 NCT03929718 786 788 B-Eq-Value
mL NCT03929718 789 791 B-Eq-Unit
/ NCT03929718 792 793 O
min NCT03929718 794 797 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:minute
/ NCT03929718 798 799 O
1.73 NCT03929718 801 805 B-Eq-Unit
m NCT03929718 806 807 I-Eq-Unit
2 NCT03929718 808 809 I-Eq-Unit
) NCT03929718 810 811 O

- NCT03929718 815 816 O
life NCT03929718 818 822 B-Observation-Name
expectancy NCT03929718 823 833 I-Observation-Name
< NCT03929718 834 835 B-Eq-Operator___Eq-Operator-Value:LT
18 NCT03929718 837 839 B-Eq-Value
months NCT03929718 840 846 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

- NCT03929718 849 850 O
prior NCT03929718 852 857 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
intolerance NCT03929718 858 869 B-Condition-Name
to NCT03929718 870 872 O
treatment NCT03929718 873 882 O
with NCT03929718 883 887 O
an NCT03929718 888 890 O
aldosterone NCT03929718 891 902 B-Drug-Name
antagonist NCT03929718 903 913 I-Drug-Name

- NCT03929718 916 917 O
current NCT03929718 919 926 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
treatment NCT03929718 927 936 O
with NCT03929718 937 941 O
an NCT03929718 942 944 O
aldosterone NCT03929718 945 956 B-Drug-Name
antagonist NCT03929718 957 967 I-Drug-Name

- NCT03929718 970 971 O
need NCT03929718 973 977 O
for NCT03929718 978 981 O
treatment NCT03929718 982 991 O
with NCT03929718 992 996 O
a NCT03929718 997 998 O
class NCT03929718 999 1004 B-Eq-Unit
I NCT03929718 1005 1006 B-Eq-Value
or NCT03929718 1007 1009 O
III NCT03929718 1010 1013 B-Eq-Value
AAD NCT03929718 1014 1017 B-Drug-Name
for NCT03929718 1018 1021 O
another NCT03929718 1022 1029 O
indication NCT03929718 1030 1040 O

- NCT03929718 1043 1044 O
operative NCT03929718 1046 1055 O
AFL NCT03929718 1056 1059 B-Condition-Name
( NCT03929718 1060 1061 O
occurring NCT03929718 1062 1071 O
within NCT03929718 1072 1078 B-Eq-Operator___Eq-Operator-Value:LTEQ
30 NCT03929718 1080 1082 B-Eq-Value
days NCT03929718 1083 1087 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
of NCT03929718 1088 1090 O
surgery NCT03929718 1091 1098 B-Procedure-Name
) NCT03929718 1099 1100 O
that NCT03929718 1101 1105 O
is NCT03929718 1106 1108 O
expected NCT03929718 1109 1117 O
to NCT03929718 1118 1120 O
resolve NCT03929718 1121 1128 O

- NCT03929718 1131 1132 O
presence NCT03929718 1134 1142 O
of NCT03929718 1143 1145 O
a NCT03929718 1146 1147 O
cardiac NCT03929718 1148 1155 B-Procedure-Name
rhythm NCT03929718 1156 1162 I-Procedure-Name
device NCT03929718 1163 1169 I-Procedure-Name
( NCT03929718 1170 1171 O
pacemaker NCT03929718 1172 1181 B-Procedure-Name
or NCT03929718 1182 1184 O
ICD NCT03929718 1185 1188 B-Procedure-Name
) NCT03929718 1189 1190 O
capable NCT03929718 1191 1198 O
of NCT03929718 1199 1201 O
AF NCT03929718 1202 1204 B-Procedure-Name
monitoring NCT03929718 1205 1215 I-Procedure-Name

- NCT03929718 1218 1219 O
currently NCT03929718 1221 1230 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
pregnant NCT03929718 1231 1239 B-Condition-Name
or NCT03929718 1240 1242 O
nursing NCT03929718 1243 1250 B-Condition-Name
a NCT03929718 1251 1252 I-Condition-Name
child NCT03929718 1253 1258 I-Condition-Name

- NCT03929718 1261 1262 O
unwilling NCT03929718 1264 1273 O
not NCT03929718 1274 1277 O
to NCT03929718 1278 1280 O
become NCT03929718 1281 1287 O
pregnant NCT03929718 1288 1296 B-Condition-Name
and NCT03929718 1297 1300 O
to NCT03929718 1301 1303 O
use NCT03929718 1304 1307 O
birth NCT03929718 1308 1313 B-Procedure-Name
control NCT03929718 1314 1321 I-Procedure-Name
while NCT03929718 1322 1327 O
taking NCT03929718 1328 1334 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
spironolactone NCT03929718 1335 1349 B-Drug-Name

Inclusion NCT03926832 0 9 O
Criteria NCT03926832 10 18 O
: NCT03926832 19 20 O

- NCT03926832 24 25 O
Subjects NCT03926832 27 35 O
with NCT03926832 36 40 O
a NCT03926832 41 42 O
definite NCT03926832 43 51 O
diagnosis NCT03926832 52 61 O
of NCT03926832 62 64 O
sarcoidosis NCT03926832 65 76 B-Condition-Name
according NCT03926832 77 86 O
to NCT03926832 87 89 O
international NCT03926832 90 103 O
ATS NCT03926832 104 107 O
and NCT03926832 108 111 O
WASOG NCT03926832 112 117 O
guideline NCT03926832 118 127 O

Exclusion NCT03926832 128 137 O
Criteria NCT03926832 138 146 O
: NCT03926832 147 148 O

- NCT03926832 152 153 O
Ongoing NCT03926832 155 162 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
CPAP NCT03926832 163 167 B-Procedure-Name
treatment NCT03926832 168 177 I-Procedure-Name

- NCT03926832 180 181 O
Psychiatric NCT03926832 183 194 B-Condition-Name
disorders NCT03926832 195 204 I-Condition-Name

Inclusion NCT03923023 0 9 O
Criteria NCT03923023 10 18 O
: NCT03923023 19 20 O

- NCT03923023 24 25 O
Pregnant NCT03923023 27 35 B-Condition-Name
women NCT03923023 36 41 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
who NCT03923023 42 45 O
seek NCT03923023 46 50 O
Antenatal NCT03923023 51 60 B-Provider-Type
care NCT03923023 61 65 I-Provider-Type
services NCT03923023 66 74 O
and NCT03923023 75 78 O
plan NCT03923023 79 83 O
to NCT03923023 84 86 O
deliver NCT03923023 87 94 B-Procedure-Name
in NCT03923023 95 97 O
the NCT03923023 98 101 O
selected NCT03923023 102 110 O
health NCT03923023 111 117 B-Location___Location-Value:hospital
facilities NCT03923023 118 128 I-Location___Location-Value:hospital

- NCT03923023 131 132 O
Women NCT03923023 134 139 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
who NCT03923023 140 143 O
reside NCT03923023 144 150 O
within NCT03923023 151 157 O
the NCT03923023 158 161 O
larger NCT03923023 162 168 B-Location___Location-Value:residence
catchment NCT03923023 169 178 I-Location___Location-Value:residence
area NCT03923023 179 183 I-Location___Location-Value:residence
of NCT03923023 184 186 O
the NCT03923023 187 190 O
selected NCT03923023 191 199 O
3 NCT03923023 201 202 B-Eq-Value
health NCT03923023 203 209 B-Location___Location-Value:hospital
facilities NCT03923023 210 220 I-Location___Location-Value:hospital

Exclusion NCT03923023 221 230 O
Criteria NCT03923023 231 239 O
: NCT03923023 240 241 O

- NCT03923023 245 246 O
Women NCT03923023 248 253 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
who NCT03923023 254 257 O
reside NCT03923023 258 264 O
outside NCT03923023 265 272 O
the NCT03923023 273 276 O
larger NCT03923023 277 283 B-Location___Location-Value:residence
catchment NCT03923023 284 293 I-Location___Location-Value:residence
area NCT03923023 294 298 I-Location___Location-Value:residence
of NCT03923023 299 301 O
the NCT03923023 302 305 O
health NCT03923023 306 312 B-Location___Location-Value:hospital
facilities NCT03923023 313 323 I-Location___Location-Value:hospital

- NCT03923023 326 327 O
Women NCT03923023 329 334 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
who NCT03923023 335 338 O
have NCT03923023 339 343 O
not NCT03923023 344 347 O
sought NCT03923023 348 354 O
antenatal NCT03923023 355 364 B-Provider-Type
care NCT03923023 365 369 I-Provider-Type
services NCT03923023 370 378 O
in NCT03923023 379 381 O
the NCT03923023 382 385 O
3 NCT03923023 387 388 B-Eq-Value
health NCT03923023 389 395 B-Location___Location-Value:hospital
facilities NCT03923023 396 406 I-Location___Location-Value:hospital
and NCT03923023 407 410 O
have NCT03923023 411 415 O
come NCT03923023 416 420 O
to NCT03923023 421 423 O
only NCT03923023 424 428 O
deliver NCT03923023 429 436 O
there NCT03923023 437 442 O

Inclusion NCT03923751 0 9 O
Criteria NCT03923751 10 18 O
: NCT03923751 19 20 O

- NCT03923751 24 25 O
All NCT03923751 27 30 O
Polish NCT03923751 31 37 B-Location___Location-Value:hospital
hospitals NCT03923751 38 47 I-Location___Location-Value:hospital
practising NCT03923751 48 58 O
anesthesiology NCT03923751 59 73 O
and NCT03923751 74 77 O
intensive NCT03923751 78 87 O
care NCT03923751 88 92 O
in NCT03923751 93 95 O
the NCT03923751 96 99 O
national NCT03923751 100 108 O
register NCT03923751 109 117 O
of NCT03923751 118 120 O
medical NCT03923751 121 128 O
practices NCT03923751 129 138 O
( NCT03923751 139 140 O
www NCT03923751 141 144 O
. NCT03923751 145 146 O
rpwdl NCT03923751 147 152 O
. NCT03923751 153 154 O
csioz NCT03923751 155 160 O
. NCT03923751 161 162 O
gov NCT03923751 163 166 O
. NCT03923751 167 168 O
pl NCT03923751 169 171 O
) NCT03923751 172 173 O

Exclusion NCT03923751 175 184 O
Criteria NCT03923751 185 193 O
: NCT03923751 194 195 O

- NCT03923751 199 200 O
Hospitals NCT03923751 202 211 B-Location___Location-Value:hospital
and NCT03923751 212 215 O
medical NCT03923751 216 223 O
practices NCT03923751 224 233 O
not NCT03923751 234 237 O
practising NCT03923751 238 248 O
anesthesiology NCT03923751 249 263 O
or NCT03923751 264 266 O
intensive NCT03923751 267 276 O
care NCT03923751 277 281 O

Inclusion NCT03923816 0 9 O
Criteria NCT03923816 10 18 O
: NCT03923816 19 20 O

- NCT03923816 24 25 O
patients NCT03923816 27 35 O
> NCT03923816 36 37 B-Eq-Operator___Eq-Operator-Value:GT
18 NCT03923816 39 41 B-Eq-Value
years NCT03923816 42 47 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03923816 48 51 O
, NCT03923816 52 53 O
undergoing NCT03923816 54 64 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
elective NCT03923816 65 73 O
hepatobiliary NCT03923816 74 87 B-Procedure-Name
surgery NCT03923816 88 95 I-Procedure-Name
under NCT03923816 96 101 O
general NCT03923816 102 109 B-Procedure-Name
anesthesia NCT03923816 110 120 I-Procedure-Name
and NCT03923816 121 124 O
American NCT03923816 125 133 B-Condition-Name
Society NCT03923816 134 141 I-Condition-Name
of NCT03923816 142 144 I-Condition-Name
Anesthesiologists NCT03923816 145 162 I-Condition-Name
grade NCT03923816 163 168 B-Eq-Unit
II NCT03923816 169 171 B-Eq-Value
. NCT03923816 172 173 O

Exclusion NCT03923816 175 184 O
Criteria NCT03923816 185 193 O
: NCT03923816 194 195 O

- NCT03923816 199 200 O
1 NCT03923816 203 204 O
- NCT03923816 205 206 O
patient NCT03923816 207 214 O
refusal NCT03923816 215 222 O
. NCT03923816 223 224 O
2 NCT03923816 227 228 O
- NCT03923816 229 230 O
psychiatric NCT03923816 231 242 B-Condition-Name
disorders NCT03923816 243 252 I-Condition-Name
. NCT03923816 253 254 O
3 NCT03923816 257 258 O
- NCT03923816 259 260 O
pregnancy NCT03923816 261 270 B-Condition-Name
and NCT03923816 271 274 O
lactation NCT03923816 275 284 B-Condition-Name
. NCT03923816 285 286 O
4 NCT03923816 289 290 O
- NCT03923816 291 292 O
preexisting NCT03923816 293 304 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
neurological NCT03923816 305 317 B-Condition-Name
dysfunction NCT03923816 318 329 I-Condition-Name
( NCT03923816 330 331 O
history NCT03923816 332 339 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03923816 340 342 O
cerebrovascular NCT03923816 343 358 B-Condition-Name
stroke NCT03923816 359 365 I-Condition-Name
CVS NCT03923816 366 369 B-Condition-Name
) NCT03923816 370 371 O
5 NCT03923816 373 374 O
- NCT03923816 375 376 O
metastatic NCT03923816 377 387 O
cancer NCT03923816 388 394 B-Condition-Name
. NCT03923816 395 396 O

6 NCT03923816 404 405 O
- NCT03923816 406 407 O
Inflammatory NCT03923816 408 420 B-Condition-Name
bowel NCT03923816 421 426 I-Condition-Name
disease NCT03923816 427 434 I-Condition-Name
. NCT03923816 435 436 O
7 NCT03923816 439 440 O
- NCT03923816 441 442 O
Diabetes NCT03923816 443 451 B-Condition-Name
mellitus NCT03923816 452 460 I-Condition-Name
. NCT03923816 461 462 O
8 NCT03923816 465 466 O
- NCT03923816 467 468 O
Renal NCT03923816 469 474 B-Condition-Name
insufficiency NCT03923816 475 488 I-Condition-Name
( NCT03923816 489 490 O
serum NCT03923816 491 496 B-Observation-Name___Observation-Type-Value:lab
creatinine NCT03923816 497 507 I-Observation-Name___Observation-Type-Value:lab
level NCT03923816 508 513 I-Observation-Name___Observation-Type-Value:lab
more NCT03923816 514 518 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03923816 519 523 I-Eq-Operator___Eq-Operator-Value:GT
180 NCT03923816 525 528 B-Eq-Value
μmol NCT03923816 529 533 B-Eq-Unit
/ NCT03923816 534 535 O
l NCT03923816 536 537 B-Eq-Unit
) NCT03923816 538 539 O
. NCT03923816 541 542 O
9 NCT03923816 545 546 O
- NCT03923816 547 548 O
unexpected NCT03923816 549 559 O
intraoperative NCT03923816 560 574 B-Condition-Name
findings NCT03923816 575 583 I-Condition-Name
( NCT03923816 584 585 O
inoperable NCT03923816 586 596 O
) NCT03923816 597 598 O
. NCT03923816 600 601 O
10 NCT03923816 604 606 O
- NCT03923816 607 608 O
accidental NCT03923816 609 619 O
massive NCT03923816 620 627 O
intraoperative NCT03923816 628 642 B-Condition-Name
hemorrhage NCT03923816 643 653 I-Condition-Name
. NCT03923816 654 655 O

Inclusion NCT03926013 0 9 O
Criteria NCT03926013 10 18 O
: NCT03926013 19 20 O

- NCT03926013 24 25 O
Histology NCT03926013 27 36 O
: NCT03926013 37 38 O
Part NCT03926013 39 43 O
1 NCT03926013 45 46 O
: NCT03926013 47 48 O
Metastatic NCT03926013 49 59 O
castration NCT03926013 60 70 O
- NCT03926013 71 72 O
resistant NCT03926013 73 82 O
prostate NCT03926013 83 91 O
cancer NCT03926013 92 98 B-Condition-Name
( NCT03926013 99 100 O
mCRPC NCT03926013 101 106 B-Condition-Name
) NCT03926013 107 108 O
with NCT03926013 109 113 O
histologic NCT03926013 114 124 B-Procedure-Name
confirmation NCT03926013 125 137 O
of NCT03926013 138 140 O
adenocarcinoma NCT03926013 141 155 B-Condition-Name
. NCT03926013 156 157 O
Adenocarcinoma NCT03926013 159 173 B-Condition-Name
with NCT03926013 174 178 O
small NCT03926013 179 184 O
- NCT03926013 185 186 O
cell NCT03926013 187 191 O
or NCT03926013 192 194 O
neuroendocrine NCT03926013 195 209 O
features NCT03926013 210 218 O
is NCT03926013 219 221 O
allowed NCT03926013 222 229 O
. NCT03926013 230 231 O
mCRPC NCT03926013 233 238 B-Condition-Name
is NCT03926013 239 241 O
defined NCT03926013 242 249 O
by NCT03926013 250 252 O
prostate NCT03926013 253 261 O
Cancer NCT03926013 262 268 O
Working NCT03926013 269 276 O
Group NCT03926013 277 282 O
( NCT03926013 283 284 O
PCWG NCT03926013 285 289 O
) NCT03926013 290 291 O
3 NCT03926013 293 294 O
criteria NCT03926013 295 303 O
. NCT03926013 304 305 O
Part NCT03926013 307 311 O
2 NCT03926013 313 314 O
: NCT03926013 315 316 O
mCRPC NCT03926013 317 322 B-Condition-Name
as NCT03926013 323 325 O
defined NCT03926013 326 333 O
above NCT03926013 334 339 O
or NCT03926013 340 342 O
pathologically NCT03926013 343 357 B-Procedure-Name
confirmed NCT03926013 358 367 O
metastatic NCT03926013 368 378 O
renal NCT03926013 379 384 O
cell NCT03926013 385 389 O
carcinoma NCT03926013 390 399 B-Condition-Name
( NCT03926013 400 401 O
RCC NCT03926013 402 405 B-Condition-Name
) NCT03926013 406 407 O
as NCT03926013 408 410 O
defined NCT03926013 411 418 O
by NCT03926013 419 421 O
world NCT03926013 422 427 O
health NCT03926013 428 434 O
organization NCT03926013 435 447 O
( NCT03926013 448 449 O
WHO NCT03926013 450 453 O
) NCT03926013 454 455 O

2016 NCT03926013 463 467 O
Classifications NCT03926013 468 483 O

- NCT03926013 486 487 O
Measurable NCT03926013 489 499 O
or NCT03926013 500 502 O
evaluable NCT03926013 503 512 O
disease NCT03926013 513 520 B-Condition-Name
: NCT03926013 521 522 O
Part NCT03926013 523 527 O
1 NCT03926013 529 530 O
: NCT03926013 531 532 O
Either NCT03926013 533 539 O
measurable NCT03926013 540 550 O
or NCT03926013 551 553 O
evaluable NCT03926013 554 563 O
disease NCT03926013 564 571 B-Condition-Name
for NCT03926013 572 575 O
prostate NCT03926013 576 584 O
cancer NCT03926013 585 591 B-Condition-Name
. NCT03926013 592 593 O
Part NCT03926013 595 599 O
2 NCT03926013 601 602 O
: NCT03926013 603 604 O
At NCT03926013 605 607 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03926013 608 613 I-Eq-Operator___Eq-Operator-Value:GTEQ
one NCT03926013 614 617 B-Eq-Value
measurable NCT03926013 618 628 O
lesion NCT03926013 629 635 B-Condition-Name
as NCT03926013 636 638 O
per NCT03926013 639 642 O
RECIST NCT03926013 643 649 O
v NCT03926013 650 651 O
1.1 NCT03926013 652 655 O
. NCT03926013 655 656 O

- NCT03926013 660 661 O
Evidence NCT03926013 663 671 O
of NCT03926013 672 674 O
disease NCT03926013 675 682 B-Condition-Name
progression NCT03926013 683 694 I-Condition-Name
on NCT03926013 695 697 O
prior NCT03926013 698 703 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
therapy NCT03926013 704 711 B-Procedure-Name
that NCT03926013 712 716 O
requires NCT03926013 717 725 O
a NCT03926013 726 727 O
new NCT03926013 728 731 O
line NCT03926013 732 736 O
of NCT03926013 737 739 O
treatment NCT03926013 740 749 O

- NCT03926013 752 753 O
Participants NCT03926013 755 767 O
with NCT03926013 768 772 O
accessible NCT03926013 773 783 O
lesions NCT03926013 784 791 B-Condition-Name
enrolled NCT03926013 792 800 O
in NCT03926013 801 803 O
selected NCT03926013 804 812 O
pharmacokinetic NCT03926013 813 828 O
( NCT03926013 829 830 O
PK NCT03926013 831 833 O
) NCT03926013 834 835 O
/ NCT03926013 837 838 O
pharmacodynamics NCT03926013 839 855 O
( NCT03926013 856 857 O
PD NCT03926013 858 860 O
) NCT03926013 861 862 O
cohorts NCT03926013 863 870 O
and NCT03926013 871 874 O
in NCT03926013 875 877 O
Part NCT03926013 878 882 O
2 NCT03926013 884 885 O
must NCT03926013 886 890 O
agree NCT03926013 891 896 O
to NCT03926013 897 899 O
undergo NCT03926013 900 907 O
the NCT03926013 908 911 O
mandatory NCT03926013 912 921 O
fresh NCT03926013 922 927 O
tumor NCT03926013 928 933 O
biopsies NCT03926013 934 942 B-Procedure-Name
, NCT03926013 943 944 O
unless NCT03926013 945 951 O
collection NCT03926013 952 962 O
of NCT03926013 963 965 O
the NCT03926013 966 969 O
biopsy NCT03926013 970 976 B-Procedure-Name
presents NCT03926013 977 985 O
a NCT03926013 986 987 O
safety NCT03926013 988 994 O
risk NCT03926013 995 999 O

Exclusion NCT03926013 1000 1009 O
Criteria NCT03926013 1010 1018 O
: NCT03926013 1019 1020 O

- NCT03926013 1024 1025 O
At NCT03926013 1027 1029 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03926013 1030 1035 I-Eq-Operator___Eq-Operator-Value:GTEQ
2 NCT03926013 1037 1038 B-Eq-Value
weeks NCT03926013 1039 1044 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
between NCT03926013 1045 1052 O
prior NCT03926013 1053 1058 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
anticancer NCT03926013 1059 1069 B-Procedure-Name
treatment NCT03926013 1070 1079 I-Procedure-Name
( NCT03926013 1080 1081 O
including NCT03926013 1082 1091 O
radiotherapy NCT03926013 1092 1104 B-Procedure-Name
) NCT03926013 1105 1106 O
discontinuation NCT03926013 1107 1122 O
and NCT03926013 1123 1126 O
the NCT03926013 1127 1130 O
first NCT03926013 1131 1136 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
dose NCT03926013 1137 1141 O
of NCT03926013 1142 1144 O
study NCT03926013 1145 1150 O
drug NCT03926013 1151 1155 B-Drug-Name
, NCT03926013 1156 1157 O
and NCT03926013 1158 1161 O
toxicities NCT03926013 1162 1172 B-Observation-Name
have NCT03926013 1173 1177 O
returned NCT03926013 1178 1186 O
to NCT03926013 1187 1189 O
Grade NCT03926013 1190 1195 B-Eq-Unit
less NCT03926013 1196 1200 B-Eq-Operator___Eq-Operator-Value:LTEQ
than NCT03926013 1201 1205 I-Eq-Operator___Eq-Operator-Value:LTEQ
or NCT03926013 1206 1208 I-Eq-Operator___Eq-Operator-Value:LTEQ
equal NCT03926013 1209 1214 I-Eq-Operator___Eq-Operator-Value:LTEQ
to NCT03926013 1215 1217 O
( NCT03926013 1218 1219 O
< NCT03926013 1221 1222 B-Eq-Operator___Eq-Operator-Value:LTEQ
= NCT03926013 1224 1225 I-Eq-Operator___Eq-Operator-Value:LTEQ
) NCT03926013 1227 1228 O
1 NCT03926013 1230 1231 B-Eq-Value
or NCT03926013 1232 1234 O
baseline NCT03926013 1235 1243 O

- NCT03926013 1246 1247 O
Prior NCT03926013 1249 1254 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
treatment NCT03926013 1255 1264 O
with NCT03926013 1265 1269 O
prostate NCT03926013 1270 1278 B-Drug-Name
- NCT03926013 1279 1280 I-Drug-Name
specific NCT03926013 1281 1289 I-Drug-Name
membrane NCT03926013 1290 1298 I-Drug-Name
antigen NCT03926013 1299 1306 I-Drug-Name
( NCT03926013 1307 1308 O
PSMA NCT03926013 1309 1313 B-Drug-Name
) NCT03926013 1314 1315 O
- NCT03926013 1317 1318 O
targeted NCT03926013 1319 1327 O
therapy NCT03926013 1328 1335 O
except NCT03926013 1336 1342 O
for NCT03926013 1343 1346 O
PSMA NCT03926013 1347 1351 B-Immunization-Name
- NCT03926013 1352 1353 I-Immunization-Name
targeted NCT03926013 1354 1362 I-Immunization-Name
vaccine NCT03926013 1363 1370 I-Immunization-Name
is NCT03926013 1371 1373 O
permitted NCT03926013 1374 1383 O

- NCT03926013 1386 1387 O
Solid NCT03926013 1389 1394 O
organ NCT03926013 1395 1400 O
or NCT03926013 1401 1403 O
bone NCT03926013 1404 1408 O
marrow NCT03926013 1409 1415 O
transplantation NCT03926013 1416 1431 B-Procedure-Name

- NCT03926013 1434 1435 O
Seizure NCT03926013 1437 1444 B-Condition-Name
or NCT03926013 1445 1447 O
known NCT03926013 1448 1453 O
condition NCT03926013 1454 1463 O
that NCT03926013 1464 1468 O
may NCT03926013 1469 1472 O
predispose NCT03926013 1473 1483 O
to NCT03926013 1484 1486 O
seizure NCT03926013 1487 1494 B-Condition-Name
or NCT03926013 1495 1497 O
intracranial NCT03926013 1498 1510 B-Condition-Name
masses NCT03926013 1511 1517 I-Condition-Name

- NCT03926013 1520 1521 O
Other NCT03926013 1523 1528 O
active NCT03926013 1529 1535 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
malignancy NCT03926013 1536 1546 B-Condition-Name
requiring NCT03926013 1547 1556 O
systemic NCT03926013 1557 1565 O
treatment NCT03926013 1566 1575 O
< NCT03926013 1576 1577 B-Eq-Operator___Eq-Operator-Value:LTEQ
= NCT03926013 1579 1580 I-Eq-Operator___Eq-Operator-Value:LTEQ
12 NCT03926013 1582 1584 B-Eq-Value
months NCT03926013 1585 1591 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
prior NCT03926013 1592 1597 O
to NCT03926013 1598 1600 O
enrollment NCT03926013 1601 1611 O

Inclusion NCT03920462 0 9 O
Criteria NCT03920462 10 18 O
: NCT03920462 19 20 O

- NCT03920462 24 25 O
Capacity NCT03920462 27 35 O
to NCT03920462 36 38 O
ride NCT03920462 39 43 O
a NCT03920462 44 45 O
bike NCT03920462 46 50 O

- NCT03920462 53 54 O
Volunteer NCT03920462 56 65 O
without NCT03920462 66 73 O
a NCT03920462 74 75 O
contraindication NCT03920462 76 92 O
to NCT03920462 93 95 O
moderate NCT03920462 96 104 B-Polarity___Polarity-Value:medium
physical NCT03920462 105 113 B-Observation-Name___Observation-Type-Value:social-habit
activity NCT03920462 114 122 I-Observation-Name___Observation-Type-Value:social-habit
or NCT03920462 123 125 O
cycling NCT03920462 126 133 B-Observation-Name___Observation-Type-Value:social-habit
( NCT03920462 134 135 O
acute NCT03920462 136 141 B-Severity___Severity-Value:severe
coronary NCT03920462 142 150 B-Condition-Name
artery NCT03920462 151 157 I-Condition-Name
disease NCT03920462 158 165 I-Condition-Name
less NCT03920462 166 170 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03920462 171 175 I-Eq-Operator___Eq-Operator-Value:LT
2 NCT03920462 177 178 B-Eq-Value
years NCT03920462 179 184 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03920462 185 188 O
, NCT03920462 189 190 O
musculoskeletal NCT03920462 191 206 O
problem NCT03920462 207 214 B-Condition-Name
of NCT03920462 215 217 O
the NCT03920462 218 221 O
spine NCT03920462 222 227 O
or NCT03920462 228 230 O
lower NCT03920462 231 236 O
limbs NCT03920462 237 242 O
incompatible NCT03920462 243 255 O
with NCT03920462 256 260 O
cycling NCT03920462 261 268 B-Observation-Name
) NCT03920462 269 270 O
. NCT03920462 272 273 O

- NCT03920462 277 278 O
weight NCT03920462 280 286 B-Observation-Name___Observation-Type-Value:vital
< NCT03920462 287 288 B-Eq-Operator___Eq-Operator-Value:LT
125 NCT03920462 290 293 B-Eq-Value
kg NCT03920462 294 296 B-Eq-Unit

- NCT03920462 299 300 O
volunteer NCT03920462 302 311 O
available NCT03920462 312 321 O
for NCT03920462 322 325 O
an NCT03920462 326 328 O
intervention NCT03920462 329 341 B-Procedure-Name
of NCT03920462 342 344 O
2 NCT03920462 346 347 B-Eq-Value
- NCT03920462 348 349 B-Eq-Operator___Eq-Operator-Value:BETWEEN
3 NCT03920462 351 352 B-Eq-Value
hours NCT03920462 353 358 O
twice NCT03920462 359 364 B-Eq-Value
a NCT03920462 365 366 O
week NCT03920462 367 371 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
during NCT03920462 372 378 O
1 NCT03920462 380 381 B-Eq-Value
month NCT03920462 382 387 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
. NCT03920462 388 389 O

Exclusion NCT03920462 391 400 O
Criteria NCT03920462 401 409 O
: NCT03920462 410 411 O

- NCT03920462 415 416 O
Person NCT03920462 418 424 O
deprived NCT03920462 425 433 B-Observation-Name
of NCT03920462 434 436 I-Observation-Name
liberty NCT03920462 437 444 I-Observation-Name
or NCT03920462 445 447 O
legal NCT03920462 448 453 B-Observation-Name
protection NCT03920462 454 464 I-Observation-Name
measure NCT03920462 465 472 O

Inclusion NCT03928002 0 9 O
Criteria NCT03928002 10 18 O
: NCT03928002 19 20 O

- NCT03928002 24 25 O
Patient NCT03928002 27 34 O
≥ NCT03928002 35 36 B-Eq-Operator___Eq-Operator-Value:GTEQ
7 NCT03928002 38 39 B-Eq-Value
years NCT03928002 40 45 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03928002 46 49 O

- NCT03928002 52 53 O
Patient NCT03928002 55 62 O
affiliated NCT03928002 63 73 O
to NCT03928002 74 76 O
a NCT03928002 77 78 O
social NCT03928002 79 85 O
security NCT03928002 86 94 O
system NCT03928002 95 101 O

- NCT03928002 104 105 O
Giving NCT03928002 107 113 O
their NCT03928002 114 119 O
informed NCT03928002 120 128 O
consent NCT03928002 129 136 O
for NCT03928002 137 140 O
the NCT03928002 141 144 O
study NCT03928002 145 150 O
( NCT03928002 151 152 O
adults NCT03928002 153 159 O
, NCT03928002 160 161 O
parents NCT03928002 162 169 O
of NCT03928002 170 172 O
minors NCT03928002 173 179 O
) NCT03928002 180 181 O

- NCT03928002 185 186 O
Patients NCT03928002 188 196 O
with NCT03928002 197 201 O
PAH NCT03928002 202 205 B-Condition-Name
associated NCT03928002 206 216 O
with NCT03928002 217 221 O
congenital NCT03928002 222 232 B-Condition-Name
heart NCT03928002 233 238 I-Condition-Name
disease NCT03928002 239 246 I-Condition-Name
requiring NCT03928002 247 256 O
cardiac NCT03928002 257 264 B-Procedure-Name
catheterization NCT03928002 265 280 I-Procedure-Name
and NCT03928002 281 284 O
2 NCT03928002 286 287 O
D NCT03928002 288 289 O
MRI NCT03928002 290 293 B-Procedure-Name
for NCT03928002 294 297 O
the NCT03928002 298 301 O
diagnosis NCT03928002 302 311 O
or NCT03928002 312 314 O
follow NCT03928002 315 321 O
- NCT03928002 322 323 O
up NCT03928002 324 326 O
of NCT03928002 327 329 O
PAH NCT03928002 330 333 B-Condition-Name
associated NCT03928002 334 344 O
with NCT03928002 345 349 O
congenital NCT03928002 350 360 B-Condition-Name
heart NCT03928002 361 366 I-Condition-Name
disease NCT03928002 367 374 I-Condition-Name

Exclusion NCT03928002 375 384 O
Criteria NCT03928002 385 393 O
: NCT03928002 394 395 O

- NCT03928002 399 400 O
➢ NCT03928002 402 403 O
Patient NCT03928002 404 411 O
< NCT03928002 412 413 B-Eq-Operator___Eq-Operator-Value:LT
7 NCT03928002 415 416 B-Eq-Value
years NCT03928002 417 422 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03928002 423 426 O

- NCT03928002 434 435 O
Pregnant NCT03928002 437 445 B-Condition-Name
woman NCT03928002 446 451 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female

- NCT03928002 459 460 O
Contraindications NCT03928002 462 479 O
to NCT03928002 480 482 O
MRI NCT03928002 483 486 B-Procedure-Name
( NCT03928002 487 488 O
claustrophobia NCT03928002 489 503 B-Condition-Name
, NCT03928002 504 505 O
intraocular NCT03928002 506 517 O
metal NCT03928002 518 523 B-Condition-Name
foreign NCT03928002 524 531 I-Condition-Name
bodies NCT03928002 532 538 I-Condition-Name
, NCT03928002 539 540 O
pacemaker NCT03928002 541 550 B-Procedure-Name
, NCT03928002 551 552 O
neurostimulator NCT03928002 553 568 B-Procedure-Name
, NCT03928002 569 570 O
cochlear NCT03928002 571 579 B-Procedure-Name
implants NCT03928002 580 588 I-Procedure-Name
, NCT03928002 589 590 O
old NCT03928002 591 594 O
heart NCT03928002 595 600 B-Procedure-Name
valves NCT03928002 601 607 I-Procedure-Name
) NCT03928002 608 609 O

- NCT03928002 618 619 O
Contraindication NCT03928002 621 637 O
to NCT03928002 638 640 O
gadolinium NCT03928002 641 651 B-Drug-Name
injection NCT03928002 652 661 B-Procedure-Name
( NCT03928002 662 663 O
allergy NCT03928002 664 671 O
, NCT03928002 672 673 O
renal NCT03928002 674 679 B-Condition-Name
failure NCT03928002 680 687 I-Condition-Name
with NCT03928002 688 692 O
DFG NCT03928002 693 696 B-Observation-Name
< NCT03928002 697 698 B-Eq-Operator___Eq-Operator-Value:LT
30 NCT03928002 700 702 B-Eq-Value
ml NCT03928002 703 705 B-Eq-Unit
/ NCT03928002 706 707 O
min NCT03928002 708 711 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:minute
/ NCT03928002 712 713 O
1.73 NCT03928002 715 719 B-Eq-Unit
m² NCT03928002 720 722 I-Eq-Unit
) NCT03928002 723 724 O

- NCT03928002 733 734 O
Hemodynamically NCT03928002 736 751 O
unstable NCT03928002 752 760 O
patients NCT03928002 761 769 O

- NCT03928002 777 778 O
Refusal NCT03928002 780 787 O
to NCT03928002 788 790 O
participate NCT03928002 791 802 O

Inclusion NCT03927872 0 9 O
criteria NCT03927872 10 18 O
: NCT03927872 19 20 O

- NCT03927872 24 25 O
CES NCT03927872 27 30 B-Condition-Name
and NCT03927872 31 34 O
non NCT03927872 35 38 O
- NCT03927872 39 40 O
CES NCT03927872 41 44 B-Condition-Name
diagnosis NCT03927872 45 54 O
was NCT03927872 55 58 O
according NCT03927872 59 68 O
to NCT03927872 69 71 O
Trial NCT03927872 72 77 O
of NCT03927872 78 80 O
Org NCT03927872 81 84 O
10172 NCT03927872 86 91 O
in NCT03927872 92 94 O
Acute NCT03927872 95 100 B-Procedure-Name
Stroke NCT03927872 101 107 I-Procedure-Name
Treatment NCT03927872 108 117 I-Procedure-Name
﴾ NCT03927872 118 119 O
TOAST NCT03927872 120 125 B-Procedure-Name
﴿ NCT03927872 126 127 O
classification NCT03927872 128 142 O
criteria NCT03927872 143 151 O
. NCT03927872 152 153 O

- NCT03927872 157 158 O
non NCT03927872 160 163 O
- NCT03927872 164 165 O
CES NCT03927872 166 169 B-Condition-Name
were NCT03927872 170 174 O
selected NCT03927872 175 183 O
to NCT03927872 184 186 O
match NCT03927872 187 192 O
patients NCT03927872 193 201 O
with NCT03927872 202 206 O
CES NCT03927872 207 210 B-Condition-Name
regarding NCT03927872 211 220 O
age NCT03927872 221 224 O
and NCT03927872 225 228 O
vascular NCT03927872 229 237 O
risk NCT03927872 238 242 O
factors NCT03927872 243 250 O
as NCT03927872 251 253 O
a NCT03927872 254 255 O
control NCT03927872 256 263 O
group NCT03927872 264 269 O
. NCT03927872 270 271 O

- NCT03927872 275 276 O
Patients NCT03927872 278 286 O
with NCT03927872 287 291 O
National NCT03927872 292 300 B-Condition-Name
Institutes NCT03927872 301 311 I-Condition-Name
of NCT03927872 312 314 I-Condition-Name
Health NCT03927872 315 321 I-Condition-Name
Stroke NCT03927872 322 328 I-Condition-Name
Scale NCT03927872 329 334 I-Condition-Name
﴾ NCT03927872 335 336 O
NIHSS NCT03927872 337 342 B-Condition-Name
﴿ NCT03927872 343 344 O
score NCT03927872 345 350 O
more NCT03927872 351 355 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03927872 356 360 I-Eq-Operator___Eq-Operator-Value:GT
5 NCT03927872 362 363 B-Eq-Value
. NCT03927872 363 364 O

- NCT03927872 368 369 O
Adult NCT03927872 371 376 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
patients NCT03927872 377 385 O
with NCT03927872 386 390 O
their NCT03927872 391 396 O
ages NCT03927872 397 401 O
more NCT03927872 402 406 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03927872 407 411 I-Eq-Operator___Eq-Operator-Value:GT
18 NCT03927872 413 415 B-Eq-Value
year NCT03927872 416 420 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
. NCT03927872 421 422 O

Exclusion NCT03927872 424 433 O
criteria NCT03927872 434 442 O
: NCT03927872 443 444 O

- NCT03927872 448 449 O
Lacunar NCT03927872 451 458 O
stroke NCT03927872 459 465 B-Condition-Name
and NCT03927872 466 469 O
transient NCT03927872 470 479 B-Condition-Name
ischemic NCT03927872 480 488 I-Condition-Name
attacks NCT03927872 489 496 I-Condition-Name
( NCT03927872 497 498 O
TIAs NCT03927872 499 503 B-Condition-Name
) NCT03927872 504 505 O

- NCT03927872 509 510 O
Haemorrhagic NCT03927872 512 524 O
stroke NCT03927872 525 531 B-Condition-Name
. NCT03927872 532 533 O

- NCT03927872 537 538 O
Neurological NCT03927872 540 552 B-Condition-Name
causes NCT03927872 553 559 I-Condition-Name
of NCT03927872 560 562 O
acute NCT03927872 563 568 B-Severity___Severity-Value:severe
focal NCT03927872 569 574 O
cerebral NCT03927872 575 583 B-Condition-Name
dysfunction NCT03927872 584 595 I-Condition-Name
such NCT03927872 596 600 O
as NCT03927872 601 603 O
cerebral NCT03927872 604 612 B-Condition-Name
venous NCT03927872 613 619 I-Condition-Name
sinus NCT03927872 620 625 I-Condition-Name
thrombosis NCT03927872 626 636 I-Condition-Name
, NCT03927872 637 638 O
head NCT03927872 639 643 O
trauma NCT03927872 644 650 B-Condition-Name
, NCT03927872 651 652 O
infection NCT03927872 653 662 B-Condition-Name
, NCT03927872 663 664 O
and NCT03927872 665 668 O
auto NCT03927872 669 673 B-Condition-Name
immune NCT03927872 674 680 I-Condition-Name
disorders NCT03927872 681 690 I-Condition-Name

- NCT03927872 693 694 O
Heart NCT03927872 696 701 B-Condition-Name
failure NCT03927872 702 709 I-Condition-Name

- NCT03927872 712 713 O
Liver NCT03927872 715 720 B-Condition-Name
failure NCT03927872 721 728 I-Condition-Name

- NCT03927872 731 732 O
Chronic NCT03927872 734 741 B-Condition-Name
renal NCT03927872 742 747 I-Condition-Name
disease NCT03927872 748 755 I-Condition-Name
. NCT03927872 756 757 O

Inclusion NCT03929900 0 9 O
Criteria NCT03929900 10 18 O
: NCT03929900 19 20 O

- NCT03929900 24 25 O
Age NCT03929900 27 30 O
45 NCT03929900 32 34 B-Eq-Value
- NCT03929900 35 36 B-Eq-Operator___Eq-Operator-Value:BETWEEN
79 NCT03929900 38 40 B-Eq-Value
years NCT03929900 41 46 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03929900 49 50 O
Estimated NCT03929900 52 61 B-Observation-Name___Observation-Type-Value:lab
glomerular NCT03929900 62 72 I-Observation-Name___Observation-Type-Value:lab
filtration NCT03929900 73 83 I-Observation-Name___Observation-Type-Value:lab
rate NCT03929900 84 88 I-Observation-Name___Observation-Type-Value:lab
20 NCT03929900 90 92 B-Eq-Value
- NCT03929900 93 94 B-Eq-Operator___Eq-Operator-Value:BETWEEN
60 NCT03929900 96 98 B-Eq-Value
mL NCT03929900 99 101 B-Eq-Unit
/ NCT03929900 102 103 O
min NCT03929900 104 107 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:minute
/ NCT03929900 108 109 O
1.73 NCT03929900 111 115 B-Eq-Unit
m NCT03929900 116 117 I-Eq-Unit
2 NCT03929900 118 119 I-Eq-Unit
based NCT03929900 120 125 O
on NCT03929900 126 128 O
CKD NCT03929900 129 132 O
- NCT03929900 133 134 O
EPI NCT03929900 135 138 O
( NCT03929900 139 140 O
Cr NCT03929900 141 143 O
) NCT03929900 144 145 O
equation NCT03929900 146 154 O

- NCT03929900 157 158 O
Non NCT03929900 160 163 B-Condition-Name
- NCT03929900 164 165 I-Condition-Name
dialysis NCT03929900 166 174 I-Condition-Name
dependent NCT03929900 175 184 I-Condition-Name
( NCT03929900 185 186 O
NDD NCT03929900 187 190 B-Condition-Name
) NCT03929900 191 192 O

Exclusion NCT03929900 194 203 O
Criteria NCT03929900 204 212 O
: NCT03929900 213 214 O

- NCT03929900 218 219 O
Autosomal NCT03929900 221 230 B-Condition-Name
dominant NCT03929900 231 239 I-Condition-Name
polycystic NCT03929900 240 250 I-Condition-Name
kidney NCT03929900 251 257 I-Condition-Name
disease NCT03929900 258 265 I-Condition-Name

- NCT03929900 268 269 O
Unable NCT03929900 271 277 O
or NCT03929900 278 280 O
unwilling NCT03929900 281 290 O
to NCT03929900 291 293 O
give NCT03929900 294 298 O
consent NCT03929900 299 306 O

- NCT03929900 309 310 O
Previously NCT03929900 312 322 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
received NCT03929900 323 331 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
chronic NCT03929900 332 339 O
dialysis NCT03929900 340 348 B-Procedure-Name

- NCT03929900 351 352 O
Previous NCT03929900 354 362 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
any NCT03929900 363 366 O
organ NCT03929900 367 372 B-Procedure-Name
transplant NCT03929900 373 383 I-Procedure-Name

- NCT03929900 386 387 O
Patients NCT03929900 389 397 O
who NCT03929900 398 401 O
diagnosed NCT03929900 402 411 O
heart NCT03929900 412 417 B-Condition-Name
failure NCT03929900 418 425 I-Condition-Name
with NCT03929900 426 430 O
NYHA NCT03929900 431 435 B-Condition-Name
class NCT03929900 436 441 B-Eq-Unit
3 NCT03929900 443 444 B-Eq-Value
or NCT03929900 445 447 O
4 NCT03929900 449 450 B-Eq-Value

- NCT03929900 454 455 O
Known NCT03929900 457 462 O
liver NCT03929900 463 468 B-Condition-Name
cirrhosis NCT03929900 469 478 I-Condition-Name
( NCT03929900 479 480 O
Child NCT03929900 481 486 B-Condition-Name
- NCT03929900 487 488 I-Condition-Name
pugh NCT03929900 489 493 I-Condition-Name
class NCT03929900 494 499 B-Eq-Unit
2 NCT03929900 501 502 B-Eq-Value
or NCT03929900 503 505 O
3 NCT03929900 507 508 B-Eq-Value
) NCT03929900 509 510 O

- NCT03929900 514 515 O
Pregnant NCT03929900 517 525 B-Condition-Name
women NCT03929900 526 531 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female

- NCT03929900 534 535 O
Single NCT03929900 537 543 B-Condition-Name
kidney NCT03929900 544 550 I-Condition-Name
due NCT03929900 551 554 O
to NCT03929900 555 557 O
trauma NCT03929900 558 564 B-Condition-Name
or NCT03929900 565 567 O
donation NCT03929900 568 576 B-Condition-Name

- NCT03929900 579 580 O
Patients NCT03929900 582 590 O
who NCT03929900 591 594 O
received NCT03929900 595 603 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
immunosuppressive NCT03929900 604 621 B-Drug-Name
agent NCT03929900 622 627 I-Drug-Name
within NCT03929900 628 634 B-Eq-Operator___Eq-Operator-Value:LTEQ
the NCT03929900 635 638 O
past NCT03929900 639 643 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
1 NCT03929900 645 646 B-Eq-Value
year NCT03929900 647 651 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03929900 654 655 O
Patients NCT03929900 657 665 O
who NCT03929900 666 669 O
diagnosed NCT03929900 670 679 O
with NCT03929900 680 684 O
glomerulonephritis NCT03929900 685 703 B-Condition-Name
through NCT03929900 704 711 O
kidney NCT03929900 712 718 O
biopsy NCT03929900 719 725 B-Procedure-Name

Inclusion NCT03928834 0 9 O
Criteria NCT03928834 10 18 O
: NCT03928834 19 20 O

1 NCT03928834 25 26 O
. NCT03928834 26 27 O
HIV NCT03928834 29 32 B-Condition-Name
- NCT03928834 33 34 O
positive NCT03928834 35 43 B-Polarity___Polarity-Value:positive
adolescents NCT03928834 44 55 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
aged NCT03928834 56 60 O
10 NCT03928834 62 64 B-Eq-Value
- NCT03928834 65 66 B-Eq-Operator___Eq-Operator-Value:BETWEEN
19 NCT03928834 68 70 B-Eq-Value
years NCT03928834 71 76 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
who NCT03928834 77 80 O
know NCT03928834 81 85 O
their NCT03928834 86 91 O
status NCT03928834 92 98 O

2 NCT03928834 102 103 O
. NCT03928834 103 104 O
On NCT03928834 106 108 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
ART NCT03928834 109 112 B-Procedure-Name
for NCT03928834 113 116 O
at NCT03928834 117 119 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03928834 120 125 I-Eq-Operator___Eq-Operator-Value:GTEQ
6 NCT03928834 127 128 B-Eq-Value
months NCT03928834 129 135 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
as NCT03928834 136 138 O
per NCT03928834 139 142 O
clinic NCT03928834 143 149 O
records NCT03928834 150 157 O
: NCT03928834 158 159 O
the NCT03928834 160 163 O
patient NCT03928834 164 171 O
will NCT03928834 172 176 O
have NCT03928834 177 181 O
attended NCT03928834 182 190 O
the NCT03928834 191 194 O
clinic NCT03928834 195 201 B-Location___Location-Value:clinic
as NCT03928834 202 204 O
shown NCT03928834 205 210 O
in NCT03928834 211 213 O
clinic NCT03928834 214 220 O
records NCT03928834 221 228 O
at NCT03928834 229 231 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03928834 232 237 I-Eq-Operator___Eq-Operator-Value:GTEQ
once NCT03928834 238 242 B-Eq-Value
since NCT03928834 243 248 O
initiation NCT03928834 249 259 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
AND NCT03928834 260 263 O
will NCT03928834 264 268 O
have NCT03928834 269 273 O
re NCT03928834 274 276 O
- NCT03928834 277 278 O
filled NCT03928834 279 285 O
their NCT03928834 286 291 O
ART NCT03928834 292 295 B-Procedure-Name
at NCT03928834 296 298 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03928834 299 304 I-Eq-Operator___Eq-Operator-Value:GTEQ
once NCT03928834 305 309 B-Eq-Value
since NCT03928834 310 315 O
initiation NCT03928834 316 326 O
as NCT03928834 327 329 O
shown NCT03928834 330 335 O
in NCT03928834 336 338 O
clinic NCT03928834 339 345 O
records NCT03928834 346 353 O
. NCT03928834 354 355 O
. NCT03928834 356 357 O

3 NCT03928834 362 363 O
. NCT03928834 363 364 O
Planning NCT03928834 366 374 O
to NCT03928834 375 377 O
stay NCT03928834 378 382 O
in NCT03928834 383 385 O
care NCT03928834 386 390 O
at NCT03928834 391 393 O
that NCT03928834 394 398 O
facility NCT03928834 399 407 B-Location___Location-Value:hospital
for NCT03928834 408 411 O
at NCT03928834 412 414 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03928834 415 420 I-Eq-Operator___Eq-Operator-Value:GTEQ
12 NCT03928834 422 424 B-Eq-Value
months NCT03928834 425 431 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

Exclusion NCT03928834 432 441 O
Criteria NCT03928834 442 450 O
: NCT03928834 451 452 O

1 NCT03928834 457 458 O
. NCT03928834 458 459 O
Participant NCT03928834 461 472 O
and NCT03928834 473 476 O
/ NCT03928834 477 478 O
or NCT03928834 479 481 O
caregiver NCT03928834 482 491 O
unable NCT03928834 492 498 O
to NCT03928834 499 501 O
give NCT03928834 502 506 O
consent NCT03928834 507 514 O
and NCT03928834 515 518 O
assent NCT03928834 519 525 O

2 NCT03928834 529 530 O
. NCT03928834 530 531 O
Those NCT03928834 533 538 O
participants NCT03928834 539 551 O
who NCT03928834 552 555 O
the NCT03928834 556 559 O
healthcare NCT03928834 560 570 O
worker NCT03928834 571 577 O
considers NCT03928834 578 587 O
to NCT03928834 588 590 O
be NCT03928834 591 593 O
too NCT03928834 594 597 O
ill NCT03928834 598 601 O
to NCT03928834 602 604 O
participate NCT03928834 605 616 O

For NCT03920267 0 3 O
more NCT03920267 4 8 O
information NCT03920267 9 20 O
regarding NCT03920267 21 30 O
Bristol NCT03920267 31 38 O
- NCT03920267 39 40 O
Myers NCT03920267 41 46 O
Squibb NCT03920267 47 53 O
Clinical NCT03920267 54 62 O
Trial NCT03920267 63 68 O
participation NCT03920267 69 82 O
, NCT03920267 83 84 O
please NCT03920267 85 91 O

visit NCT03920267 92 97 O
www NCT03920267 98 101 O
. NCT03920267 102 103 O
BMSStudyConnect NCT03920267 104 119 O
. NCT03920267 120 121 O
com NCT03920267 122 125 O

Inclusion NCT03920267 126 135 O
Criteria NCT03920267 136 144 O
: NCT03920267 145 146 O

- NCT03920267 150 151 O
Completion NCT03920267 153 163 O
of NCT03920267 164 166 O
SLE NCT03920267 167 170 O
Study NCT03920267 171 176 O
( NCT03920267 177 178 O
NCT NCT03920267 179 182 O
03252587 NCT03920267 183 191 O
) NCT03920267 192 193 O
through NCT03920267 194 201 O
the NCT03920267 202 205 O
protocol NCT03920267 206 214 O
- NCT03920267 215 216 O
required NCT03920267 217 225 O
treatment NCT03920267 226 235 O
period NCT03920267 236 242 O
, NCT03920267 243 244 O
and NCT03920267 245 248 O
currently NCT03920267 249 258 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
receiving NCT03920267 259 268 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
blinded NCT03920267 269 276 O
study NCT03920267 277 282 O
drug NCT03920267 283 287 O

- NCT03920267 290 291 O
Women NCT03920267 293 298 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
of NCT03920267 299 301 O
childbearing NCT03920267 302 314 B-Condition-Name
potential NCT03920267 315 324 I-Condition-Name
( NCT03920267 325 326 O
WOCBP NCT03920267 327 332 B-Condition-Name
) NCT03920267 333 334 O
must NCT03920267 335 339 O
have NCT03920267 340 344 O
a NCT03920267 345 346 O
negative NCT03920267 347 355 B-Polarity___Polarity-Value:negative
urine NCT03920267 356 361 B-Observation-Name___Observation-Type-Value:lab
pregnancy NCT03920267 362 371 I-Observation-Name___Observation-Type-Value:lab
test NCT03920267 372 376 I-Observation-Name___Observation-Type-Value:lab
and NCT03920267 377 380 O
must NCT03920267 381 385 O
agree NCT03920267 386 391 O
to NCT03920267 392 394 O
use NCT03920267 395 398 O
correctly NCT03920267 399 408 O
a NCT03920267 409 410 O
highly NCT03920267 411 417 O
effective NCT03920267 418 427 O
method NCT03920267 428 434 O
( NCT03920267 435 436 O
s NCT03920267 437 438 O
) NCT03920267 439 440 O
of NCT03920267 441 443 O
contraception NCT03920267 444 457 B-Procedure-Name
for NCT03920267 458 461 O
the NCT03920267 462 465 O
duration NCT03920267 466 474 O
of NCT03920267 475 477 O
treatment NCT03920267 478 487 O
with NCT03920267 488 492 O
study NCT03920267 493 498 O
drug NCT03920267 499 503 O

Exclusion NCT03920267 504 513 O
Criteria NCT03920267 514 522 O
: NCT03920267 523 524 O

- NCT03920267 528 529 O
Any NCT03920267 531 534 O
disease NCT03920267 535 542 B-Condition-Name
or NCT03920267 543 545 O
medical NCT03920267 546 553 O
condition NCT03920267 554 563 O
that NCT03920267 564 568 O
, NCT03920267 569 570 O
in NCT03920267 571 573 O
the NCT03920267 574 577 O
opinion NCT03920267 578 585 O
of NCT03920267 586 588 O
the NCT03920267 589 592 O
investigator NCT03920267 593 605 O
, NCT03920267 606 607 O
would NCT03920267 608 613 O
make NCT03920267 614 618 O
the NCT03920267 619 622 O
subject NCT03920267 623 630 O
unsuitable NCT03920267 631 641 O
for NCT03920267 642 645 O
this NCT03920267 646 650 O
study NCT03920267 651 656 O
, NCT03920267 657 658 O
would NCT03920267 659 664 O
interfere NCT03920267 665 674 O
with NCT03920267 675 679 O
the NCT03920267 680 683 O
interpretation NCT03920267 684 698 O
of NCT03920267 699 701 O
subject NCT03920267 702 709 O
safety NCT03920267 710 716 O
or NCT03920267 717 719 O
study NCT03920267 720 725 O
results NCT03920267 726 733 O
, NCT03920267 734 735 O
or NCT03920267 736 738 O
considered NCT03920267 739 749 O
unsuitable NCT03920267 750 760 O
by NCT03920267 761 763 O
the NCT03920267 764 767 O
investigator NCT03920267 768 780 O
for NCT03920267 781 784 O
any NCT03920267 785 788 O
other NCT03920267 789 794 O
reason NCT03920267 795 801 O

- NCT03920267 804 805 O
Evidence NCT03920267 807 815 O
of NCT03920267 816 818 O
active NCT03920267 819 825 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
tuberculosis NCT03920267 826 838 B-Condition-Name
( NCT03920267 839 840 O
TB NCT03920267 841 843 B-Condition-Name
) NCT03920267 844 845 O

Other NCT03920267 847 852 O
protocol NCT03920267 853 861 O
defined NCT03920267 862 869 O
inclusion NCT03920267 870 879 O
/ NCT03920267 880 881 O
exclusion NCT03920267 882 891 O
criteria NCT03920267 892 900 O
could NCT03920267 901 906 O
apply NCT03920267 907 912 O

Inclusion NCT03927534 0 9 O
Criteria NCT03927534 10 18 O
: NCT03927534 19 20 O

- NCT03927534 24 25 O
Age NCT03927534 27 30 O
between NCT03927534 31 38 O
45 NCT03927534 40 42 B-Eq-Value
- NCT03927534 43 44 B-Eq-Operator___Eq-Operator-Value:BETWEEN
75 NCT03927534 46 48 B-Eq-Value
years NCT03927534 49 54 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03927534 57 58 O
Have NCT03927534 60 64 O
overweight NCT03927534 65 75 B-Condition-Name
or NCT03927534 76 78 O
obesity NCT03927534 79 86 B-Condition-Name
condition NCT03927534 87 96 O
based NCT03927534 97 102 O
in NCT03927534 103 105 O
BMI NCT03927534 106 109 B-Observation-Name___Observation-Type-Value:vital
( NCT03927534 110 111 O
Body NCT03927534 112 116 B-Observation-Name___Observation-Type-Value:vital
Mass NCT03927534 117 121 I-Observation-Name___Observation-Type-Value:vital
Index NCT03927534 122 127 I-Observation-Name___Observation-Type-Value:vital
) NCT03927534 128 129 O
. NCT03927534 131 132 O
Individuals NCT03927534 134 145 O
with NCT03927534 146 150 O
BMI NCT03927534 151 154 B-Observation-Name___Observation-Type-Value:vital
of NCT03927534 155 157 O
25 NCT03927534 159 161 B-Eq-Value
or NCT03927534 162 164 B-Eq-Operator___Eq-Operator-Value:GTEQ
more NCT03927534 165 169 I-Eq-Operator___Eq-Operator-Value:GTEQ
. NCT03927534 170 171 O

- NCT03927534 175 176 O
Have NCT03927534 178 182 O
two NCT03927534 183 186 B-Eq-Value
of NCT03927534 187 189 O
these NCT03927534 190 195 O
three NCT03927534 196 201 B-Eq-Value
risk NCT03927534 202 206 O
: NCT03927534 207 208 O
sedentary NCT03927534 209 218 B-Condition-Name
lifestyle NCT03927534 219 228 I-Condition-Name
, NCT03927534 229 230 O
poor NCT03927534 231 235 B-Condition-Name
diet NCT03927534 236 240 I-Condition-Name
and NCT03927534 241 244 O
binge NCT03927534 245 250 B-Condition-Name
episodes NCT03927534 251 259 I-Condition-Name
. NCT03927534 260 261 O

- NCT03927534 265 266 O
Ability NCT03927534 268 275 O
to NCT03927534 276 278 O
understand NCT03927534 279 289 O
oral NCT03927534 290 294 O
and NCT03927534 295 298 O
written NCT03927534 299 306 O
Spanish NCT03927534 307 314 B-Language
. NCT03927534 315 316 O

- NCT03927534 320 321 O
Willingness NCT03927534 323 334 O
to NCT03927534 335 337 O
participate NCT03927534 338 349 O
in NCT03927534 350 352 O
the NCT03927534 353 356 O
study NCT03927534 357 362 O
and NCT03927534 363 366 O
signing NCT03927534 367 374 O
informed NCT03927534 375 383 O
consent NCT03927534 384 391 O
. NCT03927534 392 393 O

Exclusion NCT03927534 395 404 O
Criteria NCT03927534 405 413 O
: NCT03927534 414 415 O

- NCT03927534 419 420 O
Any NCT03927534 422 425 O
diagnosis NCT03927534 426 435 O
of NCT03927534 436 438 O
a NCT03927534 439 440 O
disease NCT03927534 441 448 B-Condition-Name
that NCT03927534 449 453 O
may NCT03927534 454 457 O
affect NCT03927534 458 464 B-Stability___Stability-Value:change
the NCT03927534 465 468 O
central NCT03927534 469 476 B-Condition-Name
nervous NCT03927534 477 484 I-Condition-Name
system NCT03927534 485 491 I-Condition-Name
( NCT03927534 492 493 O
brain NCT03927534 494 499 O
condition NCT03927534 500 509 B-Condition-Name
, NCT03927534 510 511 O
traumatic NCT03927534 512 521 B-Condition-Name
brain NCT03927534 522 527 I-Condition-Name
injury NCT03927534 528 534 I-Condition-Name
, NCT03927534 535 536 O
dementia NCT03927534 537 545 B-Condition-Name
, NCT03927534 546 547 O
etc NCT03927534 548 551 O
) NCT03927534 552 553 O
. NCT03927534 555 556 O

- NCT03927534 560 561 O
Other NCT03927534 563 568 O
psychiatric NCT03927534 569 580 B-Condition-Name
diagnoses NCT03927534 581 590 I-Condition-Name
or NCT03927534 591 593 O
acute NCT03927534 594 599 B-Severity___Severity-Value:severe
psychiatric NCT03927534 600 611 B-Condition-Name
illness NCT03927534 612 619 I-Condition-Name
( NCT03927534 620 621 O
substance NCT03927534 622 631 B-Condition-Name
dependence NCT03927534 632 642 O
or NCT03927534 643 645 O
abuse NCT03927534 646 651 O
, NCT03927534 652 653 O
history NCT03927534 654 661 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03927534 662 664 O
schizophrenia NCT03927534 665 678 B-Condition-Name
or NCT03927534 679 681 O
other NCT03927534 682 687 O
psychotic NCT03927534 688 697 B-Condition-Name
disorders NCT03927534 698 707 I-Condition-Name
, NCT03927534 708 709 O
etc NCT03927534 710 713 O
. NCT03927534 714 715 O
) NCT03927534 716 717 O
, NCT03927534 719 720 O
except NCT03927534 721 727 O
for NCT03927534 728 731 O
anxiety NCT03927534 732 739 B-Condition-Name
disorder NCT03927534 740 748 I-Condition-Name
or NCT03927534 749 751 O
personality NCT03927534 752 763 B-Condition-Name
disorders NCT03927534 764 773 I-Condition-Name
. NCT03927534 774 775 O

- NCT03927534 779 780 O
Presence NCT03927534 782 790 O
of NCT03927534 791 793 O
delusional NCT03927534 794 804 B-Condition-Name
ideas NCT03927534 805 810 I-Condition-Name
or NCT03927534 811 813 O
hallucinations NCT03927534 814 828 B-Condition-Name
whether NCT03927534 829 836 O
consistent NCT03927534 837 847 O
or NCT03927534 848 850 O
not NCT03927534 851 854 O
with NCT03927534 855 859 O
mood NCT03927534 860 864 O
. NCT03927534 865 866 O

- NCT03927534 870 871 O
Suicide NCT03927534 873 880 B-Condition-Name
risk NCT03927534 881 885 O
. NCT03927534 886 887 O

Inclusion NCT03928613 0 9 O
Criteria NCT03928613 10 18 O
: NCT03928613 19 20 O

- NCT03928613 24 25 O
Aged NCT03928613 27 31 O
above NCT03928613 32 37 B-Eq-Operator___Eq-Operator-Value:GT
60 NCT03928613 39 41 B-Eq-Value

- NCT03928613 45 46 O
Confirmed NCT03928613 48 57 O
literacy NCT03928613 58 66 B-Condition-Name
o NCT03928613 67 68 O
Diagnosed NCT03928613 69 78 O
with NCT03928613 79 83 O
mild NCT03928613 84 88 B-Severity___Severity-Value:mild
cognitive NCT03928613 89 98 B-Condition-Name
impairment NCT03928613 99 109 I-Condition-Name
by NCT03928613 110 112 O
International NCT03928613 113 126 O
Working NCT03928613 127 134 O
Group NCT03928613 135 140 O
on NCT03928613 141 143 O
Mild NCT03928613 144 148 O
Cognitive NCT03928613 149 158 O
Impairment NCT03928613 159 169 O
and NCT03928613 170 173 O
Clinical NCT03928613 174 182 B-Observation-Name___Observation-Type-Value:clinical-score
Dementia NCT03928613 183 191 I-Observation-Name___Observation-Type-Value:clinical-score
Rating NCT03928613 192 198 I-Observation-Name___Observation-Type-Value:clinical-score
( NCT03928613 199 200 O
CDR NCT03928613 201 204 B-Observation-Name
) NCT03928613 205 206 O
of NCT03928613 207 209 O
0 NCT03928613 211 212 B-Eq-Value
or NCT03928613 213 215 O
0.5 NCT03928613 217 220 B-Eq-Value
. NCT03928613 220 221 O

Exclusion NCT03928613 223 232 O
Criteria NCT03928613 233 241 O
: NCT03928613 242 243 O

- NCT03928613 247 248 O
Evidence NCT03928613 250 258 O
of NCT03928613 259 261 O
delirium NCT03928613 262 270 B-Condition-Name
, NCT03928613 271 272 O
confusion NCT03928613 273 282 B-Condition-Name

- NCT03928613 285 286 O
Any NCT03928613 288 291 O
neurological NCT03928613 292 304 B-Condition-Name
conditions NCT03928613 305 315 I-Condition-Name
causing NCT03928613 316 323 O
cognitive NCT03928613 324 333 B-Condition-Name
decline NCT03928613 334 341 I-Condition-Name
such NCT03928613 342 346 O
as NCT03928613 347 349 O
Parkinson NCT03928613 350 359 B-Condition-Name
's NCT03928613 359 361 I-Condition-Name
disease NCT03928613 362 369 I-Condition-Name
, NCT03928613 370 371 O
brain NCT03928613 372 377 O
hemorrhage NCT03928613 378 388 B-Condition-Name
, NCT03928613 389 390 O
brain NCT03928613 391 396 O
tumor NCT03928613 397 402 B-Condition-Name
, NCT03928613 403 404 O
normal NCT03928613 405 411 B-Condition-Name
pressure NCT03928613 412 420 I-Condition-Name
hydrocephalus NCT03928613 421 434 I-Condition-Name

- NCT03928613 437 438 O
Evidence NCT03928613 440 448 O
of NCT03928613 449 451 O
severe NCT03928613 452 458 B-Severity___Severity-Value:severe
cerebrovascular NCT03928613 459 474 B-Condition-Name
pathology NCT03928613 475 484 I-Condition-Name

- NCT03928613 487 488 O
Presence NCT03928613 490 498 O
of NCT03928613 499 501 O
depressive NCT03928613 502 512 B-Condition-Name
symptoms NCT03928613 513 521 O
that NCT03928613 522 526 O
could NCT03928613 527 532 O
influence NCT03928613 533 542 B-Stability___Stability-Value:change
cognitive NCT03928613 543 552 B-Condition-Name
function NCT03928613 553 561 I-Condition-Name

- NCT03928613 564 565 O
Presence NCT03928613 567 575 O
of NCT03928613 576 578 O
medical NCT03928613 579 586 B-Condition-Name
comorbidities NCT03928613 587 600 I-Condition-Name
that NCT03928613 601 605 O
could NCT03928613 606 611 O
result NCT03928613 612 618 O
in NCT03928613 619 621 O
any NCT03928613 622 625 O
difficulties NCT03928613 626 638 O
in NCT03928613 639 641 O
study NCT03928613 642 647 O
participation NCT03928613 648 661 O

Inclusion NCT03925337 0 9 O
Criteria NCT03925337 10 18 O
: NCT03925337 19 20 O

- NCT03925337 24 25 O
Patients NCT03925337 27 35 O
age NCT03925337 36 39 O
: NCT03925337 40 41 O
≥ NCT03925337 42 43 B-Eq-Operator___Eq-Operator-Value:GTEQ
22 NCT03925337 45 47 B-Eq-Value
years NCT03925337 48 53 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03925337 56 57 O
Patients NCT03925337 59 67 O
presenting NCT03925337 68 78 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
for NCT03925337 79 82 O
routine NCT03925337 83 90 O
colonoscopy NCT03925337 91 102 B-Procedure-Name
for NCT03925337 103 106 O
screening NCT03925337 107 116 B-Procedure-Name
and NCT03925337 117 120 O
/ NCT03925337 121 122 O
or NCT03925337 123 125 O
surveillance NCT03925337 126 138 B-Procedure-Name
purposes NCT03925337 139 147 O
. NCT03925337 148 149 O

- NCT03925337 153 154 O
Willingness NCT03925337 156 167 O
to NCT03925337 168 170 O
undergo NCT03925337 171 178 O
two NCT03925337 179 182 B-Eq-Value
withdrawals NCT03925337 183 194 B-Condition-Name
with NCT03925337 195 199 O
and NCT03925337 200 203 O
without NCT03925337 204 211 O
the NCT03925337 212 215 O
use NCT03925337 216 219 O
of NCT03925337 220 222 O
computer NCT03925337 223 231 O
- NCT03925337 232 233 O
aided NCT03925337 234 239 O
software NCT03925337 240 248 O
while NCT03925337 249 254 O
undergoing NCT03925337 255 265 O
conventional NCT03925337 266 278 O
colonoscopy NCT03925337 279 290 B-Procedure-Name
with NCT03925337 291 295 O
sedation NCT03925337 296 304 B-Procedure-Name

- NCT03925337 307 308 O
Ability NCT03925337 310 317 O
to NCT03925337 318 320 O
provide NCT03925337 321 328 O
written NCT03925337 329 336 O
, NCT03925337 337 338 O
informed NCT03925337 339 347 O
consent NCT03925337 348 355 O
and NCT03925337 356 359 O
understand NCT03925337 360 370 O
the NCT03925337 371 374 O
responsibilities NCT03925337 375 391 O
of NCT03925337 392 394 O
trial NCT03925337 395 400 O
participation NCT03925337 401 414 O

Exclusion NCT03925337 415 424 O
Criteria NCT03925337 425 433 O
: NCT03925337 434 435 O

- NCT03925337 439 440 O
Minors NCT03925337 442 448 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
aged NCT03925337 449 453 O
< NCT03925337 454 455 B-Eq-Operator___Eq-Operator-Value:LT
22 NCT03925337 457 459 B-Eq-Value
years NCT03925337 460 465 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
. NCT03925337 466 467 O

- NCT03925337 471 472 O
People NCT03925337 474 480 O
with NCT03925337 481 485 O
diminished NCT03925337 486 496 B-Condition-Name
cognitive NCT03925337 497 506 I-Condition-Name
capacity NCT03925337 507 515 I-Condition-Name

- NCT03925337 518 519 O
Patients NCT03925337 521 529 O
undergoing NCT03925337 530 540 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
diagnostic NCT03925337 541 551 O
colonoscopy NCT03925337 552 563 B-Procedure-Name
( NCT03925337 564 565 O
e NCT03925337 566 567 O
. NCT03925337 568 569 O
g NCT03925337 570 571 O
. NCT03925337 572 573 O
as NCT03925337 575 577 O
an NCT03925337 578 580 O
evaluation NCT03925337 581 591 O
for NCT03925337 592 595 O
active NCT03925337 596 602 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
gastrointestinal NCT03925337 603 619 O
bleed NCT03925337 620 625 B-Condition-Name
, NCT03925337 626 627 O
referring NCT03925337 628 637 O
collectively NCT03925337 638 650 O
to NCT03925337 651 653 O
the NCT03925337 654 657 O
stomach NCT03925337 658 665 O
and NCT03925337 666 669 O
the NCT03925337 670 673 O
small NCT03925337 674 679 O
and NCT03925337 680 683 O
large NCT03925337 684 689 O
intestine NCT03925337 690 699 O
) NCT03925337 700 701 O
. NCT03925337 703 704 O

- NCT03925337 708 709 O
Patients NCT03925337 711 719 O
with NCT03925337 720 724 O
incomplete NCT03925337 725 735 O
colonoscopies NCT03925337 736 749 B-Procedure-Name
( NCT03925337 750 751 O
those NCT03925337 752 757 O
where NCT03925337 758 763 O
endoscopists NCT03925337 764 776 O
did NCT03925337 777 780 O
not NCT03925337 781 784 O
successfully NCT03925337 785 797 O
intubate NCT03925337 798 806 B-Procedure-Name
the NCT03925337 807 810 O
cecum NCT03925337 811 816 O
due NCT03925337 817 820 O
to NCT03925337 821 823 O
technical NCT03925337 824 833 O
difficulties NCT03925337 834 846 O
or NCT03925337 847 849 O
poor NCT03925337 850 854 O
bowel NCT03925337 855 860 B-Procedure-Name
preparation NCT03925337 861 872 I-Procedure-Name
) NCT03925337 873 874 O

- NCT03925337 878 879 O
Patients NCT03925337 881 889 O
that NCT03925337 890 894 O
have NCT03925337 895 899 O
standard NCT03925337 900 908 O
contraindications NCT03925337 909 926 O
to NCT03925337 927 929 O
colonoscopy NCT03925337 930 941 B-Procedure-Name
in NCT03925337 942 944 O
general NCT03925337 945 952 O
( NCT03925337 953 954 O
e NCT03925337 955 956 O
. NCT03925337 957 958 O
g NCT03925337 959 960 O
. NCT03925337 961 962 O
documented NCT03925337 964 974 O
acute NCT03925337 975 980 B-Severity___Severity-Value:severe
diverticulitis NCT03925337 981 995 B-Condition-Name
, NCT03925337 996 997 O
fulminant NCT03925337 998 1007 B-Condition-Name
colitis NCT03925337 1008 1015 I-Condition-Name
and NCT03925337 1016 1019 O
known NCT03925337 1020 1025 O
or NCT03925337 1026 1028 O
suspected NCT03925337 1029 1038 O
perforation NCT03925337 1039 1050 B-Condition-Name
) NCT03925337 1051 1052 O
. NCT03925337 1054 1055 O

- NCT03925337 1059 1060 O
Patients NCT03925337 1062 1070 O
with NCT03925337 1071 1075 O
inflammatory NCT03925337 1076 1088 B-Condition-Name
bowel NCT03925337 1089 1094 I-Condition-Name
disease NCT03925337 1095 1102 I-Condition-Name

- NCT03925337 1105 1106 O
Patients NCT03925337 1108 1116 O
with NCT03925337 1117 1121 O
any NCT03925337 1122 1125 O
polypoid NCT03925337 1126 1134 O
/ NCT03925337 1135 1136 O
ulcerated NCT03925337 1137 1146 O
lesion NCT03925337 1147 1153 B-Observation-Name___Observation-Type-Value:measurement
> NCT03925337 1154 1155 B-Eq-Operator___Eq-Operator-Value:GT
2 NCT03925337 1157 1158 B-Eq-Value
cm NCT03925337 1159 1161 B-Eq-Unit
concerning NCT03925337 1162 1172 O
for NCT03925337 1173 1176 O
invasive NCT03925337 1177 1185 O
cancer NCT03925337 1186 1192 B-Condition-Name
on NCT03925337 1193 1195 O
endoscopy NCT03925337 1196 1205 B-Procedure-Name

- NCT03925337 1208 1209 O
Patients NCT03925337 1211 1219 O
referred NCT03925337 1220 1228 B-Encounter-Type___Encounter-Type-Value:referral
for NCT03925337 1229 1232 O
endoscopic NCT03925337 1233 1243 B-Procedure-Name
mucosal NCT03925337 1244 1251 I-Procedure-Name
resection NCT03925337 1252 1261 I-Procedure-Name
( NCT03925337 1262 1263 O
EMR NCT03925337 1264 1267 B-Procedure-Name
) NCT03925337 1268 1269 O
, NCT03925337 1271 1272 O
which NCT03925337 1273 1278 O
is NCT03925337 1279 1281 O
a NCT03925337 1282 1283 O
procedure NCT03925337 1284 1293 O
to NCT03925337 1294 1296 O
remove NCT03925337 1297 1303 O
early NCT03925337 1304 1309 O
- NCT03925337 1310 1311 O
stage NCT03925337 1312 1317 O
cancer NCT03925337 1318 1324 O
and NCT03925337 1325 1328 O
precancerous NCT03925337 1329 1341 O
growths NCT03925337 1342 1349 O
from NCT03925337 1350 1354 O
the NCT03925337 1355 1358 O
lining NCT03925337 1359 1365 O
of NCT03925337 1366 1368 O
the NCT03925337 1369 1372 O
digestive NCT03925337 1373 1382 O
tract NCT03925337 1383 1388 O
. NCT03925337 1389 1390 O

Inclusion NCT03924362 0 9 O
Criteria NCT03924362 10 18 O
: NCT03924362 19 20 O

All NCT03924362 22 25 O
subjects NCT03924362 26 34 O
with NCT03924362 35 39 O
a NCT03924362 40 41 O
clinical NCT03924362 42 50 O
diagnosis NCT03924362 51 60 O
of NCT03924362 61 63 O
struvite NCT03924362 64 72 B-Condition-Name
calculi NCT03924362 73 80 I-Condition-Name
will NCT03924362 81 85 O
potentially NCT03924362 86 97 O
be NCT03924362 98 100 O
included NCT03924362 101 109 O
. NCT03924362 110 111 O

Specific NCT03924362 113 121 O
inclusion NCT03924362 122 131 O
criteria NCT03924362 132 140 O
include NCT03924362 141 148 O
the NCT03924362 149 152 O
following NCT03924362 153 162 O
: NCT03924362 163 164 O

1 NCT03924362 169 170 O
. NCT03924362 170 171 O
Age NCT03924362 173 176 O
> NCT03924362 177 178 B-Eq-Operator___Eq-Operator-Value:GT
18 NCT03924362 180 182 B-Eq-Value
years NCT03924362 183 188 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

2 NCT03924362 192 193 O
. NCT03924362 193 194 O
Any NCT03924362 196 199 O
patient NCT03924362 200 207 O
with NCT03924362 208 212 O
bilateral NCT03924362 213 222 B-Condition-Name
stone NCT03924362 223 228 I-Condition-Name
burden NCT03924362 229 235 I-Condition-Name
eligible NCT03924362 236 244 O
and NCT03924362 245 248 O
appropriate NCT03924362 249 260 O
for NCT03924362 261 264 O
PCNL NCT03924362 265 269 B-Procedure-Name
procedure NCT03924362 270 279 I-Procedure-Name

3 NCT03924362 283 284 O
. NCT03924362 284 285 O
Medically NCT03924362 287 296 O
fit NCT03924362 297 300 O
for NCT03924362 301 304 O
definitive NCT03924362 305 315 O
surgical NCT03924362 316 324 B-Procedure-Name
management NCT03924362 325 335 I-Procedure-Name
of NCT03924362 336 338 O
stone NCT03924362 339 344 B-Condition-Name
. NCT03924362 345 346 O

Exclusion NCT03924362 348 357 O
Criteria NCT03924362 358 366 O
: NCT03924362 367 368 O

Patients NCT03924362 370 378 O
with NCT03924362 379 383 O
any NCT03924362 384 387 O
of NCT03924362 388 390 O
the NCT03924362 391 394 O
following NCT03924362 395 404 O
characteristics NCT03924362 405 420 O
will NCT03924362 421 425 O
not NCT03924362 426 429 O
be NCT03924362 430 432 O
eligible NCT03924362 433 441 O
for NCT03924362 442 445 O
the NCT03924362 446 449 O
present NCT03924362 450 457 O

study NCT03924362 458 463 O
: NCT03924362 464 465 O

1 NCT03924362 470 471 O
. NCT03924362 471 472 O
Those NCT03924362 474 479 O
with NCT03924362 480 484 O
medical NCT03924362 485 492 B-Condition-Name
comorbidities NCT03924362 493 506 I-Condition-Name
preventing NCT03924362 507 517 O
them NCT03924362 518 522 O
from NCT03924362 523 527 O
safely NCT03924362 528 534 O
undergoing NCT03924362 535 545 O
definitive NCT03924362 546 556 O
surgical NCT03924362 557 565 B-Procedure-Name
therapy NCT03924362 566 573 I-Procedure-Name
. NCT03924362 574 575 O

2 NCT03924362 580 581 O
. NCT03924362 581 582 O
Patients NCT03924362 584 592 O
who NCT03924362 593 596 O
are NCT03924362 597 600 O
unable NCT03924362 601 607 O
to NCT03924362 608 610 O
provide NCT03924362 611 618 O
informed NCT03924362 619 627 O
consent NCT03924362 628 635 O
. NCT03924362 636 637 O

3 NCT03924362 642 643 O
. NCT03924362 643 644 O
Patients NCT03924362 646 654 O
who NCT03924362 655 658 O
are NCT03924362 659 662 O
planned NCT03924362 663 670 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
for NCT03924362 671 674 O
alternative NCT03924362 675 686 O
procedures NCT03924362 687 697 B-Procedure-Name
( NCT03924362 698 699 O
ureteroscopy NCT03924362 700 712 B-Procedure-Name
, NCT03924362 713 714 O
extracorporeal NCT03924362 715 729 B-Procedure-Name
shock NCT03924362 730 735 I-Procedure-Name
wave NCT03924362 736 740 I-Procedure-Name
lithotripsy NCT03924362 741 752 I-Procedure-Name
) NCT03924362 753 754 O

4 NCT03924362 759 760 O
. NCT03924362 760 761 O
Anyone NCT03924362 763 769 O
who NCT03924362 770 773 O
is NCT03924362 774 776 O
unable NCT03924362 777 783 O
to NCT03924362 784 786 O
give NCT03924362 787 791 O
their NCT03924362 792 797 O
informed NCT03924362 798 806 O
consent NCT03924362 807 814 O

5 NCT03924362 818 819 O
. NCT03924362 819 820 O
Anyone NCT03924362 822 828 O
under NCT03924362 829 834 B-Eq-Operator___Eq-Operator-Value:LT
the NCT03924362 835 838 O
age NCT03924362 839 842 O
of NCT03924362 843 845 O
19 NCT03924362 847 849 B-Eq-Value

6 NCT03924362 854 855 O
. NCT03924362 855 856 O
Anyone NCT03924362 858 864 O
who NCT03924362 865 868 O
, NCT03924362 869 870 O
in NCT03924362 871 873 O
the NCT03924362 874 877 O
opinion NCT03924362 878 885 O
of NCT03924362 886 888 O
the NCT03924362 889 892 O
PI NCT03924362 893 895 O
, NCT03924362 896 897 O
is NCT03924362 898 900 O
unfit NCT03924362 901 906 O
or NCT03924362 907 909 O
unsuitable NCT03924362 910 920 O
to NCT03924362 921 923 O
participate NCT03924362 924 935 O
in NCT03924362 936 938 O
the NCT03924362 939 942 O
study NCT03924362 943 948 O

Inclusion NCT03926039 0 9 O
Criteria NCT03926039 10 18 O
: NCT03926039 19 20 O

1 NCT03926039 25 26 O
. NCT03926039 26 27 O
Primary NCT03926039 29 36 O
liver NCT03926039 37 42 O
cancer NCT03926039 43 49 B-Condition-Name
patients NCT03926039 50 58 O
( NCT03926039 59 60 O
ICD NCT03926039 61 64 O
10 NCT03926039 66 68 O
is NCT03926039 69 71 O
C NCT03926039 72 73 B-Condition-Code
22.0 NCT03926039 74 78 I-Condition-Code
) NCT03926039 79 80 O
and NCT03926039 81 84 O
Barcelona NCT03926039 85 94 B-Condition-Name
stage NCT03926039 95 100 I-Condition-Name
( NCT03926039 101 102 O
BCLC NCT03926039 103 107 B-Condition-Name
stage NCT03926039 108 113 I-Condition-Name
) NCT03926039 114 115 O
0 NCT03926039 117 118 B-Eq-Value
- NCT03926039 119 120 B-Eq-Operator___Eq-Operator-Value:BETWEEN
A NCT03926039 121 122 B-Eq-Value
. NCT03926039 123 124 O

2 NCT03926039 129 130 O
. NCT03926039 130 131 O
At NCT03926039 133 135 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03926039 136 141 I-Eq-Operator___Eq-Operator-Value:GTEQ
20 NCT03926039 143 145 B-Eq-Value
years NCT03926039 146 151 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03926039 152 154 O
age NCT03926039 155 158 O
. NCT03926039 159 160 O

3 NCT03926039 165 166 O
. NCT03926039 166 167 O
No NCT03926039 169 171 O
mental NCT03926039 172 178 B-Condition-Name
illness NCT03926039 179 186 I-Condition-Name
. NCT03926039 187 188 O

4 NCT03926039 193 194 O
. NCT03926039 194 195 O
Patients NCT03926039 197 205 O
who NCT03926039 206 209 O
can NCT03926039 210 213 O
communicate NCT03926039 214 225 O
in NCT03926039 226 228 O
Mandarin NCT03926039 229 237 B-Language
or NCT03926039 238 240 O
Taiwanese NCT03926039 241 250 B-Language
. NCT03926039 251 252 O

Exclusion NCT03926039 254 263 O
Criteria NCT03926039 264 272 O
: NCT03926039 273 274 O

1 NCT03926039 279 280 O
. NCT03926039 280 281 O
Do NCT03926039 283 285 O
n't NCT03926039 285 288 O
know NCT03926039 289 293 O
himself NCT03926039 294 301 O
condition NCT03926039 302 311 O
. NCT03926039 312 313 O

2 NCT03926039 318 319 O
. NCT03926039 319 320 O
Unconscious NCT03926039 322 333 B-Condition-Name
patients NCT03926039 334 342 O
. NCT03926039 343 344 O

3 NCT03926039 349 350 O
. NCT03926039 350 351 O
Patients NCT03926039 353 361 O
with NCT03926039 362 366 O
liver NCT03926039 367 372 O
cancer NCT03926039 373 379 B-Procedure-Name
resection NCT03926039 380 389 I-Procedure-Name
or NCT03926039 390 392 O
partial NCT03926039 393 400 O
liver NCT03926039 401 406 O
resection NCT03926039 407 416 B-Procedure-Name
were NCT03926039 417 421 O
performed NCT03926039 422 431 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
within NCT03926039 432 438 B-Eq-Operator___Eq-Operator-Value:LTEQ
3 NCT03926039 440 441 B-Eq-Value
months NCT03926039 442 448 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
. NCT03926039 449 450 O


Inclusion NCT03927469 0 9 O
Criteria NCT03927469 10 18 O
: NCT03927469 19 20 O

- NCT03927469 24 25 O
Being NCT03927469 27 32 O
hospitalized NCT03927469 33 45 B-Encounter-Type___Encounter-Type-Value:inpatient
in NCT03927469 46 48 O
the NCT03927469 49 52 O
hospital NCT03927469 53 61 B-Location___Location-Value:hospital
between NCT03927469 62 69 B-Eq-Operator___Eq-Operator-Value:BETWEEN
January NCT03927469 70 77 B-Eq-Value
2015 NCT03927469 79 83 I-Eq-Value
and NCT03927469 84 87 O
July NCT03927469 88 92 B-Eq-Value
2018 NCT03927469 94 98 I-Eq-Value
, NCT03927469 99 100 O
according NCT03927469 101 110 O
to NCT03927469 111 113 O
ICD NCT03927469 114 117 O
10 NCT03927469 119 121 O
code NCT03927469 122 126 O
; NCT03927469 126 127 O
hemiplegia NCT03927469 128 138 B-Condition-Name
( NCT03927469 139 140 O
G NCT03927469 141 142 B-Condition-Code
81 NCT03927469 143 145 I-Condition-Code
) NCT03927469 146 147 O
, NCT03927469 149 150 O
flaccid NCT03927469 151 158 B-Condition-Name
hemiplegia NCT03927469 159 169 I-Condition-Name
( NCT03927469 170 171 O
G NCT03927469 172 173 B-Condition-Code
81.0 NCT03927469 174 178 I-Condition-Code
) NCT03927469 179 180 O
, NCT03927469 182 183 O
hemiplegia NCT03927469 184 194 B-Condition-Name
, NCT03927469 195 196 I-Condition-Name
unspecified NCT03927469 197 208 I-Condition-Name
( NCT03927469 209 210 O
G NCT03927469 211 212 B-Condition-Code
81.9 NCT03927469 213 217 I-Condition-Code
) NCT03927469 218 219 O
, NCT03927469 221 222 O
Spastic NCT03927469 223 230 B-Condition-Name
hemiplegia NCT03927469 231 241 I-Condition-Name
( NCT03927469 242 243 O
G NCT03927469 244 245 B-Condition-Code
81.1 NCT03927469 246 250 I-Condition-Code
) NCT03927469 251 252 O

- NCT03927469 256 257 O
Being NCT03927469 259 264 O
ischemic NCT03927469 265 273 O
or NCT03927469 274 276 O
hemorrhagic NCT03927469 277 288 O
stroke NCT03927469 289 295 B-Condition-Name

Exclusion NCT03927469 296 305 O
Criteria NCT03927469 306 314 O
: NCT03927469 315 316 O

- NCT03927469 320 321 O
Being NCT03927469 323 328 O
hemiplegic NCT03927469 329 339 B-Condition-Name
due NCT03927469 340 343 O
to NCT03927469 344 346 O
trauma NCT03927469 347 353 B-Condition-Name
, NCT03927469 354 355 O
cancer NCT03927469 356 362 B-Condition-Name
and NCT03927469 363 366 O
intracranial NCT03927469 367 379 B-Procedure-Name
operation NCT03927469 380 389 I-Procedure-Name

Inclusion NCT03920306 0 9 O
Criteria NCT03920306 10 18 O
: NCT03920306 19 20 O

- NCT03920306 24 25 O
Eligible NCT03920306 27 35 O
for NCT03920306 36 39 O
gastrostomy NCT03920306 40 51 B-Procedure-Name
tube NCT03920306 52 56 I-Procedure-Name
removal NCT03920306 57 64 I-Procedure-Name

Exclusion NCT03920306 65 74 O
Criteria NCT03920306 75 83 O
: NCT03920306 84 85 O

- NCT03920306 89 90 O
Recurrent NCT03920306 92 101 O
gastrocutaneous NCT03920306 102 117 B-Condition-Name
fistula NCT03920306 118 125 I-Condition-Name

- NCT03920306 128 129 O
Non NCT03920306 131 134 O
- NCT03920306 135 136 O
consenting NCT03920306 137 147 O

- NCT03920306 150 151 O
Unable NCT03920306 153 159 O
to NCT03920306 160 162 O
comply NCT03920306 163 169 O
with NCT03920306 170 174 O
follow NCT03920306 175 181 O
up NCT03920306 182 184 O
assessments NCT03920306 185 196 O

- NCT03920306 199 200 O
Known NCT03920306 202 207 O
allergic NCT03920306 208 216 O
reaction NCT03920306 217 225 O
to NCT03920306 226 228 O
study NCT03920306 229 234 O
products NCT03920306 235 243 O

Inclusion NCT03928028 0 9 O
Criteria NCT03928028 10 18 O
: NCT03928028 19 20 O
Adolescents NCT03928028 21 32 O

1 NCT03928028 36 37 O
. NCT03928028 37 38 O
Age NCT03928028 40 43 O
12 NCT03928028 45 47 B-Eq-Value
- NCT03928028 48 49 B-Eq-Operator___Eq-Operator-Value:BETWEEN
18 NCT03928028 51 53 B-Eq-Value

2 NCT03928028 58 59 O
. NCT03928028 59 60 O
Currently NCT03928028 62 71 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
meets NCT03928028 72 77 O
Diagnostic NCT03928028 78 88 O
and NCT03928028 89 92 O
Statistical NCT03928028 93 104 O
Manual NCT03928028 105 111 O
- NCT03928028 112 113 O
5 NCT03928028 115 116 O
criteria NCT03928028 117 125 O
for NCT03928028 126 129 O
Anorexia NCT03928028 130 138 B-Condition-Name
Nervosa NCT03928028 139 146 I-Condition-Name

3 NCT03928028 150 151 O
. NCT03928028 151 152 O
Medically NCT03928028 154 163 O
stable NCT03928028 164 170 B-Condition-Name
for NCT03928028 171 174 O
outpatient NCT03928028 175 185 B-Encounter-Type___Encounter-Type-Value:outpatient
treatment NCT03928028 186 195 O

4 NCT03928028 199 200 O
. NCT03928028 200 201 O
Fluent NCT03928028 203 209 O
in NCT03928028 210 212 O
English NCT03928028 213 220 B-Language

5 NCT03928028 224 225 O
. NCT03928028 225 226 O
No NCT03928028 228 230 O
co NCT03928028 231 233 B-Condition-Name
- NCT03928028 234 235 I-Condition-Name
morbid NCT03928028 236 242 I-Condition-Name
condition NCT03928028 243 252 I-Condition-Name
that NCT03928028 253 257 O
would NCT03928028 258 263 O
exclude NCT03928028 264 271 O
participation NCT03928028 272 285 O

6 NCT03928028 289 290 O
. NCT03928028 290 291 O
Medical NCT03928028 293 300 O
clearance NCT03928028 301 310 O
from NCT03928028 311 315 O
primary NCT03928028 316 323 O
care NCT03928028 324 328 O
physician NCT03928028 329 338 O
and NCT03928028 339 342 O
permission NCT03928028 343 353 O
to NCT03928028 354 356 O
speak NCT03928028 357 362 O
to NCT03928028 363 365 O
Primary NCT03928028 366 373 O
Care NCT03928028 374 378 O
Physician NCT03928028 379 388 O
about NCT03928028 389 394 O
clinical NCT03928028 395 403 O
issues NCT03928028 404 410 O

7 NCT03928028 414 415 O
. NCT03928028 415 416 O
Biological NCT03928028 418 428 O
parent NCT03928028 429 435 O
or NCT03928028 436 438 O
primary NCT03928028 439 446 O
caregiver NCT03928028 447 456 O
willing NCT03928028 457 464 O
to NCT03928028 465 467 O
engage NCT03928028 468 474 O
in NCT03928028 475 477 O
treatment NCT03928028 478 487 O
and NCT03928028 488 491 O
who NCT03928028 492 495 O
live NCT03928028 496 500 O
with NCT03928028 501 505 O
the NCT03928028 506 509 O
adolescent NCT03928028 510 520 O

Inclusion NCT03928028 521 530 O
Criteria NCT03928028 531 539 O
: NCT03928028 540 541 O
Parents NCT03928028 542 549 O

1 NCT03928028 553 554 O
. NCT03928028 554 555 O
Age NCT03928028 557 560 O
> NCT03928028 561 562 B-Eq-Operator___Eq-Operator-Value:GT
18 NCT03928028 564 566 B-Eq-Value

2 NCT03928028 571 572 O
. NCT03928028 572 573 O
Child NCT03928028 575 580 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
with NCT03928028 581 585 O
a NCT03928028 586 587 O
diagnoses NCT03928028 588 597 O
of NCT03928028 598 600 O
AN NCT03928028 601 603 B-Condition-Name

3 NCT03928028 607 608 O
. NCT03928028 608 609 O
Both NCT03928028 611 615 O
parents NCT03928028 616 623 O
willing NCT03928028 624 631 O
to NCT03928028 632 634 O
participate NCT03928028 635 646 O

4 NCT03928028 650 651 O
. NCT03928028 651 652 O
Fluent NCT03928028 654 660 O
in NCT03928028 661 663 O
English NCT03928028 664 671 B-Language

5 NCT03928028 675 676 O
. NCT03928028 676 677 O
No NCT03928028 679 681 O
co NCT03928028 682 684 B-Condition-Name
- NCT03928028 685 686 I-Condition-Name
morbid NCT03928028 687 693 I-Condition-Name
condition NCT03928028 694 703 I-Condition-Name
that NCT03928028 704 708 O
would NCT03928028 709 714 O
exclude NCT03928028 715 722 O
participation NCT03928028 723 736 O

Exclusion NCT03928028 737 746 O
Criteria NCT03928028 747 755 O
: NCT03928028 756 757 O
Adolescent NCT03928028 758 768 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child

1 NCT03928028 772 773 O
. NCT03928028 773 774 O
Adolescent NCT03928028 776 786 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
outside NCT03928028 787 794 O
age NCT03928028 795 798 O
range NCT03928028 799 804 B-Eq-Unit___Eq-Unit-Value:ref-range-high

2 NCT03928028 808 809 O
. NCT03928028 809 810 O
Adolescent NCT03928028 812 822 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
adopted NCT03928028 823 830 B-Condition-Name

3 NCT03928028 834 835 O
. NCT03928028 835 836 O
Pregnant NCT03928028 838 846 B-Condition-Name
adolescent NCT03928028 847 857 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child

4 NCT03928028 861 862 O
. NCT03928028 862 863 O
Presence NCT03928028 865 873 O
of NCT03928028 874 876 O
: NCT03928028 877 878 O
pervasive NCT03928028 879 888 O
developmental NCT03928028 889 902 B-Condition-Name
disability NCT03928028 903 913 I-Condition-Name
, NCT03928028 914 915 O
psychosis NCT03928028 916 925 B-Condition-Name
, NCT03928028 926 927 O
bipolar NCT03928028 928 935 B-Condition-Name
disorder NCT03928028 936 944 I-Condition-Name
, NCT03928028 945 946 O
substance NCT03928028 947 956 B-Condition-Name
abuse NCT03928028 957 962 I-Condition-Name
, NCT03928028 963 964 O
autism NCT03928028 965 971 B-Condition-Name
spectrum NCT03928028 972 980 I-Condition-Name
disorder NCT03928028 981 989 I-Condition-Name
, NCT03928028 990 991 O
or NCT03928028 992 994 O
intellectual NCT03928028 995 1007 B-Condition-Name
disability NCT03928028 1008 1018 I-Condition-Name

5 NCT03928028 1022 1023 O
. NCT03928028 1023 1024 O
Presence NCT03928028 1026 1034 O
of NCT03928028 1035 1037 O
: NCT03928028 1038 1039 O
a NCT03928028 1040 1041 O
brain NCT03928028 1042 1047 O
disorder NCT03928028 1048 1056 B-Condition-Name
or NCT03928028 1057 1059 O
injury NCT03928028 1060 1066 B-Condition-Name
( NCT03928028 1067 1068 O
such NCT03928028 1069 1073 O
as NCT03928028 1074 1076 O
TBI NCT03928028 1077 1080 B-Condition-Name
) NCT03928028 1081 1082 O
that NCT03928028 1083 1087 O
could NCT03928028 1088 1093 O
impact NCT03928028 1094 1100 B-Stability___Stability-Value:change
the NCT03928028 1101 1104 O
ability NCT03928028 1105 1112 O
to NCT03928028 1113 1115 O
engage NCT03928028 1116 1122 O
in NCT03928028 1123 1125 O
treatment NCT03928028 1126 1135 O

6 NCT03928028 1139 1140 O
. NCT03928028 1140 1141 O
Use NCT03928028 1143 1146 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
of NCT03928028 1147 1149 O
anti NCT03928028 1150 1154 B-Drug-Name
- NCT03928028 1155 1156 I-Drug-Name
psychotic NCT03928028 1157 1166 I-Drug-Name
medication NCT03928028 1167 1177 I-Drug-Name

7 NCT03928028 1181 1182 O
. NCT03928028 1182 1183 O
Concurrent NCT03928028 1185 1195 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
psychosocial NCT03928028 1196 1208 B-Procedure-Name
therapy NCT03928028 1209 1216 I-Procedure-Name

Exclusion NCT03928028 1217 1226 O
Criteria NCT03928028 1227 1235 O
: NCT03928028 1236 1237 O
Parents NCT03928028 1238 1245 O

1 NCT03928028 1249 1250 O
. NCT03928028 1250 1251 O
Presence NCT03928028 1253 1261 O
of NCT03928028 1262 1264 O
: NCT03928028 1265 1266 O
pervasive NCT03928028 1267 1276 O
developmental NCT03928028 1277 1290 B-Condition-Name
disability NCT03928028 1291 1301 I-Condition-Name
, NCT03928028 1302 1303 O
psychosis NCT03928028 1304 1313 B-Condition-Name
, NCT03928028 1314 1315 O
bipolar NCT03928028 1316 1323 B-Condition-Name
disorder NCT03928028 1324 1332 I-Condition-Name
, NCT03928028 1333 1334 O
substance NCT03928028 1335 1344 B-Condition-Name
abuse NCT03928028 1345 1350 I-Condition-Name
, NCT03928028 1351 1352 O
autism NCT03928028 1353 1359 B-Condition-Name
spectrum NCT03928028 1360 1368 I-Condition-Name
disorder NCT03928028 1369 1377 I-Condition-Name
, NCT03928028 1378 1379 O
or NCT03928028 1380 1382 O
intellectual NCT03928028 1383 1395 B-Condition-Name
disability NCT03928028 1396 1406 I-Condition-Name
. NCT03928028 1407 1408 O

2 NCT03928028 1413 1414 O
. NCT03928028 1414 1415 O
Presence NCT03928028 1417 1425 O
of NCT03928028 1426 1428 O
: NCT03928028 1429 1430 O
a NCT03928028 1431 1432 O
brain NCT03928028 1433 1438 O
disorder NCT03928028 1439 1447 B-Condition-Name
or NCT03928028 1448 1450 O
injury NCT03928028 1451 1457 B-Condition-Name
( NCT03928028 1458 1459 O
such NCT03928028 1460 1464 O
as NCT03928028 1465 1467 O
TBI NCT03928028 1468 1471 B-Condition-Name
) NCT03928028 1472 1473 O
that NCT03928028 1474 1478 O
could NCT03928028 1479 1484 O
impact NCT03928028 1485 1491 B-Stability___Stability-Value:change
the NCT03928028 1492 1495 O
ability NCT03928028 1496 1503 O
to NCT03928028 1504 1506 O
engage NCT03928028 1507 1513 O
in NCT03928028 1514 1516 O
treatment NCT03928028 1517 1526 O

3 NCT03928028 1530 1531 O
. NCT03928028 1531 1532 O
Use NCT03928028 1534 1537 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
of NCT03928028 1538 1540 O
anti NCT03928028 1541 1545 B-Drug-Name
- NCT03928028 1546 1547 I-Drug-Name
psychotic NCT03928028 1548 1557 I-Drug-Name
medication NCT03928028 1558 1568 I-Drug-Name

Inclusion NCT03927482 0 9 O
Criteria NCT03927482 10 18 O
: NCT03927482 19 20 O

- NCT03927482 24 25 O
Currently NCT03927482 27 36 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
enrolled NCT03927482 37 45 O
community NCT03927482 46 55 O
college NCT03927482 56 63 O
student NCT03927482 64 71 O

- NCT03927482 74 75 O
At NCT03927482 77 79 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03927482 80 85 I-Eq-Operator___Eq-Operator-Value:GTEQ
2 NCT03927482 87 88 B-Eq-Value
heavy NCT03927482 89 94 B-Condition-Name
drinking NCT03927482 95 103 I-Condition-Name
episodes NCT03927482 104 112 O
in NCT03927482 113 115 O
past NCT03927482 116 120 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
2 NCT03927482 122 123 B-Eq-Value
weeks NCT03927482 124 129 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
at NCT03927482 130 132 O
recruitment NCT03927482 133 144 O

- NCT03927482 147 148 O
Own NCT03927482 150 153 O
smart NCT03927482 154 159 O
phone NCT03927482 160 165 O

Exclusion NCT03927482 166 175 O
Criteria NCT03927482 176 184 O
: NCT03927482 185 186 O

- NCT03927482 190 191 O
Alcohol NCT03927482 193 200 B-Condition-Name
abuse NCT03927482 201 206 I-Condition-Name
disorder NCT03927482 207 215 I-Condition-Name
or NCT03927482 216 218 O
currently NCT03927482 219 228 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
in NCT03927482 229 231 O
treatment NCT03927482 232 241 O
for NCT03927482 242 245 O
alcohol NCT03927482 246 253 B-Condition-Name
- NCT03927482 254 255 I-Condition-Name
related NCT03927482 256 263 I-Condition-Name
problems NCT03927482 264 272 I-Condition-Name

Inclusion NCT03920514 0 9 O
Criteria NCT03920514 10 18 O
: NCT03920514 19 20 O

- NCT03920514 24 25 O
Mild NCT03920514 27 31 B-Severity___Severity-Value:mild
male NCT03920514 32 36 B-Condition-Name
infertility NCT03920514 37 48 I-Condition-Name
or NCT03920514 49 51 O
unexplained NCT03920514 52 63 O
infertility NCT03920514 64 75 B-Condition-Name

Exclusion NCT03920514 76 85 O
Criteria NCT03920514 86 94 O
: NCT03920514 95 96 O

- NCT03920514 100 101 O
Adanced NCT03920514 103 110 O
male NCT03920514 111 115 O
factor NCT03920514 116 122 O
endometriosis NCT03920514 123 136 B-Condition-Name
uterine NCT03920514 137 144 B-Condition-Name
abnormality NCT03920514 145 156 I-Condition-Name
sever NCT03920514 157 162 B-Severity___Severity-Value:severe
semen NCT03920514 163 168 B-Condition-Name
parameters NCT03920514 169 179 I-Condition-Name
i NCT03920514 180 181 O
impairment NCT03920514 182 192 O
according NCT03920514 193 202 O
to NCT03920514 203 205 O
WHO NCT03920514 206 209 O
2010 NCT03920514 211 215 O
non NCT03920514 216 219 B-Condition-Name
ovulatory NCT03920514 220 229 I-Condition-Name
cycles NCT03920514 230 236 I-Condition-Name
bilatral NCT03920514 237 245 O
tubal NCT03920514 246 251 B-Condition-Name
block NCT03920514 252 257 I-Condition-Name

Inclusion NCT03923790 0 9 O
Criteria NCT03923790 10 18 O
: NCT03923790 19 20 O

- NCT03923790 24 25 O
Ischemic NCT03923790 27 35 O
and NCT03923790 36 39 O
hemorrhagic NCT03923790 40 51 O
stroke NCT03923790 52 58 B-Condition-Name
patients NCT03923790 59 67 O

- NCT03923790 70 71 O
Presence NCT03923790 73 81 O
of NCT03923790 82 84 O
at NCT03923790 85 87 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03923790 88 93 I-Eq-Operator___Eq-Operator-Value:GTEQ
one NCT03923790 94 97 B-Eq-Value
of NCT03923790 98 100 O
the NCT03923790 101 104 O
following NCT03923790 105 114 O
high NCT03923790 115 119 B-Polarity___Polarity-Value:high
risk NCT03923790 120 124 O
criteria NCT03923790 125 133 O
: NCT03923790 134 135 O
uninsured NCT03923790 136 145 B-Insurance
, NCT03923790 146 147 O
Medicaid NCT03923790 148 156 B-Insurance
payer NCT03923790 157 162 O
status NCT03923790 163 169 O
, NCT03923790 170 171 O
small NCT03923790 172 177 O
vessel NCT03923790 178 184 O
ischemic NCT03923790 185 193 B-Condition-Name
stroke NCT03923790 194 200 I-Condition-Name
, NCT03923790 201 202 O
hypertensive NCT03923790 203 215 O
ICH NCT03923790 216 219 B-Condition-Name
) NCT03923790 220 221 O

- NCT03923790 225 226 O
Age NCT03923790 228 231 O
≥ NCT03923790 232 233 B-Eq-Operator___Eq-Operator-Value:GTEQ
18 NCT03923790 235 237 B-Eq-Value
; NCT03923790 238 239 O
presence NCT03923790 240 248 O
of NCT03923790 249 251 O
hypertension NCT03923790 252 264 B-Condition-Name
( NCT03923790 265 266 O
by NCT03923790 267 269 O
clinical NCT03923790 270 278 B-Observation-Name
history NCT03923790 279 286 I-Observation-Name
or NCT03923790 287 289 O
hospital NCT03923790 290 298 B-Location___Location-Value:hospital
BP NCT03923790 299 301 B-Observation-Name___Observation-Type-Value:vital
≥ NCT03923790 302 303 B-Eq-Operator___Eq-Operator-Value:GTEQ
140 NCT03923790 305 308 B-Eq-Value
/ NCT03923790 309 310 O
90 NCT03923790 312 314 B-Eq-Value
on NCT03923790 315 317 O
two NCT03923790 318 321 B-Eq-Value
occasions NCT03923790 322 331 O
) NCT03923790 332 333 O

- NCT03923790 337 338 O
Plan NCT03923790 340 344 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
to NCT03923790 345 347 O
discharge NCT03923790 348 357 B-Encounter-Type___Encounter-Type-Value:discharge
home NCT03923790 358 362 B-Location___Location-Value:residence
after NCT03923790 363 368 O
stroke NCT03923790 369 375 B-Condition-Name

- NCT03923790 378 379 O
Ability NCT03923790 381 388 O
to NCT03923790 389 391 O
provide NCT03923790 392 399 O
consent NCT03923790 400 407 O
( NCT03923790 408 409 O
patient NCT03923790 410 417 O
or NCT03923790 418 420 O
caregiver NCT03923790 421 430 O
) NCT03923790 431 432 O

- NCT03923790 436 437 O
Ability NCT03923790 439 446 O
to NCT03923790 447 449 O
communicate NCT03923790 450 461 O
in NCT03923790 462 464 O
English NCT03923790 465 472 B-Language

Exclusion NCT03923790 473 482 O
Criteria NCT03923790 483 491 O
: NCT03923790 492 493 O

- NCT03923790 497 498 O
modified NCT03923790 500 508 B-Observation-Name___Observation-Type-Value:clinical-score
Rankin NCT03923790 509 515 I-Observation-Name___Observation-Type-Value:clinical-score
scale NCT03923790 516 521 I-Observation-Name___Observation-Type-Value:clinical-score
> NCT03923790 522 523 B-Eq-Operator___Eq-Operator-Value:GT
4 NCT03923790 525 526 B-Eq-Value
at NCT03923790 527 529 O
the NCT03923790 530 533 O
time NCT03923790 534 538 O
of NCT03923790 539 541 O
enrollment NCT03923790 542 552 O
( NCT03923790 553 554 O
severe NCT03923790 555 561 B-Severity___Severity-Value:severe
disability NCT03923790 562 572 B-Condition-Name
) NCT03923790 573 574 O

- NCT03923790 578 579 O
life NCT03923790 581 585 B-Observation-Name
expectancy NCT03923790 586 596 I-Observation-Name
< NCT03923790 597 598 B-Eq-Operator___Eq-Operator-Value:LT
1 NCT03923790 600 601 B-Eq-Value
year NCT03923790 602 606 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
or NCT03923790 607 609 O
terminal NCT03923790 610 618 B-Condition-Name
illness NCT03923790 619 626 I-Condition-Name
, NCT03923790 627 628 O

- NCT03923790 632 633 O
eGFR NCT03923790 635 639 B-Observation-Name___Observation-Type-Value:lab
< NCT03923790 640 641 B-Eq-Operator___Eq-Operator-Value:LT
30 NCT03923790 643 645 B-Eq-Value
at NCT03923790 646 648 O
time NCT03923790 649 653 O
of NCT03923790 654 656 O
discharge NCT03923790 657 666 B-Encounter-Type___Encounter-Type-Value:discharge

- NCT03923790 669 670 O
pregnancy NCT03923790 672 681 B-Condition-Name

- NCT03923790 684 685 O
symptomatic NCT03923790 687 698 B-Condition-Name
flow NCT03923790 699 703 I-Condition-Name
limiting NCT03923790 704 712 B-Stability___Stability-Value:change
carotid NCT03923790 713 720 B-Condition-Name
stenosis NCT03923790 721 729 I-Condition-Name
without NCT03923790 730 737 O
plan NCT03923790 738 742 O
for NCT03923790 743 746 O
intervention NCT03923790 747 759 B-Procedure-Name

- NCT03923790 762 763 O
urine NCT03923790 765 770 B-Observation-Specimen
toxicology NCT03923790 771 781 B-Observation-Name___Observation-Type-Value:lab
positive NCT03923790 782 790 B-Polarity___Polarity-Value:positive
for NCT03923790 791 794 O
cocaine NCT03923790 795 802 B-Drug-Name
or NCT03923790 803 805 O
methamphetamine NCT03923790 806 821 B-Drug-Name
or NCT03923790 822 824 O
recent NCT03923790 825 831 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:recent
use NCT03923790 832 835 O

- NCT03923790 838 839 O
long NCT03923790 841 845 O
- NCT03923790 846 847 O
term NCT03923790 848 852 O
BP NCT03923790 853 855 B-Observation-Name___Observation-Type-Value:lab
goal NCT03923790 856 860 O
≥ NCT03923790 861 862 B-Eq-Operator___Eq-Operator-Value:GTEQ
130 NCT03923790 864 867 B-Eq-Value
/ NCT03923790 868 869 O
80 NCT03923790 871 873 B-Eq-Value
mmHg NCT03923790 874 878 B-Eq-Unit
according NCT03923790 879 888 O
to NCT03923790 889 891 O
clinical NCT03923790 892 900 O
team NCT03923790 901 905 O

Inclusion NCT03929068 0 9 O
Criteria NCT03929068 10 18 O
: NCT03929068 19 20 O

- NCT03929068 24 25 O
Diagnosis NCT03929068 27 36 O
of NCT03929068 37 39 O
ALS NCT03929068 40 43 B-Condition-Name
or NCT03929068 44 46 O
PLS NCT03929068 47 50 B-Condition-Name

- NCT03929068 53 54 O
Age NCT03929068 56 59 O
greater NCT03929068 60 67 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03929068 68 72 I-Eq-Operator___Eq-Operator-Value:GT
18 NCT03929068 74 76 B-Eq-Value
years NCT03929068 77 82 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03929068 85 86 O
Clinically NCT03929068 88 98 O
significant NCT03929068 99 110 B-Severity___Severity-Value:severe
spasticity NCT03929068 111 121 B-Condition-Name
. NCT03929068 122 123 O

Exclusion NCT03929068 125 134 O
Criteria NCT03929068 135 143 O
: NCT03929068 144 145 O

- NCT03929068 149 150 O
Individuals NCT03929068 152 163 O
currently NCT03929068 164 173 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
taking NCT03929068 174 180 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
carbidopa NCT03929068 181 190 B-Drug-Name
- NCT03929068 191 192 I-Drug-Name
levodopa NCT03929068 193 201 I-Drug-Name
or NCT03929068 202 204 O
with NCT03929068 205 209 O
known NCT03929068 210 215 O
hypersensitivity NCT03929068 216 232 B-Condition-Name
of NCT03929068 233 235 O
any NCT03929068 236 239 O
component NCT03929068 240 249 O
of NCT03929068 250 252 O
carbidopa NCT03929068 253 262 B-Drug-Name
- NCT03929068 263 264 I-Drug-Name
levodopa NCT03929068 265 273 I-Drug-Name

- NCT03929068 276 277 O
Narrow NCT03929068 279 285 B-Condition-Name
- NCT03929068 286 287 I-Condition-Name
angle NCT03929068 288 293 I-Condition-Name
glaucoma NCT03929068 294 302 I-Condition-Name

- NCT03929068 305 306 O
Current NCT03929068 308 315 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
use NCT03929068 316 319 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
of NCT03929068 320 322 O
a NCT03929068 323 324 O
non NCT03929068 325 328 B-Drug-Name
- NCT03929068 329 330 I-Drug-Name
selective NCT03929068 331 340 I-Drug-Name
monoamine NCT03929068 341 350 I-Drug-Name
oxidase NCT03929068 351 358 I-Drug-Name
inhibitor NCT03929068 359 368 I-Drug-Name
( NCT03929068 369 370 O
MAOI NCT03929068 371 375 B-Drug-Name
) NCT03929068 376 377 O

- NCT03929068 381 382 O
History NCT03929068 384 391 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03929068 392 394 O
malignant NCT03929068 395 404 B-Condition-Name
melanoma NCT03929068 405 413 I-Condition-Name
or NCT03929068 414 416 O
suspicious NCT03929068 417 427 O
skin NCT03929068 428 432 B-Condition-Name
lesions NCT03929068 433 440 I-Condition-Name

- NCT03929068 443 444 O
History NCT03929068 446 453 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03929068 454 456 O
depression NCT03929068 457 467 B-Condition-Name
, NCT03929068 468 469 O
suicidal NCT03929068 470 478 B-Condition-Name
ideation NCT03929068 479 487 I-Condition-Name
, NCT03929068 488 489 O
or NCT03929068 490 492 O
psychosis NCT03929068 493 502 B-Condition-Name

- NCT03929068 505 506 O
History NCT03929068 508 515 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03929068 516 518 O
myocardial NCT03929068 519 529 B-Condition-Name
infarction NCT03929068 530 540 I-Condition-Name
, NCT03929068 541 542 O
ventricular NCT03929068 543 554 B-Condition-Name
arrhythmia NCT03929068 555 565 I-Condition-Name
, NCT03929068 566 567 O
or NCT03929068 568 570 O
severe NCT03929068 571 577 B-Severity___Severity-Value:severe
cardiopulmonary NCT03929068 578 593 B-Condition-Name
disease NCT03929068 594 601 I-Condition-Name

- NCT03929068 604 605 O
Uncontrolled NCT03929068 607 619 O
hypertension NCT03929068 620 632 B-Condition-Name

- NCT03929068 635 636 O
Asthma NCT03929068 638 644 B-Condition-Name

- NCT03929068 647 648 O
Renal NCT03929068 650 655 B-Condition-Name
disease NCT03929068 656 663 I-Condition-Name

- NCT03929068 666 667 O
Hepatic NCT03929068 669 676 B-Condition-Name
disease NCT03929068 677 684 I-Condition-Name

- NCT03929068 687 688 O
Endocrine NCT03929068 690 699 B-Condition-Name
disease NCT03929068 700 707 I-Condition-Name

- NCT03929068 710 711 O
History NCT03929068 713 720 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03929068 721 723 O
peptic NCT03929068 724 730 B-Condition-Name
ulcer NCT03929068 731 736 I-Condition-Name

- NCT03929068 739 740 O
Pregnant NCT03929068 742 750 O
and NCT03929068 751 754 O
/ NCT03929068 755 756 O
or NCT03929068 757 759 O
breastfeeding NCT03929068 760 773 O

- NCT03929068 776 777 O
Current NCT03929068 779 786 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
participation NCT03929068 787 800 O
in NCT03929068 801 803 O
another NCT03929068 804 811 O
interventional NCT03929068 812 826 O
study NCT03929068 827 832 O

Inclusion NCT03926429 0 9 O
Criteria NCT03926429 10 18 O
: NCT03926429 19 20 O

- NCT03926429 24 25 O
reactive NCT03926429 27 35 B-Condition-Name
arthritis NCT03926429 36 45 I-Condition-Name
diagnosed NCT03926429 46 55 O
in NCT03926429 56 58 O
one NCT03926429 59 62 O
of NCT03926429 63 65 O
the NCT03926429 66 69 O
two NCT03926429 70 73 O
rheumatology NCT03926429 74 86 B-Location___Location-Value:clinic
departments NCT03926429 87 98 I-Location___Location-Value:clinic
from NCT03926429 99 103 O
Centre NCT03926429 104 110 B-Location___Location-Value:hospital
Hospitalier NCT03926429 111 122 I-Location___Location-Value:hospital
Lyon NCT03926429 123 127 I-Location___Location-Value:hospital
Sud NCT03926429 128 131 I-Location___Location-Value:hospital
or NCT03926429 132 134 O
Besançon NCT03926429 135 143 B-Location___Location-Value:hospital

Exclusion NCT03926429 144 153 O
Criteria NCT03926429 154 162 O
: NCT03926429 163 164 O

- NCT03926429 168 169 O
presence NCT03926429 171 179 O
of NCT03926429 180 182 O
other NCT03926429 183 188 O
known NCT03926429 189 194 O
causes NCT03926429 195 201 O
of NCT03926429 202 204 O
arthritis NCT03926429 205 214 B-Condition-Name
, NCT03926429 215 216 O
such NCT03926429 217 221 O
as NCT03926429 222 224 O
other NCT03926429 225 230 O
defined NCT03926429 231 238 O
spondyloarthritides NCT03926429 239 258 B-Condition-Name
, NCT03926429 259 260 O
septic NCT03926429 261 267 O
arthritis NCT03926429 268 277 B-Condition-Name
, NCT03926429 278 279 O
Lyme NCT03926429 280 284 B-Condition-Name
disease NCT03926429 285 292 I-Condition-Name
, NCT03926429 293 294 O
microcrystalline NCT03926429 295 311 O
arthritis NCT03926429 312 321 B-Condition-Name
or NCT03926429 322 324 O
rheumatoid NCT03926429 325 335 O
arthritis NCT03926429 336 345 B-Condition-Name

Inclusion NCT03927079 0 9 O
Criteria NCT03927079 10 18 O
: NCT03927079 19 20 O

- NCT03927079 24 25 O
patients NCT03927079 27 35 O
who NCT03927079 36 39 O
undergo NCT03927079 40 47 O
a NCT03927079 48 49 O
flexible NCT03927079 50 58 O
bronchoscopic NCT03927079 59 72 B-Procedure-Name
lavage NCT03927079 73 79 I-Procedure-Name
and NCT03927079 80 83 O
with NCT03927079 84 88 O
a NCT03927079 89 90 O
beta NCT03927079 91 95 B-Drug-Name
lactamines NCT03927079 96 106 I-Drug-Name
treatment NCT03927079 107 116 O
as NCT03927079 117 119 O
cephalosporin NCT03927079 120 133 B-Drug-Name
of NCT03927079 134 136 O
3 NCT03927079 138 139 O
rd NCT03927079 140 142 O
generation NCT03927079 143 153 O
( NCT03927079 154 155 O
CEFTRIAXONE NCT03927079 156 167 B-Drug-Name
/ NCT03927079 168 169 O
CEFOTAXIME NCT03927079 170 180 B-Drug-Name
, NCT03927079 181 182 O
CEFTAZIDIME NCT03927079 183 194 B-Drug-Name
) NCT03927079 195 196 O
, NCT03927079 198 199 O
of NCT03927079 200 202 O
4 NCT03927079 204 205 O
th NCT03927079 206 208 O
generation NCT03927079 209 219 O
( NCT03927079 220 221 O
CEFEPIM NCT03927079 222 229 B-Drug-Name
) NCT03927079 230 231 O
, NCT03927079 233 234 O
or NCT03927079 235 237 O
AMOXICILLIN NCT03927079 238 249 B-Drug-Name
- NCT03927079 250 251 I-Drug-Name
CLAVULANIC NCT03927079 252 262 I-Drug-Name
ACID NCT03927079 263 267 I-Drug-Name
, NCT03927079 268 269 O
or NCT03927079 270 272 O
PIPERACILLIN NCT03927079 273 285 B-Drug-Name
- NCT03927079 286 287 I-Drug-Name
TAZOBACTAM NCT03927079 288 298 I-Drug-Name

- NCT03927079 301 302 O
patient NCT03927079 304 311 O
major NCT03927079 312 317 O

- NCT03927079 320 321 O
informed NCT03927079 323 331 O
and NCT03927079 332 335 O
signed NCT03927079 336 342 O
consent NCT03927079 343 350 O
form NCT03927079 351 355 O

Exclusion NCT03927079 356 365 O
Criteria NCT03927079 366 374 O
: NCT03927079 375 376 O

- NCT03927079 380 381 O
patient NCT03927079 383 390 O
under NCT03927079 391 396 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
chronic NCT03927079 397 404 O
dialysis NCT03927079 405 413 B-Procedure-Name

- NCT03927079 416 417 O
patient NCT03927079 419 426 O
placed NCT03927079 427 433 O
under NCT03927079 434 439 O
judicial NCT03927079 440 448 B-Observation-Name
protection NCT03927079 449 459 I-Observation-Name

Inclusion NCT03922698 0 9 O
Criteria NCT03922698 10 18 O
: NCT03922698 19 20 O

- NCT03922698 24 25 O
age NCT03922698 27 30 O
≥ NCT03922698 31 32 B-Eq-Operator___Eq-Operator-Value:GTEQ
45 NCT03922698 34 36 B-Eq-Value
and NCT03922698 37 40 O
≤ NCT03922698 41 42 B-Eq-Operator___Eq-Operator-Value:LTEQ
90 NCT03922698 44 46 B-Eq-Value
years NCT03922698 47 52 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
; NCT03922698 52 53 O

- NCT03922698 56 57 O
patients NCT03922698 59 67 O
with NCT03922698 68 72 O
severe NCT03922698 73 79 B-Severity___Severity-Value:severe
( NCT03922698 80 81 O
70 NCT03922698 83 85 O
- NCT03922698 86 87 B-Eq-Operator___Eq-Operator-Value:BETWEEN
99 NCT03922698 89 91 B-Eq-Value
% NCT03922698 92 93 B-Eq-Unit
) NCT03922698 95 96 O
carotid NCT03922698 97 104 B-Observation-Name___Observation-Type-Value:measurement
stenosis NCT03922698 105 113 I-Observation-Name___Observation-Type-Value:measurement
, NCT03922698 114 115 O
diagnosed NCT03922698 116 125 O
with NCT03922698 126 130 O
color NCT03922698 131 136 B-Procedure-Name
doppler NCT03922698 137 144 I-Procedure-Name
echography NCT03922698 145 155 I-Procedure-Name
or NCT03922698 156 158 O
angio NCT03922698 159 164 O
- NCT03922698 165 166 O
MRI NCT03922698 167 170 B-Procedure-Name
or NCT03922698 171 173 O
angiography NCT03922698 174 185 B-Procedure-Name
; NCT03922698 185 186 O

- NCT03922698 189 190 O
written NCT03922698 192 199 O
informed NCT03922698 200 208 O
consent NCT03922698 209 216 O
. NCT03922698 217 218 O

Exclusion NCT03922698 220 229 O
Criteria NCT03922698 230 238 O
: NCT03922698 239 240 O

- NCT03922698 244 245 O
carotid NCT03922698 247 254 B-Observation-Name___Observation-Type-Value:measurement
stenosis NCT03922698 255 263 I-Observation-Name___Observation-Type-Value:measurement
< NCT03922698 264 265 B-Eq-Operator___Eq-Operator-Value:LT
70 NCT03922698 267 269 B-Eq-Value
% NCT03922698 270 271 B-Eq-Unit
at NCT03922698 272 274 O
carotid NCT03922698 275 282 O
bifurcation NCT03922698 283 294 O
or NCT03922698 295 297 O
diagnosed NCT03922698 298 307 O
with NCT03922698 308 312 O
color NCT03922698 313 318 B-Procedure-Name
doppler NCT03922698 319 326 I-Procedure-Name
echography NCT03922698 327 337 I-Procedure-Name
or NCT03922698 338 340 O
angio NCT03922698 341 346 O
- NCT03922698 347 348 O
MRI NCT03922698 349 352 B-Procedure-Name
or NCT03922698 353 355 O
angiography NCT03922698 356 367 B-Procedure-Name
; NCT03922698 367 368 O

- NCT03922698 371 372 O
severe NCT03922698 374 380 B-Severity___Severity-Value:severe
neoplasia NCT03922698 381 390 B-Condition-Name
; NCT03922698 390 391 O

- NCT03922698 394 395 O
participation NCT03922698 397 410 O
to NCT03922698 411 413 O
other NCT03922698 414 419 O
clinical NCT03922698 420 428 O
trial NCT03922698 429 434 O
, NCT03922698 435 436 O
ongoing NCT03922698 437 444 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
or NCT03922698 445 447 O
terminated NCT03922698 448 458 O
less NCT03922698 459 463 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03922698 464 468 I-Eq-Operator___Eq-Operator-Value:LT
one NCT03922698 469 472 B-Eq-Value
month NCT03922698 473 478 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
before NCT03922698 479 485 O
enrolment NCT03922698 486 495 O
in NCT03922698 496 498 O
this NCT03922698 499 503 O
study NCT03922698 504 509 O
. NCT03922698 510 511 O

Inclusion NCT03927092 0 9 O
Criteria NCT03927092 10 18 O
: NCT03927092 19 20 O

- NCT03927092 24 25 O
Diagnosed NCT03927092 27 36 O
as NCT03927092 37 39 O
having NCT03927092 40 46 O
Multiple NCT03927092 47 55 B-Condition-Name
Sclerosis NCT03927092 56 65 I-Condition-Name

- NCT03927092 68 69 O
Attends NCT03927092 71 78 O
the NCT03927092 79 82 O
annual NCT03927092 83 89 O
patient NCT03927092 90 97 O
education NCT03927092 98 107 O
seminar NCT03927092 108 115 O
at NCT03927092 116 118 O
the NCT03927092 119 122 O
investigators NCT03927092 123 136 O
' NCT03927092 136 137 O
university NCT03927092 138 148 B-Location___Location-Value:hospital
hospital NCT03927092 149 157 I-Location___Location-Value:hospital

- NCT03927092 160 161 O
Older NCT03927092 163 168 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03927092 169 173 I-Eq-Operator___Eq-Operator-Value:GT
18 NCT03927092 175 177 B-Eq-Value
years NCT03927092 178 183 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03927092 184 186 O
age NCT03927092 187 190 O

- NCT03927092 193 194 O
Can NCT03927092 196 199 O
read NCT03927092 200 204 O
and NCT03927092 205 208 O
write NCT03927092 209 214 O

Exclusion NCT03927092 215 224 O
Criteria NCT03927092 225 233 O
: NCT03927092 234 235 O

- NCT03927092 239 240 O
Does NCT03927092 242 246 O
not NCT03927092 247 250 O
accept NCT03927092 251 257 O
to NCT03927092 258 260 O
answer NCT03927092 261 267 O
the NCT03927092 268 271 O
questionnaire NCT03927092 272 285 B-Observation-Name___Observation-Type-Value:survey-or-questionnaire

- NCT03927092 288 289 O
Unable NCT03927092 291 297 O
to NCT03927092 298 300 O
answer NCT03927092 301 307 O
the NCT03927092 308 311 O
questions NCT03927092 312 321 B-Procedure-Name
due NCT03927092 322 325 O
to NCT03927092 326 328 O
a NCT03927092 329 330 O
cognitive NCT03927092 331 340 B-Condition-Name
impairment NCT03927092 341 351 I-Condition-Name

Inclusion NCT03920930 0 9 O
Criteria NCT03920930 10 18 O
: NCT03920930 19 20 O

• NCT03920930 22 23 O
patients NCT03920930 24 32 O
undergoing NCT03920930 33 43 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
elective NCT03920930 44 52 O
, NCT03920930 53 54 O
primary NCT03920930 55 62 O
knee NCT03920930 63 67 B-Procedure-Name
joint NCT03920930 68 73 I-Procedure-Name
replacement NCT03920930 74 85 I-Procedure-Name
in NCT03920930 86 88 O
combined NCT03920930 89 97 O
general NCT03920930 98 105 B-Procedure-Name
anaesthesia NCT03920930 106 117 I-Procedure-Name

Exclusion NCT03920930 118 127 O
Criteria NCT03920930 128 136 O
: NCT03920930 137 138 O

- NCT03920930 142 143 O
heart NCT03920930 145 150 B-Condition-Name
insufficiency NCT03920930 151 164 I-Condition-Name
NYHA NCT03920930 165 169 B-Condition-Name
> NCT03920930 170 171 B-Eq-Operator___Eq-Operator-Value:GT
2 NCT03920930 173 174 B-Eq-Value

- NCT03920930 178 179 O
liver NCT03920930 181 186 B-Condition-Name
insufficiency NCT03920930 187 200 I-Condition-Name
> NCT03920930 201 202 B-Eq-Operator___Eq-Operator-Value:GT
CHILD NCT03920930 203 208 O
B NCT03920930 209 210 O

- NCT03920930 213 214 O
evidence NCT03920930 216 224 O
of NCT03920930 225 227 O
diabetic NCT03920930 228 236 B-Condition-Name
polyneuropathy NCT03920930 237 251 I-Condition-Name

- NCT03920930 254 255 O
severe NCT03920930 257 263 B-Severity___Severity-Value:severe
adipositas NCT03920930 264 274 B-Condition-Name
BMI NCT03920930 275 278 B-Observation-Name___Observation-Type-Value:vital
> NCT03920930 279 280 B-Eq-Operator___Eq-Operator-Value:GT
40 NCT03920930 282 284 B-Eq-Value

- NCT03920930 288 289 O
patients NCT03920930 291 299 O
< NCT03920930 300 301 B-Eq-Operator___Eq-Operator-Value:LT
18 NCT03920930 303 305 B-Eq-Value
years NCT03920930 306 311 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03920930 314 315 O
pregnancy NCT03920930 317 326 B-Condition-Name

- NCT03920930 329 330 O
in NCT03920930 332 334 O
case NCT03920930 335 339 O
of NCT03920930 340 342 O
police NCT03920930 343 349 B-Observation-Name
custody NCT03920930 350 357 I-Observation-Name

- NCT03920930 360 361 O
participation NCT03920930 363 376 O
in NCT03920930 377 379 O
a NCT03920930 380 381 O
paralleled NCT03920930 382 392 O
interventional NCT03920930 393 407 O
RCT NCT03920930 408 411 O
in NCT03920930 412 414 O
a NCT03920930 415 416 O
time NCT03920930 417 421 O
frame NCT03920930 422 427 O
of NCT03920930 428 430 O
30 NCT03920930 432 434 B-Eq-Value
days NCT03920930 435 439 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day

- NCT03920930 442 443 O
chronic NCT03920930 445 452 O
opioid NCT03920930 453 459 B-Procedure-Name
therapy NCT03920930 460 467 I-Procedure-Name
> NCT03920930 468 469 B-Eq-Operator___Eq-Operator-Value:GT
3 NCT03920930 471 472 B-Eq-Value
months NCT03920930 473 479 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
before NCT03920930 480 486 O
scheduled NCT03920930 487 496 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
surgery NCT03920930 497 504 B-Procedure-Name

- NCT03920930 507 508 O
allergy NCT03920930 510 517 O
against NCT03920930 518 525 O
medication NCT03920930 526 536 O
required NCT03920930 537 545 O
for NCT03920930 546 549 O
surgery NCT03920930 550 557 B-Procedure-Name
or NCT03920930 558 560 O
anaesthesia NCT03920930 561 572 B-Procedure-Name


Inclusion NCT03922841 0 9 O
Criteria NCT03922841 10 18 O
: NCT03922841 19 20 O

- NCT03922841 24 25 O
The NCT03922841 27 30 O
subject NCT03922841 31 38 O
must NCT03922841 39 43 O
meet NCT03922841 44 48 O
all NCT03922841 49 52 O
of NCT03922841 53 55 O
the NCT03922841 56 59 O
following NCT03922841 60 69 O
inclusion NCT03922841 70 79 O
criteria NCT03922841 80 88 O
to NCT03922841 89 91 O
participate NCT03922841 92 103 O
in NCT03922841 104 106 O
this NCT03922841 107 111 O
study NCT03922841 112 117 O
. NCT03922841 118 119 O

1 NCT03922841 129 130 O
. NCT03922841 130 131 O
Evidence NCT03922841 133 141 O
of NCT03922841 142 144 O
pleural NCT03922841 145 152 B-Condition-Name
disease NCT03922841 153 160 I-Condition-Name
on NCT03922841 161 163 O
chest NCT03922841 164 169 B-Procedure-Name
radiograph NCT03922841 170 180 I-Procedure-Name
or NCT03922841 181 183 O
bedside NCT03922841 184 191 B-Procedure-Name
ultrasound NCT03922841 192 202 I-Procedure-Name
or NCT03922841 203 205 O
Computed NCT03922841 206 214 B-Procedure-Name
Tomography NCT03922841 215 225 I-Procedure-Name
regardless NCT03922841 226 236 O
of NCT03922841 237 239 O
underlying NCT03922841 240 250 O
aetiology NCT03922841 251 260 O

2 NCT03922841 269 270 O
. NCT03922841 270 271 O
No NCT03922841 273 275 O
age NCT03922841 276 279 O
or NCT03922841 280 282 O
gender NCT03922841 283 289 B-Life-Stage-And-Gender
restrictions NCT03922841 290 302 O

3 NCT03922841 311 312 O
. NCT03922841 312 313 O
Ability NCT03922841 315 322 O
to NCT03922841 323 325 O
provide NCT03922841 326 333 O
informed NCT03922841 334 342 O
consent NCT03922841 343 350 O

Exclusion NCT03922841 351 360 O
Criteria NCT03922841 361 369 O
: NCT03922841 370 371 O

- NCT03922841 375 376 O
Subjects NCT03922841 378 386 O
who NCT03922841 387 390 O
no NCT03922841 391 393 O
radiographic NCT03922841 394 406 B-Procedure-Name
evidence NCT03922841 407 415 O
of NCT03922841 416 418 O
pleural NCT03922841 419 426 B-Condition-Name
disease NCT03922841 427 434 I-Condition-Name
or NCT03922841 435 437 O
who NCT03922841 438 441 O
are NCT03922841 442 445 O
unwilling NCT03922841 446 455 O
/ NCT03922841 456 457 O
unable NCT03922841 458 464 O
to NCT03922841 465 467 O
provide NCT03922841 468 475 O
informed NCT03922841 476 484 O
consent NCT03922841 485 492 O

Inclusion NCT03922672 0 9 O
Criteria NCT03922672 10 18 O
: NCT03922672 19 20 O

- NCT03922672 24 25 O
Caregiver NCT03922672 27 36 O
: NCT03922672 37 38 O

- NCT03922672 47 48 O
Are NCT03922672 50 53 O
currently NCT03922672 54 63 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
a NCT03922672 64 65 O
primary NCT03922672 66 73 B-Observation-Name
caregiver NCT03922672 74 83 I-Observation-Name
to NCT03922672 84 86 O
an NCT03922672 87 89 O
adult NCT03922672 90 95 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
with NCT03922672 96 100 O
PD NCT03922672 101 103 B-Condition-Name

- NCT03922672 111 112 O
Are NCT03922672 114 117 O
between NCT03922672 118 125 O
the NCT03922672 126 129 O
age NCT03922672 130 133 O
of NCT03922672 134 136 O
40 NCT03922672 138 140 B-Eq-Value
- NCT03922672 141 142 B-Eq-Operator___Eq-Operator-Value:BETWEEN
80 NCT03922672 144 146 B-Eq-Value
years NCT03922672 147 152 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03922672 160 161 O
Have NCT03922672 163 167 O
less NCT03922672 168 172 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03922672 173 177 I-Eq-Operator___Eq-Operator-Value:LT
5 NCT03922672 179 180 B-Eq-Value
years NCT03922672 181 186 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03922672 187 189 O
music NCT03922672 190 195 B-Observation-Name
training NCT03922672 196 204 I-Observation-Name

- NCT03922672 212 213 O
Speak NCT03922672 215 220 O
and NCT03922672 221 224 O
read NCT03922672 225 229 O
English NCT03922672 230 237 B-Language
fluently NCT03922672 238 246 O

Adult NCT03922672 247 252 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
with NCT03922672 253 257 O
PD NCT03922672 258 260 B-Condition-Name
: NCT03922672 261 262 O

- NCT03922672 266 267 O
Stage NCT03922672 269 274 B-Eq-Unit
1 NCT03922672 276 277 B-Eq-Value
- NCT03922672 278 279 B-Eq-Operator___Eq-Operator-Value:BETWEEN
3 NCT03922672 281 282 B-Eq-Value
Parkinson NCT03922672 283 292 B-Condition-Name
's NCT03922672 292 294 I-Condition-Name
disease NCT03922672 295 302 I-Condition-Name

- NCT03922672 305 306 O
Are NCT03922672 308 311 O
between NCT03922672 312 319 O
the NCT03922672 320 323 O
age NCT03922672 324 327 O
of NCT03922672 328 330 O
40 NCT03922672 332 334 B-Eq-Value
- NCT03922672 335 336 B-Eq-Operator___Eq-Operator-Value:BETWEEN
80 NCT03922672 338 340 B-Eq-Value

- NCT03922672 344 345 O
Have NCT03922672 347 351 O
less NCT03922672 352 356 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03922672 357 361 I-Eq-Operator___Eq-Operator-Value:LT
5 NCT03922672 363 364 B-Eq-Value
years NCT03922672 365 370 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03922672 371 373 O
music NCT03922672 374 379 B-Observation-Name
training NCT03922672 380 388 I-Observation-Name

- NCT03922672 391 392 O
Speak NCT03922672 394 399 O
and NCT03922672 400 403 O
read NCT03922672 404 408 O
English NCT03922672 409 416 B-Language
fluently NCT03922672 417 425 O

Exclusion NCT03922672 426 435 O
Criteria NCT03922672 436 444 O
: NCT03922672 445 446 O

- NCT03922672 450 451 O
Does NCT03922672 453 457 O
n't NCT03922672 457 460 O
meet NCT03922672 461 465 O
all NCT03922672 466 469 O
the NCT03922672 470 473 O
inclusion NCT03922672 474 483 O
criteria NCT03922672 484 492 O

Inclusion NCT03929055 0 9 O
Criteria NCT03929055 10 18 O
: NCT03929055 19 20 O

- NCT03929055 24 25 O
patient NCT03929055 27 34 O
with NCT03929055 35 39 O
acute NCT03929055 40 45 B-Condition-Name
respiratory NCT03929055 46 57 I-Condition-Name
failure NCT03929055 58 65 I-Condition-Name
, NCT03929055 66 67 O
not NCT03929055 68 71 O
intubated NCT03929055 72 81 B-Procedure-Name
, NCT03929055 82 83 O
who NCT03929055 84 87 O
require NCT03929055 88 95 O
non NCT03929055 96 99 O
invasive NCT03929055 100 108 O
mechanical NCT03929055 109 119 B-Procedure-Name
ventilation NCT03929055 120 131 I-Procedure-Name

Exclusion NCT03929055 132 141 O
Criteria NCT03929055 142 150 O
: NCT03929055 151 152 O

- NCT03929055 156 157 O
patients NCT03929055 159 167 O
in NCT03929055 168 170 O
which NCT03929055 171 176 O
it NCT03929055 177 179 O
is NCT03929055 180 182 O
not NCT03929055 183 186 O
possible NCT03929055 187 195 O
to NCT03929055 196 198 O
place NCT03929055 199 204 O
the NCT03929055 205 208 O
esophageal NCT03929055 209 219 O
catheter NCT03929055 220 228 B-Procedure-Name
or NCT03929055 229 231 O
it NCT03929055 232 234 O
is NCT03929055 235 237 O
not NCT03929055 238 241 O
possible NCT03929055 242 250 O
to NCT03929055 251 253 O
detect NCT03929055 254 260 O
the NCT03929055 261 264 O
diaphragm NCT03929055 265 274 B-Condition-Name
by NCT03929055 275 277 O
ultrasound NCT03929055 278 288 B-Procedure-Name
or NCT03929055 289 291 O
it NCT03929055 292 294 O
is NCT03929055 295 297 O
not NCT03929055 298 301 O
possible NCT03929055 302 310 O
to NCT03929055 311 313 O
apply NCT03929055 314 319 O
the NCT03929055 320 323 O
nasal NCT03929055 324 329 B-Procedure-Name
cannula NCT03929055 330 337 I-Procedure-Name
device NCT03929055 338 344 I-Procedure-Name

Inclusion NCT03928405 0 9 O
Criteria NCT03928405 10 18 O
: NCT03928405 19 20 O

- NCT03928405 24 25 O
Having NCT03928405 27 33 O
mild NCT03928405 34 38 B-Severity___Severity-Value:mild
or NCT03928405 39 41 O
moderate NCT03928405 42 50 B-Severity___Severity-Value:moderate
severity NCT03928405 51 59 O
of NCT03928405 60 62 O
AD NCT03928405 63 65 B-Condition-Name

- NCT03928405 68 69 O
Lack NCT03928405 71 75 O
of NCT03928405 76 78 O
communication NCT03928405 79 92 B-Condition-Name
difficulties NCT03928405 93 105 O
or NCT03928405 106 108 O
problems NCT03928405 109 117 O

- NCT03928405 120 121 O
Volunteering NCT03928405 123 135 O
to NCT03928405 136 138 O
participate NCT03928405 139 150 O
in NCT03928405 151 153 O
the NCT03928405 154 157 O
study NCT03928405 158 163 O

- NCT03928405 166 167 O
Cerebrovascular NCT03928405 169 184 B-Condition-Name
event NCT03928405 185 190 I-Condition-Name
, NCT03928405 191 192 O

- NCT03928405 196 197 O
Having NCT03928405 199 205 O
disturbing NCT03928405 206 216 B-Stability___Stability-Value:change
the NCT03928405 217 220 O
balance NCT03928405 221 228 B-Condition-Name
and NCT03928405 229 232 O
coordination NCT03928405 233 245 B-Condition-Name
of NCT03928405 246 248 O
neurological NCT03928405 249 261 B-Condition-Name
disease NCT03928405 262 269 I-Condition-Name
such NCT03928405 270 274 O
as NCT03928405 275 277 O
Parkinson NCT03928405 278 287 B-Condition-Name
, NCT03928405 288 289 O
MS NCT03928405 290 292 B-Condition-Name
, NCT03928405 293 294 O

- NCT03928405 298 299 O
Mini NCT03928405 301 305 B-Observation-Name___Observation-Type-Value:clinical-score
Mental NCT03928405 306 312 I-Observation-Name___Observation-Type-Value:clinical-score
Test NCT03928405 313 317 I-Observation-Name___Observation-Type-Value:clinical-score
Score NCT03928405 318 323 I-Observation-Name___Observation-Type-Value:clinical-score
, NCT03928405 324 325 O
18 NCT03928405 327 329 B-Eq-Value
to NCT03928405 330 332 B-Eq-Operator___Eq-Operator-Value:BETWEEN
24 NCT03928405 334 336 B-Eq-Value
points NCT03928405 337 343 O
from NCT03928405 344 348 O
being NCT03928405 349 354 O
scored NCT03928405 355 361 O

- NCT03928405 364 365 O
being NCT03928405 367 372 O
65 NCT03928405 374 376 B-Eq-Value
- NCT03928405 377 378 B-Eq-Operator___Eq-Operator-Value:BETWEEN
80 NCT03928405 380 382 B-Eq-Value
aged NCT03928405 383 387 O
. NCT03928405 388 389 O

Exclusion NCT03928405 391 400 O
Criteria NCT03928405 401 409 O
: NCT03928405 410 411 O

- NCT03928405 415 416 O
Patients NCT03928405 418 426 O
diagnosed NCT03928405 427 436 O
with NCT03928405 437 441 O
dementia NCT03928405 442 450 B-Condition-Name
( NCT03928405 451 452 O
infection NCT03928405 453 462 B-Condition-Name
, NCT03928405 463 464 O
vascular NCT03928405 465 473 B-Condition-Name
, NCT03928405 474 475 O
hematological NCT03928405 476 489 B-Condition-Name
diseases NCT03928405 490 498 I-Condition-Name
) NCT03928405 499 500 O
, NCT03928405 502 503 O
patients NCT03928405 504 512 O
who NCT03928405 513 516 O
could NCT03928405 517 522 O
not NCT03928405 523 526 O
be NCT03928405 527 529 O
contacted NCT03928405 530 539 B-Observation-Name
during NCT03928405 540 546 O
the NCT03928405 547 550 O
follow NCT03928405 551 557 O
- NCT03928405 558 559 O
up NCT03928405 560 562 O
period NCT03928405 563 569 O
or NCT03928405 570 572 O
who NCT03928405 573 576 O
did NCT03928405 577 580 O
not NCT03928405 581 584 O
come NCT03928405 585 589 O
to NCT03928405 590 592 O
control NCT03928405 593 600 O
, NCT03928405 601 602 O
cardiac NCT03928405 603 610 O
and NCT03928405 611 614 O
cerebrovascular NCT03928405 615 630 O
event NCT03928405 631 636 B-Condition-Name
, NCT03928405 637 638 O

- NCT03928405 642 643 O
Endocrine NCT03928405 645 654 B-Condition-Name
disorder NCT03928405 655 663 I-Condition-Name
, NCT03928405 664 665 O
fluid NCT03928405 666 671 B-Condition-Name
- NCT03928405 672 673 I-Condition-Name
electrolyte NCT03928405 674 685 I-Condition-Name
imbalance NCT03928405 686 695 I-Condition-Name
and NCT03928405 696 699 O
infection NCT03928405 700 709 B-Condition-Name

- NCT03928405 712 713 O
Patients NCT03928405 715 723 O
with NCT03928405 724 728 O
malignancy NCT03928405 729 739 B-Condition-Name
and NCT03928405 740 743 O
malignancy NCT03928405 744 754 B-Condition-Name
, NCT03928405 755 756 O
chemotherapy NCT03928405 757 769 B-Procedure-Name
and NCT03928405 770 773 O
radiotherapy NCT03928405 774 786 B-Procedure-Name
, NCT03928405 787 788 O

- NCT03928405 792 793 O
Patients NCT03928405 795 803 O
with NCT03928405 804 808 O
delirium NCT03928405 809 817 B-Condition-Name
or NCT03928405 818 820 O
depression NCT03928405 821 831 B-Condition-Name

- NCT03928405 834 835 O
Those NCT03928405 837 842 O
with NCT03928405 843 847 O
protective NCT03928405 848 858 B-Condition-Name
sensation NCT03928405 859 868 I-Condition-Name
loss NCT03928405 869 873 I-Condition-Name
( NCT03928405 874 875 O
those NCT03928405 876 881 O
with NCT03928405 882 886 O
Semmes NCT03928405 887 893 B-Observation-Name___Observation-Type-Value:measurement
- NCT03928405 894 895 I-Observation-Name___Observation-Type-Value:measurement
Weinstein NCT03928405 896 905 I-Observation-Name___Observation-Type-Value:measurement
Monofilament NCT03928405 906 918 I-Observation-Name___Observation-Type-Value:measurement
Thickness NCT03928405 919 928 I-Observation-Name___Observation-Type-Value:measurement
4.56 NCT03928405 930 934 B-Eq-Value
and NCT03928405 935 938 B-Eq-Operator___Eq-Operator-Value:GTEQ
above NCT03928405 939 944 I-Eq-Operator___Eq-Operator-Value:GTEQ
) NCT03928405 945 946 O

- NCT03928405 950 951 O
patients NCT03928405 953 961 O
with NCT03928405 962 966 O
lower NCT03928405 967 972 O
or NCT03928405 973 975 O
upper NCT03928405 976 981 O
extremity NCT03928405 982 991 O
amputations NCT03928405 992 1003 B-Procedure-Name
at NCT03928405 1004 1006 O
any NCT03928405 1007 1010 O
level NCT03928405 1011 1016 O

Inclusion NCT03921970 0 9 O
Criteria NCT03921970 10 18 O
: NCT03921970 19 20 O

- NCT03921970 24 25 O
American NCT03921970 27 35 B-Condition-Name
Society NCT03921970 36 43 I-Condition-Name
of NCT03921970 44 46 I-Condition-Name
Anesthesiologists NCT03921970 47 64 I-Condition-Name
( NCT03921970 65 66 O
ASA NCT03921970 67 70 B-Condition-Name
) NCT03921970 71 72 O
classification NCT03921970 73 87 B-Eq-Unit
I NCT03921970 88 89 B-Eq-Value
- NCT03921970 90 91 B-Eq-Operator___Eq-Operator-Value:BETWEEN
II NCT03921970 92 94 B-Eq-Value

- NCT03921970 97 98 O
Scheduled NCT03921970 100 109 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
for NCT03921970 110 113 O
laparoscopic NCT03921970 114 126 B-Procedure-Name
sleeve NCT03921970 127 133 I-Procedure-Name
gastrectomy NCT03921970 134 145 I-Procedure-Name
under NCT03921970 146 151 O
general NCT03921970 152 159 B-Procedure-Name
anesthesia NCT03921970 160 170 I-Procedure-Name

Exclusion NCT03921970 171 180 O
Criteria NCT03921970 181 189 O
: NCT03921970 190 191 O

- NCT03921970 195 196 O
Bleeding NCT03921970 198 206 B-Condition-Name
diathesis NCT03921970 207 216 I-Condition-Name

- NCT03921970 219 220 O
Receiving NCT03921970 222 231 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
anticoagulant NCT03921970 232 245 B-Drug-Name
treatment NCT03921970 246 255 O

- NCT03921970 258 259 O
Known NCT03921970 261 266 O
local NCT03921970 267 272 B-Allergy-Name
anesthetics NCT03921970 273 284 I-Allergy-Name
and NCT03921970 285 288 O
opioid NCT03921970 289 295 B-Drug-Name
allergy NCT03921970 296 303 O

- NCT03921970 306 307 O
Infection NCT03921970 309 318 B-Condition-Name
of NCT03921970 319 321 O
the NCT03921970 322 325 O
skin NCT03921970 326 330 O
at NCT03921970 331 333 O
the NCT03921970 334 337 O
site NCT03921970 338 342 O
of NCT03921970 343 345 O
the NCT03921970 346 349 O
needle NCT03921970 350 356 O
puncture NCT03921970 357 365 O

- NCT03921970 368 369 O
Pregnancy NCT03921970 371 380 B-Condition-Name
or NCT03921970 381 383 O
lactation NCT03921970 384 393 B-Condition-Name

- NCT03921970 396 397 O
Patients NCT03921970 399 407 O
who NCT03921970 408 411 O
do NCT03921970 412 414 O
not NCT03921970 415 418 O
accept NCT03921970 419 425 O
the NCT03921970 426 429 O
procedure NCT03921970 430 439 B-Procedure-Name

Inclusion NCT03923829 0 9 O
Criteria NCT03923829 10 18 O
: NCT03923829 19 20 O

- NCT03923829 24 25 O
Controlled NCT03923829 27 37 O
Type NCT03923829 38 42 O
- NCT03923829 43 44 O
2 NCT03923829 46 47 O
diabetes NCT03923829 48 56 B-Condition-Name
mellitus NCT03923829 57 65 I-Condition-Name

- NCT03923829 68 69 O
Stage NCT03923829 71 76 B-Eq-Unit
- NCT03923829 77 78 O
II NCT03923829 79 81 B-Eq-Value
& NCT03923829 82 83 O
III NCT03923829 83 86 B-Eq-Value
periodontitis NCT03923829 87 100 B-Condition-Name

- NCT03923829 103 104 O
At NCT03923829 106 108 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03923829 109 114 I-Eq-Operator___Eq-Operator-Value:GTEQ
2 NCT03923829 116 117 B-Eq-Value
sites NCT03923829 118 123 B-Eq-Unit
with NCT03923829 124 128 O
clinical NCT03923829 129 137 O
attachment NCT03923829 138 148 B-Observation-Name___Observation-Type-Value:measurement
loss NCT03923829 149 153 I-Observation-Name___Observation-Type-Value:measurement
3 NCT03923829 155 156 B-Eq-Value
or NCT03923829 157 159 O
4 NCT03923829 161 162 B-Eq-Value
mm NCT03923829 163 165 B-Eq-Unit
to NCT03923829 166 168 O
≥ NCT03923829 169 170 B-Eq-Operator___Eq-Operator-Value:GTEQ
5 NCT03923829 172 173 B-Eq-Value
mm NCT03923829 174 176 B-Eq-Unit
and NCT03923829 177 180 O
radiographic NCT03923829 181 193 B-Procedure-Name
bone NCT03923829 194 198 B-Observation-Name___Observation-Type-Value:measurement
loss NCT03923829 199 203 I-Observation-Name___Observation-Type-Value:measurement
15 NCT03923829 205 207 B-Eq-Value
% NCT03923829 208 209 B-Eq-Unit
Extending NCT03923829 210 219 O
to NCT03923829 220 222 O
mid NCT03923829 223 226 O
- NCT03923829 227 228 O
third NCT03923829 229 234 O
of NCT03923829 235 237 O
root NCT03923829 238 242 O
and NCT03923829 243 246 O
beyond NCT03923829 247 253 O
. NCT03923829 254 255 O

- NCT03923829 259 260 O
Probing NCT03923829 262 269 B-Observation-Name___Observation-Type-Value:measurement
depth NCT03923829 270 275 I-Observation-Name___Observation-Type-Value:measurement
from NCT03923829 276 280 O
≤ NCT03923829 281 282 B-Eq-Operator___Eq-Operator-Value:LTEQ
5 NCT03923829 284 285 B-Eq-Value
mm NCT03923829 286 288 B-Eq-Unit
to NCT03923829 289 291 B-Eq-Operator___Eq-Operator-Value:BETWEEN
≥ NCT03923829 292 293 B-Eq-Operator___Eq-Operator-Value:GTEQ
6 NCT03923829 295 296 B-Eq-Value
mm NCT03923829 297 299 B-Eq-Unit

Exclusion NCT03923829 300 309 O
Criteria NCT03923829 310 318 O
: NCT03923829 319 320 O

- NCT03923829 324 325 O
Any NCT03923829 327 330 O
periodontal NCT03923829 331 342 B-Procedure-Name
or NCT03923829 343 345 O
Antibiotic NCT03923829 346 356 B-Drug-Name
treatment NCT03923829 357 366 O
during NCT03923829 367 373 O
the NCT03923829 374 377 O
last NCT03923829 378 382 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
six NCT03923829 383 386 B-Eq-Value
months NCT03923829 387 393 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
. NCT03923829 394 395 O

- NCT03923829 399 400 O
Receiving NCT03923829 402 411 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
trace NCT03923829 412 417 B-Drug-Name
element NCT03923829 418 425 I-Drug-Name
supplements NCT03923829 426 437 I-Drug-Name
in NCT03923829 438 440 O
the NCT03923829 441 444 O
previous NCT03923829 445 453 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
three NCT03923829 454 459 B-Eq-Value
months NCT03923829 460 466 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

- NCT03923829 469 470 O
Pregnant NCT03923829 472 480 B-Condition-Name
or NCT03923829 481 483 O
lactating NCT03923829 484 493 B-Condition-Name
females NCT03923829 494 501 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female

- NCT03923829 504 505 O
Gastric NCT03923829 507 514 O
or NCT03923829 515 517 O
diuretic NCT03923829 518 526 O
treatment NCT03923829 527 536 B-Procedure-Name

- NCT03923829 539 540 O
Acute NCT03923829 542 547 B-Severity___Severity-Value:severe
renal NCT03923829 548 553 B-Condition-Name
failure NCT03923829 554 561 I-Condition-Name

- NCT03923829 564 565 O
smoking NCT03923829 567 574 B-Condition-Name

Inclusion NCT03920475 0 9 O
Criteria NCT03920475 10 18 O
: NCT03920475 19 20 O

- NCT03920475 24 25 O
Patients NCT03920475 27 35 O
with NCT03920475 36 40 O
uni NCT03920475 41 44 O
- NCT03920475 45 46 O
or NCT03920475 47 49 O
bipolar NCT03920475 50 57 O
depression NCT03920475 58 68 B-Condition-Name
, NCT03920475 69 70 O
diagnosed NCT03920475 71 80 O
according NCT03920475 81 90 O
to NCT03920475 91 93 O
the NCT03920475 94 97 O
criteria NCT03920475 98 106 O
of NCT03920475 107 109 O
the NCT03920475 110 113 O
DSM NCT03920475 114 117 O
- NCT03920475 118 119 O
IV NCT03920475 120 122 O
via NCT03920475 123 126 O
MINI NCT03920475 127 131 O
6.0 NCT03920475 133 136 O
diagnostic NCT03920475 137 147 O
tool NCT03920475 148 152 O
. NCT03920475 153 154 O

- NCT03920475 158 159 O
At NCT03920475 161 163 O
the NCT03920475 164 167 O
time NCT03920475 168 172 O
of NCT03920475 173 175 O
inclusion NCT03920475 176 185 O
in NCT03920475 186 188 O
the NCT03920475 189 192 O
study NCT03920475 193 198 O
, NCT03920475 199 200 O
the NCT03920475 201 204 O
symptoms NCT03920475 205 213 O
must NCT03920475 214 218 O
meet NCT03920475 219 223 O
at NCT03920475 224 226 O
least NCT03920475 227 232 O
the NCT03920475 233 236 O
requirements NCT03920475 237 249 O
of NCT03920475 250 252 O
a NCT03920475 253 254 O
moderately NCT03920475 255 265 O
severe NCT03920475 266 272 B-Severity___Severity-Value:severe
depression NCT03920475 273 283 B-Condition-Name
, NCT03920475 284 285 O
defined NCT03920475 286 293 O
by NCT03920475 294 296 O
a NCT03920475 297 298 O
minimum NCT03920475 299 306 O
score NCT03920475 307 312 O
of NCT03920475 313 315 O
≥ NCT03920475 316 317 B-Eq-Operator___Eq-Operator-Value:GTEQ
22 NCT03920475 319 321 B-Eq-Value
on NCT03920475 322 324 O
the NCT03920475 325 328 O
Montgomery NCT03920475 329 339 B-Observation-Name___Observation-Type-Value:clinical-score
- NCT03920475 340 341 I-Observation-Name___Observation-Type-Value:clinical-score
Åsberg NCT03920475 342 348 I-Observation-Name___Observation-Type-Value:clinical-score
Depression NCT03920475 349 359 I-Observation-Name___Observation-Type-Value:clinical-score
Scale NCT03920475 360 365 I-Observation-Name___Observation-Type-Value:clinical-score
. NCT03920475 366 367 O

Exclusion NCT03920475 369 378 O
Criteria NCT03920475 379 387 O
: NCT03920475 388 389 O

- NCT03920475 393 394 O
Patients NCT03920475 396 404 O
with NCT03920475 405 409 O
severe NCT03920475 410 416 B-Severity___Severity-Value:severe
somatic NCT03920475 417 424 O
, NCT03920475 425 426 O
rheumatic NCT03920475 427 436 O
, NCT03920475 437 438 O
endocrine NCT03920475 439 448 O
or NCT03920475 449 451 O
neurological NCT03920475 452 464 O
comorbidities NCT03920475 465 478 B-Condition-Name
. NCT03920475 479 480 O
This NCT03920475 482 486 O
includes NCT03920475 487 495 O
in NCT03920475 496 498 O
particular NCT03920475 499 509 O
neurological NCT03920475 510 522 B-Condition-Name
disorders NCT03920475 523 532 I-Condition-Name
associated NCT03920475 533 543 O
with NCT03920475 544 548 O
cognitive NCT03920475 549 558 B-Condition-Name
disorder NCT03920475 559 567 I-Condition-Name
, NCT03920475 568 569 O
severe NCT03920475 570 576 B-Severity___Severity-Value:severe
liver NCT03920475 577 582 O
, NCT03920475 583 584 O
kidney NCT03920475 585 591 O
and NCT03920475 592 595 O
cardiac NCT03920475 596 603 O
diseases NCT03920475 604 612 B-Condition-Name
. NCT03920475 613 614 O

- NCT03920475 618 619 O
Patients NCT03920475 621 629 O
, NCT03920475 630 631 O
who NCT03920475 632 635 O
are NCT03920475 636 639 O
being NCT03920475 640 645 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
treated NCT03920475 646 653 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
permanently NCT03920475 654 665 O
with NCT03920475 666 670 O
anti NCT03920475 671 675 B-Drug-Name
- NCT03920475 676 677 I-Drug-Name
inflammatory NCT03920475 678 690 I-Drug-Name
or NCT03920475 691 693 O
immunosuppressive NCT03920475 694 711 B-Drug-Name
drugs NCT03920475 712 717 I-Drug-Name
( NCT03920475 718 719 O
e NCT03920475 720 721 O
. NCT03920475 722 723 O
g NCT03920475 724 725 O
. NCT03920475 726 727 O
corticosteroids NCT03920475 729 744 B-Drug-Name
or NCT03920475 745 747 O
alpha NCT03920475 748 753 O
/ NCT03920475 754 755 O
beta NCT03920475 756 760 O
- NCT03920475 761 762 O
a NCT03920475 763 764 B-Drug-Name
( NCT03920475 765 766 I-Drug-Name
nta NCT03920475 767 770 I-Drug-Name
) NCT03920475 771 772 I-Drug-Name
gonists NCT03920475 773 780 I-Drug-Name
, NCT03920475 781 782 O
immuno NCT03920475 783 789 B-Drug-Name
suppressant NCT03920475 790 801 I-Drug-Name
drugs NCT03920475 802 807 I-Drug-Name
) NCT03920475 808 809 O
. NCT03920475 811 812 O

- NCT03920475 816 817 O
Patients NCT03920475 819 827 O
with NCT03920475 828 832 O
severe NCT03920475 833 839 B-Severity___Severity-Value:severe
psychiatric NCT03920475 840 851 B-Condition-Name
disorders NCT03920475 852 861 I-Condition-Name
( NCT03920475 862 863 O
Axis NCT03920475 864 868 B-Eq-Unit
I NCT03920475 869 870 B-Eq-Value
) NCT03920475 871 872 O
such NCT03920475 873 877 O
as NCT03920475 878 880 O
schizophrenia NCT03920475 881 894 B-Condition-Name
, NCT03920475 895 896 O
dementia NCT03920475 897 905 B-Condition-Name
, NCT03920475 906 907 O
ADHD NCT03920475 908 912 B-Condition-Name
, NCT03920475 913 914 O
obsessive NCT03920475 915 924 B-Condition-Name
- NCT03920475 925 926 I-Condition-Name
compulsive NCT03920475 927 937 I-Condition-Name
disorder NCT03920475 938 946 I-Condition-Name
, NCT03920475 947 948 O
current NCT03920475 949 956 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
alcohol NCT03920475 957 964 O
, NCT03920475 965 966 O
drugs NCT03920475 967 972 O
or NCT03920475 973 975 O
drug NCT03920475 976 980 O
addiction NCT03920475 981 990 B-Condition-Name
. NCT03920475 991 992 O

- NCT03920475 996 997 O
Patients NCT03920475 999 1007 O
who NCT03920475 1008 1011 O
have NCT03920475 1012 1016 O
already NCT03920475 1017 1024 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
been NCT03920475 1025 1029 O
treated NCT03920475 1030 1037 O
unsuccessfully NCT03920475 1038 1052 O
with NCT03920475 1053 1057 O
sertraline NCT03920475 1058 1068 B-Drug-Name
and NCT03920475 1069 1072 O
all NCT03920475 1073 1076 O
alternate NCT03920475 1077 1086 O
medications NCT03920475 1087 1098 O
allowed NCT03920475 1099 1106 O
in NCT03920475 1107 1109 O
the NCT03920475 1110 1113 O
study NCT03920475 1114 1119 O
. NCT03920475 1120 1121 O

- NCT03920475 1125 1126 O
Pregnant NCT03920475 1128 1136 B-Condition-Name
or NCT03920475 1137 1139 O
lactating NCT03920475 1140 1149 B-Condition-Name
( NCT03920475 1150 1151 O
breast NCT03920475 1152 1158 B-Condition-Name
feeding NCT03920475 1159 1166 I-Condition-Name
) NCT03920475 1167 1168 O
women NCT03920475 1169 1174 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
. NCT03920475 1175 1176 O

Inclusion NCT03925519 0 9 O
Criteria NCT03925519 10 18 O
: NCT03925519 19 20 O

- NCT03925519 24 25 O
patients NCT03925519 27 35 O
with NCT03925519 36 40 O
type NCT03925519 41 45 B-Condition-Name
2 NCT03925519 47 48 I-Condition-Name
diabetes NCT03925519 49 57 I-Condition-Name
for NCT03925519 58 61 O
more NCT03925519 62 66 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03925519 67 71 I-Eq-Operator___Eq-Operator-Value:GT
5 NCT03925519 73 74 B-Eq-Value
years NCT03925519 75 80 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
. NCT03925519 81 82 O

- NCT03925519 86 87 O
Patients NCT03925519 89 97 O
who NCT03925519 98 101 O
were NCT03925519 102 106 O
diagnosed NCT03925519 107 116 O
according NCT03925519 117 126 O
to NCT03925519 127 129 O
the NCT03925519 130 133 O
criteria NCT03925519 134 142 O
of NCT03925519 143 145 O
the NCT03925519 146 149 O
American NCT03925519 150 158 O
diabetes NCT03925519 159 167 O
association NCT03925519 168 179 O
. NCT03925519 180 181 O

- NCT03925519 185 186 O
Not NCT03925519 188 191 O
receiving NCT03925519 192 201 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
any NCT03925519 202 205 O
drugs NCT03925519 206 211 O
affecting NCT03925519 212 221 B-Stability___Stability-Value:change
the NCT03925519 222 225 O
data NCT03925519 226 230 O
obtained NCT03925519 231 239 O

- NCT03925519 242 243 O
had NCT03925519 245 248 O
Normal NCT03925519 249 255 B-Polarity___Polarity-Value:normal
daily NCT03925519 256 261 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
diets NCT03925519 262 267 B-Observation-Name___Observation-Type-Value:social-habit

- NCT03925519 270 271 O
Not NCT03925519 273 276 O
participating NCT03925519 277 290 O
in NCT03925519 291 293 O
any NCT03925519 294 297 O
other NCT03925519 298 303 O
exercise NCT03925519 304 312 B-Procedure-Name
programs NCT03925519 313 321 I-Procedure-Name

- NCT03925519 324 325 O
Without NCT03925519 327 334 O
any NCT03925519 335 338 O
musculoskeletal NCT03925519 339 354 B-Condition-Name
disorders NCT03925519 355 364 I-Condition-Name
affecting NCT03925519 365 374 B-Stability___Stability-Value:change
an NCT03925519 375 377 O
exercise NCT03925519 378 386 B-Procedure-Name
program NCT03925519 387 394 I-Procedure-Name

Exclusion NCT03925519 395 404 O
Criteria NCT03925519 405 413 O
: NCT03925519 414 415 O

- NCT03925519 419 420 O
Exclusion NCT03925519 422 431 O
criteria NCT03925519 432 440 O
included NCT03925519 441 449 O
anemia NCT03925519 450 456 B-Condition-Name
, NCT03925519 457 458 O
overt NCT03925519 459 464 O
complications NCT03925519 465 478 O
of NCT03925519 479 481 O
diabetes NCT03925519 482 490 B-Condition-Name
like NCT03925519 491 495 O
nephropathy NCT03925519 496 507 B-Condition-Name
, NCT03925519 508 509 O
neuropathy NCT03925519 510 520 B-Condition-Name
, NCT03925519 521 522 O
retinopathy NCT03925519 523 534 B-Condition-Name
, NCT03925519 535 536 O
obvious NCT03925519 537 544 O
ischemic NCT03925519 545 553 B-Condition-Name
heart NCT03925519 554 559 I-Condition-Name
disease NCT03925519 560 567 I-Condition-Name
( NCT03925519 568 569 O
angina NCT03925519 570 576 B-Condition-Name
, NCT03925519 577 578 O
myocardial NCT03925519 579 589 B-Condition-Name
infarction NCT03925519 590 600 I-Condition-Name
, NCT03925519 601 602 O
and NCT03925519 603 606 O
lead NCT03925519 607 611 B-Procedure-Name
electrocardiogram NCT03925519 612 629 I-Procedure-Name
abnormalities NCT03925519 630 643 B-Polarity___Polarity-Value:abnormal
) NCT03925519 644 645 O
, NCT03925519 647 648 O
HCV NCT03925519 649 652 B-Condition-Name
, NCT03925519 653 654 O
HBV NCT03925519 655 658 B-Condition-Name
, NCT03925519 659 660 O
chronic NCT03925519 661 668 O
liver NCT03925519 669 674 O
and NCT03925519 675 678 O
kidney NCT03925519 679 685 O
diseases NCT03925519 686 694 B-Condition-Name
, NCT03925519 695 696 O
hypothyroidism NCT03925519 697 711 B-Condition-Name
, NCT03925519 712 713 O
and NCT03925519 714 717 O
drugs NCT03925519 718 723 O
( NCT03925519 724 725 O
diuretics NCT03925519 726 735 B-Drug-Name
; NCT03925519 735 736 O
oral NCT03925519 737 741 B-Drug-Name
contraceptives NCT03925519 742 756 I-Drug-Name
) NCT03925519 757 758 O
. NCT03925519 760 761 O

Inclusion NCT03927326 0 9 O
Criteria NCT03927326 10 18 O
: NCT03927326 19 20 O

- NCT03927326 24 25 O
Patients NCT03927326 27 35 O
scheduled NCT03927326 36 45 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
for NCT03927326 46 49 O
elective NCT03927326 50 58 O
laparoscopic NCT03927326 59 71 B-Procedure-Name
colorectal NCT03927326 72 82 I-Procedure-Name
surgery NCT03927326 83 90 I-Procedure-Name
at NCT03927326 91 93 O
UWMC NCT03927326 94 98 B-Location___Location-Value:hospital
requiring NCT03927326 99 108 O
inpatient NCT03927326 109 118 B-Encounter-Type___Encounter-Type-Value:inpatient
stay NCT03927326 119 123 I-Encounter-Type___Encounter-Type-Value:inpatient

Exclusion NCT03927326 124 133 O
Criteria NCT03927326 134 142 O
: NCT03927326 143 144 O

- NCT03927326 148 149 O
Patients NCT03927326 151 159 O
on NCT03927326 160 162 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
chronic NCT03927326 163 170 O
pain NCT03927326 171 175 B-Condition-Name
mediations NCT03927326 176 186 O
equaling NCT03927326 187 195 B-Eq-Operator___Eq-Operator-Value:GTEQ
or NCT03927326 196 198 I-Eq-Operator___Eq-Operator-Value:GTEQ
exceeding NCT03927326 199 208 I-Eq-Operator___Eq-Operator-Value:GTEQ
> NCT03927326 209 210 B-Eq-Operator___Eq-Operator-Value:GT
25 NCT03927326 212 214 B-Eq-Value
morphine NCT03927326 215 223 B-Eq-Unit
daily NCT03927326 224 229 I-Eq-Unit
equivalents NCT03927326 230 241 I-Eq-Unit

- NCT03927326 244 245 O
Patients NCT03927326 247 255 O
allergic NCT03927326 256 264 O
to NCT03927326 265 267 O
bupivacaine NCT03927326 268 279 B-Drug-Name

- NCT03927326 282 283 O
Patients NCT03927326 285 293 O
with NCT03927326 294 298 O
ASA NCT03927326 299 302 B-Condition-Name
status NCT03927326 303 309 O
IV NCT03927326 310 312 B-Eq-Value
, NCT03927326 313 314 O
V NCT03927326 315 316 B-Eq-Value
, NCT03927326 317 318 O
or NCT03927326 319 321 O
VI NCT03927326 322 324 B-Eq-Value

- NCT03927326 327 328 O
Patients NCT03927326 330 338 O
unable NCT03927326 339 345 O
to NCT03927326 346 348 O
consent NCT03927326 349 356 O

- NCT03927326 359 360 O
Patients NCT03927326 362 370 O
that NCT03927326 371 375 O
are NCT03927326 376 379 O
pregnant NCT03927326 380 388 B-Condition-Name

- NCT03927326 391 392 O
Patients NCT03927326 394 402 O
that NCT03927326 403 407 O
are NCT03927326 408 411 O
incarcerated NCT03927326 412 424 B-Observation-Name

- NCT03927326 427 428 O
Patients NCT03927326 430 438 O
receiving NCT03927326 439 448 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
procedures NCT03927326 449 459 O
in NCT03927326 460 462 O
addition NCT03927326 463 471 O
to NCT03927326 472 474 O
laparoscopic NCT03927326 475 487 B-Procedure-Name
colorectal NCT03927326 488 498 I-Procedure-Name
procedure NCT03927326 499 508 I-Procedure-Name

- NCT03927326 511 512 O
Patients NCT03927326 514 522 O
on NCT03927326 523 525 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
systemic NCT03927326 526 534 O
anticoagulation NCT03927326 535 550 B-Procedure-Name
precluding NCT03927326 551 561 O
them NCT03927326 562 566 O
from NCT03927326 567 571 O
regional NCT03927326 572 580 B-Procedure-Name
blocks NCT03927326 581 587 I-Procedure-Name

Inclusion NCT03928015 0 9 O
Criteria NCT03928015 10 18 O
: NCT03928015 19 20 O

1 NCT03928015 25 26 O
. NCT03928015 26 27 O
Male NCT03928015 29 33 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
or NCT03928015 34 36 O
female NCT03928015 37 43 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
, NCT03928015 44 45 O
18 NCT03928015 47 49 B-Eq-Value
years NCT03928015 50 55 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
to NCT03928015 56 58 B-Eq-Operator___Eq-Operator-Value:BETWEEN
65 NCT03928015 60 62 B-Eq-Value
years NCT03928015 63 68 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03928015 69 72 O
( NCT03928015 73 74 O
inclusive NCT03928015 75 84 O
) NCT03928015 85 86 O

2 NCT03928015 91 92 O
. NCT03928015 92 93 O
Index NCT03928015 95 100 O
admission NCT03928015 101 110 B-Encounter-Type___Encounter-Type-Value:inpatient
for NCT03928015 111 114 O
traumatic NCT03928015 115 124 B-Condition-Name
injury NCT03928015 125 131 I-Condition-Name

3 NCT03928015 135 136 O
. NCT03928015 136 137 O
High NCT03928015 139 143 B-Polarity___Polarity-Value:high
initial NCT03928015 144 151 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
morphine NCT03928015 152 160 B-Drug-Name
equivalent NCT03928015 161 171 O
use NCT03928015 172 175 O
≥ NCT03928015 176 177 B-Eq-Operator___Eq-Operator-Value:GTEQ
90 NCT03928015 179 181 B-Eq-Value
mg NCT03928015 182 184 B-Eq-Unit
in NCT03928015 185 187 O
the NCT03928015 188 191 O
first NCT03928015 192 197 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
24 NCT03928015 199 201 B-Eq-Value
hours NCT03928015 202 207 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:hour
from NCT03928015 208 212 O
admission NCT03928015 213 222 B-Encounter-Type___Encounter-Type-Value:inpatient

4 NCT03928015 226 227 O
. NCT03928015 227 228 O
Baseline NCT03928015 230 238 O
pain NCT03928015 239 243 B-Condition-Name
assessed NCT03928015 244 252 O
at NCT03928015 253 255 O
screening NCT03928015 256 265 B-Procedure-Name
of NCT03928015 266 268 O
≥ NCT03928015 269 270 B-Eq-Operator___Eq-Operator-Value:GTEQ
5 NCT03928015 272 273 B-Eq-Value
on NCT03928015 274 276 O
the NCT03928015 277 280 O
pain NCT03928015 281 285 B-Observation-Name___Observation-Type-Value:clinical-score
numeric NCT03928015 286 293 I-Observation-Name___Observation-Type-Value:clinical-score
rating NCT03928015 294 300 I-Observation-Name___Observation-Type-Value:clinical-score
score NCT03928015 301 306 I-Observation-Name___Observation-Type-Value:clinical-score
( NCT03928015 307 308 O
NRS NCT03928015 309 312 B-Observation-Name
) NCT03928015 313 314 O

5 NCT03928015 319 320 O
. NCT03928015 320 321 O
Willing NCT03928015 323 330 O
to NCT03928015 331 333 O
divulge NCT03928015 334 341 O
habitual NCT03928015 342 350 O
marijuana NCT03928015 351 360 B-Condition-Name
usage NCT03928015 361 366 O
( NCT03928015 367 368 O
yes NCT03928015 369 372 O
or NCT03928015 373 375 O
no NCT03928015 376 378 O
. NCT03928015 379 380 O
Yes NCT03928015 382 385 O
, NCT03928015 386 387 O
habitual NCT03928015 388 396 O
/ NCT03928015 397 398 O
chronic NCT03928015 399 406 O
usage NCT03928015 407 412 O
; NCT03928015 412 413 O
no NCT03928015 414 416 O
, NCT03928015 417 418 O
recreational NCT03928015 419 431 O
, NCT03928015 432 433 O
former NCT03928015 434 440 O
, NCT03928015 441 442 O
or NCT03928015 443 445 O
never NCT03928015 446 451 O
usage NCT03928015 452 457 O
) NCT03928015 458 459 O

Exclusion NCT03928015 465 474 O
Criteria NCT03928015 475 483 O
: NCT03928015 484 485 O

1 NCT03928015 490 491 O
. NCT03928015 491 492 O
Patients NCT03928015 494 502 O
on NCT03928015 503 505 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
a NCT03928015 506 507 O
pain NCT03928015 508 512 B-Procedure-Name
management NCT03928015 513 523 I-Procedure-Name
agreement NCT03928015 524 533 O

2 NCT03928015 537 538 O
. NCT03928015 538 539 O
Patients NCT03928015 541 549 O
who NCT03928015 550 553 O
are NCT03928015 554 557 O
nil NCT03928015 558 561 B-Procedure-Name
per NCT03928015 562 565 I-Procedure-Name
os NCT03928015 566 568 I-Procedure-Name
( NCT03928015 569 570 O
NPO NCT03928015 571 574 B-Procedure-Name
) NCT03928015 575 576 O
at NCT03928015 577 579 O
the NCT03928015 580 583 O
time NCT03928015 584 588 O
of NCT03928015 589 591 O
randomization NCT03928015 592 605 O
or NCT03928015 606 608 O
are NCT03928015 609 612 O
expected NCT03928015 613 621 O
to NCT03928015 622 624 O
be NCT03928015 625 627 O
NPO NCT03928015 628 631 B-Procedure-Name
within NCT03928015 632 638 B-Eq-Operator___Eq-Operator-Value:LTEQ
the NCT03928015 639 642 O
next NCT03928015 643 647 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
48 NCT03928015 649 651 B-Eq-Value
hours NCT03928015 652 657 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:hour

3 NCT03928015 661 662 O
. NCT03928015 662 663 O
Patients NCT03928015 665 673 O
who NCT03928015 674 677 O
have NCT03928015 678 682 O
received NCT03928015 683 691 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
or NCT03928015 692 694 O
are NCT03928015 695 698 O
expected NCT03928015 699 707 O
to NCT03928015 708 710 O
receive NCT03928015 711 718 O
neuraxial NCT03928015 719 728 O
/ NCT03928015 729 730 O
locoregional NCT03928015 731 743 O
blocks NCT03928015 744 750 B-Drug-Name
for NCT03928015 751 754 O
pain NCT03928015 755 759 B-Condition-Name
within NCT03928015 760 766 B-Eq-Operator___Eq-Operator-Value:LTEQ
the NCT03928015 767 770 O
next NCT03928015 771 775 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
48 NCT03928015 777 779 B-Eq-Value
hours NCT03928015 780 785 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:hour

4 NCT03928015 789 790 O
. NCT03928015 790 791 O
Known NCT03928015 793 798 O
allergy NCT03928015 799 806 O
or NCT03928015 807 809 O
previous NCT03928015 810 818 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
hypersensitivity NCT03928015 819 835 B-Condition-Name
reaction NCT03928015 836 844 O
to NCT03928015 845 847 O
dronabinol NCT03928015 848 858 B-Drug-Name
or NCT03928015 859 861 O
sesame NCT03928015 862 868 B-Drug-Name
oil NCT03928015 869 872 I-Drug-Name

5 NCT03928015 876 877 O
. NCT03928015 877 878 O
Patients NCT03928015 880 888 O
prescribed NCT03928015 889 899 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
dronabinol NCT03928015 900 910 B-Drug-Name
between NCT03928015 911 918 O
arrival NCT03928015 919 926 B-Encounter-Type___Encounter-Type-Value:inpatient
and NCT03928015 927 930 O
prior NCT03928015 931 936 O
to NCT03928015 937 939 O
screening NCT03928015 940 949 O
/ NCT03928015 950 951 O
randomization NCT03928015 952 965 O

6 NCT03928015 969 970 O
. NCT03928015 970 971 O
Pregnancy NCT03928015 973 982 B-Condition-Name
or NCT03928015 983 985 O
breast NCT03928015 986 992 B-Condition-Name
feeding NCT03928015 993 1000 I-Condition-Name

7 NCT03928015 1004 1005 O
. NCT03928015 1005 1006 O
Incarceration NCT03928015 1008 1021 B-Observation-Name


Inclusion NCT03920449 0 9 O
Criteria NCT03920449 10 18 O
: NCT03920449 19 20 O

- NCT03920449 24 25 O
Chronic NCT03920449 27 34 O
anal NCT03920449 35 39 B-Condition-Name
fissure NCT03920449 40 47 I-Condition-Name
lasting NCT03920449 48 55 O
more NCT03920449 56 60 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03920449 61 65 I-Eq-Operator___Eq-Operator-Value:GT
6 NCT03920449 67 68 B-Eq-Value
weeks NCT03920449 69 74 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week

Exclusion NCT03920449 75 84 O
Criteria NCT03920449 85 93 O
: NCT03920449 94 95 O

- NCT03920449 99 100 O
Pregnant NCT03920449 102 110 B-Condition-Name

- NCT03920449 113 114 O
cardiovascular NCT03920449 116 130 B-Condition-Name
disease NCT03920449 131 138 I-Condition-Name
or NCT03920449 139 141 O
heart NCT03920449 142 147 B-Condition-Name
failure NCT03920449 148 155 I-Condition-Name

- NCT03920449 158 159 O
on NCT03920449 161 163 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
antihypertensive NCT03920449 164 180 B-Drug-Name
medications NCT03920449 181 192 I-Drug-Name

- NCT03920449 195 196 O
recurrent NCT03920449 198 207 O
anal NCT03920449 208 212 B-Condition-Name
fissure NCT03920449 213 220 I-Condition-Name
after NCT03920449 221 226 O
previous NCT03920449 227 235 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
sphincterotomy NCT03920449 236 250 B-Procedure-Name

- NCT03920449 253 254 O
prior NCT03920449 256 261 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
history NCT03920449 262 269 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03920449 270 272 O
anal NCT03920449 273 277 O
surgery NCT03920449 278 285 B-Procedure-Name

- NCT03920449 288 289 O
other NCT03920449 291 296 O
benign NCT03920449 297 303 O
anorectal NCT03920449 304 313 B-Condition-Name
diseases NCT03920449 314 322 I-Condition-Name

- NCT03920449 325 326 O
with NCT03920449 328 332 O
inflammatory NCT03920449 333 345 B-Condition-Name
bowel NCT03920449 346 351 I-Condition-Name
diseases NCT03920449 352 360 I-Condition-Name

Inclusion NCT03923140 0 9 O
Criteria NCT03923140 10 18 O
: NCT03923140 19 20 O

- NCT03923140 24 25 O
All NCT03923140 27 30 O
patients NCT03923140 31 39 O
must NCT03923140 40 44 O
meet NCT03923140 45 49 O
the NCT03923140 50 53 O
following NCT03923140 54 63 O
diagnostic NCT03923140 64 74 O
criteria NCT03923140 75 83 O
of NCT03923140 84 86 O
CAPS NCT03923140 87 91 B-Condition-Name
and NCT03923140 92 95 O
have NCT03923140 96 100 O
pathogenic NCT03923140 101 111 B-Condition-Name
mutation NCT03923140 112 120 I-Condition-Name
( NCT03923140 121 122 I-Condition-Name
s NCT03923140 123 124 I-Condition-Name
) NCT03923140 125 126 I-Condition-Name
in NCT03923140 127 129 O
NLRP NCT03923140 130 134 O
3 NCT03923140 135 136 O
gene NCT03923140 137 141 O
. NCT03923140 142 143 O

1 NCT03923140 153 154 O
. NCT03923140 154 155 O
Raised NCT03923140 157 163 B-Condition-Name
inflammatory NCT03923140 164 176 I-Condition-Name
markers NCT03923140 177 184 I-Condition-Name
( NCT03923140 185 186 O
CRP NCT03923140 187 190 B-Condition-Name
/ NCT03923140 191 192 O
SAA NCT03923140 193 196 B-Condition-Name
) NCT03923140 197 198 O
( NCT03923140 199 200 O
mandatory NCT03923140 201 210 O
criteria NCT03923140 211 219 O
) NCT03923140 220 221 O

2 NCT03923140 231 232 O
. NCT03923140 232 233 O
≥ NCT03923140 235 236 B-Eq-Operator___Eq-Operator-Value:GTEQ
2 NCT03923140 238 239 B-Eq-Value
of NCT03923140 240 242 O
6 NCT03923140 244 245 B-Eq-Value
CAPS NCT03923140 246 250 B-Condition-Name
typical NCT03923140 251 258 O
signs NCT03923140 259 264 O
/ NCT03923140 265 266 O
symptoms NCT03923140 267 275 O
: NCT03923140 276 277 O

1 NCT03923140 292 293 O
. NCT03923140 293 294 O
Urticaria NCT03923140 296 305 B-Condition-Name
- NCT03923140 306 307 I-Condition-Name
like NCT03923140 308 312 I-Condition-Name
rash NCT03923140 313 317 I-Condition-Name
; NCT03923140 317 318 O

2 NCT03923140 332 333 O
. NCT03923140 333 334 O
Cold NCT03923140 336 340 B-Condition-Name
/ NCT03923140 341 342 O
stress NCT03923140 343 349 B-Condition-Name
triggered NCT03923140 350 359 O
episodes NCT03923140 360 368 O
; NCT03923140 368 369 O

3 NCT03923140 383 384 O
. NCT03923140 384 385 O
Sensorineural NCT03923140 387 400 B-Condition-Name
hearing NCT03923140 401 408 I-Condition-Name
loss NCT03923140 409 413 I-Condition-Name
; NCT03923140 413 414 O

4 NCT03923140 428 429 O
. NCT03923140 429 430 O
Musculoskeletal NCT03923140 432 447 B-Condition-Name
symptoms NCT03923140 448 456 O
( NCT03923140 457 458 O
arthralgia NCT03923140 459 469 B-Condition-Name
/ NCT03923140 470 471 O
arthritis NCT03923140 472 481 B-Condition-Name
/ NCT03923140 482 483 O
myalgia NCT03923140 484 491 B-Condition-Name
) NCT03923140 492 493 O
; NCT03923140 494 495 O

5 NCT03923140 509 510 O
. NCT03923140 510 511 O
Chronic NCT03923140 513 520 O
aseptic NCT03923140 521 528 B-Condition-Name
meningitis NCT03923140 529 539 I-Condition-Name
; NCT03923140 539 540 O

6 NCT03923140 554 555 O
. NCT03923140 555 556 O
Skeletal NCT03923140 558 566 O
abnormalities NCT03923140 567 580 B-Condition-Name
( NCT03923140 581 582 O
epiphyseal NCT03923140 583 593 B-Condition-Name
overgrowth NCT03923140 594 604 I-Condition-Name
/ NCT03923140 605 606 O
frontal NCT03923140 607 614 B-Condition-Name
bossing NCT03923140 615 622 I-Condition-Name
) NCT03923140 623 624 O
. NCT03923140 626 627 O

Exclusion NCT03923140 629 638 O
Criteria NCT03923140 639 647 O
: NCT03923140 648 649 O

- NCT03923140 653 654 O
Patients NCT03923140 656 664 O
will NCT03923140 665 669 O
not NCT03923140 670 673 O
be NCT03923140 674 676 O
included NCT03923140 677 685 O
if NCT03923140 686 688 O
meets NCT03923140 689 694 O
any NCT03923140 695 698 O
of NCT03923140 699 701 O
the NCT03923140 702 705 O
following NCT03923140 706 715 O
criteria NCT03923140 716 724 O
: NCT03923140 725 726 O

1 NCT03923140 736 737 O
. NCT03923140 737 738 O
Being NCT03923140 740 745 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
treated NCT03923140 746 753 O
with NCT03923140 754 758 O
IL NCT03923140 759 761 B-Drug-Name
- NCT03923140 762 763 I-Drug-Name
1 NCT03923140 765 766 I-Drug-Name
inhibitor NCT03923140 767 776 I-Drug-Name
, NCT03923140 777 778 O
other NCT03923140 779 784 O
biological NCT03923140 785 795 B-Drug-Name
agents NCT03923140 796 802 I-Drug-Name
and NCT03923140 803 806 O
immunosuppressants NCT03923140 807 825 B-Drug-Name

2 NCT03923140 834 835 O
. NCT03923140 835 836 O
Pregnant NCT03923140 838 846 B-Condition-Name
and NCT03923140 847 850 O
lactating NCT03923140 851 860 B-Condition-Name
women NCT03923140 861 866 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female

3 NCT03923140 875 876 O
. NCT03923140 876 877 O
Serious NCT03923140 879 886 B-Severity___Severity-Value:severe
organ NCT03923140 887 892 B-Condition-Name
function NCT03923140 893 901 I-Condition-Name
failure NCT03923140 902 909 I-Condition-Name
, NCT03923140 910 911 O
expected NCT03923140 912 920 B-Observation-Name
life NCT03923140 921 925 I-Observation-Name
time NCT03923140 926 930 I-Observation-Name
less NCT03923140 931 935 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03923140 936 940 I-Eq-Operator___Eq-Operator-Value:LT
6 NCT03923140 942 943 B-Eq-Value
months NCT03923140 944 950 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

Inclusion NCT03929848 0 9 O
Criteria NCT03929848 10 18 O
: NCT03929848 19 20 O

- NCT03929848 24 25 O
patients NCT03929848 27 35 O
who NCT03929848 36 39 O
is NCT03929848 40 42 O
scheduled NCT03929848 43 52 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
for NCT03929848 53 56 O
laryngomicrosurgery NCT03929848 57 76 B-Procedure-Name
due NCT03929848 77 80 O
to NCT03929848 81 83 O
simple NCT03929848 84 90 O
vocal NCT03929848 91 96 O
cord NCT03929848 97 101 O
cyst NCT03929848 102 106 B-Condition-Name
or NCT03929848 107 109 O
nodule NCT03929848 110 116 B-Condition-Name

Exclusion NCT03929848 117 126 O
Criteria NCT03929848 127 135 O
: NCT03929848 136 137 O

- NCT03929848 141 142 O
Who NCT03929848 144 147 O
does NCT03929848 148 152 O
n't NCT03929848 152 155 O
agree NCT03929848 156 161 O
to NCT03929848 162 164 O
enroll NCT03929848 165 171 O

- NCT03929848 174 175 O
do NCT03929848 177 179 O
not NCT03929848 180 183 O
use NCT03929848 184 187 O
a NCT03929848 188 189 O
reinforced NCT03929848 190 200 B-Procedure-Name
tracheal NCT03929848 201 209 I-Procedure-Name
tube NCT03929848 210 214 I-Procedure-Name
of NCT03929848 215 217 O
internal NCT03929848 218 226 B-Observation-Name___Observation-Type-Value:measurement
diameter NCT03929848 227 235 I-Observation-Name___Observation-Type-Value:measurement
of NCT03929848 236 238 O
5.5 NCT03929848 240 243 B-Eq-Value
mm NCT03929848 244 246 B-Eq-Unit
for NCT03929848 247 250 O
male NCT03929848 251 255 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
patient NCT03929848 256 263 O

- NCT03929848 266 267 O
do NCT03929848 269 271 O
not NCT03929848 272 275 O
use NCT03929848 276 279 O
a NCT03929848 280 281 O
reinforced NCT03929848 282 292 B-Procedure-Name
tracheal NCT03929848 293 301 I-Procedure-Name
tube NCT03929848 302 306 I-Procedure-Name
of NCT03929848 307 309 O
internal NCT03929848 310 318 B-Observation-Name___Observation-Type-Value:measurement
diameter NCT03929848 319 327 I-Observation-Name___Observation-Type-Value:measurement
of NCT03929848 328 330 O
5.0 NCT03929848 332 335 B-Eq-Value
mm NCT03929848 336 338 B-Eq-Unit
for NCT03929848 339 342 O
female NCT03929848 343 349 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
patient NCT03929848 350 357 O

Inclusion NCT03920878 0 9 O
Criteria NCT03920878 10 18 O
: NCT03920878 19 20 O

- NCT03920878 24 25 O
Adults NCT03920878 27 33 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
over NCT03920878 34 38 B-Eq-Operator___Eq-Operator-Value:GT
age NCT03920878 39 42 O
18 NCT03920878 44 46 B-Eq-Value
with NCT03920878 47 51 O
diabetes NCT03920878 52 60 B-Condition-Name
mellitus NCT03920878 61 69 I-Condition-Name
, NCT03920878 70 71 O
diabetic NCT03920878 72 80 B-Condition-Name
macular NCT03920878 81 88 I-Condition-Name
edema NCT03920878 89 94 I-Condition-Name
and NCT03920878 95 98 O
visually NCT03920878 99 107 O
significant NCT03920878 108 119 B-Severity___Severity-Value:severe
cataracts NCT03920878 120 129 B-Condition-Name
planning NCT03920878 130 138 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
to NCT03920878 139 141 O
undergo NCT03920878 142 149 O
cataract NCT03920878 150 158 B-Procedure-Name
surgery NCT03920878 159 166 I-Procedure-Name

Exclusion NCT03920878 167 176 O
Criteria NCT03920878 177 185 O
: NCT03920878 186 187 O

- NCT03920878 191 192 O
Patients NCT03920878 194 202 O
who NCT03920878 203 206 O
have NCT03920878 207 211 O
undergone NCT03920878 212 221 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
panretinal NCT03920878 222 232 B-Procedure-Name
photocoagulation NCT03920878 233 249 I-Procedure-Name
( NCT03920878 250 251 O
PRP NCT03920878 252 255 B-Procedure-Name
) NCT03920878 256 257 O
in NCT03920878 258 260 O
prior NCT03920878 261 266 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
4 NCT03920878 268 269 B-Eq-Value
months NCT03920878 270 276 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
or NCT03920878 277 279 O
an NCT03920878 280 282 O
ocular NCT03920878 283 289 B-Condition-Name
condition NCT03920878 290 299 I-Condition-Name
( NCT03920878 300 301 O
other NCT03920878 302 307 O
than NCT03920878 308 312 O
cataract NCT03920878 313 321 B-Condition-Name
and NCT03920878 322 325 O
DME NCT03920878 326 329 B-Condition-Name
) NCT03920878 330 331 O
that NCT03920878 332 336 O
might NCT03920878 337 342 O
affect NCT03920878 343 349 B-Stability___Stability-Value:change
visual NCT03920878 350 356 B-Condition-Name
acuity NCT03920878 357 363 I-Condition-Name
during NCT03920878 364 370 O
course NCT03920878 371 377 O
of NCT03920878 378 380 O
study NCT03920878 381 386 O
. NCT03920878 387 388 O

- NCT03920878 392 393 O
Patients NCT03920878 395 403 O
with NCT03920878 404 408 O
history NCT03920878 409 416 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03920878 417 419 O
vitrectomy NCT03920878 420 430 B-Condition-Name
. NCT03920878 431 432 O

- NCT03920878 436 437 O
Patients NCT03920878 439 447 O
with NCT03920878 448 452 O
neovascular NCT03920878 453 464 B-Condition-Name
glaucoma NCT03920878 465 473 I-Condition-Name
. NCT03920878 474 475 O

Inclusion NCT03929874 0 9 O
Criteria NCT03929874 10 18 O
: NCT03929874 19 20 O

- NCT03929874 24 25 O
Patients NCT03929874 27 35 O
under NCT03929874 36 41 B-Eq-Operator___Eq-Operator-Value:LT
40 NCT03929874 43 45 B-Eq-Value
or NCT03929874 46 48 O
over NCT03929874 49 53 B-Eq-Operator___Eq-Operator-Value:GT
60 NCT03929874 55 57 B-Eq-Value
years NCT03929874 58 63 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03929874 64 66 O
age NCT03929874 67 70 O
who NCT03929874 71 74 O
require NCT03929874 75 82 O
spinal NCT03929874 83 89 B-Procedure-Name
anesthesia NCT03929874 90 100 I-Procedure-Name
for NCT03929874 101 104 O
orthopedic NCT03929874 105 115 B-Procedure-Name
surgery NCT03929874 116 123 I-Procedure-Name
, NCT03929874 124 125 O

- NCT03929874 129 130 O
with NCT03929874 132 136 O
ASA NCT03929874 137 140 B-Condition-Name
physical NCT03929874 141 149 O
status NCT03929874 150 156 O
classification NCT03929874 157 171 O
system NCT03929874 172 178 O
I NCT03929874 179 180 B-Eq-Value
, NCT03929874 181 182 O
II NCT03929874 183 185 B-Eq-Value
, NCT03929874 186 187 O
III NCT03929874 188 191 B-Eq-Value

Exclusion NCT03929874 192 201 O
Criteria NCT03929874 202 210 O
: NCT03929874 211 212 O

- NCT03929874 216 217 O
Patients NCT03929874 219 227 O
with NCT03929874 228 232 O
contraindication NCT03929874 233 249 O
to NCT03929874 250 252 O
spinal NCT03929874 253 259 B-Procedure-Name
anesthesia NCT03929874 260 270 I-Procedure-Name
( NCT03929874 271 272 O
coagulopathy NCT03929874 273 285 B-Condition-Name
, NCT03929874 286 287 O
local NCT03929874 288 293 O
infection NCT03929874 294 303 B-Condition-Name
, NCT03929874 304 305 O
allergy NCT03929874 306 313 O
to NCT03929874 314 316 O
local NCT03929874 317 322 B-Procedure-Name
anesthetic NCT03929874 323 333 I-Procedure-Name
) NCT03929874 334 335 O

- NCT03929874 339 340 O
Patients NCT03929874 342 350 O
with NCT03929874 351 355 O
communication NCT03929874 356 369 B-Condition-Name
difficulties NCT03929874 370 382 I-Condition-Name

- NCT03929874 385 386 O
Patient NCT03929874 388 395 O
who NCT03929874 396 399 O
can NCT03929874 400 403 O
not NCT03929874 404 407 O
take NCT03929874 408 412 O
a NCT03929874 413 414 O
sitting NCT03929874 415 422 O
or NCT03929874 423 425 O
lateral NCT03929874 426 433 O
decubitus NCT03929874 434 443 O
position NCT03929874 444 452 B-Condition-Name
( NCT03929874 453 454 O
fracture NCT03929874 455 463 B-Condition-Name
) NCT03929874 464 465 O

- NCT03929874 469 470 O
Patients NCT03929874 472 480 O
with NCT03929874 481 485 O
a NCT03929874 486 487 O
history NCT03929874 488 495 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03929874 496 498 O
spinal NCT03929874 499 505 B-Procedure-Name
surgery NCT03929874 506 513 I-Procedure-Name

- NCT03929874 516 517 O
Patient NCT03929874 519 526 O
with NCT03929874 527 531 O
anatomical NCT03929874 532 542 B-Condition-Name
abnormality NCT03929874 543 554 I-Condition-Name
of NCT03929874 555 557 O
the NCT03929874 558 561 O
spine NCT03929874 562 567 O

Inclusion NCT03927859 0 9 O
Criteria NCT03927859 10 18 O
: NCT03927859 19 20 O

Only NCT03927859 22 26 O
patients NCT03927859 27 35 O
diagnosed NCT03927859 36 45 O
with NCT03927859 46 50 O
Type NCT03927859 51 55 O
I NCT03927859 56 57 O
or NCT03927859 58 60 O
Type NCT03927859 61 65 O
II NCT03927859 66 68 O
Diabetes NCT03927859 69 77 B-Condition-Name
with NCT03927859 78 82 O
no NCT03927859 83 85 O
evidence NCT03927859 86 94 O
in NCT03927859 95 97 O
their NCT03927859 98 103 O
medical NCT03927859 104 111 O
records NCT03927859 112 119 O
of NCT03927859 120 122 O
a NCT03927859 123 124 O
screening NCT03927859 125 134 B-Procedure-Name
within NCT03927859 135 141 B-Eq-Operator___Eq-Operator-Value:LTEQ
the NCT03927859 142 145 O
last NCT03927859 146 150 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
2 NCT03927859 152 153 B-Eq-Value
years NCT03927859 154 159 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
will NCT03927859 160 164 O
be NCT03927859 165 167 O
included NCT03927859 168 176 O
in NCT03927859 177 179 O
the NCT03927859 180 183 O
study NCT03927859 184 189 O
and NCT03927859 190 193 O
only NCT03927859 194 198 O
individuals NCT03927859 199 210 O
18 NCT03927859 212 214 B-Eq-Value
years NCT03927859 215 220 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03927859 221 223 O
age NCT03927859 224 227 O
or NCT03927859 228 230 B-Eq-Operator___Eq-Operator-Value:GTEQ
older NCT03927859 231 236 I-Eq-Operator___Eq-Operator-Value:GTEQ
will NCT03927859 237 241 O
be NCT03927859 242 244 O
included NCT03927859 245 253 O
. NCT03927859 254 255 O

Exclusion NCT03927859 257 266 O
Criteria NCT03927859 267 275 O
: NCT03927859 276 277 O

Patients NCT03927859 279 287 O
screened NCT03927859 288 296 B-Procedure-Name
within NCT03927859 297 303 B-Eq-Operator___Eq-Operator-Value:LTEQ
the NCT03927859 304 307 O
last NCT03927859 308 312 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
year NCT03927859 313 317 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
. NCT03927859 318 319 O
In NCT03927859 321 323 O
addition NCT03927859 324 332 O
, NCT03927859 333 334 O
individuals NCT03927859 335 346 O
who NCT03927859 347 350 O
can NCT03927859 351 354 O
not NCT03927859 354 357 O
speak NCT03927859 358 363 O
English NCT03927859 364 371 B-Language
will NCT03927859 372 376 O
be NCT03927859 377 379 O
excluded NCT03927859 380 388 O
from NCT03927859 389 393 O
the NCT03927859 394 397 O
study NCT03927859 398 403 O
to NCT03927859 404 406 O
minimize NCT03927859 407 415 O
additional NCT03927859 416 426 O
workload NCT03927859 427 435 O
placed NCT03927859 436 442 O
on NCT03927859 443 445 O
administrative NCT03927859 446 460 O
staff NCT03927859 461 466 O
. NCT03927859 467 468 O


Inclusion NCT03929653 0 9 O
Criteria NCT03929653 10 18 O
: NCT03929653 19 20 O

1 NCT03929653 25 26 O
. NCT03929653 26 27 O
Is NCT03929653 29 31 O
equal NCT03929653 32 37 B-Eq-Operator___Eq-Operator-Value:GTEQ
to NCT03929653 38 40 I-Eq-Operator___Eq-Operator-Value:GTEQ
or NCT03929653 41 43 I-Eq-Operator___Eq-Operator-Value:GTEQ
greater NCT03929653 44 51 I-Eq-Operator___Eq-Operator-Value:GTEQ
than NCT03929653 52 56 I-Eq-Operator___Eq-Operator-Value:GTEQ
18 NCT03929653 58 60 B-Eq-Value
years NCT03929653 61 66 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03929653 67 69 O
age NCT03929653 70 73 O
. NCT03929653 74 75 O

2 NCT03929653 80 81 O
. NCT03929653 81 82 O
Histologic NCT03929653 84 94 B-Procedure-Name
or NCT03929653 95 97 O
cytologic NCT03929653 98 107 B-Procedure-Name
confirmation NCT03929653 108 120 O
of NCT03929653 121 123 O
advanced NCT03929653 124 132 O
refractory NCT03929653 133 143 O
solid NCT03929653 144 149 B-Condition-Name
tumors NCT03929653 150 156 I-Condition-Name
with NCT03929653 157 161 O
no NCT03929653 162 164 O
standard NCT03929653 165 173 O
treatment NCT03929653 174 183 O
options NCT03929653 184 191 O
, NCT03929653 192 193 O
including NCT03929653 194 203 O
some NCT03929653 204 208 O
patients NCT03929653 209 217 O
with NCT03929653 218 222 O
advanced NCT03929653 223 231 O
disease NCT03929653 232 239 O
in NCT03929653 240 242 O
reduced NCT03929653 243 250 B-Condition-Name
general NCT03929653 251 258 I-Condition-Name
condition NCT03929653 259 268 I-Condition-Name
( NCT03929653 269 270 O
Eastern NCT03929653 271 278 B-Condition-Name
Cooperative NCT03929653 279 290 I-Condition-Name
Oncology NCT03929653 291 299 I-Condition-Name
Group NCT03929653 300 305 I-Condition-Name
( NCT03929653 306 307 O
ECOG NCT03929653 308 312 B-Condition-Name
) NCT03929653 313 314 O
3 NCT03929653 316 317 B-Eq-Value
and NCT03929653 318 321 O
4 NCT03929653 323 324 B-Eq-Value
) NCT03929653 325 326 O
. NCT03929653 328 329 O

3 NCT03929653 334 335 O
. NCT03929653 335 336 O
Patients NCT03929653 338 346 O
with NCT03929653 347 351 O
measurable NCT03929653 352 362 O
or NCT03929653 363 365 O
evaluable NCT03929653 366 375 O
disease NCT03929653 376 383 B-Condition-Name
per NCT03929653 384 387 O
Response NCT03929653 388 396 O
Evaluation NCT03929653 397 407 O
Criteria NCT03929653 408 416 O
In NCT03929653 417 419 O
Solid NCT03929653 420 425 O
Tumors NCT03929653 426 432 O
( NCT03929653 433 434 O
RECIST NCT03929653 435 441 O
) NCT03929653 442 443 O
version NCT03929653 444 451 O
1.1 NCT03929653 453 456 O
. NCT03929653 456 457 O

4 NCT03929653 462 463 O
. NCT03929653 463 464 O
Patients NCT03929653 466 474 O
must NCT03929653 475 479 O
be NCT03929653 480 482 O
able NCT03929653 483 487 O
to NCT03929653 488 490 O
provide NCT03929653 491 498 O
blood NCT03929653 499 504 B-Observation-Specimen
samples NCT03929653 505 512 O
or NCT03929653 513 515 O
tissue NCT03929653 516 522 B-Observation-Specimen
samples NCT03929653 523 530 O
for NCT03929653 531 534 O
NGS NCT03929653 535 538 B-Procedure-Name
( NCT03929653 539 540 O
Next NCT03929653 541 545 B-Procedure-Name
Generation NCT03929653 546 556 I-Procedure-Name
Sequencing NCT03929653 557 567 I-Procedure-Name
) NCT03929653 568 569 O
testing NCT03929653 570 577 O
. NCT03929653 578 579 O
The NCT03929653 581 584 O
amount NCT03929653 585 591 O
of NCT03929653 592 594 O
blood NCT03929653 595 600 B-Observation-Specimen
and NCT03929653 601 604 O
tissue NCT03929653 605 611 B-Observation-Specimen
samples NCT03929653 612 619 O
should NCT03929653 620 626 O
be NCT03929653 627 629 O
able NCT03929653 630 634 O
to NCT03929653 635 637 O
meet NCT03929653 638 642 O
the NCT03929653 643 646 O
requirements NCT03929653 647 659 O
of NCT03929653 660 662 O
DNA NCT03929653 663 666 O
extraction NCT03929653 667 677 O
and NCT03929653 678 681 O
quality NCT03929653 682 689 O
control NCT03929653 690 697 O
. NCT03929653 698 699 O

5 NCT03929653 704 705 O
. NCT03929653 705 706 O
Adequate NCT03929653 708 716 B-Polarity___Polarity-Value:normal
baseline NCT03929653 717 725 O
organ NCT03929653 726 731 B-Condition-Name
system NCT03929653 732 738 I-Condition-Name
function NCT03929653 739 747 I-Condition-Name
. NCT03929653 748 749 O

6 NCT03929653 754 755 O
. NCT03929653 755 756 O
Patients NCT03929653 758 766 O
could NCT03929653 767 772 O
receive NCT03929653 773 780 O
treatment NCT03929653 781 790 O
program NCT03929653 791 798 O
from NCT03929653 799 803 O
MTB NCT03929653 804 807 B-Procedure-Name
( NCT03929653 808 809 O
Molecular NCT03929653 810 819 B-Procedure-Name
Tumor NCT03929653 820 825 I-Procedure-Name
Board NCT03929653 826 831 I-Procedure-Name
) NCT03929653 832 833 O
. NCT03929653 835 836 O

7 NCT03929653 841 842 O
. NCT03929653 842 843 O
Ability NCT03929653 845 852 O
to NCT03929653 853 855 O
understand NCT03929653 856 866 O
and NCT03929653 867 870 O
the NCT03929653 871 874 O
willingness NCT03929653 875 886 O
to NCT03929653 887 889 O
provide NCT03929653 890 897 O
a NCT03929653 898 899 O
written NCT03929653 900 907 O
informed NCT03929653 908 916 O
consent NCT03929653 917 924 O
document NCT03929653 925 933 O
. NCT03929653 934 935 O

Exclusion NCT03929653 937 946 O
Criteria NCT03929653 947 955 O
: NCT03929653 956 957 O

1 NCT03929653 960 961 O
. NCT03929653 961 962 O
According NCT03929653 963 972 O
to NCT03929653 973 975 O
the NCT03929653 976 979 O
investigator NCT03929653 980 992 O
' NCT03929653 992 993 O
judgment NCT03929653 994 1002 O
, NCT03929653 1003 1004 O
there NCT03929653 1005 1010 O
are NCT03929653 1011 1014 O
serious NCT03929653 1015 1022 B-Severity___Severity-Value:severe
, NCT03929653 1023 1024 O
uncontrollable NCT03929653 1025 1039 O
risks NCT03929653 1040 1045 O
to NCT03929653 1046 1048 O
patients NCT03929653 1049 1057 O
' NCT03929653 1057 1058 O
safety NCT03929653 1059 1065 O
, NCT03929653 1066 1067 O
or NCT03929653 1068 1070 O
associated NCT03929653 1071 1081 O
diseases NCT03929653 1082 1090 B-Condition-Name
( NCT03929653 1091 1092 O
such NCT03929653 1093 1097 O
as NCT03929653 1098 1100 O
severe NCT03929653 1101 1107 B-Severity___Severity-Value:severe
diabetes NCT03929653 1108 1116 B-Condition-Name
, NCT03929653 1117 1118 O
thyroid NCT03929653 1119 1126 B-Condition-Name
disease NCT03929653 1127 1134 I-Condition-Name
, NCT03929653 1135 1136 O
infection NCT03929653 1137 1146 B-Condition-Name
, NCT03929653 1147 1148 O
spinal NCT03929653 1149 1155 B-Condition-Name
cord NCT03929653 1156 1160 I-Condition-Name
compression NCT03929653 1161 1172 I-Condition-Name
, NCT03929653 1173 1174 O
superior NCT03929653 1175 1183 B-Condition-Name
vena NCT03929653 1184 1188 I-Condition-Name
cava NCT03929653 1189 1193 I-Condition-Name
syndrome NCT03929653 1194 1202 I-Condition-Name
, NCT03929653 1203 1204 O
neurological NCT03929653 1205 1217 O
or NCT03929653 1218 1220 O
psychiatric NCT03929653 1221 1232 O
disorders NCT03929653 1233 1242 B-Condition-Name
and NCT03929653 1243 1246 O
so NCT03929653 1247 1249 O
on NCT03929653 1250 1252 O
) NCT03929653 1253 1254 O
that NCT03929653 1255 1259 O
affect NCT03929653 1260 1266 B-Stability___Stability-Value:change
the NCT03929653 1267 1270 O
patients NCT03929653 1271 1279 O
completion NCT03929653 1280 1290 O
of NCT03929653 1291 1293 O
the NCT03929653 1294 1297 O
study NCT03929653 1298 1303 O
. NCT03929653 1304 1305 O


Inclusion NCT03927118 0 9 O
Criteria NCT03927118 10 18 O

Patients NCT03927118 19 27 O
who NCT03927118 28 31 O
underwent NCT03927118 32 41 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
first NCT03927118 42 47 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
time NCT03927118 48 52 I-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
intravitreal NCT03927118 53 65 B-Procedure-Name
injection NCT03927118 66 75 I-Procedure-Name

Exclusion NCT03927118 76 85 O
Criteria NCT03927118 86 94 O

Previously NCT03927118 95 105 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
received NCT03927118 106 114 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
any NCT03927118 115 118 O
surgery NCT03927118 119 126 B-Procedure-Name

Proliferative NCT03927118 127 140 B-Condition-Name
diabetic NCT03927118 141 149 I-Condition-Name
retinopathy NCT03927118 150 161 I-Condition-Name

Glaucoma NCT03927118 162 170 B-Condition-Name
or NCT03927118 171 173 O
glaucoma NCT03927118 174 182 B-Condition-Name
suspicion NCT03927118 183 192 O

Optic NCT03927118 193 198 B-Condition-Name
disc NCT03927118 199 203 I-Condition-Name
fatigue NCT03927118 204 211 I-Condition-Name

Optic NCT03927118 212 217 B-Condition-Name
disc NCT03927118 218 222 I-Condition-Name
edema NCT03927118 223 228 I-Condition-Name

Uveitis NCT03927118 229 236 B-Condition-Name
and NCT03927118 237 240 O
media NCT03927118 241 246 B-Condition-Name
opacity NCT03927118 247 254 I-Condition-Name

Blurred NCT03927118 255 262 B-Condition-Name
of NCT03927118 263 265 I-Condition-Name
image NCT03927118 266 271 I-Condition-Name
clarity NCT03927118 272 279 I-Condition-Name

Inclusion NCT03922074 0 9 O
Criteria NCT03922074 10 18 O
: NCT03922074 19 20 O

Healthy NCT03922074 22 29 B-Condition-Name
patients NCT03922074 30 38 O
- NCT03922074 39 40 O

Exclusion NCT03922074 42 51 O
Criteria NCT03922074 52 60 O
: NCT03922074 61 62 O

Patients NCT03922074 64 72 O
with NCT03922074 73 77 O
familial NCT03922074 78 86 O
colorectal NCT03922074 87 97 O
cancer NCT03922074 98 104 B-Condition-Name
history NCT03922074 105 112 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past

- NCT03922074 114 115 O

Inclusion NCT03925727 0 9 O
Criteria NCT03925727 10 18 O
: NCT03925727 19 20 O

- NCT03925727 24 25 O
Subject NCT03925727 27 34 O
- NCT03925727 35 36 O
reported NCT03925727 37 45 O
history NCT03925727 46 53 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03925727 54 56 O
dry NCT03925727 57 60 B-Condition-Name
eye NCT03925727 61 64 I-Condition-Name
disease NCT03925727 65 72 I-Condition-Name
in NCT03925727 73 75 O
both NCT03925727 76 80 O
eyes NCT03925727 81 85 O
for NCT03925727 86 89 O
at NCT03925727 90 92 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03925727 93 98 I-Eq-Operator___Eq-Operator-Value:GTEQ
6 NCT03925727 100 101 B-Eq-Value
months NCT03925727 102 108 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
; NCT03925727 108 109 O

- NCT03925727 112 113 O
History NCT03925727 115 122 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03925727 123 125 O
use NCT03925727 126 129 O
of NCT03925727 130 132 O
artificial NCT03925727 133 143 B-Procedure-Name
tear NCT03925727 144 148 I-Procedure-Name
eye NCT03925727 149 152 I-Procedure-Name
drops NCT03925727 153 158 I-Procedure-Name
for NCT03925727 159 162 O
dry NCT03925727 163 166 B-Condition-Name
eye NCT03925727 167 170 I-Condition-Name
symptoms NCT03925727 171 179 O
; NCT03925727 179 180 O

- NCT03925727 183 184 O
Total NCT03925727 186 191 O
score NCT03925727 192 197 O
of NCT03925727 198 200 O
≥ NCT03925727 201 202 B-Eq-Operator___Eq-Operator-Value:GTEQ
40 NCT03925727 204 206 B-Eq-Value
on NCT03925727 207 209 O
SANDE NCT03925727 210 215 B-Observation-Name
; NCT03925727 215 216 O

- NCT03925727 219 220 O
TFBUT NCT03925727 222 227 B-Observation-Name
; NCT03925727 227 228 O

- NCT03925727 231 232 O
Corneal NCT03925727 234 241 B-Condition-Name
fluorescein NCT03925727 242 253 I-Condition-Name
staining NCT03925727 254 262 I-Condition-Name
; NCT03925727 262 263 O

- NCT03925727 266 267 O
Lissamine NCT03925727 269 278 O
green NCT03925727 279 284 O
conjunctival NCT03925727 285 297 B-Condition-Name
staining NCT03925727 298 306 I-Condition-Name
; NCT03925727 306 307 O

- NCT03925727 310 311 O
Schirmer NCT03925727 313 321 B-Observation-Name
's NCT03925727 321 323 I-Observation-Name
test NCT03925727 324 328 I-Observation-Name
score NCT03925727 329 334 O
. NCT03925727 335 336 O

Exclusion NCT03925727 338 347 O
Criteria NCT03925727 348 356 O
: NCT03925727 357 358 O

- NCT03925727 362 363 O
Have NCT03925727 365 369 O
participated NCT03925727 370 382 O
in NCT03925727 383 385 O
a NCT03925727 386 387 O
previous NCT03925727 388 396 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
tavilermide NCT03925727 397 408 B-Drug-Name
( NCT03925727 409 410 O
MIM NCT03925727 411 414 B-Drug-Name
- NCT03925727 415 416 I-Drug-Name
D NCT03925727 417 418 I-Drug-Name
3 NCT03925727 419 420 I-Drug-Name
) NCT03925727 421 422 O
study NCT03925727 423 428 O
; NCT03925727 428 429 O

- NCT03925727 432 433 O
Have NCT03925727 435 439 O
clinically NCT03925727 440 450 O
significant NCT03925727 451 462 O
slit NCT03925727 463 467 B-Condition-Name
lamp NCT03925727 468 472 I-Condition-Name
findings NCT03925727 473 481 I-Condition-Name
at NCT03925727 482 484 O
Visit NCT03925727 485 490 O
1 NCT03925727 492 493 O
; NCT03925727 494 495 O

- NCT03925727 498 499 O
Have NCT03925727 501 505 O
a NCT03925727 506 507 O
history NCT03925727 508 515 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03925727 516 518 O
lacrimal NCT03925727 519 527 B-Condition-Name
duct NCT03925727 528 532 I-Condition-Name
obstruction NCT03925727 533 544 I-Condition-Name
within NCT03925727 545 551 B-Eq-Operator___Eq-Operator-Value:LTEQ
12 NCT03925727 553 555 B-Eq-Value
months NCT03925727 556 562 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
of NCT03925727 563 565 O
Visit NCT03925727 566 571 O
1 NCT03925727 573 574 O
; NCT03925727 575 576 O

- NCT03925727 579 580 O
Have NCT03925727 582 586 O
an NCT03925727 587 589 O
uncontrolled NCT03925727 590 602 O
systemic NCT03925727 603 611 B-Condition-Name
disease NCT03925727 612 619 I-Condition-Name
; NCT03925727 619 620 O

- NCT03925727 623 624 O
Be NCT03925727 626 628 O
a NCT03925727 629 630 O
woman NCT03925727 631 636 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
who NCT03925727 637 640 O
is NCT03925727 641 643 O
pregnant NCT03925727 644 652 B-Condition-Name
, NCT03925727 653 654 O
nursing NCT03925727 655 662 B-Condition-Name
or NCT03925727 663 665 O
planning NCT03925727 666 674 O
a NCT03925727 675 676 O
pregnancy NCT03925727 677 686 B-Condition-Name
; NCT03925727 686 687 O

- NCT03925727 690 691 O
Be NCT03925727 693 695 O
a NCT03925727 696 697 O
woman NCT03925727 698 703 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
of NCT03925727 704 706 O
childbearing NCT03925727 707 719 B-Condition-Name
potential NCT03925727 720 729 I-Condition-Name
who NCT03925727 730 733 O
is NCT03925727 734 736 O
not NCT03925727 737 740 O
using NCT03925727 741 746 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
an NCT03925727 747 749 O
acceptable NCT03925727 750 760 O
means NCT03925727 761 766 O
of NCT03925727 767 769 O
birth NCT03925727 770 775 B-Procedure-Name
control NCT03925727 776 783 I-Procedure-Name
; NCT03925727 783 784 O

- NCT03925727 787 788 O
Have NCT03925727 790 794 O
a NCT03925727 795 796 O
condition NCT03925727 797 806 O
or NCT03925727 807 809 O
be NCT03925727 810 812 O
in NCT03925727 813 815 O
a NCT03925727 816 817 O
situation NCT03925727 818 827 O
which NCT03925727 828 833 O
the NCT03925727 834 837 O
investigator NCT03925727 838 850 O
feels NCT03925727 851 856 O
may NCT03925727 857 860 O
put NCT03925727 861 864 O
the NCT03925727 865 868 O
subject NCT03925727 869 876 O
at NCT03925727 877 879 O
significant NCT03925727 880 891 B-Severity___Severity-Value:severe
risk NCT03925727 892 896 O
, NCT03925727 897 898 O
may NCT03925727 899 902 O
confound NCT03925727 903 911 B-Stability___Stability-Value:change
the NCT03925727 912 915 O
study NCT03925727 916 921 O
results NCT03925727 922 929 O
, NCT03925727 930 931 O
or NCT03925727 932 934 O
may NCT03925727 935 938 O
interfere NCT03925727 939 948 B-Stability___Stability-Value:change
significantly NCT03925727 949 962 O
with NCT03925727 963 967 O
the NCT03925727 968 971 O
subject NCT03925727 972 979 O
's NCT03925727 979 981 O
participation NCT03925727 982 995 O
in NCT03925727 996 998 O
the NCT03925727 999 1002 O
study NCT03925727 1003 1008 O
; NCT03925727 1008 1009 O

- NCT03925727 1012 1013 O
Be NCT03925727 1015 1017 O
currently NCT03925727 1018 1027 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
enrolled NCT03925727 1028 1036 O
in NCT03925727 1037 1039 O
an NCT03925727 1040 1042 O
investigational NCT03925727 1043 1058 O
drug NCT03925727 1059 1063 O
or NCT03925727 1064 1066 O
device NCT03925727 1067 1073 O
study NCT03925727 1074 1079 O
or NCT03925727 1080 1082 O
have NCT03925727 1083 1087 O
used NCT03925727 1088 1092 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
an NCT03925727 1093 1095 O
investigational NCT03925727 1096 1111 O
drug NCT03925727 1112 1116 O
or NCT03925727 1117 1119 O
device NCT03925727 1120 1126 O
within NCT03925727 1127 1133 B-Eq-Operator___Eq-Operator-Value:LTEQ
45 NCT03925727 1135 1137 B-Eq-Value
days NCT03925727 1138 1142 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
prior NCT03925727 1143 1148 O
to NCT03925727 1149 1151 O
Visit NCT03925727 1152 1157 O
1 NCT03925727 1159 1160 O
. NCT03925727 1160 1161 O

Inclusion NCT03929939 0 9 O
Criteria NCT03929939 10 18 O
: NCT03929939 19 20 O

1 NCT03929939 25 26 O
. NCT03929939 26 27 O
Be NCT03929939 29 31 O
either NCT03929939 32 38 O
a NCT03929939 39 40 O
female NCT03929939 41 47 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
veteran NCT03929939 48 55 B-Observation-Name
with NCT03929939 56 60 O
a NCT03929939 61 62 O
current NCT03929939 63 70 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
diagnosis NCT03929939 71 80 O
of NCT03929939 81 83 O
PTSD NCT03929939 84 88 B-Condition-Name
( NCT03929939 89 90 O
for NCT03929939 91 94 O
the NCT03929939 95 98 O
PTSD NCT03929939 99 103 B-Condition-Name
group NCT03929939 104 109 O
) NCT03929939 110 111 O
or NCT03929939 112 114 O
a NCT03929939 115 116 O
female NCT03929939 117 123 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
non NCT03929939 124 127 O
- NCT03929939 128 129 O
veteran NCT03929939 130 137 B-Observation-Name
without NCT03929939 138 145 O
a NCT03929939 146 147 O
current NCT03929939 148 155 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
diagnosis NCT03929939 156 165 O
of NCT03929939 166 168 O
PTSD NCT03929939 169 173 B-Condition-Name
( NCT03929939 174 175 O
for NCT03929939 176 179 O
the NCT03929939 180 183 O
non NCT03929939 184 187 O
- NCT03929939 188 189 O
PTSD NCT03929939 190 194 B-Condition-Name
control NCT03929939 195 202 O
group NCT03929939 203 208 O
) NCT03929939 209 210 O
. NCT03929939 212 213 O

2 NCT03929939 218 219 O
. NCT03929939 219 220 O
Be NCT03929939 222 224 O
between NCT03929939 225 232 O
the NCT03929939 233 236 O
ages NCT03929939 237 241 O
of NCT03929939 242 244 O
18 NCT03929939 246 248 B-Eq-Value
- NCT03929939 249 250 B-Eq-Operator___Eq-Operator-Value:BETWEEN
65 NCT03929939 252 254 B-Eq-Value
. NCT03929939 254 255 O

3 NCT03929939 260 261 O
. NCT03929939 261 262 O
Sedentary NCT03929939 264 273 B-Condition-Name
( NCT03929939 274 275 O
exercises NCT03929939 276 285 B-Observation-Name___Observation-Type-Value:social-habit
less NCT03929939 286 290 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03929939 291 295 I-Eq-Operator___Eq-Operator-Value:LT
three NCT03929939 296 301 B-Eq-Value
times NCT03929939 302 307 O
a NCT03929939 308 309 O
week NCT03929939 310 314 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
for NCT03929939 315 318 O
thirty NCT03929939 319 325 B-Eq-Value
minutes NCT03929939 326 333 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:minute
or NCT03929939 334 336 B-Eq-Operator___Eq-Operator-Value:LTEQ
less NCT03929939 337 341 I-Eq-Operator___Eq-Operator-Value:LTEQ
) NCT03929939 342 343 O
. NCT03929939 345 346 O

Exclusion NCT03929939 348 357 O
Criteria NCT03929939 358 366 O
: NCT03929939 367 368 O

1 NCT03929939 373 374 O
. NCT03929939 374 375 O
Any NCT03929939 377 380 O
evidence NCT03929939 381 389 O
of NCT03929939 390 392 O
cardiopulmonary NCT03929939 393 408 O
and NCT03929939 409 412 O
neurological NCT03929939 413 425 O
diseases NCT03929939 426 434 B-Condition-Name
by NCT03929939 435 437 O
history NCT03929939 438 445 O
or NCT03929939 446 448 O
by NCT03929939 449 451 O
physical NCT03929939 452 460 B-Procedure-Name
examination NCT03929939 461 472 I-Procedure-Name
. NCT03929939 473 474 O

2 NCT03929939 479 480 O
. NCT03929939 480 481 O
Chronic NCT03929939 483 490 O
kidney NCT03929939 491 497 B-Condition-Name
disease NCT03929939 498 505 I-Condition-Name
( NCT03929939 506 507 O
serum NCT03929939 508 513 B-Observation-Name___Observation-Type-Value:lab
creatinine NCT03929939 514 524 I-Observation-Name___Observation-Type-Value:lab
> NCT03929939 525 526 B-Eq-Operator___Eq-Operator-Value:GT
1.5 NCT03929939 528 531 B-Eq-Value
mg NCT03929939 532 534 B-Eq-Unit
/ NCT03929939 535 536 O
dL NCT03929939 537 539 B-Eq-Unit
) NCT03929939 540 541 O
. NCT03929939 543 544 O

3 NCT03929939 549 550 O
. NCT03929939 550 551 O
Peripheral NCT03929939 553 563 B-Condition-Name
vascular NCT03929939 564 572 I-Condition-Name
disease NCT03929939 573 580 I-Condition-Name
. NCT03929939 581 582 O

4 NCT03929939 587 588 O
. NCT03929939 588 589 O
Peripheral NCT03929939 591 601 B-Condition-Name
neuropathy NCT03929939 602 612 I-Condition-Name
. NCT03929939 613 614 O

5 NCT03929939 619 620 O
. NCT03929939 620 621 O
Current NCT03929939 623 630 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
substance NCT03929939 631 640 B-Condition-Name
use NCT03929939 641 644 I-Condition-Name
disorder NCT03929939 645 653 I-Condition-Name
other NCT03929939 654 659 O
than NCT03929939 660 664 O
tobacco NCT03929939 665 672 B-Drug-Name
related NCT03929939 673 680 O
. NCT03929939 681 682 O

6 NCT03929939 687 688 O
. NCT03929939 688 689 O
Endurance NCT03929939 691 700 B-Condition-Name
- NCT03929939 701 702 I-Condition-Name
trained NCT03929939 703 710 I-Condition-Name
athletes NCT03929939 711 719 I-Condition-Name
due NCT03929939 720 723 O
to NCT03929939 724 726 O
the NCT03929939 727 730 O
effects NCT03929939 731 738 B-Stability___Stability-Value:change
of NCT03929939 739 741 O
exercise NCT03929939 742 750 B-Procedure-Name
training NCT03929939 751 759 I-Procedure-Name
on NCT03929939 760 762 O
sympathetic NCT03929939 763 774 B-Condition-Name
neural NCT03929939 775 781 I-Condition-Name
control NCT03929939 782 789 I-Condition-Name
and NCT03929939 790 793 O
cardiac NCT03929939 794 801 B-Condition-Name
- NCT03929939 802 803 I-Condition-Name
vascular NCT03929939 804 812 I-Condition-Name
function NCT03929939 813 821 I-Condition-Name
. NCT03929939 822 823 O

7 NCT03929939 828 829 O
. NCT03929939 829 830 O
Current NCT03929939 832 839 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
pregnancy NCT03929939 840 849 B-Condition-Name
. NCT03929939 850 851 O

Inclusion NCT03928366 0 9 O
Criteria NCT03928366 10 18 O
: NCT03928366 19 20 O

- NCT03928366 24 25 O
Healthy NCT03928366 27 34 B-Condition-Name
adult NCT03928366 35 40 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
volunteers NCT03928366 41 51 O
( NCT03928366 52 53 O
ASA NCT03928366 54 57 B-Condition-Name
1 NCT03928366 59 60 B-Eq-Value
physical NCT03928366 61 69 O
state NCT03928366 70 75 O
) NCT03928366 76 77 O
who NCT03928366 78 81 O
agree NCT03928366 82 87 O
to NCT03928366 88 90 O
participate NCT03928366 91 102 O
voluntarily NCT03928366 103 114 O
in NCT03928366 115 117 O
the NCT03928366 118 121 O
study NCT03928366 122 127 O
, NCT03928366 128 129 O
previous NCT03928366 130 138 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
information NCT03928366 139 150 O
about NCT03928366 151 156 O
it NCT03928366 157 159 O
by NCT03928366 160 162 O
the NCT03928366 163 166 O
Principal NCT03928366 167 176 O
Investigators NCT03928366 177 190 O
( NCT03928366 191 192 O
IP NCT03928366 193 195 O
) NCT03928366 196 197 O
. NCT03928366 199 200 O

Exclusion NCT03928366 202 211 O
Criteria NCT03928366 212 220 O
: NCT03928366 221 222 O

- NCT03928366 226 227 O
Psychological NCT03928366 229 242 O
, NCT03928366 243 244 O
psychiatric NCT03928366 245 256 O
or NCT03928366 257 259 O
neurological NCT03928366 260 272 O
disorders NCT03928366 273 282 B-Condition-Name
. NCT03928366 283 284 O
Consumption NCT03928366 286 297 O
of NCT03928366 298 300 O
drugs NCT03928366 301 306 O
. NCT03928366 307 308 O
Alterations NCT03928366 310 321 B-Condition-Name
cutaneous NCT03928366 322 331 O
or NCT03928366 332 334 O
anatomical NCT03928366 335 345 O
cranial NCT03928366 346 353 O
. NCT03928366 354 355 O
Idiomatic NCT03928366 357 366 O
or NCT03928366 367 369 O
communication NCT03928366 370 383 O
barrier NCT03928366 384 391 B-Condition-Name
. NCT03928366 392 393 O
Allergy NCT03928366 395 402 O
to NCT03928366 403 405 O
propofol NCT03928366 406 414 B-Drug-Name
, NCT03928366 415 416 O
remifentanil NCT03928366 417 429 B-Drug-Name
or NCT03928366 430 432 O
to NCT03928366 433 435 O
some NCT03928366 436 440 O
of NCT03928366 441 443 O
its NCT03928366 444 447 O
excipients NCT03928366 448 458 O
. NCT03928366 459 460 O
Body NCT03928366 462 466 B-Observation-Name___Observation-Type-Value:vital
mass NCT03928366 467 471 I-Observation-Name___Observation-Type-Value:vital
index NCT03928366 472 477 I-Observation-Name___Observation-Type-Value:vital
( NCT03928366 478 479 O
BMI NCT03928366 480 483 B-Observation-Name___Observation-Type-Value:vital
) NCT03928366 484 485 O
< NCT03928366 486 487 B-Eq-Operator___Eq-Operator-Value:LT
18 NCT03928366 489 491 B-Eq-Value
or NCT03928366 492 494 O
> NCT03928366 495 496 B-Eq-Operator___Eq-Operator-Value:GT
30 NCT03928366 498 500 B-Eq-Value
kg NCT03928366 501 503 B-Eq-Unit
/ NCT03928366 504 505 I-Eq-Unit
m NCT03928366 506 507 I-Eq-Unit
2 NCT03928366 508 509 I-Eq-Unit
. NCT03928366 509 510 O
Pregnancy NCT03928366 512 521 B-Condition-Name
. NCT03928366 522 523 O
Airway NCT03928366 525 531 O
or NCT03928366 532 534 O
ventilation NCT03928366 535 546 O
criteria NCT03928366 547 555 O
hard NCT03928366 556 560 B-Condition-Name
. NCT03928366 561 562 O
Absence NCT03928366 564 571 O
of NCT03928366 572 574 O
accompanying NCT03928366 575 587 O
adult NCT03928366 588 593 O
at NCT03928366 594 596 O
the NCT03928366 597 600 O
end NCT03928366 601 604 O
of NCT03928366 605 607 O
the NCT03928366 608 611 O
study NCT03928366 612 617 O
. NCT03928366 618 619 O

Inclusion NCT03922893 0 9 O
Criteria NCT03922893 10 18 O
: NCT03922893 19 20 O

- NCT03922893 24 25 O
Individuals NCT03922893 27 38 O
who NCT03922893 39 42 O
have NCT03922893 43 47 O
undergone NCT03922893 48 57 O
clinical NCT03922893 58 66 O
and NCT03922893 67 70 O
/ NCT03922893 71 72 O
or NCT03922893 73 75 O
research NCT03922893 76 84 O
genetic NCT03922893 85 92 B-Procedure-Name
evaluation NCT03922893 93 103 I-Procedure-Name
, NCT03922893 104 105 O
found NCT03922893 106 111 O
to NCT03922893 112 114 O
have NCT03922893 115 119 O
or NCT03922893 120 122 O
not NCT03922893 123 126 O
have NCT03922893 127 131 O
a NCT03922893 132 133 O
germline NCT03922893 134 142 B-Condition-Name
genetic NCT03922893 143 150 I-Condition-Name
variant NCT03922893 151 158 I-Condition-Name
( NCT03922893 159 160 O
pathogenic NCT03922893 161 171 O
, NCT03922893 172 173 O
likely NCT03922893 174 180 O
pathogenic NCT03922893 181 191 O
, NCT03922893 192 193 O
variant NCT03922893 194 201 O
of NCT03922893 202 204 O
uncertain NCT03922893 205 214 O
/ NCT03922893 215 216 O
unknown NCT03922893 217 224 O
significance NCT03922893 225 237 B-Severity
, NCT03922893 238 239 O
likely NCT03922893 240 246 O
benign NCT03922893 247 253 O
) NCT03922893 254 255 O
. NCT03922893 257 258 O

- NCT03922893 262 263 O
Individuals NCT03922893 265 276 O
with NCT03922893 277 281 O
or NCT03922893 282 284 O
without NCT03922893 285 292 O
a NCT03922893 293 294 O
personal NCT03922893 295 303 O
history NCT03922893 304 311 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03922893 312 314 O
malignant NCT03922893 315 324 O
or NCT03922893 325 327 O
pre NCT03922893 328 331 O
- NCT03922893 332 333 O
malignant NCT03922893 334 343 O
lesions NCT03922893 344 351 B-Condition-Name
who NCT03922893 352 355 O
demonstrate NCT03922893 356 367 O
: NCT03922893 368 369 O
a NCT03922893 370 371 O
) NCT03922893 372 373 O
clinical NCT03922893 374 382 O
findings NCT03922893 383 391 O
suggestive NCT03922893 392 402 O
of NCT03922893 403 405 O
a NCT03922893 406 407 O
genetic NCT03922893 408 415 B-Condition-Name
cancer NCT03922893 416 422 I-Condition-Name
susceptibility NCT03922893 423 437 I-Condition-Name
syndrome NCT03922893 438 446 I-Condition-Name
including NCT03922893 447 456 O
very NCT03922893 457 461 O
early NCT03922893 462 467 O
age NCT03922893 468 471 O
at NCT03922893 472 474 O
onset NCT03922893 475 480 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
, NCT03922893 481 482 O
multiple NCT03922893 483 491 O
primary NCT03922893 492 499 O
malignancies NCT03922893 500 512 B-Condition-Name
, NCT03922893 513 514 O
or NCT03922893 515 517 O
other NCT03922893 518 523 O
features NCT03922893 524 532 O
; NCT03922893 532 533 O
and NCT03922893 534 537 O
/ NCT03922893 538 539 O
or NCT03922893 540 542 O
b NCT03922893 543 544 O
) NCT03922893 545 546 O
family NCT03922893 547 553 O
histories NCT03922893 554 563 O
suggestive NCT03922893 564 574 O
of NCT03922893 575 577 O
a NCT03922893 578 579 O
genetic NCT03922893 580 587 B-Condition-Name
cancer NCT03922893 588 594 I-Condition-Name
susceptibility NCT03922893 595 609 I-Condition-Name
syndrome NCT03922893 610 618 I-Condition-Name
, NCT03922893 619 620 O
or NCT03922893 621 623 O
c NCT03922893 624 625 O
) NCT03922893 626 627 O
other NCT03922893 628 633 O
features NCT03922893 634 642 O
suggesting NCT03922893 643 653 O
inherited NCT03922893 654 663 O
etiology NCT03922893 664 672 O
of NCT03922893 673 675 O
malignancy NCT03922893 676 686 B-Condition-Name
as NCT03922893 687 689 O
determined NCT03922893 690 700 O
by NCT03922893 701 703 O
the NCT03922893 704 707 O
PI NCT03922893 708 710 O
. NCT03922893 711 712 O

- NCT03922893 716 717 O
Family NCT03922893 719 725 O
members NCT03922893 726 733 O
of NCT03922893 734 736 O
the NCT03922893 737 740 O
above NCT03922893 741 746 O
participants NCT03922893 747 759 O
. NCT03922893 760 761 O
Both NCT03922893 763 767 O
children NCT03922893 768 776 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
( NCT03922893 777 778 O
with NCT03922893 779 783 O
parental NCT03922893 784 792 O
consent NCT03922893 793 800 O
as NCT03922893 801 803 O
age NCT03922893 804 807 O
appropriate NCT03922893 808 819 O
) NCT03922893 820 821 O
and NCT03922893 822 825 O
adults NCT03922893 826 832 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
are NCT03922893 833 836 O
eligible NCT03922893 837 845 O
to NCT03922893 846 848 O
participation NCT03922893 849 862 O
. NCT03922893 863 864 O

- NCT03922893 868 869 O
Individuals NCT03922893 871 882 O
may NCT03922893 883 886 O
or NCT03922893 887 889 O
may NCT03922893 890 893 O
not NCT03922893 894 897 O
be NCT03922893 898 900 O
enrolled NCT03922893 901 909 O
MSK NCT03922893 910 913 O
patients NCT03922893 914 922 O
; NCT03922893 922 923 O
probands NCT03922893 924 932 O
may NCT03922893 933 936 O
be NCT03922893 937 939 O
referred NCT03922893 940 948 O
to NCT03922893 949 951 O
( NCT03922893 952 953 O
or NCT03922893 954 956 O
self NCT03922893 957 961 O
- NCT03922893 962 963 O
referred NCT03922893 964 972 O
to NCT03922893 973 975 O
) NCT03922893 976 977 O
the NCT03922893 978 981 O
study NCT03922893 982 987 O
and NCT03922893 988 991 O
may NCT03922893 992 995 O
be NCT03922893 996 998 O
enrolled NCT03922893 999 1007 O
at NCT03922893 1008 1010 O
discretion NCT03922893 1011 1021 O
of NCT03922893 1022 1024 O
the NCT03922893 1025 1028 O
PI NCT03922893 1029 1031 O
and NCT03922893 1032 1035 O
if NCT03922893 1036 1038 O
able NCT03922893 1039 1043 O
to NCT03922893 1044 1046 O
provide NCT03922893 1047 1054 O
informed NCT03922893 1055 1063 O
consent NCT03922893 1064 1071 O
. NCT03922893 1072 1073 O

- NCT03922893 1077 1078 O
Biospecimens NCT03922893 1080 1092 O
derived NCT03922893 1093 1100 O
from NCT03922893 1101 1105 O
deceased NCT03922893 1106 1114 O
family NCT03922893 1115 1121 O
members NCT03922893 1122 1129 O
may NCT03922893 1130 1133 O
be NCT03922893 1134 1136 O
used NCT03922893 1137 1141 O
for NCT03922893 1142 1145 O
research NCT03922893 1146 1154 O
in NCT03922893 1155 1157 O
this NCT03922893 1158 1162 O
study NCT03922893 1163 1168 O
if NCT03922893 1169 1171 O
consent NCT03922893 1172 1179 O
if NCT03922893 1180 1182 O
provided NCT03922893 1183 1191 O
by NCT03922893 1192 1194 O
the NCT03922893 1195 1198 O
executor NCT03922893 1199 1207 O
of NCT03922893 1208 1210 O
the NCT03922893 1211 1214 O
estate NCT03922893 1215 1221 O
of NCT03922893 1222 1224 O
that NCT03922893 1225 1229 O
individual NCT03922893 1230 1240 O
. NCT03922893 1241 1242 O

Exclusion NCT03922893 1244 1253 O
Criteria NCT03922893 1254 1262 O
: NCT03922893 1263 1264 O

- NCT03922893 1268 1269 O
Patients NCT03922893 1271 1279 O
will NCT03922893 1280 1284 O
be NCT03922893 1285 1287 O
excluded NCT03922893 1288 1296 O
from NCT03922893 1297 1301 O
this NCT03922893 1302 1306 O
study NCT03922893 1307 1312 O
if NCT03922893 1313 1315 O
he NCT03922893 1316 1318 O
/ NCT03922893 1319 1320 O
she NCT03922893 1321 1324 O
has NCT03922893 1325 1328 O
physical NCT03922893 1329 1337 O
, NCT03922893 1338 1339 O
cognitive NCT03922893 1340 1349 O
or NCT03922893 1350 1352 O
psychiatric NCT03922893 1353 1364 O
conditions NCT03922893 1365 1375 B-Condition-Name
that NCT03922893 1376 1380 O
interfere NCT03922893 1381 1390 O
with NCT03922893 1391 1395 O
ability NCT03922893 1396 1403 O
to NCT03922893 1404 1406 O
give NCT03922893 1407 1411 O
meaningful NCT03922893 1412 1422 O
informed NCT03922893 1423 1431 O
consent NCT03922893 1432 1439 O
. NCT03922893 1440 1441 O

Inclusion NCT03926377 0 9 O
Criteria NCT03926377 10 18 O
: NCT03926377 19 20 O

- NCT03926377 24 25 O
patients NCT03926377 27 35 O
presenting NCT03926377 36 46 O
a NCT03926377 47 48 O
multi NCT03926377 49 54 O
- NCT03926377 55 56 O
bullous NCT03926377 57 64 O
pemphigoid NCT03926377 65 75 B-Condition-Name
newly NCT03926377 76 81 O
diagnosed NCT03926377 82 91 O
or NCT03926377 92 94 O
relapsed NCT03926377 95 103 O
more NCT03926377 104 108 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03926377 109 113 I-Eq-Operator___Eq-Operator-Value:GT
3 NCT03926377 115 116 B-Eq-Value
months NCT03926377 117 123 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
after NCT03926377 124 129 O
stopping NCT03926377 130 138 O
corticosteroids NCT03926377 139 154 B-Drug-Name
and NCT03926377 155 158 O
treated NCT03926377 159 166 O
according NCT03926377 167 176 O
to NCT03926377 177 179 O
the NCT03926377 180 183 O
national NCT03926377 184 192 O
protocol NCT03926377 193 201 O
for NCT03926377 202 205 O
diagnosis NCT03926377 206 215 O
and NCT03926377 216 219 O
care NCT03926377 220 224 O
issued NCT03926377 225 231 O
by NCT03926377 232 234 O
the NCT03926377 235 238 O
reference NCT03926377 239 248 O
center NCT03926377 249 255 O
for NCT03926377 256 259 O
autoimmune NCT03926377 260 270 O
bullous NCT03926377 271 278 O
diseases NCT03926377 279 287 O
of NCT03926377 288 290 O
April NCT03926377 291 296 O
2016 NCT03926377 298 302 O

- NCT03926377 306 307 O
patients NCT03926377 309 317 O
having NCT03926377 318 324 O
received NCT03926377 325 333 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
written NCT03926377 334 341 O
and NCT03926377 342 345 O
oral NCT03926377 346 350 O
information NCT03926377 351 362 O
and NCT03926377 363 366 O
signed NCT03926377 367 373 O
informed NCT03926377 374 382 O
consent NCT03926377 383 390 O

- NCT03926377 393 394 O
patients NCT03926377 396 404 O
covered NCT03926377 405 412 O
by NCT03926377 413 415 O
national NCT03926377 416 424 B-Insurance
health NCT03926377 425 431 I-Insurance
insurance NCT03926377 432 441 I-Insurance

Exclusion NCT03926377 442 451 O
Criteria NCT03926377 452 460 O
: NCT03926377 461 462 O

- NCT03926377 466 467 O
Patients NCT03926377 469 477 O
under NCT03926377 478 483 O
tutorship NCT03926377 484 493 O
or NCT03926377 494 496 O
curatorship NCT03926377 497 508 O
or NCT03926377 509 511 O
inability NCT03926377 512 521 O
to NCT03926377 522 524 O
give NCT03926377 525 529 O
informed NCT03926377 530 538 O
consent NCT03926377 539 546 O

- NCT03926377 549 550 O
Patients NCT03926377 552 560 O
receiving NCT03926377 561 570 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
an NCT03926377 571 573 O
anti NCT03926377 574 578 B-Drug-Name
- NCT03926377 579 580 I-Drug-Name
osteoporotic NCT03926377 581 593 I-Drug-Name
treatment NCT03926377 594 603 O

- NCT03926377 606 607 O
Patients NCT03926377 609 617 O
requiring NCT03926377 618 627 O
an NCT03926377 628 630 O
anti NCT03926377 631 635 B-Drug-Name
- NCT03926377 636 637 I-Drug-Name
osteoporotic NCT03926377 638 650 I-Drug-Name
baseline NCT03926377 651 659 O
treatment NCT03926377 660 669 O
( NCT03926377 670 671 O
T NCT03926377 672 673 B-Observation-Name___Observation-Type-Value:measurement
- NCT03926377 674 675 I-Observation-Name___Observation-Type-Value:measurement
score NCT03926377 676 681 I-Observation-Name___Observation-Type-Value:measurement
⩽ NCT03926377 682 683 B-Eq-Operator___Eq-Operator-Value:LTEQ
- NCT03926377 684 685 B-Eq-Value
3 NCT03926377 687 688 I-Eq-Value
DS NCT03926377 689 691 B-Eq-Unit
on NCT03926377 692 694 O
at NCT03926377 695 697 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03926377 698 703 I-Eq-Operator___Eq-Operator-Value:GTEQ
1 NCT03926377 705 706 B-Eq-Value
site NCT03926377 707 711 B-Eq-Unit
or NCT03926377 712 714 O
FRAX NCT03926377 715 719 B-Observation-Name___Observation-Type-Value:clinical-score
score NCT03926377 720 725 I-Observation-Name___Observation-Type-Value:clinical-score
above NCT03926377 726 731 B-Eq-Operator___Eq-Operator-Value:GT
the NCT03926377 732 735 O
therapeutic NCT03926377 736 747 B-Eq-Unit___Eq-Unit-Value:ref-range-high
intervention NCT03926377 748 760 I-Eq-Unit___Eq-Unit-Value:ref-range-high
threshold NCT03926377 761 770 I-Eq-Unit___Eq-Unit-Value:ref-range-high
) NCT03926377 771 772 O

- NCT03926377 780 781 O
Patients NCT03926377 783 791 O
with NCT03926377 792 796 O
one NCT03926377 797 800 B-Eq-Value
or NCT03926377 801 803 B-Eq-Operator___Eq-Operator-Value:GTEQ
more NCT03926377 804 808 I-Eq-Operator___Eq-Operator-Value:GTEQ
major NCT03926377 809 814 B-Severity___Severity-Value:severe
risk NCT03926377 815 819 O
factors NCT03926377 820 827 O
for NCT03926377 828 831 O
osteoporosis NCT03926377 832 844 B-Condition-Name

- NCT03926377 847 848 O
Patients NCT03926377 850 858 O
who NCT03926377 859 862 O
have NCT03926377 863 867 O
received NCT03926377 868 876 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
topical NCT03926377 877 884 B-Drug-Name
corticosteroids NCT03926377 885 900 I-Drug-Name
in NCT03926377 901 903 O
less NCT03926377 904 908 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03926377 909 913 I-Eq-Operator___Eq-Operator-Value:LT
3 NCT03926377 915 916 B-Eq-Value
months NCT03926377 917 923 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month


Inclusion NCT03923569 0 9 O
Criteria NCT03923569 10 18 O
: NCT03923569 19 20 O

For NCT03923569 22 25 O
all NCT03923569 26 29 O
participants NCT03923569 30 42 O
: NCT03923569 43 44 O

- NCT03923569 48 49 O
age NCT03923569 51 54 O
from NCT03923569 55 59 O
50 NCT03923569 61 63 B-Eq-Value
to NCT03923569 64 66 B-Eq-Operator___Eq-Operator-Value:BETWEEN
75 NCT03923569 68 70 B-Eq-Value
years NCT03923569 71 76 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03923569 77 80 O

- NCT03923569 83 84 O
affiliated NCT03923569 86 96 O
to NCT03923569 97 99 O
the NCT03923569 100 103 O
French NCT03923569 104 110 B-Language
health NCT03923569 111 117 O
care NCT03923569 118 122 O
system NCT03923569 123 129 O

For NCT03923569 130 133 O
AD NCT03923569 134 136 B-Condition-Name
patients NCT03923569 137 145 O
: NCT03923569 146 147 O

- NCT03923569 151 152 O
meeting NCT03923569 154 161 O
International NCT03923569 162 175 O
Working NCT03923569 176 183 O
Group NCT03923569 184 189 O
( NCT03923569 190 191 O
IWG NCT03923569 192 195 O
) NCT03923569 196 197 O
- NCT03923569 199 200 O
2 NCT03923569 202 203 O
criteria NCT03923569 204 212 O
for NCT03923569 213 216 O
diagnosis NCT03923569 217 226 O

- NCT03923569 229 230 O
Mini NCT03923569 232 236 B-Observation-Name___Observation-Type-Value:clinical-score
- NCT03923569 237 238 I-Observation-Name___Observation-Type-Value:clinical-score
Mental NCT03923569 239 245 I-Observation-Name___Observation-Type-Value:clinical-score
State NCT03923569 246 251 I-Observation-Name___Observation-Type-Value:clinical-score
Examination NCT03923569 252 263 I-Observation-Name___Observation-Type-Value:clinical-score
( NCT03923569 264 265 O
MMSE NCT03923569 266 270 B-Observation-Name
) NCT03923569 271 272 O
≥ NCT03923569 273 274 B-Eq-Operator___Eq-Operator-Value:GTEQ
20 NCT03923569 276 278 B-Eq-Value
( NCT03923569 279 280 O
Greco NCT03923569 281 286 O
version NCT03923569 287 294 O
) NCT03923569 295 296 O

For NCT03923569 298 301 O
healthy NCT03923569 302 309 B-Condition-Name
volunteers NCT03923569 310 320 O
: NCT03923569 321 322 O

- NCT03923569 326 327 O
MMSE NCT03923569 329 333 B-Observation-Name
> NCT03923569 334 335 B-Eq-Operator___Eq-Operator-Value:GT
25 NCT03923569 337 339 B-Eq-Value

- NCT03923569 343 344 O
Dubois NCT03923569 346 352 B-Observation-Name___Observation-Type-Value:clinical-score
5 NCT03923569 354 355 I-Observation-Name___Observation-Type-Value:clinical-score
words NCT03923569 356 361 I-Observation-Name___Observation-Type-Value:clinical-score
test NCT03923569 362 366 I-Observation-Name___Observation-Type-Value:clinical-score
≥ NCT03923569 367 368 B-Eq-Operator___Eq-Operator-Value:GTEQ
9 NCT03923569 370 371 B-Eq-Value

Exclusion NCT03923569 373 382 O
Criteria NCT03923569 383 391 O
: NCT03923569 392 393 O

For NCT03923569 395 398 O
all NCT03923569 399 402 O
participants NCT03923569 403 415 O
: NCT03923569 416 417 O

- NCT03923569 421 422 O
Pregnancy NCT03923569 424 433 B-Condition-Name

- NCT03923569 436 437 O
people NCT03923569 439 445 O
not NCT03923569 446 449 O
able NCT03923569 450 454 O
to NCT03923569 455 457 O
give NCT03923569 458 462 O
consent NCT03923569 463 470 O

- NCT03923569 473 474 O
contraindication NCT03923569 476 492 O
for NCT03923569 493 496 O
MRI NCT03923569 497 500 B-Procedure-Name
( NCT03923569 501 502 O
metallic NCT03923569 503 511 B-Condition-Name
body NCT03923569 512 516 I-Condition-Name
parts NCT03923569 517 522 I-Condition-Name
, NCT03923569 523 524 O
claustrophobia NCT03923569 525 539 B-Condition-Name
) NCT03923569 540 541 O
, NCT03923569 543 544 O

- NCT03923569 548 549 O
aphasia NCT03923569 551 558 B-Condition-Name
, NCT03923569 559 560 O
apraxia NCT03923569 561 568 B-Condition-Name
or NCT03923569 569 571 O
agnosia NCT03923569 572 579 B-Condition-Name

- NCT03923569 582 583 O
neurological NCT03923569 585 597 O
( NCT03923569 598 599 O
other NCT03923569 600 605 O
than NCT03923569 606 610 O
AD NCT03923569 611 613 B-Condition-Name
) NCT03923569 614 615 O
or NCT03923569 616 618 O
any NCT03923569 619 622 O
other NCT03923569 623 628 O
serious NCT03923569 629 636 B-Severity___Severity-Value:severe
disease NCT03923569 637 644 B-Condition-Name
( NCT03923569 645 646 O
cancer NCT03923569 647 653 O
, NCT03923569 654 655 O
addiction NCT03923569 656 665 B-Condition-Name
, NCT03923569 666 667 O
systemic NCT03923569 668 676 B-Condition-Name
disease NCT03923569 677 684 I-Condition-Name
) NCT03923569 685 686 O

- NCT03923569 690 691 O
sleep NCT03923569 693 698 O
apnea NCT03923569 699 704 O

- NCT03923569 707 708 O
major NCT03923569 710 715 B-Severity___Severity-Value:severe
depression NCT03923569 716 726 B-Condition-Name
or NCT03923569 727 729 O
anxiety NCT03923569 730 737 B-Condition-Name
for NCT03923569 738 741 O
more NCT03923569 742 746 B-Eq-Operator___Eq-Operator-Value:GTEQ
than NCT03923569 747 751 I-Eq-Operator___Eq-Operator-Value:GTEQ
3 NCT03923569 753 754 B-Eq-Value
months NCT03923569 755 761 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
( NCT03923569 762 763 O
Beck NCT03923569 764 768 B-Observation-Name
> NCT03923569 769 770 B-Eq-Operator___Eq-Operator-Value:GT
10 NCT03923569 772 774 B-Eq-Value
) NCT03923569 775 776 O
or NCT03923569 777 779 O
psychiatric NCT03923569 780 791 B-Condition-Name
disease NCT03923569 792 799 I-Condition-Name

- NCT03923569 802 803 O
documented NCT03923569 805 815 O
epilepsy NCT03923569 816 824 B-Condition-Name

- NCT03923569 827 828 O
use NCT03923569 830 833 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
of NCT03923569 834 836 O
neuroleptics NCT03923569 837 849 B-Drug-Name
( NCT03923569 850 851 O
more NCT03923569 852 856 B-Eq-Operator___Eq-Operator-Value:GTEQ
than NCT03923569 857 861 I-Eq-Operator___Eq-Operator-Value:GTEQ
one NCT03923569 862 865 B-Eq-Value
dose NCT03923569 866 870 O
per NCT03923569 871 874 O
day NCT03923569 875 878 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
) NCT03923569 879 880 O

- NCT03923569 884 885 O
use NCT03923569 887 890 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
of NCT03923569 891 893 O
antiepileptics NCT03923569 894 908 B-Drug-Name

- NCT03923569 911 912 O
use NCT03923569 914 917 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
of NCT03923569 918 920 O
benzodiazepines NCT03923569 921 936 B-Drug-Name
at NCT03923569 937 939 O
a NCT03923569 940 941 O
dose NCT03923569 942 946 O
superior NCT03923569 947 955 B-Eq-Operator___Eq-Operator-Value:GTEQ
or NCT03923569 956 958 I-Eq-Operator___Eq-Operator-Value:GTEQ
equal NCT03923569 959 964 I-Eq-Operator___Eq-Operator-Value:GTEQ
to NCT03923569 965 967 O
two NCT03923569 968 971 B-Eq-Value
intakes NCT03923569 972 979 O
per NCT03923569 980 983 O
day NCT03923569 984 987 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day

- NCT03923569 990 991 O
use NCT03923569 993 996 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
of NCT03923569 997 999 O
antidepressants NCT03923569 1000 1015 B-Drug-Name

- NCT03923569 1018 1019 O
restless NCT03923569 1021 1029 B-Condition-Name
leg NCT03923569 1030 1033 I-Condition-Name
syndrome NCT03923569 1034 1042 I-Condition-Name
treated NCT03923569 1043 1050 O
by NCT03923569 1051 1053 O
dopaminergic NCT03923569 1054 1066 B-Drug-Name
agonists NCT03923569 1067 1075 I-Drug-Name
. NCT03923569 1076 1077 O

For NCT03923569 1079 1082 O
AD NCT03923569 1083 1085 B-Condition-Name
patients NCT03923569 1086 1094 O
: NCT03923569 1095 1096 O

- NCT03923569 1100 1101 O
other NCT03923569 1103 1108 O
causes NCT03923569 1109 1115 O
of NCT03923569 1116 1118 O
dementia NCT03923569 1119 1127 B-Condition-Name

- NCT03923569 1130 1131 O
non NCT03923569 1133 1136 O
- NCT03923569 1137 1138 O
degenerative NCT03923569 1139 1151 O
neurological NCT03923569 1152 1164 O
lesions NCT03923569 1165 1172 B-Condition-Name

- NCT03923569 1175 1176 O
white NCT03923569 1178 1183 B-Condition-Name
matter NCT03923569 1184 1190 I-Condition-Name
hypersignals NCT03923569 1191 1203 I-Condition-Name

- NCT03923569 1206 1207 O
acute NCT03923569 1209 1214 B-Severity___Severity-Value:severe
cognitive NCT03923569 1215 1224 B-Condition-Name
deficits NCT03923569 1225 1233 I-Condition-Name

Inclusion NCT03924206 0 9 O
Criteria NCT03924206 10 18 O
: NCT03924206 19 20 O

- NCT03924206 23 24 O
All NCT03924206 25 28 O
surgical NCT03924206 29 37 B-Procedure-Name
procedures NCT03924206 38 48 I-Procedure-Name
with NCT03924206 49 53 O
a NCT03924206 54 55 O
planned NCT03924206 56 63 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
duration NCT03924206 64 72 O
of NCT03924206 73 75 O
more NCT03924206 76 80 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03924206 81 85 I-Eq-Operator___Eq-Operator-Value:GT
1 NCT03924206 87 88 B-Eq-Value
hour NCT03924206 89 93 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:hour

Exclusion NCT03924206 94 103 O
Criteria NCT03924206 104 112 O
: NCT03924206 113 114 O

- NCT03924206 118 119 O
Patients NCT03924206 121 129 O
with NCT03924206 130 134 O
a NCT03924206 135 136 O
contraindication NCT03924206 137 153 O
for NCT03924206 154 157 O
electrocautery NCT03924206 158 172 B-Procedure-Name
use NCT03924206 173 176 O

- NCT03924206 179 180 O
Patients NCT03924206 182 190 O
with NCT03924206 191 195 O
Pacemaker NCT03924206 196 205 B-Procedure-Name
or NCT03924206 206 208 O
implantable NCT03924206 209 220 B-Procedure-Name
cardioverter NCT03924206 221 233 I-Procedure-Name
- NCT03924206 234 235 I-Procedure-Name
defibrillator NCT03924206 236 249 I-Procedure-Name
( NCT03924206 250 251 O
ICD NCT03924206 252 255 B-Procedure-Name
) NCT03924206 256 257 O

- NCT03924206 261 262 O
Patients NCT03924206 264 272 O
with NCT03924206 273 277 O
an NCT03924206 278 280 O
implanted NCT03924206 281 290 B-Procedure-Name
neurostimulator NCT03924206 291 306 I-Procedure-Name
device NCT03924206 307 313 I-Procedure-Name

Inclusion NCT03925454 0 9 O
Criteria NCT03925454 10 18 O
: NCT03925454 19 20 O

- NCT03925454 24 25 O
Receiving NCT03925454 27 36 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
HHD NCT03925454 37 40 B-Procedure-Name
or NCT03925454 41 43 O
ICHDF NCT03925454 44 49 B-Procedure-Name
for NCT03925454 50 53 O
more NCT03925454 54 58 B-Eq-Operator
than NCT03925454 59 63 I-Eq-Operator
3 NCT03925454 65 66 B-Eq-Value
months NCT03925454 67 73 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
and NCT03925454 74 77 O
less NCT03925454 78 82 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03925454 83 87 I-Eq-Operator___Eq-Operator-Value:LT
36 NCT03925454 89 91 B-Eq-Value
months NCT03925454 92 98 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
. NCT03925454 99 100 O

- NCT03925454 104 105 O
Haemoglobin NCT03925454 107 118 B-Observation-Name___Observation-Type-Value:lab
equal NCT03925454 119 124 B-Eq-Operator___Eq-Operator-Value:GTEQ
to NCT03925454 125 127 I-Eq-Operator___Eq-Operator-Value:GTEQ
or NCT03925454 128 130 I-Eq-Operator___Eq-Operator-Value:GTEQ
greater NCT03925454 131 138 I-Eq-Operator___Eq-Operator-Value:GTEQ
than NCT03925454 139 143 O
100 NCT03925454 144 147 B-Eq-Value
g NCT03925454 148 149 B-Eq-Unit
/ NCT03925454 150 151 O
L NCT03925454 152 153 B-Eq-Unit
at NCT03925454 154 156 O
enrolment NCT03925454 157 166 O
. NCT03925454 167 168 O

- NCT03925454 172 173 O
Willing NCT03925454 175 182 O
and NCT03925454 183 186 O
physically NCT03925454 187 197 O
able NCT03925454 198 202 O
to NCT03925454 203 205 O
undertake NCT03925454 206 215 O
the NCT03925454 216 219 O
study NCT03925454 220 225 O
assessments NCT03925454 226 237 B-Procedure-Name
/ NCT03925454 238 239 O
tests NCT03925454 240 245 B-Procedure-Name

- NCT03925454 248 249 O
Willing NCT03925454 251 258 O
to NCT03925454 259 261 O
provide NCT03925454 262 269 O
blood NCT03925454 270 275 B-Observation-Specimen
for NCT03925454 276 279 O
storage NCT03925454 280 287 O
and NCT03925454 288 291 O
future NCT03925454 292 298 O
analysis NCT03925454 299 307 O

- NCT03925454 310 311 O
Able NCT03925454 313 317 O
to NCT03925454 318 320 O
give NCT03925454 321 325 O
informed NCT03925454 326 334 O
consent NCT03925454 335 342 O

Exclusion NCT03925454 343 352 O
Criteria NCT03925454 353 361 O
: NCT03925454 362 363 O

- NCT03925454 367 368 O
Living NCT03925454 370 376 B-Procedure-Name
donor NCT03925454 377 382 I-Procedure-Name
transplant NCT03925454 383 393 I-Procedure-Name
or NCT03925454 394 396 O
change NCT03925454 397 403 B-Stability___Stability-Value:change
to NCT03925454 404 406 O
peritoneal NCT03925454 407 417 B-Procedure-Name
dialysis NCT03925454 418 426 I-Procedure-Name
planned NCT03925454 427 434 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future

- NCT03925454 437 438 O
Physical NCT03925454 440 448 B-Procedure-Name
assessments NCT03925454 449 460 I-Procedure-Name
contraindicated NCT03925454 461 476 O
for NCT03925454 477 480 O
the NCT03925454 481 484 O
following NCT03925454 485 494 O
clinical NCT03925454 495 503 O
reasons NCT03925454 504 511 O

- NCT03925454 519 520 O
Acute NCT03925454 522 527 B-Condition-Name
Coronary NCT03925454 528 536 I-Condition-Name
Syndrome NCT03925454 537 545 I-Condition-Name
( NCT03925454 546 547 O
ACS NCT03925454 548 551 B-Condition-Name
) NCT03925454 552 553 O
within NCT03925454 554 560 B-Eq-Operator___Eq-Operator-Value:LTEQ
the NCT03925454 561 564 O
last NCT03925454 565 569 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
3 NCT03925454 571 572 B-Eq-Value
months NCT03925454 573 579 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
( NCT03925454 580 581 O
chest NCT03925454 582 587 O
pain NCT03925454 588 592 B-Condition-Name
, NCT03925454 593 594 O
ECG NCT03925454 595 598 B-Procedure-Name
changes NCT03925454 599 606 B-Stability___Stability-Value:change
or NCT03925454 607 609 O
typical NCT03925454 610 617 O
biomarker NCT03925454 618 627 B-Observation-Name
elevation NCT03925454 628 637 B-Polarity___Polarity-Value:high
) NCT03925454 638 639 O
. NCT03925454 641 642 O

- NCT03925454 651 652 O
Any NCT03925454 654 657 O
current NCT03925454 658 665 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
uncontrolled NCT03925454 666 678 O
cardiac NCT03925454 679 686 B-Condition-Name
dysrhythmias NCT03925454 687 699 I-Condition-Name
causing NCT03925454 700 707 O
symptoms NCT03925454 708 716 O
( NCT03925454 717 718 O
chest NCT03925454 719 724 O
pain NCT03925454 725 729 B-Condition-Name
, NCT03925454 730 731 O
palpitations NCT03925454 732 744 B-Condition-Name
, NCT03925454 745 746 O
syncope NCT03925454 747 754 B-Condition-Name
or NCT03925454 755 757 O
dizziness NCT03925454 758 767 B-Condition-Name
) NCT03925454 768 769 O

- NCT03925454 778 779 O
Symptomatic NCT03925454 781 792 B-Condition-Name
aortic NCT03925454 793 799 I-Condition-Name
stenosis NCT03925454 800 808 I-Condition-Name

- NCT03925454 816 817 O
New NCT03925454 819 822 B-Condition-Name
York NCT03925454 823 827 I-Condition-Name
Heart NCT03925454 828 833 I-Condition-Name
Association NCT03925454 834 845 I-Condition-Name
grade NCT03925454 846 851 B-Eq-Unit
IV NCT03925454 852 854 B-Eq-Value
Heart NCT03925454 855 860 B-Condition-Name
failure NCT03925454 861 868 I-Condition-Name

- NCT03925454 876 877 O
Severe NCT03925454 879 885 B-Severity___Severity-Value:severe
chronic NCT03925454 886 893 O
obstructive NCT03925454 894 905 B-Condition-Name
pulmonary NCT03925454 906 915 I-Condition-Name
disease NCT03925454 916 923 I-Condition-Name

- NCT03925454 931 932 O
Acute NCT03925454 934 939 B-Severity___Severity-Value:severe
pulmonary NCT03925454 940 949 B-Condition-Name
embolus NCT03925454 950 957 I-Condition-Name
or NCT03925454 958 960 O
pulmonary NCT03925454 961 970 B-Condition-Name
infarction NCT03925454 971 981 I-Condition-Name
in NCT03925454 982 984 O
the NCT03925454 985 988 O
last NCT03925454 989 993 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
3 NCT03925454 995 996 B-Eq-Value
months NCT03925454 997 1003 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

- NCT03925454 1011 1012 O
Current NCT03925454 1014 1021 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
acute NCT03925454 1022 1027 B-Condition-Name
myocarditis NCT03925454 1028 1039 I-Condition-Name
or NCT03925454 1040 1042 O
pericarditis NCT03925454 1043 1055 B-Condition-Name

- NCT03925454 1063 1064 O
Suspected NCT03925454 1066 1075 O
or NCT03925454 1076 1078 O
known NCT03925454 1079 1084 O
dissecting NCT03925454 1085 1095 B-Condition-Name
aneurysm NCT03925454 1096 1104 I-Condition-Name

- NCT03925454 1112 1113 O
Acute NCT03925454 1115 1120 B-Severity___Severity-Value:severe
systemic NCT03925454 1121 1129 O
infection NCT03925454 1130 1139 B-Condition-Name
, NCT03925454 1140 1141 O
accompanied NCT03925454 1142 1153 O
by NCT03925454 1154 1156 O
fever NCT03925454 1157 1162 B-Condition-Name
, NCT03925454 1163 1164 O
body NCT03925454 1165 1169 B-Condition-Name
aches NCT03925454 1170 1175 I-Condition-Name
or NCT03925454 1176 1178 O
swollen NCT03925454 1179 1186 B-Condition-Name
lymph NCT03925454 1187 1192 I-Condition-Name
glands NCT03925454 1193 1199 I-Condition-Name

- NCT03925454 1202 1203 O
Pregnancy NCT03925454 1205 1214 B-Condition-Name

- NCT03925454 1217 1218 O
Life NCT03925454 1220 1224 B-Observation-Name
expectancy NCT03925454 1225 1235 I-Observation-Name
of NCT03925454 1236 1238 O
less NCT03925454 1239 1243 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03925454 1244 1248 I-Eq-Operator___Eq-Operator-Value:LT
twelve NCT03925454 1249 1255 B-Eq-Value
months NCT03925454 1256 1262 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

Inclusion NCT03921632 0 9 O
Criteria NCT03921632 10 18 O
: NCT03921632 19 20 O

- NCT03921632 24 25 O
Patient NCT03921632 27 34 O
of NCT03921632 35 37 O
the NCT03921632 38 41 O
UNC NCT03921632 42 45 B-Location
Center NCT03921632 46 52 I-Location
for NCT03921632 53 56 I-Location
Excellence NCT03921632 57 67 I-Location
for NCT03921632 68 71 I-Location
Eating NCT03921632 72 78 I-Location
Disorders NCT03921632 79 88 I-Location
inpatient NCT03921632 89 98 B-Location___Location-Value:unit
unit NCT03921632 99 103 I-Location___Location-Value:unit
or NCT03921632 104 106 O
outpatient NCT03921632 107 117 B-Location___Location-Value:clinic
clinic NCT03921632 118 124 I-Location___Location-Value:clinic
. NCT03921632 125 126 O

- NCT03921632 130 131 O
Diagnosis NCT03921632 133 142 O
of NCT03921632 143 145 O
anorexia NCT03921632 146 154 B-Condition-Name
nervosa NCT03921632 155 162 I-Condition-Name
or NCT03921632 163 165 O
bulimia NCT03921632 166 173 B-Condition-Name
nervosa NCT03921632 174 181 I-Condition-Name

- NCT03921632 184 185 O
Aged NCT03921632 187 191 O
13 NCT03921632 193 195 B-Eq-Value
- NCT03921632 196 197 B-Eq-Operator___Eq-Operator-Value:BETWEEN
50 NCT03921632 199 201 B-Eq-Value
years NCT03921632 202 207 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03921632 210 211 O
English NCT03921632 213 220 B-Language
- NCT03921632 221 222 O
speaking NCT03921632 223 231 O

Exclusion NCT03921632 232 241 O
Criteria NCT03921632 242 250 O
: NCT03921632 251 252 O

- NCT03921632 256 257 O
Decisionally NCT03921632 259 271 B-Condition-Name
impaired NCT03921632 272 280 I-Condition-Name
( NCT03921632 281 282 O
i NCT03921632 283 284 O
. NCT03921632 285 286 O
e NCT03921632 287 288 O
. NCT03921632 289 290 O
, NCT03921632 291 292 O
Incapable NCT03921632 293 302 O
of NCT03921632 303 305 O
providing NCT03921632 306 315 O
informed NCT03921632 316 324 O
consent NCT03921632 325 332 O
in NCT03921632 333 335 O
the NCT03921632 336 339 O
opinion NCT03921632 340 347 O
of NCT03921632 348 350 O
the NCT03921632 351 354 O
primary NCT03921632 355 362 O
care NCT03921632 363 367 O
provider NCT03921632 368 376 O
in NCT03921632 377 379 O
UNC NCT03921632 380 383 O
Center NCT03921632 384 390 O
for NCT03921632 391 394 O
Excellence NCT03921632 395 405 O
for NCT03921632 406 409 O
Eating NCT03921632 410 416 O
Disorders NCT03921632 417 426 O
) NCT03921632 427 428 O

- NCT03921632 432 433 O
Involuntarily NCT03921632 435 448 B-Observation-Name
committed NCT03921632 449 458 I-Observation-Name
to NCT03921632 459 461 O
the NCT03921632 462 465 O
inpatient NCT03921632 466 475 B-Location___Location-Value:unit
service NCT03921632 476 483 I-Location___Location-Value:unit
of NCT03921632 484 486 O
the NCT03921632 487 490 O
UNC NCT03921632 491 494 O
Department NCT03921632 495 505 O
of NCT03921632 506 508 O
Psychiatry NCT03921632 509 519 B-Provider-Type

Inclusion NCT03928158 0 9 O
Criteria NCT03928158 10 18 O
: NCT03928158 19 20 O

1 NCT03928158 25 26 O
. NCT03928158 26 27 O
Moderate NCT03928158 29 37 B-Severity___Severity-Value:moderate
/ NCT03928158 38 39 O
severe NCT03928158 40 46 B-Severity___Severity-Value:severe
hypertensive NCT03928158 47 59 O
left NCT03928158 60 64 O
ventricular NCT03928158 65 76 O
( NCT03928158 77 78 O
LV NCT03928158 79 81 O
) NCT03928158 82 83 O
hypertrophy NCT03928158 84 95 B-Condition-Name
( NCT03928158 96 97 O
LVMi NCT03928158 98 102 B-Observation-Name___Observation-Type-Value:measurement
≥ NCT03928158 103 104 B-Eq-Operator___Eq-Operator-Value:GTEQ
109 NCT03928158 106 109 B-Eq-Value
g NCT03928158 110 111 B-Eq-Unit
/ NCT03928158 112 113 O
m² NCT03928158 114 116 B-Eq-Unit
in NCT03928158 117 119 O
women NCT03928158 120 125 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
and NCT03928158 126 129 O
≥ NCT03928158 130 131 B-Eq-Operator___Eq-Operator-Value:GTEQ
132 NCT03928158 133 136 B-Eq-Value
g NCT03928158 137 138 B-Eq-Unit
/ NCT03928158 139 140 O
m² NCT03928158 141 143 B-Eq-Unit
in NCT03928158 144 146 O
men NCT03928158 147 150 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
) NCT03928158 151 152 O
; NCT03928158 153 154 O

2 NCT03928158 158 159 O
. NCT03928158 159 160 O
New NCT03928158 162 165 B-Condition-Name
York NCT03928158 166 170 I-Condition-Name
Heart NCT03928158 171 176 I-Condition-Name
Association NCT03928158 177 188 I-Condition-Name
( NCT03928158 189 190 O
NYHA NCT03928158 191 195 B-Condition-Name
) NCT03928158 196 197 O
class NCT03928158 198 203 B-Eq-Unit
II NCT03928158 204 206 B-Eq-Value
- NCT03928158 207 208 O
III NCT03928158 209 212 B-Eq-Value
heart NCT03928158 213 218 B-Condition-Name
failure NCT03928158 219 226 I-Condition-Name
; NCT03928158 226 227 O

3 NCT03928158 231 232 O
. NCT03928158 232 233 O
Left NCT03928158 235 239 B-Observation-Name___Observation-Type-Value:measurement
ventricular NCT03928158 240 251 I-Observation-Name___Observation-Type-Value:measurement
ejection NCT03928158 252 260 I-Observation-Name___Observation-Type-Value:measurement
fraction NCT03928158 261 269 I-Observation-Name___Observation-Type-Value:measurement
> NCT03928158 270 271 B-Eq-Operator___Eq-Operator-Value:GT
50 NCT03928158 273 275 B-Eq-Value
% NCT03928158 276 277 B-Eq-Unit
; NCT03928158 278 279 O

4 NCT03928158 283 284 O
. NCT03928158 284 285 O
Increased NCT03928158 287 296 B-Polarity___Polarity-Value:high
LV NCT03928158 297 299 B-Observation-Name
filling NCT03928158 300 307 I-Observation-Name
pressures NCT03928158 308 317 I-Observation-Name
assessed NCT03928158 318 326 O
at NCT03928158 327 329 O
rest NCT03928158 330 334 O
or NCT03928158 335 337 O
at NCT03928158 338 340 O
peak NCT03928158 341 345 O
exercise NCT03928158 346 354 O
by NCT03928158 355 357 O
echocardiography NCT03928158 358 374 B-Procedure-Name

5 NCT03928158 378 379 O
. NCT03928158 379 380 O
Body NCT03928158 382 386 B-Observation-Name___Observation-Type-Value:vital
mass NCT03928158 387 391 I-Observation-Name___Observation-Type-Value:vital
index NCT03928158 392 397 I-Observation-Name___Observation-Type-Value:vital
( NCT03928158 398 399 O
BMI NCT03928158 400 403 B-Observation-Name___Observation-Type-Value:vital
) NCT03928158 404 405 O
> NCT03928158 406 407 B-Eq-Operator___Eq-Operator-Value:GT
30 NCT03928158 409 411 B-Eq-Value
kg NCT03928158 412 414 B-Eq-Unit
/ NCT03928158 415 416 O
m² NCT03928158 417 419 B-Eq-Unit

6 NCT03928158 423 424 O
. NCT03928158 424 425 O
Signed NCT03928158 427 433 O
and NCT03928158 434 437 O
data NCT03928158 438 442 O
informed NCT03928158 443 451 O
consent NCT03928158 452 459 O

Exclusion NCT03928158 460 469 O
Criteria NCT03928158 470 478 O
: NCT03928158 479 480 O

1 NCT03928158 485 486 O
. NCT03928158 486 487 O
Age NCT03928158 489 492 O
≤ NCT03928158 493 494 B-Eq-Operator___Eq-Operator-Value:LTEQ
18 NCT03928158 496 498 B-Eq-Value
years NCT03928158 499 504 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
; NCT03928158 504 505 O

2 NCT03928158 509 510 O
. NCT03928158 510 511 O
Evidence NCT03928158 513 521 O
of NCT03928158 522 524 O
myocardial NCT03928158 525 535 B-Condition-Name
ischemia NCT03928158 536 544 I-Condition-Name
during NCT03928158 545 551 O
stress NCT03928158 552 558 B-Procedure-Name
echocardiography NCT03928158 559 575 I-Procedure-Name
; NCT03928158 575 576 O

3 NCT03928158 580 581 O
. NCT03928158 581 582 O
Chronic NCT03928158 584 591 O
atrial NCT03928158 592 598 B-Condition-Name
flutter NCT03928158 599 606 I-Condition-Name
or NCT03928158 607 609 O
atrial NCT03928158 610 616 B-Condition-Name
fibrillation NCT03928158 617 629 I-Condition-Name
; NCT03928158 629 630 O

4 NCT03928158 634 635 O
. NCT03928158 635 636 O
Alternative NCT03928158 638 649 O
cause NCT03928158 650 655 O
of NCT03928158 656 658 O
left NCT03928158 659 663 B-Condition-Name
ventricular NCT03928158 664 675 I-Condition-Name
hypertrophy NCT03928158 676 687 I-Condition-Name
and NCT03928158 688 691 O
impaired NCT03928158 692 700 B-Condition-Name
diastolic NCT03928158 701 710 I-Condition-Name
function NCT03928158 711 719 I-Condition-Name
( NCT03928158 720 721 O
hypertrophic NCT03928158 722 734 O
/ NCT03928158 735 736 O
restictive NCT03928158 737 747 O
cardiomyopathy NCT03928158 748 762 B-Condition-Name
, NCT03928158 763 764 O
aortic NCT03928158 765 771 B-Condition-Name
stenosis NCT03928158 772 780 I-Condition-Name
, NCT03928158 781 782 O
constrictive NCT03928158 783 795 B-Condition-Name
pericarditis NCT03928158 796 808 I-Condition-Name
and NCT03928158 809 812 O
etc NCT03928158 813 816 O
. NCT03928158 817 818 O
) NCT03928158 819 820 O
; NCT03928158 821 822 O

5 NCT03928158 826 827 O
. NCT03928158 827 828 O
NYHA NCT03928158 830 834 B-Condition-Name
classification NCT03928158 835 849 B-Eq-Unit
I NCT03928158 850 851 B-Eq-Value
or NCT03928158 852 854 O
decompensated NCT03928158 855 868 O
heart NCT03928158 869 874 B-Condition-Name
failure NCT03928158 875 882 I-Condition-Name
at NCT03928158 883 885 O
screening NCT03928158 886 895 O
; NCT03928158 895 896 O

6 NCT03928158 900 901 O
. NCT03928158 901 902 O
Systolic NCT03928158 904 912 B-Observation-Name___Observation-Type-Value:vital
blood NCT03928158 913 918 I-Observation-Name___Observation-Type-Value:vital
pressure NCT03928158 919 927 I-Observation-Name___Observation-Type-Value:vital
< NCT03928158 928 929 B-Eq-Operator___Eq-Operator-Value:LT
110 NCT03928158 931 934 B-Eq-Value
mmHg NCT03928158 935 939 B-Eq-Unit
or NCT03928158 940 942 O
> NCT03928158 943 944 B-Eq-Operator___Eq-Operator-Value:GT
180 NCT03928158 946 949 B-Eq-Value
mmHg NCT03928158 950 954 B-Eq-Unit
; NCT03928158 954 955 O

7 NCT03928158 959 960 O
. NCT03928158 960 961 O
Diastolic NCT03928158 963 972 B-Observation-Name___Observation-Type-Value:vital
blood NCT03928158 973 978 I-Observation-Name___Observation-Type-Value:vital
pressure NCT03928158 979 987 I-Observation-Name___Observation-Type-Value:vital
< NCT03928158 988 989 B-Eq-Operator___Eq-Operator-Value:LT
40 NCT03928158 991 993 B-Eq-Value
mmHg NCT03928158 994 998 B-Eq-Unit
or NCT03928158 999 1001 O
> NCT03928158 1002 1003 B-Eq-Operator___Eq-Operator-Value:GT
100 NCT03928158 1005 1008 B-Eq-Value
mmHg NCT03928158 1009 1013 B-Eq-Unit
; NCT03928158 1013 1014 O

8 NCT03928158 1018 1019 O
. NCT03928158 1019 1020 O
Anemia NCT03928158 1022 1028 B-Condition-Name
( NCT03928158 1029 1030 O
Hb NCT03928158 1031 1033 B-Observation-Name___Observation-Type-Value:lab
< NCT03928158 1034 1035 B-Eq-Operator___Eq-Operator-Value:LT
100 NCT03928158 1037 1040 B-Eq-Value
g NCT03928158 1041 1042 B-Eq-Unit
/ NCT03928158 1043 1044 O
l NCT03928158 1045 1046 B-Eq-Unit
) NCT03928158 1047 1048 O
; NCT03928158 1049 1050 O

9 NCT03928158 1054 1055 O
. NCT03928158 1055 1056 O
Significant NCT03928158 1058 1069 B-Severity___Severity-Value:severe
left NCT03928158 1070 1074 O
sided NCT03928158 1075 1080 O
structural NCT03928158 1081 1091 B-Condition-Name
valve NCT03928158 1092 1097 I-Condition-Name
disease NCT03928158 1098 1105 I-Condition-Name
; NCT03928158 1105 1106 O

10 NCT03928158 1109 1111 O
. NCT03928158 1111 1112 O
Secondary NCT03928158 1114 1123 O
hypertension NCT03928158 1124 1136 B-Condition-Name
; NCT03928158 1136 1137 O

11 NCT03928158 1140 1142 O
. NCT03928158 1142 1143 O
Dyspnea NCT03928158 1145 1152 B-Condition-Name
due NCT03928158 1153 1156 O
to NCT03928158 1157 1159 O
non NCT03928158 1160 1163 O
- NCT03928158 1164 1165 O
cardiac NCT03928158 1166 1173 O
causes NCT03928158 1174 1180 O
such NCT03928158 1181 1185 O
as NCT03928158 1186 1188 O
pulmonary NCT03928158 1189 1198 B-Condition-Name
disease NCT03928158 1199 1206 I-Condition-Name
, NCT03928158 1207 1208 O
anemia NCT03928158 1209 1215 B-Condition-Name
, NCT03928158 1216 1217 O
severe NCT03928158 1218 1224 B-Severity___Severity-Value:severe
obesity NCT03928158 1225 1232 B-Condition-Name
, NCT03928158 1233 1234 O
primary NCT03928158 1235 1242 B-Condition-Name
valvular NCT03928158 1243 1251 I-Condition-Name
, NCT03928158 1252 1253 O
or NCT03928158 1254 1256 O
myocardial NCT03928158 1257 1267 B-Condition-Name
diseases NCT03928158 1268 1276 I-Condition-Name
; NCT03928158 1276 1277 O

12 NCT03928158 1280 1282 O
. NCT03928158 1282 1283 O
Myocardial NCT03928158 1285 1295 B-Condition-Name
infarction NCT03928158 1296 1306 I-Condition-Name
or NCT03928158 1307 1309 O
myocardial NCT03928158 1310 1320 B-Procedure-Name
revascularization NCT03928158 1321 1338 I-Procedure-Name
within NCT03928158 1339 1345 B-Eq-Operator___Eq-Operator-Value:LTEQ
the NCT03928158 1346 1349 O
last NCT03928158 1350 1354 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
3 NCT03928158 1356 1357 B-Eq-Value
months NCT03928158 1358 1364 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
of NCT03928158 1365 1367 O
screening NCT03928158 1368 1377 O
; NCT03928158 1377 1378 O

13 NCT03928158 1381 1383 O
. NCT03928158 1383 1384 O
Stroke NCT03928158 1386 1392 B-Condition-Name
or NCT03928158 1393 1395 O
TIA NCT03928158 1396 1399 B-Condition-Name
within NCT03928158 1400 1406 B-Eq-Operator___Eq-Operator-Value:LTEQ
the NCT03928158 1407 1410 O
last NCT03928158 1411 1415 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
3 NCT03928158 1417 1418 B-Eq-Value
months NCT03928158 1419 1425 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
of NCT03928158 1426 1428 O
screening NCT03928158 1429 1438 O
; NCT03928158 1438 1439 O

14 NCT03928158 1442 1444 O
. NCT03928158 1444 1445 O
Autoimmunic NCT03928158 1447 1458 O
and NCT03928158 1459 1462 O
oncological NCT03928158 1463 1474 O
diseases NCT03928158 1475 1483 B-Condition-Name
; NCT03928158 1483 1484 O

15 NCT03928158 1487 1489 O
. NCT03928158 1489 1490 O
Impaired NCT03928158 1492 1500 B-Condition-Name
renal NCT03928158 1501 1506 I-Condition-Name
function NCT03928158 1507 1515 I-Condition-Name
, NCT03928158 1516 1517 O
defined NCT03928158 1518 1525 O
as NCT03928158 1526 1528 O
eGFR NCT03928158 1529 1533 B-Observation-Name___Observation-Type-Value:lab
< NCT03928158 1534 1535 B-Eq-Operator___Eq-Operator-Value:LT
30 NCT03928158 1537 1539 B-Eq-Value
ml NCT03928158 1540 1542 B-Eq-Unit
/ NCT03928158 1543 1544 O
min NCT03928158 1545 1548 B-Eq-Unit
/ NCT03928158 1549 1550 O
1.73 NCT03928158 1552 1556 B-Eq-Unit
m² NCT03928158 1557 1559 I-Eq-Unit
; NCT03928158 1559 1560 O

16 NCT03928158 1563 1565 O
. NCT03928158 1565 1566 O
Impaired NCT03928158 1568 1576 B-Condition-Name
liver NCT03928158 1577 1582 I-Condition-Name
function NCT03928158 1583 1591 I-Condition-Name
; NCT03928158 1591 1592 O

17 NCT03928158 1595 1597 O
. NCT03928158 1597 1598 O
Potassium NCT03928158 1600 1609 B-Observation-Name___Observation-Type-Value:lab
concentration NCT03928158 1610 1623 I-Observation-Name___Observation-Type-Value:lab
> NCT03928158 1624 1625 B-Eq-Operator___Eq-Operator-Value:GT
5.2 NCT03928158 1627 1630 B-Eq-Value
mmol NCT03928158 1631 1635 B-Eq-Unit
/ NCT03928158 1636 1637 O
L NCT03928158 1638 1639 B-Eq-Unit
. NCT03928158 1640 1641 O

Inclusion NCT03929497 0 9 O
Criteria NCT03929497 10 18 O
: NCT03929497 19 20 O

- NCT03929497 24 25 O
The NCT03929497 27 30 O
patient NCT03929497 31 38 O
completed NCT03929497 39 48 O
Study NCT03929497 49 54 O
17972 NCT03929497 56 61 O
A NCT03929497 62 63 O
. NCT03929497 64 65 O

- NCT03929497 69 70 O
The NCT03929497 72 75 O
patient NCT03929497 76 83 O
and NCT03929497 84 87 O
the NCT03929497 88 91 O
patient NCT03929497 92 99 O
's NCT03929497 99 101 O
caregiver NCT03929497 102 111 O
or NCT03929497 112 114 O
identified NCT03929497 115 125 O
responsible NCT03929497 126 137 O
person NCT03929497 138 144 O
is NCT03929497 145 147 O
able NCT03929497 148 152 O
to NCT03929497 153 155 O
read NCT03929497 156 160 O
and NCT03929497 161 164 O
understand NCT03929497 165 175 O
the NCT03929497 176 179 O
Informed NCT03929497 180 188 O
Consent NCT03929497 189 196 O
Form NCT03929497 197 201 O
. NCT03929497 202 203 O

- NCT03929497 207 208 O
The NCT03929497 210 213 O
patient NCT03929497 214 221 O
has NCT03929497 222 225 O
signed NCT03929497 226 232 O
the NCT03929497 233 236 O
Informed NCT03929497 237 245 O
Consent NCT03929497 246 253 O
Form NCT03929497 254 258 O
specific NCT03929497 259 267 O
for NCT03929497 268 271 O
Study NCT03929497 272 277 O
17972 NCT03929497 279 284 O
B NCT03929497 285 286 O
. NCT03929497 287 288 O

- NCT03929497 292 293 O
The NCT03929497 295 298 O
patient NCT03929497 299 306 O
can NCT03929497 307 310 O
potentially NCT03929497 311 322 O
benefit NCT03929497 323 330 O
from NCT03929497 331 335 O
24 NCT03929497 337 339 B-Eq-Value
weeks NCT03929497 340 345 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
of NCT03929497 346 348 O
treatment NCT03929497 349 358 O
with NCT03929497 359 363 O
Lu NCT03929497 364 366 B-Drug-Name
AF NCT03929497 367 369 I-Drug-Name
11167 NCT03929497 370 375 I-Drug-Name
according NCT03929497 376 385 O
to NCT03929497 386 388 O
the NCT03929497 389 392 O
investigator NCT03929497 393 405 O
's NCT03929497 405 407 O
clinical NCT03929497 408 416 O
judgment NCT03929497 417 425 O
. NCT03929497 426 427 O

Exclusion NCT03929497 429 438 O
Criteria NCT03929497 439 447 O
: NCT03929497 448 449 O

- NCT03929497 453 454 O
The NCT03929497 456 459 O
patient NCT03929497 460 467 O
has NCT03929497 468 471 O
any NCT03929497 472 475 O
current NCT03929497 476 483 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
primary NCT03929497 484 491 O
psychiatric NCT03929497 492 503 B-Condition-Name
disorder NCT03929497 504 512 I-Condition-Name
other NCT03929497 513 518 O
than NCT03929497 519 523 O
schizophrenia NCT03929497 524 537 B-Condition-Name
diagnosed NCT03929497 538 547 O
during NCT03929497 548 554 O
study NCT03929497 555 560 O
17972 NCT03929497 562 567 O
A NCT03929497 568 569 O

- NCT03929497 572 573 O
The NCT03929497 575 578 O
patient NCT03929497 579 586 O
, NCT03929497 587 588 O
in NCT03929497 589 591 O
the NCT03929497 592 595 O
opinion NCT03929497 596 603 O
of NCT03929497 604 606 O
the NCT03929497 607 610 O
investigator NCT03929497 611 623 O
, NCT03929497 624 625 O
is NCT03929497 626 628 O
at NCT03929497 629 631 O
significant NCT03929497 632 643 B-Severity___Severity-Value:severe
risk NCT03929497 644 648 O
of NCT03929497 649 651 O
suicide NCT03929497 652 659 B-Condition-Name

Other NCT03929497 660 665 O
in NCT03929497 666 668 O
- NCT03929497 669 670 O
and NCT03929497 671 674 O
exclusion NCT03929497 675 684 O
criteria NCT03929497 685 693 O
may NCT03929497 694 697 O
apply NCT03929497 698 703 O

Inclusion NCT03921593 0 9 O
Criteria NCT03921593 10 18 O
: NCT03921593 19 20 O

- NCT03921593 24 25 O
Willing NCT03921593 27 34 O
and NCT03921593 35 38 O
able NCT03921593 39 43 O
to NCT03921593 44 46 O
give NCT03921593 47 51 O
informed NCT03921593 52 60 O
consent NCT03921593 61 68 O
for NCT03921593 69 72 O
participation NCT03921593 73 86 O
in NCT03921593 87 89 O
the NCT03921593 90 93 O
study NCT03921593 94 99 O

- NCT03921593 102 103 O
Insulin NCT03921593 105 112 O
Dependent NCT03921593 113 122 O
Diabetic NCT03921593 123 131 B-Condition-Name
Patients NCT03921593 132 140 O

- NCT03921593 143 144 O
Active NCT03921593 146 152 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
on NCT03921593 153 155 O
Pancreas NCT03921593 156 164 B-Observation-Name
Transplant NCT03921593 165 175 I-Observation-Name
Wait NCT03921593 176 180 I-Observation-Name
List NCT03921593 181 185 I-Observation-Name

Exclusion NCT03921593 186 195 O
Criteria NCT03921593 196 204 O
: NCT03921593 205 206 O

- NCT03921593 210 211 O
Not NCT03921593 213 216 O
fluent NCT03921593 217 223 O
in NCT03921593 224 226 O
English NCT03921593 227 234 B-Language

Inclusion NCT03927690 0 9 O
Criteria NCT03927690 10 18 O

1 NCT03927690 22 23 O
. NCT03927690 23 24 O
Written NCT03927690 26 33 O
informed NCT03927690 34 42 O
consent NCT03927690 43 50 O
must NCT03927690 51 55 O
be NCT03927690 56 58 O
obtained NCT03927690 59 67 O
before NCT03927690 68 74 O
any NCT03927690 75 78 O
assessment NCT03927690 79 89 O
is NCT03927690 90 92 O
performed NCT03927690 93 102 O
. NCT03927690 103 104 O

2 NCT03927690 109 110 O
. NCT03927690 110 111 O
Male NCT03927690 113 117 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
and NCT03927690 118 121 O
female NCT03927690 122 128 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
patients NCT03927690 129 137 O
age NCT03927690 138 141 O
18 NCT03927690 143 145 B-Eq-Value
to NCT03927690 146 148 B-Eq-Operator___Eq-Operator-Value:BETWEEN
85 NCT03927690 150 152 B-Eq-Value
years NCT03927690 153 158 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03927690 159 161 O
age NCT03927690 162 165 O
inclusive NCT03927690 166 175 O
at NCT03927690 176 178 O
screening NCT03927690 179 188 O

3 NCT03927690 192 193 O
. NCT03927690 193 194 O
Presence NCT03927690 196 204 O
of NCT03927690 205 207 O
type NCT03927690 208 212 O
I NCT03927690 213 214 O
or NCT03927690 215 217 O
type NCT03927690 218 222 O
II NCT03927690 223 225 O
diabetes NCT03927690 226 234 B-Condition-Name
mellitus NCT03927690 235 243 I-Condition-Name

4 NCT03927690 247 248 O
. NCT03927690 248 249 O
The NCT03927690 251 254 O
ETDRS NCT03927690 255 260 B-Observation-Name___Observation-Type-Value:clinical-score
letter NCT03927690 261 267 I-Observation-Name___Observation-Type-Value:clinical-score
score NCT03927690 268 273 I-Observation-Name___Observation-Type-Value:clinical-score
in NCT03927690 274 276 O
the NCT03927690 277 280 O
study NCT03927690 281 286 O
eye NCT03927690 287 290 O
must NCT03927690 291 295 O
be NCT03927690 296 298 O
between NCT03927690 299 306 B-Eq-Operator___Eq-Operator-Value:BETWEEN
24 NCT03927690 308 310 B-Eq-Value
and NCT03927690 311 314 O
70 NCT03927690 316 318 B-Eq-Value
letters NCT03927690 319 326 B-Eq-Unit
( NCT03927690 327 328 O
approximate NCT03927690 329 340 O
Snellen NCT03927690 341 348 B-Observation-Name
equivalent NCT03927690 349 359 O
of NCT03927690 360 362 O
20 NCT03927690 364 366 B-Eq-Value
/ NCT03927690 367 368 O
40 NCT03927690 370 372 B-Eq-Value
- NCT03927690 373 374 B-Eq-Operator___Eq-Operator-Value:BETWEEN
20 NCT03927690 376 378 B-Eq-Value
/ NCT03927690 379 380 O
320 NCT03927690 382 385 B-Eq-Value
) NCT03927690 386 387 O
. NCT03927690 389 390 O
The NCT03927690 392 395 O
non NCT03927690 396 399 O
- NCT03927690 400 401 O
study NCT03927690 402 407 O
eye NCT03927690 408 411 O
( NCT03927690 412 413 O
fellow NCT03927690 414 420 O
eye NCT03927690 421 424 O
) NCT03927690 425 426 O
should NCT03927690 427 433 O
be NCT03927690 434 436 O
≥ NCT03927690 437 438 B-Eq-Operator___Eq-Operator-Value:GTEQ
34 NCT03927690 440 442 B-Eq-Value
letters NCT03927690 443 450 B-Eq-Unit
or NCT03927690 451 453 B-Eq-Operator___Eq-Operator-Value:GTEQ
better NCT03927690 454 460 I-Eq-Operator___Eq-Operator-Value:GTEQ
( NCT03927690 461 462 O
approximate NCT03927690 463 474 O
Snellen NCT03927690 475 482 B-Observation-Name
equivalent NCT03927690 483 493 O
of NCT03927690 494 496 O
20 NCT03927690 498 500 B-Eq-Value
/ NCT03927690 501 502 O
200 NCT03927690 504 507 B-Eq-Value
) NCT03927690 508 509 O
at NCT03927690 510 512 O
screening NCT03927690 513 522 O

5 NCT03927690 526 527 O
. NCT03927690 527 528 O
Presence NCT03927690 530 538 O
of NCT03927690 539 541 O
DME NCT03927690 542 545 B-Condition-Name
in NCT03927690 546 548 O
the NCT03927690 549 552 O
study NCT03927690 553 558 O
eye NCT03927690 559 562 O
, NCT03927690 563 564 O
with NCT03927690 565 569 O
decrease NCT03927690 570 578 B-Stability___Stability-Value:change
in NCT03927690 579 581 O
vision NCT03927690 582 588 B-Condition-Name
due NCT03927690 589 592 O
to NCT03927690 593 595 O
foveal NCT03927690 596 602 B-Condition-Name
thickening NCT03927690 603 613 I-Condition-Name
of NCT03927690 614 616 O
central NCT03927690 617 624 B-Observation-Name___Observation-Type-Value:measurement
macular NCT03927690 625 632 I-Observation-Name___Observation-Type-Value:measurement
thickness NCT03927690 633 642 I-Observation-Name___Observation-Type-Value:measurement
≥ NCT03927690 643 644 B-Eq-Operator___Eq-Operator-Value:GTEQ
320 NCT03927690 646 649 B-Eq-Value
µm NCT03927690 650 652 B-Eq-Unit
in NCT03927690 653 655 O
the NCT03927690 656 659 O
central NCT03927690 660 667 O
subfield NCT03927690 668 676 O
, NCT03927690 677 678 O
as NCT03927690 679 681 O
assessed NCT03927690 682 690 O
on NCT03927690 691 693 O
SD NCT03927690 694 696 B-Procedure-Name
- NCT03927690 697 698 I-Procedure-Name
OCT NCT03927690 699 702 I-Procedure-Name
and NCT03927690 703 706 O
confirmed NCT03927690 707 716 O
by NCT03927690 717 719 O
the NCT03927690 720 723 O
central NCT03927690 724 731 O
reading NCT03927690 732 739 O
center NCT03927690 740 746 O
at NCT03927690 747 749 O
screening NCT03927690 750 759 O

Other NCT03927690 760 765 O
protocol NCT03927690 766 774 O
specified NCT03927690 775 784 O
inclusion NCT03927690 785 794 O
/ NCT03927690 795 796 O
exclusion NCT03927690 797 806 O
criteria NCT03927690 807 815 O
apply NCT03927690 816 821 O
. NCT03927690 822 823 O

Inclusion NCT03926559 0 9 O
Criteria NCT03926559 10 18 O
: NCT03926559 19 20 O

- NCT03926559 24 25 O
Patients NCT03926559 27 35 O
with NCT03926559 36 40 O
a NCT03926559 41 42 O
second NCT03926559 43 49 O
degree NCT03926559 50 56 O
, NCT03926559 57 58 O
third NCT03926559 59 64 O
degree NCT03926559 65 71 O
, NCT03926559 72 73 O
or NCT03926559 74 76 O
fourth NCT03926559 77 83 O
degree NCT03926559 84 90 O
perineal NCT03926559 91 99 B-Condition-Name
tear NCT03926559 100 104 I-Condition-Name
identified NCT03926559 105 115 O
in NCT03926559 116 118 O
the NCT03926559 119 122 O
immediate NCT03926559 123 132 O
postpartum NCT03926559 133 143 B-Condition-Name
period NCT03926559 144 150 O
. NCT03926559 151 152 O

- NCT03926559 156 157 O
Pregnant NCT03926559 159 167 B-Condition-Name
patients NCT03926559 168 176 O
who NCT03926559 177 180 O
received NCT03926559 181 189 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
neuraxial NCT03926559 190 199 B-Procedure-Name
anesthesia NCT03926559 200 210 I-Procedure-Name
during NCT03926559 211 217 O
their NCT03926559 218 223 O
labor NCT03926559 224 229 B-Condition-Name
course NCT03926559 230 236 O

- NCT03926559 239 240 O
Women NCT03926559 242 247 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
> NCT03926559 248 249 B-Eq-Operator___Eq-Operator-Value:GT
18 NCT03926559 251 253 B-Eq-Value
yo NCT03926559 254 256 O

Exclusion NCT03926559 257 266 O
Criteria NCT03926559 267 275 O
: NCT03926559 276 277 O

- NCT03926559 281 282 O
Unwillingness NCT03926559 284 297 O
to NCT03926559 298 300 O
participate NCT03926559 301 312 O
in NCT03926559 313 315 O
the NCT03926559 316 319 O
study NCT03926559 320 325 O

- NCT03926559 328 329 O
Allergy NCT03926559 331 338 O
to NCT03926559 339 341 O
morphine NCT03926559 342 350 B-Drug-Name

- NCT03926559 353 354 O
Women NCT03926559 356 361 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
with NCT03926559 362 366 O
history NCT03926559 367 374 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03926559 375 377 O
polysubstance NCT03926559 378 391 B-Condition-Name
abuse NCT03926559 392 397 I-Condition-Name
/ NCT03926559 398 399 O
narcotic NCT03926559 400 408 B-Condition-Name
abuse NCT03926559 409 414 I-Condition-Name

- NCT03926559 417 418 O
Women NCT03926559 420 425 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
< NCT03926559 426 427 B-Eq-Operator___Eq-Operator-Value:LT
18 NCT03926559 429 431 B-Eq-Value
yo NCT03926559 432 434 O

Inclusion NCT03924414 0 9 O
Criteria NCT03924414 10 18 O
: NCT03924414 19 20 O

- NCT03924414 24 25 O
Men NCT03924414 27 30 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
and NCT03924414 31 34 O
women NCT03924414 35 40 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
age NCT03924414 41 44 O
65 NCT03924414 46 48 B-Eq-Value
years NCT03924414 49 54 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
or NCT03924414 55 57 B-Eq-Operator___Eq-Operator-Value:GTEQ
older NCT03924414 58 63 I-Eq-Operator___Eq-Operator-Value:GTEQ

- NCT03924414 66 67 O
Current NCT03924414 69 76 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
PD NCT03924414 77 79 B-Condition-Name
diagnosis NCT03924414 80 89 O
with NCT03924414 90 94 O
symptoms NCT03924414 95 103 O
severity NCT03924414 104 112 O
at NCT03924414 113 115 O
Hoehn NCT03924414 116 121 B-Condition-Name
& NCT03924414 122 123 I-Condition-Name
Yahr NCT03924414 124 128 I-Condition-Name
( NCT03924414 129 130 O
H&Y NCT03924414 131 134 B-Condition-Name
) NCT03924414 135 136 O
stage NCT03924414 137 142 B-Eq-Unit
1 NCT03924414 144 145 B-Eq-Value
- NCT03924414 146 147 B-Eq-Operator___Eq-Operator-Value:BETWEEN
4 NCT03924414 149 150 B-Eq-Value
based NCT03924414 151 156 O
on NCT03924414 157 159 O
an NCT03924414 160 162 O
expert NCT03924414 163 169 O
assessment NCT03924414 170 180 O
( NCT03924414 181 182 O
movement NCT03924414 183 191 B-Condition-Name
disorders NCT03924414 192 201 I-Condition-Name
neurologist NCT03924414 202 213 B-Provider-Type
report NCT03924414 214 220 O
or NCT03924414 221 223 O
telemedicine NCT03924414 224 236 B-Procedure-Name
evaluation NCT03924414 237 247 I-Procedure-Name
) NCT03924414 248 249 O

- NCT03924414 253 254 O
Willing NCT03924414 256 263 O
and NCT03924414 264 267 O
able NCT03924414 268 272 O
to NCT03924414 273 275 O
continue NCT03924414 276 284 O
in NCT03924414 285 287 O
follow NCT03924414 288 294 O
- NCT03924414 295 296 O
up NCT03924414 297 299 O
for NCT03924414 300 303 O
at NCT03924414 304 306 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03924414 307 312 I-Eq-Operator___Eq-Operator-Value:GTEQ
2 NCT03924414 314 315 B-Eq-Value
years NCT03924414 316 321 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03924414 324 325 O
Willing NCT03924414 327 334 O
and NCT03924414 335 338 O
able NCT03924414 339 343 O
to NCT03924414 344 346 O
provide NCT03924414 347 354 O
informed NCT03924414 355 363 O
consent NCT03924414 364 371 O

Exclusion NCT03924414 372 381 O
Criteria NCT03924414 382 390 O
: NCT03924414 391 392 O

- NCT03924414 396 397 O
History NCT03924414 399 406 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03924414 407 409 O
hip NCT03924414 410 413 O
fracture NCT03924414 414 422 B-Condition-Name

- NCT03924414 425 426 O
Any NCT03924414 428 431 O
use NCT03924414 432 435 O
of NCT03924414 436 438 O
a NCT03924414 439 440 O
bisphosphonate NCT03924414 441 455 B-Drug-Name
drug NCT03924414 456 460 I-Drug-Name
within NCT03924414 461 467 B-Eq-Operator___Eq-Operator-Value:LTEQ
the NCT03924414 468 471 O
last NCT03924414 472 476 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
12 NCT03924414 478 480 B-Eq-Value
months NCT03924414 481 487 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

- NCT03924414 490 491 O
Use NCT03924414 493 496 O
of NCT03924414 497 499 O
any NCT03924414 500 503 O
other NCT03924414 504 509 O
osteoporosis NCT03924414 510 522 B-Procedure-Name
treatment NCT03924414 523 532 I-Procedure-Name
( NCT03924414 533 534 O
such NCT03924414 535 539 O
as NCT03924414 540 542 O
SERMs NCT03924414 543 548 B-Drug-Name
and NCT03924414 549 552 O
denosumab NCT03924414 553 562 B-Drug-Name
) NCT03924414 563 564 O
within NCT03924414 565 571 B-Eq-Operator___Eq-Operator-Value:LTEQ
the NCT03924414 572 575 O
last NCT03924414 576 580 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
6 NCT03924414 582 583 B-Eq-Value
months NCT03924414 584 590 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

- NCT03924414 598 599 O
Tooth NCT03924414 601 606 B-Procedure-Name
extraction NCT03924414 607 617 I-Procedure-Name
or NCT03924414 618 620 O
invasive NCT03924414 621 629 O
dental NCT03924414 630 636 B-Procedure-Name
procedures NCT03924414 637 647 I-Procedure-Name
within NCT03924414 648 654 B-Eq-Operator___Eq-Operator-Value:LTEQ
the NCT03924414 655 658 O
past NCT03924414 659 663 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
30 NCT03924414 665 667 B-Eq-Value
days NCT03924414 668 672 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
or NCT03924414 673 675 O
planned NCT03924414 676 683 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
/ NCT03924414 684 685 O
scheduled NCT03924414 686 695 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
extraction NCT03924414 696 706 B-Procedure-Name
/ NCT03924414 707 708 O
procedure NCT03924414 709 718 B-Procedure-Name
in NCT03924414 719 721 O
the NCT03924414 722 725 O
next NCT03924414 726 730 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
12 NCT03924414 732 734 B-Eq-Value
months NCT03924414 735 741 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

- NCT03924414 744 745 O
Non NCT03924414 747 750 B-Condition-Name
- NCT03924414 751 752 I-Condition-Name
ambulatory NCT03924414 753 763 I-Condition-Name
, NCT03924414 764 765 O
i NCT03924414 766 767 O
. NCT03924414 768 769 O
e NCT03924414 770 771 O
. NCT03924414 772 773 O
, NCT03924414 774 775 O
unable NCT03924414 776 782 B-Condition-Name
to NCT03924414 783 785 I-Condition-Name
walk NCT03924414 786 790 I-Condition-Name
without NCT03924414 791 798 O
assistance NCT03924414 799 809 O
of NCT03924414 810 812 O
another NCT03924414 813 820 O
person NCT03924414 821 827 O
. NCT03924414 828 829 O

- NCT03924414 833 834 O
Undergoing NCT03924414 836 846 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
kidney NCT03924414 847 853 B-Procedure-Name
dialysis NCT03924414 854 862 I-Procedure-Name

- NCT03924414 865 866 O
A NCT03924414 868 869 O
diagnosis NCT03924414 870 879 O
of NCT03924414 880 882 O
multiple NCT03924414 883 891 B-Condition-Name
myeloma NCT03924414 892 899 I-Condition-Name
or NCT03924414 900 902 O
Paget NCT03924414 903 908 B-Condition-Name
's NCT03924414 908 910 I-Condition-Name
disease NCT03924414 911 918 I-Condition-Name

- NCT03924414 921 922 O
Unable NCT03924414 924 930 O
to NCT03924414 931 933 O
speak NCT03924414 934 939 O
or NCT03924414 940 942 O
read NCT03924414 943 947 O
English NCT03924414 948 955 B-Language
sufficiently NCT03924414 956 968 O
to NCT03924414 969 971 O
complete NCT03924414 972 980 O
informed NCT03924414 981 989 O
consent NCT03924414 990 997 O

- NCT03924414 1000 1001 O
Any NCT03924414 1003 1006 O
other NCT03924414 1007 1012 O
criteria NCT03924414 1013 1021 O
, NCT03924414 1022 1023 O
which NCT03924414 1024 1029 O
would NCT03924414 1030 1035 O
make NCT03924414 1036 1040 O
the NCT03924414 1041 1044 O
patient NCT03924414 1045 1052 O
unsuitable NCT03924414 1053 1063 O
to NCT03924414 1064 1066 O
participate NCT03924414 1067 1078 O
in NCT03924414 1079 1081 O
this NCT03924414 1082 1086 O
study NCT03924414 1087 1092 O
as NCT03924414 1093 1095 O
determined NCT03924414 1096 1106 O
by NCT03924414 1107 1109 O
the NCT03924414 1110 1113 O
study NCT03924414 1114 1119 O
staff NCT03924414 1120 1125 O
( NCT03924414 1126 1127 O
e NCT03924414 1128 1129 O
. NCT03924414 1130 1131 O
g NCT03924414 1132 1133 O
. NCT03924414 1134 1135 O
, NCT03924414 1136 1137 O
an NCT03924414 1138 1140 O
uncontrolled NCT03924414 1141 1153 O
drug NCT03924414 1154 1158 O
and NCT03924414 1159 1162 O
/ NCT03924414 1163 1164 O
or NCT03924414 1165 1167 O
alcohol NCT03924414 1168 1175 O
addiction NCT03924414 1176 1185 B-Condition-Name
) NCT03924414 1186 1187 O


Inclusion NCT03928548 0 9 O
Criteria NCT03928548 10 18 O
: NCT03928548 19 20 O

- NCT03928548 24 25 O
Adult NCT03928548 27 32 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
and NCT03928548 33 36 O
pediatric NCT03928548 37 46 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
acute NCT03928548 47 52 B-Encounter-Type___Encounter-Type-Value:icu
care NCT03928548 53 57 I-Encounter-Type___Encounter-Type-Value:icu
patients NCT03928548 58 66 O
at NCT03928548 67 69 O
participating NCT03928548 70 83 O
facility NCT03928548 84 92 B-Location___Location-Value:hospital

- NCT03928548 95 96 O
Newly NCT03928548 98 103 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
identified NCT03928548 104 114 I-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
as NCT03928548 115 117 O
needing NCT03928548 118 125 O
in NCT03928548 126 128 B-Encounter-Type___Encounter-Type-Value:inpatient
- NCT03928548 129 130 I-Encounter-Type___Encounter-Type-Value:inpatient
patient NCT03928548 131 138 I-Encounter-Type___Encounter-Type-Value:inpatient
nutrition NCT03928548 139 148 B-Procedure-Name
care NCT03928548 149 153 I-Procedure-Name
through NCT03928548 154 161 O
current NCT03928548 162 169 O
facility NCT03928548 170 178 O
policy NCT03928548 179 185 O

- NCT03928548 188 189 O
Receive NCT03928548 191 198 O
initial NCT03928548 199 206 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
nutrition NCT03928548 207 216 B-Procedure-Name
care NCT03928548 217 221 I-Procedure-Name
one NCT03928548 222 225 B-Eq-Value
day NCT03928548 226 229 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
before NCT03928548 230 236 O
study NCT03928548 237 242 O
enrollment NCT03928548 243 253 O
day NCT03928548 254 257 O

- NCT03928548 260 261 O
Patient NCT03928548 263 270 O
is NCT03928548 271 273 O
over NCT03928548 274 278 B-Eq-Operator___Eq-Operator-Value:GT
one NCT03928548 279 282 B-Eq-Value
month NCT03928548 283 288 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
of NCT03928548 289 291 O
age NCT03928548 292 295 O
, NCT03928548 296 297 O
including NCT03928548 298 307 O
infants NCT03928548 308 315 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
, NCT03928548 316 317 O
children NCT03928548 318 326 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
, NCT03928548 327 328 O
teenagers NCT03928548 329 338 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
and NCT03928548 339 342 O
adult NCT03928548 343 348 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
patients NCT03928548 349 357 O
who NCT03928548 358 361 O
are NCT03928548 362 365 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
intubated NCT03928548 366 375 B-Procedure-Name
and NCT03928548 376 379 O
/ NCT03928548 380 381 O
or NCT03928548 382 384 O
sedated NCT03928548 385 392 B-Procedure-Name

- NCT03928548 395 396 O
Patient NCT03928548 398 405 O
, NCT03928548 406 407 O
parent NCT03928548 408 414 O
, NCT03928548 415 416 O
legal NCT03928548 417 422 O
guardian NCT03928548 423 431 O
or NCT03928548 432 434 O
legally NCT03928548 435 442 O
authorized NCT03928548 443 453 O
representative NCT03928548 454 468 O
provide NCT03928548 469 476 O
informed NCT03928548 477 485 O
consent NCT03928548 486 493 O
; NCT03928548 493 494 O
children NCT03928548 495 503 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
7 NCT03928548 505 506 B-Eq-Value
and NCT03928548 507 510 B-Eq-Operator___Eq-Operator-Value:GTEQ
older NCT03928548 511 516 I-Eq-Operator___Eq-Operator-Value:GTEQ
provide NCT03928548 517 524 O
assent NCT03928548 525 531 O

- NCT03928548 534 535 O
Patient NCT03928548 537 544 O
and NCT03928548 545 548 O
/ NCT03928548 549 550 O
or NCT03928548 551 553 O
parent NCT03928548 554 560 O
, NCT03928548 561 562 O
legal NCT03928548 563 568 O
guardian NCT03928548 569 577 O
or NCT03928548 578 580 O
legally NCT03928548 581 588 O
authorized NCT03928548 589 599 O
representative NCT03928548 600 614 O
are NCT03928548 615 618 O
fluent NCT03928548 619 625 O
in NCT03928548 626 628 O
English NCT03928548 629 636 B-Language
or NCT03928548 637 639 O
Spanish NCT03928548 640 647 B-Language

Exclusion NCT03928548 648 657 O
Criteria NCT03928548 658 666 O
: NCT03928548 667 668 O

- NCT03928548 672 673 O
Received NCT03928548 675 683 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
nutrition NCT03928548 684 693 B-Procedure-Name
care NCT03928548 694 698 I-Procedure-Name
previously NCT03928548 699 709 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
during NCT03928548 710 716 O
current NCT03928548 717 724 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
admission NCT03928548 725 734 B-Encounter-Type___Encounter-Type-Value:inpatient

- NCT03928548 737 738 O
Pregnant NCT03928548 740 748 B-Condition-Name
women NCT03928548 749 754 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female

- NCT03928548 757 758 O
Prisoners NCT03928548 760 769 B-Observation-Name

- NCT03928548 772 773 O
Infants NCT03928548 775 782 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:infant
currently NCT03928548 783 792 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
in NCT03928548 793 795 B-Encounter-Type___Encounter-Type-Value:inpatient
the NCT03928548 796 799 O
neonatal NCT03928548 800 808 B-Location___Location-Value:unit
intensive NCT03928548 809 818 I-Location___Location-Value:unit
care NCT03928548 819 823 I-Location___Location-Value:unit
unit NCT03928548 824 828 I-Location___Location-Value:unit
( NCT03928548 829 830 O
NICU NCT03928548 831 835 B-Location___Location-Value:unit
) NCT03928548 836 837 O
with NCT03928548 838 842 O
a NCT03928548 843 844 O
diagnosis NCT03928548 845 854 O
of NCT03928548 855 857 O
prematurity NCT03928548 858 869 B-Condition-Name

- NCT03928548 872 873 O
Neonates NCT03928548 875 883 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:infant
of NCT03928548 884 886 O
uncertain NCT03928548 887 896 B-Condition-Name
viability NCT03928548 897 906 I-Condition-Name
or NCT03928548 907 909 O
non NCT03928548 910 913 B-Condition-Name
- NCT03928548 914 915 I-Condition-Name
viable NCT03928548 916 922 I-Condition-Name
neonates NCT03928548 923 931 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:infant

- NCT03928548 934 935 O
Patients NCT03928548 937 945 O
receiving NCT03928548 946 955 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
palliative NCT03928548 956 966 B-Location
/ NCT03928548 967 968 O
hospice NCT03928548 969 976 B-Location
care NCT03928548 977 981 O

- NCT03928548 984 985 O
Patient NCT03928548 987 994 O
admitted NCT03928548 995 1003 B-Encounter-Type___Encounter-Type-Value:inpatient
for NCT03928548 1004 1007 O
long NCT03928548 1008 1012 B-Procedure-Name
- NCT03928548 1013 1014 I-Procedure-Name
term NCT03928548 1015 1019 I-Procedure-Name
acute NCT03928548 1020 1025 I-Procedure-Name
care NCT03928548 1026 1030 I-Procedure-Name
( NCT03928548 1031 1032 O
LTAC NCT03928548 1033 1037 B-Procedure-Name
) NCT03928548 1038 1039 O

Subject NCT03927781 0 7 O
Population NCT03927781 8 18 O
Undergoing NCT03927781 19 29 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
elective NCT03927781 30 38 O
ureteroscopy NCT03927781 39 51 B-Procedure-Name
with NCT03927781 52 56 O
stent NCT03927781 57 62 B-Procedure-Name
placement NCT03927781 63 72 I-Procedure-Name
by NCT03927781 73 75 O
Dr NCT03927781 76 78 B-Provider-Role
. NCT03927781 79 80 O
Murray NCT03927781 82 88 O
at NCT03927781 89 91 O
University NCT03927781 92 102 B-Location___Location-Value:hospital
of NCT03927781 103 105 I-Location___Location-Value:hospital
Missouri NCT03927781 106 114 I-Location___Location-Value:hospital
Hospital NCT03927781 115 123 I-Location___Location-Value:hospital
and NCT03927781 124 127 O
affiliated NCT03927781 128 138 O
facilities NCT03927781 139 149 O

Subject NCT03927781 150 157 O
Inclusion NCT03927781 158 167 O

Age NCT03927781 168 171 O
> NCT03927781 172 173 B-Eq-Operator___Eq-Operator-Value:GTEQ
= NCT03927781 175 176 I-Eq-Operator___Eq-Operator-Value:GTEQ
18 NCT03927781 178 180 B-Eq-Value
years NCT03927781 181 186 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

Subject NCT03927781 187 194 O
Exclusion NCT03927781 195 204 O

- NCT03927781 207 208 O
Renal NCT03927781 210 215 B-Condition-Name
insufficiency NCT03927781 216 229 I-Condition-Name
( NCT03927781 230 231 O
eGFR NCT03927781 232 236 B-Observation-Name___Observation-Type-Value:lab
< NCT03927781 237 238 B-Eq-Operator___Eq-Operator-Value:LT
30 NCT03927781 240 242 B-Eq-Value
mL NCT03927781 243 245 B-Eq-Unit
/ NCT03927781 246 247 O
minute NCT03927781 248 254 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:minute
/ NCT03927781 255 256 O
1.73 NCT03927781 258 262 B-Eq-Unit
m NCT03927781 263 264 I-Eq-Unit
2 NCT03927781 265 266 I-Eq-Unit
) NCT03927781 267 268 O

- NCT03927781 272 273 O
Chronic NCT03927781 275 282 O
indwelling NCT03927781 283 293 O
ureteral NCT03927781 294 302 B-Procedure-Name
stent NCT03927781 303 308 I-Procedure-Name

- NCT03927781 311 312 O
Chronic NCT03927781 314 321 O
opioid NCT03927781 322 328 B-Condition-Name
use NCT03927781 329 332 I-Condition-Name

- NCT03927781 335 336 O
History NCT03927781 338 345 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03927781 346 348 O
opioid NCT03927781 349 355 B-Condition-Name
abuse NCT03927781 356 361 I-Condition-Name

- NCT03927781 364 365 O
Chronic NCT03927781 367 374 O
gabapentinoid NCT03927781 375 388 B-Drug-Name
use NCT03927781 389 392 O

- NCT03927781 395 396 O
Plan NCT03927781 398 402 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
for NCT03927781 403 406 O
inpatient NCT03927781 407 416 B-Encounter-Type___Encounter-Type-Value:inpatient
hospitalization NCT03927781 417 432 I-Encounter-Type___Encounter-Type-Value:inpatient

- NCT03927781 435 436 O
Pregnancy NCT03927781 438 447 B-Condition-Name

- NCT03927781 450 451 O
Inability NCT03927781 453 462 O
of NCT03927781 463 465 O
the NCT03927781 466 469 O
patient NCT03927781 470 477 O
to NCT03927781 478 480 O
consent NCT03927781 481 488 O
for NCT03927781 489 492 O
themselves NCT03927781 493 503 O
in NCT03927781 504 506 O
English NCT03927781 507 514 B-Language

- NCT03927781 517 518 O
Allergy NCT03927781 520 527 O
to NCT03927781 528 530 O
gabapentinoid NCT03927781 531 544 B-Drug-Name

- NCT03927781 547 548 O
Liver NCT03927781 550 555 B-Condition-Name
failure NCT03927781 556 563 I-Condition-Name
or NCT03927781 564 566 O
hepatic NCT03927781 567 574 B-Condition-Name
dysfunction NCT03927781 575 586 I-Condition-Name


Inclusion NCT03924908 0 9 O
Criteria NCT03924908 10 18 O
: NCT03924908 19 20 O

- NCT03924908 24 25 O
Burn NCT03924908 27 31 B-Condition-Name
patient NCT03924908 32 39 O
treated NCT03924908 40 47 O
as NCT03924908 48 50 O
outpatient NCT03924908 51 61 B-Encounter-Type___Encounter-Type-Value:outpatient

- NCT03924908 64 65 O
Burn NCT03924908 67 71 B-Observation-Name___Observation-Type-Value:measurement
surface NCT03924908 72 79 I-Observation-Name___Observation-Type-Value:measurement
area NCT03924908 80 84 I-Observation-Name___Observation-Type-Value:measurement
> NCT03924908 85 86 B-Eq-Operator___Eq-Operator-Value:GTEQ
or NCT03924908 87 89 I-Eq-Operator___Eq-Operator-Value:GTEQ
= NCT03924908 90 91 I-Eq-Operator___Eq-Operator-Value:GTEQ
5 NCT03924908 93 94 B-Eq-Value
% NCT03924908 95 96 B-Eq-Unit
of NCT03924908 97 99 O
the NCT03924908 100 103 O
total NCT03924908 104 109 O
body NCT03924908 110 114 O
surface NCT03924908 115 122 O
area NCT03924908 123 127 O

- NCT03924908 130 131 O
mainly NCT03924908 133 139 O
2 NCT03924908 141 142 B-Condition-Name
nd NCT03924908 143 145 I-Condition-Name
degree NCT03924908 146 152 I-Condition-Name
burn NCT03924908 153 157 I-Condition-Name

Exclusion NCT03924908 158 167 O
Criteria NCT03924908 168 176 O
: NCT03924908 177 178 O

- NCT03924908 182 183 O
Psychiatric NCT03924908 185 196 B-Condition-Name
antecedents NCT03924908 197 208 I-Condition-Name

- NCT03924908 211 212 O
Claustrophobia NCT03924908 214 228 B-Condition-Name

- NCT03924908 231 232 O
Heavy NCT03924908 234 239 B-Condition-Name
hearing NCT03924908 240 247 I-Condition-Name

- NCT03924908 250 251 O
Visual NCT03924908 253 259 B-Condition-Name
impairment NCT03924908 260 270 I-Condition-Name

- NCT03924908 273 274 O
Face NCT03924908 276 280 O
burn NCT03924908 281 285 B-Condition-Name

- NCT03924908 288 289 O
Conjunctivitis NCT03924908 291 305 B-Condition-Name

- NCT03924908 308 309 O
Consent NCT03924908 311 318 O
not NCT03924908 319 322 O
obtained NCT03924908 323 331 O

Inclusion NCT03924934 0 9 O
Criteria NCT03924934 10 18 O
: NCT03924934 19 20 O

Category NCT03924934 22 30 O
1 NCT03924934 32 33 O
: NCT03924934 34 35 O
Patients NCT03924934 36 44 O
who NCT03924934 45 48 O
live NCT03924934 49 53 O
at NCT03924934 54 56 O
home NCT03924934 57 61 O
and NCT03924934 62 65 O
meet NCT03924934 66 70 O
the NCT03924934 71 74 O
following NCT03924934 75 84 O
criteria NCT03924934 85 93 O
: NCT03924934 94 95 O

- NCT03924934 99 100 O
CDC NCT03924934 102 105 O
- NCT03924934 106 107 O
defined NCT03924934 108 115 O
CRE NCT03924934 116 119 B-Organism-Name
isolated NCT03924934 120 128 I-Organism-Name
during NCT03924934 129 135 O
hospitalization NCT03924934 136 151 B-Encounter-Type___Encounter-Type-Value:inpatient
or NCT03924934 152 154 O
outpatient NCT03924934 155 165 B-Encounter-Type___Encounter-Type-Value:outpatient
visit NCT03924934 166 171 I-Encounter-Type___Encounter-Type-Value:outpatient

- NCT03924934 174 175 O
Home NCT03924934 177 181 O
origin NCT03924934 182 188 O

- NCT03924934 191 192 O
First NCT03924934 194 199 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
positive NCT03924934 200 208 B-Polarity___Polarity-Value:positive
CRE NCT03924934 209 212 B-Organism-Name
culture NCT03924934 213 220 I-Organism-Name
within NCT03924934 221 227 B-Eq-Operator___Eq-Operator-Value:LTEQ
48 NCT03924934 229 231 B-Eq-Value
hours NCT03924934 232 237 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:hour
of NCT03924934 238 240 O
admission NCT03924934 241 250 B-Encounter-Type___Encounter-Type-Value:inpatient
( NCT03924934 251 252 O
in NCT03924934 253 255 O
case NCT03924934 256 260 O
of NCT03924934 261 263 O
hospitalization NCT03924934 264 279 B-Encounter-Type___Encounter-Type-Value:inpatient
) NCT03924934 280 281 O

Category NCT03924934 283 291 O
2 NCT03924934 293 294 O
: NCT03924934 295 296 O
Hospitalized NCT03924934 297 309 B-Encounter-Type___Encounter-Type-Value:inpatient
patients NCT03924934 310 318 O
with NCT03924934 319 323 O
CDC NCT03924934 324 327 O
- NCT03924934 328 329 O
defined NCT03924934 330 337 O
CRE NCT03924934 338 341 B-Organism-Name
isolated NCT03924934 342 350 I-Organism-Name
during NCT03924934 351 357 O
hospitalization NCT03924934 358 373 B-Encounter-Type___Encounter-Type-Value:inpatient
who NCT03924934 374 377 O
are NCT03924934 378 381 O
not NCT03924934 382 385 O
discharged NCT03924934 386 396 B-Encounter-Type___Encounter-Type-Value:discharge
home NCT03924934 397 401 B-Location___Location-Value:residence
and NCT03924934 402 405 O
who NCT03924934 406 409 O
meet NCT03924934 410 414 O
any NCT03924934 415 418 O
of NCT03924934 419 421 O
the NCT03924934 422 425 O
following NCT03924934 426 435 O
criteria NCT03924934 436 444 O
: NCT03924934 445 446 O

- NCT03924934 450 451 O
Admitted NCT03924934 453 461 B-Encounter-Type___Encounter-Type-Value:inpatient
from NCT03924934 462 466 O
other NCT03924934 467 472 O
care NCT03924934 473 477 O
facility NCT03924934 478 486 B-Location___Location-Value:hospital
( NCT03924934 487 488 O
not NCT03924934 489 492 O
home NCT03924934 493 497 O
origin NCT03924934 498 504 O
) NCT03924934 505 506 O

- NCT03924934 510 511 O
Do NCT03924934 513 515 O
not NCT03924934 516 519 O
have NCT03924934 520 524 O
first NCT03924934 525 530 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
positive NCT03924934 531 539 B-Polarity___Polarity-Value:positive
CRE NCT03924934 540 543 B-Organism-Name
culture NCT03924934 544 551 I-Organism-Name
within NCT03924934 552 558 B-Eq-Operator___Eq-Operator-Value:LTEQ
48 NCT03924934 560 562 B-Eq-Value
hours NCT03924934 563 568 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:hour
of NCT03924934 569 571 O
admission NCT03924934 572 581 B-Encounter-Type___Encounter-Type-Value:inpatient

Category NCT03924934 582 590 O
3 NCT03924934 592 593 O
: NCT03924934 594 595 O
Patients NCT03924934 596 604 O
with NCT03924934 605 609 O
CDC NCT03924934 610 613 O
- NCT03924934 614 615 O
defined NCT03924934 616 623 O
CRE NCT03924934 624 627 B-Organism-Name
isolated NCT03924934 628 636 I-Organism-Name
during NCT03924934 637 643 O
hospitalization NCT03924934 644 659 B-Encounter-Type___Encounter-Type-Value:inpatient
or NCT03924934 660 662 O
outpatient NCT03924934 663 673 B-Encounter-Type___Encounter-Type-Value:outpatient
visit NCT03924934 674 679 I-Encounter-Type___Encounter-Type-Value:outpatient
who NCT03924934 680 683 O
are NCT03924934 684 687 O
discharged NCT03924934 688 698 B-Encounter-Type___Encounter-Type-Value:discharge
home NCT03924934 699 703 B-Location___Location-Value:residence
and NCT03924934 704 707 O
who NCT03924934 708 711 O
meet NCT03924934 712 716 O
any NCT03924934 717 720 O
of NCT03924934 721 723 O
the NCT03924934 724 727 O
following NCT03924934 728 737 O
criteria NCT03924934 738 746 O
: NCT03924934 747 748 O

- NCT03924934 752 753 O
Admitted NCT03924934 755 763 B-Encounter-Type___Encounter-Type-Value:inpatient
from NCT03924934 764 768 O
other NCT03924934 769 774 O
care NCT03924934 775 779 O
facility NCT03924934 780 788 B-Location___Location-Value:hospital
( NCT03924934 789 790 O
not NCT03924934 791 794 O
home NCT03924934 795 799 O
origin NCT03924934 800 806 O
) NCT03924934 807 808 O

- NCT03924934 812 813 O
Do NCT03924934 815 817 O
not NCT03924934 818 821 O
have NCT03924934 822 826 O
first NCT03924934 827 832 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
positive NCT03924934 833 841 B-Polarity___Polarity-Value:positive
CRE NCT03924934 842 845 B-Organism-Name
culture NCT03924934 846 853 I-Organism-Name
within NCT03924934 854 860 B-Eq-Operator___Eq-Operator-Value:LTEQ
48 NCT03924934 862 864 B-Eq-Value
hours NCT03924934 865 870 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:hour
of NCT03924934 871 873 O
admission NCT03924934 874 883 B-Encounter-Type___Encounter-Type-Value:inpatient
( NCT03924934 884 885 O
in NCT03924934 886 888 O
case NCT03924934 889 893 O
of NCT03924934 894 896 O
hospitalization NCT03924934 897 912 B-Encounter-Type___Encounter-Type-Value:inpatient
) NCT03924934 913 914 O

Category NCT03924934 916 924 O
4 NCT03924934 926 927 O
: NCT03924934 928 929 O
Participants NCT03924934 930 942 O
who NCT03924934 943 946 O
meet NCT03924934 947 951 O
the NCT03924934 952 955 O
following NCT03924934 956 965 O
criteria NCT03924934 966 974 O
: NCT03924934 975 976 O

• NCT03924934 978 979 O
Community NCT03924934 980 989 O
contact NCT03924934 990 997 O
of NCT03924934 998 1000 O
a NCT03924934 1001 1002 O
participant NCT03924934 1003 1014 O
in NCT03924934 1015 1017 O
Category NCT03924934 1018 1026 O
1 NCT03924934 1028 1029 O
and NCT03924934 1030 1033 O
/ NCT03924934 1034 1035 O
or NCT03924934 1036 1038 O
3 NCT03924934 1040 1041 O
. NCT03924934 1041 1042 O

Exclusion NCT03924934 1044 1053 O
Criteria NCT03924934 1054 1062 O
: NCT03924934 1063 1064 O

In NCT03924934 1066 1068 O
all NCT03924934 1069 1072 O
categories NCT03924934 1073 1083 O
, NCT03924934 1084 1085 O
participants NCT03924934 1086 1098 O
who NCT03924934 1099 1102 O
meet NCT03924934 1103 1107 O
the NCT03924934 1108 1111 O
following NCT03924934 1112 1121 O
criteria NCT03924934 1122 1130 O
will NCT03924934 1131 1135 O
be NCT03924934 1136 1138 O
excluded NCT03924934 1139 1147 O
: NCT03924934 1148 1149 O

• NCT03924934 1151 1152 O
Age NCT03924934 1153 1156 O
< NCT03924934 1157 1158 B-Eq-Operator___Eq-Operator-Value:LT
18 NCT03924934 1160 1162 B-Eq-Value
years NCT03924934 1163 1168 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

In NCT03924934 1169 1171 O
category NCT03924934 1172 1180 O
1 NCT03924934 1182 1183 O
, NCT03924934 1184 1185 O
the NCT03924934 1186 1189 O
following NCT03924934 1190 1199 O
are NCT03924934 1200 1203 O
exclusionary NCT03924934 1204 1216 O
: NCT03924934 1217 1218 O

- NCT03924934 1222 1223 O
pre NCT03924934 1225 1228 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
- NCT03924934 1229 1230 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
existing NCT03924934 1231 1239 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
renal NCT03924934 1240 1245 B-Condition-Name
failure NCT03924934 1246 1253 I-Condition-Name

- NCT03924934 1256 1257 O
pre NCT03924934 1259 1262 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
- NCT03924934 1263 1264 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
existing NCT03924934 1265 1273 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
liver NCT03924934 1274 1279 B-Condition-Name
disease NCT03924934 1280 1287 I-Condition-Name

- NCT03924934 1290 1291 O
immunocompromised NCT03924934 1293 1310 B-Condition-Name

- NCT03924934 1313 1314 O
history NCT03924934 1316 1323 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03924934 1324 1326 O
malignancy NCT03924934 1327 1337 B-Condition-Name

- NCT03924934 1340 1341 O
pregnancy NCT03924934 1343 1352 B-Condition-Name

In NCT03924934 1353 1355 O
addition NCT03924934 1356 1364 O
, NCT03924934 1365 1366 O
in NCT03924934 1367 1369 O
category NCT03924934 1370 1378 O
1 NCT03924934 1380 1381 O
, NCT03924934 1382 1383 O
3 NCT03924934 1385 1386 O
and NCT03924934 1387 1390 O
4 NCT03924934 1392 1393 O
, NCT03924934 1394 1395 O
who NCT03924934 1396 1399 O
meet NCT03924934 1400 1404 O
the NCT03924934 1405 1408 O
following NCT03924934 1409 1418 O
criteria NCT03924934 1419 1427 O
will NCT03924934 1428 1432 O
be NCT03924934 1433 1435 O
excluded NCT03924934 1436 1444 O
: NCT03924934 1445 1446 O

• NCT03924934 1448 1449 O
Unable NCT03924934 1450 1456 O
to NCT03924934 1457 1459 O
provide NCT03924934 1460 1467 O
informed NCT03924934 1468 1476 O
consent NCT03924934 1477 1484 O


Inclusion NCT03924713 0 9 O
Criteria NCT03924713 10 18 O
: NCT03924713 19 20 O

- NCT03924713 24 25 O
Either NCT03924713 27 33 O
have NCT03924713 34 38 O
had NCT03924713 39 42 O
more NCT03924713 43 47 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03924713 48 52 I-Eq-Operator___Eq-Operator-Value:GT
3 NCT03924713 54 55 B-Eq-Value
ED NCT03924713 56 58 B-Encounter-Type___Encounter-Type-Value:emergency
visits NCT03924713 59 65 I-Encounter-Type___Encounter-Type-Value:emergency
in NCT03924713 66 68 O
the NCT03924713 69 72 O
prior NCT03924713 73 78 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
12 NCT03924713 80 82 B-Eq-Value
months NCT03924713 83 89 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
, NCT03924713 90 91 O
or NCT03924713 92 94 O
at NCT03924713 95 97 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03924713 98 103 I-Eq-Operator___Eq-Operator-Value:GTEQ
1 NCT03924713 105 106 B-Eq-Value
ambulatory NCT03924713 107 117 O
care NCT03924713 118 122 O
- NCT03924713 123 124 O
sensitive NCT03924713 125 134 O
hospitalization NCT03924713 135 150 B-Encounter-Type___Encounter-Type-Value:inpatient
in NCT03924713 151 153 O
the NCT03924713 154 157 O
prior NCT03924713 158 163 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
12 NCT03924713 165 167 B-Eq-Value
months NCT03924713 168 174 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

Exclusion NCT03924713 175 184 O
Criteria NCT03924713 185 193 O
: NCT03924713 194 195 O

- NCT03924713 199 200 O
None NCT03924713 202 206 O
if NCT03924713 207 209 O
they NCT03924713 210 214 O
meet NCT03924713 215 219 O
above NCT03924713 220 225 O
criteria NCT03924713 226 234 O
. NCT03924713 235 236 O

Inclusion NCT03929237 0 9 O
Criteria NCT03929237 10 18 O
: NCT03929237 19 20 O

- NCT03929237 24 25 O
ACL NCT03929237 27 30 B-Procedure-Name
reconstruction NCT03929237 31 45 I-Procedure-Name
surgery NCT03929237 46 53 I-Procedure-Name

- NCT03929237 56 57 O
currently NCT03929237 59 68 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
enrolled NCT03929237 69 77 O
in NCT03929237 78 80 O
middle NCT03929237 81 87 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
or NCT03929237 88 90 I-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
high NCT03929237 91 95 I-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
school NCT03929237 96 102 I-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
( NCT03929237 103 104 O
grades NCT03929237 105 111 O
6 NCT03929237 113 114 O
- NCT03929237 115 116 O
12 NCT03929237 118 120 O
) NCT03929237 121 122 O

- NCT03929237 126 127 O
Surgery NCT03929237 129 136 B-Procedure-Name
occurs NCT03929237 137 143 O
during NCT03929237 144 150 O
the NCT03929237 151 154 O
school NCT03929237 155 161 B-Observation-Name
year NCT03929237 162 166 I-Observation-Name

- NCT03929237 169 170 O
No NCT03929237 172 174 O
concomitant NCT03929237 175 186 O
additional NCT03929237 187 197 O
ligament NCT03929237 198 206 B-Procedure-Name
surgery NCT03929237 207 214 I-Procedure-Name
( NCT03929237 215 216 O
ie NCT03929237 217 219 O
. NCT03929237 220 221 O
PCL NCT03929237 223 226 B-Procedure-Name
, NCT03929237 227 228 O
MCL NCT03929237 229 232 B-Procedure-Name
, NCT03929237 233 234 O
LCL NCT03929237 235 238 B-Procedure-Name
or NCT03929237 239 241 O
MPFL NCT03929237 242 246 B-Procedure-Name
) NCT03929237 247 248 O

Exclusion NCT03929237 250 259 O
Criteria NCT03929237 260 268 O
: NCT03929237 269 270 O

- NCT03929237 274 275 O
patient NCT03929237 277 284 O
is NCT03929237 285 287 O
home NCT03929237 288 292 B-Observation-Name
schooled NCT03929237 293 301 I-Observation-Name
or NCT03929237 302 304 O
in NCT03929237 305 307 O
non NCT03929237 308 311 B-Observation-Name
- NCT03929237 312 313 I-Observation-Name
traditional NCT03929237 314 325 I-Observation-Name
school NCT03929237 326 332 I-Observation-Name
setting NCT03929237 333 340 I-Observation-Name
( NCT03929237 341 342 O
ie NCT03929237 343 345 O
. NCT03929237 346 347 O
school NCT03929237 349 355 B-Observation-Name
for NCT03929237 356 359 I-Observation-Name
special NCT03929237 360 367 I-Observation-Name
needs NCT03929237 368 373 I-Observation-Name
) NCT03929237 374 375 O

- NCT03929237 379 380 O
concomitant NCT03929237 382 393 O
additional NCT03929237 394 404 O
ligament NCT03929237 405 413 B-Procedure-Name
surgery NCT03929237 414 421 I-Procedure-Name

- NCT03929237 424 425 O
surgery NCT03929237 427 434 B-Procedure-Name
occurs NCT03929237 435 441 O
outside NCT03929237 442 449 O
of NCT03929237 450 452 O
the NCT03929237 453 456 O
school NCT03929237 457 463 B-Observation-Name
year NCT03929237 464 468 I-Observation-Name
or NCT03929237 469 471 O
on NCT03929237 472 474 O
a NCT03929237 475 476 O
scheduled NCT03929237 477 486 O
break NCT03929237 487 492 O
from NCT03929237 493 497 O
school NCT03929237 498 504 O

Inclusion NCT03926104 0 9 O
Criteria NCT03926104 10 18 O
: NCT03926104 19 20 O

- NCT03926104 24 25 O
Ability NCT03926104 27 34 O
to NCT03926104 35 37 O
provide NCT03926104 38 45 O
an NCT03926104 46 48 O
informed NCT03926104 49 57 O
consent NCT03926104 58 65 O

- NCT03926104 68 69 O
Age NCT03926104 71 74 O
> NCT03926104 75 76 B-Eq-Operator___Eq-Operator-Value:GT
18 NCT03926104 78 80 B-Eq-Value
years NCT03926104 81 86 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03926104 87 90 O

- NCT03926104 93 94 O
Elective NCT03926104 96 104 O
abdominal NCT03926104 105 114 B-Condition-Name
aortic NCT03926104 115 121 I-Condition-Name
aneurysm NCT03926104 122 130 I-Condition-Name
surgery NCT03926104 131 138 B-Procedure-Name

Exclusion NCT03926104 139 148 O
Criteria NCT03926104 149 157 O
: NCT03926104 158 159 O

- NCT03926104 163 164 O
Emergency NCT03926104 166 175 O
surgery NCT03926104 176 183 B-Procedure-Name

- NCT03926104 186 187 O
Age NCT03926104 189 192 O
˂ NCT03926104 193 194 B-Eq-Operator___Eq-Operator-Value:LT
18 NCT03926104 196 198 B-Eq-Value
years NCT03926104 199 204 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03926104 205 208 O

- NCT03926104 211 212 O
Creatinine NCT03926104 214 224 B-Observation-Name___Observation-Type-Value:lab
> NCT03926104 225 226 B-Eq-Operator___Eq-Operator-Value:GT
2 NCT03926104 228 229 B-Eq-Value
mg NCT03926104 230 232 B-Eq-Unit
/ NCT03926104 233 234 O
dl NCT03926104 235 237 B-Eq-Unit

- NCT03926104 240 241 O
Diseases NCT03926104 243 251 B-Condition-Name
of NCT03926104 252 254 O
ascending NCT03926104 255 264 O
aorta NCT03926104 265 270 O
, NCT03926104 271 272 O
aortic NCT03926104 273 279 O
arch NCT03926104 280 284 O
or NCT03926104 285 287 O
thoracic NCT03926104 288 296 O
aorta NCT03926104 297 302 O

- NCT03926104 305 306 O
Chronic NCT03926104 308 315 O
atrial NCT03926104 316 322 B-Condition-Name
fibrillation NCT03926104 323 335 I-Condition-Name

- NCT03926104 338 339 O
Patient NCT03926104 341 348 O
refusal NCT03926104 349 356 O
to NCT03926104 357 359 O
provide NCT03926104 360 367 O
informed NCT03926104 368 376 O
consent NCT03926104 377 384 O

Inclusion NCT03926676 0 9 O
Criteria NCT03926676 10 18 O
: NCT03926676 19 20 O

- NCT03926676 24 25 O
patients NCT03926676 27 35 O
with NCT03926676 36 40 O
badly NCT03926676 41 46 O
broken NCT03926676 47 53 B-Condition-Name
vital NCT03926676 54 59 I-Condition-Name
teeth NCT03926676 60 65 I-Condition-Name

good NCT03926676 66 70 O
oral NCT03926676 71 75 B-Condition-Name
hygiene NCT03926676 76 83 I-Condition-Name
measures NCT03926676 84 92 O

young NCT03926676 93 98 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
adults NCT03926676 99 105 I-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
males NCT03926676 106 111 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
or NCT03926676 112 114 O
females NCT03926676 115 122 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female

cooperative NCT03926676 123 134 O
patients NCT03926676 135 143 O
approving NCT03926676 144 153 O
to NCT03926676 154 156 O
participate NCT03926676 157 168 O
in NCT03926676 169 171 O
the NCT03926676 172 175 O
study NCT03926676 176 181 O

Exclusion NCT03926676 182 191 O
Criteria NCT03926676 192 200 O
: NCT03926676 201 202 O

- NCT03926676 206 207 O
patients NCT03926676 209 217 O
with NCT03926676 218 222 O
compromised NCT03926676 223 234 O
medical NCT03926676 235 242 O
history NCT03926676 243 250 O

lack NCT03926676 251 255 O
of NCT03926676 256 258 O
compliance NCT03926676 259 269 O

severe NCT03926676 270 276 B-Severity___Severity-Value:severe
medical NCT03926676 277 284 O
condition NCT03926676 285 294 O

severe NCT03926676 295 301 B-Severity___Severity-Value:severe
or NCT03926676 302 304 O
active NCT03926676 305 311 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
periodontal NCT03926676 312 323 B-Condition-Name
disease NCT03926676 324 331 I-Condition-Name

Inclusion NCT03922438 0 9 O
Criteria NCT03922438 10 18 O
: NCT03922438 19 20 O

- NCT03922438 24 25 O
Non NCT03922438 27 30 O
syndromic NCT03922438 31 40 B-Condition-Name
patients NCT03922438 41 49 O

- NCT03922438 52 53 O
Medically NCT03922438 55 64 O
fit NCT03922438 65 68 O
for NCT03922438 69 72 O
Surgery NCT03922438 73 80 B-Procedure-Name

- NCT03922438 83 84 O
Patient NCT03922438 86 93 O
with NCT03922438 94 98 O
Primary NCT03922438 99 106 O
, NCT03922438 107 108 O
complete NCT03922438 109 117 O
cleft NCT03922438 118 123 B-Condition-Name
lip NCT03922438 124 127 I-Condition-Name

- NCT03922438 130 131 O
Patient NCT03922438 133 140 O
's NCT03922438 140 142 O
age NCT03922438 143 146 O
younger NCT03922438 147 154 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03922438 155 159 I-Eq-Operator___Eq-Operator-Value:LT
six NCT03922438 160 163 B-Eq-Value
months NCT03922438 164 170 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

Exclusion NCT03922438 171 180 O
Criteria NCT03922438 181 189 O
: NCT03922438 190 191 O

- NCT03922438 195 196 O
Patient NCT03922438 198 205 O
with NCT03922438 206 210 O
syndromic NCT03922438 211 220 O
cleft NCT03922438 221 226 B-Condition-Name
lip NCT03922438 227 230 I-Condition-Name

- NCT03922438 233 234 O
Previous NCT03922438 236 244 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
operated NCT03922438 245 253 B-Procedure-Name
cases NCT03922438 254 259 O

- NCT03922438 262 263 O
Incomplete NCT03922438 265 275 O
cleft NCT03922438 276 281 B-Condition-Name
lip NCT03922438 282 285 I-Condition-Name

- NCT03922438 288 289 O
Patient NCT03922438 291 298 O
older NCT03922438 299 304 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03922438 305 309 I-Eq-Operator___Eq-Operator-Value:GT
six NCT03922438 310 313 B-Eq-Value
months NCT03922438 314 320 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

- NCT03922438 323 324 O
Patients NCT03922438 326 334 O
with NCT03922438 335 339 O
any NCT03922438 340 343 O
systemic NCT03922438 344 352 O
condition NCT03922438 353 362 O

Inclusion NCT03921125 0 9 O
Criteria NCT03921125 10 18 O
: NCT03921125 19 20 O

- NCT03921125 24 25 O
Sample NCT03921125 27 33 O
of NCT03921125 34 36 O
40 NCT03921125 38 40 O
healthy NCT03921125 41 48 O
ASA NCT03921125 49 52 B-Condition-Name
I NCT03921125 53 54 B-Eq-Value
or NCT03921125 55 57 O
II NCT03921125 58 60 B-Eq-Value
donors NCT03921125 61 67 O
' NCT03921125 67 68 O
candidate NCT03921125 69 78 O
for NCT03921125 79 82 O
right NCT03921125 83 88 O
lobe NCT03921125 89 93 O
hepatectomy NCT03921125 94 105 B-Procedure-Name
for NCT03921125 106 109 O
living NCT03921125 110 116 O
donor NCT03921125 117 122 O
liver NCT03921125 123 128 B-Procedure-Name
transplantation NCT03921125 129 144 I-Procedure-Name

Exclusion NCT03921125 145 154 O
Criteria NCT03921125 155 163 O
: NCT03921125 164 165 O

- NCT03921125 169 170 O
Lack NCT03921125 172 176 O
of NCT03921125 177 179 O
consent NCT03921125 180 187 O

Inclusion NCT03928561 0 9 O
Criteria NCT03928561 10 18 O
: NCT03928561 19 20 O

- NCT03928561 24 25 O
Controlled NCT03928561 27 37 O
intermittent NCT03928561 38 50 O
asthma NCT03928561 51 57 B-Condition-Name
( NCT03928561 58 59 O
step NCT03928561 60 64 O
1 NCT03928561 66 67 O
treatment NCT03928561 68 77 O
, NCT03928561 78 79 O
according NCT03928561 80 89 O
to NCT03928561 90 92 O
GINA NCT03928561 93 97 O
Guideline NCT03928561 98 107 O
2016 NCT03928561 109 113 O
) NCT03928561 114 115 O
with NCT03928561 116 120 O
or NCT03928561 121 123 O
without NCT03928561 124 131 O
association NCT03928561 132 143 O
with NCT03928561 144 148 O
cat NCT03928561 149 152 B-Allergy-Name
allergy NCT03928561 153 160 O
related NCT03928561 161 168 O
rhino NCT03928561 169 174 O
- NCT03928561 175 176 O
conjunctivitis NCT03928561 177 191 B-Condition-Name
; NCT03928561 191 192 O

- NCT03928561 195 196 O
Sensitization NCT03928561 198 211 O
to NCT03928561 212 214 O
cat NCT03928561 215 218 B-Allergy-Name
allergen NCT03928561 219 227 I-Allergy-Name
extract NCT03928561 228 235 I-Allergy-Name
as NCT03928561 236 238 O
defined NCT03928561 239 246 O
by NCT03928561 247 249 O
skin NCT03928561 250 254 B-Observation-Name___Observation-Type-Value:lab
prick NCT03928561 255 260 I-Observation-Name___Observation-Type-Value:lab
test NCT03928561 261 265 I-Observation-Name___Observation-Type-Value:lab
for NCT03928561 266 269 O
cat NCT03928561 270 273 O
extract NCT03928561 274 281 O
with NCT03928561 282 286 O
a NCT03928561 287 288 O
wheal NCT03928561 289 294 O
diameter NCT03928561 295 303 O
of NCT03928561 304 306 O
≥ NCT03928561 307 308 B-Eq-Operator___Eq-Operator-Value:GTEQ
3 NCT03928561 310 311 B-Eq-Value
mm NCT03928561 312 314 B-Eq-Unit
greater NCT03928561 315 322 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03928561 323 327 I-Eq-Operator___Eq-Operator-Value:GT
negative NCT03928561 328 336 B-Eq-Unit___Eq-Unit-Value:ref-range-normal
control NCT03928561 337 344 I-Eq-Unit___Eq-Unit-Value:ref-range-normal
( NCT03928561 345 346 O
ALK NCT03928561 347 350 O
, NCT03928561 351 352 O
HØrsholm NCT03928561 353 361 O
, NCT03928561 362 363 O
Denmark NCT03928561 364 371 O
) NCT03928561 372 373 O
and NCT03928561 374 377 O
specific NCT03928561 378 386 O
IgE NCT03928561 387 390 B-Observation-Name___Observation-Type-Value:lab
anti NCT03928561 391 395 I-Observation-Name___Observation-Type-Value:lab
Fel NCT03928561 396 399 I-Observation-Name___Observation-Type-Value:lab
d NCT03928561 400 401 I-Observation-Name___Observation-Type-Value:lab
1 NCT03928561 403 404 B-Eq-Value
≥ NCT03928561 405 406 B-Eq-Operator___Eq-Operator-Value:GTEQ
0.7 NCT03928561 408 411 B-Eq-Value
kU NCT03928561 412 414 B-Eq-Unit
/ NCT03928561 415 416 O
L NCT03928561 417 418 B-Eq-Unit
( NCT03928561 419 420 O
ImmunoCAP NCT03928561 421 430 O
, NCT03928561 431 432 O
Thermofisher NCT03928561 433 445 O
, NCT03928561 446 447 O
Uppsala NCT03928561 448 455 O
, NCT03928561 456 457 O
Sweden NCT03928561 458 464 O
) NCT03928561 465 466 O
; NCT03928561 467 468 O

- NCT03928561 471 472 O
FEV NCT03928561 474 477 B-Observation-Name___Observation-Type-Value:lab
1 NCT03928561 478 479 I-Observation-Name___Observation-Type-Value:lab
≥ NCT03928561 480 481 B-Eq-Operator___Eq-Operator-Value:GTEQ
70 NCT03928561 483 485 B-Eq-Value
% NCT03928561 486 487 B-Eq-Unit
of NCT03928561 488 490 O
the NCT03928561 491 494 O
predicted NCT03928561 495 504 O
value NCT03928561 505 510 O
; NCT03928561 510 511 O

- NCT03928561 514 515 O
No NCT03928561 517 519 O
cat NCT03928561 520 523 B-Condition-Name
exposure NCT03928561 524 532 I-Condition-Name
at NCT03928561 533 535 O
home NCT03928561 536 540 B-Location___Location-Value:residence
or NCT03928561 541 543 O
outside NCT03928561 544 551 O
of NCT03928561 552 554 O
the NCT03928561 555 558 O
home NCT03928561 559 563 B-Location___Location-Value:residence
during NCT03928561 564 570 O
the NCT03928561 571 574 O
study NCT03928561 575 580 O
; NCT03928561 580 581 O

- NCT03928561 584 585 O
Positive NCT03928561 587 595 B-Polarity___Polarity-Value:positive
methacholine NCT03928561 596 608 B-Observation-Name___Observation-Type-Value:lab
challenge NCT03928561 609 618 I-Observation-Name___Observation-Type-Value:lab
test NCT03928561 619 623 I-Observation-Name___Observation-Type-Value:lab
performed NCT03928561 624 633 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
using NCT03928561 634 639 O
an NCT03928561 640 642 O
AeroDoseur NCT03928561 643 653 O
DTF NCT03928561 654 657 O
- NCT03928561 658 659 O
Atomisor NCT03928561 660 668 O
ATO NCT03928561 669 672 O
- NCT03928561 673 674 O
AD NCT03928561 675 677 O
12 NCT03928561 679 681 O
( NCT03928561 682 683 O
Saint NCT03928561 684 689 O
- NCT03928561 690 691 O
Etienne NCT03928561 692 699 O
, NCT03928561 700 701 O
France NCT03928561 702 708 O
) NCT03928561 709 710 O
; NCT03928561 711 712 O

- NCT03928561 720 721 O
Early NCT03928561 723 728 O
asthmatic NCT03928561 729 738 B-Condition-Name
response NCT03928561 739 747 O
during NCT03928561 748 754 O
baseline NCT03928561 755 763 O
cat NCT03928561 764 767 B-Condition-Name
allergen NCT03928561 768 776 I-Condition-Name
exposure NCT03928561 777 785 I-Condition-Name
. NCT03928561 786 787 O

Exclusion NCT03928561 789 798 O
Criteria NCT03928561 799 807 O
: NCT03928561 808 809 O

- NCT03928561 813 814 O
Uncontrolled NCT03928561 816 828 O
asthma NCT03928561 829 835 B-Condition-Name
, NCT03928561 836 837 O
asthma NCT03928561 838 844 B-Observation-Name___Observation-Type-Value:measurement
control NCT03928561 845 852 I-Observation-Name___Observation-Type-Value:measurement
test NCT03928561 853 857 I-Observation-Name___Observation-Type-Value:measurement
inferior NCT03928561 858 866 B-Eq-Operator___Eq-Operator-Value:LT
to NCT03928561 867 869 O
20 NCT03928561 871 873 B-Eq-Value
within NCT03928561 874 880 B-Eq-Operator___Eq-Operator-Value:LTEQ
the NCT03928561 881 884 O
4 NCT03928561 886 887 B-Eq-Value
weeks NCT03928561 888 893 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
preceding NCT03928561 894 903 O
the NCT03928561 904 907 O
study NCT03928561 908 913 O
. NCT03928561 914 915 O

- NCT03928561 919 920 O
Uncontrolled NCT03928561 922 934 O
asthma NCT03928561 935 941 B-Condition-Name
2 NCT03928561 943 944 B-Eq-Value
weeks NCT03928561 945 950 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
after NCT03928561 951 956 O
stopping NCT03928561 957 965 O
LABA NCT03928561 966 970 B-Drug-Name
treatment NCT03928561 971 980 O
. NCT03928561 981 982 O

- NCT03928561 986 987 O
LABA NCT03928561 989 993 B-Drug-Name
treatment NCT03928561 994 1003 O
within NCT03928561 1004 1010 B-Eq-Operator___Eq-Operator-Value:LTEQ
the NCT03928561 1011 1014 O
2 NCT03928561 1016 1017 B-Eq-Value
weeks NCT03928561 1018 1023 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
preceding NCT03928561 1024 1033 O
the NCT03928561 1034 1037 O
study NCT03928561 1038 1043 O
. NCT03928561 1044 1045 O

- NCT03928561 1049 1050 O
Severe NCT03928561 1052 1058 B-Severity___Severity-Value:severe
asthma NCT03928561 1059 1065 B-Condition-Name
( NCT03928561 1066 1067 O
> NCT03928561 1069 1070 B-Eq-Operator___Eq-Operator-Value:GT
GINA NCT03928561 1071 1075 B-Observation-Name
2 NCT03928561 1077 1078 B-Eq-Value
) NCT03928561 1079 1080 O

- NCT03928561 1084 1085 O
Subject NCT03928561 1087 1094 O
lives NCT03928561 1095 1100 O
with NCT03928561 1101 1105 O
a NCT03928561 1106 1107 O
cat NCT03928561 1108 1111 O

- NCT03928561 1114 1115 O
Cat NCT03928561 1117 1120 B-Condition-Name
desensibilisation NCT03928561 1121 1138 I-Condition-Name
within NCT03928561 1139 1145 B-Eq-Operator___Eq-Operator-Value:LTEQ
the NCT03928561 1146 1149 O
6 NCT03928561 1151 1152 B-Eq-Value
previous NCT03928561 1153 1161 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
months NCT03928561 1162 1168 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
. NCT03928561 1169 1170 O

- NCT03928561 1174 1175 O
Active NCT03928561 1177 1183 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
smoker NCT03928561 1184 1190 B-Condition-Name


Inclusion NCT03922919 0 9 O
Criteria NCT03922919 10 18 O
: NCT03922919 19 20 O

- NCT03922919 24 25 O
Age NCT03922919 27 30 O
≥ NCT03922919 31 32 B-Eq-Operator___Eq-Operator-Value:GTEQ
18 NCT03922919 34 36 B-Eq-Value
years NCT03922919 37 42 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03922919 43 46 O

- NCT03922919 49 50 O
Indication NCT03922919 52 62 O
for NCT03922919 63 66 O
antibiotic NCT03922919 67 77 B-Drug-Name
treatment NCT03922919 78 87 O
with NCT03922919 88 92 O
a NCT03922919 93 94 O
3 NCT03922919 96 97 O
rd NCT03922919 98 100 O
generation NCT03922919 101 111 O
injectable NCT03922919 112 122 O
cephalosporin NCT03922919 123 136 B-Drug-Name
( NCT03922919 137 138 O
cefotaxime NCT03922919 139 149 B-Drug-Name
or NCT03922919 150 152 O
ceftriaxone NCT03922919 153 164 B-Drug-Name
) NCT03922919 165 166 O

- NCT03922919 170 171 O
Signed NCT03922919 173 179 O
Informed NCT03922919 180 188 O
Consent NCT03922919 189 196 O

Exclusion NCT03922919 197 206 O
Criteria NCT03922919 207 215 O
: NCT03922919 216 217 O

- NCT03922919 221 222 O
Hypersensitivity NCT03922919 224 240 B-Condition-Name
to NCT03922919 241 243 O
ceftriaxone NCT03922919 244 255 B-Drug-Name
or NCT03922919 256 258 O
cefotaxime NCT03922919 259 269 B-Drug-Name
, NCT03922919 270 271 O
to NCT03922919 272 274 O
another NCT03922919 275 282 O
cephalosporin NCT03922919 283 296 B-Drug-Name
or NCT03922919 297 299 O
to NCT03922919 300 302 O
any NCT03922919 303 306 O
of NCT03922919 307 309 O
the NCT03922919 310 313 O
excipients NCT03922919 314 324 O
of NCT03922919 325 327 O
the NCT03922919 328 331 O
specialities NCT03922919 332 344 O
concerned NCT03922919 345 354 O
. NCT03922919 355 356 O

- NCT03922919 360 361 O
History NCT03922919 363 370 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03922919 371 373 O
severe NCT03922919 374 380 B-Severity___Severity-Value:severe
hypersensitivity NCT03922919 381 397 B-Condition-Name
( NCT03922919 398 399 O
e NCT03922919 400 401 O
. NCT03922919 402 403 O
g NCT03922919 404 405 O
. NCT03922919 406 407 O
, NCT03922919 408 409 O
anaphylactic NCT03922919 410 422 B-Condition-Name
reaction NCT03922919 423 431 I-Condition-Name
) NCT03922919 432 433 O
to NCT03922919 434 436 O
another NCT03922919 437 444 O
class NCT03922919 445 450 O
of NCT03922919 451 453 O
antibacterial NCT03922919 454 467 B-Drug-Name
agent NCT03922919 468 473 I-Drug-Name
of NCT03922919 474 476 O
the NCT03922919 477 480 O
beta NCT03922919 481 485 O
- NCT03922919 486 487 O
lactam NCT03922919 488 494 O
family NCT03922919 495 501 O
( NCT03922919 502 503 O
penicillins NCT03922919 504 515 B-Drug-Name
, NCT03922919 516 517 O
monobactams NCT03922919 518 529 B-Drug-Name
and NCT03922919 530 533 O
carbapenes NCT03922919 534 544 B-Drug-Name
) NCT03922919 545 546 O

- NCT03922919 550 551 O
Subcutaneous NCT03922919 553 565 O
administration NCT03922919 566 580 O
of NCT03922919 581 583 O
ceftriaxone NCT03922919 584 595 B-Drug-Name

- NCT03922919 598 599 O
Pregnant NCT03922919 601 609 B-Condition-Name
and NCT03922919 610 613 O
breastfeeding NCT03922919 614 627 B-Condition-Name
woman NCT03922919 628 633 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female

- NCT03922919 636 637 O
Suspicion NCT03922919 639 648 O
of NCT03922919 649 651 O
Pseudomonas NCT03922919 652 663 B-Condition-Name
infection NCT03922919 664 673 I-Condition-Name
or NCT03922919 674 676 O
documented NCT03922919 677 687 O
Pseudomonas NCT03922919 688 699 B-Condition-Name
infection NCT03922919 700 709 I-Condition-Name
requiring NCT03922919 710 719 O
ceftazidime NCT03922919 720 731 B-Drug-Name
treatment NCT03922919 732 741 O

- NCT03922919 744 745 O
Suspicion NCT03922919 747 756 O
of NCT03922919 757 759 O
group NCT03922919 760 765 B-Eq-Unit
III NCT03922919 766 769 B-Eq-Value
enterobacteriaceae NCT03922919 770 788 B-Condition-Name
infection NCT03922919 789 798 I-Condition-Name
or NCT03922919 799 801 O
group NCT03922919 802 807 B-Eq-Unit
III NCT03922919 808 811 B-Eq-Value
enterobacteriaceae NCT03922919 812 830 B-Condition-Name
infection NCT03922919 831 840 I-Condition-Name
requiring NCT03922919 841 850 O
cefepime NCT03922919 851 859 B-Drug-Name
treatment NCT03922919 860 869 O

Inclusion NCT03926000 0 9 O
Criteria NCT03926000 10 18 O
: NCT03926000 19 20 O

- NCT03926000 24 25 O
Patients NCT03926000 27 35 O
scheduled NCT03926000 36 45 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
for NCT03926000 46 49 O
elective NCT03926000 50 58 O
knee NCT03926000 59 63 O
arthroscopy NCT03926000 64 75 B-Procedure-Name
. NCT03926000 76 77 O

- NCT03926000 81 82 O
Patients NCT03926000 84 92 O
aged NCT03926000 93 97 O
between NCT03926000 98 105 B-Eq-Operator___Eq-Operator-Value:BETWEEN
21 NCT03926000 107 109 B-Eq-Value
and NCT03926000 110 113 O
50 NCT03926000 115 117 B-Eq-Value
years NCT03926000 118 123 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03926000 124 127 O
. NCT03926000 128 129 O

- NCT03926000 133 134 O
Patients NCT03926000 136 144 O
with NCT03926000 145 149 O
American NCT03926000 150 158 B-Condition-Name
Society NCT03926000 159 166 I-Condition-Name
of NCT03926000 167 169 I-Condition-Name
Anaesthesiologists NCT03926000 170 188 I-Condition-Name
physical NCT03926000 189 197 O
status NCT03926000 198 204 O
I NCT03926000 205 206 B-Eq-Value
or NCT03926000 207 209 O
II NCT03926000 210 212 B-Eq-Value
. NCT03926000 213 214 O

Exclusion NCT03926000 216 225 O
Criteria NCT03926000 226 234 O
: NCT03926000 235 236 O

- NCT03926000 240 241 O
Patients NCT03926000 243 251 O
with NCT03926000 252 256 O
known NCT03926000 257 262 O
allergy NCT03926000 263 270 O
to NCT03926000 271 273 O
any NCT03926000 274 277 O
drug NCT03926000 278 282 O
used NCT03926000 283 287 O
in NCT03926000 288 290 O
the NCT03926000 291 294 O
study NCT03926000 295 300 O
. NCT03926000 301 302 O

- NCT03926000 306 307 O
Patients NCT03926000 309 317 O
with NCT03926000 318 322 O
chronic NCT03926000 323 330 O
use NCT03926000 331 334 O
of NCT03926000 335 337 O
analgesics NCT03926000 338 348 B-Drug-Name
and NCT03926000 349 352 O
/ NCT03926000 353 354 O
or NCT03926000 355 357 O
sedatives NCT03926000 358 367 B-Drug-Name
. NCT03926000 368 369 O

- NCT03926000 373 374 O
Patients NCT03926000 376 384 O
with NCT03926000 385 389 O
sleep NCT03926000 390 395 B-Condition-Name
apnea NCT03926000 396 401 I-Condition-Name
syndrome NCT03926000 402 410 I-Condition-Name
. NCT03926000 411 412 O

- NCT03926000 416 417 O
Patients NCT03926000 419 427 O
with NCT03926000 428 432 O
renal NCT03926000 433 438 O
or NCT03926000 439 441 O
hepatic NCT03926000 442 449 O
dysfunction NCT03926000 450 461 B-Condition-Name
. NCT03926000 462 463 O

- NCT03926000 467 468 O
Patients NCT03926000 470 478 O
with NCT03926000 479 483 O
psychiatric NCT03926000 484 495 B-Condition-Name
disorders NCT03926000 496 505 I-Condition-Name
. NCT03926000 506 507 O

Inclusion NCT03924830 0 9 O
Criteria NCT03924830 10 18 O
: NCT03924830 19 20 O

- NCT03924830 24 25 O
All NCT03924830 27 30 O
patients NCT03924830 31 39 O
must NCT03924830 40 44 O
have NCT03924830 45 49 O
at NCT03924830 50 52 O
only NCT03924830 53 57 B-Eq-Operator___Eq-Operator-Value:EQ
20 NCT03924830 59 61 B-Eq-Value
teeth NCT03924830 62 67 B-Condition-Name
in NCT03924830 68 70 I-Condition-Name
function NCT03924830 71 79 I-Condition-Name
, NCT03924830 80 81 O
must NCT03924830 82 86 O
have NCT03924830 87 91 O
at NCT03924830 92 94 O
only NCT03924830 95 99 B-Eq-Operator___Eq-Operator-Value:EQ
3 NCT03924830 101 102 B-Eq-Value
carious NCT03924830 103 110 O
occlusal NCT03924830 111 119 O
or NCT03924830 120 122 O
proximo NCT03924830 123 130 O
- NCT03924830 131 132 O
occlusal NCT03924830 133 141 O
lesions NCT03924830 142 149 B-Condition-Name
, NCT03924830 150 151 O
or NCT03924830 152 154 O
old NCT03924830 155 158 O
restorations NCT03924830 159 171 B-Condition-Name
that NCT03924830 172 176 O
need NCT03924830 177 181 O
to NCT03924830 182 184 O
be NCT03924830 185 187 O
changed NCT03924830 188 195 B-Stability___Stability-Value:change
, NCT03924830 196 197 O
in NCT03924830 198 200 O
different NCT03924830 201 210 O
teeth NCT03924830 211 216 O
. NCT03924830 217 218 O
Those NCT03924830 220 225 O
lesions NCT03924830 226 233 B-Condition-Name
must NCT03924830 234 238 O
be NCT03924830 239 241 O
more NCT03924830 242 246 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03924830 247 251 I-Eq-Operator___Eq-Operator-Value:GT
2 NCT03924830 253 254 B-Eq-Value
mm NCT03924830 255 257 B-Eq-Unit
deep NCT03924830 258 262 B-Observation-Name___Observation-Type-Value:measurement
, NCT03924830 263 264 O
should NCT03924830 265 271 O
have NCT03924830 272 276 O
exposed NCT03924830 277 284 B-Condition-Name
dentin NCT03924830 285 291 I-Condition-Name
, NCT03924830 292 293 O
and NCT03924830 294 297 O
must NCT03924830 298 302 O
have NCT03924830 303 307 O
at NCT03924830 308 310 O
only NCT03924830 311 315 B-Eq-Operator___Eq-Operator-Value:EQ
50 NCT03924830 317 319 B-Eq-Value
% NCT03924830 320 321 B-Eq-Unit
of NCT03924830 322 324 O
margins NCT03924830 325 332 B-Observation-Name___Observation-Type-Value:measurement
in NCT03924830 333 335 I-Observation-Name___Observation-Type-Value:measurement
enamel NCT03924830 336 342 I-Observation-Name___Observation-Type-Value:measurement
. NCT03924830 343 344 O
Teeth NCT03924830 346 351 O
should NCT03924830 352 358 O
not NCT03924830 359 362 O
present NCT03924830 363 370 O
periodontal NCT03924830 371 382 B-Condition-Name
mobility NCT03924830 383 391 I-Condition-Name
. NCT03924830 392 393 O

Exclusion NCT03924830 395 404 O
Criteria NCT03924830 405 413 O
: NCT03924830 414 415 O

- NCT03924830 419 420 O
Volunteers NCT03924830 422 432 O
with NCT03924830 433 437 O
periodontal NCT03924830 438 449 B-Condition-Name
disease NCT03924830 450 457 I-Condition-Name
; NCT03924830 457 458 O
with NCT03924830 459 463 O
gingival NCT03924830 464 472 B-Condition-Name
bleeding NCT03924830 473 481 I-Condition-Name
; NCT03924830 481 482 O
use NCT03924830 483 486 O
of NCT03924830 487 489 O
anti NCT03924830 490 494 B-Drug-Name
- NCT03924830 495 496 I-Drug-Name
inflammatory NCT03924830 497 509 I-Drug-Name
drugs NCT03924830 510 515 I-Drug-Name
in NCT03924830 516 518 O
the NCT03924830 519 522 O
last NCT03924830 523 527 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
30 NCT03924830 529 531 B-Eq-Value
days NCT03924830 532 536 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
. NCT03924830 537 538 O

Inclusion NCT03924011 0 9 O
Criteria NCT03924011 10 18 O
: NCT03924011 19 20 O

- NCT03924011 24 25 O
Informed NCT03924011 27 35 O
Consent NCT03924011 36 43 O
as NCT03924011 44 46 O
documented NCT03924011 47 57 O
by NCT03924011 58 60 O
signature NCT03924011 61 70 O

- NCT03924011 73 74 O
Diagnosis NCT03924011 76 85 O
of NCT03924011 86 88 O
non NCT03924011 89 92 O
- NCT03924011 93 94 O
invasive NCT03924011 95 103 O
( NCT03924011 104 105 O
stage NCT03924011 106 111 B-Eq-Unit
0 NCT03924011 113 114 B-Eq-Value
) NCT03924011 115 116 O
or NCT03924011 117 119 O
invasive NCT03924011 120 128 O
( NCT03924011 129 130 O
stage NCT03924011 131 136 B-Eq-Unit
1 NCT03924011 138 139 B-Eq-Value
, NCT03924011 140 141 O
2 NCT03924011 143 144 B-Eq-Value
and NCT03924011 145 148 O
3 NCT03924011 150 151 B-Eq-Value
A NCT03924011 152 153 I-Eq-Value
) NCT03924011 154 155 O
breast NCT03924011 156 162 B-Condition-Name
adenocarcinoma NCT03924011 163 177 I-Condition-Name

- NCT03924011 180 181 O
Treatment NCT03924011 183 192 O
with NCT03924011 193 197 O
primary NCT03924011 198 205 O
breast NCT03924011 206 212 B-Procedure-Name
- NCT03924011 213 214 I-Procedure-Name
sparing NCT03924011 215 222 I-Procedure-Name
surgery NCT03924011 223 230 I-Procedure-Name
( NCT03924011 231 232 O
lumpectomy NCT03924011 233 243 B-Procedure-Name
) NCT03924011 244 245 O
and NCT03924011 246 249 O
/ NCT03924011 250 251 O
or NCT03924011 252 254 O
neoadjuvant NCT03924011 255 266 O
( NCT03924011 267 268 O
pre NCT03924011 269 272 O
operative NCT03924011 273 282 O
) NCT03924011 283 284 O
or NCT03924011 285 287 O
adjuvant NCT03924011 288 296 O
( NCT03924011 297 298 O
post NCT03924011 299 303 O
operative NCT03924011 304 313 O
) NCT03924011 314 315 O
chemotherapy NCT03924011 316 328 B-Procedure-Name
or NCT03924011 329 331 O
hormonal NCT03924011 332 340 B-Procedure-Name
therapy NCT03924011 341 348 I-Procedure-Name

- NCT03924011 351 352 O
Scheduled NCT03924011 354 363 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
for NCT03924011 364 367 O
post NCT03924011 368 372 O
operative NCT03924011 373 382 O
radiotherapy NCT03924011 383 395 B-Procedure-Name
at NCT03924011 396 398 O
Ziekenhuis NCT03924011 399 409 B-Location___Location-Value:hospital
Oost NCT03924011 410 414 I-Location___Location-Value:hospital
- NCT03924011 415 416 I-Location___Location-Value:hospital
Limburg NCT03924011 417 424 I-Location___Location-Value:hospital
, NCT03924011 425 426 I-Location___Location-Value:hospital
Genk NCT03924011 427 431 I-Location___Location-Value:hospital
: NCT03924011 432 433 O

- NCT03924011 437 438 O
Hypofractionated NCT03924011 440 456 B-Procedure-Name
radiotherapy NCT03924011 457 469 I-Procedure-Name
regimen NCT03924011 470 477 O
( NCT03924011 478 479 O
i NCT03924011 480 481 O
. NCT03924011 482 483 O
e NCT03924011 484 485 O
. NCT03924011 486 487 O
16 NCT03924011 490 492 B-Eq-Value
daily NCT03924011 493 498 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
fractions NCT03924011 499 508 O
of NCT03924011 509 511 O
2.66 NCT03924011 513 517 B-Procedure-Name
Gray NCT03924011 518 522 I-Procedure-Name
to NCT03924011 523 525 O
the NCT03924011 526 529 O
whole NCT03924011 530 535 O
breast NCT03924011 536 542 O
followed NCT03924011 543 551 O
by NCT03924011 552 554 O
a NCT03924011 555 556 O
boost NCT03924011 557 562 O
of NCT03924011 563 565 O
5 NCT03924011 567 568 B-Eq-Value
fractions NCT03924011 569 578 O
of NCT03924011 579 581 O
2.66 NCT03924011 583 587 B-Procedure-Name
Gray NCT03924011 588 592 I-Procedure-Name
to NCT03924011 593 595 O
the NCT03924011 596 599 O
tumor NCT03924011 600 605 O
bed NCT03924011 606 609 O
, NCT03924011 610 611 O
5 NCT03924011 613 614 B-Eq-Value
x NCT03924011 615 616 O
/ NCT03924011 617 618 O
week NCT03924011 619 623 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
) NCT03924011 624 625 O

Exclusion NCT03924011 631 640 O
Criteria NCT03924011 641 649 O
: NCT03924011 650 651 O

- NCT03924011 655 656 O
Scheduled NCT03924011 658 667 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
for NCT03924011 668 671 O
post NCT03924011 672 676 O
operative NCT03924011 677 686 O
radiotherapy NCT03924011 687 699 B-Procedure-Name
at NCT03924011 700 702 O
Jessa NCT03924011 703 708 B-Location___Location-Value:hospital
Hospital NCT03924011 709 717 I-Location___Location-Value:hospital
, NCT03924011 718 719 I-Location___Location-Value:hospital
Hasselt NCT03924011 720 727 I-Location___Location-Value:hospital
, NCT03924011 728 729 I-Location___Location-Value:hospital
Belgium NCT03924011 730 737 I-Location___Location-Value:hospital

- NCT03924011 740 741 O
Previous NCT03924011 743 751 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
irradiation NCT03924011 752 763 B-Procedure-Name
to NCT03924011 764 766 O
the NCT03924011 767 770 O
same NCT03924011 771 775 O
breast NCT03924011 776 782 O

- NCT03924011 785 786 O
Metastatic NCT03924011 788 798 O
disease NCT03924011 799 806 O

- NCT03924011 809 810 O
Concurrent NCT03924011 812 822 O
chemotherapy NCT03924011 823 835 B-Procedure-Name

- NCT03924011 838 839 O
Required NCT03924011 841 849 O
use NCT03924011 850 853 O
of NCT03924011 854 856 O
bolus NCT03924011 857 862 B-Procedure-Name
material NCT03924011 863 871 O
to NCT03924011 872 874 O
deliver NCT03924011 875 882 O
radiotherapy NCT03924011 883 895 B-Procedure-Name
( NCT03924011 896 897 O
i NCT03924011 898 899 O
. NCT03924011 900 901 O
e NCT03924011 902 903 O
material NCT03924011 904 912 O
placed NCT03924011 913 919 O
on NCT03924011 920 922 O
the NCT03924011 923 926 O
to NCT03924011 927 929 O
- NCT03924011 930 931 O
be NCT03924011 932 934 O
- NCT03924011 935 936 O
irradiated NCT03924011 937 947 O
zone NCT03924011 948 952 O
to NCT03924011 953 955 O
modulate NCT03924011 956 964 O
the NCT03924011 965 968 O
delivered NCT03924011 969 978 O
dose NCT03924011 979 983 O
in NCT03924011 984 986 O
order NCT03924011 987 992 O
to NCT03924011 993 995 O
ensure NCT03924011 996 1002 O
an NCT03924011 1003 1005 O
optimal NCT03924011 1006 1013 O
distribution NCT03924011 1014 1026 O
of NCT03924011 1027 1029 O
the NCT03924011 1030 1033 O
radiation NCT03924011 1034 1043 O
dose NCT03924011 1044 1048 O
; NCT03924011 1048 1049 O
mostly NCT03924011 1050 1056 O
used NCT03924011 1057 1061 O
for NCT03924011 1062 1065 O
treatment NCT03924011 1066 1075 O
of NCT03924011 1076 1078 O
superficial NCT03924011 1079 1090 O
tumors NCT03924011 1091 1097 O
) NCT03924011 1098 1099 O

- NCT03924011 1103 1104 O
Known NCT03924011 1106 1111 O
or NCT03924011 1112 1114 O
suspected NCT03924011 1115 1124 O
non NCT03924011 1125 1128 B-Condition-Name
- NCT03924011 1129 1130 I-Condition-Name
compliance NCT03924011 1131 1141 I-Condition-Name
, NCT03924011 1142 1143 O
drug NCT03924011 1144 1148 O
or NCT03924011 1149 1151 O
alcohol NCT03924011 1152 1159 O
abuse NCT03924011 1160 1165 B-Condition-Name

- NCT03924011 1168 1169 O
Inability NCT03924011 1171 1180 O
to NCT03924011 1181 1183 O
follow NCT03924011 1184 1190 O
the NCT03924011 1191 1194 O
procedures NCT03924011 1195 1205 O
of NCT03924011 1206 1208 O
the NCT03924011 1209 1212 O
study NCT03924011 1213 1218 O
, NCT03924011 1219 1220 O
e NCT03924011 1221 1222 O
. NCT03924011 1223 1224 O
g NCT03924011 1225 1226 O
. NCT03924011 1227 1228 O
due NCT03924011 1230 1233 O
to NCT03924011 1234 1236 O
language NCT03924011 1237 1245 B-Condition-Name
problems NCT03924011 1246 1254 I-Condition-Name
, NCT03924011 1255 1256 O
psyschological NCT03924011 1257 1271 B-Condition-Name
disorders NCT03924011 1272 1281 I-Condition-Name
, NCT03924011 1282 1283 O
dementia NCT03924011 1284 1292 B-Condition-Name
, NCT03924011 1293 1294 O
etc NCT03924011 1295 1298 O
. NCT03924011 1299 1300 O
of NCT03924011 1302 1304 O
the NCT03924011 1305 1308 O
participant NCT03924011 1309 1320 O

- NCT03924011 1323 1324 O
Seizure NCT03924011 1326 1333 B-Condition-Name

- NCT03924011 1336 1337 O
Disorders NCT03924011 1339 1348 B-Condition-Name
triggered NCT03924011 1349 1358 O
by NCT03924011 1359 1361 O
lighttake NCT03924011 1362 1371 O
anticoagulants NCT03924011 1372 1386 B-Drug-Name

- NCT03924011 1389 1390 O
Hemorrhagic NCT03924011 1392 1403 B-Condition-Name
diatheses NCT03924011 1404 1413 I-Condition-Name

- NCT03924011 1416 1417 O
Pregnancy NCT03924011 1419 1428 B-Condition-Name

- NCT03924011 1431 1432 O
Suspected NCT03924011 1434 1443 O
of NCT03924011 1444 1446 O
carrying NCT03924011 1447 1455 O
serious NCT03924011 1456 1463 B-Severity___Severity-Value:severe
infectious NCT03924011 1464 1474 B-Condition-Name
disease NCT03924011 1475 1482 I-Condition-Name

- NCT03924011 1485 1486 O
HIV NCT03924011 1488 1491 B-Condition-Name
positive NCT03924011 1492 1500 B-Polarity___Polarity-Value:positive
history NCT03924011 1501 1508 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past


Inclusion NCT03928171 0 9 O
Criteria NCT03928171 10 18 O
: NCT03928171 19 20 O

- NCT03928171 24 25 O
Adults NCT03928171 27 33 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
( NCT03928171 34 35 O
≥ NCT03928171 37 38 B-Eq-Operator___Eq-Operator-Value:GTEQ
18 NCT03928171 40 42 B-Eq-Value
years NCT03928171 43 48 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03928171 49 52 O
) NCT03928171 53 54 O

- NCT03928171 58 59 O
Scheduled NCT03928171 61 70 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
for NCT03928171 71 74 O
robot NCT03928171 75 80 O
- NCT03928171 81 82 O
assisted NCT03928171 83 91 O
colorectal NCT03928171 92 102 O
laparoscopic NCT03928171 103 115 B-Procedure-Name
surgery NCT03928171 116 123 I-Procedure-Name

Exclusion NCT03928171 124 133 O
Criteria NCT03928171 134 142 O
: NCT03928171 143 144 O

- NCT03928171 148 149 O
Severe NCT03928171 151 157 B-Severity___Severity-Value:severe
liver NCT03928171 158 163 O
- NCT03928171 164 165 O
or NCT03928171 166 168 O
renal NCT03928171 169 174 O
disease NCT03928171 175 182 B-Condition-Name

- NCT03928171 185 186 O
Pregnancy NCT03928171 188 197 B-Condition-Name
or NCT03928171 198 200 O
lactation NCT03928171 201 210 B-Condition-Name

- NCT03928171 213 214 O
Planned NCT03928171 216 223 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
diagnostics NCT03928171 224 235 B-Procedure-Name
or NCT03928171 236 238 O
treatment NCT03928171 239 248 O
with NCT03928171 249 253 O
radioactive NCT03928171 254 265 B-Procedure-Name
iodine NCT03928171 266 272 I-Procedure-Name
< NCT03928171 273 274 B-Eq-Operator___Eq-Operator-Value:LT
1 NCT03928171 276 277 B-Eq-Value
week NCT03928171 278 282 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
after NCT03928171 283 288 O
surgery NCT03928171 289 296 B-Procedure-Name

- NCT03928171 299 300 O
BMI NCT03928171 302 305 B-Observation-Name___Observation-Type-Value:vital
> NCT03928171 306 307 B-Eq-Operator___Eq-Operator-Value:GT
35 NCT03928171 309 311 B-Eq-Value
kg NCT03928171 312 314 B-Eq-Unit
/ NCT03928171 315 316 I-Eq-Unit
m NCT03928171 317 318 I-Eq-Unit
2 NCT03928171 319 320 I-Eq-Unit

- NCT03928171 323 324 O
Known NCT03928171 326 331 O
or NCT03928171 332 334 O
suspected NCT03928171 335 344 O
hypersensitivity NCT03928171 345 361 B-Condition-Name
to NCT03928171 362 364 O
indocyanine NCT03928171 365 376 O
green NCT03928171 377 382 O
, NCT03928171 383 384 O
sodium NCT03928171 385 391 O
iodide NCT03928171 392 398 O
or NCT03928171 399 401 O
iodine NCT03928171 402 408 O

- NCT03928171 411 412 O
Hyperthyroidism NCT03928171 414 429 B-Condition-Name
or NCT03928171 430 432 O
thyroid NCT03928171 433 440 B-Condition-Name
adenomas NCT03928171 441 449 I-Condition-Name

- NCT03928171 452 453 O
Use NCT03928171 455 458 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
of NCT03928171 459 461 O
medication NCT03928171 462 472 O
interfering NCT03928171 473 484 B-Stability___Stability-Value:change
with NCT03928171 485 489 O
ICG NCT03928171 490 493 B-Condition-Name
absorption NCT03928171 494 504 I-Condition-Name
as NCT03928171 505 507 O
listed NCT03928171 508 514 O
in NCT03928171 515 517 O
the NCT03928171 518 521 O
summary NCT03928171 522 529 O
of NCT03928171 530 532 O
product NCT03928171 533 540 O
characteristics NCT03928171 541 556 O
. NCT03928171 557 558 O

Inclusion NCT03925441 0 9 O
Criteria NCT03925441 10 18 O
: NCT03925441 19 20 O

- NCT03925441 24 25 O
Children NCT03925441 27 35 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
and NCT03925441 36 39 O
adolescents NCT03925441 40 51 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
who NCT03925441 52 55 O
are NCT03925441 56 59 O
diagnosed NCT03925441 60 69 O
with NCT03925441 70 74 O
pediatric NCT03925441 75 84 O
chronic NCT03925441 85 92 O
severe NCT03925441 93 99 B-Severity___Severity-Value:severe
plaque NCT03925441 100 106 B-Condition-Name
psoriasis NCT03925441 107 116 I-Condition-Name
. NCT03925441 117 118 O

- NCT03925441 122 123 O
Prior NCT03925441 125 130 O
to NCT03925441 131 133 O
participating NCT03925441 134 147 O
in NCT03925441 148 150 O
the NCT03925441 151 154 O
study NCT03925441 155 160 O
, NCT03925441 161 162 O
adalimumab NCT03925441 163 173 B-Drug-Name
treatment NCT03925441 174 183 O
was NCT03925441 184 187 O
determined NCT03925441 188 198 O
according NCT03925441 199 208 O
to NCT03925441 209 211 O
clinical NCT03925441 212 220 O
judgement NCT03925441 221 230 O
of NCT03925441 231 233 O
the NCT03925441 234 237 O
physician NCT03925441 238 247 O
. NCT03925441 248 249 O

- NCT03925441 253 254 O
Participants NCT03925441 256 268 O
( NCT03925441 269 270 O
or NCT03925441 271 273 O
legal NCT03925441 274 279 O
representative NCT03925441 280 294 O
) NCT03925441 295 296 O
who NCT03925441 297 300 O
voluntarily NCT03925441 301 312 O
agreed NCT03925441 313 319 O
to NCT03925441 320 322 O
participate NCT03925441 323 334 O
in NCT03925441 335 337 O
this NCT03925441 338 342 O
study NCT03925441 343 348 O
and NCT03925441 349 352 O
signed NCT03925441 353 359 O
informed NCT03925441 360 368 O
consent NCT03925441 369 376 O
. NCT03925441 377 378 O

Exclusion NCT03925441 380 389 O
Criteria NCT03925441 390 398 O
: NCT03925441 399 400 O

- NCT03925441 404 405 O
Participants NCT03925441 407 419 O
with NCT03925441 420 424 O
contraindication NCT03925441 425 441 O
to NCT03925441 442 444 O
adalimumab NCT03925441 445 455 B-Drug-Name
as NCT03925441 456 458 O
listed NCT03925441 459 465 O
in NCT03925441 466 468 O
the NCT03925441 469 472 O
approved NCT03925441 473 481 O
Korean NCT03925441 482 488 O
label NCT03925441 489 494 O
. NCT03925441 495 496 O

- NCT03925441 500 501 O
Participants NCT03925441 503 515 O
with NCT03925441 516 520 O
prior NCT03925441 521 526 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
treatment NCT03925441 527 536 O
with NCT03925441 537 541 O
adalimumab NCT03925441 542 552 B-Drug-Name
. NCT03925441 553 554 O

Inclusion NCT03923959 0 9 O
Criteria NCT03923959 10 18 O
: NCT03923959 19 20 O

1 NCT03923959 25 26 O
. NCT03923959 26 27 O
Provision NCT03923959 29 38 O
of NCT03923959 39 41 O
written NCT03923959 42 49 O
informed NCT03923959 50 58 O
consent NCT03923959 59 66 O

2 NCT03923959 70 71 O
. NCT03923959 71 72 O
Age NCT03923959 74 77 O
> NCT03923959 78 79 B-Eq-Operator___Eq-Operator-Value:GTEQ
or NCT03923959 80 82 I-Eq-Operator___Eq-Operator-Value:GTEQ
= NCT03923959 83 84 I-Eq-Operator___Eq-Operator-Value:GTEQ
to NCT03923959 85 87 O
65 NCT03923959 89 91 B-Eq-Value
years NCT03923959 92 97 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

3 NCT03923959 101 102 O
. NCT03923959 102 103 O
Hip NCT03923959 105 108 O
fracture NCT03923959 109 117 B-Condition-Name
location NCT03923959 118 126 O
within NCT03923959 127 133 O
the NCT03923959 134 137 O
femoral NCT03923959 138 145 O
neck NCT03923959 146 150 O
, NCT03923959 151 152 O
intertrochanteric NCT03923959 153 170 O
, NCT03923959 171 172 O
and NCT03923959 173 176 O
subtrochanteric NCT03923959 177 192 O
regions NCT03923959 193 200 O

4 NCT03923959 204 205 O
. NCT03923959 205 206 O
Indication NCT03923959 208 218 O
for NCT03923959 219 222 O
one NCT03923959 223 226 B-Eq-Value
of NCT03923959 227 229 O
the NCT03923959 230 233 O
following NCT03923959 234 243 O
surgical NCT03923959 244 252 B-Procedure-Name
interventions NCT03923959 253 266 I-Procedure-Name
: NCT03923959 267 268 O
hemiarthroplasty NCT03923959 269 285 B-Procedure-Name
, NCT03923959 286 287 O
total NCT03923959 288 293 B-Procedure-Name
hip NCT03923959 294 297 I-Procedure-Name
replacement NCT03923959 298 309 I-Procedure-Name
, NCT03923959 310 311 O
sliding NCT03923959 312 319 O
plate NCT03923959 320 325 O
and NCT03923959 326 329 O
screw NCT03923959 330 335 O
fixation NCT03923959 336 344 B-Procedure-Name
, NCT03923959 345 346 O
or NCT03923959 347 349 O
intramedullary NCT03923959 350 364 O
fixation NCT03923959 365 373 B-Procedure-Name

Exclusion NCT03923959 374 383 O
Criteria NCT03923959 384 392 O
: NCT03923959 393 394 O

1 NCT03923959 399 400 O
. NCT03923959 400 401 O
Indication NCT03923959 403 413 O
for NCT03923959 414 417 O
closed NCT03923959 418 424 B-Procedure-Name
reduction NCT03923959 425 434 I-Procedure-Name
or NCT03923959 435 437 O
percutaneous NCT03923959 438 450 B-Procedure-Name
screw NCT03923959 451 456 I-Procedure-Name

2 NCT03923959 460 461 O
. NCT03923959 461 462 O
Allergy NCT03923959 464 471 O
to NCT03923959 472 474 O
TXA NCT03923959 475 478 B-Drug-Name

3 NCT03923959 482 483 O
. NCT03923959 483 484 O
Cerebrovascular NCT03923959 486 501 B-Condition-Name
accident NCT03923959 502 510 I-Condition-Name
/ NCT03923959 511 512 O
stroke NCT03923959 513 519 B-Condition-Name
, NCT03923959 520 521 O
active NCT03923959 522 528 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
coronary NCT03923959 529 537 B-Condition-Name
disease NCT03923959 538 545 I-Condition-Name
/ NCT03923959 546 547 O
myocardial NCT03923959 548 558 B-Condition-Name
infarction NCT03923959 559 569 I-Condition-Name
, NCT03923959 570 571 O
or NCT03923959 572 574 O
deep NCT03923959 575 579 B-Condition-Name
vein NCT03923959 580 584 I-Condition-Name
thrombosis NCT03923959 585 595 I-Condition-Name
/ NCT03923959 596 597 O
pulmonary NCT03923959 598 607 B-Condition-Name
emboli NCT03923959 608 614 I-Condition-Name
within NCT03923959 615 621 B-Eq-Operator___Eq-Operator-Value:LTEQ
one NCT03923959 622 625 B-Eq-Value
( NCT03923959 626 627 O
1 NCT03923959 629 630 B-Eq-Value
) NCT03923959 631 632 O
month NCT03923959 633 638 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
of NCT03923959 639 641 O
the NCT03923959 642 645 O
fracture NCT03923959 646 654 B-Condition-Name

4 NCT03923959 658 659 O
. NCT03923959 659 660 O
Presence NCT03923959 662 670 O
of NCT03923959 671 673 O
hypercoaguable NCT03923959 674 688 B-Condition-Name
disorder NCT03923959 689 697 I-Condition-Name

Inclusion NCT03923192 0 9 O
Criteria NCT03923192 10 18 O
: NCT03923192 19 20 O

- NCT03923192 24 25 O
Patients NCT03923192 27 35 O
aged NCT03923192 36 40 O
from NCT03923192 41 45 O
15 NCT03923192 47 49 B-Eq-Value
to NCT03923192 50 52 B-Eq-Operator___Eq-Operator-Value:BETWEEN
50 NCT03923192 54 56 B-Eq-Value
years NCT03923192 57 62 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
. NCT03923192 63 64 O

- NCT03923192 68 69 O
No NCT03923192 71 73 O
gender NCT03923192 74 80 O
restriction NCT03923192 81 92 O
. NCT03923192 93 94 O

- NCT03923192 98 99 O
Patients NCT03923192 101 109 O
should NCT03923192 110 116 O
have NCT03923192 117 121 O
an NCT03923192 122 124 O
acceptable NCT03923192 125 135 O
oral NCT03923192 136 140 O
hygiene NCT03923192 141 148 O
level NCT03923192 149 154 O
. NCT03923192 155 156 O

- NCT03923192 160 161 O
Patients NCT03923192 163 171 O
must NCT03923192 172 176 O
have NCT03923192 177 181 O
at NCT03923192 182 184 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03923192 185 190 I-Eq-Operator___Eq-Operator-Value:GTEQ
one NCT03923192 191 194 B-Eq-Value
posterior NCT03923192 195 204 O
proximal NCT03923192 205 213 O
caries NCT03923192 214 220 B-Condition-Name

Exclusion NCT03923192 221 230 O
Criteria NCT03923192 231 239 O
: NCT03923192 240 241 O

- NCT03923192 245 246 O
Patients NCT03923192 248 256 O
with NCT03923192 257 261 O
a NCT03923192 262 263 O
compromised NCT03923192 264 275 O
medical NCT03923192 276 283 O
history NCT03923192 284 291 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
. NCT03923192 292 293 O

- NCT03923192 297 298 O
Severe NCT03923192 300 306 B-Severity___Severity-Value:severe
or NCT03923192 307 309 O
active NCT03923192 310 316 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
periodontal NCT03923192 317 328 B-Condition-Name
disease NCT03923192 329 336 I-Condition-Name
. NCT03923192 337 338 O

- NCT03923192 342 343 O
Heavy NCT03923192 345 350 O
bruxism NCT03923192 351 358 B-Condition-Name
or NCT03923192 359 361 O
a NCT03923192 362 363 O
traumatic NCT03923192 364 373 O
occlusion NCT03923192 374 383 B-Condition-Name
. NCT03923192 384 385 O

- NCT03923192 389 390 O
Acute NCT03923192 392 397 B-Severity___Severity-Value:severe
or NCT03923192 398 400 O
chronic NCT03923192 401 408 O
dental NCT03923192 409 415 O
infection NCT03923192 416 425 B-Condition-Name
. NCT03923192 426 427 O

- NCT03923192 431 432 O
Pregnant NCT03923192 434 442 B-Condition-Name
or NCT03923192 443 445 O
breastfeeding NCT03923192 446 459 B-Condition-Name
women NCT03923192 460 465 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
. NCT03923192 466 467 O

- NCT03923192 471 472 O
Patients NCT03923192 474 482 O
with NCT03923192 483 487 O
posterior NCT03923192 488 497 O
restorations NCT03923192 498 510 B-Procedure-Name
on NCT03923192 511 513 O
molars NCT03923192 514 520 O
or NCT03923192 521 523 O
premolars NCT03923192 524 533 O

Inclusion NCT03925285 0 9 O
Criteria NCT03925285 10 18 O
: NCT03925285 19 20 O

- NCT03925285 24 25 O
Biopsy NCT03925285 27 33 B-Procedure-Name
confirmed NCT03925285 34 43 O
diagnosis NCT03925285 44 53 O
of NCT03925285 54 56 O
SNIP NCT03925285 57 61 B-Condition-Name
and NCT03925285 62 65 O
scheduled NCT03925285 66 75 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
to NCT03925285 76 78 O
undergo NCT03925285 79 86 O
surgical NCT03925285 87 95 B-Procedure-Name
resection NCT03925285 96 105 I-Procedure-Name
; NCT03925285 105 106 O

- NCT03925285 109 110 O
Age NCT03925285 112 115 O
≥ NCT03925285 116 117 B-Eq-Operator___Eq-Operator-Value:GTEQ
18 NCT03925285 119 121 B-Eq-Value
years NCT03925285 122 127 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
; NCT03925285 127 128 O

- NCT03925285 131 132 O
Written NCT03925285 134 141 O
informed NCT03925285 142 150 O
consent NCT03925285 151 158 O
; NCT03925285 158 159 O

- NCT03925285 162 163 O
Mentally NCT03925285 165 173 B-Condition-Name
competent NCT03925285 174 183 I-Condition-Name
person NCT03925285 184 190 O
that NCT03925285 191 195 O
is NCT03925285 196 198 O
able NCT03925285 199 203 O
and NCT03925285 204 207 O
willing NCT03925285 208 215 O
to NCT03925285 216 218 O
comply NCT03925285 219 225 O
with NCT03925285 226 230 O
study NCT03925285 231 236 O
procedures NCT03925285 237 247 O
. NCT03925285 248 249 O

Exclusion NCT03925285 251 260 O
Criteria NCT03925285 261 269 O
: NCT03925285 270 271 O

- NCT03925285 275 276 O
Medical NCT03925285 278 285 O
or NCT03925285 286 288 O
psychiatric NCT03925285 289 300 O
conditions NCT03925285 301 311 B-Condition-Name
that NCT03925285 312 316 O
compromise NCT03925285 317 327 O
the NCT03925285 328 331 O
patient NCT03925285 332 339 O
's NCT03925285 339 341 O
ability NCT03925285 342 349 O
to NCT03925285 350 352 O
give NCT03925285 353 357 O
informed NCT03925285 358 366 O
consent NCT03925285 367 374 O
; NCT03925285 374 375 O

- NCT03925285 378 379 O
Concurrent NCT03925285 381 391 O
uncontrolled NCT03925285 392 404 O
medical NCT03925285 405 412 O
conditions NCT03925285 413 423 O
; NCT03925285 423 424 O

- NCT03925285 427 428 O
Received NCT03925285 430 438 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
an NCT03925285 439 441 O
investigational NCT03925285 442 457 O
drug NCT03925285 458 462 O
within NCT03925285 463 469 B-Eq-Operator___Eq-Operator-Value:LTEQ
30 NCT03925285 471 473 B-Eq-Value
days NCT03925285 474 478 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
prior NCT03925285 479 484 O
to NCT03925285 485 487 O
the NCT03925285 488 491 O
dose NCT03925285 492 496 O
of NCT03925285 497 499 O
bevacizumab NCT03925285 500 511 B-Drug-Name
- NCT03925285 512 513 I-Drug-Name
IRDye NCT03925285 514 519 I-Drug-Name
800 NCT03925285 520 523 I-Drug-Name
CW NCT03925285 524 526 I-Drug-Name
; NCT03925285 526 527 O

- NCT03925285 530 531 O
Tumors NCT03925285 533 539 B-Condition-Name
at NCT03925285 540 542 O
sites NCT03925285 543 548 O
of NCT03925285 549 551 O
which NCT03925285 552 557 O
the NCT03925285 558 561 O
surgeon NCT03925285 562 569 O
would NCT03925285 570 575 O
assess NCT03925285 576 582 O
that NCT03925285 583 587 O
in NCT03925285 588 590 B-Procedure-Name
vivo NCT03925285 591 595 I-Procedure-Name
imaging NCT03925285 596 603 I-Procedure-Name
would NCT03925285 604 609 O
not NCT03925285 610 613 O
be NCT03925285 614 616 O
feasible NCT03925285 617 625 O
; NCT03925285 625 626 O

- NCT03925285 629 630 O
History NCT03925285 632 639 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03925285 640 642 O
myocardial NCT03925285 643 653 B-Condition-Name
infarction NCT03925285 654 664 I-Condition-Name
, NCT03925285 665 666 O
cerebrovascular NCT03925285 667 682 B-Condition-Name
accident NCT03925285 683 691 I-Condition-Name
, NCT03925285 692 693 O
uncontrolled NCT03925285 694 706 O
cardiac NCT03925285 707 714 O
heart NCT03925285 715 720 B-Condition-Name
failure NCT03925285 721 728 I-Condition-Name
, NCT03925285 729 730 O
significant NCT03925285 731 742 B-Severity___Severity-Value:severe
liver NCT03925285 743 748 B-Condition-Name
disease NCT03925285 749 756 I-Condition-Name
or NCT03925285 757 759 O
unstable NCT03925285 760 768 B-Condition-Name
angina NCT03925285 769 775 I-Condition-Name
within NCT03925285 776 782 B-Eq-Operator___Eq-Operator-Value:LTEQ
6 NCT03925285 784 785 B-Eq-Value
months NCT03925285 786 792 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
prior NCT03925285 793 798 O
to NCT03925285 799 801 O
enrollment NCT03925285 802 812 O
; NCT03925285 812 813 O

- NCT03925285 816 817 O
Inadequately NCT03925285 819 831 O
controlled NCT03925285 832 842 O
hypertension NCT03925285 843 855 B-Condition-Name
with NCT03925285 856 860 O
or NCT03925285 861 863 O
without NCT03925285 864 871 O
current NCT03925285 872 879 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
antihypertensive NCT03925285 880 896 B-Drug-Name
medications NCT03925285 897 908 I-Drug-Name
; NCT03925285 908 909 O

- NCT03925285 912 913 O
History NCT03925285 915 922 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03925285 923 925 O
infusion NCT03925285 926 934 O
reactions NCT03925285 935 944 B-Condition-Name
to NCT03925285 945 947 O
bevacizumab NCT03925285 948 959 B-Drug-Name
or NCT03925285 960 962 O
other NCT03925285 963 968 O
monoclonal NCT03925285 969 979 B-Procedure-Name
antibody NCT03925285 980 988 I-Procedure-Name
therapies NCT03925285 989 998 I-Procedure-Name
; NCT03925285 998 999 O

- NCT03925285 1002 1003 O
Pregnant NCT03925285 1005 1013 B-Condition-Name
or NCT03925285 1014 1016 O
lactating NCT03925285 1017 1026 B-Condition-Name
women NCT03925285 1027 1032 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
. NCT03925285 1033 1034 O
Documentation NCT03925285 1036 1049 O
of NCT03925285 1050 1052 O
a NCT03925285 1053 1054 O
negative NCT03925285 1055 1063 B-Polarity___Polarity-Value:negative
pregnancy NCT03925285 1064 1073 B-Observation-Name___Observation-Type-Value:lab
test NCT03925285 1074 1078 I-Observation-Name___Observation-Type-Value:lab
must NCT03925285 1079 1083 O
be NCT03925285 1084 1086 O
available NCT03925285 1087 1096 O
for NCT03925285 1097 1100 O
women NCT03925285 1101 1106 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
of NCT03925285 1107 1109 O
childbearing NCT03925285 1110 1122 B-Condition-Name
potential NCT03925285 1123 1132 I-Condition-Name
. NCT03925285 1133 1134 O
Woman NCT03925285 1136 1141 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
of NCT03925285 1142 1144 O
childbearing NCT03925285 1145 1157 B-Condition-Name
potential NCT03925285 1158 1167 I-Condition-Name
are NCT03925285 1168 1171 O
premenopausal NCT03925285 1172 1185 B-Condition-Name
women NCT03925285 1186 1191 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
with NCT03925285 1192 1196 O
intact NCT03925285 1197 1203 B-Condition-Name
reproductive NCT03925285 1204 1216 I-Condition-Name
organs NCT03925285 1217 1223 I-Condition-Name
and NCT03925285 1224 1227 O
women NCT03925285 1228 1233 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
less NCT03925285 1234 1238 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03925285 1239 1243 I-Eq-Operator___Eq-Operator-Value:LT
two NCT03925285 1244 1247 B-Eq-Value
years NCT03925285 1248 1253 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
after NCT03925285 1254 1259 O
menopause NCT03925285 1260 1269 B-Condition-Name
; NCT03925285 1269 1270 O

- NCT03925285 1273 1274 O
Lab NCT03925285 1276 1279 B-Observation-Name___Observation-Type-Value:lab
values NCT03925285 1280 1286 I-Observation-Name___Observation-Type-Value:lab
that NCT03925285 1287 1291 O
in NCT03925285 1292 1294 O
the NCT03925285 1295 1298 O
opinion NCT03925285 1299 1306 O
of NCT03925285 1307 1309 O
the NCT03925285 1310 1313 O
primary NCT03925285 1314 1321 O
surgeon NCT03925285 1322 1329 O
would NCT03925285 1330 1335 O
prevent NCT03925285 1336 1343 O
surgical NCT03925285 1344 1352 B-Procedure-Name
resection NCT03925285 1353 1362 I-Procedure-Name
; NCT03925285 1362 1363 O

- NCT03925285 1366 1367 O
Life NCT03925285 1369 1373 B-Observation-Name
expectancy NCT03925285 1374 1384 I-Observation-Name
< NCT03925285 1385 1386 B-Eq-Operator___Eq-Operator-Value:LT
12 NCT03925285 1388 1390 B-Eq-Value
weeks NCT03925285 1391 1396 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
; NCT03925285 1396 1397 O

Inclusion NCT03928951 0 9 O
Criteria NCT03928951 10 18 O
: NCT03928951 19 20 O

- NCT03928951 24 25 O
Every NCT03928951 27 32 O
patient NCT03928951 33 40 O
more NCT03928951 41 45 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03928951 46 50 I-Eq-Operator___Eq-Operator-Value:GT
18 NCT03928951 52 54 B-Eq-Value
years NCT03928951 55 60 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
who NCT03928951 61 64 O
was NCT03928951 65 68 O
administered NCT03928951 69 81 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
antibiotherapy NCT03928951 82 96 B-Procedure-Name
for NCT03928951 97 100 O
urinary NCT03928951 101 108 O
infection NCT03928951 109 118 B-Condition-Name
in NCT03928951 119 121 O
emergency NCT03928951 122 131 B-Location___Location-Value:emergency-dept
department NCT03928951 132 142 I-Location___Location-Value:emergency-dept
or NCT03928951 143 145 O
for NCT03928951 146 149 O
whom NCT03928951 150 154 O
urinary NCT03928951 155 162 O
infection NCT03928951 163 172 B-Condition-Name
was NCT03928951 173 176 O
diagnosed NCT03928951 177 186 O
in NCT03928951 187 189 O
emergency NCT03928951 190 199 B-Location___Location-Value:emergency-dept
department NCT03928951 200 210 I-Location___Location-Value:emergency-dept
( NCT03928951 211 212 O
cystitis NCT03928951 213 221 B-Condition-Name
, NCT03928951 222 223 O
acute NCT03928951 224 229 B-Severity___Severity-Value:severe
pyelonephritis NCT03928951 230 244 B-Condition-Name
, NCT03928951 245 246 O
prostatitis NCT03928951 247 258 B-Condition-Name
) NCT03928951 259 260 O

Exclusion NCT03928951 262 271 O
Criteria NCT03928951 272 280 O
: NCT03928951 281 282 O

- NCT03928951 286 287 O
Patients NCT03928951 289 297 O
less NCT03928951 298 302 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03928951 303 307 I-Eq-Operator___Eq-Operator-Value:LT
18 NCT03928951 309 311 B-Eq-Value
years NCT03928951 312 317 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03928951 318 321 O

- NCT03928951 324 325 O
Patients NCT03928951 327 335 O
opposed NCT03928951 336 343 O
to NCT03928951 344 346 O
their NCT03928951 347 352 O
data NCT03928951 353 357 O
use NCT03928951 358 361 O

- NCT03928951 364 365 O
Patients NCT03928951 367 375 O
hospitalized NCT03928951 376 388 B-Encounter-Type___Encounter-Type-Value:inpatient
more NCT03928951 389 393 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03928951 394 398 I-Eq-Operator___Eq-Operator-Value:GT
24 NCT03928951 400 402 B-Eq-Value
hours NCT03928951 403 408 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:hour

- NCT03928951 411 412 O
Patients NCT03928951 414 422 O
taking NCT03928951 423 429 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
antibiotherapy NCT03928951 430 444 B-Procedure-Name
already NCT03928951 445 452 O
before NCT03928951 453 459 O
their NCT03928951 460 465 O
arrival NCT03928951 466 473 B-Encounter-Type___Encounter-Type-Value:emergency
in NCT03928951 474 476 O
emergency NCT03928951 477 486 B-Location___Location-Value:emergency-dept
department NCT03928951 487 497 I-Location___Location-Value:emergency-dept

- NCT03928951 500 501 O
Patients NCT03928951 503 511 O
without NCT03928951 512 519 O
sufficient NCT03928951 520 530 O
reading NCT03928951 531 538 O
capacities NCT03928951 539 549 O
or NCT03928951 550 552 O
understanding NCT03928951 553 566 O
of NCT03928951 567 569 O
french NCT03928951 570 576 B-Language
language NCT03928951 577 585 O
to NCT03928951 586 588 O
express NCT03928951 589 596 O
opposition NCT03928951 597 607 O
to NCT03928951 608 610 O
their NCT03928951 611 616 O
research NCT03928951 617 625 O
participation NCT03928951 626 639 O

- NCT03928951 642 643 O
Any NCT03928951 645 648 O
other NCT03928951 649 654 O
reason NCT03928951 655 661 O
which NCT03928951 662 667 O
, NCT03928951 668 669 O
according NCT03928951 670 679 O
to NCT03928951 680 682 O
investigator NCT03928951 683 695 O
, NCT03928951 696 697 O
might NCT03928951 698 703 O
interfere NCT03928951 704 713 O
with NCT03928951 714 718 O
research NCT03928951 719 727 O
objective NCT03928951 728 737 O
evaluation NCT03928951 738 748 O

Inclusion NCT03921034 0 9 O
Criteria NCT03921034 10 18 O
: NCT03921034 19 20 O

- NCT03921034 24 25 O
Unilateral NCT03921034 27 37 O
, NCT03921034 38 39 O
primary NCT03921034 40 47 O
tricompartment NCT03921034 48 62 O
total NCT03921034 63 68 O
knee NCT03921034 69 73 O
arthroplasty NCT03921034 74 86 B-Procedure-Name

- NCT03921034 89 90 O
Age NCT03921034 92 95 O
18 NCT03921034 97 99 B-Eq-Value
years NCT03921034 100 105 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
or NCT03921034 106 108 B-Eq-Operator___Eq-Operator-Value:GTEQ
older NCT03921034 109 114 I-Eq-Operator___Eq-Operator-Value:GTEQ

- NCT03921034 117 118 O
ASA NCT03921034 120 123 B-Condition-Name
I NCT03921034 124 125 B-Eq-Value
- NCT03921034 126 127 B-Eq-Operator___Eq-Operator-Value:BETWEEN
III NCT03921034 128 131 B-Eq-Value

- NCT03921034 134 135 O
Eligible NCT03921034 137 145 O
for NCT03921034 146 149 O
spinal NCT03921034 150 156 O
or NCT03921034 157 159 O
combined NCT03921034 160 168 O
spinal NCT03921034 169 175 O
epidural NCT03921034 176 184 B-Procedure-Name
anesthetic NCT03921034 185 195 I-Procedure-Name

- NCT03921034 198 199 O
Able NCT03921034 201 205 O
to NCT03921034 206 208 O
speak NCT03921034 209 214 O
, NCT03921034 215 216 O
read NCT03921034 217 221 O
, NCT03921034 222 223 O
and NCT03921034 224 227 O
understand NCT03921034 228 238 O
English NCT03921034 239 246 B-Language

- NCT03921034 249 250 O
Willing NCT03921034 252 259 O
to NCT03921034 260 262 O
participate NCT03921034 263 274 O
in NCT03921034 275 277 O
the NCT03921034 278 281 O
trial NCT03921034 282 287 O

Exclusion NCT03921034 288 297 O
Criteria NCT03921034 298 306 O
: NCT03921034 307 308 O

- NCT03921034 312 313 O
Contraindication NCT03921034 315 331 O
to NCT03921034 332 334 O
regional NCT03921034 335 343 B-Procedure-Name
anesthesia NCT03921034 344 354 I-Procedure-Name
or NCT03921034 355 357 O
peripheral NCT03921034 358 368 O
nerve NCT03921034 369 374 B-Procedure-Name
blocks NCT03921034 375 381 I-Procedure-Name

- NCT03921034 384 385 O
Allergy NCT03921034 387 394 O
to NCT03921034 395 397 O
local NCT03921034 398 403 B-Procedure-Name
anesthetics NCT03921034 404 415 I-Procedure-Name

- NCT03921034 418 419 O
Allergy NCT03921034 421 428 O
to NCT03921034 429 431 O
NSAIDs NCT03921034 432 438 B-Drug-Name

- NCT03921034 441 442 O
Chronic NCT03921034 444 451 O
renal NCT03921034 452 457 B-Condition-Name
insufficiency NCT03921034 458 471 I-Condition-Name
with NCT03921034 472 476 O
Cr NCT03921034 477 479 B-Observation-Name___Observation-Type-Value:lab
> NCT03921034 480 481 B-Eq-Operator___Eq-Operator-Value:GT
1.4 NCT03921034 483 486 B-Eq-Value
or NCT03921034 487 489 O
GFR NCT03921034 490 493 B-Observation-Name___Observation-Type-Value:lab
< NCT03921034 494 495 B-Eq-Operator___Eq-Operator-Value:LT
60 NCT03921034 497 499 B-Eq-Value

- NCT03921034 503 504 O
Have NCT03921034 506 510 O
chronic NCT03921034 511 518 O
pain NCT03921034 519 523 B-Condition-Name
that NCT03921034 524 528 O
is NCT03921034 529 531 O
not NCT03921034 532 535 O
related NCT03921034 536 543 O
to NCT03921034 544 546 O
their NCT03921034 547 552 O
knee NCT03921034 553 557 O
joint NCT03921034 558 563 O

- NCT03921034 566 567 O
Have NCT03921034 569 573 O
been NCT03921034 574 578 O
using NCT03921034 579 584 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
opioids NCT03921034 585 592 B-Drug-Name
on NCT03921034 593 595 O
a NCT03921034 596 597 O
chronic NCT03921034 598 605 O
basis NCT03921034 606 611 O
( NCT03921034 612 613 O
daily NCT03921034 614 619 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
or NCT03921034 620 622 O
almost NCT03921034 623 629 O
daily NCT03921034 630 635 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
opioid NCT03921034 636 642 B-Drug-Name
use NCT03921034 643 646 O
for NCT03921034 647 650 O
3 NCT03921034 652 653 B-Eq-Value
months NCT03921034 654 660 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
or NCT03921034 661 663 B-Eq-Operator___Eq-Operator-Value:GTEQ
longer NCT03921034 664 670 I-Eq-Operator___Eq-Operator-Value:GTEQ
) NCT03921034 671 672 O

- NCT03921034 676 677 O
Have NCT03921034 679 683 O
a NCT03921034 684 685 O
pre NCT03921034 686 689 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
- NCT03921034 690 691 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
existing NCT03921034 692 700 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
peripheral NCT03921034 701 711 B-Condition-Name
neuropathy NCT03921034 712 722 I-Condition-Name
involving NCT03921034 723 732 O
the NCT03921034 733 736 O
operative NCT03921034 737 746 O
site NCT03921034 747 751 O

- NCT03921034 754 755 O
Body NCT03921034 757 761 B-Observation-Name___Observation-Type-Value:vital
mass NCT03921034 762 766 I-Observation-Name___Observation-Type-Value:vital
index NCT03921034 767 772 I-Observation-Name___Observation-Type-Value:vital
greater NCT03921034 773 780 B-Eq-Operator___Eq-Operator-Value:GTEQ
than NCT03921034 781 785 I-Eq-Operator___Eq-Operator-Value:GTEQ
or NCT03921034 786 788 I-Eq-Operator___Eq-Operator-Value:GTEQ
equal NCT03921034 789 794 I-Eq-Operator___Eq-Operator-Value:GTEQ
to NCT03921034 795 797 O
40 NCT03921034 799 801 B-Eq-Value

Inclusion NCT03922529 0 9 O
Criteria NCT03922529 10 18 O
: NCT03922529 19 20 O

- NCT03922529 24 25 O
Age NCT03922529 27 30 O
≥ NCT03922529 31 32 B-Eq-Operator___Eq-Operator-Value:GTEQ
70 NCT03922529 34 36 B-Eq-Value
year NCT03922529 37 41 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03922529 44 45 O
Eligible NCT03922529 47 55 O
cardiovascular NCT03922529 56 70 B-Condition-Name
disease NCT03922529 71 78 I-Condition-Name
( NCT03922529 79 80 O
CVD NCT03922529 81 84 B-Condition-Name
) NCT03922529 85 86 O
diagnosis NCT03922529 87 96 O
( NCT03922529 97 98 O
hospitalization NCT03922529 99 114 B-Encounter-Type___Encounter-Type-Value:inpatient
for NCT03922529 115 118 O
Acute NCT03922529 119 124 B-Condition-Name
myocardial NCT03922529 125 135 I-Condition-Name
infarction NCT03922529 136 146 I-Condition-Name
( NCT03922529 147 148 O
AMI NCT03922529 149 152 B-Condition-Name
) NCT03922529 153 154 O
/ NCT03922529 156 157 O
Acute NCT03922529 158 163 B-Condition-Name
coronary NCT03922529 164 172 I-Condition-Name
syndrome NCT03922529 173 181 I-Condition-Name
( NCT03922529 182 183 O
ACS NCT03922529 184 187 B-Condition-Name
) NCT03922529 188 189 O
, NCT03922529 191 192 O
stable NCT03922529 193 199 B-Stability___Stability-Value:stable
Ischemic NCT03922529 200 208 B-Condition-Name
Heart NCT03922529 209 214 I-Condition-Name
Disease NCT03922529 215 222 I-Condition-Name
, NCT03922529 223 224 O
revascularization NCT03922529 225 242 O
Coronary NCT03922529 243 251 B-Procedure-Name
artery NCT03922529 252 258 I-Procedure-Name
bypass NCT03922529 259 265 I-Procedure-Name
graft NCT03922529 266 271 I-Procedure-Name
surgery NCT03922529 272 279 I-Procedure-Name
and NCT03922529 280 283 O
Percutaneous NCT03922529 284 296 B-Procedure-Name
Coronary NCT03922529 297 305 I-Procedure-Name
Intervention NCT03922529 306 318 I-Procedure-Name
[ NCT03922529 319 320 O
CABG NCT03922529 321 325 B-Procedure-Name
, NCT03922529 326 327 O
PCI NCT03922529 328 331 B-Procedure-Name
] NCT03922529 332 333 O
, NCT03922529 335 336 O
valvular NCT03922529 337 345 B-Condition-Name
heart NCT03922529 346 351 I-Condition-Name
disease NCT03922529 352 359 I-Condition-Name
[ NCT03922529 360 361 O
specifically NCT03922529 362 374 O
, NCT03922529 375 376 O
surgical NCT03922529 377 385 O
or NCT03922529 386 388 O
percutaneous NCT03922529 389 401 O
intervention NCT03922529 402 414 B-Procedure-Name
for NCT03922529 415 418 O
mitral NCT03922529 419 425 B-Condition-Name
regurgitation NCT03922529 426 439 I-Condition-Name
or NCT03922529 440 442 O
aortic NCT03922529 443 449 B-Condition-Name
stenosis NCT03922529 450 458 I-Condition-Name
] NCT03922529 459 460 O
, NCT03922529 462 463 O
or NCT03922529 464 466 O
heart NCT03922529 467 472 B-Condition-Name
failure NCT03922529 473 480 I-Condition-Name
( NCT03922529 481 482 O
HF NCT03922529 483 485 B-Condition-Name
) NCT03922529 486 487 O
) NCT03922529 489 490 O

- NCT03922529 494 495 O
English NCT03922529 497 504 B-Language
speaking NCT03922529 505 513 O

- NCT03922529 516 517 O
able NCT03922529 519 523 O
to NCT03922529 524 526 O
provide NCT03922529 527 534 O
written NCT03922529 535 542 O
informed NCT03922529 543 551 O
consent NCT03922529 552 559 O

- NCT03922529 562 563 O
able NCT03922529 565 569 O
to NCT03922529 570 572 O
be NCT03922529 573 575 O
assessed NCT03922529 576 584 O
and NCT03922529 585 588 O
undergo NCT03922529 589 596 O
study NCT03922529 597 602 O
interventions NCT03922529 603 616 O
. NCT03922529 617 618 O

Exclusion NCT03922529 620 629 O
Criteria NCT03922529 630 638 O
: NCT03922529 639 640 O

- NCT03922529 644 645 O
Unstable NCT03922529 647 655 B-Stability___Stability-Value:change
medical NCT03922529 656 663 O
condition NCT03922529 664 673 O
as NCT03922529 674 676 O
indicated NCT03922529 677 686 O
by NCT03922529 687 689 O
history NCT03922529 690 697 O
, NCT03922529 698 699 O
physical NCT03922529 700 708 B-Procedure-Name
exam NCT03922529 709 713 I-Procedure-Name
, NCT03922529 714 715 O
and NCT03922529 716 719 O
/ NCT03922529 720 721 O
or NCT03922529 722 724 O
laboratory NCT03922529 725 735 B-Observation-Name___Observation-Type-Value:lab
findings NCT03922529 736 744 I-Observation-Name___Observation-Type-Value:lab

- NCT03922529 747 748 O
Presence NCT03922529 750 758 O
of NCT03922529 759 761 O
non NCT03922529 762 765 O
- NCT03922529 766 767 O
CVD NCT03922529 768 771 B-Condition-Name
conditions NCT03922529 772 782 O
likely NCT03922529 783 789 O
to NCT03922529 790 792 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
be NCT03922529 793 795 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
fatal NCT03922529 796 801 O
within NCT03922529 802 808 B-Eq-Operator___Eq-Operator-Value:LTEQ
12 NCT03922529 810 812 B-Eq-Value
months NCT03922529 813 819 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
( NCT03922529 820 821 O
e NCT03922529 822 823 O
. NCT03922529 824 825 O
g NCT03922529 826 827 O
. NCT03922529 828 829 O
, NCT03922529 830 831 O
metastatic NCT03922529 832 842 O
cancer NCT03922529 843 849 B-Condition-Name
) NCT03922529 850 851 O

- NCT03922529 855 856 O
Severe NCT03922529 858 864 B-Severity___Severity-Value:severe
cognitive NCT03922529 865 874 B-Condition-Name
impairment NCT03922529 875 885 I-Condition-Name
: NCT03922529 886 887 O
Short NCT03922529 888 893 B-Observation-Name___Observation-Type-Value:clinical-score
Blessed NCT03922529 894 901 I-Observation-Name___Observation-Type-Value:clinical-score
screening NCT03922529 902 911 I-Observation-Name___Observation-Type-Value:clinical-score
with NCT03922529 912 916 O
a NCT03922529 917 918 O
score NCT03922529 919 924 O
of NCT03922529 925 927 O
13 NCT03922529 929 931 B-Eq-Value
or NCT03922529 932 934 B-Eq-Operator___Eq-Operator-Value:GTEQ
greater NCT03922529 935 942 I-Eq-Operator___Eq-Operator-Value:GTEQ
or NCT03922529 943 945 O
can NCT03922529 946 949 O
not NCT03922529 949 952 O
consent NCT03922529 953 960 O
( NCT03922529 961 962 O
as NCT03922529 963 965 O
indicated NCT03922529 966 975 O
by NCT03922529 976 978 O
medical NCT03922529 979 986 O
record NCT03922529 987 993 O
) NCT03922529 994 995 O

- NCT03922529 999 1000 O
Long NCT03922529 1002 1006 B-Procedure-Name
- NCT03922529 1007 1008 I-Procedure-Name
term NCT03922529 1009 1013 I-Procedure-Name
care NCT03922529 1014 1018 I-Procedure-Name
resident NCT03922529 1019 1027 O
at NCT03922529 1028 1030 O
admission NCT03922529 1031 1040 B-Encounter-Type___Encounter-Type-Value:inpatient
with NCT03922529 1041 1045 O
no NCT03922529 1046 1048 O
plans NCT03922529 1049 1054 O
to NCT03922529 1055 1057 O
return NCT03922529 1058 1064 O
to NCT03922529 1065 1067 O
independent NCT03922529 1068 1079 B-Observation-Name___Observation-Type-Value:social-habit
living NCT03922529 1080 1086 I-Observation-Name___Observation-Type-Value:social-habit

- NCT03922529 1089 1090 O
anticipates NCT03922529 1092 1103 O
inability NCT03922529 1104 1113 O
to NCT03922529 1114 1116 O
return NCT03922529 1117 1123 O
for NCT03922529 1124 1127 O
required NCT03922529 1128 1136 O
reassessments NCT03922529 1137 1150 B-Procedure-Name
at NCT03922529 1151 1153 O
3 NCT03922529 1155 1156 B-Eq-Value
, NCT03922529 1157 1158 O
6 NCT03922529 1160 1161 B-Eq-Value
and NCT03922529 1162 1165 O
12 NCT03922529 1167 1169 B-Eq-Value
months NCT03922529 1170 1176 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

- NCT03922529 1179 1180 O
long NCT03922529 1182 1186 B-Procedure-Name
- NCT03922529 1187 1188 I-Procedure-Name
term NCT03922529 1189 1193 I-Procedure-Name
care NCT03922529 1194 1198 I-Procedure-Name
residents NCT03922529 1199 1208 O
at NCT03922529 1209 1211 O
admission NCT03922529 1212 1221 B-Encounter-Type___Encounter-Type-Value:inpatient
with NCT03922529 1222 1226 O
no NCT03922529 1227 1229 O
plans NCT03922529 1230 1235 O
to NCT03922529 1236 1238 O
return NCT03922529 1239 1245 O
to NCT03922529 1246 1248 O
independent NCT03922529 1249 1260 B-Observation-Name___Observation-Type-Value:social-habit
living NCT03922529 1261 1267 I-Observation-Name___Observation-Type-Value:social-habit
. NCT03922529 1268 1269 O

Inclusion NCT03926767 0 9 O
Criteria NCT03926767 10 18 O
: NCT03926767 19 20 O

- NCT03926767 24 25 O
A NCT03926767 27 28 O
diagnosis NCT03926767 29 38 O
of NCT03926767 39 41 O
painful NCT03926767 42 49 O
TMD NCT03926767 50 53 B-Condition-Name
Research NCT03926767 54 62 O
Diagnostic NCT03926767 63 73 O
Criteria NCT03926767 74 82 O
for NCT03926767 83 86 O
TMD NCT03926767 87 90 O
( NCT03926767 91 92 O
RDC NCT03926767 93 96 O
/ NCT03926767 97 98 O
TMD NCT03926767 99 102 O
) NCT03926767 103 104 O

- NCT03926767 108 109 O
A NCT03926767 111 112 O
history NCT03926767 113 120 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03926767 121 123 O
orofacial NCT03926767 124 133 O
pain NCT03926767 134 138 B-Condition-Name
at NCT03926767 139 141 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03926767 142 147 I-Eq-Operator___Eq-Operator-Value:GTEQ
three NCT03926767 148 153 B-Eq-Value
months NCT03926767 154 160 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
prior NCT03926767 161 166 O
to NCT03926767 167 169 O
the NCT03926767 170 173 O
study NCT03926767 174 179 O
( NCT03926767 180 181 O
TREEDE NCT03926767 182 188 O
et NCT03926767 189 191 O
al NCT03926767 192 194 O
, NCT03926767 195 196 O
2015 NCT03926767 198 202 O
) NCT03926767 203 204 O

- NCT03926767 212 213 O
age NCT03926767 215 218 O
ranging NCT03926767 219 226 O
between NCT03926767 227 234 O
18 NCT03926767 236 238 B-Eq-Value
to NCT03926767 239 241 B-Eq-Operator___Eq-Operator-Value:BETWEEN
55 NCT03926767 243 245 B-Eq-Value
years NCT03926767 246 251 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
, NCT03926767 252 253 O
considering NCT03926767 254 265 O
the NCT03926767 266 269 O
greater NCT03926767 270 277 O
prevalence NCT03926767 278 288 O
of NCT03926767 289 291 O
TMD NCT03926767 292 295 O
associated NCT03926767 296 306 O
with NCT03926767 307 311 O
this NCT03926767 312 316 O
age NCT03926767 317 320 O
period NCT03926767 321 327 O
. NCT03926767 328 329 O

Exclusion NCT03926767 331 340 O
Criteria NCT03926767 341 349 O
: NCT03926767 350 351 O

- NCT03926767 355 356 O
Patients NCT03926767 358 366 O
with NCT03926767 367 371 O
illiteracy NCT03926767 372 382 B-Condition-Name
, NCT03926767 383 384 O
severe NCT03926767 385 391 B-Severity___Severity-Value:severe
depression NCT03926767 392 402 B-Condition-Name
( NCT03926767 403 404 O
medical NCT03926767 405 412 O
diagnoses NCT03926767 413 422 O
) NCT03926767 423 424 O
, NCT03926767 426 427 O
clinical NCT03926767 428 436 O
history NCT03926767 437 444 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03926767 445 447 O
tumors NCT03926767 448 454 B-Condition-Name
in NCT03926767 455 457 O
the NCT03926767 458 461 O
craniofacial NCT03926767 462 474 O
region NCT03926767 475 481 O
, NCT03926767 482 483 O
patients NCT03926767 484 492 O
in NCT03926767 493 495 O
the NCT03926767 496 499 O
post NCT03926767 500 504 O
dental NCT03926767 505 511 B-Procedure-Name
surgery NCT03926767 512 519 I-Procedure-Name
period NCT03926767 520 526 O
or NCT03926767 527 529 O
submitted NCT03926767 530 539 O
to NCT03926767 540 542 O
previous NCT03926767 543 551 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
physical NCT03926767 552 560 B-Procedure-Name
therapy NCT03926767 561 568 I-Procedure-Name
in NCT03926767 569 571 O
the NCT03926767 572 575 O
past NCT03926767 576 580 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
year NCT03926767 581 585 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
or NCT03926767 586 588 O
to NCT03926767 589 591 O
any NCT03926767 592 595 O
health NCT03926767 596 602 O
/ NCT03926767 603 604 O
pain NCT03926767 605 609 O
education NCT03926767 610 619 B-Procedure-Name
strategy NCT03926767 620 628 I-Procedure-Name
, NCT03926767 629 630 O
pregnant NCT03926767 631 639 B-Condition-Name
women NCT03926767 640 645 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
, NCT03926767 646 647 O
infections NCT03926767 648 658 B-Condition-Name
, NCT03926767 659 660 O
whiplash NCT03926767 661 669 B-Condition-Name
- NCT03926767 670 671 O
associated NCT03926767 672 682 O
disorders NCT03926767 683 692 B-Condition-Name
and NCT03926767 693 696 O
with NCT03926767 697 701 O
chronic NCT03926767 702 709 O
degenerative NCT03926767 710 722 O
inflammatory NCT03926767 723 735 O
or NCT03926767 736 738 O
neurologic NCT03926767 739 749 O
disorders NCT03926767 750 759 B-Condition-Name
were NCT03926767 760 764 O
excluded NCT03926767 765 773 O
from NCT03926767 774 778 O
this NCT03926767 779 783 O
study NCT03926767 784 789 O
. NCT03926767 790 791 O
Patients NCT03926767 793 801 O
will NCT03926767 802 806 O
be NCT03926767 807 809 O
instructed NCT03926767 810 820 O
to NCT03926767 821 823 O
not NCT03926767 824 827 O
use NCT03926767 828 831 O
pain NCT03926767 832 836 B-Condition-Name
relief NCT03926767 837 843 O
medications NCT03926767 844 855 O
during NCT03926767 856 862 O
the NCT03926767 863 866 O
intervention NCT03926767 867 879 O
period NCT03926767 880 886 O
of NCT03926767 887 889 O
this NCT03926767 890 894 O
trial NCT03926767 895 900 O
and NCT03926767 901 904 O
if NCT03926767 905 907 O
any NCT03926767 908 911 O
medication NCT03926767 912 922 O
be NCT03926767 923 925 O
used NCT03926767 926 930 O
, NCT03926767 931 932 O
participants NCT03926767 933 945 O
will NCT03926767 946 950 O
be NCT03926767 951 953 O
encouraged NCT03926767 954 964 O
to NCT03926767 965 967 O
report NCT03926767 968 974 O
. NCT03926767 975 976 O


Inclusion NCT03920670 0 9 O
Criteria NCT03920670 10 18 O

- NCT03920670 21 22 O
Age NCT03920670 24 27 O
> NCT03920670 28 29 B-Eq-Operator___Eq-Operator-Value:GTEQ
or NCT03920670 30 32 I-Eq-Operator___Eq-Operator-Value:GTEQ
= NCT03920670 33 34 I-Eq-Operator___Eq-Operator-Value:GTEQ
18 NCT03920670 36 38 B-Eq-Value
years NCT03920670 39 44 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03920670 45 48 O

- NCT03920670 51 52 O
Patients NCT03920670 54 62 O
willing NCT03920670 63 70 O
to NCT03920670 71 73 O
participate NCT03920670 74 85 O
and NCT03920670 86 89 O
provide NCT03920670 90 97 O
an NCT03920670 98 100 O
informed NCT03920670 101 109 O
consent NCT03920670 110 117 O

- NCT03920670 120 121 O
Patients NCT03920670 123 131 O
undergoing NCT03920670 132 142 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
an NCT03920670 143 145 O
elective NCT03920670 146 154 O
surgical NCT03920670 155 163 B-Procedure-Name
procedure NCT03920670 164 173 I-Procedure-Name
that NCT03920670 174 178 O
requires NCT03920670 179 187 O
use NCT03920670 188 191 O
of NCT03920670 192 194 O
non NCT03920670 195 198 B-Drug-Name
- NCT03920670 199 200 I-Drug-Name
depolarizing NCT03920670 201 213 I-Drug-Name
NMBA NCT03920670 214 218 I-Drug-Name
agents NCT03920670 219 225 I-Drug-Name
administered NCT03920670 226 238 O
intraoperatively NCT03920670 239 255 O
. NCT03920670 256 257 O

Exclusion NCT03920670 259 268 O
Criteria NCT03920670 269 277 O

- NCT03920670 280 281 O
Patients NCT03920670 283 291 O
with NCT03920670 292 296 O
unilateral NCT03920670 297 307 B-Condition-Name
disorders NCT03920670 308 317 I-Condition-Name
, NCT03920670 318 319 O
such NCT03920670 320 324 O
as NCT03920670 325 327 O
stroke NCT03920670 328 334 B-Condition-Name
, NCT03920670 335 336 O
carpal NCT03920670 337 343 B-Condition-Name
tunnel NCT03920670 344 350 I-Condition-Name
syndrome NCT03920670 351 359 I-Condition-Name
, NCT03920670 360 361 O
broken NCT03920670 362 368 B-Condition-Name
wrist NCT03920670 369 374 O
with NCT03920670 375 379 O
nerve NCT03920670 380 385 O
damage NCT03920670 386 392 O
, NCT03920670 393 394 O
Dupuytren NCT03920670 395 404 B-Condition-Name
contracture NCT03920670 405 416 I-Condition-Name
, NCT03920670 417 418 O
or NCT03920670 419 421 O
any NCT03920670 422 425 O
similar NCT03920670 426 433 O
wrist NCT03920670 434 439 O
injury NCT03920670 440 446 B-Condition-Name
. NCT03920670 447 448 O

- NCT03920670 452 453 O
Patients NCT03920670 455 463 O
with NCT03920670 464 468 O
systemic NCT03920670 469 477 O
neuromuscular NCT03920670 478 491 B-Condition-Name
diseases NCT03920670 492 500 I-Condition-Name
such NCT03920670 501 505 O
as NCT03920670 506 508 O
myasthenia NCT03920670 509 519 B-Condition-Name
gravis NCT03920670 520 526 I-Condition-Name

- NCT03920670 529 530 O
Patients NCT03920670 532 540 O
with NCT03920670 541 545 O
significant NCT03920670 546 557 B-Severity___Severity-Value:severe
organ NCT03920670 558 563 B-Condition-Name
dysfunction NCT03920670 564 575 I-Condition-Name
that NCT03920670 576 580 O
can NCT03920670 581 584 O
significantly NCT03920670 585 598 O
affect NCT03920670 599 605 B-Stability___Stability-Value:change
pharmacokinetics NCT03920670 606 622 O
of NCT03920670 623 625 O
neuromuscular NCT03920670 626 639 O
blocking NCT03920670 640 648 O
and NCT03920670 649 652 O
reversal NCT03920670 653 661 O
agents NCT03920670 662 668 B-Drug-Name
, NCT03920670 669 670 O
i NCT03920670 671 672 O
. NCT03920670 673 674 O
e NCT03920670 675 676 O
. NCT03920670 677 678 O
, NCT03920670 679 680 O
severe NCT03920670 681 687 B-Severity___Severity-Value:severe
renal NCT03920670 688 693 B-Condition-Name
impairment NCT03920670 694 704 I-Condition-Name
or NCT03920670 705 707 O
end NCT03920670 708 711 O
- NCT03920670 712 713 O
stage NCT03920670 714 719 O
liver NCT03920670 720 725 B-Condition-Name
disease NCT03920670 726 733 I-Condition-Name
. NCT03920670 734 735 O

Inclusion NCT03929640 0 9 O
Criteria NCT03929640 10 18 O
: NCT03929640 19 20 O

- NCT03929640 24 25 O
Pregnant NCT03929640 27 35 B-Condition-Name
women NCT03929640 36 41 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
at NCT03929640 42 44 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03929640 45 50 I-Eq-Operator___Eq-Operator-Value:GTEQ
18 NCT03929640 52 54 B-Eq-Value
years NCT03929640 55 60 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03929640 61 63 O
age NCT03929640 64 67 O

- NCT03929640 70 71 O
Planned NCT03929640 73 80 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
delivery NCT03929640 81 89 B-Procedure-Name
via NCT03929640 90 93 O
C NCT03929640 94 95 B-Procedure-Name
- NCT03929640 96 97 I-Procedure-Name
section NCT03929640 98 105 I-Procedure-Name

- NCT03929640 108 109 O
Pfannenstiel NCT03929640 111 123 O
skin NCT03929640 124 128 B-Procedure-Name
incision NCT03929640 129 137 I-Procedure-Name

- NCT03929640 140 141 O
Lower NCT03929640 143 148 O
uterine NCT03929640 149 156 O
segment NCT03929640 157 164 O
transverse NCT03929640 165 175 O
hysterotomy NCT03929640 176 187 B-Procedure-Name

- NCT03929640 190 191 O
English NCT03929640 193 200 B-Language
speaking NCT03929640 201 209 O

Exclusion NCT03929640 210 219 O
Criteria NCT03929640 220 228 O
: NCT03929640 229 230 O

- NCT03929640 234 235 O
Major NCT03929640 237 242 B-Severity___Severity-Value:severe
intra NCT03929640 243 248 O
- NCT03929640 249 250 O
operative NCT03929640 251 260 B-Procedure-Name
or NCT03929640 261 263 O
post NCT03929640 264 268 O
- NCT03929640 269 270 O
operative NCT03929640 271 280 B-Procedure-Name
complication NCT03929640 281 293 O
such NCT03929640 294 298 O
that NCT03929640 299 303 O
clinician NCT03929640 304 313 O
recommends NCT03929640 314 324 O
patient NCT03929640 325 332 O
should NCT03929640 333 339 O
not NCT03929640 340 343 O
receive NCT03929640 344 351 O
non NCT03929640 352 355 B-Drug-Name
- NCT03929640 356 357 I-Drug-Name
steroidal NCT03929640 358 367 I-Drug-Name
anti NCT03929640 368 372 I-Drug-Name
- NCT03929640 373 374 I-Drug-Name
inflammatory NCT03929640 375 387 I-Drug-Name
drugs NCT03929640 388 393 I-Drug-Name
or NCT03929640 394 396 O
that NCT03929640 397 401 O
patient NCT03929640 402 409 O
requires NCT03929640 410 418 O
acetaminophen NCT03929640 419 432 B-Drug-Name
to NCT03929640 433 435 O
treat NCT03929640 436 441 O
fever NCT03929640 442 447 B-Condition-Name
( NCT03929640 448 449 O
ie NCT03929640 450 452 O
suspected NCT03929640 453 462 O
endometritis NCT03929640 463 475 B-Condition-Name
) NCT03929640 476 477 O

- NCT03929640 481 482 O
Unplanned NCT03929640 484 493 O
surgery NCT03929640 494 501 B-Procedure-Name
( NCT03929640 502 503 O
hysterectomy NCT03929640 504 516 B-Procedure-Name
, NCT03929640 517 518 O
bowel NCT03929640 519 524 O
/ NCT03929640 525 526 O
bladder NCT03929640 527 534 O
repair NCT03929640 535 541 B-Procedure-Name
) NCT03929640 542 543 O

- NCT03929640 547 548 O
Allergy NCT03929640 550 557 O
or NCT03929640 558 560 O
contraindication NCT03929640 561 577 O
to NCT03929640 578 580 O
study NCT03929640 581 586 O
medication NCT03929640 587 597 O

- NCT03929640 600 601 O
Non NCT03929640 603 606 O
- NCT03929640 607 608 O
English NCT03929640 609 616 B-Language
speaking NCT03929640 617 625 O

- NCT03929640 628 629 O
Inability NCT03929640 631 640 O
to NCT03929640 641 643 O
provide NCT03929640 644 651 O
informed NCT03929640 652 660 O
consent NCT03929640 661 668 O

- NCT03929640 671 672 O
History NCT03929640 674 681 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03929640 682 684 O
opioid NCT03929640 685 691 O
, NCT03929640 692 693 O
other NCT03929640 694 699 O
illicit NCT03929640 700 707 O
substance NCT03929640 708 717 B-Condition-Name
, NCT03929640 718 719 O
or NCT03929640 720 722 O
alcohol NCT03929640 723 730 B-Condition-Name
use NCT03929640 731 734 I-Condition-Name
disorder NCT03929640 735 743 I-Condition-Name
either NCT03929640 744 750 O
before NCT03929640 751 757 O
or NCT03929640 758 760 O
during NCT03929640 761 767 O
pregnancy NCT03929640 768 777 B-Condition-Name

- NCT03929640 780 781 O
Severe NCT03929640 783 789 B-Severity___Severity-Value:severe
renal NCT03929640 790 795 O
or NCT03929640 796 798 O
hepatic NCT03929640 799 806 O
impairment NCT03929640 807 817 B-Condition-Name

Inclusion NCT03927651 0 9 O
Criteria NCT03927651 10 18 O
: NCT03927651 19 20 O

- NCT03927651 24 25 O
Patients NCT03927651 27 35 O
attending NCT03927651 36 45 O
a NCT03927651 46 47 O
pre NCT03927651 48 51 O
operative NCT03927651 52 61 B-Procedure-Name
visit NCT03927651 62 67 B-Encounter-Type___Encounter-Type-Value:outpatient
at NCT03927651 68 70 O
the NCT03927651 71 74 O
Center NCT03927651 75 81 B-Location___Location-Value:clinic
for NCT03927651 82 85 I-Location___Location-Value:clinic
Comprehensive NCT03927651 86 99 I-Location___Location-Value:clinic
Gynecology NCT03927651 100 110 I-Location___Location-Value:clinic
who NCT03927651 111 114 O
will NCT03927651 115 119 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
undergo NCT03927651 120 127 O
surgery NCT03927651 128 135 B-Procedure-Name
. NCT03927651 136 137 O

Exclusion NCT03927651 139 148 O
Criteria NCT03927651 149 157 O
: NCT03927651 158 159 O

- NCT03927651 163 164 O
Not NCT03927651 166 169 O
able NCT03927651 170 174 O
to NCT03927651 175 177 O
comprehend NCT03927651 178 188 O
and NCT03927651 189 192 O
sign NCT03927651 193 197 O
a NCT03927651 198 199 O
written NCT03927651 200 207 O
consent NCT03927651 208 215 O

- NCT03927651 218 219 O
Patients NCT03927651 221 229 O
with NCT03927651 230 234 O
a NCT03927651 235 236 O
history NCT03927651 237 244 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03927651 245 247 O
allergy NCT03927651 248 255 O
to NCT03927651 256 258 O
iodides NCT03927651 259 266 B-Allergy-Name

- NCT03927651 269 270 O
Patients NCT03927651 272 280 O
history NCT03927651 281 288 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03927651 289 291 O
renal NCT03927651 292 297 B-Condition-Name
failure NCT03927651 298 305 I-Condition-Name
or NCT03927651 306 308 O
uremia NCT03927651 309 315 B-Condition-Name
, NCT03927651 316 317 O
and NCT03927651 318 321 O
those NCT03927651 322 327 O
on NCT03927651 328 330 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
dialysis NCT03927651 331 339 B-Procedure-Name

Inclusion NCT03926598 0 9 O
Criteria NCT03926598 10 18 O
: NCT03926598 19 20 O

- NCT03926598 24 25 O
Existing NCT03926598 27 35 O
patients NCT03926598 36 44 O
of NCT03926598 45 47 O
Children NCT03926598 48 56 B-Location___Location-Value:hospital
's NCT03926598 56 58 I-Location___Location-Value:hospital
Healthcare NCT03926598 59 69 I-Location___Location-Value:hospital
of NCT03926598 70 72 I-Location___Location-Value:hospital
Atlanta NCT03926598 73 80 I-Location___Location-Value:hospital
( NCT03926598 81 82 O
CHOA NCT03926598 83 87 B-Location
) NCT03926598 88 89 O
with NCT03926598 90 94 O
Type NCT03926598 95 99 B-Condition-Name
2 NCT03926598 101 102 I-Condition-Name
Diabetes NCT03926598 103 111 I-Condition-Name
that NCT03926598 112 116 O
are NCT03926598 117 120 O
12 NCT03926598 122 124 B-Eq-Value
or NCT03926598 125 127 B-Eq-Operator___Eq-Operator-Value:GTEQ
older NCT03926598 128 133 I-Eq-Operator___Eq-Operator-Value:GTEQ
at NCT03926598 134 136 O
the NCT03926598 137 140 O
time NCT03926598 141 145 O
of NCT03926598 146 148 O
participation NCT03926598 149 162 O
or NCT03926598 163 165 O
caretakers NCT03926598 166 176 O
of NCT03926598 177 179 O
existing NCT03926598 180 188 O
patients NCT03926598 189 197 O
of NCT03926598 198 200 O
CHOA NCT03926598 201 205 O
with NCT03926598 206 210 O
Type NCT03926598 211 215 B-Condition-Name
2 NCT03926598 217 218 I-Condition-Name
Diabetes NCT03926598 219 227 I-Condition-Name

- NCT03926598 230 231 O
Front NCT03926598 233 238 O
desk NCT03926598 239 243 O
staff NCT03926598 244 249 O

- NCT03926598 252 253 O
Nurses NCT03926598 255 261 B-Provider-Role
at NCT03926598 262 264 O
CHOA NCT03926598 265 269 B-Location

- NCT03926598 272 273 O
Certified NCT03926598 275 284 O
Diabetes NCT03926598 285 293 O
Educators NCT03926598 294 303 O
at NCT03926598 304 306 O
CHOA NCT03926598 307 311 B-Location

- NCT03926598 314 315 O
Physicians NCT03926598 317 327 B-Provider-Role
working NCT03926598 328 335 O
at NCT03926598 336 338 O
CHOA NCT03926598 339 343 B-Location

- NCT03926598 346 347 O
Participants NCT03926598 349 361 O
must NCT03926598 362 366 O
also NCT03926598 367 371 O
be NCT03926598 372 374 O
fluent NCT03926598 375 381 O
in NCT03926598 382 384 O
English NCT03926598 385 392 B-Language
, NCT03926598 393 394 O
either NCT03926598 395 401 O
as NCT03926598 402 404 O
a NCT03926598 405 406 O
first NCT03926598 407 412 O
or NCT03926598 413 415 O
secondary NCT03926598 416 425 O
language NCT03926598 426 434 O
, NCT03926598 435 436 O
as NCT03926598 437 439 O
the NCT03926598 440 443 O
Guide NCT03926598 444 449 O
- NCT03926598 450 451 O
To NCT03926598 452 454 O
- NCT03926598 455 456 O
Goals NCT03926598 457 462 O
app NCT03926598 463 466 O
is NCT03926598 467 469 O
in NCT03926598 470 472 O
English NCT03926598 473 480 O
. NCT03926598 481 482 O

Exclusion NCT03926598 484 493 O
Criteria NCT03926598 494 502 O
: NCT03926598 503 504 O

- NCT03926598 508 509 O
Individuals NCT03926598 511 522 O
that NCT03926598 523 527 O
are NCT03926598 528 531 O
using NCT03926598 532 537 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
a NCT03926598 538 539 O
care NCT03926598 540 544 B-Procedure-Name
coordination NCT03926598 545 557 I-Procedure-Name
tool NCT03926598 558 562 I-Procedure-Name
other NCT03926598 563 568 O
than NCT03926598 569 573 O
GTG NCT03926598 574 577 B-Procedure-Name
to NCT03926598 578 580 O
translate NCT03926598 581 590 O
ADA NCT03926598 591 594 O
clinical NCT03926598 595 603 O
standards NCT03926598 604 613 O
of NCT03926598 614 616 O
care NCT03926598 617 621 O
for NCT03926598 622 625 O
children NCT03926598 626 634 O
with NCT03926598 635 639 O
T NCT03926598 640 641 B-Condition-Name
2D NCT03926598 642 644 I-Condition-Name
during NCT03926598 645 651 O
the NCT03926598 652 655 O
study NCT03926598 656 661 O
period NCT03926598 662 668 O
will NCT03926598 669 673 O
be NCT03926598 674 676 O
excluded NCT03926598 677 685 O
from NCT03926598 686 690 O
this NCT03926598 691 695 O
study NCT03926598 696 701 O
in NCT03926598 702 704 O
order NCT03926598 705 710 O
to NCT03926598 711 713 O
avoid NCT03926598 714 719 O
confounding NCT03926598 720 731 B-Stability___Stability-Value:change
factors NCT03926598 732 739 O
. NCT03926598 740 741 O
Examples NCT03926598 743 751 O
of NCT03926598 752 754 O
care NCT03926598 755 759 O
coordination NCT03926598 760 772 O
tools NCT03926598 773 778 O
include NCT03926598 779 786 O
products NCT03926598 787 795 O
that NCT03926598 796 800 O
have NCT03926598 801 805 O
the NCT03926598 806 809 O
capabilities NCT03926598 810 822 O
to NCT03926598 823 825 O
send NCT03926598 826 830 O
and NCT03926598 831 834 O
receive NCT03926598 835 842 O
electronic NCT03926598 843 853 O
messages NCT03926598 854 862 O
to NCT03926598 863 865 O
the NCT03926598 866 869 O
care NCT03926598 870 874 O
team NCT03926598 875 879 O
, NCT03926598 880 881 O
receive NCT03926598 882 889 O
and NCT03926598 890 893 O
discuss NCT03926598 894 901 O
care NCT03926598 902 906 O
plans NCT03926598 907 912 O
, NCT03926598 913 914 O
and NCT03926598 915 918 O
create NCT03926598 919 925 O
and NCT03926598 926 929 O
share NCT03926598 930 935 O
health NCT03926598 936 942 O
logs NCT03926598 943 947 O
. NCT03926598 948 949 O

Participant NCT03922932 0 11 O
- NCT03922932 12 13 O
Related NCT03922932 14 21 O
Inclusion NCT03922932 22 31 O
Criteria NCT03922932 32 40 O
: NCT03922932 41 42 O

I NCT03922932 44 45 O
. NCT03922932 46 47 O
All NCT03922932 49 52 O
Diabetics NCT03922932 53 62 B-Condition-Name
( NCT03922932 63 64 O
Groups NCT03922932 65 71 O
A NCT03922932 72 73 O
, NCT03922932 74 75 O
B NCT03922932 76 77 O
, NCT03922932 78 79 O
C NCT03922932 80 81 O
) NCT03922932 82 83 O

- NCT03922932 87 88 O
Type NCT03922932 90 94 B-Condition-Name
1 NCT03922932 96 97 I-Condition-Name
diabetes NCT03922932 98 106 I-Condition-Name
of NCT03922932 107 109 O
at NCT03922932 110 112 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03922932 113 118 I-Eq-Operator___Eq-Operator-Value:GTEQ
5 NCT03922932 120 121 B-Eq-Value
years NCT03922932 122 127 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
duration NCT03922932 128 136 O
or NCT03922932 137 139 O

- NCT03922932 142 143 O
Type NCT03922932 145 149 B-Condition-Name
2 NCT03922932 151 152 I-Condition-Name
diabetes NCT03922932 153 161 I-Condition-Name
of NCT03922932 162 164 O
any NCT03922932 165 168 O
duration NCT03922932 169 177 O
II NCT03922932 178 180 O
. NCT03922932 181 182 O
Group NCT03922932 184 189 O
B NCT03922932 190 191 O

- NCT03922932 194 195 O
Able NCT03922932 197 201 O
to NCT03922932 202 204 O
return NCT03922932 205 211 O
for NCT03922932 212 215 O
follow NCT03922932 216 222 O
- NCT03922932 223 224 O
up NCT03922932 225 227 O
over NCT03922932 228 232 B-Eq-Operator___Eq-Operator-Value:GT
3 NCT03922932 234 235 B-Eq-Value
years NCT03922932 236 241 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

Participant NCT03922932 242 253 O
- NCT03922932 254 255 O
Related NCT03922932 256 263 O
Exclusion NCT03922932 264 273 O
Criteria NCT03922932 274 282 O
: NCT03922932 283 284 O

I NCT03922932 286 287 O
. NCT03922932 288 289 O
Group NCT03922932 291 296 O
B NCT03922932 297 298 O

- NCT03922932 301 302 O
Significant NCT03922932 304 315 B-Severity___Severity-Value:severe
medical NCT03922932 316 323 O
condition NCT03922932 324 333 O
that NCT03922932 334 338 O
would NCT03922932 339 344 O
make NCT03922932 345 349 O
long NCT03922932 350 354 O
- NCT03922932 355 356 O
term NCT03922932 357 361 O
follow NCT03922932 362 368 O
- NCT03922932 369 370 O
up NCT03922932 371 373 O
difficult NCT03922932 374 383 O
II NCT03922932 384 386 O
. NCT03922932 387 388 O
Controls NCT03922932 390 398 O
( NCT03922932 399 400 O
Group NCT03922932 401 406 O
D NCT03922932 407 408 O
) NCT03922932 409 410 O

- NCT03922932 414 415 O
Any NCT03922932 417 420 O
medical NCT03922932 421 428 O
problems NCT03922932 429 437 O
associated NCT03922932 438 448 O
with NCT03922932 449 453 O
retinal NCT03922932 454 461 B-Condition-Name
vascular NCT03922932 462 470 I-Condition-Name
abnormalities NCT03922932 471 484 I-Condition-Name
( NCT03922932 485 486 O
i NCT03922932 487 488 O
. NCT03922932 489 490 O
e NCT03922932 491 492 O
. NCT03922932 493 494 O
, NCT03922932 495 496 O
hypertension NCT03922932 497 509 B-Condition-Name
, NCT03922932 510 511 O
systemic NCT03922932 512 520 B-Condition-Name
vasculitis NCT03922932 521 531 I-Condition-Name
, NCT03922932 532 533 O
carotid NCT03922932 534 541 B-Condition-Name
insufficiency NCT03922932 542 555 I-Condition-Name
, NCT03922932 556 557 O
etc NCT03922932 558 561 O
. NCT03922932 562 563 O
) NCT03922932 564 565 O

Eye NCT03922932 567 570 O
- NCT03922932 571 572 O
Related NCT03922932 573 580 O
Inclusion NCT03922932 581 590 O
Criteria NCT03922932 591 599 O
: NCT03922932 600 601 O

I NCT03922932 603 604 O
. NCT03922932 605 606 O
Group NCT03922932 608 613 O
A NCT03922932 614 615 O
: NCT03922932 616 617 O

- NCT03922932 621 622 O
Presence NCT03922932 624 632 O
of NCT03922932 633 635 O
active NCT03922932 636 642 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
neovascularization NCT03922932 643 661 B-Condition-Name
, NCT03922932 662 663 O
with NCT03922932 664 668 O
or NCT03922932 669 671 O
without NCT03922932 672 679 O
prior NCT03922932 680 685 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
treatment NCT03922932 686 695 O

- NCT03922932 698 699 O
Presence NCT03922932 701 709 O
of NCT03922932 710 712 O
involuted NCT03922932 713 722 O
fibrovascular NCT03922932 723 736 B-Condition-Name
proliferans NCT03922932 737 748 I-Condition-Name

II NCT03922932 749 751 O
. NCT03922932 752 753 O
Group NCT03922932 755 760 O
B NCT03922932 761 762 O
: NCT03922932 763 764 O

- NCT03922932 768 769 O
NPDR NCT03922932 771 775 B-Condition-Name
of NCT03922932 776 778 O
any NCT03922932 779 782 O
severity NCT03922932 783 791 O
as NCT03922932 792 794 O
defined NCT03922932 795 802 O
by NCT03922932 803 805 O
the NCT03922932 806 809 O
International NCT03922932 810 823 B-Observation-Name
Clinical NCT03922932 824 832 I-Observation-Name
Diabetic NCT03922932 833 841 I-Observation-Name
Retinopathy NCT03922932 842 853 I-Observation-Name
Severity NCT03922932 854 862 I-Observation-Name
Scale NCT03922932 863 868 I-Observation-Name

III NCT03922932 869 872 O
. NCT03922932 873 874 O
Groups NCT03922932 876 882 O
C NCT03922932 883 884 O
& NCT03922932 885 886 O
D NCT03922932 887 888 O
: NCT03922932 889 890 O

- NCT03922932 894 895 O
No NCT03922932 897 899 O
evidence NCT03922932 900 908 O
of NCT03922932 909 911 O
diabetic NCT03922932 912 920 B-Condition-Name
retinopathy NCT03922932 921 932 I-Condition-Name

IV NCT03922932 933 935 O
. NCT03922932 936 937 O
Group NCT03922932 939 944 O
ME NCT03922932 945 947 O
: NCT03922932 948 949 O

- NCT03922932 953 954 O
Presence NCT03922932 956 964 O
of NCT03922932 965 967 O
center NCT03922932 968 974 O
- NCT03922932 975 976 O
involving NCT03922932 977 986 O
macular NCT03922932 987 994 B-Condition-Name
edema NCT03922932 995 1000 I-Condition-Name
requiring NCT03922932 1001 1010 O
treatment NCT03922932 1011 1020 B-Procedure-Name

Eye NCT03922932 1021 1024 O
- NCT03922932 1025 1026 O
Related NCT03922932 1027 1034 O
Exclusion NCT03922932 1035 1044 O
Criteria NCT03922932 1045 1053 O
: NCT03922932 1054 1055 O
( NCT03922932 1056 1057 O
Applies NCT03922932 1058 1065 O
to NCT03922932 1066 1068 O
study NCT03922932 1069 1074 O
eye NCT03922932 1075 1078 O
only NCT03922932 1079 1083 O
. NCT03922932 1084 1085 O
May NCT03922932 1087 1090 O
be NCT03922932 1091 1093 O
present NCT03922932 1094 1101 O
in NCT03922932 1102 1104 O
non NCT03922932 1105 1108 O
- NCT03922932 1109 1110 O
study NCT03922932 1111 1116 O
eye NCT03922932 1117 1120 O
. NCT03922932 1121 1122 O
) NCT03922932 1123 1124 O

- NCT03922932 1128 1129 O
Visual NCT03922932 1131 1137 B-Observation-Name___Observation-Type-Value:measurement
acuity NCT03922932 1138 1144 I-Observation-Name___Observation-Type-Value:measurement
worse NCT03922932 1145 1150 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03922932 1151 1155 I-Eq-Operator___Eq-Operator-Value:LT
20 NCT03922932 1157 1159 B-Eq-Value
/ NCT03922932 1160 1161 O
200 NCT03922932 1163 1166 B-Eq-Unit

- NCT03922932 1170 1171 O
Inability NCT03922932 1173 1182 O
to NCT03922932 1183 1185 O
maintain NCT03922932 1186 1194 O
stable NCT03922932 1195 1201 B-Stability___Stability-Value:stable
fixation NCT03922932 1202 1210 O
for NCT03922932 1211 1214 O
OCT NCT03922932 1215 1218 B-Procedure-Name
imaging NCT03922932 1219 1226 I-Procedure-Name

- NCT03922932 1229 1230 O
History NCT03922932 1232 1239 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03922932 1240 1242 O
major NCT03922932 1243 1248 B-Severity___Severity-Value:severe
eye NCT03922932 1249 1252 B-Procedure-Name
surgery NCT03922932 1253 1260 I-Procedure-Name
( NCT03922932 1261 1262 O
vitrectomy NCT03922932 1263 1273 B-Procedure-Name
, NCT03922932 1274 1275 O
cataract NCT03922932 1276 1284 B-Procedure-Name
surgery NCT03922932 1285 1292 I-Procedure-Name
, NCT03922932 1293 1294 O
scleral NCT03922932 1295 1302 B-Procedure-Name
buckle NCT03922932 1303 1309 I-Procedure-Name
, NCT03922932 1310 1311 O
other NCT03922932 1312 1317 O
intraocular NCT03922932 1318 1329 B-Procedure-Name
surgery NCT03922932 1330 1337 I-Procedure-Name
, NCT03922932 1338 1339 O
etc NCT03922932 1340 1343 O
. NCT03922932 1344 1345 O
) NCT03922932 1346 1347 O
within NCT03922932 1348 1354 B-Eq-Operator___Eq-Operator-Value:LTEQ
90 NCT03922932 1356 1358 B-Eq-Value
days NCT03922932 1359 1363 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
of NCT03922932 1364 1366 O
enrollment NCT03922932 1367 1377 O

- NCT03922932 1380 1381 O
History NCT03922932 1383 1390 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03922932 1391 1393 O
another NCT03922932 1394 1401 O
eye NCT03922932 1402 1405 B-Condition-Name
disease NCT03922932 1406 1413 I-Condition-Name
or NCT03922932 1414 1416 O
condition NCT03922932 1417 1426 O
that NCT03922932 1427 1431 O
may NCT03922932 1432 1435 O
alter NCT03922932 1436 1441 B-Stability___Stability-Value:change
retinal NCT03922932 1442 1449 B-Condition-Name
perfusion NCT03922932 1450 1459 O
, NCT03922932 1460 1461 O
permeability NCT03922932 1462 1474 O
, NCT03922932 1475 1476 O
or NCT03922932 1477 1479 O
retinal NCT03922932 1480 1487 O
anatomy NCT03922932 1488 1495 O

- NCT03922932 1498 1499 O
Substantial NCT03922932 1501 1512 B-Severity___Severity-Value:severe
media NCT03922932 1513 1518 B-Condition-Name
opacity NCT03922932 1519 1526 I-Condition-Name
( NCT03922932 1527 1528 O
cataract NCT03922932 1529 1537 B-Condition-Name
, NCT03922932 1538 1539 O
corneal NCT03922932 1540 1547 B-Condition-Name
scar NCT03922932 1548 1552 I-Condition-Name
, NCT03922932 1553 1554 O
vitreous NCT03922932 1555 1563 B-Condition-Name
hemorrhage NCT03922932 1564 1574 I-Condition-Name
) NCT03922932 1575 1576 O
that NCT03922932 1577 1581 O
may NCT03922932 1582 1585 O
interfere NCT03922932 1586 1595 B-Stability___Stability-Value:change
with NCT03922932 1596 1600 O
study NCT03922932 1601 1606 O
imaging NCT03922932 1607 1614 B-Procedure-Name


Inclusion NCT03922503 0 9 O
Criteria NCT03922503 10 18 O
: NCT03922503 19 20 O

- NCT03922503 24 25 O
Stage NCT03922503 27 32 B-Eq-Unit
III NCT03922503 33 36 B-Eq-Value
periodontitis NCT03922503 37 50 B-Condition-Name
patient NCT03922503 51 58 O
having NCT03922503 59 65 O
at NCT03922503 66 68 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03922503 69 74 I-Eq-Operator___Eq-Operator-Value:GTEQ
one NCT03922503 75 78 B-Eq-Value
tooth NCT03922503 79 84 B-Observation-Name
with NCT03922503 85 89 O
one NCT03922503 90 93 O
wall NCT03922503 94 98 O
or NCT03922503 99 101 O
combined NCT03922503 102 110 O
1 NCT03922503 111 112 O
- NCT03922503 113 114 O
to NCT03922503 115 117 O
2 NCT03922503 119 120 O
- NCT03922503 121 122 O
wall NCT03922503 123 127 O
intraosseous NCT03922503 128 140 B-Observation-Name___Observation-Type-Value:measurement
defect NCT03922503 141 147 I-Observation-Name___Observation-Type-Value:measurement
≥ NCT03922503 148 149 B-Eq-Operator___Eq-Operator-Value:GTEQ
3 NCT03922503 151 152 B-Eq-Value
mm NCT03922503 153 155 B-Eq-Unit
deep NCT03922503 156 160 O
( NCT03922503 161 162 O
assessed NCT03922503 163 171 O
by NCT03922503 172 174 O
trans NCT03922503 175 180 B-Procedure-Name
- NCT03922503 181 182 I-Procedure-Name
gingival NCT03922503 183 191 I-Procedure-Name
probing NCT03922503 192 199 I-Procedure-Name
, NCT03922503 200 201 O
radiographic NCT03922503 202 214 B-Procedure-Name
examination NCT03922503 215 226 I-Procedure-Name
) NCT03922503 227 228 O
with NCT03922503 229 233 O
clinical NCT03922503 234 242 B-Observation-Name___Observation-Type-Value:measurement
attachment NCT03922503 243 253 I-Observation-Name___Observation-Type-Value:measurement
level NCT03922503 254 259 I-Observation-Name___Observation-Type-Value:measurement
( NCT03922503 260 261 O
CAL NCT03922503 262 265 B-Observation-Name
) NCT03922503 266 267 O
≥ NCT03922503 268 269 B-Eq-Operator___Eq-Operator-Value:GTEQ
5 NCT03922503 271 272 B-Eq-Value
mm NCT03922503 273 275 B-Eq-Unit
and NCT03922503 276 279 O
pocket NCT03922503 280 286 B-Observation-Name___Observation-Type-Value:measurement
depth NCT03922503 287 292 I-Observation-Name___Observation-Type-Value:measurement
( NCT03922503 293 294 O
PD NCT03922503 295 297 B-Observation-Name
) NCT03922503 298 299 O
≥ NCT03922503 300 301 B-Eq-Operator___Eq-Operator-Value:GTEQ
6 NCT03922503 303 304 B-Eq-Value
mm NCT03922503 305 307 B-Eq-Unit
. NCT03922503 308 309 O

- NCT03922503 313 314 O
Defect NCT03922503 316 322 B-Condition-Name
not NCT03922503 323 326 O
extending NCT03922503 327 336 O
to NCT03922503 337 339 O
a NCT03922503 340 341 O
root NCT03922503 342 346 O
furcation NCT03922503 347 356 O
area NCT03922503 357 361 O

- NCT03922503 364 365 O
Vital NCT03922503 367 372 B-Condition-Name
teeth NCT03922503 373 378 I-Condition-Name

- NCT03922503 381 382 O
Non NCT03922503 384 387 O
- NCT03922503 388 389 O
smokers NCT03922503 390 397 B-Condition-Name
. NCT03922503 398 399 O

- NCT03922503 403 404 O
No NCT03922503 406 408 O
history NCT03922503 409 416 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03922503 417 419 O
intake NCT03922503 420 426 O
of NCT03922503 427 429 O
antibiotics NCT03922503 430 441 B-Drug-Name
or NCT03922503 442 444 O
other NCT03922503 445 450 O
medications NCT03922503 451 462 O
affecting NCT03922503 463 472 B-Stability___Stability-Value:change
the NCT03922503 473 476 O
periodontium NCT03922503 477 489 B-Condition-Name
in NCT03922503 490 492 O
the NCT03922503 493 496 O
previous NCT03922503 497 505 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
6 NCT03922503 507 508 B-Eq-Value
months NCT03922503 509 515 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
. NCT03922503 516 517 O

- NCT03922503 521 522 O
No NCT03922503 524 526 O
periodontal NCT03922503 527 538 B-Procedure-Name
therapy NCT03922503 539 546 I-Procedure-Name
carried NCT03922503 547 554 O
out NCT03922503 555 558 O
in NCT03922503 559 561 O
the NCT03922503 562 565 O
past NCT03922503 566 570 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
6 NCT03922503 572 573 B-Eq-Value
months NCT03922503 574 580 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
. NCT03922503 581 582 O

- NCT03922503 586 587 O
Able NCT03922503 589 593 O
to NCT03922503 594 596 O
sign NCT03922503 597 601 O
an NCT03922503 602 604 O
informed NCT03922503 605 613 O
consent NCT03922503 614 621 O
form NCT03922503 622 626 O
. NCT03922503 627 628 O

- NCT03922503 632 633 O
Patients NCT03922503 635 643 O
age NCT03922503 644 647 O
between NCT03922503 648 655 B-Eq-Operator___Eq-Operator-Value:BETWEEN
25 NCT03922503 657 659 B-Eq-Value
and NCT03922503 660 663 O
50 NCT03922503 665 667 B-Eq-Value
years NCT03922503 668 673 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
old NCT03922503 674 677 O
. NCT03922503 678 679 O

- NCT03922503 683 684 O
Patients NCT03922503 686 694 O
who NCT03922503 695 698 O
are NCT03922503 699 702 O
cooperative NCT03922503 703 714 O
, NCT03922503 715 716 O
motivated NCT03922503 717 726 O
, NCT03922503 727 728 O
and NCT03922503 729 732 O
hygiene NCT03922503 733 740 O
conscious NCT03922503 741 750 O
. NCT03922503 751 752 O

- NCT03922503 756 757 O
Systemically NCT03922503 759 771 B-Condition-Name
free NCT03922503 772 776 I-Condition-Name
according NCT03922503 777 786 O
to NCT03922503 787 789 O
Cornell NCT03922503 790 797 O
Medical NCT03922503 798 805 O
Index NCT03922503 806 811 O

Exclusion NCT03922503 812 821 O
Criteria NCT03922503 822 830 O
: NCT03922503 831 832 O

- NCT03922503 836 837 O
Pregnancy NCT03922503 839 848 B-Condition-Name
or NCT03922503 849 851 O
breast NCT03922503 852 858 B-Condition-Name
feeding NCT03922503 859 866 I-Condition-Name

- NCT03922503 869 870 O
The NCT03922503 872 875 O
presence NCT03922503 876 884 O
of NCT03922503 885 887 O
an NCT03922503 888 890 O
orthodontic NCT03922503 891 902 B-Procedure-Name
appliance NCT03922503 903 912 I-Procedure-Name

- NCT03922503 915 916 O
Teeth NCT03922503 918 923 B-Observation-Name___Observation-Type-Value:clinical-score
mobility NCT03922503 924 932 I-Observation-Name___Observation-Type-Value:clinical-score
greater NCT03922503 933 940 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03922503 941 945 I-Eq-Operator___Eq-Operator-Value:GT
grade NCT03922503 946 951 B-Eq-Unit
I NCT03922503 952 953 B-Eq-Value

Inclusion NCT03928990 0 9 O
Criteria NCT03928990 10 18 O
: NCT03928990 19 20 O

- NCT03928990 24 25 O
Patients NCT03928990 27 35 O
aged NCT03928990 36 40 O
18 NCT03928990 42 44 B-Eq-Value
to NCT03928990 45 47 B-Eq-Operator___Eq-Operator-Value:BETWEEN
80 NCT03928990 49 51 B-Eq-Value
years NCT03928990 52 57 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03928990 58 61 O

- NCT03928990 64 65 O
Multiple NCT03928990 67 75 B-Condition-Name
sclerosis NCT03928990 76 85 I-Condition-Name
according NCT03928990 86 95 O
to NCT03928990 96 98 O
McDonald NCT03928990 99 107 O
criteria NCT03928990 108 116 O
; NCT03928990 117 118 O

- NCT03928990 121 122 O
Expanded NCT03928990 124 132 B-Observation-Name___Observation-Type-Value:clinical-score
Disability NCT03928990 133 143 I-Observation-Name___Observation-Type-Value:clinical-score
Status NCT03928990 144 150 I-Observation-Name___Observation-Type-Value:clinical-score
Scale NCT03928990 151 156 I-Observation-Name___Observation-Type-Value:clinical-score
( NCT03928990 157 158 O
EDSS NCT03928990 159 163 B-Observation-Name
) NCT03928990 164 165 O
between NCT03928990 166 173 B-Eq-Operator___Eq-Operator-Value:BETWEEN
0 NCT03928990 175 176 B-Eq-Value
and NCT03928990 177 180 O
6.5 NCT03928990 182 185 B-Eq-Value
; NCT03928990 186 187 O

- NCT03928990 190 191 O
Patient NCT03928990 193 200 O
able NCT03928990 201 205 B-Condition-Name
to NCT03928990 206 208 I-Condition-Name
move NCT03928990 209 213 I-Condition-Name
with NCT03928990 214 218 O
or NCT03928990 219 221 O
without NCT03928990 222 229 O
mechanical NCT03928990 230 240 B-Procedure-Name
assistance NCT03928990 241 251 I-Procedure-Name
. NCT03928990 252 253 O

Exclusion NCT03928990 255 264 O
Criteria NCT03928990 265 273 O
: NCT03928990 274 275 O

- NCT03928990 279 280 O
Deterioration NCT03928990 282 295 B-Stability___Stability-Value:change
of NCT03928990 296 298 O
neurological NCT03928990 299 311 B-Condition-Name
symptomatology NCT03928990 312 326 I-Condition-Name
within NCT03928990 327 333 B-Eq-Operator___Eq-Operator-Value:LTEQ
60 NCT03928990 335 337 B-Eq-Value
day NCT03928990 338 341 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
before NCT03928990 342 348 O
enrollment NCT03928990 349 359 O
; NCT03928990 360 361 O

- NCT03928990 364 365 O
Changes NCT03928990 367 374 B-Stability___Stability-Value:change
brought NCT03928990 375 382 O
to NCT03928990 383 385 O
the NCT03928990 386 389 O
multiple NCT03928990 390 398 B-Condition-Name
sclerosis NCT03928990 399 408 I-Condition-Name
treatment NCT03928990 409 418 O
within NCT03928990 419 425 B-Eq-Operator___Eq-Operator-Value:LTEQ
6 NCT03928990 427 428 B-Eq-Value
months NCT03928990 429 435 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
before NCT03928990 436 442 O
enrollment NCT03928990 443 453 O
; NCT03928990 454 455 O

- NCT03928990 458 459 O
Introduction NCT03928990 461 473 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
of NCT03928990 474 476 O
a NCT03928990 477 478 O
treatment NCT03928990 479 488 O
acting NCT03928990 489 495 O
on NCT03928990 496 498 O
spasticity NCT03928990 499 509 B-Condition-Name
or NCT03928990 510 512 O
fatigue NCT03928990 513 520 B-Condition-Name
within NCT03928990 521 527 B-Eq-Operator___Eq-Operator-Value:LTEQ
30 NCT03928990 529 531 B-Eq-Value
day NCT03928990 532 535 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
before NCT03928990 536 542 O
enrollment NCT03928990 543 553 O

- NCT03928990 556 557 O
Changes NCT03928990 559 566 B-Stability___Stability-Value:change
brought NCT03928990 567 574 O
to NCT03928990 575 577 O
reeducation NCT03928990 578 589 B-Procedure-Name
protocol NCT03928990 590 598 I-Procedure-Name
throughout NCT03928990 599 609 O
the NCT03928990 610 613 O
duration NCT03928990 614 622 O
of NCT03928990 623 625 O
the NCT03928990 626 629 O
study NCT03928990 630 635 O

- NCT03928990 638 639 O
Patient NCT03928990 641 648 O
unable NCT03928990 649 655 O
to NCT03928990 656 658 O
provide NCT03928990 659 666 O
an NCT03928990 667 669 O
effort NCT03928990 670 676 O
equivalent NCT03928990 677 687 O
to NCT03928990 688 690 O
3 NCT03928990 692 693 B-Eq-Value
times NCT03928990 694 699 B-Eq-Unit
the NCT03928990 700 703 O
resting NCT03928990 704 711 B-Observation-Name
metabolic NCT03928990 712 721 I-Observation-Name
value NCT03928990 722 727 I-Observation-Name
= NCT03928990 728 729 O
3 NCT03928990 731 732 B-Eq-Value
Metabolic NCT03928990 733 742 B-Observation-Name
Equivalent NCT03928990 743 753 I-Observation-Name
of NCT03928990 754 756 I-Observation-Name
Task NCT03928990 757 761 I-Observation-Name
( NCT03928990 762 763 O
METs NCT03928990 764 768 B-Observation-Name
) NCT03928990 769 770 O
. NCT03928990 772 773 O

Inclusion NCT03923621 0 9 O
Criteria NCT03923621 10 18 O
: NCT03923621 19 20 O

- NCT03923621 24 25 O
ASA NCT03923621 27 30 B-Condition-Name
I NCT03923621 31 32 B-Eq-Value
or NCT03923621 33 35 O
II NCT03923621 36 38 B-Eq-Value

- NCT03923621 41 42 O
Pilonidal NCT03923621 44 53 B-Condition-Name
disease NCT03923621 54 61 I-Condition-Name
< NCT03923621 62 63 B-Eq-Operator___Eq-Operator-Value:LT
3 NCT03923621 65 66 B-Eq-Value
previous NCT03923621 67 75 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
treatments NCT03923621 76 86 O

- NCT03923621 89 90 O
Previous NCT03923621 92 100 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
incision NCT03923621 101 109 B-Procedure-Name
and NCT03923621 110 113 O
drainage NCT03923621 114 122 B-Procedure-Name
allowed NCT03923621 123 130 O

- NCT03923621 133 134 O
Over NCT03923621 136 140 B-Eq-Operator___Eq-Operator-Value:GT
16 NCT03923621 142 144 B-Eq-Value
years NCT03923621 145 150 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

Exclusion NCT03923621 151 160 O
Criteria NCT03923621 161 169 O
: NCT03923621 170 171 O

- NCT03923621 175 176 O
Co NCT03923621 178 180 B-Condition-Name
- NCT03923621 181 182 I-Condition-Name
morbidity NCT03923621 183 192 I-Condition-Name
> NCT03923621 193 194 B-Eq-Operator___Eq-Operator-Value:GT
ASA NCT03923621 195 198 B-Condition-Name
II NCT03923621 199 201 B-Eq-Value

- NCT03923621 204 205 O
Unable NCT03923621 207 213 O
to NCT03923621 214 216 O
consent NCT03923621 217 224 O
themselves NCT03923621 225 235 O

- NCT03923621 238 239 O
Under NCT03923621 241 246 B-Eq-Operator___Eq-Operator-Value:LT
16 NCT03923621 248 250 B-Eq-Value
years NCT03923621 251 256 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03923621 259 260 O
Vulnerable NCT03923621 262 272 B-Condition-Name
adults NCT03923621 273 279 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult

Inclusion NCT03923153 0 9 O
Criteria NCT03923153 10 18 O
: NCT03923153 19 20 O

- NCT03923153 24 25 O
No NCT03923153 27 29 O
contraindication NCT03923153 30 46 O
for NCT03923153 47 50 O
pulmonary NCT03923153 51 60 B-Procedure-Name
physiotherapy NCT03923153 61 74 I-Procedure-Name

- NCT03923153 77 78 O
Anjina NCT03923153 80 86 B-Condition-Name
patients NCT03923153 87 95 O
who NCT03923153 96 99 O
are NCT03923153 100 103 O
clinically NCT03923153 104 114 O
stable NCT03923153 115 121 B-Stability___Stability-Value:stable

- NCT03923153 124 125 O
have NCT03923153 127 131 O
no NCT03923153 132 134 O
other NCT03923153 135 140 O
disease NCT03923153 141 148 B-Condition-Name
that NCT03923153 149 153 O
may NCT03923153 154 157 O
affect NCT03923153 158 164 B-Stability___Stability-Value:change
respiratory NCT03923153 165 176 B-Condition-Name
function NCT03923153 177 185 I-Condition-Name

- NCT03923153 188 189 O
Individuals NCT03923153 191 202 O
who NCT03923153 203 206 O
have NCT03923153 207 211 O
the NCT03923153 212 215 O
good NCT03923153 216 220 O
cooperation NCT03923153 221 232 O

Exclusion NCT03923153 233 242 O
Criteria NCT03923153 243 251 O
: NCT03923153 252 253 O

- NCT03923153 257 258 O
Patients NCT03923153 260 268 O
under NCT03923153 269 274 B-Eq-Operator___Eq-Operator-Value:LT
the NCT03923153 275 278 O
age NCT03923153 279 282 O
of NCT03923153 283 285 O
18 NCT03923153 287 289 B-Eq-Value

- NCT03923153 293 294 O
Pregnancy NCT03923153 296 305 B-Condition-Name

- NCT03923153 308 309 O
Active NCT03923153 311 317 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
infection NCT03923153 318 327 B-Condition-Name

- NCT03923153 330 331 O
Patients NCT03923153 333 341 O
with NCT03923153 342 346 O
known NCT03923153 347 352 O
malignancies NCT03923153 353 365 B-Condition-Name

- NCT03923153 368 369 O
patients NCT03923153 371 379 O
without NCT03923153 380 387 O
consent NCT03923153 388 395 O

- NCT03923153 398 399 O
known NCT03923153 401 406 O
arrhythmia NCT03923153 407 417 B-Condition-Name
, NCT03923153 418 419 O
dilated NCT03923153 420 427 O
or NCT03923153 428 430 O
hypertrophic NCT03923153 431 443 O
cardiomyopathy NCT03923153 444 458 B-Condition-Name
, NCT03923153 459 460 O
heart NCT03923153 461 466 B-Condition-Name
failure NCT03923153 467 474 I-Condition-Name
( NCT03923153 475 476 O
EF NCT03923153 477 479 B-Observation-Name___Observation-Type-Value:measurement
< NCT03923153 480 481 B-Eq-Operator___Eq-Operator-Value:LT
40 NCT03923153 483 485 B-Eq-Value
% NCT03923153 486 487 B-Eq-Unit
) NCT03923153 489 490 O

Inclusion NCT03926611 0 9 O
Criteria NCT03926611 10 18 O
: NCT03926611 19 20 O

- NCT03926611 24 25 O
Male NCT03926611 27 31 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
and NCT03926611 32 35 O
female NCT03926611 36 42 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
subjects NCT03926611 43 51 O
aged NCT03926611 52 56 O
≥ NCT03926611 57 58 B-Eq-Operator___Eq-Operator-Value:GTEQ
18 NCT03926611 60 62 B-Eq-Value
years NCT03926611 63 68 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03926611 69 71 O
age NCT03926611 72 75 O

- NCT03926611 78 79 O
CSU NCT03926611 81 84 B-Condition-Name
diagnosis NCT03926611 85 94 O
for NCT03926611 95 98 O
≥ NCT03926611 99 100 B-Eq-Operator___Eq-Operator-Value:GTEQ
6 NCT03926611 102 103 B-Eq-Value
months NCT03926611 104 110 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
prior NCT03926611 111 116 O
to NCT03926611 117 119 O
screening NCT03926611 120 129 O

- NCT03926611 132 133 O
Presence NCT03926611 135 143 O
of NCT03926611 144 146 O
itch NCT03926611 147 151 B-Condition-Name
and NCT03926611 152 155 O
hives NCT03926611 156 161 B-Condition-Name
for NCT03926611 162 165 O
≥ NCT03926611 166 167 B-Eq-Operator___Eq-Operator-Value:GTEQ
6 NCT03926611 169 170 B-Eq-Value
consecutive NCT03926611 171 182 O
weeks NCT03926611 183 188 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
prior NCT03926611 189 194 O
to NCT03926611 195 197 O
screening NCT03926611 198 207 O
in NCT03926611 208 210 O
spite NCT03926611 211 216 O
of NCT03926611 217 219 O
use NCT03926611 220 223 O
of NCT03926611 224 226 O
non NCT03926611 227 230 O
- NCT03926611 231 232 O
sedating NCT03926611 233 241 O
H NCT03926611 242 243 B-Drug-Name
1 NCT03926611 244 245 I-Drug-Name
- NCT03926611 246 247 I-Drug-Name
antihistamines NCT03926611 248 262 I-Drug-Name
according NCT03926611 263 272 O
to NCT03926611 273 275 O
local NCT03926611 276 281 O
Treatment NCT03926611 282 291 O
guidelines NCT03926611 292 302 O
during NCT03926611 303 309 O
this NCT03926611 310 314 O
time NCT03926611 315 319 O
period NCT03926611 320 326 O

- NCT03926611 329 330 O
UAS NCT03926611 332 335 B-Observation-Name___Observation-Type-Value:clinical-score
7 NCT03926611 336 337 I-Observation-Name___Observation-Type-Value:clinical-score
score NCT03926611 338 343 I-Observation-Name___Observation-Type-Value:clinical-score
( NCT03926611 344 345 O
range NCT03926611 346 351 O
0 NCT03926611 353 354 B-Eq-Value
- NCT03926611 355 356 B-Eq-Operator___Eq-Operator-Value:BETWEEN
42 NCT03926611 358 360 B-Eq-Value
) NCT03926611 361 362 O
≥ NCT03926611 363 364 B-Eq-Operator___Eq-Operator-Value:GTEQ
16 NCT03926611 366 368 B-Eq-Value
and NCT03926611 369 372 O
HSS NCT03926611 373 376 B-Observation-Name___Observation-Type-Value:clinical-score
7 NCT03926611 377 378 I-Observation-Name___Observation-Type-Value:clinical-score
score NCT03926611 379 384 I-Observation-Name___Observation-Type-Value:clinical-score
( NCT03926611 385 386 O
range NCT03926611 387 392 O
0 NCT03926611 394 395 B-Eq-Value
- NCT03926611 396 397 B-Eq-Operator___Eq-Operator-Value:BETWEEN
21 NCT03926611 399 401 B-Eq-Value
) NCT03926611 402 403 O
≥ NCT03926611 404 405 B-Eq-Operator___Eq-Operator-Value:GTEQ
8 NCT03926611 407 408 B-Eq-Value
during NCT03926611 409 415 O
7 NCT03926611 417 418 B-Eq-Value
days NCT03926611 419 423 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
prior NCT03926611 424 429 O
to NCT03926611 430 432 O
randomization NCT03926611 433 446 O
( NCT03926611 447 448 O
Day NCT03926611 449 452 O
1 NCT03926611 454 455 O
) NCT03926611 456 457 O

- NCT03926611 461 462 O
Willing NCT03926611 464 471 O
and NCT03926611 472 475 O
able NCT03926611 476 480 O
to NCT03926611 481 483 O
complete NCT03926611 484 492 O
an NCT03926611 493 495 O
Urticaria NCT03926611 496 505 B-Procedure-Name
Participant NCT03926611 506 517 I-Procedure-Name
Daily NCT03926611 518 523 I-Procedure-Name
eDiary NCT03926611 524 530 I-Procedure-Name
( NCT03926611 531 532 O
UPDD NCT03926611 533 537 B-Procedure-Name
) NCT03926611 538 539 O
for NCT03926611 540 543 O
the NCT03926611 544 547 O
duration NCT03926611 548 556 O
of NCT03926611 557 559 O
the NCT03926611 560 563 O
study NCT03926611 564 569 O

Exclusion NCT03926611 570 579 O
Criteria NCT03926611 580 588 O
: NCT03926611 589 590 O

- NCT03926611 594 595 O
Hypersensitivity NCT03926611 597 613 B-Condition-Name
to NCT03926611 614 616 O
any NCT03926611 617 620 O
of NCT03926611 621 623 O
the NCT03926611 624 627 O
study NCT03926611 628 633 O
treatments NCT03926611 634 644 O

- NCT03926611 647 648 O
Clearly NCT03926611 650 657 O
defined NCT03926611 658 665 O
predominant NCT03926611 666 677 O
or NCT03926611 678 680 O
sole NCT03926611 681 685 O
trigger NCT03926611 686 693 O
of NCT03926611 694 696 O
their NCT03926611 697 702 O
chronic NCT03926611 703 710 B-Condition-Name
urticaria NCT03926611 711 720 I-Condition-Name
( NCT03926611 721 722 O
chronic NCT03926611 723 730 O
inducible NCT03926611 731 740 B-Condition-Name
urticaria NCT03926611 741 750 I-Condition-Name
) NCT03926611 751 752 O

- NCT03926611 756 757 O
Other NCT03926611 759 764 O
diseases NCT03926611 765 773 B-Condition-Name
with NCT03926611 774 778 O
symptoms NCT03926611 779 787 O
of NCT03926611 788 790 O
urticaria NCT03926611 791 800 B-Condition-Name
or NCT03926611 801 803 O
angioedema NCT03926611 804 814 B-Condition-Name

- NCT03926611 817 818 O
Other NCT03926611 820 825 O
skin NCT03926611 826 830 B-Condition-Name
disease NCT03926611 831 838 I-Condition-Name
associated NCT03926611 839 849 O
with NCT03926611 850 854 O
chronic NCT03926611 855 862 O
itching NCT03926611 863 870 B-Condition-Name
that NCT03926611 871 875 O
might NCT03926611 876 881 O
influence NCT03926611 882 891 B-Stability___Stability-Value:change
in NCT03926611 892 894 O
the NCT03926611 895 898 O
investigators NCT03926611 899 912 O
opinion NCT03926611 913 920 O
the NCT03926611 921 924 O
study NCT03926611 925 930 O
evaluations NCT03926611 931 942 O
and NCT03926611 943 946 O
results NCT03926611 947 954 O
, NCT03926611 955 956 O

- NCT03926611 960 961 O
Known NCT03926611 963 968 O
or NCT03926611 969 971 O
suspected NCT03926611 972 981 O
history NCT03926611 982 989 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03926611 990 992 O
an NCT03926611 993 995 O
ongoing NCT03926611 996 1003 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
, NCT03926611 1004 1005 O
chronic NCT03926611 1006 1013 O
or NCT03926611 1014 1016 O
recurrent NCT03926611 1017 1026 O
infectious NCT03926611 1027 1037 B-Condition-Name
disease NCT03926611 1038 1045 I-Condition-Name
including NCT03926611 1046 1055 O
but NCT03926611 1056 1059 O
not NCT03926611 1060 1063 O
limited NCT03926611 1064 1071 O
to NCT03926611 1072 1074 O
opportunistic NCT03926611 1075 1088 B-Condition-Name
infections NCT03926611 1089 1099 I-Condition-Name
( NCT03926611 1100 1101 O
eg NCT03926611 1102 1104 O
tuberculosis NCT03926611 1105 1117 B-Condition-Name
, NCT03926611 1118 1119 O
atypical NCT03926611 1120 1128 O
mycobacterioses NCT03926611 1129 1144 B-Condition-Name
, NCT03926611 1145 1146 O
listeriosis NCT03926611 1147 1158 B-Condition-Name
or NCT03926611 1159 1161 O
aspergillosis NCT03926611 1162 1175 B-Condition-Name
) NCT03926611 1176 1177 O
, NCT03926611 1179 1180 O
HIV NCT03926611 1181 1184 B-Condition-Name
, NCT03926611 1185 1186 O
Hepatitis NCT03926611 1187 1196 B-Condition-Name
B NCT03926611 1197 1198 O
/ NCT03926611 1199 1200 O
C NCT03926611 1201 1202 O
. NCT03926611 1203 1204 O

- NCT03926611 1208 1209 O
Pregnant NCT03926611 1211 1219 B-Condition-Name
or NCT03926611 1220 1222 O
nursing NCT03926611 1223 1230 B-Condition-Name
( NCT03926611 1231 1232 O
lactating NCT03926611 1233 1242 B-Condition-Name
) NCT03926611 1243 1244 O
women NCT03926611 1245 1250 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female

- NCT03926611 1253 1254 O
Women NCT03926611 1256 1261 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
of NCT03926611 1262 1264 O
child NCT03926611 1265 1270 B-Condition-Name
- NCT03926611 1271 1272 I-Condition-Name
bearing NCT03926611 1273 1280 I-Condition-Name
potential NCT03926611 1281 1290 I-Condition-Name
not NCT03926611 1291 1294 O
using NCT03926611 1295 1300 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
highly NCT03926611 1301 1307 O
effective NCT03926611 1308 1317 O
methods NCT03926611 1318 1325 O
of NCT03926611 1326 1328 O
contraception NCT03926611 1329 1342 B-Procedure-Name

Other NCT03926611 1343 1348 O
protocol NCT03926611 1349 1357 O
- NCT03926611 1358 1359 O
defined NCT03926611 1360 1367 O
inclusion NCT03926611 1368 1377 O
/ NCT03926611 1378 1379 O
exclusion NCT03926611 1380 1389 O
criteria NCT03926611 1390 1398 O
may NCT03926611 1399 1402 O
apply NCT03926611 1403 1408 O
. NCT03926611 1409 1410 O

Inclusion NCT03929536 0 9 O
Criteria NCT03929536 10 18 O
: NCT03929536 19 20 O

- NCT03929536 24 25 O
surgical NCT03929536 27 35 B-Procedure-Name
treatment NCT03929536 36 45 I-Procedure-Name
of NCT03929536 46 48 O
acetabular NCT03929536 49 59 O
fracture NCT03929536 60 68 B-Condition-Name
between NCT03929536 69 76 B-Eq-Operator___Eq-Operator-Value:BETWEEN
2009 NCT03929536 78 82 B-Eq-Value
and NCT03929536 83 86 O
2018 NCT03929536 88 92 B-Eq-Value

Exclusion NCT03929536 94 103 O
Criteria NCT03929536 104 112 O
: NCT03929536 113 114 O

- NCT03929536 118 119 O
pathological NCT03929536 121 133 O
fractures NCT03929536 134 143 B-Condition-Name
due NCT03929536 144 147 O
to NCT03929536 148 150 O
neoplasm NCT03929536 151 159 B-Condition-Name
or NCT03929536 160 162 O
metastasis NCT03929536 163 173 B-Condition-Name

- NCT03929536 176 177 O
status NCT03929536 179 185 O
after NCT03929536 186 191 O
implantation NCT03929536 192 204 B-Procedure-Name
of NCT03929536 205 207 I-Procedure-Name
an NCT03929536 208 210 I-Procedure-Name
endoprosthesis NCT03929536 211 225 I-Procedure-Name

Inclusion NCT03928600 0 9 O
Criteria NCT03928600 10 18 O
: NCT03928600 19 20 O

- NCT03928600 24 25 O
full NCT03928600 27 31 B-Condition-Name
- NCT03928600 32 33 I-Condition-Name
term NCT03928600 34 38 I-Condition-Name
( NCT03928600 39 40 O
≥ NCT03928600 42 43 B-Eq-Operator___Eq-Operator-Value:GTEQ
37 NCT03928600 45 47 B-Eq-Value
weeks NCT03928600 48 53 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
of NCT03928600 54 56 O
gestation NCT03928600 57 66 B-Observation-Name
) NCT03928600 67 68 O

- NCT03928600 72 73 O
singleton NCT03928600 75 84 B-Condition-Name

- NCT03928600 87 88 O
vertex NCT03928600 90 96 B-Condition-Name
- NCT03928600 97 98 I-Condition-Name
presenting NCT03928600 99 109 I-Condition-Name
gestations NCT03928600 110 120 I-Condition-Name

- NCT03928600 123 124 O
with NCT03928600 126 130 O
no NCT03928600 131 133 O
contraindication NCT03928600 134 150 O
to NCT03928600 151 153 O
vaginal NCT03928600 154 161 B-Procedure-Name
delivery NCT03928600 162 170 I-Procedure-Name

- NCT03928600 173 174 O
intact NCT03928600 176 182 B-Condition-Name
membranes NCT03928600 183 192 I-Condition-Name

- NCT03928600 195 196 O
Bishop NCT03928600 198 204 B-Observation-Name___Observation-Type-Value:clinical-score
score NCT03928600 205 210 I-Observation-Name___Observation-Type-Value:clinical-score
< NCT03928600 211 212 B-Eq-Operator___Eq-Operator-Value:LT
7 NCT03928600 214 215 B-Eq-Value
and NCT03928600 216 219 O
cervical NCT03928600 220 228 B-Observation-Name___Observation-Type-Value:measurement
dilation NCT03928600 229 237 I-Observation-Name___Observation-Type-Value:measurement
≤ NCT03928600 238 239 B-Eq-Operator___Eq-Operator-Value:LTEQ
2 NCT03928600 241 242 B-Eq-Value
cm NCT03928600 243 245 B-Eq-Unit

Exclusion NCT03928600 246 255 O
Criteria NCT03928600 256 264 O
: NCT03928600 265 266 O

- NCT03928600 270 271 O
contraindication NCT03928600 273 289 O
for NCT03928600 290 293 O
misoprostol NCT03928600 294 305 B-Drug-Name

- NCT03928600 308 309 O
history NCT03928600 311 318 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03928600 319 321 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
previous NCT03928600 322 330 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
caesarean NCT03928600 331 340 B-Procedure-Name

- NCT03928600 343 344 O
rupture NCT03928600 346 353 B-Condition-Name
of NCT03928600 354 356 I-Condition-Name
membranes NCT03928600 357 366 I-Condition-Name
, NCT03928600 367 368 O

- NCT03928600 372 373 O
fetal NCT03928600 375 380 O
or NCT03928600 381 383 O
maternal NCT03928600 384 392 O
morbidities NCT03928600 393 404 B-Condition-Name
( NCT03928600 405 406 O
fetal NCT03928600 407 412 B-Condition-Name
major NCT03928600 413 418 I-Condition-Name
abnormalities NCT03928600 419 432 I-Condition-Name
, NCT03928600 433 434 O
FIGO NCT03928600 435 439 O
definition NCT03928600 440 450 O
of NCT03928600 451 453 O
pathological NCT03928600 454 466 O
CTG NCT03928600 467 470 B-Condition-Name
, NCT03928600 471 472 O
HELLP NCT03928600 473 478 B-Condition-Name
syndrome NCT03928600 479 487 I-Condition-Name
, NCT03928600 488 489 O
preeclampsia NCT03928600 490 502 B-Condition-Name
or NCT03928600 503 505 O
hypertension NCT03928600 506 518 B-Condition-Name
with NCT03928600 519 523 O
severe NCT03928600 524 530 B-Severity___Severity-Value:severe
features NCT03928600 531 539 O
, NCT03928600 540 541 O
fetal NCT03928600 542 547 B-Condition-Name
growth NCT03928600 548 554 I-Condition-Name
restriction NCT03928600 555 566 I-Condition-Name
) NCT03928600 567 568 O

Inclusion NCT03923972 0 9 O
Criteria NCT03923972 10 18 O
: NCT03923972 19 20 O

- NCT03923972 24 25 O
all NCT03923972 27 30 O
adult NCT03923972 31 36 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
patients NCT03923972 37 45 O
with NCT03923972 46 50 O
non NCT03923972 51 54 O
- NCT03923972 55 56 O
dialysis NCT03923972 57 65 O
dependent NCT03923972 66 75 O
chronic NCT03923972 76 83 B-Condition-Name
kidney NCT03923972 84 90 I-Condition-Name
disease NCT03923972 91 98 I-Condition-Name
, NCT03923972 99 100 O
peritoneal NCT03923972 101 111 B-Procedure-Name
dialysis NCT03923972 112 120 I-Procedure-Name
, NCT03923972 121 122 O
hemodialysis NCT03923972 123 135 B-Procedure-Name
, NCT03923972 136 137 O
renal NCT03923972 138 143 B-Procedure-Name
transplantation NCT03923972 144 159 I-Procedure-Name

- NCT03923972 162 163 O
all NCT03923972 165 168 O
active NCT03923972 169 175 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
physicians NCT03923972 176 186 B-Provider-Role
in NCT03923972 187 189 O
the NCT03923972 190 193 O
department NCT03923972 194 204 O
of NCT03923972 205 207 O
nephrology NCT03923972 208 218 B-Provider-Type
involved NCT03923972 219 227 O
in NCT03923972 228 230 O
patient NCT03923972 231 238 O
care NCT03923972 239 243 O

- NCT03923972 246 247 O
all NCT03923972 249 252 O
active NCT03923972 253 259 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
nurses NCT03923972 260 266 B-Provider-Role
in NCT03923972 267 269 O
the NCT03923972 270 273 O
department NCT03923972 274 284 O
of NCT03923972 285 287 O
nephrology NCT03923972 288 298 B-Provider-Type
involved NCT03923972 299 307 O
in NCT03923972 308 310 O
patient NCT03923972 311 318 O
care NCT03923972 319 323 O

- NCT03923972 326 327 O
all NCT03923972 329 332 O
heads NCT03923972 333 338 O
of NCT03923972 339 341 O
nephrology NCT03923972 342 352 B-Provider-Type
departments NCT03923972 353 364 O

Exclusion NCT03923972 365 374 O
Criteria NCT03923972 375 383 O
: NCT03923972 384 385 O

- NCT03923972 389 390 O
children NCT03923972 392 400 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child

- NCT03923972 403 404 O
no NCT03923972 406 408 O
physical NCT03923972 409 417 B-Condition-Name
disability NCT03923972 418 428 I-Condition-Name
making NCT03923972 429 435 O
it NCT03923972 436 438 O
impossible NCT03923972 439 449 O
to NCT03923972 450 452 O
conduct NCT03923972 453 460 O
exercise NCT03923972 461 469 B-Procedure-Name
training NCT03923972 470 478 I-Procedure-Name

- NCT03923972 481 482 O
no NCT03923972 484 486 O
mental NCT03923972 487 493 B-Condition-Name
disability NCT03923972 494 504 I-Condition-Name
or NCT03923972 505 507 O
language NCT03923972 508 516 B-Condition-Name
problem NCT03923972 517 524 I-Condition-Name
making NCT03923972 525 531 O
it NCT03923972 532 534 O
impossible NCT03923972 535 545 O
to NCT03923972 546 548 O
understand NCT03923972 549 559 O
and NCT03923972 560 563 O
fill NCT03923972 564 568 O
in NCT03923972 569 571 O
a NCT03923972 572 573 O
questionnaire NCT03923972 574 587 B-Observation-Name___Observation-Type-Value:survey-or-questionnaire

Inclusion NCT03922113 0 9 O
Criteria NCT03922113 10 18 O
: NCT03922113 19 20 O

- NCT03922113 24 25 O
Collaborative NCT03922113 27 40 O
ICU NCT03922113 41 44 B-Encounter-Type___Encounter-Type-Value:icu
patients NCT03922113 45 53 O
with NCT03922113 54 58 O
length NCT03922113 59 65 O
of NCT03922113 66 68 O
stay NCT03922113 69 73 O
> NCT03922113 74 75 B-Eq-Operator___Eq-Operator-Value:GT
48 NCT03922113 77 79 B-Eq-Value
h NCT03922113 80 81 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:hour

- NCT03922113 84 85 O
Surgical NCT03922113 87 95 O
patients NCT03922113 96 104 O
scheduled NCT03922113 105 114 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
for NCT03922113 115 118 O
colorectal NCT03922113 119 129 B-Procedure-Name
surgery NCT03922113 130 137 I-Procedure-Name

- NCT03922113 140 141 O
Healthy NCT03922113 143 150 B-Condition-Name
subjects NCT03922113 151 159 O

Exclusion NCT03922113 160 169 O
Criteria NCT03922113 170 178 O
: NCT03922113 179 180 O

- NCT03922113 184 185 O
a NCT03922113 187 188 O
score NCT03922113 189 194 O
> NCT03922113 195 196 B-Eq-Operator___Eq-Operator-Value:GT
1 NCT03922113 198 199 B-Eq-Value
or NCT03922113 200 202 O
< NCT03922113 203 204 B-Eq-Operator___Eq-Operator-Value:LT
- NCT03922113 205 206 B-Eq-Value
1 NCT03922113 208 209 I-Eq-Value
on NCT03922113 210 212 O
the NCT03922113 213 216 O
Richmond NCT03922113 217 225 B-Observation-Name___Observation-Type-Value:clinical-score
Agitation NCT03922113 226 235 I-Observation-Name___Observation-Type-Value:clinical-score
and NCT03922113 236 239 I-Observation-Name___Observation-Type-Value:clinical-score
Sedation NCT03922113 240 248 I-Observation-Name___Observation-Type-Value:clinical-score
Scale NCT03922113 249 254 I-Observation-Name___Observation-Type-Value:clinical-score
( NCT03922113 255 256 O
RASS NCT03922113 257 261 B-Observation-Name
) NCT03922113 262 263 O

- NCT03922113 267 268 O
coma NCT03922113 270 274 B-Condition-Name

- NCT03922113 277 278 O
total NCT03922113 280 285 O
hip NCT03922113 286 289 O
or NCT03922113 290 292 O
knee NCT03922113 293 297 O
arthroplasty NCT03922113 298 310 B-Procedure-Name
in NCT03922113 311 313 O
the NCT03922113 314 317 O
dominant NCT03922113 318 326 O
limb NCT03922113 327 331 O

- NCT03922113 334 335 O
unauthorized NCT03922113 337 349 B-Condition-Name
support NCT03922113 350 357 I-Condition-Name
on NCT03922113 358 360 O
the NCT03922113 361 364 O
dominant NCT03922113 365 373 O
leg NCT03922113 374 377 O

- NCT03922113 380 381 O
open NCT03922113 383 387 B-Condition-Name
wound NCT03922113 388 393 I-Condition-Name
located NCT03922113 394 401 O
at NCT03922113 402 404 O
the NCT03922113 405 408 O
ankle NCT03922113 409 414 O
's NCT03922113 414 416 O
anterior NCT03922113 417 425 O
face NCT03922113 426 430 O
of NCT03922113 431 433 O
the NCT03922113 434 437 O
dominant NCT03922113 438 446 O
leg NCT03922113 447 450 O

- NCT03922113 453 454 O
pre NCT03922113 456 459 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
- NCT03922113 460 461 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
existing NCT03922113 462 470 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
myopathy NCT03922113 471 479 B-Condition-Name
or NCT03922113 480 482 O
polyneuropathy NCT03922113 483 497 B-Condition-Name

- NCT03922113 500 501 O
para NCT03922113 503 507 O
- NCT03922113 508 509 O
or NCT03922113 510 512 O
tetraparesis NCT03922113 513 525 B-Condition-Name
, NCT03922113 526 527 O
para NCT03922113 528 532 O
- NCT03922113 533 534 O
or NCT03922113 535 537 O
tetraplegia NCT03922113 538 549 B-Condition-Name

- NCT03922113 552 553 O
refusal NCT03922113 555 562 O
. NCT03922113 563 564 O

Inclusion NCT03923231 0 9 O
Criteria NCT03923231 10 18 O
: NCT03923231 19 20 O

1 NCT03923231 25 26 O
. NCT03923231 26 27 O
Evidence NCT03923231 29 37 O
of NCT03923231 38 40 O
a NCT03923231 41 42 O
personally NCT03923231 43 53 O
signed NCT03923231 54 60 O
and NCT03923231 61 64 O
dated NCT03923231 65 70 O
informed NCT03923231 71 79 O
consent NCT03923231 80 87 O
document NCT03923231 88 96 O
indicating NCT03923231 97 107 O
that NCT03923231 108 112 O
the NCT03923231 113 116 O
participant NCT03923231 117 128 O
( NCT03923231 129 130 O
or NCT03923231 131 133 O
a NCT03923231 134 135 O
legal NCT03923231 136 141 O
representative NCT03923231 142 156 O
) NCT03923231 157 158 O
has NCT03923231 159 162 O
been NCT03923231 163 167 O
informed NCT03923231 168 176 O
of NCT03923231 177 179 O
all NCT03923231 180 183 O
pertinent NCT03923231 184 193 O
aspects NCT03923231 194 201 O
of NCT03923231 202 204 O
the NCT03923231 205 208 O
study NCT03923231 209 214 O
. NCT03923231 215 216 O

2 NCT03923231 221 222 O
. NCT03923231 222 223 O
In NCT03923231 225 227 O
a NCT03923231 228 229 O
child NCT03923231 230 235 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
aged NCT03923231 236 240 O
≥ NCT03923231 241 242 B-Eq-Operator___Eq-Operator-Value:GTEQ
7 NCT03923231 244 245 B-Eq-Value
years NCT03923231 246 251 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
( NCT03923231 252 253 O
South NCT03923231 254 259 B-Location___Location-Value:residence
Africa NCT03923231 260 266 I-Location___Location-Value:residence
) NCT03923231 267 268 O
or NCT03923231 269 271 O
aged NCT03923231 272 276 O
≥ NCT03923231 277 278 B-Eq-Operator___Eq-Operator-Value:GTEQ
8 NCT03923231 280 281 B-Eq-Value
years NCT03923231 282 287 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
( NCT03923231 288 289 O
Uganda NCT03923231 290 296 B-Location___Location-Value:residence
) NCT03923231 297 298 O
, NCT03923231 300 301 O
evidence NCT03923231 302 310 O
of NCT03923231 311 313 O
assent NCT03923231 314 320 O
to NCT03923231 321 323 O
participate NCT03923231 324 335 O

3 NCT03923231 339 340 O
. NCT03923231 340 341 O
Participants NCT03923231 343 355 O
who NCT03923231 356 359 O
are NCT03923231 360 363 O
willing NCT03923231 364 371 O
and NCT03923231 372 375 O
able NCT03923231 376 380 O
to NCT03923231 381 383 O
comply NCT03923231 384 390 O
with NCT03923231 391 395 O
scheduled NCT03923231 396 405 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
visits NCT03923231 406 412 B-Encounter-Type___Encounter-Type-Value:outpatient
, NCT03923231 413 414 O
laboratory NCT03923231 415 425 B-Observation-Name___Observation-Type-Value:lab
tests NCT03923231 426 431 I-Observation-Name___Observation-Type-Value:lab
, NCT03923231 432 433 O
and NCT03923231 434 437 O
other NCT03923231 438 443 O
study NCT03923231 444 449 O
procedures NCT03923231 450 460 O
. NCT03923231 461 462 O

4 NCT03923231 467 468 O
. NCT03923231 468 469 O
HIV NCT03923231 471 474 B-Condition-Name
- NCT03923231 475 476 I-Condition-Name
infected NCT03923231 477 485 I-Condition-Name
, NCT03923231 486 487 O
receiving NCT03923231 488 497 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
ATV NCT03923231 498 501 B-Drug-Name
- NCT03923231 502 503 O
based NCT03923231 504 509 O
ART NCT03923231 510 513 B-Procedure-Name
treatment NCT03923231 514 523 I-Procedure-Name
OR NCT03923231 524 526 O
HIV NCT03923231 527 530 B-Condition-Name
- NCT03923231 531 532 I-Condition-Name
infected NCT03923231 533 541 I-Condition-Name
receiving NCT03923231 542 551 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
second NCT03923231 552 558 O
- NCT03923231 559 560 O
line NCT03923231 561 565 O
ART NCT03923231 566 569 B-Procedure-Name
with NCT03923231 570 574 O
concurrent NCT03923231 575 585 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
rifamycin NCT03923231 586 595 B-Drug-Name
- NCT03923231 596 597 O
based NCT03923231 598 603 O
TB NCT03923231 604 606 B-Procedure-Name
treatment NCT03923231 607 616 I-Procedure-Name

5 NCT03923231 620 621 O
. NCT03923231 621 622 O
Participant NCT03923231 624 635 O
is NCT03923231 636 638 O
within NCT03923231 639 645 O
one NCT03923231 646 649 O
of NCT03923231 650 652 O
the NCT03923231 653 656 O
target NCT03923231 657 663 O
populations NCT03923231 664 675 O
: NCT03923231 676 677 O

1 NCT03923231 687 688 O
. NCT03923231 688 689 O
Pregnant NCT03923231 691 699 B-Condition-Name
( NCT03923231 700 701 O
> NCT03923231 703 704 B-Eq-Operator___Eq-Operator-Value:GT
20 NCT03923231 706 708 B-Eq-Value
weeks NCT03923231 709 714 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
) NCT03923231 715 716 O

2 NCT03923231 726 727 O
. NCT03923231 727 728 O
Body NCT03923231 730 734 B-Observation-Name___Observation-Type-Value:vital
mass NCT03923231 735 739 I-Observation-Name___Observation-Type-Value:vital
index NCT03923231 740 745 I-Observation-Name___Observation-Type-Value:vital
> NCT03923231 746 747 B-Eq-Operator___Eq-Operator-Value:GT
30 NCT03923231 749 751 B-Eq-Value
or NCT03923231 752 754 O
< NCT03923231 755 756 B-Eq-Operator___Eq-Operator-Value:LT
18.5 NCT03923231 758 762 B-Eq-Value
Kg NCT03923231 763 765 B-Eq-Unit
/ NCT03923231 766 767 O
m NCT03923231 768 769 B-Eq-Unit
2 NCT03923231 770 771 I-Eq-Unit

3 NCT03923231 780 781 O
. NCT03923231 781 782 O
Child NCT03923231 784 789 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
or NCT03923231 790 792 O
adolescent NCT03923231 793 803 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
aged NCT03923231 804 808 O
< NCT03923231 809 810 B-Eq-Operator___Eq-Operator-Value:LT
18 NCT03923231 812 814 B-Eq-Value
years NCT03923231 815 820 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

Exclusion NCT03923231 821 830 O
Criteria NCT03923231 831 839 O
: NCT03923231 840 841 O

1 NCT03923231 846 847 O
. NCT03923231 847 848 O
Medical NCT03923231 850 857 O
, NCT03923231 858 859 O
psychiatric NCT03923231 860 871 O
or NCT03923231 872 874 O
obstetric NCT03923231 875 884 O
condition NCT03923231 885 894 O
that NCT03923231 895 899 O
might NCT03923231 900 905 O
affect NCT03923231 906 912 B-Stability___Stability-Value:change
participation NCT03923231 913 926 O
in NCT03923231 927 929 O
the NCT03923231 930 933 O
stuy NCT03923231 934 938 O
based NCT03923231 939 944 O
on NCT03923231 945 947 O
investigator NCT03923231 948 960 O
judgement NCT03923231 961 970 O

2 NCT03923231 974 975 O
. NCT03923231 975 976 O
Dissent NCT03923231 978 985 O
from NCT03923231 986 990 O
a NCT03923231 991 992 O
minor NCT03923231 993 998 O

3 NCT03923231 1002 1003 O
. NCT03923231 1003 1004 O
For NCT03923231 1006 1009 O
pregnant NCT03923231 1010 1018 B-Condition-Name
women NCT03923231 1019 1024 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
in NCT03923231 1025 1027 O
Uganda NCT03923231 1028 1034 B-Location___Location-Value:residence
, NCT03923231 1035 1036 O
where NCT03923231 1037 1042 O
the NCT03923231 1043 1046 O
husband NCT03923231 1047 1054 O
is NCT03923231 1055 1057 O
reasonably NCT03923231 1058 1068 O
involved NCT03923231 1069 1077 O
, NCT03923231 1078 1079 O
paternal NCT03923231 1080 1088 O
objection NCT03923231 1089 1098 O

Inclusion NCT03923543 0 9 O
Criteria NCT03923543 10 18 O
: NCT03923543 19 20 O

- NCT03923543 24 25 O
newborn NCT03923543 27 34 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:infant
to NCT03923543 35 37 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
be NCT03923543 38 40 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
operated NCT03923543 41 49 B-Procedure-Name
with NCT03923543 50 54 O
the NCT03923543 55 58 O
diagnosis NCT03923543 59 68 O
of NCT03923543 69 71 O
congenital NCT03923543 72 82 B-Condition-Name
heart NCT03923543 83 88 I-Condition-Name
disease NCT03923543 89 96 I-Condition-Name

Exclusion NCT03923543 97 106 O
Criteria NCT03923543 107 115 O
: NCT03923543 116 117 O

- NCT03923543 121 122 O
age NCT03923543 124 127 O
older NCT03923543 128 133 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03923543 134 138 I-Eq-Operator___Eq-Operator-Value:GT
1 NCT03923543 140 141 B-Eq-Value
month NCT03923543 142 147 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
not NCT03923543 148 151 O
to NCT03923543 152 154 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
be NCT03923543 155 157 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
operated NCT03923543 158 166 B-Procedure-Name

Inclusion NCT03923595 0 9 O
Criteria NCT03923595 10 18 O
: NCT03923595 19 20 O

- NCT03923595 24 25 O
all NCT03923595 27 30 O
consecutive NCT03923595 31 42 O
patients NCT03923595 43 51 O
from NCT03923595 52 56 O
SERD NCT03923595 57 61 B-Location___Location-Value:residence
of NCT03923595 62 64 O
18 NCT03923595 66 68 B-Eq-Value
yrs NCT03923595 69 72 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
or NCT03923595 73 75 B-Eq-Operator___Eq-Operator-Value:GTEQ
older NCT03923595 76 81 I-Eq-Operator___Eq-Operator-Value:GTEQ
either NCT03923595 82 88 O
naive NCT03923595 89 94 B-Condition-Name
or NCT03923595 95 97 O
previously NCT03923595 98 108 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
treated NCT03923595 109 116 O
including NCT03923595 117 126 O
HBsAg NCT03923595 127 132 B-Condition-Name
positive NCT03923595 133 141 B-Polarity___Polarity-Value:positive
and NCT03923595 142 145 O
HIV NCT03923595 146 149 B-Condition-Name
positive NCT03923595 150 158 B-Polarity___Polarity-Value:positive
. NCT03923595 159 160 O

Exclusion NCT03923595 162 171 O
Criteria NCT03923595 172 180 O
: NCT03923595 181 182 O

- NCT03923595 186 187 O
GFR NCT03923595 189 192 B-Observation-Name
< NCT03923595 193 194 B-Eq-Operator___Eq-Operator-Value:LT
50 NCT03923595 196 198 B-Eq-Value
ml NCT03923595 199 201 B-Eq-Unit
/ NCT03923595 202 203 O
min NCT03923595 204 207 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:minute
, NCT03923595 208 209 O
pregnancy NCT03923595 210 219 B-Condition-Name
, NCT03923595 220 221 O
breast NCT03923595 222 228 B-Condition-Name
- NCT03923595 229 230 I-Condition-Name
feeding NCT03923595 231 238 I-Condition-Name
, NCT03923595 239 240 O
cirrhosis NCT03923595 241 250 B-Condition-Name
of NCT03923595 251 253 O
CHILD NCT03923595 254 259 B-Condition-Name
- NCT03923595 260 261 I-Condition-Name
PUGH NCT03923595 262 266 I-Condition-Name
- NCT03923595 267 268 I-Condition-Name
TURCOTTE NCT03923595 269 277 I-Condition-Name
B NCT03923595 278 279 B-Eq-Value
7 NCT03923595 280 281 I-Eq-Value
o NCT03923595 282 283 O
> NCT03923595 284 285 B-Eq-Operator___Eq-Operator-Value:GT
. NCT03923595 287 288 O

Inclusion NCT03923556 0 9 O
Criteria NCT03923556 10 18 O
: NCT03923556 19 20 O

- NCT03923556 24 25 O
At NCT03923556 27 29 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03923556 30 35 I-Eq-Operator___Eq-Operator-Value:GTEQ
18 NCT03923556 37 39 B-Eq-Value
years NCT03923556 40 45 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
or NCT03923556 46 48 B-Eq-Operator___Eq-Operator-Value:GTEQ
older NCT03923556 49 54 I-Eq-Operator___Eq-Operator-Value:GTEQ

- NCT03923556 57 58 O
Diagnosed NCT03923556 60 69 O
with NCT03923556 70 74 O
severe NCT03923556 75 81 B-Severity___Severity-Value:severe
kidney NCT03923556 82 88 B-Condition-Name
dysfunction NCT03923556 89 100 I-Condition-Name
( NCT03923556 101 102 O
defined NCT03923556 103 110 O
by NCT03923556 111 113 O
plasma NCT03923556 114 120 B-Observation-Name___Observation-Type-Value:lab
creatinine NCT03923556 121 131 I-Observation-Name___Observation-Type-Value:lab
clearance NCT03923556 132 141 I-Observation-Name___Observation-Type-Value:lab
< NCT03923556 142 143 B-Eq-Operator___Eq-Operator-Value:LT
30 NCT03923556 145 147 B-Eq-Value
mL NCT03923556 148 150 B-Eq-Unit
/ NCT03923556 151 152 O
min NCT03923556 153 156 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:minute
) NCT03923556 157 158 O

- NCT03923556 162 163 O
Planning NCT03923556 165 173 O
on NCT03923556 174 176 O
kidney NCT03923556 177 183 B-Procedure-Name
transplantation NCT03923556 184 199 I-Procedure-Name
surgery NCT03923556 200 207 I-Procedure-Name
at NCT03923556 208 210 O
the NCT03923556 211 214 O
University NCT03923556 215 225 B-Location___Location-Value:hospital
of NCT03923556 226 228 I-Location___Location-Value:hospital
Colorado NCT03923556 229 237 I-Location___Location-Value:hospital
Hospital NCT03923556 238 246 I-Location___Location-Value:hospital
. NCT03923556 247 248 O

Exclusion NCT03923556 250 259 O
Criteria NCT03923556 260 268 O
: NCT03923556 269 270 O

- NCT03923556 274 275 O
Patients NCT03923556 277 285 O
unable NCT03923556 286 292 O
to NCT03923556 293 295 O
sign NCT03923556 296 300 O
the NCT03923556 301 304 O
informed NCT03923556 305 313 O
consent NCT03923556 314 321 O

- NCT03923556 324 325 O
Pregnant NCT03923556 327 335 B-Condition-Name
women NCT03923556 336 341 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female

- NCT03923556 344 345 O
Body NCT03923556 347 351 B-Observation-Name___Observation-Type-Value:vital
Mass NCT03923556 352 356 I-Observation-Name___Observation-Type-Value:vital
Index NCT03923556 357 362 I-Observation-Name___Observation-Type-Value:vital
( NCT03923556 363 364 O
BMI NCT03923556 365 368 B-Observation-Name___Observation-Type-Value:vital
) NCT03923556 369 370 O
> NCT03923556 371 372 B-Eq-Operator___Eq-Operator-Value:GT
40 NCT03923556 374 376 B-Eq-Value
kg NCT03923556 377 379 B-Eq-Unit
/ NCT03923556 380 381 O
m NCT03923556 382 383 B-Eq-Unit
2 NCT03923556 384 385 I-Eq-Unit

- NCT03923556 388 389 O
Pre NCT03923556 391 394 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
- NCT03923556 395 396 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
existing NCT03923556 397 405 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
oxygen NCT03923556 406 412 O
or NCT03923556 413 415 O
ventilatory NCT03923556 416 427 O
dependency NCT03923556 428 438 B-Condition-Name
( NCT03923556 439 440 O
24 NCT03923556 442 444 B-Eq-Value
h NCT03923556 445 446 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:hour
use NCT03923556 447 450 O
of NCT03923556 451 453 O
oxygen NCT03923556 454 460 B-Procedure-Name
or NCT03923556 461 463 O
other NCT03923556 464 469 O
noninvasive NCT03923556 470 481 O
or NCT03923556 482 484 O
invasive NCT03923556 485 493 O
ventilatory NCT03923556 494 505 B-Procedure-Name
support NCT03923556 506 513 I-Procedure-Name
) NCT03923556 514 515 O

- NCT03923556 519 520 O
Patients NCT03923556 522 530 O
with NCT03923556 531 535 O
any NCT03923556 536 539 O
pulmonary NCT03923556 540 549 O
, NCT03923556 550 551 O
neuromuscular NCT03923556 552 565 O
or NCT03923556 566 568 O
other NCT03923556 569 574 O
disease NCT03923556 575 582 B-Condition-Name
that NCT03923556 583 587 O
severely NCT03923556 588 596 B-Severity___Severity-Value:severe
limits NCT03923556 597 603 B-Stability___Stability-Value:change
their NCT03923556 604 609 O
respiratory NCT03923556 610 621 B-Condition-Name
functional NCT03923556 622 632 I-Condition-Name
status NCT03923556 633 639 O
( NCT03923556 640 641 O
e NCT03923556 642 643 O
. NCT03923556 644 645 O
g NCT03923556 646 647 O
. NCT03923556 648 649 O
unable NCT03923556 651 657 O
to NCT03923556 658 660 O
achieve NCT03923556 661 668 O
4 NCT03923556 670 671 B-Eq-Value
Metabolic NCT03923556 672 681 B-Observation-Name
Equivalent NCT03923556 682 692 I-Observation-Name
of NCT03923556 693 695 I-Observation-Name
Tasks NCT03923556 696 701 I-Observation-Name
, NCT03923556 702 703 O
METs NCT03923556 704 708 B-Observation-Name
, NCT03923556 709 710 O
such NCT03923556 711 715 O
as NCT03923556 716 718 O
climbing NCT03923556 719 727 B-Observation-Name
up NCT03923556 728 730 I-Observation-Name
1 NCT03923556 732 733 I-Observation-Name
flight NCT03923556 734 740 I-Observation-Name
of NCT03923556 741 743 I-Observation-Name
stairs NCT03923556 744 750 I-Observation-Name
) NCT03923556 751 752 O

- NCT03923556 756 757 O
Presence NCT03923556 759 767 O
of NCT03923556 768 770 O
any NCT03923556 771 774 O
contraindication NCT03923556 775 791 O
for NCT03923556 792 795 O
any NCT03923556 796 799 O
of NCT03923556 800 802 O
the NCT03923556 803 806 O
study NCT03923556 807 812 O
- NCT03923556 813 814 O
related NCT03923556 815 822 O
medications NCT03923556 823 834 O
or NCT03923556 835 837 O
interventions NCT03923556 838 851 O
. NCT03923556 852 853 O

Inclusion NCT03923218 0 9 O
Criteria NCT03923218 10 18 O
for NCT03923218 19 22 O
chronic NCT03923218 23 30 B-Condition-Name
periodontitis NCT03923218 31 44 I-Condition-Name
groups NCT03923218 45 51 O
: NCT03923218 52 53 O

- NCT03923218 57 58 O
Clinical NCT03923218 60 68 B-Observation-Name___Observation-Type-Value:measurement
attachment NCT03923218 69 79 I-Observation-Name___Observation-Type-Value:measurement
loss NCT03923218 80 84 I-Observation-Name___Observation-Type-Value:measurement
≥ NCT03923218 85 86 B-Eq-Operator___Eq-Operator-Value:GTEQ
5 NCT03923218 88 89 B-Eq-Value
mm NCT03923218 90 92 B-Eq-Unit

- NCT03923218 95 96 O
Probing NCT03923218 98 105 B-Observation-Name___Observation-Type-Value:measurement
depth NCT03923218 106 111 I-Observation-Name___Observation-Type-Value:measurement
≥ NCT03923218 112 113 B-Eq-Operator___Eq-Operator-Value:GTEQ
5 NCT03923218 115 116 B-Eq-Value
mm NCT03923218 117 119 B-Eq-Unit

- NCT03923218 122 123 O
Bone NCT03923218 125 129 B-Observation-Name___Observation-Type-Value:measurement
loss NCT03923218 130 134 I-Observation-Name___Observation-Type-Value:measurement
affecting NCT03923218 135 144 O
> NCT03923218 145 146 B-Eq-Operator___Eq-Operator-Value:GT
30 NCT03923218 148 150 B-Eq-Value
% NCT03923218 151 152 O
of NCT03923218 153 155 O
the NCT03923218 156 159 O
existing NCT03923218 160 168 O
teeth NCT03923218 169 174 O
on NCT03923218 175 177 O
clinical NCT03923218 178 186 O
and NCT03923218 187 190 O
radiographic NCT03923218 191 203 O
examination NCT03923218 204 215 B-Procedure-Name

- NCT03923218 218 219 O
gingival NCT03923218 221 229 B-Observation-Name___Observation-Type-Value:clinical-score
index NCT03923218 230 235 I-Observation-Name___Observation-Type-Value:clinical-score
( NCT03923218 236 237 O
GI NCT03923218 238 240 B-Observation-Name
) NCT03923218 241 242 O
score NCT03923218 243 248 O
> NCT03923218 249 250 B-Eq-Operator___Eq-Operator-Value:GT
1 NCT03923218 252 253 B-Eq-Value

Inclusion NCT03923218 255 264 O
criteria NCT03923218 265 273 O
for NCT03923218 274 277 O
control NCT03923218 278 285 O
group NCT03923218 286 291 O
: NCT03923218 292 293 O

- NCT03923218 297 298 O
full NCT03923218 300 304 O
- NCT03923218 305 306 O
mouth NCT03923218 307 312 O
PD NCT03923218 313 315 B-Observation-Name
was NCT03923218 316 319 O
≤ NCT03923218 320 321 B-Eq-Operator___Eq-Operator-Value:LTEQ
3 NCT03923218 323 324 B-Eq-Value
mm NCT03923218 325 327 B-Eq-Unit
, NCT03923218 328 329 O

- NCT03923218 333 334 O
Gingival NCT03923218 336 344 B-Observation-Name___Observation-Type-Value:clinical-score
index NCT03923218 345 350 I-Observation-Name___Observation-Type-Value:clinical-score
< NCT03923218 351 352 B-Eq-Operator___Eq-Operator-Value:LT
1 NCT03923218 354 355 B-Eq-Value

- NCT03923218 359 360 O
there NCT03923218 362 367 O
was NCT03923218 368 371 O
no NCT03923218 372 374 O
indication NCT03923218 375 385 O
of NCT03923218 386 388 O
Attachment NCT03923218 389 399 B-Condition-Name
Loss NCT03923218 400 404 I-Condition-Name
or NCT03923218 405 407 O
no NCT03923218 408 410 O
radiographic NCT03923218 411 423 B-Procedure-Name
evidence NCT03923218 424 432 I-Procedure-Name
of NCT03923218 433 435 O
alveolar NCT03923218 436 444 B-Condition-Name
bone NCT03923218 445 449 I-Condition-Name
loss NCT03923218 450 454 I-Condition-Name
in NCT03923218 455 457 O
control NCT03923218 458 465 O
group NCT03923218 466 471 O
. NCT03923218 472 473 O

- NCT03923218 477 478 O
Non NCT03923218 480 483 O
- NCT03923218 484 485 O
smokers NCT03923218 486 493 B-Condition-Name
. NCT03923218 494 495 O

Smoking NCT03923218 497 504 B-Condition-Name
criteria NCT03923218 505 513 O
for NCT03923218 514 517 O
groups NCT03923218 518 524 O
: NCT03923218 525 526 O

- NCT03923218 530 531 O
patients NCT03923218 533 541 O
smoked NCT03923218 542 548 B-Observation-Name___Observation-Type-Value:social-habit
more NCT03923218 549 553 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03923218 554 558 I-Eq-Operator___Eq-Operator-Value:GT
10 NCT03923218 560 562 B-Eq-Value
cigarettes NCT03923218 563 573 B-Eq-Unit
in NCT03923218 574 576 O
a NCT03923218 577 578 O
day NCT03923218 579 582 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day

- NCT03923218 585 586 O
smoking NCT03923218 588 595 B-Condition-Name
for NCT03923218 596 599 O
3 NCT03923218 601 602 B-Eq-Value
or NCT03923218 603 605 B-Eq-Operator___Eq-Operator-Value:GTEQ
more NCT03923218 606 610 I-Eq-Operator___Eq-Operator-Value:GTEQ
years NCT03923218 611 616 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
, NCT03923218 617 618 O

Exclusion NCT03923218 620 629 O
Criteria NCT03923218 630 638 O
: NCT03923218 639 640 O

- NCT03923218 644 645 O
systemic NCT03923218 647 655 O
condition NCT03923218 656 665 O
( NCT03923218 666 667 O
diabetes NCT03923218 668 676 B-Condition-Name
, NCT03923218 677 678 O
cardiovascular NCT03923218 679 693 B-Condition-Name
disease NCT03923218 694 701 I-Condition-Name
, NCT03923218 702 703 O
immunologic NCT03923218 704 715 B-Condition-Name
disorders NCT03923218 716 725 I-Condition-Name
, NCT03923218 726 727 O
hepatitis NCT03923218 728 737 B-Condition-Name
, NCT03923218 738 739 O
e NCT03923218 740 741 O
. NCT03923218 742 743 O
g NCT03923218 744 745 O
. NCT03923218 746 747 O
) NCT03923218 748 749 O

- NCT03923218 753 754 O
pregnancy NCT03923218 756 765 B-Condition-Name
, NCT03923218 766 767 O
lactation NCT03923218 768 777 B-Condition-Name
or NCT03923218 778 780 O
menopause NCT03923218 781 790 B-Condition-Name
term NCT03923218 791 795 O
, NCT03923218 796 797 O

- NCT03923218 801 802 O
antibiotic NCT03923218 804 814 B-Drug-Name
treatment NCT03923218 815 824 O
or NCT03923218 825 827 O
non NCT03923218 828 831 B-Drug-Name
- NCT03923218 832 833 I-Drug-Name
steroidal NCT03923218 834 843 I-Drug-Name
anti NCT03923218 844 848 I-Drug-Name
- NCT03923218 849 850 I-Drug-Name
inflammatory NCT03923218 851 863 I-Drug-Name
medications NCT03923218 864 875 I-Drug-Name
within NCT03923218 876 882 B-Eq-Operator___Eq-Operator-Value:LTEQ
the NCT03923218 883 886 O
last NCT03923218 887 891 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
3 NCT03923218 893 894 B-Eq-Value
months NCT03923218 895 901 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
before NCT03923218 902 908 O
the NCT03923218 909 912 O
study NCT03923218 913 918 O
, NCT03923218 919 920 O

- NCT03923218 924 925 O
non NCT03923218 927 930 O
- NCT03923218 931 932 O
surgical NCT03923218 933 941 O
periodontal NCT03923218 942 953 B-Procedure-Name
treatment NCT03923218 954 963 I-Procedure-Name
during NCT03923218 964 970 O
the NCT03923218 971 974 O
last NCT03923218 975 979 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
6 NCT03923218 981 982 B-Eq-Value
months NCT03923218 983 989 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
before NCT03923218 990 996 O
the NCT03923218 997 1000 O
study NCT03923218 1001 1006 O
, NCT03923218 1007 1008 O

- NCT03923218 1012 1013 O
treatment NCT03923218 1015 1024 O
with NCT03923218 1025 1029 O
Vitamin NCT03923218 1030 1037 B-Drug-Name
D NCT03923218 1038 1039 I-Drug-Name
supplementation NCT03923218 1040 1055 I-Drug-Name
before NCT03923218 1056 1062 O
the NCT03923218 1063 1066 O
study NCT03923218 1067 1072 O

Inclusion NCT03923998 0 9 O
Criteria NCT03923998 10 18 O
: NCT03923998 19 20 O

1 NCT03923998 25 26 O
. NCT03923998 26 27 O
Histologically NCT03923998 29 43 B-Procedure-Name
confirmed NCT03923998 44 53 O
stage NCT03923998 54 59 B-Eq-Unit
IVa NCT03923998 60 63 B-Eq-Value
squamous NCT03923998 64 72 B-Condition-Name
cell NCT03923998 73 77 I-Condition-Name
carcinoma NCT03923998 78 87 I-Condition-Name
of NCT03923998 88 90 O
the NCT03923998 91 94 O
oral NCT03923998 95 99 O
cavity NCT03923998 100 106 O
. NCT03923998 107 108 O

2 NCT03923998 113 114 O
. NCT03923998 114 115 O
Surgically NCT03923998 117 127 O
resectable NCT03923998 128 138 O
oral NCT03923998 139 143 O
squamous NCT03923998 144 152 B-Condition-Name
carcinoma NCT03923998 153 162 I-Condition-Name
with NCT03923998 163 167 O
invasion NCT03923998 168 176 O
of NCT03923998 177 179 O
mandible NCT03923998 180 188 O
or NCT03923998 189 191 O
maxilla NCT03923998 192 199 O
. NCT03923998 200 201 O

3 NCT03923998 206 207 O
. NCT03923998 207 208 O
Newly NCT03923998 210 215 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
diagnosed NCT03923998 216 225 O
or NCT03923998 226 228 O
previously NCT03923998 229 239 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
untreated NCT03923998 240 249 O
squamous NCT03923998 250 258 B-Condition-Name
cell NCT03923998 259 263 I-Condition-Name
carcinoma NCT03923998 264 273 I-Condition-Name
of NCT03923998 274 276 O
the NCT03923998 277 280 O
oral NCT03923998 281 285 O
cavity NCT03923998 286 292 O
. NCT03923998 293 294 O

Exclusion NCT03923998 296 305 O
Criteria NCT03923998 306 314 O
: NCT03923998 315 316 O

1 NCT03923998 321 322 O
. NCT03923998 322 323 O
Patients NCT03923998 325 333 O
with NCT03923998 334 338 O
distant NCT03923998 339 346 B-Condition-Name
metastases NCT03923998 347 357 I-Condition-Name
. NCT03923998 358 359 O

2 NCT03923998 364 365 O
. NCT03923998 365 366 O
Patients NCT03923998 368 376 O
with NCT03923998 377 381 O
contraindication NCT03923998 382 398 O
to NCT03923998 399 401 O
radiotherapy NCT03923998 402 414 B-Procedure-Name
. NCT03923998 415 416 O

3 NCT03923998 421 422 O
. NCT03923998 422 423 O
Patients NCT03923998 425 433 O
with NCT03923998 434 438 O
vascular NCT03923998 439 447 B-Condition-Name
disorders NCT03923998 448 457 I-Condition-Name
or NCT03923998 458 460 O
ischemic NCT03923998 461 469 B-Condition-Name
heart NCT03923998 470 475 I-Condition-Name
disease NCT03923998 476 483 I-Condition-Name
. NCT03923998 484 485 O
- NCT03923998 487 488 O

Inclusion NCT03921619 0 9 O
Criteria NCT03921619 10 18 O
: NCT03921619 19 20 O

- NCT03921619 24 25 O
Greater NCT03921619 27 34 B-Eq-Operator___Eq-Operator-Value:GTEQ
than NCT03921619 35 39 I-Eq-Operator___Eq-Operator-Value:GTEQ
or NCT03921619 40 42 I-Eq-Operator___Eq-Operator-Value:GTEQ
equal NCT03921619 43 48 I-Eq-Operator___Eq-Operator-Value:GTEQ
to NCT03921619 49 51 O
65 NCT03921619 53 55 B-Eq-Value
years NCT03921619 56 61 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03921619 62 64 O
age NCT03921619 65 68 O

Exclusion NCT03921619 69 78 O
Criteria NCT03921619 79 87 O
: NCT03921619 88 89 O

- NCT03921619 93 94 O
Younger NCT03921619 96 103 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03921619 104 108 I-Eq-Operator___Eq-Operator-Value:LT
65 NCT03921619 110 112 B-Eq-Value
years NCT03921619 113 118 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03921619 119 121 O
age NCT03921619 122 125 O

- NCT03921619 128 129 O
Pre NCT03921619 131 134 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
- NCT03921619 135 136 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
existing NCT03921619 137 145 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
cognitive NCT03921619 146 155 B-Condition-Name
impairment NCT03921619 156 166 I-Condition-Name

- NCT03921619 169 170 O
Pre NCT03921619 172 175 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
- NCT03921619 176 177 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
existing NCT03921619 178 186 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
mobility NCT03921619 187 195 B-Condition-Name
impairment NCT03921619 196 206 I-Condition-Name

- NCT03921619 209 210 O
Pre NCT03921619 212 215 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
- NCT03921619 216 217 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
existing NCT03921619 218 226 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
symptomatic NCT03921619 227 238 O
upper NCT03921619 239 244 O
or NCT03921619 245 247 O
lower NCT03921619 248 253 O
extremity NCT03921619 254 263 O
disease NCT03921619 264 271 B-Condition-Name

Inclusion NCT03929523 0 9 O
Criteria NCT03929523 10 18 O
: NCT03929523 19 20 O

- NCT03929523 24 25 O
Provide NCT03929523 27 34 O
written NCT03929523 35 42 O
informed NCT03929523 43 51 O
consent NCT03929523 52 59 O
prior NCT03929523 60 65 O
to NCT03929523 66 68 O
the NCT03929523 69 72 O
performance NCT03929523 73 84 O
of NCT03929523 85 87 O
any NCT03929523 88 91 O
study NCT03929523 92 97 O
specific NCT03929523 98 106 O
procedure NCT03929523 107 116 O

- NCT03929523 119 120 O
Affiliated NCT03929523 122 132 O
to NCT03929523 133 135 O
the NCT03929523 136 139 O
French NCT03929523 140 146 O
social NCT03929523 147 153 O
security NCT03929523 154 162 O
system NCT03929523 163 169 O

- NCT03929523 172 173 O
Recipient NCT03929523 175 184 O
age NCT03929523 185 188 O
≥ NCT03929523 189 190 B-Eq-Operator___Eq-Operator-Value:GTEQ
18 NCT03929523 192 194 B-Eq-Value
years NCT03929523 195 200 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03929523 203 204 O
Patients NCT03929523 206 214 O
undergoing NCT03929523 215 225 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
primary NCT03929523 226 233 O
liver NCT03929523 234 239 B-Procedure-Name
transplantation NCT03929523 240 255 I-Procedure-Name
. NCT03929523 256 257 O

- NCT03929523 261 262 O
Candidate NCT03929523 264 273 O
for NCT03929523 274 277 O
a NCT03929523 278 279 O
first NCT03929523 280 285 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
elective NCT03929523 286 294 O
liver NCT03929523 295 300 B-Procedure-Name
transplantation NCT03929523 301 316 I-Procedure-Name
, NCT03929523 317 318 O
whatever NCT03929523 319 327 O
the NCT03929523 328 331 O
indication NCT03929523 332 342 O
, NCT03929523 343 344 O
with NCT03929523 345 349 O
a NCT03929523 350 351 O
liver NCT03929523 352 357 B-Procedure-Name
graft NCT03929523 358 363 I-Procedure-Name
harvested NCT03929523 364 373 O
from NCT03929523 374 378 O
a NCT03929523 379 380 O
brain NCT03929523 381 386 B-Procedure-Name
- NCT03929523 387 388 I-Procedure-Name
dead NCT03929523 389 393 I-Procedure-Name
ECD NCT03929523 394 397 I-Procedure-Name
defined NCT03929523 398 405 O
by NCT03929523 406 408 O
the NCT03929523 409 412 O
presence NCT03929523 413 421 O
of NCT03929523 422 424 O
at NCT03929523 425 427 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03929523 428 433 I-Eq-Operator___Eq-Operator-Value:GTEQ
one NCT03929523 434 437 B-Eq-Value
of NCT03929523 438 440 O
the NCT03929523 441 444 O
following NCT03929523 445 454 O
criteria NCT03929523 455 463 O
: NCT03929523 464 465 O

- NCT03929523 474 475 O
Donor NCT03929523 477 482 O
age NCT03929523 483 486 O
> NCT03929523 487 488 B-Eq-Operator___Eq-Operator-Value:GT
65 NCT03929523 490 492 B-Eq-Value
years NCT03929523 493 498 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03929523 506 507 O
Intensive NCT03929523 509 518 B-Encounter-Type___Encounter-Type-Value:icu
care NCT03929523 519 523 I-Encounter-Type___Encounter-Type-Value:icu
unit NCT03929523 524 528 I-Encounter-Type___Encounter-Type-Value:icu
stay NCT03929523 529 533 O
> NCT03929523 534 535 B-Eq-Operator___Eq-Operator-Value:GT
7 NCT03929523 537 538 B-Eq-Value
days NCT03929523 539 543 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day

- NCT03929523 551 552 O
BMI NCT03929523 554 557 B-Observation-Name___Observation-Type-Value:vital
> NCT03929523 558 559 B-Eq-Operator___Eq-Operator-Value:GT
30 NCT03929523 561 563 B-Eq-Value

- NCT03929523 572 573 O
Proven NCT03929523 575 581 O
macro NCT03929523 582 587 B-Observation-Name
- NCT03929523 588 589 I-Observation-Name
steatosis NCT03929523 590 599 I-Observation-Name
biopsy NCT03929523 600 606 B-Procedure-Name
≥ NCT03929523 607 608 B-Eq-Operator___Eq-Operator-Value:GTEQ
30 NCT03929523 610 612 B-Eq-Value
% NCT03929523 613 614 B-Eq-Unit

- NCT03929523 623 624 O
Natremia NCT03929523 626 634 B-Observation-Name___Observation-Type-Value:lab
> NCT03929523 635 636 B-Eq-Operator___Eq-Operator-Value:GT
155 NCT03929523 638 641 B-Eq-Value
mmol NCT03929523 642 646 B-Eq-Unit
/ NCT03929523 647 648 O
L NCT03929523 649 650 B-Eq-Unit
at NCT03929523 651 653 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:anytime
any NCT03929523 654 657 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:anytime
time NCT03929523 658 662 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:anytime

- NCT03929523 670 671 O
AST NCT03929523 673 676 B-Observation-Name___Observation-Type-Value:lab
> NCT03929523 677 678 B-Eq-Operator___Eq-Operator-Value:GT
150 NCT03929523 680 683 B-Eq-Value
IU NCT03929523 684 686 B-Eq-Unit
/ NCT03929523 687 688 O
mL NCT03929523 689 691 B-Eq-Unit
at NCT03929523 692 694 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:anytime
any NCT03929523 695 698 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:anytime
time NCT03929523 699 703 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:anytime

- NCT03929523 711 712 O
ALT NCT03929523 714 717 B-Observation-Name___Observation-Type-Value:lab
> NCT03929523 718 719 B-Eq-Operator___Eq-Operator-Value:GT
170 NCT03929523 721 724 B-Eq-Value
IU NCT03929523 725 727 B-Eq-Unit
/ NCT03929523 728 729 O
mL NCT03929523 730 732 B-Eq-Unit
at NCT03929523 733 735 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
any NCT03929523 736 739 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
time NCT03929523 740 744 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
. NCT03929523 745 746 O

Exclusion NCT03929523 748 757 O
Criteria NCT03929523 758 766 O
: NCT03929523 767 768 O

- NCT03929523 772 773 O
Fulminant NCT03929523 775 784 B-Condition-Name
hepatic NCT03929523 785 792 I-Condition-Name
failure NCT03929523 793 800 I-Condition-Name

- NCT03929523 803 804 O
Retransplantation NCT03929523 806 823 B-Procedure-Name

- NCT03929523 826 827 O
Split NCT03929523 829 834 O
liver NCT03929523 835 840 B-Procedure-Name
transplantation NCT03929523 841 856 I-Procedure-Name

- NCT03929523 859 860 O
Living NCT03929523 862 868 O
donor NCT03929523 869 874 O
liver NCT03929523 875 880 B-Procedure-Name
transplantation NCT03929523 881 896 I-Procedure-Name

- NCT03929523 899 900 O
Grafts NCT03929523 902 908 B-Observation-Name
donated NCT03929523 909 916 I-Observation-Name
after NCT03929523 917 922 O
cardiac NCT03929523 923 930 B-Condition-Name
arrest NCT03929523 931 937 I-Condition-Name
( NCT03929523 938 939 O
DCD NCT03929523 940 943 B-Observation-Name
grafts NCT03929523 944 950 I-Observation-Name
) NCT03929523 951 952 O

- NCT03929523 956 957 O
Domino NCT03929523 959 965 O
transplantation NCT03929523 966 981 B-Procedure-Name

- NCT03929523 984 985 O
Combined NCT03929523 987 995 O
liver NCT03929523 996 1001 B-Procedure-Name
transplant NCT03929523 1002 1012 I-Procedure-Name

- NCT03929523 1015 1016 O
Unexpected NCT03929523 1018 1028 O
medical NCT03929523 1029 1036 O
contraindication NCT03929523 1037 1053 O
to NCT03929523 1054 1056 O
liver NCT03929523 1057 1062 B-Procedure-Name
transplantation NCT03929523 1063 1078 I-Procedure-Name

- NCT03929523 1081 1082 O
Patient NCT03929523 1084 1091 O
participating NCT03929523 1092 1105 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
in NCT03929523 1106 1108 O
other NCT03929523 1109 1114 O
interventional NCT03929523 1115 1129 O
research NCT03929523 1130 1138 O
, NCT03929523 1139 1140 O
excluding NCT03929523 1141 1150 O
routine NCT03929523 1151 1158 O
care NCT03929523 1159 1163 O
research NCT03929523 1164 1172 O
( NCT03929523 1173 1174 O
old NCT03929523 1175 1178 O
regulation NCT03929523 1179 1189 O
) NCT03929523 1190 1191 O
and NCT03929523 1192 1195 O
category NCT03929523 1196 1204 O
2 NCT03929523 1206 1207 O
research NCT03929523 1208 1216 O
not NCT03929523 1217 1220 O
interfering NCT03929523 1221 1232 B-Stability___Stability-Value:change
with NCT03929523 1233 1237 O
primary NCT03929523 1238 1245 O
endpoint NCT03929523 1246 1254 O
analysis NCT03929523 1255 1263 O

- NCT03929523 1266 1267 O
Patient NCT03929523 1269 1276 O
under NCT03929523 1277 1282 O
legal NCT03929523 1283 1288 B-Observation-Name
protection NCT03929523 1289 1299 I-Observation-Name

- NCT03929523 1302 1303 O
Patient NCT03929523 1305 1312 O
deprived NCT03929523 1313 1321 B-Observation-Name
of NCT03929523 1322 1324 I-Observation-Name
liberty NCT03929523 1325 1332 I-Observation-Name
by NCT03929523 1333 1335 O
a NCT03929523 1336 1337 O
judicial NCT03929523 1338 1346 O
or NCT03929523 1347 1349 O
administrative NCT03929523 1350 1364 O
decision NCT03929523 1365 1373 O

- NCT03929523 1376 1377 O
Patient NCT03929523 1379 1386 O
refusing NCT03929523 1387 1395 O
to NCT03929523 1396 1398 O
participate NCT03929523 1399 1410 O
in NCT03929523 1411 1413 O
the NCT03929523 1414 1417 O
study NCT03929523 1418 1423 O

- NCT03929523 1426 1427 O
Pregnant NCT03929523 1429 1437 B-Condition-Name
or NCT03929523 1438 1440 O
lactating NCT03929523 1441 1450 B-Condition-Name
women NCT03929523 1451 1456 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female

- NCT03929523 1459 1460 O
Inability NCT03929523 1462 1471 B-Condition-Name
to NCT03929523 1472 1474 I-Condition-Name
understand NCT03929523 1475 1485 I-Condition-Name
information NCT03929523 1486 1497 O
concerning NCT03929523 1498 1508 O
the NCT03929523 1509 1512 O
protocol NCT03929523 1513 1521 O

Inclusion NCT03922516 0 9 O
Criteria NCT03922516 10 18 O
: NCT03922516 19 20 O

- NCT03922516 24 25 O
all NCT03922516 27 30 O
patients NCT03922516 31 39 O
who NCT03922516 40 43 O
are NCT03922516 44 47 O
assigned NCT03922516 48 56 O
to NCT03922516 57 59 O
a NCT03922516 60 61 O
clinically NCT03922516 62 72 O
indicated NCT03922516 73 82 O
chest NCT03922516 83 88 O
X NCT03922516 89 90 B-Procedure-Name
- NCT03922516 91 92 I-Procedure-Name
ray NCT03922516 93 96 I-Procedure-Name
by NCT03922516 97 99 O
the NCT03922516 100 103 O
emergency NCT03922516 104 113 B-Location___Location-Value:unit
department NCT03922516 114 124 I-Location___Location-Value:unit
of NCT03922516 125 127 O
Vienna NCT03922516 128 134 B-Location___Location-Value:hospital
General NCT03922516 135 142 I-Location___Location-Value:hospital
Hospital NCT03922516 143 151 I-Location___Location-Value:hospital

- NCT03922516 154 155 O
ability NCT03922516 157 164 O
to NCT03922516 165 167 O
provide NCT03922516 168 175 O
informed NCT03922516 176 184 O
consent NCT03922516 185 192 O

- NCT03922516 195 196 O
informed NCT03922516 198 206 O
consent NCT03922516 207 214 O
after NCT03922516 215 220 O
detailed NCT03922516 221 229 O
patient NCT03922516 230 237 O
briefing NCT03922516 238 246 O

Exclusion NCT03922516 247 256 O
Criteria NCT03922516 257 265 O
: NCT03922516 266 267 O

- NCT03922516 271 272 O
the NCT03922516 274 277 O
emergency NCT03922516 278 287 B-Location___Location-Value:unit
departments NCT03922516 288 299 I-Location___Location-Value:unit
assessment NCT03922516 300 310 B-Procedure-Name
of NCT03922516 311 313 O
a NCT03922516 314 315 O
critical NCT03922516 316 324 B-Severity___Severity-Value:severe
clinical NCT03922516 325 333 O
condition NCT03922516 334 343 O
oppose NCT03922516 344 350 O
an NCT03922516 351 353 O
examination NCT03922516 354 365 B-Procedure-Name
with NCT03922516 366 370 O
both NCT03922516 371 375 O
modalities NCT03922516 376 386 O
( NCT03922516 387 388 O
ULDCT NCT03922516 389 394 B-Procedure-Name
of NCT03922516 395 397 O
the NCT03922516 398 401 O
chest NCT03922516 402 407 O
, NCT03922516 408 409 O
chest NCT03922516 410 415 O
X NCT03922516 416 417 B-Procedure-Name
- NCT03922516 418 419 I-Procedure-Name
ray NCT03922516 420 423 I-Procedure-Name
) NCT03922516 424 425 O

- NCT03922516 429 430 O
assigned NCT03922516 432 440 O
to NCT03922516 441 443 O
chest NCT03922516 444 449 O
X NCT03922516 450 451 B-Procedure-Name
- NCT03922516 452 453 I-Procedure-Name
ray NCT03922516 454 457 I-Procedure-Name
as NCT03922516 458 460 O
follow NCT03922516 461 467 O
- NCT03922516 468 469 O
up NCT03922516 470 472 O

- NCT03922516 475 476 O
women NCT03922516 478 483 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
with NCT03922516 484 488 O
positive NCT03922516 489 497 B-Polarity___Polarity-Value:positive
ß NCT03922516 498 499 B-Observation-Name___Observation-Type-Value:lab
- NCT03922516 500 501 I-Observation-Name___Observation-Type-Value:lab
HCG NCT03922516 502 505 I-Observation-Name___Observation-Type-Value:lab
- NCT03922516 506 507 I-Observation-Name___Observation-Type-Value:lab
test NCT03922516 508 512 I-Observation-Name___Observation-Type-Value:lab

Inclusion NCT03923608 0 9 O
Criteria NCT03923608 10 18 O
: NCT03923608 19 20 O
should NCT03923608 21 27 O
report NCT03923608 28 34 O
the NCT03923608 35 38 O
absence NCT03923608 39 46 O
of NCT03923608 47 49 O
: NCT03923608 50 51 O

- NCT03923608 55 56 O
anemia NCT03923608 58 64 B-Condition-Name
, NCT03923608 65 66 O

- NCT03923608 70 71 O
diabetes NCT03923608 73 81 B-Condition-Name
, NCT03923608 82 83 O

- NCT03923608 87 88 O
cardiovascular NCT03923608 90 104 B-Condition-Name
disease NCT03923608 105 112 I-Condition-Name
, NCT03923608 113 114 O

- NCT03923608 118 119 O
and NCT03923608 121 124 O
upper NCT03923608 125 130 O
limb NCT03923608 131 135 O
and NCT03923608 136 139 O
spinal NCT03923608 140 146 O
muscular NCT03923608 147 155 O
injuries NCT03923608 156 164 B-Condition-Name
in NCT03923608 165 167 O
the NCT03923608 168 171 O
last NCT03923608 172 176 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
six NCT03923608 177 180 B-Eq-Value
months NCT03923608 181 187 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

Exclusion NCT03923608 188 197 O
Criteria NCT03923608 198 206 O
: NCT03923608 207 208 O

- NCT03923608 212 213 O
absence NCT03923608 215 222 O
at NCT03923608 223 225 O
any NCT03923608 226 229 O
study NCT03923608 230 235 O
session NCT03923608 236 243 O
and NCT03923608 244 247 O

- NCT03923608 250 251 O
episode NCT03923608 253 260 O
of NCT03923608 261 263 O
muscle NCT03923608 264 270 O
- NCT03923608 271 272 O
tendon NCT03923608 273 279 O
or NCT03923608 280 282 O
osteoarticular NCT03923608 283 297 O
injury NCT03923608 298 304 B-Condition-Name
in NCT03923608 305 307 O
the NCT03923608 308 311 O
upper NCT03923608 312 317 O
limbs NCT03923608 318 323 O
during NCT03923608 324 330 O
the NCT03923608 331 334 O
study NCT03923608 335 340 O
. NCT03923608 341 342 O

Inclusion NCT03924167 0 9 O
Criteria NCT03924167 10 18 O
: NCT03924167 19 20 O

Inclusion NCT03924167 22 31 O
Criteria NCT03924167 32 40 O
for NCT03924167 41 44 O
community NCT03924167 45 54 O
health NCT03924167 55 61 O
representatives NCT03924167 62 77 O
( NCT03924167 78 79 O
CHR NCT03924167 80 83 B-Condition-Name
) NCT03924167 84 85 O
s NCT03924167 86 87 O
. NCT03924167 88 89 O
> NCT03924167 91 92 O
> NCT03924167 94 95 B-Eq-Operator___Eq-Operator-Value:GT
18 NCT03924167 97 99 B-Eq-Value
years NCT03924167 100 105 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03924167 106 108 O
age NCT03924167 109 112 O
or NCT03924167 113 115 O
older NCT03924167 116 121 O

- NCT03924167 124 125 O
have NCT03924167 127 131 O
at NCT03924167 132 134 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03924167 135 140 I-Eq-Operator___Eq-Operator-Value:GTEQ
a NCT03924167 141 142 O
high NCT03924167 143 147 B-Observation-Name
school NCT03924167 148 154 I-Observation-Name
degree NCT03924167 155 161 I-Observation-Name

- NCT03924167 164 165 O
have NCT03924167 167 171 O
experience NCT03924167 172 182 O
and NCT03924167 183 186 O
/ NCT03924167 187 188 O
or NCT03924167 189 191 O
interest NCT03924167 192 200 O
in NCT03924167 201 203 O
working NCT03924167 204 211 O
with NCT03924167 212 216 O
tribal NCT03924167 217 223 O
children NCT03924167 224 232 O
and NCT03924167 233 236 O
families NCT03924167 237 245 O
. NCT03924167 246 247 O

Exclusion NCT03924167 249 258 O
criteria NCT03924167 259 267 O
: NCT03924167 268 269 O

- NCT03924167 273 274 O
having NCT03924167 276 282 O
less NCT03924167 283 287 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03924167 288 292 I-Eq-Operator___Eq-Operator-Value:LT
a NCT03924167 293 294 O
high NCT03924167 295 299 B-Observation-Name
school NCT03924167 300 306 I-Observation-Name
degree NCT03924167 307 313 I-Observation-Name

- NCT03924167 316 317 O
not NCT03924167 319 322 O
having NCT03924167 323 329 O
experience NCT03924167 330 340 O
with NCT03924167 341 345 O
tribal NCT03924167 346 352 O
families NCT03924167 353 361 O

Inclusion NCT03924167 362 371 O
criteria NCT03924167 372 380 O
for NCT03924167 381 384 O
families NCT03924167 385 393 O

- NCT03924167 396 397 O
includes NCT03924167 399 407 O
written NCT03924167 408 415 O
consent NCT03924167 416 423 O
for NCT03924167 424 427 O
adults NCT03924167 428 434 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
and NCT03924167 435 438 O
assent NCT03924167 439 445 O
for NCT03924167 446 449 O
children NCT03924167 450 458 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
ages NCT03924167 459 463 O
12 NCT03924167 465 467 B-Eq-Value
- NCT03924167 468 469 B-Eq-Operator___Eq-Operator-Value:BETWEEN
17 NCT03924167 471 473 B-Eq-Value
. NCT03924167 473 474 O

- NCT03924167 478 479 O
at NCT03924167 481 483 O
least NCT03924167 484 489 O
one NCT03924167 490 493 O
parent NCT03924167 494 500 O
/ NCT03924167 501 502 O
caregiver NCT03924167 503 512 O
who NCT03924167 513 516 O
is NCT03924167 517 519 O
a NCT03924167 520 521 O
member NCT03924167 522 528 O
of NCT03924167 529 531 O
the NCT03924167 532 535 O
focal NCT03924167 536 541 O
tribe NCT03924167 542 547 O
and NCT03924167 548 551 O
at NCT03924167 552 554 O
least NCT03924167 555 560 O
one NCT03924167 561 564 O
child NCT03924167 565 570 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
, NCT03924167 571 572 O
aged NCT03924167 573 577 O
12 NCT03924167 579 581 B-Eq-Value
- NCT03924167 582 583 B-Eq-Operator___Eq-Operator-Value:BETWEEN
18 NCT03924167 585 587 B-Eq-Value
living NCT03924167 588 594 O
in NCT03924167 595 597 O
the NCT03924167 598 601 O
household NCT03924167 602 611 O

Exclusion NCT03924167 612 621 O
Criteria NCT03924167 622 630 O
: NCT03924167 631 632 O

- NCT03924167 636 637 O
current NCT03924167 639 646 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
protective NCT03924167 647 657 B-Observation-Name
order NCT03924167 658 663 I-Observation-Name

- NCT03924167 666 667 O
current NCT03924167 669 676 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
intimate NCT03924167 677 685 B-Condition-Name
partner NCT03924167 686 693 I-Condition-Name
violence NCT03924167 694 702 I-Condition-Name
( NCT03924167 703 704 O
IPV NCT03924167 705 708 B-Condition-Name
) NCT03924167 709 710 O
record NCT03924167 711 717 O
will NCT03924167 718 722 O
be NCT03924167 723 725 O
excluded NCT03924167 726 734 O
. NCT03924167 735 736 O

Inclusion NCT03926572 0 9 O
Criteria NCT03926572 10 18 O
: NCT03926572 19 20 O

- NCT03926572 24 25 O
Adult NCT03926572 27 32 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
patients NCT03926572 33 41 O
over NCT03926572 42 46 B-Eq-Operator___Eq-Operator-Value:GT
18 NCT03926572 48 50 B-Eq-Value
years NCT03926572 51 56 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03926572 59 60 O
Diagnosis NCT03926572 62 71 O
of NCT03926572 72 74 O
Pulmonary NCT03926572 75 84 B-Condition-Name
arterial NCT03926572 85 93 I-Condition-Name
hypertension NCT03926572 94 106 I-Condition-Name
or NCT03926572 107 109 O
non NCT03926572 110 113 O
- NCT03926572 114 115 O
operable NCT03926572 116 124 O
chronic NCT03926572 125 132 O
thromboembolic NCT03926572 133 147 B-Condition-Name
pulmonary NCT03926572 148 157 I-Condition-Name
hypertension NCT03926572 158 170 I-Condition-Name
established NCT03926572 171 182 O
by NCT03926572 183 185 O
right NCT03926572 186 191 B-Procedure-Name
cardiac NCT03926572 192 199 I-Procedure-Name
catheterization NCT03926572 200 215 I-Procedure-Name
prior NCT03926572 216 221 O
to NCT03926572 222 224 O
inclusion NCT03926572 225 234 O
in NCT03926572 235 237 O
the NCT03926572 238 241 O
study NCT03926572 242 247 O

- NCT03926572 250 251 O
Patients NCT03926572 253 261 O
admitted NCT03926572 262 270 B-Encounter-Type___Encounter-Type-Value:icu
in NCT03926572 271 273 I-Encounter-Type___Encounter-Type-Value:icu
intensive NCT03926572 274 283 I-Encounter-Type___Encounter-Type-Value:icu
care NCT03926572 284 288 I-Encounter-Type___Encounter-Type-Value:icu
unit NCT03926572 289 293 I-Encounter-Type___Encounter-Type-Value:icu
for NCT03926572 294 297 O
acute NCT03926572 298 303 B-Severity___Severity-Value:severe
decompensation NCT03926572 304 318 O
of NCT03926572 319 321 O
pulmonary NCT03926572 322 331 B-Condition-Name
hypertension NCT03926572 332 344 I-Condition-Name
requiring NCT03926572 345 354 O
intravenous NCT03926572 355 366 O
diuretic NCT03926572 367 375 B-Procedure-Name
therapy NCT03926572 376 383 I-Procedure-Name
± NCT03926572 384 385 O
use NCT03926572 386 389 O
of NCT03926572 390 392 O
inotropes NCT03926572 393 402 B-Drug-Name
or NCT03926572 403 405 O
vasopressors NCT03926572 406 418 B-Drug-Name
. NCT03926572 419 420 O

- NCT03926572 424 425 O
Patients NCT03926572 427 435 O
must NCT03926572 436 440 O
have NCT03926572 441 445 O
given NCT03926572 446 451 O
their NCT03926572 452 457 O
written NCT03926572 458 465 O
informed NCT03926572 466 474 O
consent NCT03926572 475 482 O
to NCT03926572 483 485 O
participate NCT03926572 486 497 O
in NCT03926572 498 500 O
the NCT03926572 501 504 O
study NCT03926572 505 510 O
after NCT03926572 511 516 O
having NCT03926572 517 523 O
received NCT03926572 524 532 O
adequate NCT03926572 533 541 O
previous NCT03926572 542 550 O
information NCT03926572 551 562 O
and NCT03926572 563 566 O
prior NCT03926572 567 572 O
to NCT03926572 573 575 O
any NCT03926572 576 579 O
study NCT03926572 580 585 O
- NCT03926572 586 587 O
specific NCT03926572 588 596 O
procedures NCT03926572 597 607 O

Exclusion NCT03926572 608 617 O
Criteria NCT03926572 618 626 O
: NCT03926572 627 628 O

- NCT03926572 632 633 O
Patients NCT03926572 635 643 O
with NCT03926572 644 648 O
post NCT03926572 649 653 O
- NCT03926572 654 655 O
capillary NCT03926572 656 665 O
pulmonary NCT03926572 666 675 B-Condition-Name
hypertension NCT03926572 676 688 I-Condition-Name

- NCT03926572 691 692 O
Patients NCT03926572 694 702 O
with NCT03926572 703 707 O
pulmonary NCT03926572 708 717 B-Condition-Name
hypertension NCT03926572 718 730 I-Condition-Name
associated NCT03926572 731 741 O
with NCT03926572 742 746 O
chronic NCT03926572 747 754 O
respiratory NCT03926572 755 766 B-Condition-Name
disease NCT03926572 767 774 I-Condition-Name

- NCT03926572 777 778 O
Patients NCT03926572 780 788 O
with NCT03926572 789 793 O
pulmonary NCT03926572 794 803 B-Condition-Name
hypertension NCT03926572 804 816 I-Condition-Name
with NCT03926572 817 821 O
unclear NCT03926572 822 829 O
/ NCT03926572 830 831 O
or NCT03926572 832 834 O
multifactorial NCT03926572 835 849 O
mechanisms NCT03926572 850 860 O

- NCT03926572 863 864 O
Patients NCT03926572 866 874 O
with NCT03926572 875 879 O
operable NCT03926572 880 888 O
chronic NCT03926572 889 896 O
thromboembolic NCT03926572 897 911 O
pulmonary NCT03926572 912 921 B-Condition-Name
hypertension NCT03926572 922 934 I-Condition-Name

- NCT03926572 937 938 O
Shock NCT03926572 940 945 B-Condition-Name
due NCT03926572 946 949 O
to NCT03926572 950 952 O
another NCT03926572 953 960 O
cause NCT03926572 961 966 O
than NCT03926572 967 971 O
acute NCT03926572 972 977 B-Severity___Severity-Value:severe
decompensation NCT03926572 978 992 O
of NCT03926572 993 995 O
pulmonary NCT03926572 996 1005 B-Condition-Name
hypertension NCT03926572 1006 1018 I-Condition-Name

- NCT03926572 1021 1022 O
Pregnant NCT03926572 1024 1032 B-Condition-Name
women NCT03926572 1033 1038 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
, NCT03926572 1039 1040 O
or NCT03926572 1041 1043 O
breast NCT03926572 1044 1050 B-Condition-Name
feeding NCT03926572 1051 1058 I-Condition-Name
women NCT03926572 1059 1064 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female

- NCT03926572 1067 1068 O
Adult NCT03926572 1070 1075 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
protected NCT03926572 1076 1085 B-Observation-Name
person NCT03926572 1086 1092 I-Observation-Name

- NCT03926572 1095 1096 O
Person NCT03926572 1098 1104 O
deprived NCT03926572 1105 1113 B-Observation-Name
of NCT03926572 1114 1116 I-Observation-Name
liberty NCT03926572 1117 1124 I-Observation-Name

- NCT03926572 1127 1128 O
Person NCT03926572 1130 1136 O
admitted NCT03926572 1137 1145 O
without NCT03926572 1146 1153 O
consent NCT03926572 1154 1161 O

- NCT03926572 1164 1165 O
Pregnant NCT03926572 1167 1175 B-Condition-Name
or NCT03926572 1176 1178 O
breastfeeding NCT03926572 1179 1192 B-Condition-Name
women NCT03926572 1193 1198 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female

Inclusion NCT03926273 0 9 O
Criteria NCT03926273 10 18 O
: NCT03926273 19 20 O

- NCT03926273 24 25 O
All NCT03926273 27 30 O
participants NCT03926273 31 43 O
were NCT03926273 44 48 O
included NCT03926273 49 57 O
if NCT03926273 58 60 O
their NCT03926273 61 66 O
age NCT03926273 67 70 O
more NCT03926273 71 75 B-Eq-Operator___Eq-Operator-Value:GTEQ
than NCT03926273 76 80 I-Eq-Operator___Eq-Operator-Value:GTEQ
or NCT03926273 81 83 I-Eq-Operator___Eq-Operator-Value:GTEQ
equal NCT03926273 84 89 I-Eq-Operator___Eq-Operator-Value:GTEQ
to NCT03926273 90 92 O
18 NCT03926273 94 96 B-Eq-Value
years NCT03926273 97 102 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
. NCT03926273 103 104 O
Body NCT03926273 106 110 B-Observation-Name___Observation-Type-Value:vital
mass NCT03926273 111 115 I-Observation-Name___Observation-Type-Value:vital
index NCT03926273 116 121 I-Observation-Name___Observation-Type-Value:vital
< NCT03926273 122 123 B-Eq-Operator___Eq-Operator-Value:LT
30 NCT03926273 125 127 B-Eq-Value
kg NCT03926273 128 130 B-Eq-Unit
/ NCT03926273 131 132 O
m NCT03926273 133 134 B-Eq-Unit
2 NCT03926273 135 136 I-Eq-Unit
, NCT03926273 137 138 O
total NCT03926273 139 144 B-Observation-Name___Observation-Type-Value:lab
cholesterol NCT03926273 145 156 I-Observation-Name___Observation-Type-Value:lab
< NCT03926273 157 158 B-Eq-Operator___Eq-Operator-Value:LT
200 NCT03926273 160 163 B-Eq-Value
mg NCT03926273 164 166 B-Eq-Unit
/ NCT03926273 167 168 O
dl NCT03926273 169 171 B-Eq-Unit
, NCT03926273 172 173 O
serum NCT03926273 174 179 B-Observation-Name___Observation-Type-Value:lab
triglycerides NCT03926273 180 193 I-Observation-Name___Observation-Type-Value:lab
< NCT03926273 194 195 B-Eq-Operator___Eq-Operator-Value:LT
200 NCT03926273 197 200 B-Eq-Value
mg NCT03926273 201 203 B-Eq-Unit
/ NCT03926273 204 205 O
dl NCT03926273 206 208 B-Eq-Unit
and NCT03926273 209 212 O
random NCT03926273 213 219 O
blood NCT03926273 220 225 B-Observation-Name___Observation-Type-Value:lab
glucose NCT03926273 226 233 I-Observation-Name___Observation-Type-Value:lab
level NCT03926273 234 239 I-Observation-Name___Observation-Type-Value:lab
< NCT03926273 240 241 B-Eq-Operator___Eq-Operator-Value:LT
126 NCT03926273 243 246 B-Eq-Value
mg NCT03926273 247 249 B-Eq-Unit
/ NCT03926273 250 251 O
dl NCT03926273 252 254 B-Eq-Unit
. NCT03926273 255 256 O

Exclusion NCT03926273 258 267 O
Criteria NCT03926273 268 276 O
: NCT03926273 277 278 O

- NCT03926273 282 283 O
Participants NCT03926273 285 297 O
had NCT03926273 298 301 O
acute NCT03926273 302 307 B-Severity___Severity-Value:severe
or NCT03926273 308 310 O
chronic NCT03926273 311 318 O
metabolic NCT03926273 319 328 B-Condition-Name
disorders NCT03926273 329 338 I-Condition-Name
( NCT03926273 339 340 O
liver NCT03926273 341 346 O
, NCT03926273 347 348 O
kidney NCT03926273 349 355 O
, NCT03926273 356 357 O
thyroid NCT03926273 358 365 O
, NCT03926273 366 367 O
endocrine NCT03926273 368 377 O
or NCT03926273 378 380 O
gastrointestinal NCT03926273 381 397 O
disorders NCT03926273 398 407 B-Condition-Name
) NCT03926273 408 409 O
. NCT03926273 411 412 O

- NCT03926273 416 417 O
Females NCT03926273 419 426 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
with NCT03926273 427 431 O
irregular NCT03926273 432 441 B-Condition-Name
menstrual NCT03926273 442 451 I-Condition-Name
cycle NCT03926273 452 457 I-Condition-Name
or NCT03926273 458 460 O
on NCT03926273 461 463 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
estrogen NCT03926273 464 472 B-Procedure-Name
therapy NCT03926273 473 480 I-Procedure-Name
( NCT03926273 481 482 O
7 NCT03926273 484 485 O
) NCT03926273 486 487 O
. NCT03926273 489 490 O

- NCT03926273 494 495 O
Participants NCT03926273 497 509 O
with NCT03926273 510 514 O
organic NCT03926273 515 522 O
cerebral NCT03926273 523 531 B-Condition-Name
lesion NCT03926273 532 538 I-Condition-Name
that NCT03926273 539 543 O
was NCT03926273 544 547 O
detected NCT03926273 548 556 O
on NCT03926273 557 559 O
cranial NCT03926273 560 567 O
computed NCT03926273 568 576 B-Procedure-Name
tomography NCT03926273 577 587 I-Procedure-Name
( NCT03926273 588 589 O
CT NCT03926273 590 592 B-Procedure-Name
) NCT03926273 593 594 O
or NCT03926273 595 597 O
cranial NCT03926273 598 605 O
magnetic NCT03926273 606 614 B-Procedure-Name
resonance NCT03926273 615 624 I-Procedure-Name
imaging NCT03926273 625 632 I-Procedure-Name
( NCT03926273 633 634 O
MRI NCT03926273 635 638 B-Procedure-Name
) NCT03926273 639 640 O
. NCT03926273 642 643 O

Inclusion NCT03925961 0 9 O
Criteria NCT03925961 10 18 O
: NCT03925961 19 20 O

- NCT03925961 24 25 O
General NCT03925961 27 34 O
surgical NCT03925961 35 43 O
patients NCT03925961 44 52 O
who NCT03925961 53 56 O
will NCT03925961 57 61 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
undergo NCT03925961 62 69 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
same NCT03925961 70 74 O
- NCT03925961 75 76 O
day NCT03925961 77 80 O
laparoscopic NCT03925961 81 93 B-Procedure-Name
ventral NCT03925961 94 101 I-Procedure-Name
hernia NCT03925961 102 108 I-Procedure-Name
, NCT03925961 109 110 O
inguinal NCT03925961 111 119 B-Procedure-Name
hernia NCT03925961 120 126 I-Procedure-Name
, NCT03925961 127 128 O
and NCT03925961 129 132 O
gallbladder NCT03925961 133 144 B-Procedure-Name
surgery NCT03925961 145 152 I-Procedure-Name
at NCT03925961 153 155 O
Howard NCT03925961 156 162 B-Location___Location-Value:hospital
County NCT03925961 163 169 I-Location___Location-Value:hospital
General NCT03925961 170 177 I-Location___Location-Value:hospital
Hospital NCT03925961 178 186 I-Location___Location-Value:hospital
with NCT03925961 187 191 O
the NCT03925961 192 195 O
general NCT03925961 196 203 B-Provider-Type
surgery NCT03925961 204 211 I-Provider-Type
practice NCT03925961 212 220 I-Provider-Type
at NCT03925961 221 223 O
Johns NCT03925961 224 229 O
Hopkins NCT03925961 230 237 O
Community NCT03925961 238 247 O
Physicians NCT03925961 248 258 O
. NCT03925961 259 260 O

Exclusion NCT03925961 262 271 O
Criteria NCT03925961 272 280 O
: NCT03925961 281 282 O

- NCT03925961 286 287 O
Patients NCT03925961 289 297 O
less NCT03925961 298 302 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03925961 303 307 I-Eq-Operator___Eq-Operator-Value:LT
18 NCT03925961 309 311 B-Eq-Value
years NCT03925961 312 317 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03925961 318 320 O
age NCT03925961 321 324 O

- NCT03925961 327 328 O
Adults NCT03925961 330 336 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
who NCT03925961 337 340 O
lack NCT03925961 341 345 O
the NCT03925961 346 349 O
capacity NCT03925961 350 358 O
to NCT03925961 359 361 O
consent NCT03925961 362 369 O

- NCT03925961 372 373 O
Pregnant NCT03925961 375 383 B-Condition-Name
women NCT03925961 384 389 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female

- NCT03925961 392 393 O
Prisoners NCT03925961 395 404 B-Observation-Name

- NCT03925961 407 408 O
Non NCT03925961 410 413 O
- NCT03925961 414 415 O
English NCT03925961 416 423 B-Language
speakers NCT03925961 424 432 O
. NCT03925961 433 434 O

Inclusion NCT03921736 0 9 O
Criteria NCT03921736 10 18 O
: NCT03921736 19 20 O

- NCT03921736 24 25 O
Treatment NCT03921736 27 36 O
- NCT03921736 37 38 O
naive NCT03921736 39 44 O
postmenopausal NCT03921736 45 59 B-Condition-Name
women NCT03921736 60 65 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female

- NCT03921736 68 69 O
Diagnosed NCT03921736 71 80 O
hypertension NCT03921736 81 93 B-Condition-Name
( NCT03921736 94 95 O
grade NCT03921736 96 101 O
1 NCT03921736 103 104 B-Eq-Value
or NCT03921736 105 107 O
2 NCT03921736 109 110 B-Eq-Value
according NCT03921736 111 120 O
to NCT03921736 121 123 O
ESH NCT03921736 124 127 O
/ NCT03921736 128 129 O
ESC NCT03921736 130 133 O
2013 NCT03921736 135 139 O
guidelines NCT03921736 140 150 O
) NCT03921736 151 152 O

Exclusion NCT03921736 154 163 O
Criteria NCT03921736 164 172 O
: NCT03921736 173 174 O

- NCT03921736 178 179 O
breast NCT03921736 181 187 O
cancer NCT03921736 188 194 B-Condition-Name
in NCT03921736 195 197 O
a NCT03921736 198 199 O
first NCT03921736 200 205 O
- NCT03921736 206 207 O
degree NCT03921736 208 214 O
relative NCT03921736 215 223 O

- NCT03921736 226 227 O
hyperplasia NCT03921736 229 240 B-Condition-Name
diagnosed NCT03921736 241 250 O
by NCT03921736 251 253 O
endometrial NCT03921736 254 265 B-Procedure-Name
biopsy NCT03921736 266 272 I-Procedure-Name
, NCT03921736 273 274 O

- NCT03921736 278 279 O
history NCT03921736 281 288 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03921736 289 291 O
thromboembolic NCT03921736 292 306 B-Condition-Name
diseases NCT03921736 307 315 I-Condition-Name
, NCT03921736 316 317 O

- NCT03921736 321 322 O
current NCT03921736 324 331 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
or NCT03921736 332 334 O
history NCT03921736 335 342 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03921736 343 345 O
use NCT03921736 346 349 O
of NCT03921736 350 352 O
estrogen NCT03921736 353 361 B-Procedure-Name
- NCT03921736 362 363 I-Procedure-Name
progestin NCT03921736 364 373 I-Procedure-Name
therapy NCT03921736 374 381 I-Procedure-Name
or NCT03921736 382 384 O
contraceptives NCT03921736 385 399 B-Procedure-Name

- NCT03921736 402 403 O
diabetes NCT03921736 405 413 B-Condition-Name
, NCT03921736 414 415 O

- NCT03921736 419 420 O
kidney NCT03921736 422 428 B-Condition-Name
failure NCT03921736 429 436 I-Condition-Name
, NCT03921736 437 438 O

- NCT03921736 442 443 O
thyroid NCT03921736 445 452 B-Condition-Name
disease NCT03921736 453 460 I-Condition-Name
, NCT03921736 461 462 O

- NCT03921736 466 467 O
heart NCT03921736 469 474 O
and NCT03921736 475 478 O
other NCT03921736 479 484 O
chronic NCT03921736 485 492 O
diseases NCT03921736 493 501 B-Condition-Name
( NCT03921736 502 503 O
secondary NCT03921736 504 513 B-Condition-Name
hypertension NCT03921736 514 526 I-Condition-Name
, NCT03921736 527 528 O
atrial NCT03921736 529 535 B-Condition-Name
fibrillation NCT03921736 536 548 I-Condition-Name
) NCT03921736 549 550 O

Inclusion NCT03923647 0 9 O
Criteria NCT03923647 10 18 O
: NCT03923647 19 20 O

- NCT03923647 24 25 O
stable NCT03923647 27 33 B-Stability___Stability-Value:stable
patients NCT03923647 34 42 O
with NCT03923647 43 47 O
definite NCT03923647 48 56 O
occurrence NCT03923647 57 67 O
of NCT03923647 68 70 O
intra NCT03923647 71 76 O
- NCT03923647 77 78 O
abdominal NCT03923647 79 88 O
injury NCT03923647 89 95 B-Condition-Name

- NCT03923647 98 99 O
patients NCT03923647 101 109 O
with NCT03923647 110 114 O
equivocal NCT03923647 115 124 O
result NCT03923647 125 131 O
by NCT03923647 132 134 O
clinical NCT03923647 135 143 O
and NCT03923647 144 147 O
radiological NCT03923647 148 160 B-Procedure-Name
evaluation NCT03923647 161 171 I-Procedure-Name

Exclusion NCT03923647 172 181 O
Criteria NCT03923647 182 190 O
: NCT03923647 191 192 O

- NCT03923647 196 197 O
patients NCT03923647 199 207 O
with NCT03923647 208 212 O
penetrating NCT03923647 213 224 O
abdominal NCT03923647 225 234 O
trauma NCT03923647 235 241 B-Condition-Name

- NCT03923647 244 245 O
stable NCT03923647 247 253 B-Stability___Stability-Value:stable
patients NCT03923647 254 262 O
not NCT03923647 263 266 O
in NCT03923647 267 269 O
need NCT03923647 270 274 O
for NCT03923647 275 278 O
any NCT03923647 279 282 O
intervention NCT03923647 283 295 B-Procedure-Name
for NCT03923647 296 299 O
conservative NCT03923647 300 312 B-Procedure-Name
management NCT03923647 313 323 I-Procedure-Name

- NCT03923647 326 327 O
patients NCT03923647 329 337 O
with NCT03923647 338 342 O
marked NCT03923647 343 349 O
haemodynamic NCT03923647 350 362 B-Condition-Name
instability NCT03923647 363 374 I-Condition-Name

- NCT03923647 377 378 O
polyt NCT03923647 380 385 B-Condition-Name
- NCT03923647 386 387 I-Condition-Name
traumatized NCT03923647 388 399 I-Condition-Name
Patients NCT03923647 400 408 O

Inclusion NCT03924128 0 9 O
Criteria NCT03924128 10 18 O
: NCT03924128 19 20 O

- NCT03924128 24 25 O
Selected NCT03924128 27 35 O
will NCT03924128 36 40 O
be NCT03924128 41 43 O
subjects NCT03924128 44 52 O
to NCT03924128 53 55 O
meeting NCT03924128 56 63 O
the NCT03924128 64 67 O
following NCT03924128 68 77 O
criteria NCT03924128 78 86 O
: NCT03924128 87 88 O
male NCT03924128 89 93 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
and NCT03924128 94 97 O
female NCT03924128 98 104 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
subjects NCT03924128 105 113 O
age NCT03924128 114 117 O
≥ NCT03924128 118 119 B-Eq-Operator___Eq-Operator-Value:GTEQ
20 NCT03924128 121 123 B-Eq-Value
years NCT03924128 124 129 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03924128 130 133 O
, NCT03924128 134 135 O
diagnosed NCT03924128 136 145 O
with NCT03924128 146 150 O
Osteoarthritis NCT03924128 151 165 B-Condition-Name
stages NCT03924128 166 172 B-Eq-Unit
III NCT03924128 173 176 B-Eq-Value
and NCT03924128 177 180 O
IV NCT03924128 181 183 B-Eq-Value
according NCT03924128 184 193 O
to NCT03924128 194 196 O
the NCT03924128 197 200 O
American NCT03924128 201 209 O
College NCT03924128 210 217 O
of NCT03924128 218 220 O
Rheumatology NCT03924128 221 233 O
, NCT03924128 234 235 O
manifesting NCT03924128 236 247 O
pain NCT03924128 248 252 B-Condition-Name
, NCT03924128 253 254 O
functional NCT03924128 255 265 B-Condition-Name
impairment NCT03924128 266 276 I-Condition-Name
for NCT03924128 277 280 O
more NCT03924128 281 285 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03924128 286 290 I-Eq-Operator___Eq-Operator-Value:GT
3 NCT03924128 292 293 B-Eq-Value
months NCT03924128 294 300 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
, NCT03924128 301 302 O
able NCT03924128 303 307 B-Condition-Name
to NCT03924128 308 310 I-Condition-Name
wander NCT03924128 311 317 I-Condition-Name
with NCT03924128 318 322 O
or NCT03924128 323 325 O
without NCT03924128 326 333 O
canes NCT03924128 334 339 O
. NCT03924128 340 341 O

Exclusion NCT03924128 343 352 O
Criteria NCT03924128 353 361 O
: NCT03924128 362 363 O

- NCT03924128 367 368 O
Will NCT03924128 370 374 O
be NCT03924128 375 377 O
excluded NCT03924128 378 386 O
from NCT03924128 387 391 O
study NCT03924128 392 397 O
subjects NCT03924128 398 406 O
with NCT03924128 407 411 O
history NCT03924128 412 419 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03924128 420 422 O
cancer NCT03924128 423 429 B-Condition-Name
, NCT03924128 430 431 O
unstable NCT03924128 432 440 B-Stability___Stability-Value:change
cardiovascular NCT03924128 441 455 B-Condition-Name
disease NCT03924128 456 463 I-Condition-Name
, NCT03924128 464 465 O
uncontrolled NCT03924128 466 478 O
hypertension NCT03924128 479 491 B-Condition-Name
, NCT03924128 492 493 O
morbid NCT03924128 494 500 B-Condition-Name
obesity NCT03924128 501 508 I-Condition-Name
, NCT03924128 509 510 O
that NCT03924128 511 515 O
is NCT03924128 516 518 O
, NCT03924128 519 520 O
BMI NCT03924128 521 524 B-Observation-Name___Observation-Type-Value:vital
≥ NCT03924128 525 526 B-Eq-Operator___Eq-Operator-Value:GTEQ
40 NCT03924128 528 530 B-Eq-Value
, NCT03924128 531 532 O
terminal NCT03924128 533 541 B-Condition-Name
illness NCT03924128 542 549 I-Condition-Name
, NCT03924128 550 551 O
cerebrovascular NCT03924128 552 567 B-Condition-Name
disease NCT03924128 568 575 I-Condition-Name
, NCT03924128 576 577 O
dementia NCT03924128 578 586 B-Condition-Name
, NCT03924128 587 588 O
heart NCT03924128 589 594 B-Procedure-Name
pacemaker NCT03924128 595 604 I-Procedure-Name
, NCT03924128 605 606 O
superior NCT03924128 607 615 O
or NCT03924128 616 618 O
inferior NCT03924128 619 627 O
limb NCT03924128 628 632 O
fractures NCT03924128 633 642 B-Condition-Name
. NCT03924128 643 644 O

Inclusion NCT03924882 0 9 O
Criteria NCT03924882 10 18 O
: NCT03924882 19 20 O

1 NCT03924882 25 26 O
. NCT03924882 26 27 O
Female NCT03924882 29 35 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
, NCT03924882 36 37 O
age NCT03924882 38 41 O
≥ NCT03924882 42 43 B-Eq-Operator___Eq-Operator-Value:GTEQ
18 NCT03924882 45 47 B-Eq-Value
years NCT03924882 48 53 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
and NCT03924882 54 57 O
≤ NCT03924882 58 59 B-Eq-Operator___Eq-Operator-Value:LTEQ
70 NCT03924882 61 63 B-Eq-Value
years NCT03924882 64 69 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
, NCT03924882 70 71 O
signed NCT03924882 72 78 O
informed NCT03924882 79 87 O
consent NCT03924882 88 95 O
. NCT03924882 96 97 O

2 NCT03924882 102 103 O
. NCT03924882 103 104 O
Histologically NCT03924882 106 120 B-Procedure-Name
or NCT03924882 121 123 O
pathologically NCT03924882 124 138 B-Procedure-Name
confirmed NCT03924882 139 148 O
diagnosis NCT03924882 149 158 O
of NCT03924882 159 161 O
epithelial NCT03924882 162 172 B-Condition-Name
carcinoma NCT03924882 173 182 I-Condition-Name
of NCT03924882 183 185 O
the NCT03924882 186 189 O
ovary NCT03924882 190 195 O
. NCT03924882 196 197 O

3 NCT03924882 202 203 O
. NCT03924882 203 204 O
Platinum NCT03924882 206 214 O
resistant NCT03924882 215 224 O
ovarian NCT03924882 225 232 O
cancer NCT03924882 233 239 B-Condition-Name
( NCT03924882 240 241 O
defined NCT03924882 242 249 O
as NCT03924882 250 252 O
relapsing NCT03924882 253 262 O
within NCT03924882 263 269 B-Eq-Operator___Eq-Operator-Value:LTEQ
6 NCT03924882 271 272 B-Eq-Value
months NCT03924882 273 279 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
after NCT03924882 280 285 O
the NCT03924882 286 289 O
last NCT03924882 290 294 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:most-recent-time
administration NCT03924882 295 309 O
of NCT03924882 310 312 O
platinum NCT03924882 313 321 O
- NCT03924882 322 323 O
based NCT03924882 324 329 O
chemotherapy NCT03924882 330 342 B-Procedure-Name
) NCT03924882 343 344 O
OR NCT03924882 345 347 O
platinum NCT03924882 348 356 O
refractory NCT03924882 357 367 O
ovarian NCT03924882 368 375 O
cancer NCT03924882 376 382 B-Condition-Name
( NCT03924882 383 384 O
defined NCT03924882 385 392 O
as NCT03924882 393 395 O
progressing NCT03924882 396 407 O
while NCT03924882 408 413 O
on NCT03924882 414 416 O
a NCT03924882 417 418 O
platinum NCT03924882 419 427 O
- NCT03924882 428 429 O
based NCT03924882 430 435 O
chemotherapy NCT03924882 436 448 B-Procedure-Name
) NCT03924882 449 450 O

4 NCT03924882 455 456 O
. NCT03924882 456 457 O
At NCT03924882 459 461 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03924882 462 467 I-Eq-Operator___Eq-Operator-Value:GTEQ
treated NCT03924882 468 475 O
with NCT03924882 476 480 O
one NCT03924882 481 484 B-Eq-Value
line NCT03924882 485 489 O
of NCT03924882 490 492 O
platinum NCT03924882 493 501 O
- NCT03924882 502 503 O
based NCT03924882 504 509 O
chemotherapy NCT03924882 510 522 B-Procedure-Name

5 NCT03924882 526 527 O
. NCT03924882 527 528 O
Eastern NCT03924882 530 537 B-Observation-Name___Observation-Type-Value:clinical-score
Cooperative NCT03924882 538 549 I-Observation-Name___Observation-Type-Value:clinical-score
Oncology NCT03924882 550 558 I-Observation-Name___Observation-Type-Value:clinical-score
Group NCT03924882 559 564 I-Observation-Name___Observation-Type-Value:clinical-score
( NCT03924882 565 566 O
ECOG NCT03924882 567 571 B-Observation-Name
) NCT03924882 572 573 O
performance NCT03924882 574 585 O
status NCT03924882 586 592 O
0 NCT03924882 594 595 B-Eq-Value
- NCT03924882 596 597 B-Eq-Operator___Eq-Operator-Value:BETWEEN
2 NCT03924882 599 600 B-Eq-Value

6 NCT03924882 605 606 O
. NCT03924882 606 607 O
Measurable NCT03924882 609 619 B-Observation-Name___Observation-Type-Value:measurement
disease NCT03924882 620 627 I-Observation-Name___Observation-Type-Value:measurement
according NCT03924882 628 637 O
to NCT03924882 638 640 O
Response NCT03924882 641 649 O
Evaluation NCT03924882 650 660 O
Criteria NCT03924882 661 669 O
in NCT03924882 670 672 O
Solid NCT03924882 673 678 O
Tumors NCT03924882 679 685 O
( NCT03924882 686 687 O
RECIST NCT03924882 688 694 O
) NCT03924882 695 696 O
1.1 NCT03924882 698 701 O
version NCT03924882 702 709 O
or NCT03924882 710 712 O
CA NCT03924882 713 715 B-Observation-Name___Observation-Type-Value:lab
125 NCT03924882 716 719 I-Observation-Name___Observation-Type-Value:lab

7 NCT03924882 728 729 O
. NCT03924882 729 730 O
Patients NCT03924882 732 740 O
must NCT03924882 741 745 O
have NCT03924882 746 750 O
a NCT03924882 751 752 O
life NCT03924882 753 757 B-Observation-Name
expectancy NCT03924882 758 768 I-Observation-Name
of NCT03924882 769 771 O
at NCT03924882 772 774 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03924882 775 780 I-Eq-Operator___Eq-Operator-Value:GTEQ
3 NCT03924882 782 783 B-Eq-Value
months NCT03924882 784 790 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
. NCT03924882 791 792 O

8 NCT03924882 797 798 O
. NCT03924882 798 799 O
Patients NCT03924882 801 809 O
must NCT03924882 810 814 O
have NCT03924882 815 819 O
adequate NCT03924882 820 828 B-Polarity___Polarity-Value:normal
organ NCT03924882 829 834 B-Condition-Name
function NCT03924882 835 843 I-Condition-Name
. NCT03924882 844 845 O

Exclusion NCT03924882 847 856 O
Criteria NCT03924882 857 865 O
: NCT03924882 866 867 O

1 NCT03924882 872 873 O
. NCT03924882 873 874 O
Had NCT03924882 876 879 O
prior NCT03924882 880 885 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
exposure NCT03924882 886 894 O
to NCT03924882 895 897 O
anlotinib NCT03924882 898 907 B-Drug-Name
or NCT03924882 908 910 O
has NCT03924882 911 914 O
known NCT03924882 915 920 O
allegies NCT03924882 921 929 O
to NCT03924882 930 932 O
any NCT03924882 933 936 O
of NCT03924882 937 939 O
the NCT03924882 940 943 O
excipients NCT03924882 944 954 B-Allergy-Name
, NCT03924882 955 956 O
Inadequately NCT03924882 957 969 O
controlled NCT03924882 970 980 O
hypertension NCT03924882 981 993 B-Condition-Name

2 NCT03924882 997 998 O
. NCT03924882 998 999 O
History NCT03924882 1001 1008 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03924882 1009 1011 O
myocardial NCT03924882 1012 1022 B-Condition-Name
infarction NCT03924882 1023 1033 I-Condition-Name
, NCT03924882 1034 1035 O
or NCT03924882 1036 1038 O
unstable NCT03924882 1039 1047 B-Condition-Name
angina NCT03924882 1048 1054 I-Condition-Name
, NCT03924882 1055 1056 O
or NCT03924882 1057 1059 O
New NCT03924882 1060 1063 B-Condition-Name
York NCT03924882 1064 1068 I-Condition-Name
Heart NCT03924882 1069 1074 I-Condition-Name
Association NCT03924882 1075 1086 I-Condition-Name
( NCT03924882 1087 1088 O
NYHA NCT03924882 1089 1093 B-Condition-Name
) NCT03924882 1094 1095 O
Grade NCT03924882 1096 1101 B-Eq-Unit
III NCT03924882 1102 1105 B-Eq-Value
- NCT03924882 1106 1107 B-Eq-Operator___Eq-Operator-Value:BETWEEN
IV NCT03924882 1108 1110 B-Eq-Value
within NCT03924882 1111 1117 B-Eq-Operator___Eq-Operator-Value:LTEQ
6 NCT03924882 1119 1120 B-Eq-Value
months NCT03924882 1121 1127 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
prior NCT03924882 1128 1133 O
to NCT03924882 1134 1136 O
Day NCT03924882 1137 1140 O
1 NCT03924882 1142 1143 O
. NCT03924882 1143 1144 O

3 NCT03924882 1149 1150 O
. NCT03924882 1150 1151 O
History NCT03924882 1153 1160 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03924882 1161 1163 O
abdominal NCT03924882 1164 1173 B-Condition-Name
fistula NCT03924882 1174 1181 I-Condition-Name
or NCT03924882 1182 1184 O
gastrointestinal NCT03924882 1185 1201 B-Condition-Name
perforation NCT03924882 1202 1213 I-Condition-Name
within NCT03924882 1214 1220 B-Eq-Operator___Eq-Operator-Value:LTEQ
28 NCT03924882 1222 1224 B-Eq-Value
days NCT03924882 1225 1229 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
prior NCT03924882 1230 1235 O
to NCT03924882 1236 1238 O
Day NCT03924882 1239 1242 O
1 NCT03924882 1244 1245 O

4 NCT03924882 1250 1251 O
. NCT03924882 1251 1252 O
Major NCT03924882 1254 1259 B-Severity___Severity-Value:severe
surgical NCT03924882 1260 1268 B-Procedure-Name
procedure NCT03924882 1269 1278 I-Procedure-Name
within NCT03924882 1279 1285 B-Eq-Operator___Eq-Operator-Value:LTEQ
28 NCT03924882 1287 1289 B-Eq-Value
days NCT03924882 1290 1294 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
prior NCT03924882 1295 1300 O
to NCT03924882 1301 1303 O
Day NCT03924882 1304 1307 O
1 NCT03924882 1309 1310 O
, NCT03924882 1311 1312 O
Serious NCT03924882 1313 1320 B-Severity___Severity-Value:severe
, NCT03924882 1321 1322 O
non NCT03924882 1323 1326 O
- NCT03924882 1327 1328 O
healing NCT03924882 1329 1336 O
wound NCT03924882 1337 1342 B-Condition-Name
, NCT03924882 1343 1344 O
active NCT03924882 1345 1351 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
ulcer NCT03924882 1352 1357 B-Condition-Name
, NCT03924882 1358 1359 O
bowel NCT03924882 1360 1365 B-Condition-Name
obstruction NCT03924882 1366 1377 I-Condition-Name
within NCT03924882 1378 1384 B-Eq-Operator___Eq-Operator-Value:LTEQ
28 NCT03924882 1386 1388 B-Eq-Value
days NCT03924882 1389 1393 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
prior NCT03924882 1394 1399 O
to NCT03924882 1400 1402 O
Day NCT03924882 1403 1406 O
1 NCT03924882 1408 1409 O

5 NCT03924882 1414 1415 O
. NCT03924882 1415 1416 O
Symptomatic NCT03924882 1418 1429 O
central NCT03924882 1430 1437 O
nervous NCT03924882 1438 1445 O
system NCT03924882 1446 1452 O
( NCT03924882 1453 1454 O
CNS NCT03924882 1455 1458 O
) NCT03924882 1459 1460 O
metastasis NCT03924882 1461 1471 B-Condition-Name


Inclusion NCT03921905 0 9 O
Criteria NCT03921905 10 18 O
: NCT03921905 19 20 O

- NCT03921905 24 25 O
Patients NCT03921905 27 35 O
of NCT03921905 36 38 O
both NCT03921905 39 43 O
sexes NCT03921905 44 49 O
with NCT03921905 50 54 O
a NCT03921905 55 56 O
diagnosis NCT03921905 57 66 O
of NCT03921905 67 69 O
stable NCT03921905 70 76 B-Stability___Stability-Value:stable
CAD NCT03921905 77 80 B-Condition-Name
as NCT03921905 81 83 O
follows NCT03921905 84 91 O
: NCT03921905 92 93 O
acute NCT03921905 94 99 B-Condition-Name
myocardial NCT03921905 100 110 I-Condition-Name
infarction NCT03921905 111 121 I-Condition-Name
or NCT03921905 122 124 O
percutaneous NCT03921905 125 137 B-Procedure-Name
coronary NCT03921905 138 146 I-Procedure-Name
revascularization NCT03921905 147 164 I-Procedure-Name
or NCT03921905 165 167 O
coronary NCT03921905 168 176 B-Procedure-Name
artery NCT03921905 177 183 I-Procedure-Name
bypass NCT03921905 184 190 I-Procedure-Name
graft NCT03921905 191 196 I-Procedure-Name
surgery NCT03921905 197 204 I-Procedure-Name
occured NCT03921905 205 212 O
at NCT03921905 213 215 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03921905 216 221 I-Eq-Operator___Eq-Operator-Value:GTEQ
12 NCT03921905 223 225 B-Eq-Value
months NCT03921905 226 232 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
before NCT03921905 233 239 O
entering NCT03921905 240 248 O
the NCT03921905 249 252 O
study NCT03921905 253 258 O
or NCT03921905 259 261 O
chronic NCT03921905 262 269 O
stable NCT03921905 270 276 B-Stability___Stability-Value:stable
angina NCT03921905 277 283 B-Condition-Name
. NCT03921905 284 285 O

Exclusion NCT03921905 287 296 O
Criteria NCT03921905 297 305 O
: NCT03921905 306 307 O

- NCT03921905 311 312 O
Mental NCT03921905 314 320 B-Condition-Name
illness NCT03921905 321 328 I-Condition-Name
limiting NCT03921905 329 337 B-Stability___Stability-Value:change
the NCT03921905 338 341 O
capacity NCT03921905 342 350 O
of NCT03921905 351 353 O
self NCT03921905 354 358 B-Procedure-Name
- NCT03921905 359 360 I-Procedure-Name
care NCT03921905 361 365 I-Procedure-Name
or NCT03921905 366 368 O
any NCT03921905 369 372 O
condition NCT03921905 373 382 O
limiting NCT03921905 383 391 B-Stability___Stability-Value:change
seriously NCT03921905 392 401 B-Severity___Severity-Value:severe
the NCT03921905 402 405 O
life NCT03921905 406 410 B-Observation-Name
expectancy NCT03921905 411 421 I-Observation-Name
less NCT03921905 422 426 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03921905 427 431 I-Eq-Operator___Eq-Operator-Value:LT
12 NCT03921905 433 435 B-Eq-Value
months NCT03921905 436 442 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
. NCT03921905 443 444 O

Inclusion NCT03926663 0 9 O
Criteria NCT03926663 10 18 O
: NCT03926663 19 20 O

- NCT03926663 24 25 O
Patients NCT03926663 27 35 O
aged NCT03926663 36 40 O
from NCT03926663 41 45 O
18 NCT03926663 47 49 B-Eq-Value
- NCT03926663 50 51 B-Eq-Operator___Eq-Operator-Value:BETWEEN
60 NCT03926663 53 55 B-Eq-Value
years NCT03926663 56 61 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03926663 64 65 O
ASA NCT03926663 67 70 B-Condition-Name
physical NCT03926663 71 79 O
status NCT03926663 80 86 O
I NCT03926663 87 88 B-Eq-Value

- NCT03926663 91 92 O
Undergoing NCT03926663 94 104 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
septoplasty NCT03926663 105 116 B-Procedure-Name

Exclusion NCT03926663 117 126 O
Criteria NCT03926663 127 135 O
: NCT03926663 136 137 O

- NCT03926663 141 142 O
Patients NCT03926663 144 152 O
with NCT03926663 153 157 O
cardiovascular NCT03926663 158 172 B-Condition-Name
disease NCT03926663 173 180 I-Condition-Name
( NCT03926663 181 182 O
congestive NCT03926663 183 193 B-Condition-Name
heart NCT03926663 194 199 I-Condition-Name
failure NCT03926663 200 207 I-Condition-Name
, NCT03926663 208 209 O
coronary NCT03926663 210 218 B-Condition-Name
artery NCT03926663 219 225 I-Condition-Name
disease NCT03926663 226 233 I-Condition-Name
, NCT03926663 234 235 O
hypertension NCT03926663 236 248 B-Condition-Name
. NCT03926663 249 250 O

- NCT03926663 254 255 O
History NCT03926663 257 264 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03926663 265 267 O
renal NCT03926663 268 273 O
or NCT03926663 274 276 O
hepatic NCT03926663 277 284 O
insufficiency NCT03926663 285 298 B-Condition-Name

- NCT03926663 301 302 O
Endocrinal NCT03926663 304 314 B-Condition-Name
Diseases NCT03926663 315 323 I-Condition-Name

Inclusion NCT03924921 0 9 O
Criteria NCT03924921 10 18 O
: NCT03924921 19 20 O

- NCT03924921 24 25 O
Being NCT03924921 27 32 O
older NCT03924921 33 38 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03924921 39 43 I-Eq-Operator___Eq-Operator-Value:GT
18 NCT03924921 45 47 B-Eq-Value
; NCT03924921 48 49 O

- NCT03924921 52 53 O
have NCT03924921 55 59 O
a NCT03924921 60 61 O
diagnosis NCT03924921 62 71 O
of NCT03924921 72 74 O
HIV NCT03924921 75 78 B-Condition-Name
; NCT03924921 78 79 O

- NCT03924921 82 83 O
present NCT03924921 85 92 O
at NCT03924921 93 95 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03924921 96 101 I-Eq-Operator___Eq-Operator-Value:GTEQ
one NCT03924921 102 105 B-Eq-Value
of NCT03924921 106 108 O
the NCT03924921 109 112 O
following NCT03924921 113 122 O
symptoms NCT03924921 123 131 O
during NCT03924921 132 138 O
the NCT03924921 139 142 O
preceding NCT03924921 143 152 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
two NCT03924921 153 156 B-Eq-Value
weeks NCT03924921 157 162 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
: NCT03924921 163 164 O
sleep NCT03924921 165 170 B-Condition-Name
problems NCT03924921 171 179 I-Condition-Name
, NCT03924921 180 181 O
fatigue NCT03924921 182 189 B-Condition-Name
, NCT03924921 190 191 O
pain NCT03924921 192 196 B-Condition-Name
, NCT03924921 197 198 O
anxiety NCT03924921 199 206 B-Condition-Name
or NCT03924921 207 209 O
symptoms NCT03924921 210 218 O
of NCT03924921 219 221 O
depression NCT03924921 222 232 B-Condition-Name
; NCT03924921 232 233 O

- NCT03924921 236 237 O
understand NCT03924921 239 249 O
and NCT03924921 250 253 O
speak NCT03924921 254 259 O
French NCT03924921 260 266 B-Language
and NCT03924921 267 270 O
; NCT03924921 270 271 O

- NCT03924921 274 275 O
be NCT03924921 277 279 O
able NCT03924921 280 284 O
to NCT03924921 285 287 O
follow NCT03924921 288 294 O
the NCT03924921 295 298 O
instructions NCT03924921 299 311 O
to NCT03924921 312 314 O
learn NCT03924921 315 320 O
the NCT03924921 321 324 O
relaxation NCT03924921 325 335 B-Procedure-Name
technique NCT03924921 336 345 I-Procedure-Name
. NCT03924921 346 347 O

Exclusion NCT03924921 349 358 O
Criteria NCT03924921 359 367 O
: NCT03924921 368 369 O

- NCT03924921 372 373 O

Inclusion NCT03928470 0 9 O
Criteria NCT03928470 10 18 O
: NCT03928470 19 20 O

1 NCT03928470 25 26 O
. NCT03928470 26 27 O
Male NCT03928470 29 33 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
or NCT03928470 34 36 O
Female NCT03928470 37 43 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
aged NCT03928470 44 48 O
≥ NCT03928470 49 50 B-Eq-Operator___Eq-Operator-Value:GTEQ
19 NCT03928470 52 54 B-Eq-Value
years NCT03928470 55 60 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

2 NCT03928470 64 65 O
. NCT03928470 65 66 O
Episode NCT03928470 68 75 O
of NCT03928470 76 78 O
heartburn NCT03928470 79 88 B-Condition-Name
for NCT03928470 89 92 O
3 NCT03928470 94 95 B-Eq-Value
months NCT03928470 96 102 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
or NCT03928470 103 105 B-Eq-Operator___Eq-Operator-Value:GTEQ
more NCT03928470 106 110 I-Eq-Operator___Eq-Operator-Value:GTEQ
during NCT03928470 111 117 O
prior NCT03928470 118 123 O
to NCT03928470 124 126 O
randomization NCT03928470 127 140 O
visit NCT03928470 141 146 O
. NCT03928470 147 148 O

3 NCT03928470 153 154 O
. NCT03928470 154 155 O
Episode NCT03928470 157 164 O
of NCT03928470 165 167 O
heartburn NCT03928470 168 177 B-Condition-Name
for NCT03928470 178 181 O
2 NCT03928470 183 184 B-Eq-Value
days NCT03928470 185 189 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
or NCT03928470 190 192 B-Eq-Operator___Eq-Operator-Value:GTEQ
more NCT03928470 193 197 I-Eq-Operator___Eq-Operator-Value:GTEQ
during NCT03928470 198 204 O
the NCT03928470 205 208 O
last NCT03928470 209 213 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
7 NCT03928470 215 216 B-Eq-Value
days NCT03928470 217 221 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
prior NCT03928470 222 227 O
to NCT03928470 228 230 O
randomization NCT03928470 231 244 O
visit NCT03928470 245 250 O
. NCT03928470 251 252 O

4 NCT03928470 257 258 O
. NCT03928470 258 259 O
Grade NCT03928470 261 266 B-Eq-Unit
N NCT03928470 267 268 B-Eq-Value
, NCT03928470 269 270 O
M NCT03928470 271 272 B-Eq-Value
by NCT03928470 273 275 O
EGD NCT03928470 276 279 B-Procedure-Name
test NCT03928470 280 284 I-Procedure-Name
. NCT03928470 285 286 O

Exclusion NCT03928470 288 297 O
Criteria NCT03928470 298 306 O
: NCT03928470 307 308 O

1 NCT03928470 313 314 O
. NCT03928470 314 315 O
Surgery NCT03928470 317 324 B-Procedure-Name
history NCT03928470 325 332 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
on NCT03928470 333 335 O
stomach NCT03928470 336 343 O
or NCT03928470 344 346 O
esophagus NCT03928470 347 356 O

2 NCT03928470 360 361 O
. NCT03928470 361 362 O
Active NCT03928470 364 370 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
medical NCT03928470 371 378 O
history NCT03928470 379 386 O
of NCT03928470 387 389 O
stomach NCT03928470 390 397 O
, NCT03928470 398 399 O
esophagus NCT03928470 400 409 O
area NCT03928470 410 414 O

3 NCT03928470 418 419 O
. NCT03928470 419 420 O
Other NCT03928470 422 427 O
system NCT03928470 428 434 O
disorder NCT03928470 435 443 B-Condition-Name
which NCT03928470 444 449 O
can NCT03928470 450 453 O
disturb NCT03928470 454 461 B-Stability___Stability-Value:change
this NCT03928470 462 466 O
trial NCT03928470 467 472 O

4 NCT03928470 476 477 O
. NCT03928470 477 478 O
Patients NCT03928470 480 488 O
taking NCT03928470 489 495 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
the NCT03928470 496 499 O
contraindication NCT03928470 500 516 O
of NCT03928470 517 519 O
concomitant NCT03928470 520 531 O
medications NCT03928470 532 543 O

5 NCT03928470 547 548 O
. NCT03928470 548 549 O
Clinically NCT03928470 551 561 O
significant NCT03928470 562 573 B-Severity___Severity-Value:severe
Abnormal NCT03928470 574 582 B-Polarity___Polarity-Value:abnormal
Lab NCT03928470 583 586 B-Observation-Name___Observation-Type-Value:lab
test NCT03928470 587 591 I-Observation-Name___Observation-Type-Value:lab

6 NCT03928470 595 596 O
. NCT03928470 596 597 O
Pregnant NCT03928470 599 607 B-Condition-Name
woman NCT03928470 608 613 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
, NCT03928470 614 615 O
Breastfeeding NCT03928470 616 629 B-Condition-Name
woman NCT03928470 630 635 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
. NCT03928470 636 637 O

Inclusion NCT03925168 0 9 O
Criteria NCT03925168 10 18 O
: NCT03925168 19 20 O

- NCT03925168 24 25 O
English NCT03925168 27 34 B-Language
- NCT03925168 35 36 O
speaking NCT03925168 37 45 O
, NCT03925168 46 47 O
adult NCT03925168 48 53 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
( NCT03925168 54 55 O
21 NCT03925168 57 59 B-Eq-Value
+ NCT03925168 60 61 B-Eq-Operator___Eq-Operator-Value:GTEQ
) NCT03925168 63 64 O
hemodialysis NCT03925168 65 77 B-Procedure-Name
patients NCT03925168 78 86 O
who NCT03925168 87 90 O
receive NCT03925168 91 98 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
dialysis NCT03925168 99 107 B-Procedure-Name
at NCT03925168 108 110 O
the NCT03925168 111 114 O
one NCT03925168 115 118 O
of NCT03925168 119 121 O
the NCT03925168 122 125 O
two NCT03925168 126 129 O
outpatient NCT03925168 130 140 B-Location___Location-Value:clinic
dialysis NCT03925168 141 149 I-Location___Location-Value:clinic
centers NCT03925168 150 157 I-Location___Location-Value:clinic

Exclusion NCT03925168 158 167 O
Criteria NCT03925168 168 176 O
: NCT03925168 177 178 O

- NCT03925168 182 183 O
do NCT03925168 185 187 O
not NCT03925168 188 191 O
speak NCT03925168 192 197 O
English NCT03925168 198 205 B-Language
, NCT03925168 206 207 O
deafness NCT03925168 208 216 B-Condition-Name

Inclusion NCT03922607 0 9 O
Criteria NCT03922607 10 18 O
: NCT03922607 19 20 O

- NCT03922607 24 25 O
Volunteer NCT03922607 27 36 O
should NCT03922607 37 43 O
be NCT03922607 44 46 O
between NCT03922607 47 54 B-Eq-Operator___Eq-Operator-Value:BETWEEN
18 NCT03922607 56 58 B-Eq-Value
and NCT03922607 59 62 O
55 NCT03922607 64 66 B-Eq-Value
years NCT03922607 67 72 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03922607 73 75 O
age NCT03922607 76 79 O
and NCT03922607 80 83 O
in NCT03922607 84 86 O
general NCT03922607 87 94 B-Condition-Name
good NCT03922607 95 99 I-Condition-Name
health NCT03922607 100 106 I-Condition-Name
for NCT03922607 107 110 O
Substudy NCT03922607 111 119 O
1 NCT03922607 121 122 O
and NCT03922607 123 126 O
participant NCT03922607 127 138 O
with NCT03922607 139 143 O
moderate NCT03922607 144 152 B-Severity___Severity-Value:moderate
to NCT03922607 153 155 B-Eq-Operator___Eq-Operator-Value:BETWEEN
severe NCT03922607 156 162 B-Severity___Severity-Value:severe
chronic NCT03922607 163 170 O
plaque NCT03922607 171 177 B-Condition-Name
psoriasis NCT03922607 178 187 I-Condition-Name
between NCT03922607 188 195 B-Eq-Operator___Eq-Operator-Value:BETWEEN
18 NCT03922607 197 199 B-Eq-Value
and NCT03922607 200 203 O
75 NCT03922607 205 207 B-Eq-Value
years NCT03922607 208 213 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03922607 214 216 O
age NCT03922607 217 220 O
for NCT03922607 221 224 O
Substudy NCT03922607 225 233 O
2 NCT03922607 235 236 O
at NCT03922607 237 239 O
the NCT03922607 240 243 O
time NCT03922607 244 248 O
of NCT03922607 249 251 O
enrollment NCT03922607 252 262 O
. NCT03922607 263 264 O

- NCT03922607 268 269 O
Participant NCT03922607 271 282 O
should NCT03922607 283 289 O
meet NCT03922607 290 294 O
the NCT03922607 295 298 O
laboratory NCT03922607 299 309 O
assessments NCT03922607 310 321 O
as NCT03922607 322 324 O
mentioned NCT03922607 325 334 O
in NCT03922607 335 337 O
the NCT03922607 338 341 O
protocol NCT03922607 342 350 O
. NCT03922607 351 352 O

Exclusion NCT03922607 354 363 O
Criteria NCT03922607 364 372 O
: NCT03922607 373 374 O

- NCT03922607 378 379 O
Participant NCT03922607 381 392 O
has NCT03922607 393 396 O
a NCT03922607 397 398 O
history NCT03922607 399 406 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03922607 407 409 O
epilepsy NCT03922607 410 418 B-Condition-Name
, NCT03922607 419 420 O
any NCT03922607 421 424 O
significant NCT03922607 425 436 B-Severity___Severity-Value:severe
cardiac NCT03922607 437 444 O
, NCT03922607 445 446 O
respiratory NCT03922607 447 458 O
, NCT03922607 459 460 O
renal NCT03922607 461 466 O
, NCT03922607 467 468 O
hepatic NCT03922607 469 476 O
, NCT03922607 477 478 O
gastrointestinal NCT03922607 479 495 O
, NCT03922607 496 497 O
opthalmologic NCT03922607 498 511 O
, NCT03922607 512 513 O
hematologic NCT03922607 514 525 O
, NCT03922607 526 527 O
or NCT03922607 528 530 O
psychiatric NCT03922607 531 542 O
disease NCT03922607 543 550 B-Condition-Name
or NCT03922607 551 553 O
disorder NCT03922607 554 562 B-Condition-Name
, NCT03922607 563 564 O
or NCT03922607 565 567 O
any NCT03922607 568 571 O
uncontrolled NCT03922607 572 584 O
medical NCT03922607 585 592 O
illness NCT03922607 593 600 O
. NCT03922607 601 602 O

Inclusion NCT03927794 0 9 O
Criteria NCT03927794 10 18 O
: NCT03927794 19 20 O

- NCT03927794 24 25 O
≥ NCT03927794 27 28 B-Eq-Operator___Eq-Operator-Value:GTEQ
1 NCT03927794 30 31 B-Eq-Value
Primary NCT03927794 32 39 O
Anterior NCT03927794 40 48 O
Teeth NCT03927794 49 54 O
with NCT03927794 55 59 O
early NCT03927794 60 65 O
carious NCT03927794 66 73 B-Condition-Name
lesion NCT03927794 74 80 I-Condition-Name
( NCT03927794 81 82 O
Class NCT03927794 83 88 B-Eq-Unit
V NCT03927794 89 90 B-Eq-Value
) NCT03927794 91 92 O
of NCT03927794 93 95 O
ICDAS NCT03927794 96 101 B-Observation-Name___Observation-Type-Value:clinical-score
scores NCT03927794 102 108 I-Observation-Name___Observation-Type-Value:clinical-score
1 NCT03927794 110 111 B-Eq-Value
- NCT03927794 112 113 B-Eq-Operator___Eq-Operator-Value:BETWEEN
2 NCT03927794 115 116 B-Eq-Value
. NCT03927794 116 117 O

- NCT03927794 121 122 O
Subjects NCT03927794 124 132 O
whose NCT03927794 133 138 O
parents NCT03927794 139 146 O
are NCT03927794 147 150 O
willing NCT03927794 151 158 O
and NCT03927794 159 162 O
able NCT03927794 163 167 O
to NCT03927794 168 170 O
maintain NCT03927794 171 179 B-Stability___Stability-Value:stable
good NCT03927794 180 184 B-Polarity___Polarity-Value:normal
oral NCT03927794 185 189 B-Condition-Name
hygiene NCT03927794 190 197 I-Condition-Name
for NCT03927794 198 201 O
their NCT03927794 202 207 O
children NCT03927794 208 216 O
and NCT03927794 217 220 O
attend NCT03927794 221 227 O
study NCT03927794 228 233 O
visits NCT03927794 234 240 O
. NCT03927794 241 242 O

- NCT03927794 246 247 O
Subjects NCT03927794 249 257 O
with NCT03927794 258 262 O
Saliva NCT03927794 263 269 B-Observation-Name___Observation-Type-Value:measurement
of NCT03927794 270 272 O
normal NCT03927794 273 279 B-Polarity___Polarity-Value:normal
flow NCT03927794 280 284 O
rates NCT03927794 285 290 O
( NCT03927794 291 292 O
30 NCT03927794 294 296 B-Eq-Value
- NCT03927794 297 298 B-Eq-Operator___Eq-Operator-Value:BETWEEN
60 NCT03927794 300 302 B-Eq-Value
sec NCT03927794 303 306 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:second
) NCT03927794 307 308 O
and NCT03927794 309 312 O
with NCT03927794 313 317 O
healthy NCT03927794 318 325 B-Polarity___Polarity-Value:normal
saliva NCT03927794 326 332 B-Observation-Name___Observation-Type-Value:lab
pH NCT03927794 333 335 I-Observation-Name___Observation-Type-Value:lab
6.75 NCT03927794 337 341 B-Eq-Value
- NCT03927794 342 343 B-Eq-Operator___Eq-Operator-Value:BETWEEN
7.25 NCT03927794 345 349 B-Eq-Value
. NCT03927794 349 350 O

- NCT03927794 359 360 O
Patients NCT03927794 362 370 O
aged NCT03927794 371 375 O
between NCT03927794 376 383 B-Eq-Operator___Eq-Operator-Value:BETWEEN
3 NCT03927794 385 386 B-Eq-Value
- NCT03927794 387 388 O
5 NCT03927794 390 391 B-Eq-Value
years NCT03927794 392 397 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
. NCT03927794 398 399 O

- NCT03927794 403 404 O
Subjects NCT03927794 406 414 O
with NCT03927794 415 419 O
a NCT03927794 420 421 O
minimum NCT03927794 422 429 O
of NCT03927794 430 432 O
1 NCT03927794 434 435 B-Eq-Value
and NCT03927794 436 439 O
a NCT03927794 440 441 O
maximum NCT03927794 442 449 O
of NCT03927794 450 452 O
12 NCT03927794 454 456 B-Eq-Value
primary NCT03927794 457 464 O
anterior NCT03927794 465 473 O
teeth NCT03927794 474 479 O
with NCT03927794 480 484 O
early NCT03927794 485 490 O
carious NCT03927794 491 498 B-Condition-Name
lesions NCT03927794 499 506 I-Condition-Name
Class NCT03927794 507 512 B-Eq-Unit
V NCT03927794 513 514 B-Eq-Value
of NCT03927794 515 517 O
ICDAS NCT03927794 518 523 B-Observation-Name___Observation-Type-Value:clinical-score
score NCT03927794 524 529 I-Observation-Name___Observation-Type-Value:clinical-score
1 NCT03927794 531 532 B-Eq-Value
- NCT03927794 533 534 B-Eq-Operator___Eq-Operator-Value:BETWEEN
2 NCT03927794 536 537 B-Eq-Value
. NCT03927794 537 538 O

Exclusion NCT03927794 540 549 O
Criteria NCT03927794 550 558 O
: NCT03927794 559 560 O

- NCT03927794 564 565 O
Primary NCT03927794 567 574 O
anterior NCT03927794 575 583 O
teeth NCT03927794 584 589 O
in NCT03927794 590 592 O
which NCT03927794 593 598 O
carious NCT03927794 599 606 B-Condition-Name
lesions NCT03927794 607 614 I-Condition-Name
are NCT03927794 615 618 O
scored NCT03927794 619 625 O
with NCT03927794 626 630 O
ICDAS NCT03927794 631 636 B-Observation-Name___Observation-Type-Value:clinical-score
≥ NCT03927794 637 638 B-Eq-Operator___Eq-Operator-Value:GTEQ
3 NCT03927794 640 641 B-Eq-Value
. NCT03927794 641 642 O

- NCT03927794 646 647 O
Subjects NCT03927794 649 657 O
on NCT03927794 658 660 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
medication NCT03927794 661 671 O
that NCT03927794 672 676 O
affects NCT03927794 677 684 B-Stability___Stability-Value:change
the NCT03927794 685 688 O
salivary NCT03927794 689 697 B-Observation-Name___Observation-Type-Value:measurement
flow NCT03927794 698 702 I-Observation-Name___Observation-Type-Value:measurement
rate NCT03927794 703 707 I-Observation-Name___Observation-Type-Value:measurement
. NCT03927794 708 709 O

- NCT03927794 713 714 O
Subjects NCT03927794 716 724 O
with NCT03927794 725 729 O
evidence NCT03927794 730 738 O
of NCT03927794 739 741 O
reduced NCT03927794 742 749 B-Polarity___Polarity-Value:low
salivary NCT03927794 750 758 B-Observation-Name___Observation-Type-Value:measurement
flow NCT03927794 759 763 I-Observation-Name___Observation-Type-Value:measurement
( NCT03927794 764 765 O
> NCT03927794 767 768 B-Eq-Operator___Eq-Operator-Value:GT
60 NCT03927794 770 772 B-Eq-Value
sec NCT03927794 773 776 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:second
) NCT03927794 777 778 O
or NCT03927794 779 781 O
with NCT03927794 782 786 O
acidic NCT03927794 787 793 O
saliva NCT03927794 794 800 B-Observation-Name___Observation-Type-Value:lab
pH NCT03927794 801 803 I-Observation-Name___Observation-Type-Value:lab
˂ NCT03927794 804 805 B-Eq-Operator___Eq-Operator-Value:LT
5.8 NCT03927794 807 810 B-Eq-Value
. NCT03927794 810 811 O


Inclusion NCT03924505 0 9 O
Criteria NCT03924505 10 18 O
: NCT03924505 19 20 O

- NCT03924505 24 25 O
SSPs NCT03924505 27 31 B-Condition-Name
that NCT03924505 32 36 O
participate NCT03924505 37 48 O
in NCT03924505 49 51 O
the NCT03924505 52 55 O
on NCT03924505 56 58 O
- NCT03924505 59 60 O
line NCT03924505 61 65 O
screening NCT03924505 66 75 O
survey NCT03924505 76 82 O
and NCT03924505 83 86 O
fall NCT03924505 87 91 O
into NCT03924505 92 96 O
the NCT03924505 97 100 O
implementation NCT03924505 101 115 O
phase NCT03924505 116 121 O
of NCT03924505 122 124 O
the NCT03924505 125 128 O
EPIS NCT03924505 129 133 B-Condition-Name
continuum NCT03924505 134 143 I-Condition-Name
will NCT03924505 144 148 O
be NCT03924505 149 151 O
recruited NCT03924505 152 161 O
into NCT03924505 162 166 O
the NCT03924505 167 170 O
study NCT03924505 171 176 O
. NCT03924505 177 178 O

Exclusion NCT03924505 180 189 O
Criteria NCT03924505 190 198 O
: NCT03924505 199 200 O

- NCT03924505 203 204 O

Inclusion NCT03926312 0 9 O
Criteria NCT03926312 10 18 O
: NCT03926312 19 20 O

1 NCT03926312 25 26 O
. NCT03926312 26 27 O
Signed NCT03926312 29 35 O
informed NCT03926312 36 44 O
consent NCT03926312 45 52 O
with NCT03926312 53 57 O
the NCT03926312 58 61 O
study NCT03926312 62 67 O

2 NCT03926312 71 72 O
. NCT03926312 72 73 O
Men NCT03926312 75 78 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
and NCT03926312 79 82 O
women NCT03926312 83 88 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
> NCT03926312 89 90 B-Eq-Operator___Eq-Operator-Value:GT
18 NCT03926312 92 94 B-Eq-Value
years NCT03926312 95 100 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03926312 101 103 O
age NCT03926312 104 107 O

3 NCT03926312 111 112 O
. NCT03926312 112 113 O
Patients NCT03926312 115 123 O
≥ NCT03926312 124 125 B-Eq-Operator___Eq-Operator-Value:GTEQ
1 NCT03926312 127 128 B-Eq-Value
and NCT03926312 129 132 O
≤ NCT03926312 133 134 B-Eq-Operator___Eq-Operator-Value:LTEQ
6 NCT03926312 136 137 B-Eq-Value
months NCT03926312 138 144 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
after NCT03926312 145 150 O
type NCT03926312 151 155 B-Eq-Unit
I NCT03926312 156 157 B-Eq-Value
myocardial NCT03926312 158 168 B-Condition-Name
infarction NCT03926312 169 179 I-Condition-Name

4 NCT03926312 183 184 O
. NCT03926312 184 185 O
Physical NCT03926312 187 195 B-Condition-Name
inactivity NCT03926312 196 206 I-Condition-Name
before NCT03926312 207 213 O
MI NCT03926312 214 216 B-Condition-Name
defined NCT03926312 217 224 O
as NCT03926312 225 227 O
the NCT03926312 228 231 O
absence NCT03926312 232 239 O
of NCT03926312 240 242 O
moderate NCT03926312 243 251 B-Severity___Severity-Value:moderate
to NCT03926312 252 254 O
vigorous NCT03926312 255 263 B-Severity___Severity-Value:severe
exercise NCT03926312 264 272 B-Observation-Name___Observation-Type-Value:social-habit
for NCT03926312 273 276 O
at NCT03926312 277 279 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03926312 280 285 I-Eq-Operator___Eq-Operator-Value:GTEQ
30 NCT03926312 287 289 B-Eq-Value
minutes NCT03926312 290 297 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:minute
5 NCT03926312 299 300 B-Eq-Value
or NCT03926312 301 303 B-Eq-Operator___Eq-Operator-Value:GTEQ
more NCT03926312 304 308 I-Eq-Operator___Eq-Operator-Value:GTEQ
days NCT03926312 309 313 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
a NCT03926312 314 315 O
week NCT03926312 316 320 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week

Exclusion NCT03926312 321 330 O
Criteria NCT03926312 331 339 O
: NCT03926312 340 341 O

1 NCT03926312 346 347 O
. NCT03926312 347 348 O
Heart NCT03926312 350 355 B-Condition-Name
failure NCT03926312 356 363 I-Condition-Name
NYHA NCT03926312 364 368 B-Condition-Name
IIIB NCT03926312 369 373 B-Eq-Value
- NCT03926312 374 375 B-Eq-Operator___Eq-Operator-Value:BETWEEN
IV NCT03926312 376 378 B-Eq-Value

2 NCT03926312 382 383 O
. NCT03926312 383 384 O
Planned NCT03926312 386 393 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
coronary NCT03926312 394 402 B-Procedure-Name
revascularization NCT03926312 403 420 I-Procedure-Name

3 NCT03926312 424 425 O
. NCT03926312 425 426 O
Planned NCT03926312 428 435 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
major NCT03926312 436 441 B-Severity___Severity-Value:severe
surgery NCT03926312 442 449 B-Procedure-Name
within NCT03926312 450 456 B-Eq-Operator___Eq-Operator-Value:LTEQ
the NCT03926312 457 460 O
next NCT03926312 461 465 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
12 NCT03926312 467 469 B-Eq-Value
months NCT03926312 470 476 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

4 NCT03926312 480 481 O
. NCT03926312 481 482 O
Inability NCT03926312 484 493 B-Condition-Name
to NCT03926312 494 496 I-Condition-Name
walk NCT03926312 497 501 I-Condition-Name
for NCT03926312 502 505 O
any NCT03926312 506 509 O
reason NCT03926312 510 516 O

5 NCT03926312 520 521 O
. NCT03926312 521 522 O
Comorbidities NCT03926312 524 537 B-Condition-Name
that NCT03926312 538 542 O
would NCT03926312 543 548 O
preclude NCT03926312 549 557 B-Stability___Stability-Value:change
adherence NCT03926312 558 567 O
to NCT03926312 568 570 O
the NCT03926312 571 574 O
rehabilitation NCT03926312 575 589 B-Procedure-Name
program NCT03926312 590 597 I-Procedure-Name
( NCT03926312 598 599 O
e NCT03926312 600 601 O
. NCT03926312 602 603 O
g NCT03926312 604 605 O
. NCT03926312 606 607 O
arthrosis NCT03926312 609 618 B-Condition-Name
, NCT03926312 619 620 O
active NCT03926312 621 627 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
malignancy NCT03926312 628 638 B-Condition-Name
, NCT03926312 639 640 O
major NCT03926312 641 646 B-Condition-Name
depression NCT03926312 647 657 I-Condition-Name
or NCT03926312 658 660 O
other NCT03926312 661 666 O
significant NCT03926312 667 678 B-Severity___Severity-Value:severe
psychiatric NCT03926312 679 690 B-Condition-Name
disorder NCT03926312 691 699 I-Condition-Name
, NCT03926312 700 701 O
cognitive NCT03926312 702 711 B-Condition-Name
impairment NCT03926312 712 722 I-Condition-Name
) NCT03926312 723 724 O
- NCT03926312 725 726 O
at NCT03926312 727 729 O
the NCT03926312 730 733 O
discretion NCT03926312 734 744 O
of NCT03926312 745 747 O
the NCT03926312 748 751 O
physician NCT03926312 752 761 O

6 NCT03926312 765 766 O
. NCT03926312 766 767 O
Life NCT03926312 769 773 B-Observation-Name
expectancy NCT03926312 774 784 I-Observation-Name
less NCT03926312 785 789 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03926312 790 794 I-Eq-Operator___Eq-Operator-Value:LT
12 NCT03926312 796 798 B-Eq-Value
months NCT03926312 799 805 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

7 NCT03926312 809 810 O
. NCT03926312 810 811 O
Pregnancy NCT03926312 813 822 B-Condition-Name

8 NCT03926312 826 827 O
. NCT03926312 827 828 O
Inability NCT03926312 830 839 O
to NCT03926312 840 842 O
operate NCT03926312 843 850 B-Observation-Name
the NCT03926312 851 854 I-Observation-Name
smart NCT03926312 855 860 I-Observation-Name
- NCT03926312 861 862 I-Observation-Name
watch NCT03926312 863 868 I-Observation-Name

Inclusion NCT03927742 0 9 O
Criteria NCT03927742 10 18 O
: NCT03927742 19 20 O

- NCT03927742 24 25 O
18 NCT03927742 28 30 B-Eq-Value
- NCT03927742 31 32 B-Eq-Operator___Eq-Operator-Value:BETWEEN
75 NCT03927742 34 36 B-Eq-Value
years NCT03927742 37 42 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03927742 43 46 O

- NCT03927742 49 50 O
Diagnosed NCT03927742 52 61 O
with NCT03927742 62 66 O
cutaneous NCT03927742 67 76 B-Condition-Name
invasive NCT03927742 77 85 I-Condition-Name
melanoma NCT03927742 86 94 I-Condition-Name
within NCT03927742 95 101 O
HealthPartners NCT03927742 102 116 B-Location___Location-Value:hospital
system NCT03927742 117 123 O
since NCT03927742 124 129 B-Eq-Operator___Eq-Operator-Value:GTEQ
2010 NCT03927742 131 135 B-Eq-Value

- NCT03927742 139 140 O
Able NCT03927742 142 146 O
to NCT03927742 147 149 O
read NCT03927742 150 154 O
/ NCT03927742 155 156 O
write NCT03927742 157 162 O
in NCT03927742 163 165 O
English NCT03927742 166 173 B-Language

- NCT03927742 176 177 O
Own NCT03927742 179 182 O
a NCT03927742 183 184 O
smartphone NCT03927742 185 195 O

- NCT03927742 198 199 O
Able NCT03927742 201 205 O
to NCT03927742 206 208 O
provide NCT03927742 209 216 O
voluntary NCT03927742 217 226 O
informed NCT03927742 227 235 O
consent NCT03927742 236 243 O

Exclusion NCT03927742 244 253 O
Criteria NCT03927742 254 262 O
: NCT03927742 263 264 O

- NCT03927742 268 269 O
Inability NCT03927742 271 280 O
to NCT03927742 281 283 O
provide NCT03927742 284 291 O
informed NCT03927742 292 300 O
written NCT03927742 301 308 O
consent NCT03927742 309 316 O

- NCT03927742 319 320 O
Pregnancy NCT03927742 322 331 B-Condition-Name

Inclusion NCT03925155 0 9 O
Criteria NCT03925155 10 18 O
: NCT03925155 19 20 O

- NCT03925155 24 25 O
Females NCT03925155 27 34 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
aged NCT03925155 35 39 O
18 NCT03925155 41 43 B-Eq-Value
- NCT03925155 44 45 B-Eq-Operator___Eq-Operator-Value:BETWEEN
50 NCT03925155 47 49 B-Eq-Value
years NCT03925155 50 55 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03925155 58 59 O
The NCT03925155 61 64 O
study NCT03925155 65 70 O
will NCT03925155 71 75 O
be NCT03925155 76 78 O
offered NCT03925155 79 86 O
to NCT03925155 87 89 O
women NCT03925155 90 95 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
at NCT03925155 96 98 O
> NCT03925155 99 100 B-Eq-Operator___Eq-Operator-Value:GT
24 NCT03925155 102 104 B-Eq-Value
weeks NCT03925155 105 110 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
gestation NCT03925155 111 120 B-Observation-Name___Observation-Type-Value:measurement
who NCT03925155 121 124 O
are NCT03925155 125 128 O
undergoing NCT03925155 129 139 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
nonemergent NCT03925155 140 151 O
cesarean NCT03925155 152 160 B-Procedure-Name
delivery NCT03925155 161 169 I-Procedure-Name
with NCT03925155 170 174 O
ruptured NCT03925155 175 183 B-Condition-Name
amniotic NCT03925155 184 192 I-Condition-Name
membranes NCT03925155 193 202 I-Condition-Name
. NCT03925155 203 204 O

- NCT03925155 208 209 O
All NCT03925155 211 214 O
patients NCT03925155 215 223 O
undergoing NCT03925155 224 234 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
cesarean NCT03925155 235 243 B-Procedure-Name
delivery NCT03925155 244 252 I-Procedure-Name
with NCT03925155 253 257 O
ruptured NCT03925155 258 266 B-Condition-Name
amniotic NCT03925155 267 275 I-Condition-Name
membranes NCT03925155 276 285 I-Condition-Name
. NCT03925155 286 287 O

Exclusion NCT03925155 289 298 O
Criteria NCT03925155 299 307 O
: NCT03925155 308 309 O

- NCT03925155 313 314 O
Minors NCT03925155 316 322 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child

- NCT03925155 325 326 O
Emergent NCT03925155 328 336 O
cesarean NCT03925155 337 345 B-Procedure-Name
delivery NCT03925155 346 354 I-Procedure-Name
. NCT03925155 355 356 O

- NCT03925155 360 361 O
No NCT03925155 363 365 O
ruptured NCT03925155 366 374 B-Condition-Name
membranes NCT03925155 375 384 I-Condition-Name
. NCT03925155 385 386 O

- NCT03925155 390 391 O
Allergy NCT03925155 393 400 O
to NCT03925155 401 403 O
chlorhexidine NCT03925155 404 417 B-Drug-Name
or NCT03925155 418 420 O
povidone NCT03925155 421 429 B-Drug-Name
- NCT03925155 430 431 I-Drug-Name
iodine NCT03925155 432 438 I-Drug-Name
. NCT03925155 439 440 O

Inclusion NCT03929380 0 9 O
Criteria NCT03929380 10 18 O
: NCT03929380 19 20 O

- NCT03929380 24 25 O
Males NCT03929380 27 32 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
, NCT03929380 33 34 O
with NCT03929380 35 39 O
at NCT03929380 40 42 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03929380 43 48 I-Eq-Operator___Eq-Operator-Value:GTEQ
a NCT03929380 49 50 O
year NCT03929380 51 55 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03929380 56 58 O
experience NCT03929380 59 69 O
in NCT03929380 70 72 O
heavylift NCT03929380 73 82 O
exercises NCT03929380 83 92 B-Observation-Name___Observation-Type-Value:social-habit
, NCT03929380 93 94 O
age NCT03929380 95 98 O
between NCT03929380 99 106 B-Eq-Operator___Eq-Operator-Value:BETWEEN
20 NCT03929380 108 110 B-Eq-Value
and NCT03929380 111 114 O
35 NCT03929380 116 118 B-Eq-Value
years NCT03929380 119 124 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
. NCT03929380 125 126 O

Exclusion NCT03929380 128 137 O
Criteria NCT03929380 138 146 O
: NCT03929380 147 148 O

- NCT03929380 152 153 O


Inclusion NCT03921086 0 9 O
Criteria NCT03921086 10 18 O
: NCT03921086 19 20 O

- NCT03921086 24 25 O
Adult NCT03921086 27 32 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult
( NCT03921086 33 34 O
older NCT03921086 35 40 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03921086 41 45 I-Eq-Operator___Eq-Operator-Value:GT
18 NCT03921086 47 49 B-Eq-Value
years NCT03921086 50 55 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
) NCT03921086 56 57 O

- NCT03921086 61 62 O
Elective NCT03921086 64 72 O
surgery NCT03921086 73 80 B-Procedure-Name
at NCT03921086 81 83 O
pre NCT03921086 84 87 O
operative NCT03921086 88 97 B-Procedure-Name
in NCT03921086 98 100 B-Encounter-Type___Encounter-Type-Value:outpatient
- NCT03921086 101 102 I-Encounter-Type___Encounter-Type-Value:outpatient
hospital NCT03921086 103 111 I-Encounter-Type___Encounter-Type-Value:outpatient
visit NCT03921086 112 117 I-Encounter-Type___Encounter-Type-Value:outpatient

- NCT03921086 120 121 O
All NCT03921086 123 126 O
stage NCT03921086 127 132 O
1 NCT03921086 134 135 B-Eq-Value
and NCT03921086 136 139 O
stage NCT03921086 140 145 O
2 NCT03921086 147 148 B-Eq-Value
hypertensive NCT03921086 149 161 B-Condition-Name
patients NCT03921086 162 170 O
as NCT03921086 171 173 O
defined NCT03921086 174 181 O
by NCT03921086 182 184 O
the NCT03921086 185 188 O
South NCT03921086 189 194 O
African NCT03921086 195 202 O
Hypertension NCT03921086 203 215 O
Practice NCT03921086 216 224 O
Guideline NCT03921086 225 234 O
2014 NCT03921086 236 240 O

Exclusion NCT03921086 242 251 O
Criteria NCT03921086 252 260 O
: NCT03921086 261 262 O

- NCT03921086 266 267 O
Patient NCT03921086 269 276 O
refusal NCT03921086 277 284 O

- NCT03921086 287 288 O
Day NCT03921086 290 293 O
case NCT03921086 294 298 O
surgery NCT03921086 299 306 B-Procedure-Name

- NCT03921086 309 310 O
Obstetric NCT03921086 312 321 O
and NCT03921086 322 325 O
cardiac NCT03921086 326 333 O
surgery NCT03921086 334 341 B-Procedure-Name

- NCT03921086 344 345 O
Patients NCT03921086 347 355 O
with NCT03921086 356 360 O
severe NCT03921086 361 367 B-Severity___Severity-Value:severe
hypertension NCT03921086 368 380 B-Condition-Name
( NCT03921086 381 382 O
> NCT03921086 384 385 B-Eq-Operator___Eq-Operator-Value:GT
180 NCT03921086 387 390 B-Eq-Value
/ NCT03921086 391 392 O
110 NCT03921086 394 397 B-Eq-Unit
mmHg NCT03921086 398 402 B-Eq-Unit
) NCT03921086 403 404 O
as NCT03921086 405 407 O
defined NCT03921086 408 415 O
by NCT03921086 416 418 O
the NCT03921086 419 422 O
South NCT03921086 423 428 O
African NCT03921086 429 436 O
Hypertension NCT03921086 437 449 O
Practice NCT03921086 450 458 O
Guideline NCT03921086 459 468 O
2014 NCT03921086 470 474 O

Inclusion NCT03927391 0 9 O
Criteria NCT03927391 10 18 O
: NCT03927391 19 20 O

- NCT03927391 24 25 O
Frail NCT03927391 27 32 B-Condition-Name
ᵃ NCT03927391 33 34 O
male NCT03927391 35 39 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
patients NCT03927391 40 48 I-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
with NCT03927391 49 53 O
prostate NCT03927391 54 62 O
cancer NCT03927391 63 69 B-Condition-Name
who NCT03927391 70 73 O
will NCT03927391 74 78 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
start NCT03927391 79 84 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
treatment NCT03927391 85 94 O
with NCT03927391 95 99 O
enzalutamide NCT03927391 100 112 B-Drug-Name
within NCT03927391 113 119 O
label NCT03927391 120 125 O

- NCT03927391 128 129 O
Age NCT03927391 131 134 O
at NCT03927391 135 137 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03927391 138 143 I-Eq-Operator___Eq-Operator-Value:GTEQ
18 NCT03927391 145 147 B-Eq-Value
years NCT03927391 148 153 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03927391 156 157 O
Patient NCT03927391 159 166 O
who NCT03927391 167 170 O
are NCT03927391 171 174 O
able NCT03927391 175 179 O
and NCT03927391 180 183 O
willing NCT03927391 184 191 O
to NCT03927391 192 194 O
give NCT03927391 195 199 O
written NCT03927391 200 207 O
informed NCT03927391 208 216 O
consent NCT03927391 217 224 O
prior NCT03927391 225 230 O
to NCT03927391 231 233 O
screening NCT03927391 234 243 O

- NCT03927391 246 247 O
Patients NCT03927391 249 257 O
from NCT03927391 258 262 O
whom NCT03927391 263 267 O
it NCT03927391 268 270 O
is NCT03927391 271 273 O
possible NCT03927391 274 282 O
to NCT03927391 283 285 O
collect NCT03927391 286 293 O
blood NCT03927391 294 299 B-Observation-Specimen
samples NCT03927391 300 307 B-Observation-Name___Observation-Type-Value:lab

- NCT03927391 310 311 O
Patients NCT03927391 313 321 O
who NCT03927391 322 325 O
are NCT03927391 326 329 O
willing NCT03927391 330 337 O
to NCT03927391 338 340 O
answer NCT03927391 341 347 O
the NCT03927391 348 351 O
questionnaires NCT03927391 352 366 B-Observation-Name___Observation-Type-Value:survey-or-questionnaire
and NCT03927391 367 370 O
test NCT03927391 371 375 B-Observation-Name

- NCT03927391 378 379 O
Life NCT03927391 381 385 B-Observation-Name
expectancy NCT03927391 386 396 I-Observation-Name
of NCT03927391 397 399 O
> NCT03927391 400 401 B-Eq-Operator___Eq-Operator-Value:GT
6 NCT03927391 403 404 B-Eq-Value
months NCT03927391 405 411 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

- NCT03927391 414 415 O
Capable NCT03927391 417 424 O
of NCT03927391 425 427 O
understanding NCT03927391 428 441 O
and NCT03927391 442 445 O
answering NCT03927391 446 455 O
Dutch NCT03927391 456 461 B-Language
tests NCT03927391 462 467 B-Observation-Name
and NCT03927391 468 471 O
questionnaires NCT03927391 472 486 B-Observation-Name___Observation-Type-Value:survey-or-questionnaire
, NCT03927391 487 488 O
as NCT03927391 489 491 O
determined NCT03927391 492 502 O
by NCT03927391 503 505 O
the NCT03927391 506 509 O
investigator NCT03927391 510 522 O

ᵃ NCT03927391 524 525 O
Frail NCT03927391 526 531 B-Condition-Name
is NCT03927391 532 534 O
defined NCT03927391 535 542 O
as NCT03927391 543 545 O
: NCT03927391 546 547 O

- NCT03927391 551 552 O
a NCT03927391 554 555 O
score NCT03927391 556 561 O
on NCT03927391 562 564 O
the NCT03927391 565 568 O
comprehensive NCT03927391 569 582 O
G NCT03927391 583 584 B-Observation-Name___Observation-Type-Value:clinical-score
8 NCT03927391 585 586 I-Observation-Name___Observation-Type-Value:clinical-score
assessment NCT03927391 587 597 I-Observation-Name___Observation-Type-Value:clinical-score
with NCT03927391 598 602 O
cut NCT03927391 603 606 O
- NCT03927391 607 608 O
off NCT03927391 609 612 O
≤ NCT03927391 613 614 B-Eq-Operator___Eq-Operator-Value:LTEQ
14 NCT03927391 616 618 B-Eq-Value
points NCT03927391 619 625 O
and NCT03927391 626 629 O

- NCT03927391 632 633 O
score NCT03927391 635 640 O
≥ NCT03927391 641 642 B-Eq-Operator___Eq-Operator-Value:GTEQ
grade NCT03927391 643 648 B-Eq-Unit
1 NCT03927391 650 651 B-Eq-Value
for NCT03927391 652 655 O
Central NCT03927391 656 663 B-Condition-Name
Nervous NCT03927391 664 671 I-Condition-Name
Disorders NCT03927391 672 681 I-Condition-Name
according NCT03927391 682 691 O
to NCT03927391 692 694 O
the NCT03927391 695 698 O
Common NCT03927391 699 705 O
Toxicity NCT03927391 706 714 O
Criteria NCT03927391 715 723 O
Adverse NCT03927391 724 731 O
Event NCT03927391 732 737 O
( NCT03927391 738 739 O
CTCAE NCT03927391 740 745 O
) NCT03927391 746 747 O
criteria NCT03927391 748 756 O
, NCT03927391 757 758 O
of NCT03927391 759 761 O
one NCT03927391 762 765 B-Eq-Value
of NCT03927391 766 768 O
the NCT03927391 769 772 O
following NCT03927391 773 782 O
: NCT03927391 783 784 O
Fatigue NCT03927391 785 792 B-Condition-Name
, NCT03927391 793 794 O
Concentration NCT03927391 795 808 B-Condition-Name
impairment NCT03927391 809 819 I-Condition-Name
, NCT03927391 820 821 O
cognitive NCT03927391 822 831 B-Condition-Name
disturbance NCT03927391 832 843 I-Condition-Name
, NCT03927391 844 845 O
amnesia NCT03927391 846 853 B-Condition-Name
, NCT03927391 854 855 O
depressed NCT03927391 856 865 B-Condition-Name
level NCT03927391 866 871 I-Condition-Name
of NCT03927391 872 874 I-Condition-Name
consciousness NCT03927391 875 888 I-Condition-Name
, NCT03927391 889 890 O
memory NCT03927391 891 897 B-Condition-Name
impairment NCT03927391 898 908 I-Condition-Name
, NCT03927391 909 910 O
hypersomnia NCT03927391 911 922 B-Condition-Name
. NCT03927391 923 924 O

Exclusion NCT03927391 926 935 O
Criteria NCT03927391 936 944 O
: NCT03927391 945 946 O

- NCT03927391 950 951 O
change NCT03927391 953 959 B-Stability___Stability-Value:change
in NCT03927391 960 962 O
dose NCT03927391 963 967 O
of NCT03927391 968 970 O
opioids NCT03927391 971 978 B-Drug-Name
/ NCT03927391 979 980 O
sedatives NCT03927391 981 990 B-Drug-Name
/ NCT03927391 991 992 O
benzodiazepines NCT03927391 993 1008 B-Drug-Name
during NCT03927391 1009 1015 O
last NCT03927391 1016 1020 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
2 NCT03927391 1022 1023 B-Eq-Value
weeks NCT03927391 1024 1029 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
before NCT03927391 1030 1036 O
study NCT03927391 1037 1042 O
) NCT03927391 1043 1044 O

- NCT03927391 1048 1049 O
Use NCT03927391 1051 1054 O
of NCT03927391 1055 1057 O
psychostimulants NCT03927391 1058 1074 B-Drug-Name
such NCT03927391 1075 1079 O
as NCT03927391 1080 1082 O
methylphenidate NCT03927391 1083 1098 B-Drug-Name
within NCT03927391 1099 1105 B-Eq-Operator___Eq-Operator-Value:LTEQ
1 NCT03927391 1107 1108 B-Eq-Value
week NCT03927391 1109 1113 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
of NCT03927391 1114 1116 O
start NCT03927391 1117 1122 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
of NCT03927391 1123 1125 O
study NCT03927391 1126 1131 O

- NCT03927391 1134 1135 O
Diagnosed NCT03927391 1137 1146 O
with NCT03927391 1147 1151 O
medical NCT03927391 1152 1159 O
conditions NCT03927391 1160 1170 O
that NCT03927391 1171 1175 O
affect NCT03927391 1176 1182 B-Stability___Stability-Value:change
cognition NCT03927391 1183 1192 B-Condition-Name
: NCT03927391 1193 1194 O
Dementia NCT03927391 1195 1203 B-Condition-Name
, NCT03927391 1204 1205 O
Alzheimer NCT03927391 1206 1215 B-Condition-Name
disease NCT03927391 1216 1223 I-Condition-Name
, NCT03927391 1224 1225 O
Parkinson NCT03927391 1226 1235 B-Condition-Name
's NCT03927391 1235 1237 I-Condition-Name
disease NCT03927391 1238 1245 I-Condition-Name
, NCT03927391 1246 1247 O
psychiatric NCT03927391 1248 1259 B-Condition-Name
disorders NCT03927391 1260 1269 I-Condition-Name
that NCT03927391 1270 1274 O
affect NCT03927391 1275 1281 B-Stability___Stability-Value:change
cognition NCT03927391 1282 1291 B-Condition-Name
other NCT03927391 1292 1297 O
than NCT03927391 1298 1302 O
depression NCT03927391 1303 1313 B-Condition-Name
or NCT03927391 1314 1316 O
anxiety NCT03927391 1317 1324 B-Condition-Name
complaints NCT03927391 1325 1335 O
related NCT03927391 1336 1343 O
to NCT03927391 1344 1346 O
the NCT03927391 1347 1350 O
disease NCT03927391 1351 1358 O

- NCT03927391 1361 1362 O
Active NCT03927391 1364 1370 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
infection NCT03927391 1371 1380 B-Condition-Name
or NCT03927391 1381 1383 O
other NCT03927391 1384 1389 O
comorbidities NCT03927391 1390 1403 B-Condition-Name
that NCT03927391 1404 1408 O
may NCT03927391 1409 1412 O
contribute NCT03927391 1413 1423 O
to NCT03927391 1424 1426 O
REDOSE NCT03927391 1427 1433 O
, NCT03927391 1434 1435 O
February NCT03927391 1436 1444 O
2019 NCT03927391 1446 1450 O
Page NCT03927391 1451 1455 O
7 NCT03927391 1457 1458 O
of NCT03927391 1459 1461 O
53 NCT03927391 1463 1465 O
fatigue NCT03927391 1466 1473 B-Condition-Name
or NCT03927391 1474 1476 O
cognition NCT03927391 1477 1486 B-Condition-Name
change NCT03927391 1487 1493 B-Stability___Stability-Value:change
within NCT03927391 1494 1500 B-Eq-Operator___Eq-Operator-Value:LTEQ
4 NCT03927391 1502 1503 B-Eq-Value
weeks NCT03927391 1504 1509 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
of NCT03927391 1510 1512 O
study NCT03927391 1513 1518 O
entry NCT03927391 1519 1524 O

- NCT03927391 1527 1528 O
Clinical NCT03927391 1530 1538 O
relevant NCT03927391 1539 1547 O
anaemia NCT03927391 1548 1555 B-Condition-Name

- NCT03927391 1558 1559 O
MoCa NCT03927391 1561 1565 B-Observation-Name___Observation-Type-Value:clinical-score
score NCT03927391 1566 1571 I-Observation-Name___Observation-Type-Value:clinical-score
< NCT03927391 1572 1573 B-Eq-Operator___Eq-Operator-Value:LT
20 NCT03927391 1575 1577 B-Eq-Value

- NCT03927391 1581 1582 O
Hypersensitivity NCT03927391 1584 1600 B-Condition-Name
to NCT03927391 1601 1603 O
the NCT03927391 1604 1607 O
active NCT03927391 1608 1614 O
substance NCT03927391 1615 1624 O
or NCT03927391 1625 1627 O
to NCT03927391 1628 1630 O
any NCT03927391 1631 1634 O
of NCT03927391 1635 1637 O
the NCT03927391 1638 1641 O
excipients NCT03927391 1642 1652 O
. NCT03927391 1653 1654 O

Inclusion NCT03924115 0 9 O
Criteria NCT03924115 10 18 O
: NCT03924115 19 20 O

- NCT03924115 24 25 O
People NCT03924115 27 33 O
under NCT03924115 34 39 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
treatment NCT03924115 40 49 O
for NCT03924115 50 53 O
hypertension NCT03924115 54 66 B-Condition-Name

- NCT03924115 69 70 O
Both NCT03924115 72 76 O
sexes NCT03924115 77 82 O

- NCT03924115 85 86 O
Older NCT03924115 88 93 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03924115 94 98 I-Eq-Operator___Eq-Operator-Value:GT
60 NCT03924115 100 102 B-Eq-Value
years NCT03924115 103 108 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03924115 111 112 O
Autovalent NCT03924115 114 124 B-Condition-Name

- NCT03924115 127 128 O
read NCT03924115 130 134 O
and NCT03924115 135 138 O
write NCT03924115 139 144 O

Exclusion NCT03924115 145 154 O
Criteria NCT03924115 155 163 O
: NCT03924115 164 165 O

- NCT03924115 169 170 O
Under NCT03924115 172 177 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
treatment NCT03924115 178 187 O
for NCT03924115 188 191 O
severe NCT03924115 192 198 B-Severity___Severity-Value:severe
psychiatric NCT03924115 199 210 B-Condition-Name
pathology NCT03924115 211 220 I-Condition-Name

- NCT03924115 223 224 O
Mental NCT03924115 226 232 B-Condition-Name
retardation NCT03924115 233 244 I-Condition-Name
. NCT03924115 245 246 O

Inclusion NCT03926702 0 9 O
Criteria NCT03926702 10 18 O
: NCT03926702 19 20 O

- NCT03926702 24 25 O
Healthy NCT03926702 27 34 O
Volunteers NCT03926702 35 45 O
: NCT03926702 46 47 O
Subjects NCT03926702 48 56 O
must NCT03926702 57 61 O
be NCT03926702 62 64 O
aged NCT03926702 65 69 O
50 NCT03926702 71 73 B-Eq-Value
and NCT03926702 74 77 B-Eq-Operator___Eq-Operator-Value:GTEQ
over NCT03926702 78 82 I-Eq-Operator___Eq-Operator-Value:GTEQ
. NCT03926702 83 84 O
These NCT03926702 86 91 O
individuals NCT03926702 92 103 O
will NCT03926702 104 108 O
all NCT03926702 109 112 O
be NCT03926702 113 115 O
of NCT03926702 116 118 O
good NCT03926702 119 123 B-Polarity___Polarity-Value:normal
general NCT03926702 124 131 B-Condition-Name
medical NCT03926702 132 139 I-Condition-Name
health NCT03926702 140 146 I-Condition-Name
with NCT03926702 147 151 O
no NCT03926702 152 154 O
neurological NCT03926702 155 167 B-Condition-Name
diseases NCT03926702 168 176 I-Condition-Name
and NCT03926702 177 180 O
capable NCT03926702 181 188 O
of NCT03926702 189 191 O
providing NCT03926702 192 201 O
informed NCT03926702 202 210 O
consent NCT03926702 211 218 O
. NCT03926702 219 220 O

- NCT03926702 224 225 O
Patients NCT03926702 227 235 O
: NCT03926702 236 237 O
Subjects NCT03926702 238 246 O
must NCT03926702 247 251 O
be NCT03926702 252 254 O
aged NCT03926702 255 259 O
50 NCT03926702 261 263 B-Eq-Value
and NCT03926702 264 267 B-Eq-Operator___Eq-Operator-Value:GTEQ
over NCT03926702 268 272 I-Eq-Operator___Eq-Operator-Value:GTEQ
. NCT03926702 273 274 O
Patients NCT03926702 276 284 O
will NCT03926702 285 289 O
meet NCT03926702 290 294 O
diagnostic NCT03926702 295 305 O
criteria NCT03926702 306 314 O
at NCT03926702 315 317 O
UCSF NCT03926702 318 322 B-Location___Location-Value:hospital
for NCT03926702 323 326 O
Alzheimer NCT03926702 327 336 B-Condition-Name
's NCT03926702 336 338 I-Condition-Name
disease NCT03926702 339 346 I-Condition-Name
( NCT03926702 347 348 O
AD NCT03926702 349 351 B-Condition-Name
) NCT03926702 352 353 O
, NCT03926702 355 356 O
mild NCT03926702 357 361 B-Severity___Severity-Value:mild
cognitive NCT03926702 362 371 B-Condition-Name
impairment NCT03926702 372 382 I-Condition-Name
( NCT03926702 383 384 O
MCI NCT03926702 385 388 B-Condition-Name
) NCT03926702 389 390 O
, NCT03926702 392 393 O
or NCT03926702 394 396 O
progressive NCT03926702 397 408 B-Condition-Name
supranuclear NCT03926702 409 421 I-Condition-Name
palsy NCT03926702 422 427 I-Condition-Name
( NCT03926702 428 429 O
PSP NCT03926702 430 433 B-Condition-Name
) NCT03926702 434 435 O
. NCT03926702 437 438 O

Exclusion NCT03926702 440 449 O
Criteria NCT03926702 450 458 O
: NCT03926702 459 460 O

- NCT03926702 464 465 O
Any NCT03926702 467 470 O
medical NCT03926702 471 478 O
contraindications NCT03926702 479 496 O
to NCT03926702 497 499 O
an NCT03926702 500 502 O
MRI NCT03926702 503 506 B-Procedure-Name
scan NCT03926702 507 511 I-Procedure-Name

- NCT03926702 514 515 O
A NCT03926702 517 518 O
pacemaker NCT03926702 519 528 B-Procedure-Name

- NCT03926702 531 532 O
Metal NCT03926702 534 539 B-Condition-Name
clips NCT03926702 540 545 I-Condition-Name
in NCT03926702 546 548 O
brain NCT03926702 549 554 O
or NCT03926702 555 557 O
tattoos NCT03926702 558 565 B-Observation-Name
above NCT03926702 566 571 O
neck NCT03926702 572 576 O

- NCT03926702 579 580 O
Metallic NCT03926702 582 590 B-Condition-Name
implants NCT03926702 591 599 I-Condition-Name
or NCT03926702 600 602 O
shrapnel NCT03926702 603 611 B-Condition-Name
in NCT03926702 612 614 O
body NCT03926702 615 619 O

- NCT03926702 622 623 O
Any NCT03926702 625 628 O
body NCT03926702 629 633 O
jewelry NCT03926702 634 641 B-Observation-Name
or NCT03926702 642 644 O
piercings NCT03926702 645 654 B-Observation-Name
that NCT03926702 655 659 O
are NCT03926702 660 663 O
not NCT03926702 664 667 O
removable NCT03926702 668 677 O

- NCT03926702 680 681 O
A NCT03926702 683 684 O
history NCT03926702 685 692 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03926702 693 695 O
claustrophobia NCT03926702 696 710 B-Condition-Name

- NCT03926702 713 714 O
A NCT03926702 716 717 O
known NCT03926702 718 723 O
major NCT03926702 724 729 B-Severity___Severity-Value:severe
systemic NCT03926702 730 738 B-Condition-Name
disease NCT03926702 739 746 I-Condition-Name

- NCT03926702 749 750 O
A NCT03926702 752 753 O
history NCT03926702 754 761 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03926702 762 764 O
a NCT03926702 765 766 O
psychiatric NCT03926702 767 778 B-Condition-Name
disorder NCT03926702 779 787 I-Condition-Name

- NCT03926702 790 791 O
A NCT03926702 793 794 O
history NCT03926702 795 802 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03926702 803 805 O
substance NCT03926702 806 815 B-Condition-Name
abuse NCT03926702 816 821 I-Condition-Name
( NCT03926702 822 823 O
prescription NCT03926702 824 836 O
or NCT03926702 837 839 O
non NCT03926702 840 843 O
- NCT03926702 844 845 O
prescription NCT03926702 846 858 O
) NCT03926702 859 860 O
within NCT03926702 861 867 B-Eq-Operator___Eq-Operator-Value:LTEQ
the NCT03926702 868 871 O
past NCT03926702 872 876 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
5 NCT03926702 878 879 B-Eq-Value
years NCT03926702 880 885 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03926702 888 889 O
A NCT03926702 891 892 O
current NCT03926702 893 900 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
weight NCT03926702 901 907 B-Observation-Name___Observation-Type-Value:vital
of NCT03926702 908 910 O
less NCT03926702 911 915 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03926702 916 920 I-Eq-Operator___Eq-Operator-Value:LT
45 NCT03926702 922 924 B-Eq-Value
kilograms NCT03926702 925 934 B-Eq-Unit
( NCT03926702 935 936 O
100 NCT03926702 938 941 B-Eq-Value
pounds NCT03926702 942 948 B-Eq-Unit
) NCT03926702 949 950 O

- NCT03926702 954 955 O
Difficulty NCT03926702 957 967 B-Condition-Name
in NCT03926702 968 970 I-Condition-Name
urinating NCT03926702 971 980 I-Condition-Name
or NCT03926702 981 983 O
emptying NCT03926702 984 992 B-Condition-Name
the NCT03926702 993 996 I-Condition-Name
bladder NCT03926702 997 1004 I-Condition-Name

- NCT03926702 1007 1008 O
Under NCT03926702 1010 1015 B-Eq-Operator___Eq-Operator-Value:LT
age NCT03926702 1016 1019 O
50 NCT03926702 1021 1023 B-Eq-Value

- NCT03926702 1027 1028 O
Participating NCT03926702 1030 1043 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
in NCT03926702 1044 1046 O
an NCT03926702 1047 1049 O
experimental NCT03926702 1050 1062 O
radiotracer NCT03926702 1063 1074 B-Procedure-Name
study NCT03926702 1075 1080 O

- NCT03926702 1083 1084 O
Subjects NCT03926702 1086 1094 O
must NCT03926702 1095 1099 O
be NCT03926702 1100 1102 O
fluent NCT03926702 1103 1109 O
English NCT03926702 1110 1117 B-Language
speakers NCT03926702 1118 1126 O

Inclusion NCT03929419 0 9 O
Criteria NCT03929419 10 18 O
: NCT03929419 19 20 O

- NCT03929419 24 25 O
female NCT03929419 27 33 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
volunteer NCT03929419 34 43 O
adults NCT03929419 44 50 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:adult

- NCT03929419 53 54 O
HbA NCT03929419 56 59 B-Observation-Name___Observation-Type-Value:lab
1c NCT03929419 60 62 I-Observation-Name___Observation-Type-Value:lab
< NCT03929419 63 64 B-Eq-Operator___Eq-Operator-Value:LT
6.0 NCT03929419 66 69 B-Eq-Value
% NCT03929419 70 71 B-Eq-Unit

- NCT03929419 75 76 O
Age NCT03929419 78 81 O
between NCT03929419 82 89 B-Eq-Operator___Eq-Operator-Value:BETWEEN
18 NCT03929419 91 93 B-Eq-Value
and NCT03929419 94 97 O
30 NCT03929419 99 101 B-Eq-Value
years NCT03929419 102 107 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03929419 110 111 O
Standard NCT03929419 113 121 B-Polarity___Polarity-Value:normal
routine NCT03929419 122 129 O
laboratory NCT03929419 130 140 B-Observation-Name___Observation-Type-Value:lab

- NCT03929419 143 144 O
No NCT03929419 146 148 O
underlying NCT03929419 149 159 O
diseases NCT03929419 160 168 B-Condition-Name

- NCT03929419 171 172 O
No NCT03929419 174 176 O
medication NCT03929419 177 187 O

- NCT03929419 190 191 O
No NCT03929419 193 195 O
hormonal NCT03929419 196 204 B-Procedure-Name
contraception NCT03929419 205 218 I-Procedure-Name

- NCT03929419 221 222 O
Understanding NCT03929419 224 237 O
of NCT03929419 238 240 O
the NCT03929419 241 244 O
explanations NCT03929419 245 257 O
of NCT03929419 258 260 O
the NCT03929419 261 264 O
study NCT03929419 265 270 O
and NCT03929419 271 274 O
the NCT03929419 275 278 O
instructions NCT03929419 279 291 O

Exclusion NCT03929419 292 301 O
Criteria NCT03929419 302 310 O
: NCT03929419 311 312 O

- NCT03929419 316 317 O
Persons NCT03929419 319 326 O
with NCT03929419 327 331 O
limited NCT03929419 332 339 B-Polarity___Polarity-Value:low
temperature NCT03929419 340 351 B-Condition-Name
perception NCT03929419 352 362 I-Condition-Name
and NCT03929419 363 366 O
/ NCT03929419 367 368 O
or NCT03929419 369 371 O
increased NCT03929419 372 381 B-Polarity___Polarity-Value:high
temperature NCT03929419 382 393 B-Condition-Name
Sensitivity NCT03929419 394 405 I-Condition-Name
to NCT03929419 406 408 O
warming NCT03929419 409 416 O
of NCT03929419 417 419 O
the NCT03929419 420 423 O
body NCT03929419 424 428 O

- NCT03929419 431 432 O
Cardiovascular NCT03929419 434 448 B-Condition-Name
disease NCT03929419 449 456 I-Condition-Name
, NCT03929419 457 458 O
such NCT03929419 459 463 O
as NCT03929419 464 466 O
manifest NCT03929419 467 475 O
coronary NCT03929419 476 484 B-Condition-Name
Heart NCT03929419 485 490 I-Condition-Name
disease NCT03929419 491 498 I-Condition-Name
, NCT03929419 499 500 O
heart NCT03929419 501 506 B-Condition-Name
failure NCT03929419 507 514 I-Condition-Name
greater NCT03929419 515 522 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03929419 523 527 I-Eq-Operator___Eq-Operator-Value:GT
NYHA NCT03929419 528 532 B-Condition-Name
2 NCT03929419 534 535 B-Eq-Value
, NCT03929419 536 537 O
recent NCT03929419 538 544 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:recent
myocardial NCT03929419 545 555 B-Condition-Name
infarction NCT03929419 556 566 I-Condition-Name

- NCT03929419 569 570 O
People NCT03929419 572 578 O
with NCT03929419 579 583 O
a NCT03929419 584 585 O
hearing NCT03929419 586 593 B-Condition-Name
disorder NCT03929419 594 602 I-Condition-Name
or NCT03929419 603 605 O
increased NCT03929419 606 615 B-Polarity___Polarity-Value:high
sensitivity NCT03929419 616 627 B-Condition-Name
to NCT03929419 628 630 I-Condition-Name
loud NCT03929419 631 635 I-Condition-Name
Sounds NCT03929419 636 642 I-Condition-Name

- NCT03929419 645 646 O
persons NCT03929419 648 655 O
with NCT03929419 656 660 O
claustrophobia NCT03929419 661 675 B-Condition-Name

- NCT03929419 678 679 O
Minors NCT03929419 681 687 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
or NCT03929419 688 690 O
non NCT03929419 691 694 O
- NCT03929419 695 696 O
consenting NCT03929419 697 707 O
subjects NCT03929419 708 716 O
are NCT03929419 717 720 O
also NCT03929419 721 725 O
excluded NCT03929419 726 734 O

- NCT03929419 737 738 O
Pregnancy NCT03929419 740 749 B-Condition-Name
or NCT03929419 750 752 O
breastfeeding NCT03929419 753 766 B-Condition-Name
women NCT03929419 767 772 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female

- NCT03929419 775 776 O
Surgery NCT03929419 778 785 B-Procedure-Name
less NCT03929419 786 790 B-Eq-Operator___Eq-Operator-Value:LT
than NCT03929419 791 795 I-Eq-Operator___Eq-Operator-Value:LT
3 NCT03929419 797 798 B-Eq-Value
months NCT03929419 799 805 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
ago NCT03929419 806 809 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past

- NCT03929419 812 813 O
Simultaneous NCT03929419 815 827 O
participation NCT03929419 828 841 O
in NCT03929419 842 844 O
other NCT03929419 845 850 O
interventional NCT03929419 851 865 O
studies NCT03929419 866 873 O

- NCT03929419 876 877 O
Acute NCT03929419 879 884 B-Severity___Severity-Value:severe
illness NCT03929419 885 892 B-Condition-Name
or NCT03929419 893 895 O
infection NCT03929419 896 905 B-Condition-Name
within NCT03929419 906 912 B-Eq-Operator___Eq-Operator-Value:LTEQ
the NCT03929419 913 916 O
last NCT03929419 917 921 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
4 NCT03929419 923 924 B-Eq-Value
weeks NCT03929419 925 930 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week

- NCT03929419 933 934 O
Neurological NCT03929419 936 948 O
and NCT03929419 949 952 O
psychiatric NCT03929419 953 964 O
disorders NCT03929419 965 974 B-Condition-Name

- NCT03929419 977 978 O
Subjects NCT03929419 980 988 O
with NCT03929419 989 993 O
hemoglobin NCT03929419 994 1004 B-Observation-Name___Observation-Type-Value:lab
Hb NCT03929419 1005 1007 I-Observation-Name___Observation-Type-Value:lab
< NCT03929419 1008 1009 B-Eq-Operator___Eq-Operator-Value:LT
12 NCT03929419 1011 1013 B-Eq-Value
g NCT03929419 1014 1015 B-Eq-Unit
/ NCT03929419 1016 1017 O
dl NCT03929419 1018 1020 B-Eq-Unit
( NCT03929419 1021 1022 O
at NCT03929419 1023 1025 O
screening NCT03929419 1026 1035 O
) NCT03929419 1036 1037 O

- NCT03929419 1041 1042 O
Allergic NCT03929419 1044 1052 O
diseases NCT03929419 1053 1061 B-Condition-Name

- NCT03929419 1064 1065 O
Individuals NCT03929419 1067 1078 O
with NCT03929419 1079 1083 O
a NCT03929419 1084 1085 O
history NCT03929419 1086 1093 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03929419 1094 1096 O
heparin NCT03929419 1097 1104 B-Drug-Name
- NCT03929419 1105 1106 O
induced NCT03929419 1107 1114 O
thrombocytopenia NCT03929419 1115 1131 B-Condition-Name
( NCT03929419 1132 1133 O
HIT NCT03929419 1134 1137 B-Condition-Name
) NCT03929419 1138 1139 O

Inclusion NCT03928288 0 9 O
Criteria NCT03928288 10 18 O
: NCT03928288 19 20 O

- NCT03928288 24 25 O
Female NCT03928288 27 33 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
with NCT03928288 34 38 O
surgically NCT03928288 39 49 B-Procedure-Name
- NCT03928288 50 51 O
confirmed NCT03928288 52 61 O
endometriosis NCT03928288 62 75 B-Condition-Name
, NCT03928288 76 77 O
determined NCT03928288 78 88 O
at NCT03928288 89 91 O
laparoscopy NCT03928288 92 103 B-Procedure-Name
performed NCT03928288 104 113 O
within NCT03928288 114 120 B-Eq-Operator___Eq-Operator-Value:LTEQ
3 NCT03928288 122 123 B-Eq-Value
y NCT03928288 124 125 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
prior NCT03928288 126 131 O
to NCT03928288 132 134 O
study NCT03928288 135 140 O
baseline NCT03928288 141 149 O

- NCT03928288 152 153 O
Age NCT03928288 155 158 O
15 NCT03928288 160 162 B-Eq-Value
years NCT03928288 163 168 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
to NCT03928288 169 171 B-Eq-Operator___Eq-Operator-Value:BETWEEN
40 NCT03928288 173 175 B-Eq-Value
years NCT03928288 176 181 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03928288 184 185 O
Current NCT03928288 187 194 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
use NCT03928288 195 198 O
≥ NCT03928288 199 200 B-Eq-Operator___Eq-Operator-Value:GTEQ
2 NCT03928288 202 203 B-Eq-Value
months NCT03928288 204 210 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
duration NCT03928288 211 219 O
of NCT03928288 220 222 O
hormonal NCT03928288 223 231 B-Procedure-Name
therapy NCT03928288 232 239 I-Procedure-Name
such NCT03928288 240 244 O
as NCT03928288 245 247 O
combined NCT03928288 248 256 O
oral NCT03928288 257 261 B-Procedure-Name
contraceptives NCT03928288 262 276 I-Procedure-Name
, NCT03928288 277 278 O
norethindrone NCT03928288 279 292 B-Drug-Name
acetate NCT03928288 293 300 I-Drug-Name
, NCT03928288 301 302 O
or NCT03928288 303 305 O
levonorgestrel NCT03928288 306 320 B-Procedure-Name
intrauterine NCT03928288 321 333 I-Procedure-Name
device NCT03928288 334 340 I-Procedure-Name

- NCT03928288 343 344 O
Current NCT03928288 346 353 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
pelvic NCT03928288 354 360 O
pain NCT03928288 361 365 B-Condition-Name
( NCT03928288 366 367 O
score NCT03928288 368 373 O
≥ NCT03928288 374 375 B-Eq-Operator___Eq-Operator-Value:GTEQ
3 NCT03928288 377 378 B-Eq-Value
on NCT03928288 379 381 O
Visual NCT03928288 382 388 O
Analog NCT03928288 389 395 O
Scale NCT03928288 396 401 O
, NCT03928288 402 403 O
where NCT03928288 404 409 O
0 NCT03928288 411 412 O
represents NCT03928288 413 423 O
absence NCT03928288 424 431 O
of NCT03928288 432 434 O
pain NCT03928288 435 439 O
and NCT03928288 440 443 O
10 NCT03928288 445 447 O
indicates NCT03928288 448 457 O
unbearable NCT03928288 458 468 O
pain NCT03928288 469 473 O
) NCT03928288 474 475 O
present NCT03928288 476 483 O
for NCT03928288 484 487 O
≥ NCT03928288 488 489 B-Eq-Operator___Eq-Operator-Value:GTEQ
14 NCT03928288 491 493 B-Eq-Value
days NCT03928288 494 498 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
/ NCT03928288 499 500 O
month NCT03928288 501 506 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
over NCT03928288 507 511 O
the NCT03928288 512 515 O
2 NCT03928288 517 518 B-Eq-Value
months NCT03928288 519 525 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
prior NCT03928288 526 531 O
to NCT03928288 532 534 O
study NCT03928288 535 540 O
enrollment NCT03928288 541 551 O

- NCT03928288 554 555 O
Willingness NCT03928288 557 568 O
to NCT03928288 569 571 O
comply NCT03928288 572 578 O
with NCT03928288 579 583 O
visit NCT03928288 584 589 O
schedule NCT03928288 590 598 O
and NCT03928288 599 602 O
protocol NCT03928288 603 611 O

Exclusion NCT03928288 612 621 O
Criteria NCT03928288 622 630 O
: NCT03928288 631 632 O

- NCT03928288 636 637 O
Pre NCT03928288 639 642 O
- NCT03928288 643 644 O
menarche NCT03928288 645 653 B-Condition-Name
or NCT03928288 654 656 O
post NCT03928288 657 661 O
- NCT03928288 662 663 O
menopause NCT03928288 664 673 B-Condition-Name

- NCT03928288 676 677 O
Contraindications NCT03928288 679 696 O
to NCT03928288 697 699 O
cabergoline NCT03928288 700 711 B-Drug-Name
( NCT03928288 712 713 O
e NCT03928288 714 715 O
. NCT03928288 716 717 O
g NCT03928288 718 719 O
. NCT03928288 720 721 O
, NCT03928288 722 723 O
cardiac NCT03928288 724 731 B-Condition-Name
valve NCT03928288 732 737 I-Condition-Name
disorder NCT03928288 738 746 I-Condition-Name
; NCT03928288 746 747 O
pulmonary NCT03928288 748 757 O
, NCT03928288 758 759 O
pericardial NCT03928288 760 771 O
, NCT03928288 772 773 O
retroperitoneal NCT03928288 774 789 O
fibrotic NCT03928288 790 798 O
disorder NCT03928288 799 807 B-Condition-Name
; NCT03928288 807 808 O
hypersensitivity NCT03928288 809 825 B-Condition-Name
to NCT03928288 826 828 O
ergot NCT03928288 829 834 O
derivatives NCT03928288 835 846 O
; NCT03928288 846 847 O
uncontrolled NCT03928288 848 860 O
hypertension NCT03928288 861 873 B-Condition-Name
) NCT03928288 874 875 O

- NCT03928288 879 880 O
Significant NCT03928288 882 893 B-Severity___Severity-Value:severe
mental NCT03928288 894 900 O
or NCT03928288 901 903 O
chronic NCT03928288 904 911 O
systemic NCT03928288 912 920 O
illness NCT03928288 921 928 B-Condition-Name
that NCT03928288 929 933 O
might NCT03928288 934 939 O
confound NCT03928288 940 948 B-Stability___Stability-Value:change
pain NCT03928288 949 953 B-Procedure-Name
assessment NCT03928288 954 964 I-Procedure-Name
or NCT03928288 965 967 O
the NCT03928288 968 971 O
ability NCT03928288 972 979 O
to NCT03928288 980 982 O
complete NCT03928288 983 991 O
the NCT03928288 992 995 O
study NCT03928288 996 1001 O

- NCT03928288 1004 1005 O
Pregnant NCT03928288 1007 1015 B-Condition-Name
, NCT03928288 1016 1017 O
breastfeeding NCT03928288 1018 1031 B-Condition-Name
, NCT03928288 1032 1033 O
or NCT03928288 1034 1036 O
planning NCT03928288 1037 1045 O
to NCT03928288 1046 1048 O
become NCT03928288 1049 1055 O
pregnant NCT03928288 1056 1064 B-Condition-Name
in NCT03928288 1065 1067 O
the NCT03928288 1068 1071 O
next NCT03928288 1072 1076 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
6 NCT03928288 1078 1079 B-Eq-Value
months NCT03928288 1080 1086 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

- NCT03928288 1089 1090 O
Impaired NCT03928288 1092 1100 O
liver NCT03928288 1101 1106 O
function NCT03928288 1107 1115 O
( NCT03928288 1116 1117 O
ALT NCT03928288 1118 1121 O
> NCT03928288 1122 1123 O
2 NCT03928288 1125 1126 O
x NCT03928288 1127 1128 O
normal NCT03928288 1129 1135 O
) NCT03928288 1136 1137 O
or NCT03928288 1138 1140 O
liver NCT03928288 1141 1146 O
disease NCT03928288 1147 1154 O

- NCT03928288 1157 1158 O
Breast NCT03928288 1160 1166 O
cancer NCT03928288 1167 1173 B-Condition-Name
, NCT03928288 1174 1175 O
current NCT03928288 1176 1183 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
or NCT03928288 1184 1186 O
previous NCT03928288 1187 1195 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past

- NCT03928288 1198 1199 O
Thromboembolic NCT03928288 1201 1215 B-Condition-Name
disease NCT03928288 1216 1223 I-Condition-Name
, NCT03928288 1224 1225 O
current NCT03928288 1226 1233 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
or NCT03928288 1234 1236 O
previous NCT03928288 1237 1245 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past

- NCT03928288 1248 1249 O
Use NCT03928288 1251 1254 O
of NCT03928288 1255 1257 O
other NCT03928288 1258 1263 O
drugs NCT03928288 1264 1269 O
that NCT03928288 1270 1274 O
affect NCT03928288 1275 1281 B-Stability___Stability-Value:change
dopamine NCT03928288 1282 1290 B-Drug-Name
( NCT03928288 1291 1292 O
e NCT03928288 1293 1294 O
. NCT03928288 1295 1296 O
g NCT03928288 1297 1298 O
. NCT03928288 1299 1300 O
, NCT03928288 1301 1302 O
phenothiazines NCT03928288 1303 1317 B-Drug-Name
, NCT03928288 1318 1319 O
metoclopramide NCT03928288 1320 1334 B-Drug-Name
, NCT03928288 1335 1336 O
butyrophenones NCT03928288 1337 1351 B-Drug-Name
) NCT03928288 1352 1353 O

Inclusion NCT03925948 0 9 O
Criteria NCT03925948 10 18 O
: NCT03925948 19 20 O

- NCT03925948 24 25 O
African NCT03925948 27 34 B-Ethnicity
Americans NCT03925948 35 44 I-Ethnicity
residing NCT03925948 45 53 O
in NCT03925948 54 56 O
Baltimore NCT03925948 57 66 B-Location___Location-Value:residence
, NCT03925948 67 68 I-Location___Location-Value:residence
Maryland NCT03925948 69 77 I-Location___Location-Value:residence

- NCT03925948 80 81 O
had NCT03925948 83 86 O
uncontrolled NCT03925948 87 99 O
diabetes NCT03925948 100 108 B-Condition-Name
( NCT03925948 109 110 O
defined NCT03925948 111 118 O
as NCT03925948 119 121 O
HbA NCT03925948 122 125 B-Observation-Name___Observation-Type-Value:lab
1C NCT03925948 126 128 I-Observation-Name___Observation-Type-Value:lab
> NCT03925948 129 130 B-Eq-Operator___Eq-Operator-Value:GT
7 NCT03925948 132 133 B-Eq-Value
% NCT03925948 134 135 B-Eq-Unit
) NCT03925948 137 138 O

Exclusion NCT03925948 140 149 O
Criteria NCT03925948 150 158 O
: NCT03925948 159 160 O

- NCT03925948 164 165 O
Unable NCT03925948 167 173 O
to NCT03925948 174 176 O
give NCT03925948 177 181 O
informed NCT03925948 182 190 O
consent NCT03925948 191 198 O

- NCT03925948 201 202 O
Physical NCT03925948 204 212 O
or NCT03925948 213 215 O
mental NCT03925948 216 222 O
health NCT03925948 223 229 B-Condition-Name
conditions NCT03925948 230 240 I-Condition-Name
that NCT03925948 241 245 O
could NCT03925948 246 251 O
limit NCT03925948 252 257 B-Stability___Stability-Value:change
active NCT03925948 258 264 O
participation NCT03925948 265 278 O
in NCT03925948 279 281 O
the NCT03925948 282 285 O
study NCT03925948 286 291 O
( NCT03925948 292 293 O
e NCT03925948 294 295 O
. NCT03925948 296 297 O
g NCT03925948 298 299 O
. NCT03925948 300 301 O
, NCT03925948 302 303 O
blindness NCT03925948 304 313 B-Condition-Name
in NCT03925948 314 316 O
both NCT03925948 317 321 O
eyes NCT03925948 322 326 O
, NCT03925948 327 328 O
severe NCT03925948 329 335 B-Severity___Severity-Value:severe
immobility NCT03925948 336 346 B-Condition-Name
, NCT03925948 347 348 O
psychiatric NCT03925948 349 360 B-Condition-Name
diseases NCT03925948 361 369 I-Condition-Name
) NCT03925948 370 371 O

- NCT03925948 375 376 O
Hematological NCT03925948 378 391 B-Condition-Name
condition NCT03925948 392 401 I-Condition-Name
that NCT03925948 402 406 O
would NCT03925948 407 412 O
affect NCT03925948 413 419 B-Stability___Stability-Value:change
HbA NCT03925948 420 423 B-Observation-Name___Observation-Type-Value:lab
1C NCT03925948 424 426 I-Observation-Name___Observation-Type-Value:lab
assay NCT03925948 427 432 I-Observation-Name___Observation-Type-Value:lab
, NCT03925948 433 434 O
e NCT03925948 435 436 O
. NCT03925948 437 438 O
g NCT03925948 439 440 O
. NCT03925948 441 442 O
, NCT03925948 443 444 O
hemolytic NCT03925948 445 454 B-Condition-Name
anemia NCT03925948 455 461 I-Condition-Name
, NCT03925948 462 463 O
sickle NCT03925948 464 470 B-Condition-Name
cell NCT03925948 471 475 I-Condition-Name
anemia NCT03925948 476 482 I-Condition-Name

Inclusion NCT03926299 0 9 O
criteria NCT03926299 10 18 O
: NCT03926299 19 20 O

- NCT03926299 24 25 O
Diagnosis NCT03926299 27 36 O
of NCT03926299 37 39 O
vulvar NCT03926299 40 46 B-Condition-Name
lichen NCT03926299 47 53 I-Condition-Name
sclerosus NCT03926299 54 63 I-Condition-Name

- NCT03926299 66 67 O
Clinical NCT03926299 69 77 O
LS NCT03926299 78 80 B-Observation-Name___Observation-Type-Value:clinical-score
score NCT03926299 81 86 I-Observation-Name___Observation-Type-Value:clinical-score
≥ NCT03926299 87 88 B-Eq-Operator___Eq-Operator-Value:GTEQ
4 NCT03926299 90 91 B-Eq-Value

Exclusion NCT03926299 93 102 O
criteria NCT03926299 103 111 O
: NCT03926299 112 113 O

- NCT03926299 117 118 O
Concomitant NCT03926299 120 131 O
steroid NCT03926299 132 139 B-Drug-Name
, NCT03926299 140 141 O
calcineurin NCT03926299 142 153 B-Drug-Name
inhibitor NCT03926299 154 163 I-Drug-Name
or NCT03926299 164 166 O
any NCT03926299 167 170 O
other NCT03926299 171 176 O
topical NCT03926299 177 184 O
or NCT03926299 185 187 O
systemic NCT03926299 188 196 O
treatment NCT03926299 197 206 O
for NCT03926299 207 210 O
LS NCT03926299 211 213 B-Condition-Name

- NCT03926299 216 217 O
< NCT03926299 219 220 B-Eq-Operator___Eq-Operator-Value:LT
3 NCT03926299 222 223 B-Eq-Value
months NCT03926299 224 230 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
since NCT03926299 231 236 O
start NCT03926299 237 242 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
of NCT03926299 243 245 O
vaginal NCT03926299 246 253 O
estrogen NCT03926299 254 262 B-Procedure-Name
treatment NCT03926299 263 272 I-Procedure-Name

- NCT03926299 275 276 O
Malignant NCT03926299 278 287 B-Condition-Name
disease NCT03926299 288 295 I-Condition-Name
as NCT03926299 296 298 O
the NCT03926299 299 302 O
cause NCT03926299 303 308 O
of NCT03926299 309 311 O
the NCT03926299 312 315 O
vulval NCT03926299 316 322 B-Condition-Name
symptoms NCT03926299 323 331 O

- NCT03926299 334 335 O
BMI NCT03926299 337 340 B-Observation-Name___Observation-Type-Value:vital
> NCT03926299 341 342 B-Eq-Operator___Eq-Operator-Value:GT
35 NCT03926299 344 346 B-Eq-Value
kg NCT03926299 347 349 B-Eq-Unit
/ NCT03926299 350 351 O
m² NCT03926299 352 354 B-Eq-Unit

- NCT03926299 357 358 O
Acute NCT03926299 360 365 B-Severity___Severity-Value:severe
infection NCT03926299 366 375 B-Condition-Name
( NCT03926299 376 377 O
fungal NCT03926299 378 384 O
, NCT03926299 385 386 O
bacterial NCT03926299 387 396 O
, NCT03926299 397 398 O
viral NCT03926299 399 404 O
) NCT03926299 405 406 O
of NCT03926299 407 409 O
the NCT03926299 410 413 O
vulva NCT03926299 414 419 O
, NCT03926299 420 421 O
vagina NCT03926299 422 428 O
or NCT03926299 429 431 O
bladder NCT03926299 432 439 O

- NCT03926299 442 443 O
Presence NCT03926299 445 453 O
of NCT03926299 454 456 O
contraindications NCT03926299 457 474 O
for NCT03926299 475 478 O
the NCT03926299 479 482 O
laser NCT03926299 483 488 B-Procedure-Name
treatment NCT03926299 489 498 I-Procedure-Name
or NCT03926299 499 501 O
topical NCT03926299 502 509 B-Drug-Name
steroid NCT03926299 510 517 I-Drug-Name
treatment NCT03926299 518 527 O

Inclusion NCT03923478 0 9 O
Criteria NCT03923478 10 18 O
: NCT03923478 19 20 O

- NCT03923478 24 25 O
Established NCT03923478 27 38 O
diagnosis NCT03923478 39 48 O
of NCT03923478 49 51 O
UC NCT03923478 52 54 B-Condition-Name
for NCT03923478 55 58 O
at NCT03923478 59 61 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03923478 62 67 I-Eq-Operator___Eq-Operator-Value:GTEQ
3 NCT03923478 69 70 B-Eq-Value
months NCT03923478 71 77 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
prior NCT03923478 78 83 O
to NCT03923478 84 86 O
screening NCT03923478 87 96 O
, NCT03923478 97 98 O
with NCT03923478 99 103 O
minimum NCT03923478 104 111 B-Observation-Name___Observation-Type-Value:measurement
disease NCT03923478 112 119 I-Observation-Name___Observation-Type-Value:measurement
extent NCT03923478 120 126 I-Observation-Name___Observation-Type-Value:measurement
of NCT03923478 127 129 O
15 NCT03923478 131 133 B-Eq-Value
cm NCT03923478 134 136 B-Eq-Unit
from NCT03923478 137 141 O
the NCT03923478 142 145 O
anal NCT03923478 146 150 O
verge NCT03923478 151 156 O

- NCT03923478 159 160 O
Mildly NCT03923478 162 168 B-Severity___Severity-Value:mild
to NCT03923478 169 171 O
moderately NCT03923478 172 182 B-Severity___Severity-Value:moderate
active NCT03923478 183 189 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
UC NCT03923478 190 192 B-Condition-Name

- NCT03923478 195 196 O
Inadequate NCT03923478 198 208 O
response NCT03923478 209 217 O
to NCT03923478 218 220 O
ongoing NCT03923478 221 228 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
treatment NCT03923478 229 238 O
with NCT03923478 239 243 O
oral NCT03923478 244 248 B-Drug-Name
mesalamine NCT03923478 249 259 I-Drug-Name
≥ NCT03923478 260 261 B-Eq-Operator___Eq-Operator-Value:GTEQ
2.4 NCT03923478 263 266 B-Eq-Value
g NCT03923478 267 268 B-Eq-Unit
/ NCT03923478 269 270 O
day NCT03923478 271 274 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
for NCT03923478 275 278 O
≥ NCT03923478 279 280 B-Eq-Operator___Eq-Operator-Value:GTEQ
4 NCT03923478 282 283 B-Eq-Value
weeks NCT03923478 284 289 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
from NCT03923478 290 294 O
screening NCT03923478 295 304 O
visit NCT03923478 305 310 O

Exclusion NCT03923478 311 320 O
Criteria NCT03923478 321 329 O
: NCT03923478 330 331 O

- NCT03923478 335 336 O
Possible NCT03923478 338 346 O
or NCT03923478 347 349 O
confirmed NCT03923478 350 359 O
diagnosis NCT03923478 360 369 O
of NCT03923478 370 372 O
Crohn NCT03923478 373 378 B-Condition-Name
's NCT03923478 378 380 I-Condition-Name
Disease NCT03923478 381 388 I-Condition-Name
or NCT03923478 389 391 O
other NCT03923478 392 397 O
forms NCT03923478 398 403 O
of NCT03923478 404 406 O
inflammatory NCT03923478 407 419 O
bowel NCT03923478 420 425 B-Condition-Name
disorders NCT03923478 426 435 I-Condition-Name

- NCT03923478 438 439 O
Ongoing NCT03923478 441 448 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
or NCT03923478 449 451 O
failed NCT03923478 452 458 O
prior NCT03923478 459 464 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
treatment NCT03923478 465 474 O
for NCT03923478 475 478 O
UC NCT03923478 479 481 B-Condition-Name
with NCT03923478 482 486 O
methotrexate NCT03923478 487 499 B-Drug-Name
, NCT03923478 500 501 O
azathioprine NCT03923478 502 514 B-Drug-Name
, NCT03923478 515 516 O

6 NCT03923478 524 525 B-Drug-Name
- NCT03923478 526 527 I-Drug-Name
mercaptopurine NCT03923478 528 542 I-Drug-Name
, NCT03923478 543 544 O
cyclosporine NCT03923478 545 557 B-Drug-Name
, NCT03923478 558 559 O
tofacitinib NCT03923478 560 571 B-Drug-Name
, NCT03923478 572 573 O
mycophenolate NCT03923478 574 587 B-Drug-Name
mofetil NCT03923478 588 595 I-Drug-Name
, NCT03923478 596 597 O
sirolimus NCT03923478 598 607 B-Drug-Name
( NCT03923478 608 609 O
rapamycin NCT03923478 610 619 B-Drug-Name
) NCT03923478 620 621 O
, NCT03923478 623 624 O
thalidomide NCT03923478 625 636 B-Drug-Name
, NCT03923478 637 638 O
tacrolimus NCT03923478 639 649 B-Drug-Name
( NCT03923478 650 651 O
FK NCT03923478 652 654 B-Drug-Name
- NCT03923478 655 656 I-Drug-Name
506 NCT03923478 658 661 I-Drug-Name
) NCT03923478 662 663 O
, NCT03923478 665 666 O
or NCT03923478 667 669 O
biologics NCT03923478 670 679 B-Drug-Name
( NCT03923478 680 681 O
e NCT03923478 682 683 O
. NCT03923478 684 685 O
g NCT03923478 686 687 O
. NCT03923478 688 689 O
, NCT03923478 690 691 O
TNF NCT03923478 692 695 B-Drug-Name
- NCT03923478 696 697 I-Drug-Name
alpha NCT03923478 698 703 I-Drug-Name
- NCT03923478 704 705 I-Drug-Name
antagonists NCT03923478 706 717 I-Drug-Name
, NCT03923478 718 719 O
anti NCT03923478 720 724 B-Drug-Name
- NCT03923478 725 726 I-Drug-Name
integrin NCT03923478 727 735 I-Drug-Name
therapies NCT03923478 736 745 I-Drug-Name
, NCT03923478 746 747 O
or NCT03923478 748 750 O
agents NCT03923478 751 757 B-Drug-Name
targeting NCT03923478 758 767 I-Drug-Name
IL NCT03923478 768 770 O
- NCT03923478 771 772 O
12 NCT03923478 774 776 O
or NCT03923478 777 779 O
IL NCT03923478 780 782 O
- NCT03923478 783 784 O
23 NCT03923478 786 788 O
, NCT03923478 789 790 O
etc NCT03923478 791 794 O
. NCT03923478 795 796 O
) NCT03923478 797 798 O

- NCT03923478 802 803 O
Any NCT03923478 805 808 O
immunosuppressive NCT03923478 809 826 B-Condition-Name
condition NCT03923478 827 836 I-Condition-Name
or NCT03923478 837 839 O
treatment NCT03923478 840 849 O
with NCT03923478 850 854 O
immunosuppressive NCT03923478 855 872 B-Drug-Name
medications NCT03923478 873 884 I-Drug-Name

- NCT03923478 887 888 O
History NCT03923478 890 897 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03923478 898 900 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
prior NCT03923478 901 906 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
surgical NCT03923478 907 915 B-Procedure-Name
intervention NCT03923478 916 928 I-Procedure-Name
in NCT03923478 929 931 O
any NCT03923478 932 935 O
region NCT03923478 936 942 O
of NCT03923478 943 945 O
the NCT03923478 946 949 O
gastrointestinal NCT03923478 950 966 O
tract NCT03923478 967 972 O
( NCT03923478 973 974 O
excluding NCT03923478 975 984 O
minor NCT03923478 985 990 B-Procedure-Name
surgery NCT03923478 991 998 I-Procedure-Name
) NCT03923478 999 1000 O

- NCT03923478 1004 1005 O
Prior NCT03923478 1007 1012 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
diagnosis NCT03923478 1013 1022 O
of NCT03923478 1023 1025 O
any NCT03923478 1026 1029 O
cardiovascular NCT03923478 1030 1044 O
, NCT03923478 1045 1046 O
renal NCT03923478 1047 1052 O
, NCT03923478 1053 1054 O
hepatic NCT03923478 1055 1062 O
, NCT03923478 1063 1064 O
endocrine NCT03923478 1065 1074 O
, NCT03923478 1075 1076 O
infectious NCT03923478 1077 1087 O
, NCT03923478 1088 1089 O
hematological NCT03923478 1090 1103 O
, NCT03923478 1104 1105 O
oncologic NCT03923478 1106 1115 O
, NCT03923478 1116 1117 O
neuro NCT03923478 1118 1123 O
- NCT03923478 1124 1125 O
psychiatric NCT03923478 1126 1137 O
or NCT03923478 1138 1140 O
immune NCT03923478 1141 1147 O
- NCT03923478 1148 1149 O
mediated NCT03923478 1150 1158 O
disorder NCT03923478 1159 1167 B-Condition-Name
, NCT03923478 1168 1169 O
which NCT03923478 1170 1175 O
in NCT03923478 1176 1178 O
the NCT03923478 1179 1182 O
opinion NCT03923478 1183 1190 O
of NCT03923478 1191 1193 O
the NCT03923478 1194 1197 O
Principal NCT03923478 1198 1207 O
Investigator NCT03923478 1208 1220 O
might NCT03923478 1221 1226 O
impact NCT03923478 1227 1233 B-Stability___Stability-Value:change
the NCT03923478 1234 1237 O
subject NCT03923478 1238 1245 O
's NCT03923478 1245 1247 O
safety NCT03923478 1248 1254 O
or NCT03923478 1255 1257 O
compliance NCT03923478 1258 1268 O
, NCT03923478 1269 1270 O
or NCT03923478 1271 1273 O
the NCT03923478 1274 1277 O
interpretation NCT03923478 1278 1292 O
of NCT03923478 1293 1295 O
results NCT03923478 1296 1303 O

- NCT03923478 1306 1307 O
Treatment NCT03923478 1309 1318 O
with NCT03923478 1319 1323 O
any NCT03923478 1324 1327 O
other NCT03923478 1328 1333 O
investigational NCT03923478 1334 1349 O
drugs NCT03923478 1350 1355 O
≤ NCT03923478 1356 1357 B-Eq-Operator___Eq-Operator-Value:LTEQ
12 NCT03923478 1359 1361 B-Eq-Value
weeks NCT03923478 1362 1367 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
prior NCT03923478 1368 1373 O
to NCT03923478 1374 1376 O
baseline NCT03923478 1377 1385 O
visit NCT03923478 1386 1391 O

- NCT03923478 1394 1395 O
The NCT03923478 1397 1400 O
participant NCT03923478 1401 1412 O
has NCT03923478 1413 1416 O
a NCT03923478 1417 1418 O
condition NCT03923478 1419 1428 O
or NCT03923478 1429 1431 O
is NCT03923478 1432 1434 O
in NCT03923478 1435 1437 O
a NCT03923478 1438 1439 O
situation NCT03923478 1440 1449 O
which NCT03923478 1450 1455 O
, NCT03923478 1456 1457 O
in NCT03923478 1458 1460 O
the NCT03923478 1461 1464 O
Principal NCT03923478 1465 1474 O
Investigator NCT03923478 1475 1487 O
's NCT03923478 1487 1489 O
opinion NCT03923478 1490 1497 O
, NCT03923478 1498 1499 O
may NCT03923478 1500 1503 O
put NCT03923478 1504 1507 O
the NCT03923478 1508 1511 O
participant NCT03923478 1512 1523 O
at NCT03923478 1524 1526 O
significant NCT03923478 1527 1538 B-Severity___Severity-Value:severe
risk NCT03923478 1539 1543 O
, NCT03923478 1544 1545 O
may NCT03923478 1546 1549 O
confound NCT03923478 1550 1558 B-Stability___Stability-Value:change
the NCT03923478 1559 1562 O
study NCT03923478 1563 1568 O
results NCT03923478 1569 1576 O
, NCT03923478 1577 1578 O
or NCT03923478 1579 1581 O
may NCT03923478 1582 1585 O
interfere NCT03923478 1586 1595 B-Stability___Stability-Value:change
significantly NCT03923478 1596 1609 O
with NCT03923478 1610 1614 O
the NCT03923478 1615 1618 O
participant NCT03923478 1619 1630 O
's NCT03923478 1630 1632 O
participation NCT03923478 1633 1646 O
in NCT03923478 1647 1649 O
the NCT03923478 1650 1653 O
study NCT03923478 1654 1659 O

Inclusion NCT03925753 0 9 O
Criteria NCT03925753 10 18 O
: NCT03925753 19 20 O

- NCT03925753 24 25 O
Both NCT03925753 27 31 O
sexes NCT03925753 32 37 O
aged NCT03925753 38 42 O
between NCT03925753 43 50 O
20 NCT03925753 52 54 B-Eq-Value
- NCT03925753 55 56 B-Eq-Operator___Eq-Operator-Value:BETWEEN
90 NCT03925753 58 60 B-Eq-Value
years NCT03925753 61 66 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
. NCT03925753 67 68 O

- NCT03925753 72 73 O
Received NCT03925753 75 83 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
stable NCT03925753 84 90 B-Stability___Stability-Value:stable
hemodialysis NCT03925753 91 103 B-Procedure-Name
at NCT03925753 104 106 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03925753 107 112 I-Eq-Operator___Eq-Operator-Value:GTEQ
3 NCT03925753 114 115 B-Eq-Value
months NCT03925753 116 122 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
. NCT03925753 123 124 O

- NCT03925753 128 129 O
Written NCT03925753 131 138 O
informed NCT03925753 139 147 O
consent NCT03925753 148 155 O
. NCT03925753 156 157 O

Exclusion NCT03925753 159 168 O
Criteria NCT03925753 169 177 O
: NCT03925753 178 179 O

- NCT03925753 183 184 O
patients NCT03925753 186 194 O
with NCT03925753 195 199 O
severe NCT03925753 200 206 B-Severity___Severity-Value:severe
infections NCT03925753 207 217 B-Condition-Name
, NCT03925753 218 219 O
severe NCT03925753 220 226 B-Severity___Severity-Value:severe
heart NCT03925753 227 232 B-Condition-Name
disease NCT03925753 233 240 I-Condition-Name
and NCT03925753 241 244 O
liver NCT03925753 245 250 B-Condition-Name
disease NCT03925753 251 258 I-Condition-Name
, NCT03925753 259 260 O
malignancy NCT03925753 261 271 B-Condition-Name
, NCT03925753 272 273 O
autoimmune NCT03925753 274 284 B-Condition-Name
disorders NCT03925753 285 294 I-Condition-Name
, NCT03925753 295 296 O
severe NCT03925753 297 303 B-Severity___Severity-Value:severe
malnutrition NCT03925753 304 316 B-Condition-Name
, NCT03925753 317 318 O
or NCT03925753 319 321 O
clinical NCT03925753 322 330 O
conditions NCT03925753 331 341 O
requiring NCT03925753 342 351 O
oral NCT03925753 352 356 B-Procedure-Name
nutrition NCT03925753 357 366 I-Procedure-Name
supplements NCT03925753 367 378 I-Procedure-Name
; NCT03925753 378 379 O

- NCT03925753 382 383 O
Inability NCT03925753 385 394 O
to NCT03925753 395 397 O
follow NCT03925753 398 404 O
protocol NCT03925753 405 413 O
. NCT03925753 414 415 O

- NCT03925753 419 420 O
Pregnancy NCT03925753 422 431 B-Condition-Name
or NCT03925753 432 434 O
wishing NCT03925753 435 442 O
/ NCT03925753 443 444 O
trying NCT03925753 445 451 O
to NCT03925753 452 454 O
get NCT03925753 455 458 O
pregnant NCT03925753 459 467 B-Condition-Name

Inclusion NCT03925779 0 9 O
Criteria NCT03925779 10 18 O
: NCT03925779 19 20 O

- NCT03925779 24 25 O
ASA NCT03925779 27 30 B-Condition-Name
I NCT03925779 31 32 B-Eq-Value
or NCT03925779 33 35 O
II NCT03925779 36 38 B-Eq-Value
physical NCT03925779 39 47 O
status NCT03925779 48 54 O

- NCT03925779 57 58 O
18 NCT03925779 61 63 B-Eq-Value
- NCT03925779 64 65 B-Eq-Operator___Eq-Operator-Value:BETWEEN
65 NCT03925779 67 69 B-Eq-Value
years NCT03925779 70 75 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03925779 78 79 O
Scheduled NCT03925779 81 90 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
for NCT03925779 91 94 O
elective NCT03925779 95 103 O
colonoscopy NCT03925779 104 115 B-Procedure-Name

Exclusion NCT03925779 116 125 O
Criteria NCT03925779 126 134 O
: NCT03925779 135 136 O

- NCT03925779 140 141 O
History NCT03925779 143 150 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03925779 151 153 O
allergy NCT03925779 154 161 O
to NCT03925779 162 164 O
any NCT03925779 165 168 O
of NCT03925779 169 171 O
the NCT03925779 172 175 O
study NCT03925779 176 181 O
drugs NCT03925779 182 187 O

- NCT03925779 190 191 O
Alcohol NCT03925779 193 200 O
or NCT03925779 201 203 O
drug NCT03925779 204 208 O
abuse NCT03925779 209 214 B-Condition-Name
. NCT03925779 215 216 O

- NCT03925779 220 221 O
Second NCT03925779 223 229 B-Eq-Value
and NCT03925779 230 233 O
third NCT03925779 234 239 B-Eq-Value
- NCT03925779 240 241 O
degree NCT03925779 242 248 B-Eq-Unit
heart NCT03925779 249 254 B-Condition-Name
block NCT03925779 255 260 I-Condition-Name
. NCT03925779 261 262 O

- NCT03925779 266 267 O
Morbid NCT03925779 269 275 B-Condition-Name
obesity NCT03925779 276 283 I-Condition-Name
. NCT03925779 284 285 O

- NCT03925779 289 290 O
Pregnant NCT03925779 292 300 B-Condition-Name
and NCT03925779 301 304 O
lactating NCT03925779 305 314 B-Condition-Name
women NCT03925779 315 320 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
. NCT03925779 321 322 O

- NCT03925779 326 327 O
Psychiatric NCT03925779 329 340 B-Condition-Name
disorders NCT03925779 341 350 I-Condition-Name
. NCT03925779 351 352 O

- NCT03925779 356 357 O
Severe NCT03925779 359 365 B-Severity___Severity-Value:severe
cardiac NCT03925779 366 373 O
, NCT03925779 374 375 O
respiratory NCT03925779 376 387 O
, NCT03925779 388 389 O
renal NCT03925779 390 395 O
, NCT03925779 396 397 O
and NCT03925779 398 401 O
liver NCT03925779 402 407 O
diseases NCT03925779 408 416 B-Condition-Name

Inclusion NCT03921047 0 9 O
Criteria NCT03921047 10 18 O
: NCT03921047 19 20 O

- NCT03921047 24 25 O
Diagnosis NCT03921047 27 36 O
of NCT03921047 37 39 O
AML NCT03921047 40 43 B-Condition-Name
scheduled NCT03921047 44 53 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
to NCT03921047 54 56 O
undergo NCT03921047 57 64 O
HSCT NCT03921047 65 69 B-Procedure-Name
at NCT03921047 70 72 O
University NCT03921047 73 83 B-Location___Location-Value:hospital
of NCT03921047 84 86 I-Location___Location-Value:hospital
Southern NCT03921047 87 95 I-Location___Location-Value:hospital
California NCT03921047 96 106 I-Location___Location-Value:hospital
( NCT03921047 107 108 O
USC NCT03921047 109 112 B-Location
) NCT03921047 113 114 O

Exclusion NCT03921047 116 125 O
Criteria NCT03921047 126 134 O
: NCT03921047 135 136 O

- NCT03921047 140 141 O
Inability NCT03921047 143 152 O
to NCT03921047 153 155 O
provide NCT03921047 156 163 O
consent NCT03921047 164 171 O
because NCT03921047 172 179 O
of NCT03921047 180 182 O
severe NCT03921047 183 189 B-Condition-Name
mental NCT03921047 190 196 I-Condition-Name
disorders NCT03921047 197 206 I-Condition-Name

- NCT03921047 209 210 O
Donor NCT03921047 212 217 O
unwilling NCT03921047 218 227 O
to NCT03921047 228 230 O
provide NCT03921047 231 238 O
consent NCT03921047 239 246 O

Inclusion NCT03929341 0 9 O
Criteria NCT03929341 10 18 O
: NCT03929341 19 20 O

- NCT03929341 24 25 O
Men NCT03929341 27 30 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
and NCT03929341 31 34 O
women NCT03929341 35 40 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
age NCT03929341 41 44 O
≥ NCT03929341 45 46 B-Eq-Operator___Eq-Operator-Value:GTEQ
40 NCT03929341 48 50 B-Eq-Value
years NCT03929341 51 56 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03929341 57 59 O
age NCT03929341 60 63 O

- NCT03929341 66 67 O
Stable NCT03929341 69 75 B-Stability___Stability-Value:stable
chest NCT03929341 76 81 O
pain NCT03929341 82 86 B-Condition-Name
or NCT03929341 87 89 O
equivalent NCT03929341 90 100 O
symptoms NCT03929341 101 109 O

- NCT03929341 112 113 O
Planned NCT03929341 115 122 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:future
non NCT03929341 123 126 O
- NCT03929341 127 128 O
urgent NCT03929341 129 135 O
, NCT03929341 136 137 O
non NCT03929341 138 141 O
- NCT03929341 142 143 O
invasive NCT03929341 144 152 O
testing NCT03929341 153 160 B-Procedure-Name
for NCT03929341 161 164 O
diagnosis NCT03929341 165 174 O
of NCT03929341 175 177 O
chest NCT03929341 178 183 O
pain NCT03929341 184 188 B-Condition-Name
or NCT03929341 189 191 O
equivalent NCT03929341 192 202 O
symptoms NCT03929341 203 211 O

Exclusion NCT03929341 212 221 O
Criteria NCT03929341 222 230 O
: NCT03929341 231 232 O

- NCT03929341 236 237 O
Acute NCT03929341 239 244 B-Severity___Severity-Value:severe
coronary NCT03929341 245 253 B-Condition-Name
syndrome NCT03929341 254 262 I-Condition-Name
, NCT03929341 263 264 O
including NCT03929341 265 274 O
acute NCT03929341 275 280 B-Severity___Severity-Value:severe
myocardial NCT03929341 281 291 B-Condition-Name
infarction NCT03929341 292 302 I-Condition-Name
or NCT03929341 303 305 O
unstable NCT03929341 306 314 B-Stability___Stability-Value:change
angina NCT03929341 315 321 B-Condition-Name
, NCT03929341 322 323 O
known NCT03929341 324 329 O
non NCT03929341 330 333 O
- NCT03929341 334 335 O
ischemic NCT03929341 336 344 O
cardiomyopathy NCT03929341 345 359 B-Condition-Name
or NCT03929341 360 362 O
other NCT03929341 363 368 O
cardiac NCT03929341 369 376 B-Condition-Name
disease NCT03929341 377 384 I-Condition-Name
( NCT03929341 385 386 O
e NCT03929341 387 388 O
. NCT03929341 389 390 O
g NCT03929341 391 392 O
. NCT03929341 393 394 O
mitral NCT03929341 396 402 B-Condition-Name
valve NCT03929341 403 408 I-Condition-Name
prolapse NCT03929341 409 417 I-Condition-Name
, NCT03929341 418 419 O
etc NCT03929341 420 423 O
. NCT03929341 424 425 O
) NCT03929341 426 427 O
which NCT03929341 428 433 O
would NCT03929341 434 439 O
require NCT03929341 440 447 O
urgent NCT03929341 448 454 O
cardiac NCT03929341 455 462 B-Procedure-Name
evaluation NCT03929341 463 473 I-Procedure-Name

- NCT03929341 476 477 O
Known NCT03929341 479 484 O
CAD NCT03929341 485 488 B-Condition-Name

- NCT03929341 491 492 O
Prior NCT03929341 494 499 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
cardiac NCT03929341 500 507 B-Procedure-Name
evaluation NCT03929341 508 518 I-Procedure-Name
for NCT03929341 519 522 O
current NCT03929341 523 530 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
episode NCT03929341 531 538 O
of NCT03929341 539 541 O
symptoms NCT03929341 542 550 O

- NCT03929341 553 554 O
Previously NCT03929341 556 566 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
investigated NCT03929341 567 579 O
for NCT03929341 580 583 O
CAD NCT03929341 584 587 B-Condition-Name
in NCT03929341 588 590 O
the NCT03929341 591 594 O
last NCT03929341 595 599 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
12 NCT03929341 601 603 B-Eq-Value
months NCT03929341 604 610 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month

- NCT03929341 613 614 O
Severe NCT03929341 616 622 B-Severity___Severity-Value:severe
allergic NCT03929341 623 631 O
reaction NCT03929341 632 640 O
to NCT03929341 641 643 O
iodinated NCT03929341 644 653 B-Allergy-Name
contrast NCT03929341 654 662 I-Allergy-Name
( NCT03929341 663 664 O
mild NCT03929341 665 669 B-Severity___Severity-Value:mild
reactions NCT03929341 670 679 O
such NCT03929341 680 684 O
as NCT03929341 685 687 O
urticaria NCT03929341 688 697 B-Condition-Name
that NCT03929341 698 702 O
can NCT03929341 703 706 O
be NCT03929341 707 709 O
controlled NCT03929341 710 720 B-Stability___Stability-Value:stable
by NCT03929341 721 723 O
premedication NCT03929341 724 737 B-Procedure-Name
with NCT03929341 738 742 O
Benadryl NCT03929341 743 751 B-Drug-Name
& NCT03929341 752 753 O
Prednisone NCT03929341 754 764 B-Drug-Name
may NCT03929341 765 768 O
be NCT03929341 769 771 O
included NCT03929341 772 780 O
in NCT03929341 781 783 O
the NCT03929341 784 787 O
study NCT03929341 788 793 O
) NCT03929341 794 795 O

- NCT03929341 799 800 O
Renal NCT03929341 802 807 B-Condition-Name
failure NCT03929341 808 815 I-Condition-Name
or NCT03929341 816 818 O
dysfunction NCT03929341 819 830 B-Condition-Name
( NCT03929341 831 832 O
estimated NCT03929341 833 842 B-Observation-Name___Observation-Type-Value:lab
Glomerular NCT03929341 843 853 I-Observation-Name___Observation-Type-Value:lab
Filtration NCT03929341 854 864 I-Observation-Name___Observation-Type-Value:lab
Rate NCT03929341 865 869 I-Observation-Name___Observation-Type-Value:lab
< NCT03929341 870 871 B-Eq-Operator___Eq-Operator-Value:LT
30 NCT03929341 873 875 B-Eq-Value
ml NCT03929341 876 878 B-Eq-Unit
/ NCT03929341 879 880 O
min NCT03929341 881 884 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:minute
/ NCT03929341 885 886 O
m NCT03929341 887 888 B-Eq-Unit
2 NCT03929341 889 890 I-Eq-Unit
within NCT03929341 891 897 B-Eq-Operator___Eq-Operator-Value:LTEQ
the NCT03929341 898 901 O
past NCT03929341 902 906 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
3 NCT03929341 908 909 B-Eq-Value
months NCT03929341 910 916 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
) NCT03929341 917 918 O

- NCT03929341 922 923 O
Pregnancy NCT03929341 925 934 B-Condition-Name
( NCT03929341 935 936 O
status NCT03929341 937 943 O
will NCT03929341 944 948 O
be NCT03929341 949 951 O
confirmed NCT03929341 952 961 O
verbally NCT03929341 962 970 O
. NCT03929341 971 972 O
For NCT03929341 974 977 O
premenopausal NCT03929341 978 991 B-Condition-Name
patients NCT03929341 992 1000 O
who NCT03929341 1001 1004 O
are NCT03929341 1005 1008 O
unsure NCT03929341 1009 1015 O
, NCT03929341 1016 1017 O
status NCT03929341 1018 1024 O
will NCT03929341 1025 1029 O
be NCT03929341 1030 1032 O
confirmed NCT03929341 1033 1042 O
by NCT03929341 1043 1045 O
completing NCT03929341 1046 1056 O
a NCT03929341 1057 1058 O
pregnancy NCT03929341 1059 1068 B-Observation-Name___Observation-Type-Value:lab
strip NCT03929341 1069 1074 I-Observation-Name___Observation-Type-Value:lab
test NCT03929341 1075 1079 I-Observation-Name___Observation-Type-Value:lab
) NCT03929341 1080 1081 O
. NCT03929341 1083 1084 O

Inclusion NCT03927378 0 9 O
Criteria NCT03927378 10 18 O
: NCT03927378 19 20 O

- NCT03927378 24 25 O
Parturients NCT03927378 27 38 O
with NCT03927378 39 43 O
age NCT03927378 44 47 O
≥ NCT03927378 48 49 B-Eq-Operator___Eq-Operator-Value:GTEQ
18 NCT03927378 51 53 B-Eq-Value
years NCT03927378 54 59 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
; NCT03927378 59 60 O

- NCT03927378 63 64 O
Presence NCT03927378 66 74 O
of NCT03927378 75 77 O
prenatal NCT03927378 78 86 O
depression NCT03927378 87 97 B-Condition-Name
( NCT03927378 98 99 O
EPDS NCT03927378 100 104 B-Observation-Name___Observation-Type-Value:clinical-score
score NCT03927378 105 110 I-Observation-Name___Observation-Type-Value:clinical-score
≥ NCT03927378 111 112 B-Eq-Operator___Eq-Operator-Value:GTEQ
10 NCT03927378 114 116 B-Eq-Value
) NCT03927378 117 118 O
; NCT03927378 119 120 O

- NCT03927378 123 124 O
Provide NCT03927378 126 133 O
written NCT03927378 134 141 O
informed NCT03927378 142 150 O
consents NCT03927378 151 159 O
. NCT03927378 160 161 O

Exclusion NCT03927378 163 172 O
Criteria NCT03927378 173 181 O
: NCT03927378 182 183 O

- NCT03927378 187 188 O
History NCT03927378 190 197 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03927378 198 200 O
psychiatric NCT03927378 201 212 B-Condition-Name
disease NCT03927378 213 220 I-Condition-Name
( NCT03927378 221 222 O
schizophrenia NCT03927378 223 236 B-Condition-Name
) NCT03927378 237 238 O
or NCT03927378 239 241 O
communication NCT03927378 242 255 B-Condition-Name
barriers NCT03927378 256 264 I-Condition-Name
that NCT03927378 265 269 O
prevent NCT03927378 270 277 O
normal NCT03927378 278 284 B-Polarity___Polarity-Value:normal
communication NCT03927378 285 298 B-Observation-Name
before NCT03927378 299 305 O
childbirth NCT03927378 306 316 B-Procedure-Name
; NCT03927378 316 317 O

- NCT03927378 320 321 O
Severe NCT03927378 323 329 B-Severity___Severity-Value:severe
complications NCT03927378 330 343 B-Condition-Name
during NCT03927378 344 350 O
pregnancy NCT03927378 351 360 B-Condition-Name
( NCT03927378 361 362 O
such NCT03927378 363 367 O
as NCT03927378 368 370 O
severe NCT03927378 371 377 B-Severity___Severity-Value:severe
preeclampsia NCT03927378 378 390 B-Condition-Name
, NCT03927378 391 392 O
placenta NCT03927378 393 401 B-Condition-Name
accreta NCT03927378 402 409 I-Condition-Name
, NCT03927378 410 411 O
or NCT03927378 412 414 O
HELLP NCT03927378 415 420 B-Condition-Name
[ NCT03927378 421 422 O
Hemolysis NCT03927378 423 432 B-Condition-Name
, NCT03927378 433 434 I-Condition-Name
Elevated NCT03927378 435 443 I-Condition-Name
Liver NCT03927378 444 449 I-Condition-Name
enzymes NCT03927378 450 457 I-Condition-Name
and NCT03927378 458 461 I-Condition-Name
Low NCT03927378 462 465 I-Condition-Name
Platelets NCT03927378 466 475 I-Condition-Name
] NCT03927378 476 477 O
syndrome NCT03927378 478 486 O
) NCT03927378 487 488 O
; NCT03927378 489 490 O

- NCT03927378 493 494 O
ASA NCT03927378 496 499 B-Condition-Name
physical NCT03927378 500 508 O
status NCT03927378 509 515 O
classification NCT03927378 516 530 B-Eq-Unit
≥ NCT03927378 531 532 B-Eq-Operator___Eq-Operator-Value:GTEQ
III NCT03927378 533 536 B-Eq-Value
; NCT03927378 536 537 O

- NCT03927378 540 541 O
Presence NCT03927378 543 551 O
of NCT03927378 552 554 O
contraindications NCT03927378 555 572 O
to NCT03927378 573 575 O
ketamine NCT03927378 576 584 B-Drug-Name
, NCT03927378 585 586 O
including NCT03927378 587 596 O
refractory NCT03927378 597 607 O
hypertension NCT03927378 608 620 B-Condition-Name
, NCT03927378 621 622 O
severe NCT03927378 623 629 B-Severity___Severity-Value:severe
cardiovascular NCT03927378 630 644 B-Condition-Name
disease NCT03927378 645 652 I-Condition-Name
( NCT03927378 653 654 O
heart NCT03927378 655 660 B-Condition-Name
function NCT03927378 661 669 I-Condition-Name
classification NCT03927378 670 684 B-Eq-Unit
≥ NCT03927378 685 686 B-Eq-Operator___Eq-Operator-Value:GTEQ
III NCT03927378 687 690 B-Eq-Value
) NCT03927378 691 692 O
, NCT03927378 694 695 O
or NCT03927378 696 698 O
hyperthyroidism NCT03927378 699 714 B-Condition-Name
; NCT03927378 714 715 O

- NCT03927378 718 719 O
Refuse NCT03927378 721 727 O
to NCT03927378 728 730 O
participate NCT03927378 731 742 O
. NCT03927378 743 744 O

Inclusion NCT03925584 0 9 O
Criteria NCT03925584 10 18 O
: NCT03925584 19 20 O

- NCT03925584 24 25 O
Greater NCT03925584 27 34 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03925584 35 39 I-Eq-Operator___Eq-Operator-Value:GT
37 NCT03925584 41 43 B-Eq-Value
weeks NCT03925584 44 49 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
gestation NCT03925584 50 59 B-Observation-Name___Observation-Type-Value:measurement
, NCT03925584 60 61 O

- NCT03925584 65 66 O
Between NCT03925584 68 75 B-Eq-Operator___Eq-Operator-Value:BETWEEN
0 NCT03925584 77 78 B-Eq-Value
to NCT03925584 79 81 O
30 NCT03925584 83 85 B-Eq-Value
days NCT03925584 86 90 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
of NCT03925584 91 93 O
age NCT03925584 94 97 O

- NCT03925584 100 101 O
24 NCT03925584 104 106 B-Eq-Value
hours NCT03925584 107 112 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:hour
post NCT03925584 113 117 O
congenital NCT03925584 118 128 O
heart NCT03925584 129 134 B-Procedure-Name
surgery NCT03925584 135 142 I-Procedure-Name

- NCT03925584 145 146 O
Receiving NCT03925584 148 157 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
mechanical NCT03925584 158 168 B-Procedure-Name
ventilation NCT03925584 169 180 I-Procedure-Name

- NCT03925584 183 184 O
Background NCT03925584 186 196 B-Observation-Name
noise NCT03925584 197 202 I-Observation-Name
level NCT03925584 203 208 I-Observation-Name
( NCT03925584 209 210 O
at NCT03925584 211 213 O
bedside NCT03925584 214 221 O
) NCT03925584 222 223 O
at NCT03925584 224 226 O
the NCT03925584 227 230 O
time NCT03925584 231 235 O
of NCT03925584 236 238 O
music NCT03925584 239 244 B-Procedure-Name
therapy NCT03925584 245 252 I-Procedure-Name
must NCT03925584 253 257 O
be NCT03925584 258 260 O
55 NCT03925584 262 264 B-Eq-Value
dB NCT03925584 265 267 B-Eq-Unit
or NCT03925584 268 270 B-Eq-Operator___Eq-Operator-Value:LTEQ
less NCT03925584 271 275 I-Eq-Operator___Eq-Operator-Value:LTEQ
. NCT03925584 276 277 O

Exclusion NCT03925584 279 288 O
Criteria NCT03925584 289 297 O
: NCT03925584 298 299 O

- NCT03925584 303 304 O
Hemodynamically NCT03925584 306 321 B-Condition-Name
unstable NCT03925584 322 330 B-Stability___Stability-Value:change
or NCT03925584 331 333 O
end NCT03925584 334 337 O
of NCT03925584 338 340 O
life NCT03925584 341 345 O

- NCT03925584 348 349 O
If NCT03925584 351 353 O
patient NCT03925584 354 361 O
is NCT03925584 362 364 O
in NCT03925584 365 367 O
a NCT03925584 368 369 O
closed NCT03925584 370 376 O
Giraffe NCT03925584 377 384 O
bed NCT03925584 385 388 O

- NCT03925584 391 392 O
Evidence NCT03925584 394 402 O
of NCT03925584 403 405 O
hearing NCT03925584 406 413 B-Condition-Name
impairment NCT03925584 414 424 I-Condition-Name

- NCT03925584 427 428 O
Patient NCT03925584 430 437 O
has NCT03925584 438 441 O
known NCT03925584 442 447 O
or NCT03925584 448 450 O
suspected NCT03925584 451 460 O
active NCT03925584 461 467 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
seizure NCT03925584 468 475 B-Condition-Name
disorder NCT03925584 476 484 I-Condition-Name

Inclusion NCT03925181 0 9 O
Criteria NCT03925181 10 18 O
for NCT03925181 19 22 O
Patients NCT03925181 23 31 O
: NCT03925181 32 33 O

- NCT03925181 37 38 O
Spent NCT03925181 40 45 O
more NCT03925181 46 50 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03925181 51 55 I-Eq-Operator___Eq-Operator-Value:GT
4 NCT03925181 57 58 B-Eq-Value
days NCT03925181 59 63 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
in NCT03925181 64 66 O
the NCT03925181 67 70 O
ICU NCT03925181 71 74 B-Encounter-Type___Encounter-Type-Value:icu
, NCT03925181 75 76 O

- NCT03925181 80 81 O
Were NCT03925181 83 87 O
discharged NCT03925181 88 98 B-Encounter-Type___Encounter-Type-Value:discharge
into NCT03925181 99 103 O
the NCT03925181 104 107 O
community NCT03925181 108 117 B-Location___Location-Value:residence
within NCT03925181 118 124 B-Eq-Operator___Eq-Operator-Value:LTEQ
4 NCT03925181 126 127 B-Eq-Value
months NCT03925181 128 134 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
of NCT03925181 135 137 O
transfer NCT03925181 138 146 B-Encounter-Type___Encounter-Type-Value:transfer
out NCT03925181 147 150 O
of NCT03925181 151 153 O
the NCT03925181 154 157 O
ICU NCT03925181 158 161 B-Location___Location-Value:unit
( NCT03925181 162 163 O
excluding NCT03925181 164 173 O
patients NCT03925181 174 182 O
who NCT03925181 183 186 O
were NCT03925181 187 191 O
in NCT03925181 192 194 O
hospital NCT03925181 195 203 B-Encounter-Type___Encounter-Type-Value:inpatient
long NCT03925181 204 208 B-Eq-Value
- NCT03925181 209 210 I-Eq-Value
term NCT03925181 211 215 I-Eq-Value
) NCT03925181 216 217 O

- NCT03925181 221 222 O
Speaks NCT03925181 224 230 O
English NCT03925181 231 238 B-Language

- NCT03925181 241 242 O
Has NCT03925181 244 247 O
a NCT03925181 248 249 O
fixed NCT03925181 250 255 O
address NCT03925181 256 263 O

- NCT03925181 266 267 O
Does NCT03925181 269 273 O
not NCT03925181 274 277 O
have NCT03925181 278 282 O
pre NCT03925181 283 286 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
- NCT03925181 287 288 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
existing NCT03925181 289 297 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
psychiatric NCT03925181 298 309 B-Condition-Name
diagnoses NCT03925181 310 319 O
documented NCT03925181 320 330 O
in NCT03925181 331 333 O
the NCT03925181 334 337 O
ICU NCT03925181 338 341 B-Location___Location-Value:unit
transfer NCT03925181 342 350 B-Encounter-Type___Encounter-Type-Value:transfer
summary NCT03925181 351 358 O

- NCT03925181 361 362 O
Lives NCT03925181 364 369 B-Observation-Name
within NCT03925181 370 376 O
or NCT03925181 377 379 O
surrounding NCT03925181 380 391 O
Calgary NCT03925181 392 399 B-Location___Location-Value:residence
. NCT03925181 400 401 O

Inclusion NCT03925181 403 412 O
Criteria NCT03925181 413 421 O
for NCT03925181 422 425 O
Caregivers NCT03925181 426 436 O
: NCT03925181 437 438 O

- NCT03925181 442 443 O
Caregiver NCT03925181 445 454 O
of NCT03925181 455 457 O
an NCT03925181 458 460 O
ICU NCT03925181 461 464 O
survivor NCT03925181 465 473 O
participant NCT03925181 474 485 O
meeting NCT03925181 486 493 O
criteria NCT03925181 494 502 O
above NCT03925181 503 508 O

- NCT03925181 511 512 O
Speaks NCT03925181 514 520 O
English NCT03925181 521 528 B-Language

- NCT03925181 531 532 O
Has NCT03925181 534 537 O
a NCT03925181 538 539 O
fixed NCT03925181 540 545 O
address NCT03925181 546 553 O

- NCT03925181 556 557 O
Lives NCT03925181 559 564 B-Observation-Name
within NCT03925181 565 571 O
or NCT03925181 572 574 O
surrounding NCT03925181 575 586 O
Calgary NCT03925181 587 594 B-Location___Location-Value:residence
. NCT03925181 595 596 O

Exclusion NCT03925181 598 607 O
Criteria NCT03925181 608 616 O
for NCT03925181 617 620 O
Patients NCT03925181 621 629 O
: NCT03925181 630 631 O

- NCT03925181 634 635 O
Long NCT03925181 636 640 B-Eq-Value
- NCT03925181 641 642 I-Eq-Value
term NCT03925181 643 647 I-Eq-Value
hospital NCT03925181 648 656 B-Encounter-Type___Encounter-Type-Value:inpatient
stay NCT03925181 657 661 O

Excluding NCT03925181 662 671 O
Criteria NCT03925181 672 680 O
for NCT03925181 681 684 O
Caregivers NCT03925181 685 695 O
: NCT03925181 696 697 O

- NCT03925181 700 701 O
None NCT03925181 702 706 O

Inclusion NCT03929744 0 9 O
Criteria NCT03929744 10 18 O
: NCT03929744 19 20 O

- NCT03929744 24 25 O
Healthy NCT03929744 27 34 B-Condition-Name
male NCT03929744 35 39 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
or NCT03929744 40 42 O
females NCT03929744 43 50 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
, NCT03929744 51 52 O
as NCT03929744 53 55 O
determined NCT03929744 56 66 O
by NCT03929744 67 69 O
medical NCT03929744 70 77 O
history NCT03929744 78 85 O

- NCT03929744 88 89 O
Have NCT03929744 91 95 O
safety NCT03929744 96 102 O
laboratory NCT03929744 103 113 B-Observation-Name___Observation-Type-Value:lab
results NCT03929744 114 121 I-Observation-Name___Observation-Type-Value:lab
within NCT03929744 122 128 B-Eq-Operator___Eq-Operator-Value:EQ
normal NCT03929744 129 135 B-Eq-Unit___Eq-Unit-Value:ref-range-normal
reference NCT03929744 136 145 I-Eq-Unit___Eq-Unit-Value:ref-range-normal
ranges NCT03929744 146 152 I-Eq-Unit___Eq-Unit-Value:ref-range-normal

Exclusion NCT03929744 153 162 O
Criteria NCT03929744 163 171 O
: NCT03929744 172 173 O

- NCT03929744 177 178 O
Have NCT03929744 180 184 O
known NCT03929744 185 190 O
allergies NCT03929744 191 200 O
to NCT03929744 201 203 O
LY NCT03929744 204 206 B-Drug-Name
3502970 NCT03929744 207 214 I-Drug-Name
, NCT03929744 215 216 O
glucagon NCT03929744 217 225 B-Drug-Name
- NCT03929744 226 227 I-Drug-Name
like NCT03929744 228 232 I-Drug-Name
peptide NCT03929744 233 240 I-Drug-Name
- NCT03929744 241 242 I-Drug-Name
1 NCT03929744 244 245 I-Drug-Name
( NCT03929744 246 247 O
GLP NCT03929744 248 251 B-Drug-Name
- NCT03929744 252 253 I-Drug-Name
1 NCT03929744 255 256 I-Drug-Name
) NCT03929744 257 258 O
analogs NCT03929744 259 266 O
, NCT03929744 267 268 O
related NCT03929744 269 276 O
compounds NCT03929744 277 286 O

- NCT03929744 289 290 O
Abnormal NCT03929744 292 300 B-Polarity___Polarity-Value:abnormal
electrocardiogram NCT03929744 301 318 B-Procedure-Name
( NCT03929744 319 320 O
ECG NCT03929744 321 324 B-Procedure-Name
) NCT03929744 325 326 O
at NCT03929744 327 329 O
screening NCT03929744 330 339 O

- NCT03929744 342 343 O
Significant NCT03929744 345 356 B-Severity___Severity-Value:severe
history NCT03929744 357 364 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03929744 365 367 O
or NCT03929744 368 370 O
current NCT03929744 371 378 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
cardiovascular NCT03929744 379 393 O
, NCT03929744 394 395 O
respiratory NCT03929744 396 407 O
, NCT03929744 408 409 O
hepatic NCT03929744 410 417 O
, NCT03929744 418 419 O
renal NCT03929744 420 425 O
, NCT03929744 426 427 O
gastrointestinal NCT03929744 428 444 O
, NCT03929744 445 446 O
endocrine NCT03929744 447 456 O
, NCT03929744 457 458 O
hematological NCT03929744 459 472 O
or NCT03929744 473 475 O
neurological NCT03929744 476 488 O
disorders NCT03929744 489 498 B-Condition-Name
. NCT03929744 499 500 O

Inclusion NCT03920774 0 9 O
Criteria NCT03920774 10 18 O
: NCT03920774 19 20 O

- NCT03920774 24 25 O
Patients NCT03920774 27 35 O
of NCT03920774 36 38 O
any NCT03920774 39 42 O
age NCT03920774 43 46 O
with NCT03920774 47 51 O
a NCT03920774 52 53 O
diagnosis NCT03920774 54 63 O
of NCT03920774 64 66 O
familial NCT03920774 67 75 B-Condition-Name
dysautonomia NCT03920774 76 88 I-Condition-Name
( NCT03920774 89 90 O
FD NCT03920774 91 93 B-Condition-Name
) NCT03920774 94 95 O
with NCT03920774 96 100 O
molecular NCT03920774 101 110 O
confirmation NCT03920774 111 123 O
of NCT03920774 124 126 O
the NCT03920774 127 130 O
IKBKAP NCT03920774 131 137 B-Condition-Name
mutation NCT03920774 138 146 I-Condition-Name
. NCT03920774 147 148 O

- NCT03920774 152 153 O
Ability NCT03920774 155 162 O
to NCT03920774 163 165 O
provide NCT03920774 166 173 O
informed NCT03920774 174 182 O
consent NCT03920774 183 190 O
( NCT03920774 191 192 O
or NCT03920774 193 195 O
assent NCT03920774 196 202 O
) NCT03920774 203 204 O
and NCT03920774 205 208 O
comply NCT03920774 209 215 O
with NCT03920774 216 220 O
the NCT03920774 221 224 O
study NCT03920774 225 230 O
protocol NCT03920774 231 239 O

Exclusion NCT03920774 240 249 O
Criteria NCT03920774 250 258 O
: NCT03920774 259 260 O

- NCT03920774 264 265 O
Subjects NCT03920774 267 275 O
that NCT03920774 276 280 O
do NCT03920774 281 283 O
not NCT03920774 284 287 O
wish NCT03920774 288 292 O
to NCT03920774 293 295 O
be NCT03920774 296 298 O
a NCT03920774 299 300 O
part NCT03920774 301 305 O
of NCT03920774 306 308 O
the NCT03920774 309 312 O
study NCT03920774 313 318 O
. NCT03920774 319 320 O

Inclusion NCT03925142 0 9 O
Criteria NCT03925142 10 18 O
: NCT03925142 19 20 O

- NCT03925142 24 25 O
Male NCT03925142 27 31 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
or NCT03925142 32 34 O
female NCT03925142 35 41 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female

- NCT03925142 44 45 O
30 NCT03925142 48 50 B-Eq-Value
- NCT03925142 51 52 B-Eq-Operator___Eq-Operator-Value:BETWEEN
69 NCT03925142 54 56 B-Eq-Value
years NCT03925142 57 62 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03925142 63 66 O

- NCT03925142 69 70 O
BMI NCT03925142 72 75 B-Observation-Name___Observation-Type-Value:vital
25 NCT03925142 77 79 B-Eq-Value
- NCT03925142 80 81 B-Eq-Operator___Eq-Operator-Value:BETWEEN
37 NCT03925142 83 85 B-Eq-Value
kg NCT03925142 86 88 B-Eq-Unit
/ NCT03925142 89 90 O
m NCT03925142 91 92 B-Eq-Unit
2 NCT03925142 93 94 I-Eq-Unit

- NCT03925142 97 98 O
Total NCT03925142 100 105 B-Observation-Name___Observation-Type-Value:lab
cholesterol NCT03925142 106 117 I-Observation-Name___Observation-Type-Value:lab
< NCT03925142 118 119 B-Eq-Operator___Eq-Operator-Value:LT
260 NCT03925142 121 124 B-Eq-Value
mg NCT03925142 125 127 B-Eq-Unit
/ NCT03925142 128 129 O
dL NCT03925142 130 132 B-Eq-Unit

- NCT03925142 135 136 O
Low NCT03925142 138 141 B-Observation-Name___Observation-Type-Value:lab
- NCT03925142 142 143 I-Observation-Name___Observation-Type-Value:lab
density NCT03925142 144 151 I-Observation-Name___Observation-Type-Value:lab
lipoprotein NCT03925142 152 163 I-Observation-Name___Observation-Type-Value:lab
cholesterol NCT03925142 164 175 I-Observation-Name___Observation-Type-Value:lab
< NCT03925142 176 177 B-Eq-Operator___Eq-Operator-Value:LT
190 NCT03925142 179 182 B-Eq-Value
mg NCT03925142 183 185 B-Eq-Unit
/ NCT03925142 186 187 O
dL NCT03925142 188 190 B-Eq-Unit

- NCT03925142 193 194 O
Glucose NCT03925142 196 203 B-Observation-Name___Observation-Type-Value:lab
< NCT03925142 204 205 B-Eq-Operator___Eq-Operator-Value:LT
110 NCT03925142 207 210 B-Eq-Value
mg NCT03925142 211 213 B-Eq-Unit
/ NCT03925142 214 215 O
dL NCT03925142 216 218 B-Eq-Unit

- NCT03925142 221 222 O
Systolic NCT03925142 224 232 O
/ NCT03925142 233 234 O
diastolic NCT03925142 235 244 O
blood NCT03925142 245 250 B-Observation-Name___Observation-Type-Value:vital
pressure NCT03925142 251 259 I-Observation-Name___Observation-Type-Value:vital
< NCT03925142 260 261 B-Eq-Operator___Eq-Operator-Value:LT
140 NCT03925142 263 266 B-Eq-Value
/ NCT03925142 267 268 O
90 NCT03925142 270 272 B-Eq-Value

- NCT03925142 276 277 O
Body NCT03925142 279 283 B-Observation-Name___Observation-Type-Value:vital
weight NCT03925142 284 290 I-Observation-Name___Observation-Type-Value:vital
stable NCT03925142 291 297 B-Stability___Stability-Value:stable
for NCT03925142 298 301 O
3 NCT03925142 303 304 B-Eq-Value
months NCT03925142 305 311 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
prior NCT03925142 312 317 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
( NCT03925142 318 319 O
± NCT03925142 321 322 B-Eq-Operator___Eq-Operator-Value:PLUS-MINUS
3 NCT03925142 324 325 B-Eq-Value
kg NCT03925142 326 328 B-Eq-Unit
) NCT03925142 329 330 O

- NCT03925142 334 335 O
Stable NCT03925142 337 343 B-Stability___Stability-Value:stable
physical NCT03925142 344 352 B-Observation-Name___Observation-Type-Value:social-habit
activity NCT03925142 353 361 I-Observation-Name___Observation-Type-Value:social-habit
regimen NCT03925142 362 369 O
3 NCT03925142 371 372 B-Eq-Value
months NCT03925142 373 379 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
prior NCT03925142 380 385 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past

- NCT03925142 388 389 O
Medication NCT03925142 391 401 O
use NCT03925142 402 405 O
stable NCT03925142 406 412 B-Stability___Stability-Value:stable
for NCT03925142 413 416 O
6 NCT03925142 418 419 B-Eq-Value
months NCT03925142 420 426 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
prior NCT03925142 427 432 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past

- NCT03925142 435 436 O
Non NCT03925142 438 441 O
- NCT03925142 442 443 O
smoking NCT03925142 444 451 B-Condition-Name

- NCT03925142 454 455 O
Not NCT03925142 457 460 O
drinking NCT03925142 461 469 B-Condition-Name
more NCT03925142 470 474 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03925142 475 479 I-Eq-Operator___Eq-Operator-Value:GT
2 NCT03925142 481 482 B-Eq-Value
alcoholic NCT03925142 483 492 B-Eq-Unit
drinks NCT03925142 493 499 I-Eq-Unit
per NCT03925142 500 503 O
day NCT03925142 504 507 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day

- NCT03925142 510 511 O
Non NCT03925142 513 516 O
- NCT03925142 517 518 O
diabetic NCT03925142 519 527 B-Condition-Name

- NCT03925142 530 531 O
Not NCT03925142 533 536 O
lactose NCT03925142 537 544 B-Condition-Name
- NCT03925142 545 546 I-Condition-Name
intolerant NCT03925142 547 557 I-Condition-Name

- NCT03925142 560 561 O
Not NCT03925142 563 566 O
acutely NCT03925142 567 574 B-Severity___Severity-Value:severe
ill NCT03925142 575 578 B-Condition-Name

- NCT03925142 581 582 O
Non NCT03925142 584 587 O
- NCT03925142 588 589 O
pregnant NCT03925142 590 598 B-Condition-Name
and NCT03925142 599 602 O
not NCT03925142 603 606 O
lactating NCT03925142 607 616 B-Condition-Name
. NCT03925142 617 618 O

- NCT03925142 622 623 O
Participants NCT03925142 625 637 O
must NCT03925142 638 642 O
be NCT03925142 643 645 O
willing NCT03925142 646 653 O
and NCT03925142 654 657 O
able NCT03925142 658 662 O
to NCT03925142 663 665 O
consume NCT03925142 666 673 O
the NCT03925142 674 677 O
prescribed NCT03925142 678 688 O
diets NCT03925142 689 694 B-Procedure-Name
( NCT03925142 695 696 O
lacto NCT03925142 697 702 O
- NCT03925142 703 704 O
ovo NCT03925142 705 708 O
vegetarian NCT03925142 709 719 O
and NCT03925142 720 723 O
omnivorous NCT03925142 724 734 O
) NCT03925142 735 736 O
. NCT03925142 738 739 O

Exclusion NCT03925142 741 750 O
Criteria NCT03925142 751 759 O
: NCT03925142 760 761 O

- NCT03925142 765 766 O
< NCT03925142 768 769 B-Eq-Operator___Eq-Operator-Value:LT
30 NCT03925142 771 773 B-Eq-Value
or NCT03925142 774 776 O
> NCT03925142 777 778 B-Eq-Operator___Eq-Operator-Value:GT
69 NCT03925142 780 782 B-Eq-Value
years NCT03925142 783 788 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03925142 789 792 O

- NCT03925142 795 796 O
BMI NCT03925142 798 801 B-Observation-Name___Observation-Type-Value:vital
< NCT03925142 802 803 B-Eq-Operator___Eq-Operator-Value:LT
25.0 NCT03925142 805 809 B-Eq-Value
or NCT03925142 810 812 O
> NCT03925142 813 814 B-Eq-Operator___Eq-Operator-Value:GT
37 NCT03925142 816 818 B-Eq-Value
kg NCT03925142 819 821 B-Eq-Unit
/ NCT03925142 822 823 O
m NCT03925142 824 825 B-Eq-Unit
2 NCT03925142 826 827 I-Eq-Unit

- NCT03925142 830 831 O
Fasting NCT03925142 833 840 O
serum NCT03925142 841 846 B-Observation-Name___Observation-Type-Value:lab
total NCT03925142 847 852 I-Observation-Name___Observation-Type-Value:lab
cholesterol NCT03925142 853 864 I-Observation-Name___Observation-Type-Value:lab
> NCT03925142 865 866 B-Eq-Operator___Eq-Operator-Value:GT
260 NCT03925142 868 871 B-Eq-Value
mg NCT03925142 872 874 B-Eq-Unit
/ NCT03925142 875 876 O
dL NCT03925142 877 879 B-Eq-Unit

- NCT03925142 882 883 O
Low NCT03925142 885 888 B-Observation-Name___Observation-Type-Value:lab
- NCT03925142 889 890 I-Observation-Name___Observation-Type-Value:lab
density NCT03925142 891 898 I-Observation-Name___Observation-Type-Value:lab
lipoprotein NCT03925142 899 910 I-Observation-Name___Observation-Type-Value:lab
cholesterol NCT03925142 911 922 I-Observation-Name___Observation-Type-Value:lab
> NCT03925142 923 924 B-Eq-Operator___Eq-Operator-Value:GT
189 NCT03925142 926 929 B-Eq-Value
mg NCT03925142 930 932 B-Eq-Unit
/ NCT03925142 933 934 O
dL NCT03925142 935 937 B-Eq-Unit

- NCT03925142 940 941 O
Glucose NCT03925142 943 950 B-Observation-Name___Observation-Type-Value:lab
> NCT03925142 951 952 B-Eq-Operator___Eq-Operator-Value:GT
110 NCT03925142 954 957 B-Eq-Value
mg NCT03925142 958 960 B-Eq-Unit
/ NCT03925142 961 962 O
dL NCT03925142 963 965 B-Eq-Unit

- NCT03925142 968 969 O
Systolic NCT03925142 971 979 O
/ NCT03925142 980 981 O
diastolic NCT03925142 982 991 O
blood NCT03925142 992 997 B-Observation-Name___Observation-Type-Value:vital
pressure NCT03925142 998 1006 I-Observation-Name___Observation-Type-Value:vital
> NCT03925142 1007 1008 B-Eq-Operator___Eq-Operator-Value:GT
140 NCT03925142 1010 1013 B-Eq-Value
/ NCT03925142 1014 1015 O
90 NCT03925142 1017 1019 B-Eq-Value

- NCT03925142 1023 1024 O
Body NCT03925142 1026 1030 B-Observation-Name___Observation-Type-Value:vital
weight NCT03925142 1031 1037 I-Observation-Name___Observation-Type-Value:vital
stable NCT03925142 1038 1044 B-Stability___Stability-Value:stable
for NCT03925142 1045 1048 O
< NCT03925142 1049 1050 B-Eq-Operator___Eq-Operator-Value:LT
3 NCT03925142 1052 1053 B-Eq-Value
months NCT03925142 1054 1060 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
prior NCT03925142 1061 1066 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
( NCT03925142 1067 1068 O
± NCT03925142 1070 1071 B-Eq-Operator___Eq-Operator-Value:PLUS-MINUS
3 NCT03925142 1073 1074 B-Eq-Value
kg NCT03925142 1075 1077 B-Eq-Unit
) NCT03925142 1078 1079 O

- NCT03925142 1083 1084 O
Stable NCT03925142 1086 1092 B-Stability___Stability-Value:stable
physical NCT03925142 1093 1101 B-Observation-Name___Observation-Type-Value:social-habit
activity NCT03925142 1102 1110 I-Observation-Name___Observation-Type-Value:social-habit
regimen NCT03925142 1111 1118 O
< NCT03925142 1119 1120 B-Eq-Operator___Eq-Operator-Value:LT
3 NCT03925142 1122 1123 B-Eq-Value
months NCT03925142 1124 1130 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
prior NCT03925142 1131 1136 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past

- NCT03925142 1139 1140 O
Medication NCT03925142 1142 1152 O
use NCT03925142 1153 1156 O
unstable NCT03925142 1157 1165 B-Stability___Stability-Value:change
for NCT03925142 1166 1169 O
6 NCT03925142 1171 1172 B-Eq-Value
months NCT03925142 1173 1179 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
prior NCT03925142 1180 1185 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
and NCT03925142 1186 1189 O
using NCT03925142 1190 1195 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
medications NCT03925142 1196 1207 O

- NCT03925142 1210 1211 O
Smoking NCT03925142 1213 1220 O

- NCT03925142 1223 1224 O
Drinking NCT03925142 1226 1234 B-Condition-Name
more NCT03925142 1235 1239 B-Eq-Operator___Eq-Operator-Value:GT
than NCT03925142 1240 1244 I-Eq-Operator___Eq-Operator-Value:GT
2 NCT03925142 1246 1247 B-Eq-Value
alcoholic NCT03925142 1248 1257 B-Eq-Unit
drinks NCT03925142 1258 1264 I-Eq-Unit
per NCT03925142 1265 1268 O
day NCT03925142 1269 1272 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day

- NCT03925142 1275 1276 O
Diabetic NCT03925142 1278 1286 B-Condition-Name

- NCT03925142 1289 1290 O
Have NCT03925142 1292 1296 O
renal NCT03925142 1297 1302 B-Condition-Name
failure NCT03925142 1303 1310 I-Condition-Name

- NCT03925142 1313 1314 O
Have NCT03925142 1316 1320 O
liver NCT03925142 1321 1326 B-Condition-Name
failure NCT03925142 1327 1334 I-Condition-Name

- NCT03925142 1337 1338 O
Have NCT03925142 1340 1344 O
cardiovascular NCT03925142 1345 1359 B-Condition-Name
events NCT03925142 1360 1366 I-Condition-Name
( NCT03925142 1367 1368 O
myocardial NCT03925142 1369 1379 B-Condition-Name
infarction NCT03925142 1380 1390 I-Condition-Name
or NCT03925142 1391 1393 O
stroke NCT03925142 1394 1400 B-Condition-Name
) NCT03925142 1401 1402 O
during NCT03925142 1403 1409 O
the NCT03925142 1410 1413 O
6 NCT03925142 1415 1416 B-Eq-Value
months NCT03925142 1417 1423 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
prior NCT03925142 1424 1429 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
to NCT03925142 1430 1432 O
the NCT03925142 1433 1436 O
study NCT03925142 1437 1442 O

- NCT03925142 1445 1446 O
Pregnant NCT03925142 1448 1456 B-Condition-Name
or NCT03925142 1457 1459 O
lactating NCT03925142 1460 1469 B-Condition-Name

Inclusion NCT03927755 0 9 O
Criteria NCT03927755 10 18 O
: NCT03927755 19 20 O

- NCT03927755 24 25 O
Physicians NCT03927755 27 37 B-Provider-Role
with NCT03927755 38 42 O
experience NCT03927755 43 53 O
in NCT03927755 54 56 O
bedside NCT03927755 57 64 O
cardiac NCT03927755 65 72 B-Procedure-Name
ultrasound NCT03927755 73 83 I-Procedure-Name

Exclusion NCT03927755 84 93 O
Criteria NCT03927755 94 102 O
: NCT03927755 103 104 O

- NCT03927755 108 109 O
Unwilling NCT03927755 111 120 O
to NCT03927755 121 123 O
consent NCT03927755 124 131 O
to NCT03927755 132 134 O
study NCT03927755 135 140 O

- NCT03927755 143 144 O
Appropriate NCT03927755 146 157 O
ultrasound NCT03927755 158 168 B-Procedure-Name
equipment NCT03927755 169 178 O
not NCT03927755 179 182 O
available NCT03927755 183 192 O

Inclusion NCT03920748 0 9 O
Criteria NCT03920748 10 18 O
: NCT03920748 19 20 O

- NCT03920748 24 25 O
Newborn NCT03920748 27 34 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:infant
and NCT03920748 35 38 O
infant NCT03920748 39 45 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:infant
age NCT03920748 46 49 O
group NCT03920748 50 55 O

- NCT03920748 58 59 O
Undergoing NCT03920748 61 71 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
elective NCT03920748 72 80 O
surgery NCT03920748 81 88 B-Procedure-Name
requiring NCT03920748 89 98 O
intubation NCT03920748 99 109 B-Procedure-Name
under NCT03920748 110 115 O
general NCT03920748 116 123 B-Procedure-Name
anesthesia NCT03920748 124 134 I-Procedure-Name

Exclusion NCT03920748 135 144 O
Criteria NCT03920748 145 153 O
: NCT03920748 154 155 O

- NCT03920748 159 160 O
History NCT03920748 162 169 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03920748 170 172 O
congenital NCT03920748 173 183 O
maxillofacial NCT03920748 184 197 B-Condition-Name
defect NCT03920748 198 204 I-Condition-Name
, NCT03920748 205 206 O

- NCT03920748 210 211 O
History NCT03920748 213 220 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03920748 221 223 O
upper NCT03920748 224 229 B-Condition-Name
airway NCT03920748 230 236 I-Condition-Name
pathology NCT03920748 237 246 I-Condition-Name
( NCT03920748 247 248 O
tumor NCT03920748 249 254 B-Condition-Name
, NCT03920748 255 256 O
cleft NCT03920748 257 262 B-Condition-Name
palate NCT03920748 263 269 I-Condition-Name
- NCT03920748 270 271 I-Condition-Name
lips NCT03920748 272 276 I-Condition-Name
, NCT03920748 277 278 O
etc NCT03920748 279 282 O
. NCT03920748 283 284 O
) NCT03920748 285 286 O

- NCT03920748 290 291 O
History NCT03920748 293 300 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03920748 301 303 O
head NCT03920748 304 308 O
and NCT03920748 309 312 O
neck NCT03920748 313 317 O
trauma NCT03920748 318 324 B-Condition-Name
( NCT03920748 325 326 O
fracture NCT03920748 327 335 B-Condition-Name
, NCT03920748 336 337 O
swelling NCT03920748 338 346 B-Condition-Name
, NCT03920748 347 348 O
scar NCT03920748 349 353 B-Condition-Name
) NCT03920748 354 355 O

Inclusion NCT03921697 0 9 O
Criteria NCT03921697 10 18 O
: NCT03921697 19 20 O

- NCT03921697 24 25 O
Idiopathic NCT03921697 27 37 O
Parkinson NCT03921697 38 47 B-Condition-Name
's NCT03921697 47 49 I-Condition-Name
disease NCT03921697 50 57 I-Condition-Name
diagnosed NCT03921697 58 67 O
by NCT03921697 68 70 O
a NCT03921697 71 72 O
neurologist NCT03921697 73 84 B-Provider-Type

- NCT03921697 87 88 O
Ability NCT03921697 90 97 O
to NCT03921697 98 100 O
sign NCT03921697 101 105 O
informed NCT03921697 106 114 O
consent NCT03921697 115 122 O

Exclusion NCT03921697 123 132 O
Criteria NCT03921697 133 141 O
: NCT03921697 142 143 O

- NCT03921697 147 148 O
Inability NCT03921697 150 159 O
to NCT03921697 160 162 O
sign NCT03921697 163 167 O
informed NCT03921697 168 176 O
consent NCT03921697 177 184 O

- NCT03921697 187 188 O
Inability NCT03921697 190 199 O
to NCT03921697 200 202 O
fill NCT03921697 203 207 O
out NCT03921697 208 211 O
questionnaires NCT03921697 212 226 B-Observation-Name___Observation-Type-Value:survey-or-questionnaire
( NCT03921697 227 228 O
i NCT03921697 229 230 O
. NCT03921697 231 232 O
e NCT03921697 233 234 O
. NCT03921697 235 236 O
due NCT03921697 238 241 O
to NCT03921697 242 244 O
poor NCT03921697 245 249 B-Condition-Name
vision NCT03921697 250 256 I-Condition-Name
, NCT03921697 257 258 O
inability NCT03921697 259 268 B-Condition-Name
to NCT03921697 269 271 I-Condition-Name
read NCT03921697 272 276 I-Condition-Name
, NCT03921697 277 278 O
etc NCT03921697 279 282 O
) NCT03921697 283 284 O

- NCT03921697 288 289 O
Presence NCT03921697 291 299 O
of NCT03921697 300 302 O
psychiatric NCT03921697 303 314 B-Condition-Name
diseases NCT03921697 315 323 I-Condition-Name
( NCT03921697 324 325 O
episode NCT03921697 326 333 O
or NCT03921697 334 336 O
any NCT03921697 337 340 O
form NCT03921697 341 345 O
of NCT03921697 346 348 O
psychosis NCT03921697 349 358 B-Condition-Name
, NCT03921697 359 360 O
diagnosed NCT03921697 361 370 O
by NCT03921697 371 373 O
a NCT03921697 374 375 O
psychiatrist NCT03921697 376 388 B-Provider-Type
in NCT03921697 389 391 O
the NCT03921697 392 395 O
last NCT03921697 396 400 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
year NCT03921697 401 405 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
) NCT03921697 406 407 O
. NCT03921697 409 410 O

- NCT03921697 414 415 O
Age NCT03921697 417 420 O
under NCT03921697 421 426 B-Eq-Operator___Eq-Operator-Value:LT
18 NCT03921697 428 430 B-Eq-Value
yrs NCT03921697 431 434 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03921697 435 438 O

Inclusion NCT03924076 0 9 O
Criteria NCT03924076 10 18 O
: NCT03924076 19 20 O

- NCT03924076 24 25 O
children NCT03924076 27 35 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:child
at NCT03924076 36 38 O
age NCT03924076 39 42 O
of NCT03924076 43 45 O
7 NCT03924076 47 48 B-Eq-Value
- NCT03924076 49 50 B-Eq-Operator___Eq-Operator-Value:BETWEEN
9 NCT03924076 52 53 B-Eq-Value
years NCT03924076 54 59 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03924076 62 63 O
have NCT03924076 65 69 O
normal NCT03924076 70 76 B-Polarity___Polarity-Value:normal
body NCT03924076 77 81 B-Observation-Name___Observation-Type-Value:vital
mass NCT03924076 82 86 I-Observation-Name___Observation-Type-Value:vital
index NCT03924076 87 92 I-Observation-Name___Observation-Type-Value:vital
( NCT03924076 93 94 O
BMI NCT03924076 95 98 B-Observation-Name___Observation-Type-Value:vital
) NCT03924076 99 100 O
i NCT03924076 101 102 O
. NCT03924076 103 104 O
e NCT03924076 105 106 O
. NCT03924076 107 108 O
- NCT03924076 110 111 B-Eq-Value
2 NCT03924076 113 114 I-Eq-Value
≤ NCT03924076 115 116 B-Eq-Operator___Eq-Operator-Value:LTEQ
z NCT03924076 117 118 B-Eq-Unit___Eq-Unit-Value:ref-range-normal
- NCT03924076 119 120 I-Eq-Unit___Eq-Unit-Value:ref-range-normal
score NCT03924076 121 126 I-Eq-Unit___Eq-Unit-Value:ref-range-normal
< NCT03924076 127 128 B-Eq-Operator___Eq-Operator-Value:LT
+ NCT03924076 129 130 B-Eq-Value
1 NCT03924076 132 133 I-Eq-Value
, NCT03924076 134 135 O
slightly NCT03924076 136 144 B-Severity___Severity-Value:mild
overweight NCT03924076 145 155 B-Observation-Name___Observation-Type-Value:vital
z NCT03924076 156 157 B-Eq-Unit___Eq-Unit-Value:ref-range-normal
- NCT03924076 158 159 I-Eq-Unit___Eq-Unit-Value:ref-range-normal
score NCT03924076 160 165 I-Eq-Unit___Eq-Unit-Value:ref-range-normal
< NCT03924076 166 167 B-Eq-Operator___Eq-Operator-Value:LT
+ NCT03924076 168 169 B-Eq-Value
1.5 NCT03924076 171 174 I-Eq-Value
, NCT03924076 175 176 O
and NCT03924076 177 180 O
slightly NCT03924076 181 189 B-Severity___Severity-Value:mild
underweight NCT03924076 190 201 B-Observation-Name___Observation-Type-Value:vital
z NCT03924076 202 203 B-Eq-Unit___Eq-Unit-Value:ref-range-normal
- NCT03924076 204 205 I-Eq-Unit___Eq-Unit-Value:ref-range-normal
score NCT03924076 206 211 I-Eq-Unit___Eq-Unit-Value:ref-range-normal
> NCT03924076 212 213 B-Eq-Operator___Eq-Operator-Value:GT
- NCT03924076 214 215 B-Eq-Value
3 NCT03924076 217 218 I-Eq-Value
. NCT03924076 218 219 O

Exclusion NCT03924076 221 230 O
Criteria NCT03924076 231 239 O
: NCT03924076 240 241 O

- NCT03924076 245 246 O
allergic NCT03924076 248 256 O
to NCT03924076 257 259 O
milk NCT03924076 260 264 B-Allergy-Name

- NCT03924076 267 268 O
consuming NCT03924076 270 279 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
other NCT03924076 280 285 O
probiotic NCT03924076 286 295 B-Drug-Name
product NCT03924076 296 303 I-Drug-Name

- NCT03924076 306 307 O
he NCT03924076 309 311 O
/ NCT03924076 312 313 O
she NCT03924076 314 317 O
do NCT03924076 318 320 O
not NCT03924076 321 324 O
want NCT03924076 325 329 O
to NCT03924076 330 332 O
stop NCT03924076 333 337 O
consumption NCT03924076 338 349 O
& NCT03924076 350 351 O
doing NCT03924076 352 357 O
washout NCT03924076 358 365 B-Procedure-Name
for NCT03924076 366 369 O
2 NCT03924076 371 372 B-Eq-Value
weeks NCT03924076 373 378 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
. NCT03924076 379 380 O

Inclusion NCT03923686 0 9 O
Criteria NCT03923686 10 18 O
: NCT03923686 19 20 O

- NCT03923686 24 25 O
walled NCT03923686 27 33 B-Condition-Name
- NCT03923686 34 35 I-Condition-Name
off NCT03923686 36 39 I-Condition-Name
pancreatic NCT03923686 40 50 I-Condition-Name
necrosis NCT03923686 51 59 I-Condition-Name
( NCT03923686 60 61 O
WON NCT03923686 62 65 B-Condition-Name
) NCT03923686 66 67 O
indicated NCT03923686 68 77 O
for NCT03923686 78 81 O
endoscopical NCT03923686 82 94 B-Procedure-Name
drainage NCT03923686 95 103 I-Procedure-Name

- NCT03923686 106 107 O
signed NCT03923686 109 115 O
informed NCT03923686 116 124 O
consent NCT03923686 125 132 O
form NCT03923686 133 137 O

Exclusion NCT03923686 138 147 O
Criteria NCT03923686 148 156 O
: NCT03923686 157 158 O

- NCT03923686 162 163 O
patient NCT03923686 165 172 O
disagreement NCT03923686 173 185 O
with NCT03923686 186 190 O
the NCT03923686 191 194 O
study NCT03923686 195 200 O

- NCT03923686 203 204 O
types NCT03923686 206 211 O
of NCT03923686 212 214 O
collections NCT03923686 215 226 B-Condition-Name
other NCT03923686 227 232 O
than NCT03923686 233 237 O
WON NCT03923686 238 241 B-Condition-Name

- NCT03923686 244 245 O
drainage NCT03923686 247 255 B-Procedure-Name
with NCT03923686 256 260 O
stents NCT03923686 261 267 B-Procedure-Name
other NCT03923686 268 273 O
than NCT03923686 274 278 O
LAMS NCT03923686 279 283 B-Procedure-Name

- NCT03923686 286 287 O
previous NCT03923686 289 297 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
attempts NCT03923686 298 306 O
at NCT03923686 307 309 O
drainage NCT03923686 310 318 B-Procedure-Name
of NCT03923686 319 321 O
WON NCT03923686 322 325 B-Condition-Name

- NCT03923686 328 329 O
severe NCT03923686 331 337 B-Severity___Severity-Value:severe
coagulopathy NCT03923686 338 350 B-Condition-Name
or NCT03923686 351 353 O
thrombocytopenia NCT03923686 354 370 B-Condition-Name

Inclusion NCT03924843 0 9 O
Criteria NCT03924843 10 18 O
: NCT03924843 19 20 O

- NCT03924843 24 25 O
Men NCT03924843 27 30 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
/ NCT03924843 31 32 O
Women NCT03924843 33 38 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
age NCT03924843 39 42 O
> NCT03924843 43 44 B-Eq-Operator___Eq-Operator-Value:GT
40 NCT03924843 46 48 B-Eq-Value
years NCT03924843 49 54 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
. NCT03924843 55 56 O

- NCT03924843 60 61 O
Diagnoses NCT03924843 63 72 O
of NCT03924843 73 75 O
COPD NCT03924843 76 80 B-Condition-Name
according NCT03924843 81 90 O
to NCT03924843 91 93 O
criteria NCT03924843 94 102 O
of NCT03924843 103 105 O
the NCT03924843 106 109 O
American NCT03924843 110 118 O
Thoracic NCT03924843 119 127 O
Society NCT03924843 128 135 O
( NCT03924843 136 137 O
ATS NCT03924843 138 141 O
) NCT03924843 142 143 O
, NCT03924843 145 146 O
a NCT03924843 147 148 O
disease NCT03924843 149 156 O
state NCT03924843 157 162 O
characterized NCT03924843 163 176 O
by NCT03924843 177 179 O
the NCT03924843 180 183 O
presence NCT03924843 184 192 O
of NCT03924843 193 195 O
chronic NCT03924843 196 203 B-Condition-Name
airway NCT03924843 204 210 I-Condition-Name
obstruction NCT03924843 211 222 I-Condition-Name
due NCT03924843 223 226 O
to NCT03924843 227 229 O
chronic NCT03924843 230 237 B-Condition-Name
bronchitis NCT03924843 238 248 I-Condition-Name
( NCT03924843 249 250 O
cough NCT03924843 251 256 B-Condition-Name
/ NCT03924843 257 258 O
sputum NCT03924843 259 265 B-Condition-Name
on NCT03924843 266 268 O
most NCT03924843 269 273 O
days NCT03924843 274 278 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:day
a NCT03924843 279 280 O
week NCT03924843 281 285 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
for NCT03924843 286 289 O
3 NCT03924843 291 292 B-Eq-Value
months NCT03924843 293 299 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
in NCT03924843 300 302 O
a NCT03924843 303 304 O
year NCT03924843 305 309 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
for NCT03924843 310 313 O
at NCT03924843 314 316 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03924843 317 322 I-Eq-Operator___Eq-Operator-Value:GTEQ
two NCT03924843 323 326 B-Eq-Value
successive NCT03924843 327 337 O
years NCT03924843 338 343 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
) NCT03924843 344 345 O
and NCT03924843 346 349 O
/ NCT03924843 350 351 O
or NCT03924843 352 354 O
emphysema NCT03924843 355 364 B-Condition-Name

- NCT03924843 367 368 O
Diagnosis NCT03924843 370 379 O
of NCT03924843 380 382 O
moderate NCT03924843 383 391 B-Severity___Severity-Value:severe
or NCT03924843 392 394 O
severe NCT03924843 395 401 B-Severity___Severity-Value:severe
COPD NCT03924843 402 406 B-Condition-Name
exacerbation NCT03924843 407 419 I-Condition-Name
( NCT03924843 420 421 O
see NCT03924843 422 425 O
" NCT03924843 426 427 O
Definitions NCT03924843 427 438 O
" NCT03924843 438 439 O
) NCT03924843 440 441 O

- NCT03924843 445 446 O
FEV NCT03924843 448 451 B-Observation-Name___Observation-Type-Value:lab
1 NCT03924843 452 453 I-Observation-Name___Observation-Type-Value:lab
> NCT03924843 454 455 B-Eq-Operator___Eq-Operator-Value:GT
0.8 NCT03924843 457 460 B-Eq-Value
L NCT03924843 461 462 B-Eq-Unit
and NCT03924843 463 466 O
ability NCT03924843 467 474 O
to NCT03924843 475 477 O
produce NCT03924843 478 485 B-Condition-Name
sputum NCT03924843 486 492 I-Condition-Name
after NCT03924843 493 498 O
hypertonic NCT03924843 499 509 B-Drug-Name
saline NCT03924843 510 516 I-Drug-Name
production NCT03924843 517 527 I-Drug-Name

- NCT03924843 530 531 O
Post NCT03924843 533 537 O
bronchodilator NCT03924843 538 552 B-Procedure-Name
FEV NCT03924843 553 556 B-Observation-Name___Observation-Type-Value:lab
1 NCT03924843 557 558 I-Observation-Name___Observation-Type-Value:lab
/ NCT03924843 559 560 O
Forced NCT03924843 561 567 B-Observation-Name___Observation-Type-Value:lab
Vital NCT03924843 568 573 I-Observation-Name___Observation-Type-Value:lab
Capacity NCT03924843 574 582 I-Observation-Name___Observation-Type-Value:lab
( NCT03924843 583 584 O
FVC NCT03924843 585 588 B-Observation-Name
) NCT03924843 589 590 O
ratio NCT03924843 591 596 O
< NCT03924843 597 598 B-Eq-Operator___Eq-Operator-Value:LT
70 NCT03924843 600 602 B-Eq-Value
% NCT03924843 603 604 B-Eq-Unit
and NCT03924843 605 608 O
post NCT03924843 609 613 O
bronchodilator NCT03924843 614 628 B-Procedure-Name
FEV NCT03924843 629 632 B-Observation-Name___Observation-Type-Value:lab
1 NCT03924843 633 634 I-Observation-Name___Observation-Type-Value:lab
< NCT03924843 635 636 B-Eq-Operator___Eq-Operator-Value:LT
80 NCT03924843 638 640 B-Eq-Value
% NCT03924843 641 642 B-Eq-Unit
pred NCT03924843 643 647 O
. NCT03924843 648 649 O

- NCT03924843 653 654 O
A NCT03924843 656 657 O
smoking NCT03924843 658 665 B-Condition-Name
history NCT03924843 666 673 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03924843 674 676 O
> NCT03924843 677 678 B-Eq-Operator___Eq-Operator-Value:GT
10 NCT03924843 680 682 B-Eq-Value
pack NCT03924843 683 687 O
years NCT03924843 688 693 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

Exclusion NCT03924843 694 703 O
Criteria NCT03924843 704 712 O
: NCT03924843 713 714 O

- NCT03924843 718 719 O
Pneumonia NCT03924843 721 730 B-Condition-Name
as NCT03924843 731 733 O
determined NCT03924843 734 744 O
by NCT03924843 745 747 O
X NCT03924843 748 749 B-Procedure-Name
- NCT03924843 750 751 I-Procedure-Name
ray NCT03924843 752 755 I-Procedure-Name

- NCT03924843 758 759 O
> NCT03924843 761 762 B-Eq-Operator___Eq-Operator-Value:GT
48 NCT03924843 764 766 B-Eq-Value
h NCT03924843 767 768 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:hour
intake NCT03924843 769 775 O
of NCT03924843 776 778 O
prednisolon NCT03924843 779 790 B-Drug-Name
/ NCT03924843 791 792 O
antibiotics NCT03924843 793 804 B-Drug-Name

- NCT03924843 807 808 O
Need NCT03924843 810 814 O
for NCT03924843 815 818 O
mechanical NCT03924843 819 829 B-Procedure-Name
ventilation NCT03924843 830 841 I-Procedure-Name
( NCT03924843 842 843 O
either NCT03924843 844 850 O
invasive NCT03924843 851 859 O
or NCT03924843 860 862 O
non NCT03924843 863 866 O
- NCT03924843 867 868 O
invasive NCT03924843 869 877 O
) NCT03924843 878 879 O

- NCT03924843 883 884 O
Treatment NCT03924843 886 895 O
with NCT03924843 896 900 O
immune NCT03924843 901 907 B-Drug-Name
- NCT03924843 908 909 I-Drug-Name
modulating NCT03924843 910 920 I-Drug-Name
agents NCT03924843 921 927 I-Drug-Name
for NCT03924843 928 931 O
any NCT03924843 932 935 O
disease NCT03924843 936 943 B-Condition-Name

- NCT03924843 946 947 O
Experimental NCT03924843 949 961 O
interventions NCT03924843 962 975 O
for NCT03924843 976 979 O
COPD NCT03924843 980 984 B-Condition-Name
last NCT03924843 985 989 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
half NCT03924843 990 994 B-Eq-Value
year NCT03924843 995 999 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year

- NCT03924843 1002 1003 O
Former NCT03924843 1005 1011 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
/ NCT03924843 1012 1013 O
concomitant NCT03924843 1014 1025 O
diagnosis NCT03924843 1026 1035 O
of NCT03924843 1036 1038 O
asthma NCT03924843 1039 1045 B-Condition-Name

- NCT03924843 1048 1049 O
Any NCT03924843 1051 1054 O
significant NCT03924843 1055 1066 B-Severity___Severity-Value:severe
other NCT03924843 1067 1072 O
pulmonary NCT03924843 1073 1082 O
disease NCT03924843 1083 1090 B-Condition-Name
or NCT03924843 1091 1093 O
disorder NCT03924843 1094 1102 B-Condition-Name

- NCT03924843 1105 1106 O
Other NCT03924843 1108 1113 O
significant NCT03924843 1114 1125 B-Severity___Severity-Value:severe
disease NCT03924843 1126 1133 B-Condition-Name
or NCT03924843 1134 1136 O
disorder NCT03924843 1137 1145 B-Condition-Name
( NCT03924843 1146 1147 O
like NCT03924843 1148 1152 O
alpha NCT03924843 1153 1158 B-Condition-Name
- NCT03924843 1159 1160 I-Condition-Name
1 NCT03924843 1162 1163 I-Condition-Name
- NCT03924843 1164 1165 I-Condition-Name
antitrypsine NCT03924843 1166 1178 I-Condition-Name
deficiency NCT03924843 1179 1189 I-Condition-Name
, NCT03924843 1190 1191 O
significant NCT03924843 1192 1203 B-Severity___Severity-Value:severe
bronchiectasis NCT03924843 1204 1218 B-Condition-Name
, NCT03924843 1219 1220 O
cardiovascular NCT03924843 1221 1235 O
, NCT03924843 1236 1237 O
gastrointestinal NCT03924843 1238 1254 O
, NCT03924843 1255 1256 O
liver NCT03924843 1257 1262 O
, NCT03924843 1263 1264 O
renal NCT03924843 1265 1270 O
, NCT03924843 1271 1272 O
neurological NCT03924843 1273 1285 O
, NCT03924843 1286 1287 O
musculoskeletal NCT03924843 1288 1303 O
, NCT03924843 1304 1305 O
endocrine NCT03924843 1306 1315 O
, NCT03924843 1316 1317 O
metabolic NCT03924843 1318 1327 O
( NCT03924843 1328 1329 O
including NCT03924843 1330 1339 O
diagnosed NCT03924843 1340 1349 O
diabetes NCT03924843 1350 1358 B-Condition-Name
) NCT03924843 1359 1360 O
, NCT03924843 1362 1363 O
malignant NCT03924843 1364 1373 O
, NCT03924843 1374 1375 O
psychiatric NCT03924843 1376 1387 O
, NCT03924843 1388 1389 O
major NCT03924843 1390 1395 O
physical NCT03924843 1396 1404 O
impairment NCT03924843 1405 1415 B-Condition-Name
) NCT03924843 1416 1417 O
, NCT03924843 1419 1420 O
which NCT03924843 1421 1426 O
, NCT03924843 1427 1428 O
in NCT03924843 1429 1431 O
the NCT03924843 1432 1435 O
opinion NCT03924843 1436 1443 O
of NCT03924843 1444 1446 O
the NCT03924843 1447 1450 O
investigators NCT03924843 1451 1464 O
may NCT03924843 1465 1468 O
either NCT03924843 1469 1475 O
put NCT03924843 1476 1479 O
the NCT03924843 1480 1483 O
patient NCT03924843 1484 1491 O
at NCT03924843 1492 1494 O
risk NCT03924843 1495 1499 O
because NCT03924843 1500 1507 O
of NCT03924843 1508 1510 O
participation NCT03924843 1511 1524 O
in NCT03924843 1525 1527 O
the NCT03924843 1528 1531 O
study NCT03924843 1532 1537 O
, NCT03924843 1538 1539 O
or NCT03924843 1540 1542 O
may NCT03924843 1543 1546 O
influence NCT03924843 1547 1556 B-Stability___Stability-Value:change
the NCT03924843 1557 1560 O
results NCT03924843 1561 1568 O
of NCT03924843 1569 1571 O
the NCT03924843 1572 1575 O
study NCT03924843 1576 1581 O
, NCT03924843 1582 1583 O
or NCT03924843 1584 1586 O
the NCT03924843 1587 1590 O
patient NCT03924843 1591 1598 O
's NCT03924843 1598 1600 O
ability NCT03924843 1601 1608 O
to NCT03924843 1609 1611 O
participate NCT03924843 1612 1623 O
in NCT03924843 1624 1626 O
the NCT03924843 1627 1630 O
study NCT03924843 1631 1636 O
. NCT03924843 1637 1638 O

- NCT03924843 1642 1643 O
Existing NCT03924843 1645 1653 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
pregnancy NCT03924843 1654 1663 B-Condition-Name
/ NCT03924843 1664 1665 O
current NCT03924843 1666 1673 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
willingness NCT03924843 1674 1685 O
for NCT03924843 1686 1689 O
becoming NCT03924843 1690 1698 O
pregnant NCT03924843 1699 1707 B-Condition-Name

Inclusion NCT03929432 0 9 O
Criteria NCT03929432 10 18 O
: NCT03929432 19 20 O

- NCT03929432 24 25 O
Presence NCT03929432 27 35 O
of NCT03929432 36 38 O
post NCT03929432 39 43 O
- NCT03929432 44 45 O
stroke NCT03929432 46 52 B-Condition-Name
aphasia NCT03929432 53 60 B-Condition-Name

- NCT03929432 63 64 O
Single NCT03929432 66 72 B-Eq-Value
left NCT03929432 73 77 O
hemisphere NCT03929432 78 88 O
stroke NCT03929432 89 95 B-Condition-Name
etiology NCT03929432 96 104 O

- NCT03929432 107 108 O
At NCT03929432 110 112 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03929432 113 118 I-Eq-Operator___Eq-Operator-Value:GTEQ
6 NCT03929432 120 121 B-Eq-Value
months NCT03929432 122 128 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:month
post NCT03929432 129 133 O
- NCT03929432 134 135 O
stroke NCT03929432 136 142 B-Condition-Name

- NCT03929432 145 146 O
Age NCT03929432 148 151 O
range NCT03929432 152 157 O
between NCT03929432 158 165 B-Eq-Operator___Eq-Operator-Value:BETWEEN
18 NCT03929432 167 169 B-Eq-Value
and NCT03929432 170 173 O
80 NCT03929432 175 177 B-Eq-Value
years NCT03929432 178 183 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
old NCT03929432 184 187 O

- NCT03929432 190 191 O
Speak NCT03929432 193 198 O
English NCT03929432 199 206 B-Language
as NCT03929432 207 209 O
a NCT03929432 210 211 O
native NCT03929432 212 218 O
language NCT03929432 219 227 O

- NCT03929432 230 231 O
Adequate NCT03929432 233 241 B-Polarity___Polarity-Value:normal
hearing NCT03929432 242 249 B-Condition-Name
and NCT03929432 250 253 O
vision NCT03929432 254 260 B-Condition-Name
to NCT03929432 261 263 O
complete NCT03929432 264 272 O
the NCT03929432 273 276 O
tasks NCT03929432 277 282 B-Observation-Name

Exclusion NCT03929432 283 292 O
Criteria NCT03929432 293 301 O
: NCT03929432 302 303 O

- NCT03929432 307 308 O
Severe NCT03929432 310 316 B-Severity___Severity-Value:severe
auditory NCT03929432 317 325 B-Condition-Name
comprehension NCT03929432 326 339 I-Condition-Name
deficits NCT03929432 340 348 I-Condition-Name
( NCT03929432 349 350 O
determined NCT03929432 351 361 O
by NCT03929432 362 364 O
pretest NCT03929432 365 372 B-Procedure-Name
) NCT03929432 373 374 O
( NCT03929432 375 376 O
i NCT03929432 377 378 O
. NCT03929432 379 380 O
e NCT03929432 381 382 O
. NCT03929432 383 384 O
, NCT03929432 385 386 O
global NCT03929432 387 393 B-Condition-Name
aphasia NCT03929432 394 401 I-Condition-Name
, NCT03929432 402 403 O
Wernicke NCT03929432 404 412 B-Condition-Name
's NCT03929432 412 414 I-Condition-Name
aphasia NCT03929432 415 422 I-Condition-Name
, NCT03929432 423 424 O
transcortical NCT03929432 425 438 B-Condition-Name
sensory NCT03929432 439 446 I-Condition-Name
aphasia NCT03929432 447 454 I-Condition-Name
) NCT03929432 455 456 O

- NCT03929432 460 461 O
Inability NCT03929432 463 472 O
to NCT03929432 473 475 O
provide NCT03929432 476 483 O
informed NCT03929432 484 492 O
consent NCT03929432 493 500 O

- NCT03929432 503 504 O
Co NCT03929432 506 508 O
- NCT03929432 509 510 O
occurring NCT03929432 511 520 O
history NCT03929432 521 528 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03929432 529 531 O
neurological NCT03929432 532 544 O
disease NCT03929432 545 552 B-Condition-Name
/ NCT03929432 553 554 O
disorder NCT03929432 555 563 B-Condition-Name
/ NCT03929432 564 565 O
injury NCT03929432 566 572 B-Condition-Name
( NCT03929432 573 574 O
e NCT03929432 575 576 O
. NCT03929432 577 578 O
g NCT03929432 579 580 O
. NCT03929432 581 582 O
, NCT03929432 583 584 O
traumatic NCT03929432 585 594 B-Condition-Name
brain NCT03929432 595 600 I-Condition-Name
injury NCT03929432 601 607 I-Condition-Name
, NCT03929432 608 609 O
right NCT03929432 610 615 O
hemisphere NCT03929432 616 626 O
stroke NCT03929432 627 633 B-Condition-Name
, NCT03929432 634 635 O
dementia NCT03929432 636 644 B-Condition-Name
) NCT03929432 645 646 O

- NCT03929432 650 651 O
Co NCT03929432 653 655 O
- NCT03929432 656 657 O
occurring NCT03929432 658 667 O
history NCT03929432 668 675 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
of NCT03929432 676 678 O
a NCT03929432 679 680 O
major NCT03929432 681 686 B-Severity___Severity-Value:severe
mental NCT03929432 687 693 B-Condition-Name
illness NCT03929432 694 701 I-Condition-Name
( NCT03929432 702 703 O
e NCT03929432 704 705 O
. NCT03929432 706 707 O
g NCT03929432 708 709 O
. NCT03929432 710 711 O
, NCT03929432 712 713 O
schizophrenia NCT03929432 714 727 B-Condition-Name
, NCT03929432 728 729 O
drug NCT03929432 730 734 B-Condition-Name
addiction NCT03929432 735 744 I-Condition-Name
, NCT03929432 745 746 O
bipolar NCT03929432 747 754 B-Condition-Name
) NCT03929432 755 756 O

- NCT03929432 760 761 O
Clinical NCT03929432 763 771 O
conditions NCT03929432 772 782 O
contraindicated NCT03929432 783 798 O
for NCT03929432 799 802 O
MRI NCT03929432 803 806 B-Procedure-Name
or NCT03929432 807 809 O
tDCS NCT03929432 810 814 B-Procedure-Name
( NCT03929432 815 816 O
e NCT03929432 817 818 O
. NCT03929432 819 820 O
g NCT03929432 821 822 O
. NCT03929432 823 824 O
, NCT03929432 825 826 O
implanted NCT03929432 827 836 B-Procedure-Name
electrical NCT03929432 837 847 I-Procedure-Name
devices NCT03929432 848 855 I-Procedure-Name
, NCT03929432 856 857 O
claustrophobia NCT03929432 858 872 B-Condition-Name
, NCT03929432 873 874 O
seizure NCT03929432 875 882 B-Condition-Name
disorder NCT03929432 883 891 I-Condition-Name
) NCT03929432 892 893 O

- NCT03929432 897 898 O
Positive NCT03929432 900 908 B-Polarity___Polarity-Value:positive
pregnancy NCT03929432 909 918 B-Observation-Name___Observation-Type-Value:lab
test NCT03929432 919 923 I-Observation-Name___Observation-Type-Value:lab
( NCT03929432 924 925 O
for NCT03929432 926 929 O
females NCT03929432 930 937 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:male
) NCT03929432 938 939 O

Inclusion NCT03924102 0 9 O
Criteria NCT03924102 10 18 O
: NCT03924102 19 20 O

- NCT03924102 24 25 O
At NCT03924102 27 29 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03924102 30 35 I-Eq-Operator___Eq-Operator-Value:GTEQ
18 NCT03924102 37 39 B-Eq-Value
years NCT03924102 40 45 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03924102 46 48 O
age NCT03924102 49 52 O
. NCT03924102 53 54 O

- NCT03924102 58 59 O
Enrollment NCT03924102 61 71 O
in NCT03924102 72 74 O
the NCT03924102 75 78 O
UAB NCT03924102 79 82 B-Location___Location-Value:hospital
CMC NCT03924102 83 86 O
- NCT03924102 87 88 O
ADHF NCT03924102 89 93 O
study NCT03924102 94 99 O
under NCT03924102 100 105 O
the NCT03924102 106 109 O
separate NCT03924102 110 118 O
UAB NCT03924102 119 122 O
approved NCT03924102 123 131 O
research NCT03924102 132 140 O
protocol NCT03924102 141 149 O
( NCT03924102 150 151 O
IRB NCT03924102 152 155 O
- NCT03924102 156 157 O
300000114 NCT03924102 159 168 O
, NCT03924102 169 170 O
PI NCT03924102 171 173 O
Rajapreyar NCT03924102 174 184 O
) NCT03924102 185 186 O

- NCT03924102 190 191 O
Negative NCT03924102 193 201 B-Polarity___Polarity-Value:negative
urine NCT03924102 202 207 B-Observation-Specimen
or NCT03924102 208 210 O
serum NCT03924102 211 216 B-Observation-Specimen
β NCT03924102 217 218 B-Observation-Name___Observation-Type-Value:lab
- NCT03924102 219 220 I-Observation-Name___Observation-Type-Value:lab
hCG NCT03924102 221 224 I-Observation-Name___Observation-Type-Value:lab
test NCT03924102 225 229 I-Observation-Name___Observation-Type-Value:lab
within NCT03924102 230 236 B-Eq-Operator___Eq-Operator-Value:LTEQ
48 NCT03924102 238 240 B-Eq-Value
hours NCT03924102 241 246 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:hour
of NCT03924102 247 249 O
[ NCT03924102 250 251 O
11 NCT03924102 253 255 O
C NCT03924102 256 257 O
] NCT03924102 258 259 O
acetate NCT03924102 260 267 B-Drug-Name
administration NCT03924102 268 282 I-Drug-Name
in NCT03924102 283 285 O
women NCT03924102 286 291 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
of NCT03924102 292 294 O
child NCT03924102 295 300 B-Condition-Name
bearing NCT03924102 301 308 I-Condition-Name
potential NCT03924102 309 318 I-Condition-Name
. NCT03924102 319 320 O
Women NCT03924102 322 327 B-Life-Stage-And-Gender___Life-Stage-And-Gender-Type:female
who NCT03924102 328 331 O
are NCT03924102 332 335 O
post NCT03924102 336 340 B-Condition-Name
- NCT03924102 341 342 I-Condition-Name
menopausal NCT03924102 343 353 I-Condition-Name
with NCT03924102 354 358 O
at NCT03924102 359 361 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03924102 362 367 I-Eq-Operator___Eq-Operator-Value:GTEQ
1 NCT03924102 369 370 B-Eq-Value
year NCT03924102 371 375 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
since NCT03924102 376 381 O
last NCT03924102 382 386 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:most-recent-time
menses NCT03924102 387 393 B-Condition-Name
or NCT03924102 394 396 O
documented NCT03924102 397 407 O
surgical NCT03924102 408 416 B-Procedure-Name
sterilization NCT03924102 417 430 I-Procedure-Name
will NCT03924102 431 435 O
not NCT03924102 436 439 O
require NCT03924102 440 447 O
pregnancy NCT03924102 448 457 B-Observation-Name___Observation-Type-Value:lab
testing NCT03924102 458 465 I-Observation-Name___Observation-Type-Value:lab
. NCT03924102 466 467 O

Exclusion NCT03924102 469 478 O
Criteria NCT03924102 479 487 O
: NCT03924102 488 489 O

- NCT03924102 493 494 O
Inability NCT03924102 496 505 O
to NCT03924102 506 508 O
provide NCT03924102 509 516 O
informed NCT03924102 517 525 O
consent NCT03924102 526 533 O

- NCT03924102 536 537 O
Pregnancy NCT03924102 539 548 B-Condition-Name

- NCT03924102 551 552 O
Inability NCT03924102 554 563 O
to NCT03924102 564 566 O
lie NCT03924102 567 570 O
still NCT03924102 571 576 O
for NCT03924102 577 580 O
the NCT03924102 581 584 O
imaging NCT03924102 585 592 B-Procedure-Name
study NCT03924102 593 598 I-Procedure-Name

- NCT03924102 601 602 O
Weight NCT03924102 604 610 B-Observation-Name___Observation-Type-Value:vital
exceeding NCT03924102 611 620 B-Eq-Operator___Eq-Operator-Value:GT
the NCT03924102 621 624 O
weight NCT03924102 625 631 O
limit NCT03924102 632 637 O
of NCT03924102 638 640 O
the NCT03924102 641 644 O
PET NCT03924102 645 648 B-Procedure-Name
imaging NCT03924102 649 656 I-Procedure-Name
table NCT03924102 657 662 I-Procedure-Name
( NCT03924102 663 664 O
500 NCT03924102 666 669 B-Eq-Value
pounds NCT03924102 670 676 B-Eq-Unit
) NCT03924102 677 678 O
. NCT03924102 680 681 O

Inclusion NCT03924466 0 9 O
Criteria NCT03924466 10 18 O
: NCT03924466 19 20 O

Patients NCT03924466 22 30 O
will NCT03924466 31 35 O
only NCT03924466 36 40 O
be NCT03924466 41 43 O
included NCT03924466 44 52 O
in NCT03924466 53 55 O
the NCT03924466 56 59 O
study NCT03924466 60 65 O
if NCT03924466 66 68 O
they NCT03924466 69 73 O
meet NCT03924466 74 78 O
all NCT03924466 79 82 O
of NCT03924466 83 85 O
the NCT03924466 86 89 O
following NCT03924466 90 99 O
criteria NCT03924466 100 108 O
: NCT03924466 109 110 O

- NCT03924466 114 115 O
Patient NCT03924466 117 124 O
who NCT03924466 125 128 O
has NCT03924466 129 132 O
given NCT03924466 133 138 O
informed NCT03924466 139 147 O
consent NCT03924466 148 155 O

- NCT03924466 158 159 O
Patient NCT03924466 161 168 O
with NCT03924466 169 173 O
age NCT03924466 174 177 O
18 NCT03924466 179 181 B-Eq-Value
years NCT03924466 182 187 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
or NCT03924466 188 190 B-Eq-Operator___Eq-Operator-Value:GTEQ
older NCT03924466 191 196 I-Eq-Operator___Eq-Operator-Value:GTEQ

- NCT03924466 199 200 O
Patient NCT03924466 202 209 O
with NCT03924466 210 214 O
locally NCT03924466 215 222 O
or NCT03924466 223 225 O
distantly NCT03924466 226 235 O
advanced NCT03924466 236 244 O
breast NCT03924466 245 251 O
carcinoma NCT03924466 252 261 B-Condition-Name
, NCT03924466 262 263 O
with NCT03924466 264 268 O
at NCT03924466 269 271 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03924466 272 277 I-Eq-Operator___Eq-Operator-Value:GTEQ
1 NCT03924466 279 280 B-Eq-Value
lesion NCT03924466 281 287 B-Condition-Name
of NCT03924466 288 290 O
at NCT03924466 291 293 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03924466 294 299 I-Eq-Operator___Eq-Operator-Value:GTEQ
12 NCT03924466 301 303 B-Eq-Value
mm NCT03924466 304 306 B-Eq-Unit
maximal NCT03924466 307 314 O
diameter NCT03924466 315 323 O
. NCT03924466 324 325 O
For NCT03924466 327 330 O
lymph NCT03924466 331 336 O
node NCT03924466 337 341 O
metastases NCT03924466 342 352 B-Condition-Name
, NCT03924466 353 354 O
the NCT03924466 355 358 O
largest NCT03924466 359 366 O
diameter NCT03924466 367 375 O
should NCT03924466 376 382 O
be NCT03924466 383 385 O
at NCT03924466 386 388 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03924466 389 394 I-Eq-Operator___Eq-Operator-Value:GTEQ
15 NCT03924466 396 398 B-Eq-Value
mm NCT03924466 399 401 B-Eq-Unit
and NCT03924466 402 405 O
the NCT03924466 406 409 O
short NCT03924466 410 415 B-Observation-Name
axis NCT03924466 416 420 I-Observation-Name
at NCT03924466 421 423 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03924466 424 429 I-Eq-Operator___Eq-Operator-Value:GTEQ
12 NCT03924466 431 433 B-Eq-Value
mm NCT03924466 434 436 B-Eq-Unit
. NCT03924466 437 438 O

Exclusion NCT03924466 440 449 O
Criteria NCT03924466 450 458 O
: NCT03924466 459 460 O

Patients NCT03924466 462 470 O
will NCT03924466 471 475 O
not NCT03924466 476 479 O
be NCT03924466 480 482 O
included NCT03924466 483 491 O
in NCT03924466 492 494 O
the NCT03924466 495 498 O
study NCT03924466 499 504 O
if NCT03924466 505 507 O
one NCT03924466 508 511 O
or NCT03924466 512 514 O
more NCT03924466 515 519 O
of NCT03924466 520 522 O
the NCT03924466 523 526 O
following NCT03924466 527 536 O
criteria NCT03924466 537 545 O

applies NCT03924466 546 553 O
: NCT03924466 554 555 O

- NCT03924466 559 560 O
Patient NCT03924466 562 569 O
is NCT03924466 570 572 O
pregnant NCT03924466 573 581 B-Condition-Name

- NCT03924466 584 585 O
Patient NCT03924466 587 594 O
is NCT03924466 595 597 O
breast NCT03924466 598 604 B-Condition-Name
feeding NCT03924466 605 612 I-Condition-Name

- NCT03924466 615 616 O
Patient NCT03924466 618 625 O
with NCT03924466 626 630 O
recent NCT03924466 631 637 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:recent
( NCT03924466 638 639 O
< NCT03924466 641 642 B-Eq-Operator___Eq-Operator-Value:LT
1 NCT03924466 644 645 B-Eq-Value
week NCT03924466 646 650 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:week
) NCT03924466 651 652 O
gastrointestinal NCT03924466 653 669 B-Condition-Name
disorders NCT03924466 670 679 I-Condition-Name
with NCT03924466 680 684 O
diarrhea NCT03924466 685 693 B-Condition-Name
as NCT03924466 694 696 O
major NCT03924466 697 702 O
symptom NCT03924466 703 710 O

- NCT03924466 713 714 O
Patient NCT03924466 716 723 O
with NCT03924466 724 728 O
any NCT03924466 729 732 O
serious NCT03924466 733 740 B-Severity___Severity-Value:severe
active NCT03924466 741 747 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:present
infection NCT03924466 748 757 B-Condition-Name

- NCT03924466 760 761 O
Patient NCT03924466 763 770 O
who NCT03924466 771 774 O
has NCT03924466 775 778 O
any NCT03924466 779 782 O
other NCT03924466 783 788 O
life NCT03924466 789 793 O
- NCT03924466 794 795 O
threatening NCT03924466 796 807 O
illness NCT03924466 808 815 B-Condition-Name
or NCT03924466 816 818 O
organ NCT03924466 819 824 O
system NCT03924466 825 831 O
dysfunction NCT03924466 832 843 B-Condition-Name
, NCT03924466 844 845 O
which NCT03924466 846 851 O
in NCT03924466 852 854 O
the NCT03924466 855 858 O
opinion NCT03924466 859 866 O
of NCT03924466 867 869 O
the NCT03924466 870 873 O
investigator NCT03924466 874 886 O
would NCT03924466 887 892 O
either NCT03924466 893 899 O
compromise NCT03924466 900 910 O
patient NCT03924466 911 918 O
safety NCT03924466 919 925 O
or NCT03924466 926 928 O
interfere NCT03924466 929 938 B-Stability___Stability-Value:change
with NCT03924466 939 943 O
the NCT03924466 944 947 O
evaluation NCT03924466 948 958 O
of NCT03924466 959 961 O
the NCT03924466 962 965 O
test NCT03924466 966 970 O
radiopharmaceutical NCT03924466 971 990 B-Procedure-Name

- NCT03924466 993 994 O
Patient NCT03924466 996 1003 O
who NCT03924466 1004 1007 O
can NCT03924466 1008 1011 O
not NCT03924466 1011 1014 O
communicate NCT03924466 1015 1026 B-Condition-Name
reliably NCT03924466 1027 1035 O
with NCT03924466 1036 1040 O
the NCT03924466 1041 1044 O
investigator NCT03924466 1045 1057 O

- NCT03924466 1060 1061 O
Patient NCT03924466 1063 1070 O
who NCT03924466 1071 1074 O
is NCT03924466 1075 1077 O
unlikely NCT03924466 1078 1086 O
to NCT03924466 1087 1089 O
cooperate NCT03924466 1090 1099 O
with NCT03924466 1100 1104 O
the NCT03924466 1105 1108 O
requirements NCT03924466 1109 1121 O
of NCT03924466 1122 1124 O
the NCT03924466 1125 1128 O
study NCT03924466 1129 1134 O

- NCT03924466 1137 1138 O
Patient NCT03924466 1140 1147 O
who NCT03924466 1148 1151 O
is NCT03924466 1152 1154 O
unwilling NCT03924466 1155 1164 O
and NCT03924466 1165 1168 O
/ NCT03924466 1169 1170 O
or NCT03924466 1171 1173 O
unable NCT03924466 1174 1180 O
to NCT03924466 1181 1183 O
give NCT03924466 1184 1188 O
informed NCT03924466 1189 1197 O
consent NCT03924466 1198 1205 O

- NCT03924466 1208 1209 O
Patient NCT03924466 1211 1218 O
at NCT03924466 1219 1221 O
increased NCT03924466 1222 1231 B-Polarity___Polarity-Value:high
risk NCT03924466 1232 1236 O
of NCT03924466 1237 1239 O
death NCT03924466 1240 1245 O
from NCT03924466 1246 1250 O
a NCT03924466 1251 1252 O
pre NCT03924466 1253 1256 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
- NCT03924466 1257 1258 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
existing NCT03924466 1259 1267 I-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
concurrent NCT03924466 1268 1278 O
illness NCT03924466 1279 1286 O

- NCT03924466 1289 1290 O
Patient NCT03924466 1292 1299 O
who NCT03924466 1300 1303 O
participated NCT03924466 1304 1316 O
already NCT03924466 1317 1324 O
in NCT03924466 1325 1327 O
this NCT03924466 1328 1332 O
study NCT03924466 1333 1338 O
. NCT03924466 1339 1340 O

Inclusion NCT03923309 0 9 O
Criteria NCT03923309 10 18 O
: NCT03923309 19 20 O

- NCT03923309 24 25 O
biopsy NCT03923309 27 33 B-Procedure-Name
proven NCT03923309 34 40 O
rectal NCT03923309 41 47 O
cancer NCT03923309 48 54 B-Condition-Name
( NCT03923309 55 56 O
anal NCT03923309 57 61 B-Observation-Name___Observation-Type-Value:measurement
verge NCT03923309 62 67 I-Observation-Name___Observation-Type-Value:measurement
≤ NCT03923309 68 69 B-Eq-Operator___Eq-Operator-Value:LTEQ
10 NCT03923309 71 73 B-Eq-Value
cm NCT03923309 74 76 B-Eq-Unit
) NCT03923309 77 78 O

- NCT03923309 82 83 O
neoadjuvant NCT03923309 85 96 O
radiotherapy NCT03923309 97 109 B-Procedure-Name
or NCT03923309 110 112 O
chemoradiotherapy NCT03923309 113 130 B-Procedure-Name

- NCT03923309 133 134 O
no NCT03923309 136 138 O
radical NCT03923309 139 146 O
surgery NCT03923309 147 154 B-Procedure-Name
after NCT03923309 155 160 O
neoadjuvant NCT03923309 161 172 B-Procedure-Name
therapy NCT03923309 173 180 I-Procedure-Name

Exclusion NCT03923309 181 190 O
Criteria NCT03923309 191 199 O
: NCT03923309 200 201 O

- NCT03923309 205 206 O
other NCT03923309 208 213 O
malignant NCT03923309 214 223 B-Condition-Name
disease NCT03923309 224 231 I-Condition-Name

- NCT03923309 234 235 O
other NCT03923309 237 242 O
fatel NCT03923309 243 248 B-Condition-Name
disease NCT03923309 249 256 I-Condition-Name

- NCT03923309 259 260 O
incompletion NCT03923309 262 274 O
of NCT03923309 275 277 O
half NCT03923309 278 282 O
of NCT03923309 283 285 O
radiotherapy NCT03923309 286 298 B-Procedure-Name
course NCT03923309 299 305 O

- NCT03923309 308 309 O
metastasis NCT03923309 311 321 B-Condition-Name
on NCT03923309 322 324 O
initial NCT03923309 325 332 B-Eq-Temporal-Recency___Eq-Temporal-Recency-Value:first-time
presentation NCT03923309 333 345 B-Condition-Name

Inclusion NCT03923335 0 9 O
Criteria NCT03923335 10 18 O
: NCT03923335 19 20 O

1 NCT03923335 25 26 O
. NCT03923335 26 27 O
TNM NCT03923335 29 32 O
stage NCT03923335 33 38 O
I NCT03923335 39 40 O
- NCT03923335 41 42 O
II NCT03923335 43 45 O
( NCT03923335 46 47 O
T NCT03923335 48 49 B-Eq-Value
1 NCT03923335 50 51 I-Eq-Value
- NCT03923335 52 53 B-Eq-Operator___Eq-Operator-Value:BETWEEN
4 NCT03923335 55 56 B-Eq-Value
N NCT03923335 57 58 I-Eq-Value
0 NCT03923335 59 60 I-Eq-Value
M NCT03923335 60 61 I-Eq-Value
0 NCT03923335 62 63 I-Eq-Value
) NCT03923335 64 65 O
colorectal NCT03923335 66 76 O
cancer NCT03923335 77 83 B-Condition-Name
cases NCT03923335 84 89 O

2 NCT03923335 93 94 O
. NCT03923335 94 95 O
receive NCT03923335 97 104 O
radical NCT03923335 105 112 O
surgical NCT03923335 113 121 B-Procedure-Name
resection NCT03923335 122 131 I-Procedure-Name

3 NCT03923335 135 136 O
. NCT03923335 136 137 O
have NCT03923335 139 143 O
completed NCT03923335 144 153 O
data NCT03923335 154 158 O
of NCT03923335 159 161 O
tumor NCT03923335 162 167 B-Condition-Name
location NCT03923335 168 176 O
, NCT03923335 177 178 O
histological NCT03923335 179 191 O
type NCT03923335 192 196 O
, NCT03923335 197 198 O
behavioral NCT03923335 199 209 O
characteristics NCT03923335 210 225 O
or NCT03923335 226 228 O
TNM NCT03923335 229 232 O
staging NCT03923335 233 240 O

4 NCT03923335 244 245 O
. NCT03923335 245 246 O
have NCT03923335 248 252 O
tumor NCT03923335 253 258 B-Observation-Specimen
specimens NCT03923335 259 268 I-Observation-Specimen
and NCT03923335 269 272 O
either NCT03923335 273 279 O
a NCT03923335 280 281 O
valid NCT03923335 282 287 O
microsatellite NCT03923335 288 302 B-Observation-Name
instability NCT03923335 303 314 I-Observation-Name
( NCT03923335 315 316 O
MSI NCT03923335 317 320 B-Observation-Name
) NCT03923335 321 322 O
or NCT03923335 323 325 O
immuno NCT03923335 326 332 B-Observation-Name
- NCT03923335 333 334 I-Observation-Name
histochemistry NCT03923335 335 349 I-Observation-Name
( NCT03923335 350 351 O
IHC NCT03923335 352 355 B-Observation-Name
) NCT03923335 356 357 O
data NCT03923335 358 362 O

5 NCT03923335 366 367 O
. NCT03923335 367 368 O
have NCT03923335 370 374 O
valid NCT03923335 375 380 O
V NCT03923335 381 382 B-Observation-Name___Observation-Type-Value:lab
- NCT03923335 383 384 I-Observation-Name___Observation-Type-Value:lab
raf NCT03923335 385 388 I-Observation-Name___Observation-Type-Value:lab
murine NCT03923335 389 395 I-Observation-Name___Observation-Type-Value:lab
sarcoma NCT03923335 396 403 I-Observation-Name___Observation-Type-Value:lab
viral NCT03923335 404 409 I-Observation-Name___Observation-Type-Value:lab
oncogene NCT03923335 410 418 I-Observation-Name___Observation-Type-Value:lab
homolog NCT03923335 419 426 I-Observation-Name___Observation-Type-Value:lab
B NCT03923335 427 428 I-Observation-Name___Observation-Type-Value:lab
1 NCT03923335 429 430 I-Observation-Name___Observation-Type-Value:lab
( NCT03923335 431 432 O
BRAF NCT03923335 433 437 B-Observation-Name
) NCT03923335 438 439 O
, NCT03923335 441 442 O
kirsten NCT03923335 443 450 B-Observation-Name___Observation-Type-Value:lab
rat NCT03923335 451 454 I-Observation-Name___Observation-Type-Value:lab
sarcoma NCT03923335 455 462 I-Observation-Name___Observation-Type-Value:lab
viral NCT03923335 463 468 I-Observation-Name___Observation-Type-Value:lab
oncogene NCT03923335 469 477 I-Observation-Name___Observation-Type-Value:lab
( NCT03923335 478 479 O
KRAS NCT03923335 480 484 B-Observation-Name
) NCT03923335 485 486 O
, NCT03923335 488 489 O
CpG NCT03923335 490 493 B-Observation-Name___Observation-Type-Value:lab
island NCT03923335 494 500 I-Observation-Name___Observation-Type-Value:lab
methylator NCT03923335 501 511 I-Observation-Name___Observation-Type-Value:lab
phenotype NCT03923335 512 521 I-Observation-Name___Observation-Type-Value:lab
( NCT03923335 522 523 O
CIMP NCT03923335 524 528 B-Observation-Name
) NCT03923335 529 530 O
results NCT03923335 531 538 O

6 NCT03923335 542 543 O
. NCT03923335 543 544 O
have NCT03923335 546 550 O
at NCT03923335 551 553 B-Eq-Operator___Eq-Operator-Value:GTEQ
least NCT03923335 554 559 I-Eq-Operator___Eq-Operator-Value:GTEQ
4 NCT03923335 561 562 B-Eq-Value
years NCT03923335 563 568 B-Eq-Temporal-Unit___Eq-Temporal-Unit-Value:year
of NCT03923335 569 571 O
follow NCT03923335 572 578 O
- NCT03923335 579 580 O
up NCT03923335 581 583 O

7 NCT03923335 587 588 O
. NCT03923335 588 589 O
have NCT03923335 591 595 O
valid NCT03923335 596 601 O
time NCT03923335 602 606 O
to NCT03923335 607 609 O
local NCT03923335 610 615 O
recurrence NCT03923335 616 626 B-Condition-Name
/ NCT03923335 627 628 O
metastasis NCT03923335 629 639 B-Condition-Name
in NCT03923335 640 642 O
follow NCT03923335 643 649 O
- NCT03923335 650 651 O
up NCT03923335 652 654 O

8 NCT03923335 658 659 O
. NCT03923335 659 660 O
have NCT03923335 662 666 O
clinical NCT03923335 667 675 O
/ NCT03923335 676 677 O
treatment NCT03923335 678 687 O
record NCT03923335 688 694 O
data NCT03923335 695 699 O
and NCT03923335 700 703 O
valid NCT03923335 704 709 O
pre NCT03923335 710 713 O
operative NCT03923335 714 723 B-Procedure-Name
status NCT03923335 724 730 O
of NCT03923335 731 733 O
intestinal NCT03923335 734 744 B-Condition-Name
obstruction NCT03923335 745 756 I-Condition-Name
or NCT03923335 757 759 I-Condition-Name
perforation NCT03923335 760 771 I-Condition-Name
( NCT03923335 772 773 O
IOP NCT03923335 774 777 B-Condition-Name
) NCT03923335 778 779 O
, NCT03923335 781 782 O
counts NCT03923335 783 789 O
of NCT03923335 790 792 O
lymph NCT03923335 793 798 B-Procedure-Name
node NCT03923335 799 803 I-Procedure-Name
removed NCT03923335 804 811 I-Procedure-Name
in NCT03923335 812 814 O
surgical NCT03923335 815 823 B-Procedure-Name
resection NCT03923335 824 833 I-Procedure-Name
. NCT03923335 834 835 O

Exclusion NCT03923335 837 846 O
Criteria NCT03923335 847 855 O
: NCT03923335 856 857 O

1 NCT03923335 862 863 O
. NCT03923335 863 864 O
have NCT03923335 866 870 O
had NCT03923335 871 874 O
a NCT03923335 875 876 O
previous NCT03923335 877 885 B-Eq-Temporal-Period___Eq-Temporal-Period-Value:past
diagnosis NCT03923335 886 895 O
of NCT03923335 896 898 O
any NCT03923335 899 902 O
cancer NCT03923335 903 909 B-Condition-Name
or NCT03923335 910 912 O
presence NCT03923335 913 921 O
of NCT03923335 922 924 O
any NCT03923335 925 928 O
tumor NCT03923335 929 934 B-Condition-Name
other NCT03923335 935 940 O
than NCT03923335 941 945 O
the NCT03923335 946 949 O
CRC NCT03923335 950 953 B-Condition-Name

2 NCT03923335 957 958 O
. NCT03923335 958 959 O
have NCT03923335 961 965 O
had NCT03923335 966 969 O
inflammatory NCT03923335 970 982 B-Condition-Name
bowel NCT03923335 983 988 I-Condition-Name
disease NCT03923335 989 996 I-Condition-Name

3 NCT03923335 1000 1001 O
. NCT03923335 1001 1002 O
have NCT03923335 1004 1008 O
had NCT03923335 1009 1012 O
hereditary NCT03923335 1013 1023 O
colorectal NCT03923335 1024 1034 O
cancer NCT03923335 1035 1041 B-Condition-Name
syndromes NCT03923335 1042 1051 I-Condition-Name
, NCT03923335 1052 1053 O
including NCT03923335 1054 1063 O
Familial NCT03923335 1064 1072 B-Condition-Name
adenomatous NCT03923335 1073 1084 I-Condition-Name
polyposis NCT03923335 1085 1094 I-Condition-Name
, NCT03923335 1095 1096 O
mutyh NCT03923335 1097 1102 O
( NCT03923335 1103 1104 O
MYH NCT03923335 1105 1108 O
) NCT03923335 1109 1110 O
- NCT03923335 1112 1113 O
associated NCT03923335 1114 1124 O
polyposis NCT03923335 1125 1134 B-Condition-Name
, NCT03923335 1135 1136 O
Peutz NCT03923335 1137 1142 B-Condition-Name
- NCT03923335 1143 1144 I-Condition-Name
Jeghers NCT03923335 1145 1152 I-Condition-Name
syndrome NCT03923335 1153 1161 I-Condition-Name
, NCT03923335 1162 1163 O
Juvenile NCT03923335 1164 1172 B-Condition-Name
polyposis NCT03923335 1173 1182 I-Condition-Name
coli NCT03923335 1183 1187 I-Condition-Name
, NCT03923335 1188 1189 O
phosphate NCT03923335 1190 1199 B-Condition-Name
and NCT03923335 1200 1203 I-Condition-Name
tension NCT03923335 1204 1211 I-Condition-Name
homology NCT03923335 1212 1220 I-Condition-Name
deleted NCT03923335 1221 1228 I-Condition-Name
on NCT03923335 1229 1231 I-Condition-Name
chromosome NCT03923335 1232 1242 I-Condition-Name
ten NCT03923335 1243 1246 I-Condition-Name
( NCT03923335 1247 1248 O
PTEN NCT03923335 1249 1253 B-Condition-Name
) NCT03923335 1254 1255 O
tumor NCT03923335 1256 1261 B-Condition-Name
- NCT03923335 1262 1263 I-Condition-Name
hamartoma NCT03923335 1264 1273 I-Condition-Name
syndromes NCT03923335 1274 1283 I-Condition-Name
, NCT03923335 1284 1285 O
Lynch NCT03923335 1286 1291 B-Condition-Name
Syndrome NCT03923335 1292 1300 I-Condition-Name
, NCT03923335 1301 1302 O
and NCT03923335 1303 1306 O
Familial NCT03923335 1307 1315 O
Colorectal NCT03923335 1316 1326 O
Cancer NCT03923335 1327 1333 B-Condition-Name
Type NCT03923335 1334 1338 O
X NCT03923335 1339 1340 O
. NCT03923335 1341 1342 O

